UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
Form 20-F
|
|
|
(Mark One)
|
o
|
|
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF
THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
or
|
þ
|
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the fiscal year ended December 31,
2010
|
or
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the transition period
from to
|
|
|
or
|
o
|
|
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
Date of event requiring this shell company report
|
Commission file number
001-32749
FRESENIUS MEDICAL CARE
AG & Co. KGaA
(Exact name of Registrant as
specified in its charter)
FRESENIUS MEDICAL CARE
AG & Co. KGaA
(Translation of Registrants
name into English)
Germany
(Jurisdiction of incorporation or
organization)
Else-Kröner Strasse 1,
61352 Bad Homburg, Germany
(Address of principal executive
offices)
Josef Dinger, +49 6172 608 2522,
Josef.Dinger@FMC-AG.com,
Else-Kröner Strasse 1,
61352 Bad Homburg, Germany
(Name, Telephone,
E-mail
and/or Facsimile number and Address of Company Contact Person)
Securities
registered or to be registered pursuant to Section 12(b) of
the Act:
|
|
|
Title of each class
|
|
Name of each exchange on which registered
|
|
American Depositary Shares representing Preference Shares
|
|
New York Stock Exchange
|
Preference Shares, no par value
|
|
New York Stock
Exchange
(1)
|
American Depositary Shares representing Ordinary Shares
|
|
New York Stock Exchange
|
Ordinary Shares, no par value
|
|
New York Stock
Exchange
(1)
|
|
|
(1)
|
Not for trading, but only in connection with the registration of
American Depositary Shares representing such shares.
|
Securities registered or to be registered pursuant to
Section 12(g) of the Act:
None
Securities for which there is a reporting obligation pursuant
to Section 15(d) of the Act:
7
7
/
8
%
USD Trust Preferred Securities due 2011
7
3
/
8
%
Euro Trust Preferred Securities due 2011
6
7
/
8
% Senior Notes due 2017
5.50% Senior Notes due 2016
Indicate the number of outstanding shares of each of the
issuers classes of capital or common stock as of the close
of the period covered by the annual report:
Preference Shares, no par value: 3,957,168
Ordinary Shares, no par value: 298,279,001
Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Security Act.
Yes
þ
No
o
If this report is an annual or transition report, indicate by
check mark if the registrant is not required to file reports
pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934.
Yes
o
No
þ
Note Checking the box above will not relieve any
registrant required to file reports pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934 from their
obligations under those Sections.
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports) and (2) has been subject
to such filing requirements for the past 90 days.
Yes
þ
No
o
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any,
every Interactive Date File required to be submitted and posted
pursuant to Rule 405 of
Regulation S-T
(§ 232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant
was required to submit and post such files).
Yes
þ
No
o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, or a non-accelerated
filer. See definition of accelerated filer and large
accelerated filer in
Rule 12b-2
of the Exchange Act. (Check one):
|
|
|
|
|
|
|
|
|
|
Large accelerated
filer
þ
|
|
Accelerated
filer
o
|
|
Non-accelerated
filer
o
|
Indicate by check mark which basis of accounting the registrant
has used to prepare the financial statements included in this
filing:
þ
U.S. GAAP
o
International
Financial Reporting Standards as issued by the International
Accounting Standards Board
o
Other
If Other has been checked in response to the
previous question, indicate by check mark which financial
statement item the registrant has elected to follow:
o
Item 17
o
Item 18
If this is an annual report, indicate by check mark whether the
registrant is a shell company (as defined in
Rule 12b-2
of the Exchange Act).
Yes
o
No
þ
Certain
Defined Terms
In this report, (1) the Company refers to both
Fresenius Medical Care AG prior to the transformation of legal
form discussed in Item 4.A, Information on the
Company History and Development of the
Company History below and to Fresenius Medical
Care AG & Co. KGaA after the transformation;
(2) we, us and our
refers either to the Company or the Company and its subsidiaries
on a consolidated basis both before and after the
transformation, as the context requires;
(3) Fresenius Medical Care AG and
FMC-AG refers to the Company as a German stock
corporation before the transformation of legal form and
FMC-AG & Co. KGaA refers to the Company as
a German partnership limited by shares after the transformation
and (4) FMCH and D-GmbH refer,
respectively, to Fresenius Medical Care Holdings, Inc., the
holding company for our North American operations and to
Fresenius Medical Care Deutschland GmbH, one of our German
subsidiaries. In addition, Fresenius SE refers to
Fresenius SE & Co. KGaA, a German partnership limited
by shares resulting from the change of legal form of Fresenius
SE (effective as of January 2011), a European Company (Societas
Europaea) previously called Fresenius AG, a German stock
corporation. Fresenius SE owns 100% of the share capital of our
general partner and approximately 35.7% of our ordinary shares
as of December 31, 2010 (prior to the transformation of our
legal form, it held approximately 51.8% of our voting shares).
In this report, we use Fresenius SE to refer to that company as
a partnership limited by shares, effective on and after
January 28, 2011, as well as both before and after the
conversion of Fresenius AG from a stock corporation into a
European Company on July 13, 2007. Management
AG refers to Fresenius Medical Care Management AG,
FMC-AG & Co. KGaAs general partner and a wholly
owned subsidiary of Fresenius SE. All references in this report
to the notes to our financial statements are to the Notes to
Consolidated Financial Statements included in this report.
Forward-looking
Statements
This report contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of
1934, as amended. When used in this report, the words
expects, anticipates,
intends, plans, believes,
seeks, estimates and similar expressions
are generally intended to identify forward looking statements.
Although we believe that the expectations reflected in such
forward-looking statements are reasonable, forward-looking
statements are inherently subject to risks and uncertainties,
many of which cannot be predicted with accuracy and some of
which might not even be anticipated, and future events and
actual results, financial and otherwise, could differ materially
from those set forth in or contemplated by the forward-looking
statements contained elsewhere in this report. We have based
these forward-looking statements on current estimates and
assumptions made to the best of our knowledge. By their nature,
such forward-looking statements involve risks, uncertainties,
assumptions and other factors which could cause actual results,
including our financial condition and profitability, to differ
materially and be more negative than the results expressly or
implicitly described in or suggested by these statements.
Moreover, forward-looking estimates or predictions derived from
third parties studies or information may prove to be
inaccurate. Consequently, we cannot give any assurance regarding
the future accuracy of the opinions set forth in this report or
the actual occurrence of the developments described herein. In
addition, even if our future results meet the expectations
expressed here, those results may not be indicative of our
performance in future periods.
These risks, uncertainties, assumptions, and other factors that
could cause actual results to differ from our projected results
include, among others, the following:
|
|
|
|
|
changes in governmental and commercial insurer reimbursement for
our products and services, including the mandated change in the
United States beginning in 2011 to an expanded
bundled Medicare reimbursement system for dialysis
services;
|
|
|
|
reductions in erythropoietin, or EPO, utilization or EPO
reimbursement, changes in utilization patterns for other
pharmaceuticals, and increases in our costs of purchasing
pharmaceuticals;
|
|
|
|
the outcome of ongoing government investigations;
|
|
|
|
the influence of private insurers and managed care organizations;
|
|
|
|
the impact of recently enacted and possible future health care
reforms;
|
|
|
|
product liability risks;
|
|
|
|
the outcome of ongoing potentially material litigation;
|
|
|
|
risks relating to the integration of acquisitions and our
dependence on additional acquisitions;
|
|
|
|
the impact of currency fluctuations;
|
|
|
|
introduction of generic or new pharmaceuticals that compete with
our pharmaceutical products; and
|
|
|
|
changes in raw material and energy costs.
|
1
Important factors that could contribute to such differences are
noted in this report in Item 3, Risk Factors,
in Item 4, Information on the Company, under
Business Overview, in Item 5, Operating
and Financial Review and Prospects and in Note 18 of
the Notes to Consolidated Financial Statements, Legal
Proceedings.
Our business is also subject to other risks and uncertainties
that we describe from time to time in our public filings.
Developments in any of these areas could cause our results to
differ materially from the results that we or others have
projected or may project.
Our reported financial condition and results of operations are
sensitive to accounting methods, assumptions and estimates that
are the basis of our financial statements. The actual accounting
policies, the judgments made in the selection and application of
these policies, and the sensitivities of reported results to
changes in accounting policies, assumptions and estimates, are
factors to be considered along with our financial statements and
the discussion below under Results of Operations.
For a discussion of our critical accounting policies, see
Item 5, Operating and Financial Review and
Prospects Critical Accounting Policies.
2
PART I
|
|
Item 1.
|
Identity
of Directors, Senior Management and Advisors
|
Not applicable
|
|
Item 2.
|
Other
Statistics and Expected Timetable
|
Not applicable
|
|
A.
|
Selected
Financial Data
|
The following table summarizes the consolidated financial
information for our business for each of the years 2010 through
2006. We derived the selected financial information from our
consolidated financial statements. We prepared our financial
statements in accordance with accounting principles generally
accepted in the United States of America and KPMG AG
Wirtschaftsprüfungsgesellschaft (KPMG), an
independent registered public accounting firm, audited these
financial statements. The statement of operations data for 2006
include the results of, and related financing costs to acquire,
Renal Care Group (RCG) from April 1, 2006, the
effective date of the RCG acquisition; balance sheet data at
December 31, 2006 include the assets and liabilities of RCG
and debt incurred to finance the acquisition. You should read
this information together with our consolidated financial
statements and the notes to those statements appearing elsewhere
in this report and the information under Item 5,
Operating and Financial Review and Prospects.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
|
(in millions except share and per share amounts)
|
|
|
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenues
|
|
$
|
12,053
|
|
|
$
|
11,247
|
|
|
$
|
10,612
|
|
|
$
|
9,720
|
|
|
$
|
8,499
|
|
Cost of revenues
|
|
|
7,908
|
|
|
|
7,415
|
|
|
|
6,983
|
|
|
|
6,364
|
|
|
|
5,621
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
4,145
|
|
|
|
3,832
|
|
|
|
3,629
|
|
|
|
3,356
|
|
|
|
2,878
|
|
Selling, general and administrative
|
|
|
2,124
|
|
|
|
1,982
|
|
|
|
1,877
|
|
|
|
1,709
|
|
|
|
1,549
|
|
Gain on sale of dialysis clinics
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(40
|
)
|
Research and development
|
|
|
97
|
|
|
|
94
|
|
|
|
80
|
|
|
|
67
|
|
|
|
51
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
1,924
|
|
|
|
1,756
|
|
|
|
1,672
|
|
|
|
1,580
|
|
|
|
1,318
|
|
Interest expense, net
|
|
|
280
|
|
|
|
300
|
|
|
|
336
|
|
|
|
371
|
|
|
|
351
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
1,644
|
|
|
|
1,456
|
|
|
|
1,336
|
|
|
|
1,209
|
|
|
|
967
|
|
Net income attributable to FMC-AG & Co. KGaA
|
|
$
|
979
|
|
|
$
|
891
|
|
|
$
|
818
|
|
|
$
|
717
|
|
|
$
|
537
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average ordinary shares outstanding
|
|
|
296,808,978
|
|
|
|
294,418,795
|
|
|
|
293,233,477
|
|
|
|
291,929,141
|
|
|
|
290,621,904
|
|
Basic earnings per Ordinary share and Ordinary ADS
|
|
$
|
3.25
|
|
|
$
|
2.99
|
|
|
$
|
2.75
|
|
|
$
|
2.43
|
|
|
$
|
1.82
|
|
Fully diluted earnings per Ordinary share and Ordinary ADS
|
|
|
3.24
|
|
|
|
2.99
|
|
|
|
2.75
|
|
|
|
2.42
|
|
|
|
1.81
|
|
Basic earnings per Preference share and Preference ADS
|
|
|
3.28
|
|
|
|
3.02
|
|
|
|
2.78
|
|
|
|
2.45
|
|
|
|
1.85
|
|
Fully diluted earnings per Preference share and Preference ADS
|
|
|
3.27
|
|
|
|
3.02
|
|
|
|
2.78
|
|
|
|
2.44
|
|
|
|
1.84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends declared and paid per Ordinary share
()
(a)
|
|
|
0.61
|
|
|
|
0.58
|
|
|
|
0.54
|
|
|
|
0.47
|
|
|
|
0.41
|
|
Dividends declared and paid per Preference share
()
(a)
|
|
|
0.63
|
|
|
|
0.60
|
|
|
|
0.56
|
|
|
|
0.49
|
|
|
|
0.43
|
|
Dividends declared and paid per Ordinary share
($)
(a)
|
|
|
0.77
|
|
|
|
0.78
|
|
|
|
0.85
|
|
|
|
0.64
|
|
|
|
0.52
|
|
Dividends declared and paid per Preference share
($)
(a)
|
|
|
0.79
|
|
|
|
0.81
|
|
|
|
0.88
|
|
|
|
0.67
|
|
|
|
0.55
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance Sheet Data at December 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Working capital
|
|
$
|
1,363
|
|
|
$
|
2,118
|
|
|
$
|
1,068
|
|
|
$
|
833
|
|
|
$
|
1,036
|
|
Total assets
|
|
|
17,095
|
|
|
|
15,821
|
|
|
|
14,920
|
|
|
|
14,170
|
|
|
|
13,045
|
|
Total long-term debt (excluding current portion)
|
|
|
4,310
|
|
|
|
5,084
|
|
|
|
4,598
|
|
|
|
4,668
|
|
|
|
5,083
|
|
Shareholders equity
|
|
|
7,524
|
|
|
|
6,798
|
|
|
|
5,961
|
|
|
|
5,567
|
|
|
|
4,864
|
|
Capital Stock Preference shares Nominal
Value
|
|
|
4
|
|
|
|
4
|
|
|
|
4
|
|
|
|
4
|
|
|
|
4
|
|
Capital Stock Ordinary shares Nominal
Value
|
|
|
369
|
|
|
|
366
|
|
|
|
363
|
|
|
|
361
|
|
|
|
360
|
|
|
|
(a)
|
Amounts shown for each year from 2010 to 2006 represent
dividends declared and paid in each such year with respect to
our operations in the year preceding payment. Our general
partners Management Board has proposed dividends with
respect to our operations in 2010 of 0.65 per Ordinary
share and 0.67 per Preference share. These dividends are
subject to approval by our shareholders at our Annual General
Meeting to be held on May 12, 2011.
|
We conduct our business on a global basis in various currencies,
although our operations are located principally in the United
States and Germany. We prepare our consolidated financial
statements, from which we derived the selected financial data
above, utilizing the U.S. dollar as our reporting currency.
We have converted the balance sheets of our
non-U.S. dollar
denominated operations into U.S. dollars at the exchange
rates prevailing at the balance sheet date. Revenues and
expenses are translated at the average exchange rates for the
period. For information regarding the exchange rates used in
preparing our consolidated financial statements, see
Item 11, Quantitative and Qualitative Disclosures
About Market Risk Management of Foreign Exchange and
Interest Rate Risks Foreign Exchange Risks.
3
Before you invest in our securities, you should be aware that
the occurrence of any of the events described in the following
risk factors or elsewhere in this report, and other events that
we have not predicted or assessed could have a material adverse
effect on our results of operations, financial condition and
business. If the events described below or other unpredicted
events occur, then the trading price of our securities could
decline and you may lose all or part of your investment.
Risks
Relating to Litigation and Regulatory Matters.
A
change in U.S. government reimbursement for dialysis care could
materially decrease our revenues and operating
profit.
For the twelve months ended December 31, 2010,
approximately 32% of our consolidated revenues resulted from
Medicare and Medicaid reimbursement. Legislative changes or
changes in government reimbursement practice may affect the
reimbursement rates for the services we provide, as well as the
scope of Medicare and Medicaid coverage. A decrease in Medicare
or Medicaid reimbursement rates or covered services could have a
material adverse effect on our business, financial condition and
results of operations. Effective January 1, 2011, Medicare
reimbursement is based on an expanded bundled rate. For a
discussion of the new end-stage renal disease (ESRD)
prospective payment system (ESRD PPS) for Medicare
reimbursement of renal dialysis items and services implemented
by the Centers for Medicare and Medicaid Services
(CMS) effective January 1, 2011, see
Item 5, Operating and Financial Review and
Prospects Overview. Beginning January 1,
2012, the ESRD PPS will include a quality improvement program
(QIP) in which full payment of the Medicare ESRD PPS
rate to a dialysis facility will be contingent upon such
dialysis facilitys achievement of certain minimum
performance criteria for anemia management and toxin clearance.
Failure to achieve these minimum criteria in any year subjects
the facility to up to a 2% reduction in Medicare reimbursement
two years later. Reimbursement in 2012 will be dependent in part
upon quality achievements in 2010. A material failure by the
Company to achieve the minimum clinical quality standards under
the QIP could materially and adversely affect the Companys
business, financial condition and results of operations.
A
reduction in reimbursement for or a change in the utilization of
EPO could materially reduce our revenue and operating profit. An
interruption of supply or our inability to obtain satisfactory
terms for EPO could reduce our revenues.
Reimbursement and revenue from the administration of
erythropoietin, or EPO, accounted for approximately 19% of total
dialysis care revenue in our North America segment for the year
ended December 31, 2010. Synthetic EPO is produced in the
U.S. by a single source manufacturer, Amgen Inc., under the
brand names
Epogen
®
(epoeitin alfa) and
Aranesp
®
(darbepoetin alfa). Our supply contract with Amgen USA, Inc., a
subsidiary of Amgen, Inc. covers the period from October 1,
2006 to December 31, 2011. Pricing is based on Amgens
list price and is subject to change within certain parameters.
Any of the following developments could materially adversely
affect our business, financial condition and results of
operations: (i) an increase in Amgens price for EPO,
(ii) a reduction of the current overfill amount in EPO
vials which we currently use (liquid medications, such as EPO,
typically include a small overfill amount to ensure that the
fill volume can be extracted from the vial as administered to
the patient), or (iii) an interruption of supply of EPO.
Under the new ESRD PPS, effective January 1, 2011, payment
for EPO is included in the bundled rate. Material increases in
the utilization of or acquisition costs for EPO or reduction in
EPO overfill could materially and adversely affect our business,
financial condition and results of operations.
If we
do not comply with the many governmental regulations applicable
to our business, we could be excluded from government health
care reimbursement programs or our authority to conduct business
could be terminated, either of which would result in a material
decrease in our revenue.
Our operations in both our provider business and our products
business are subject to extensive governmental regulation in
virtually every country in which we operate. We are also subject
to other laws of general applicability, including antitrust
laws. The applicable regulations, which differ from country to
country, cover areas that include:
|
|
|
|
|
the quality, safety and efficacy of medical and pharmaceutical
products and supplies;
|
|
|
|
the operation of manufacturing facilities, laboratories and
dialysis clinics;
|
|
|
|
product advertising and other promotion;
|
4
|
|
|
|
|
accurate reporting and billing for government and third-party
reimbursement; and
|
|
|
|
compensation of medical directors and other financial
arrangements with physicians and other referral sources.
|
Failure to comply with one or more of these laws or regulations,
may give rise to a number of legal consequences. These include,
in particular, monetary and administrative penalties, increased
costs for compliance with government orders, complete or partial
exclusion from government reimbursement programs or complete or
partial curtailment of our authority to conduct business. Any of
these consequences could have a material adverse impact on our
business, financial condition and results of operations.
In the QIP final rule, issued on December 29, 2010, CMS
announced that its monitoring of the ESRD PPS and the QIP would
focus, among other things, on changes in care practices,
including increases and decreases in utilization of EPO and
other injectable ESRD drugs and the use of home modalities for
certain groups of beneficiaries with ESRD.
The Companys medical and pharmaceutical products are
subject to detailed, rigorous and frequently changing regulation
by the U.S. Food and Drug Administration (FDA),
and numerous other national, supranational, federal and state
authorities. These regulations include, among other things,
regulations regarding manufacturing practices, product labeling,
quality control, quality assurance, advertising and
post-marketing reporting, including adverse event reports and
field alerts due to manufacturing quality concerns. We cannot
assure that all necessary regulation approvals for new products
or product improvements will be granted on a timely basis or at
all. In addition, the Companys facilities and procedures
and those of its suppliers are subject to periodic inspection by
the FDA and other regulatory authorities. The FDA and comparable
regulatory authorities outside the U.S. may suspend,
revoke, or adversely amend the authority necessary for
manufacture, marketing, or sale of our products and those of our
suppliers. The Company and its suppliers must incur expense and
spend time and effort to ensure compliance with these complex
regulations, and if such compliance is not maintained, they
could be subject to significant adverse regulatory actions in
the future. These possible regulatory actions could include
warning letters, injunctions, civil penalties, seizures of the
Companys products and criminal prosecution as well as
other dissemination of information to the public about such
regulatory actions. These actions could result in, among other
things, substantial modifications to the Companys business
practices and operations; refunds; a total or partial shutdown
of production while the alleged violation is remedied; and
withdrawals or suspensions of current products from the market.
Any of these events, in combination or alone, could disrupt the
Companys business and have a material adverse effect on
the Companys business, financial condition and results of
operations.
We rely upon the Companys management structure, regulatory
and legal resources and the effective operation of our
compliance programs to direct, manage and monitor our operations
to comply with government regulations. If employees were to
deliberately or inadvertently fail to adhere to these
regulations, then our authority to conduct business could be
terminated and our operations could be significantly curtailed.
Such actions could also lead to claims for repayment or other
sanctions. Any such terminations or reductions could materially
reduce our sales, with a resulting material adverse effect on
our business, financial condition and results of operations.
FMCH and its subsidiaries, including Renal Care Group
(RCG) (prior to the RCG Acquisition), received
subpoenas in 2005 from the U.S. Department of Justice for
the Eastern District of Missouri, in connection with a joint
civil and criminal investigation. The subpoenas require
production of a broad range of documents relating to FMCHs
and RCGs operations, with specific attention to documents
related to clinical quality programs, business development
activities, medical director compensation and physician
relationships, joint ventures, and anemia management programs,
RCGs Method II home dialysis supply company,
pharmaceutical and other services that RCG provides to patients,
RCGs relationships to pharmaceutical companies, and
RCGs purchase of dialysis equipment from FMCH. The Office
of the Inspector General of the U.S. Department of Health
and Human Services and the U.S. Attorneys office for
the Eastern District of Texas participated in the Eastern
District of Missouris investigation of FMCHs and
RCGs utilization of Epogen begun in 2005. On July 17,
2007, the U.S. Attorneys office filed a civil
complaint against RCG and FMCH in its capacity as RCGs
current corporate parent in United States District Court,
Eastern District of Missouri. The complaint seeks monetary
damages and penalties with respect to issues arising out of the
operation of RCGs Method II supply company through
2005, prior to the date of FMCHs acquisition of RCG. On
August 11, 2009, the Missouri District Court granted
RCGs motion to transfer venue to the United States
District Court for the Middle District of Tennessee (Nashville).
On March 22, 2010, the Tennessee District Court entered
judgment against defendants for approximately $23 million
in damages and interest under the unjust enrichment count of the
complaint but denied all relief under the six False Claims Act
counts of the complaint. The Company appealed the Tennessee
District Courts decision to the United States Court of
Appeals for the Sixth Circuit and secured a stay of enforcement
of the judgment pending appeal. The United States Attorney
filed a cross appeal, but also asked the Tennessee District
Court for an indicative or
5
supplemental ruling. On June 23, 2010, the Tennessee
District Court issued an indicative ruling to the effect that,
if the case were remanded to the District Court, it would expect
to enter a judgment under the False Claims Act against the
Company for approximately $104 million. On
September 23, 2010, the Court of Appeals remanded the case
to the Tennessee District Court to permit revision or
supplementation of the original judgment, after which the
Company may pursue its appeals to the Court of Appeals. The
Company believes that RCGs operation of its Method II
supply company was in compliance with applicable law, that no
relief is due to the United States, and that its position in the
litigation will ultimately be sustained. See Note 18 in the
Notes to Consolidated Financial Statements.
If our
joint ventures violate the law, our business could be adversely
affected.
A number of the dialysis centers we operate are owned by joint
ventures in which we hold a controlling interest and one or more
hospitals, physicians or physician practice groups hold a
minority interest. The physician owners may also provide medical
director services and refer patients to those centers or other
centers we own and operate. While we have structured our joint
ventures to comply with many of the criteria for safe harbor
protection under the U.S. Federal Anti-Kickback Statute,
our investments in these joint venture arrangements do not
satisfy all elements of such safe harbor. While we have
established comprehensive compliance policies, procedures and
programs to ensure ethical and compliant joint venture business
operations, if one or more of our joint ventures were found to
be in violation of the Anti-Kickback Statute or the Stark Law,
we could be required to restructure or terminate them. We also
could be required to repay to Medicare amounts received by the
joint ventures pursuant to any prohibited referrals, and we
could be subject to monetary penalties and exclusion from
Medicare, Medicaid and other U.S. federal and state health
care programs. Imposition of any of these penalties could have a
material adverse effect on our business, financial condition and
results of operations.
Proposals
for health care reform, or relating to regulatory approvals,
could decrease our revenues and operating profit.
Many of the countries in which we operate have been considering
proposals to modify their current health care systems to improve
access to health care and control costs. We cannot predict
whether and when these reform proposals will be adopted in
countries in which we operate or what impact they might have on
us. Any decrease in spending or other significant changes in
state funding in countries in which we operate, particularly
significant changes in the U.S. Medicare and Medicaid
programs, could reduce our sales and profitability and have a
material adverse effect on our business, financial condition and
results of operations.
The Patient Protection and Affordable Care Act was enacted in
the United States on March 23, 2010 and subsequently
amended by the Health Care and Educational Affordability
Reconciliation Act (as amended, ACA). ACA will
implement broad healthcare system reforms, including
(i) provisions to facilitate access to affordable health
insurance for all Americans, (ii) expansion of the Medicaid
program, (iii) an industry fee on pharmaceutical companies
starting in 2011 based on sales of brand name pharmaceuticals to
government healthcare programs, (iv) a 2.3% excise tax on
manufacturers medical device sales starting in 2013,
(v) increases in Medicaid prescription drug rebates
effective January 1, 2010, (vi) commercial insurance
market reforms that protect consumers, such as bans on lifetime
and annual limits, coverage of pre-existing conditions, limits
on administrative costs, and limits on waiting periods,
(vii) provisions encouraging integrated care, efficiency
and coordination among providers and (viii) provisions for
reduction of healthcare program waste and fraud. ACA does not
modify the dialysis reimbursement provisions of the Medicare
Improvements for Patients and Providers Act of 2008, or
MIPPA. ACAs medical device excise tax,
Medicaid drug rebate increases and annual pharmaceutical
industry fees will adversely impact our product business
earnings and cash flows. We expect modest favorable impact to
our business from ACAs integrated care and commercial
insurance consumer protection provisions. Further changes in the
U.S. reforms may be debated by Congress, but whether these
deliberations will lead to significant changes in policy is
unknown.
Any significant healthcare reforms that substantially change the
financing and regulation of the healthcare industry in countries
in which we operate could reduce our sales and profitability and
have a material adverse effect on our business, financial
condition and results of operations. In addition, there may be
legislative or regulatory proposals that could affect FDA
procedures or decision-making for approving medical or
pharmaceutical products. Such legislation or regulations, if
adopted, could result in a delay or denial of regulatory
approval for our products. If any of our products do not receive
regulatory approval, or there is a delay in obtaining approval,
this also could have a material adverse effect on our business,
financial condition and results of operations.
6
Risks
Relating to Our Business
A
significant portion of our North American profits are dependent
on the services we provide to a minority of our patients who are
covered by private insurance.
In recent reviews of dialysis reimbursement, the Medicare
Payment Advisory Commission, also known as MedPAC, has noted
that Medicare payments for dialysis services are less than the
average costs that providers incur to provide the services.
Since Medicaid rates are comparable to those of Medicare and
because Medicare only pays us 80% of the Medicare allowable
amount (the patient, Medicaid or secondary insurance being
responsible for the remaining 20%), the amount we receive from
Medicare and Medicaid is less than our average cost per
treatment. As a result, the payments we receive from private
payors both subsidize the losses we incur on services for
Medicare and Medicaid patients and generate a substantial
portion of the profits we report. We estimate that Medicare and
Medicaid are the primary payors for approximately 86% of the
patients to whom we provide care in North America but that for
2010, only 53% of our North America Dialysis Care net revenues
were derived from Medicare and Medicaid. Therefore, if the
private payors who pay for the care of the other 14% of our
patients reduce their payments for our services, or if we
experience a material shift in our revenue mix toward Medicare
or Medicaid reimbursement, then our revenue, cash flow and
earnings would materially decrease.
Over the last few years, we have generally been able to
implement modest annual price increases for private insurers and
managed care organizations, but government reimbursement has
remained flat or has been increased at rates below typical
consumer price index (CPI) increases. Based on the
assessment of the CMS, we believe that reimbursement rates will
be lower under the new ESRD PPS for dialysis services furnished
after January 1, 2011. See Item 5, Operating and
Financial Review and Prospects Overview. There
can be no assurance that we can achieve similar future price
increases to private insurers and managed care organizations.
Any reductions in reimbursement from private insurers and
managed care organizations could materially and adversely impact
our operating results. Any reduction in our ability to attract
private pay patients to utilize our dialysis services relative
to historical levels could adversely impact our operating
results. Any of the following events, among others, could have a
material adverse effect on our operating results:
|
|
|
|
|
a portion of our business that is currently reimbursed by
private insurers or hospitals may become reimbursed by managed
care organizations, which generally have lower rates for our
services; or
|
|
|
|
a portion of our business that is currently reimbursed by
private insurers at rates based on our billed charges may become
reimbursed under a contract at lower rates.
|
We are
exposed to product liability, patent infringement and other
claims which could result in significant costs and liability
which we may not be able to insure on acceptable terms in the
future.
Health care companies are typically subject to claims alleging
negligence, product liability, breach of warranty, malpractice
and other legal theories that may involve large claims and
significant defense costs whether or not liability is ultimately
imposed. Health care products may also be subject to recalls and
patent infringement claims which, in addition to monetary
penalties, may restrict our ability to sell or use our products.
We cannot assure you that such claims will not be asserted
against us, for example that significant adverse verdicts will
not be reached against us for patent infringements or that large
scale recalls of our products will not become necessary. In
addition, the laws of some of the countries in which we operate
provide legal rights to users of pharmaceutical products that
could increase the risk of product liability claims. Product
liability and patent infringement claims, other actions for
negligence or breach of contract and product recalls or related
sanctions could result in significant costs. These costs could
have a material adverse effect on our business, financial
condition and results of operations. See Note 18 of the
Notes to Consolidated Financial Statements, Legal
Proceedings.
While we have been able to obtain liability insurance in the
past to partially cover our business risks, we cannot assure
that such insurance will be available in the future either on
acceptable terms or at all. In addition, FMCH, our largest
subsidiary, is partially self-insured for professional, product
and general liability, auto liability and workers
compensation claims, up to pre-determined levels above which our
third-party insurance applies. A successful claim in excess of
the limits of our insurance coverage could have a material
adverse effect on our business, results of operations and
financial condition. Liability claims, regardless of their merit
or eventual outcome, also may have a material adverse effect on
our business and reputation, which could in turn reduce our
sales and profitability.
The Company is vigorously defending certain patent infringement
lawsuits described in Note 18 of the Notes to Consolidated
Financial Statements, Legal Proceedings
Commercial Litigation. While we believe we have valid
defenses to these claims, an adverse determination in any of
these matters could have a material adverse effect on the
Companys business, financial condition and results of
operations.
7
Our
growth depends, in part, on our ability to continue to make
acquisitions.
The health care industry has experienced significant
consolidation in recent years, particularly in the dialysis
services sector. Our ability to make future acquisitions
depends, in part, on our available financial resources and could
be limited by restrictions imposed by the United States or other
countries competition laws or under our credit agreements.
If we make future acquisitions, we may need to borrow additional
debt, assume significant liabilities or create additional
expenses relating to intangible assets, any of which might
increase our financial leverage and cause our stock price to
decline. In addition, any financing that we might need for
future acquisitions might be available to us only on terms that
restrict our business. Acquisitions that we complete are also
subject to risks relating to, among other matters, integration
of the acquired businesses (including combining the acquired
companys infrastructure and management information systems
with ours, harmonization of its marketing, patient service and
logistical procedures with ours and, potentially, reconciling
divergent corporate and management cultures), possible
non-realization of anticipated synergies from the combination,
potential loss of key personnel or customers of the acquired
companies, and the risk of assuming unknown liabilities not
disclosed by the seller or not uncovered during due diligence.
If we are not able to effect acquisitions on reasonable terms,
there could be an adverse effect on our business, financial
condition and results of operations.
We also compete with other dialysis products and services
companies in seeking suitable acquisition targets and the
continuing consolidation of dialysis providers and combinations
of dialysis providers with dialysis product manufacturers could
affect future growth of our product sales. If we are not able to
continue to effect acquisitions on reasonable terms, especially
in the international area, this could have an adverse effect on
our business, financial condition and results of operations.
We
face specific risks from international operations.
We operate dialysis clinics in more than 35 countries and sell a
range of equipment, products and services to customers in over
120 countries. Our international operations are subject to a
number of risks, including but not limited to the following:
|
|
|
|
|
the economic situation in developing or other countries could
deteriorate;
|
|
|
|
fluctuations in exchange rates could adversely affect
profitability;
|
|
|
|
we could face difficulties in enforcing and collecting accounts
receivable under some countries legal systems;
|
|
|
|
local regulations could restrict our ability to obtain a direct
ownership interest in dialysis clinics or other operations;
|
|
|
|
political and economic instability, especially in developing and
newly industrializing countries, could disrupt our operations;
|
|
|
|
some customers and governments could increase their payment
cycles, with resulting adverse effects on our cash flow;
|
|
|
|
some countries could impose additional or higher taxes or
restrict the import of our products; and
|
|
|
|
we could fail to receive or could lose required licenses,
certifications or other regulatory approvals for operation of
dialysis clinics or sale of equipment, products, or services.
|
Any one or more of these or other factors could increase our
costs, reduce our revenues, or disrupt our operations, with
possible material adverse effects on our business, financial
condition and results of operations.
If
physicians and other referral sources cease referring patients
to our dialysis clinics or cease purchasing or prescribing our
dialysis products, our revenues would decrease.
Our dialysis services business is dependent upon patients
choosing our clinics as the location for their treatments.
Patients may select a clinic based, in whole or in part, on the
recommendation of their physician. We believe that physicians
and other clinicians typically consider a number of factors when
recommending a particular dialysis facility to an ESRD patient,
including, but not limited to, the quality of care at a clinic,
the competency of a clinics staff, convenient scheduling,
and a clinics location and physical condition. Physicians
may change their facility recommendations at any time, which may
result in the transfer of our existing patients to competing
clinics, including clinics established by the physicians
themselves. At most of our clinics, a relatively small number of
physicians often account for the referral of all or a
significant portion of the patient base. Our dialysis care
business also depends on recommendations by hospitals, managed
care plans and other health care institutions. If a
8
significant number of physicians, hospitals or other health care
institutions cease referring their patients to our clinics, this
would reduce our dialysis care revenue and could materially
adversely affect our overall operations.
The decision to purchase or prescribe our dialysis products and
other services or competing dialysis products and other services
will be made in some instances by medical directors and other
referring physicians at our dialysis clinics and by the managing
medical personnel and referring physicians at other dialysis
clinics, subject to applicable regulatory requirements. A
decline in physician recommendations or recommendations from
other sources for purchases of our products or ancillary
services would reduce our dialysis product and other services
revenue, and would materially adversely affect our business,
financial condition and results of operations.
Our
pharmaceutical product business could lose sales to generic drug
manufacturers or new branded drugs.
Our branded pharmaceutical product business is subject to
significant risk as a result of competition from manufacturers
of generic drugs and other new competing medicines or therapies.
We are obligated to make certain minimum annual royalty payments
under certain of our pharmaceutical product license agreements,
irrespective of our annual sales of the licensed products.
Either the expiration or loss of patent protection for one of
our products, or the at-risk launch by a generic
manufacturer of a generic version of one of our branded
pharmaceutical products or the launch of new branded drugs that
compete with one or more of our products, could result in the
loss of a major portion of sales of that branded pharmaceutical
product in a very short time period, which could materially and
adversely affect our business, financial condition and results
of operations.
Our
competitors could develop superior technology or otherwise
impact our sales.
We face numerous competitors in both our dialysis services
business and our dialysis products business, some of which may
possess substantial financial, marketing or research and
development resources. Competition and especially new
competitive developments could materially adversely affect the
future pricing and sale of our products and services. In
particular, technological innovation has historically been a
significant competitive factor in the dialysis products
business. The introduction of new products by competitors could
render one or more of our products or services less competitive
or even obsolete.
Global
economic conditions may have an adverse effect on our
businesses.
There was a material deterioration of the global economy and
tightening of the financial markets in 2008 and 2009. Although
there has been some improvement in the global economy and
financial markets in 2010, the outlook for the global economy in
2011 remains uncertain. We depend on the financial markets for
access to capital, as do our renal product customers and
commercial healthcare insurers. Limited or expensive access to
capital could make it more difficult for these customers to do
business with us, remit payments to us in the future or to do
business generally, which could adversely affect our businesses.
We expect that most of our accounts receivables will be
collectable due to the fact that a large portion of our
reimbursement is provided by public health care organizations
and private insurers. However, payment in the International
segment may potentially be more slowly in the immediate future,
particularly in countries which continue to be severely affected
by the global financial crisis. The continuation, or worsening,
of domestic and global economic conditions could continue to
adversely affect our businesses and results of operations.
If we
are unable to attract and retain skilled medical, technical and
engineering personnel, we may be unable to manage our growth or
continue our technological development.
Our continued growth in the provider business will depend upon
our ability to attract and retain skilled employees, such as
highly skilled nurses and other medical personnel. Competition
for those employees is intense and the current nursing shortage
has increased our personnel and recruiting costs. Moreover, we
believe that future success in the provider business will be
significantly dependent on our ability to attract and retain
qualified physicians to serve as medical directors of our
dialysis clinics. If we are unable to achieve that goal or if
doing so requires us to bear increased costs this could
adversely impact our growth and results of operations.
Our dialysis products business depends on the development of new
products, technologies and treatment concepts to be competitive.
Competition is also intense for skilled engineers and other
technical research and development personnel. If we are unable
to obtain and retain the services of key personnel, the ability
of our officers and key employees to manage our growth would
suffer and our operations could suffer in other respects. These
factors could preclude us from integrating acquired companies
into our operations, which could increase our costs and prevent
us from realizing synergies from acquisitions. Lack of skilled
research and development personnel could impair our
technological development, which would increase our costs and
impair our reputation for production of technologically advanced
products.
9
Diverging
views of fiscal authorities could require us to make additional
tax payments.
We are in dispute with the German tax authorities and the
U.S. Internal Revenue Service (IRS) on certain tax
deductions disallowed in past and current tax audits. We are
also subject to ongoing tax audits in the U.S., Germany and
other jurisdictions. We have received notices of unfavorable
adjustments and disallowances in connection with certain of
these audits and we may be subject to additional unfavorable
adjustments and disallowances. We are contesting, and in some
cases appealing certain of the unfavorable determinations. If
our objections, audit appeals or court claims are unsuccessful,
we could be required to make additional tax payments, which
could have a material adverse impact on our results of
operations and operating cash flow in the relevant reporting
period. See Item 5, Operating and Financial Review
and Prospects B. Liquidity and Capital
Resources Liquidity as well as Note 18 of
the Notes to Consolidated Financial Statements, Legal
Proceedings.
Risks
Relating to our Securities
Our
indebtedness may limit our ability to pay dividends or implement
certain elements of our business strategy.
At December 31, 2010, we had consolidated debt of
$5,880 million, including $626 million of our
Trust Preferred Securities, and consolidated total
shareholders equity of $7,524 million. Our debt could
have significant consequences to our operations and our
financial condition. For example, it could require us to
dedicate a substantial portion of our cash flow from operations,
as well as the proceeds of certain financings and asset
dispositions, to payments on our indebtedness, thereby reducing
the availability of our cash flow and such proceeds to fund
working capital, capital expenditures and for other general
corporate purposes.
Our Amended 2006 Senior Credit Agreement, Senior Notes, European
Investment Bank (EIB) Agreements, Euro Notes and the
indentures relating to our Trust Preferred Securities
include covenants that require us to maintain certain financial
ratios or meet other financial tests. Under our Amended 2006
Senior Credit Agreement, we are obligated to maintain a minimum
consolidated fixed charge ratio (ratio of EBITDAR
consolidated earnings before interest, taxes, depreciation and
amortization (EBITDA) plus rent to consolidated
fixed charges (interest, rent, scheduled debt maturities,
restrictive payments and cash tax payments)) and we are subject
to a maximum consolidated leverage ratio (ratio of consolidated
funded debt to EBITDA).
Our Amended 2006 Senior Credit Agreement and the indentures
related to our Trust Preferred Securities include other
covenants which, among other things, restrict or have the effect
of restricting our ability to dispose of assets, incur debt, pay
dividends and other restricted payments, create liens or make
investments or acquisitions. These covenants may otherwise limit
our activities. The breach of any of the covenants could result
in a default and acceleration of the indebtedness under the
credit agreement or the indentures, which could, in turn, create
additional defaults and acceleration of the indebtedness under
the agreements relating to our other long-term indebtedness
which would have an adverse effect on our business, financial
condition and results of operations
Fresenius
SE owns 100% of the shares in the general partner of our Company
and is able to exercise management control of FMC-AG &
Co. KGaA.
Fresenius SE owns approximately 35.7% of our voting ordinary
shares and 100% of the outstanding shares of the general partner
of the Company. As the sole shareholder of Fresenius Medical
Care Management AG, the general partner of the Company,
Fresenius SE has the sole right to elect the supervisory board
of the general partner which, in turn, appoints the management
board of the general partner. The management board of the
general partner is responsible for the management of the
Company. Through its ownership of the general partner, Fresenius
SE is able to exercise de facto management control of
FMC-AG & Co. KGaA even though it owns less than a
majority of our outstanding voting shares. Such de facto control
limits public shareholder influence on management of the Company
and precludes a takeover or change of control of the Company
without Fresenius SEs consent, either or both of which
could adversely affect the prices of our shares.
Because
we are not organized under U.S. law, we are subject to certain
less detailed disclosure requirements under U.S. federal
securities laws.
Under the pooling agreement that we have entered into for the
benefit of minority holders of our ordinary shares and holders
of our preference shares (including, in each case, holders of
American Depositary Receipts representing beneficial ownership
of such shares), we have agreed to file quarterly reports with
the SEC, to prepare annual and quarterly financial statements in
accordance with United States generally accepted accounting
principles (U.S. GAAP), and to file information
with the SEC with respect to annual and general meetings of our
shareholders. These pooling agreements also require that the
supervisory board of Fresenius Medical Care
10
Management AG, our general partner, include at least two members
who do not have any substantial business or professional
relationship with Fresenius SE, Fresenius Medical Care
Management AG or FMC-AG & Co. KGaA and its affiliates
and requires the consent of those independent directors to
certain transactions between us and Fresenius SE and its
affiliates.
We are a foreign private issuer, as defined in the
SECs regulations, and consequently we are not subject to
all of the same disclosure requirements applicable to domestic
companies. We are exempt from the SECs proxy rules, and
our annual reports contain less detailed disclosure than reports
of domestic issuers regarding such matters as management,
executive compensation and outstanding options, beneficial
ownership of our securities and certain related party
transactions. Also, our officers, directors and beneficial
owners of more than 10% of our equity securities are exempt from
the reporting requirements and short swing profit
recovery provisions of Section 16 of the Securities
Exchange Act of 1934. We are also generally exempt from most of
the governance rules applicable to companies listed on the New
York Stock Exchange, other than the obligation to maintain an
audit committee in accordance with Rule 10A 3
under the Securities Exchange Act of 1934, as amended. These
limits on available information about our company and exemptions
from many governance rules applicable to U.S. domestic
issuers may adversely affect the market prices for our
securities.
|
|
Item 4.
|
Information
on the Company
|
|
|
A.
|
History
and Development of the Company
|
General
Fresenius Medical Care AG & Co. KGaA
(FMC-AG & Co. KGaA or the
Company), is a German partnership limited by shares
(
Kommanditgesellschaft auf Aktien
), formerly known as
Fresenius Medical Care AG (FMC-AG), a German stock
corporation (
Aktiengesellschaft
) organized under the laws
of Germany.
The Company was originally incorporated on August 5, 1996
as a stock corporation and transformed into a partnership
limited by shares upon registration on February 10, 2006.
FMC-AG & Co. KGaA is registered with the commercial
register of the local court (Amtsgericht) of Hof an der Saale,
Germany, under the registration number HRB 4019. Our registered
office (
Sitz
) is Hof an der Saale, Germany. Our business
address is Else-Kröner-Strasse 1, 61352 Bad Homburg,
Germany, telephone +49-6172-609-0.
History
The Company was originally created by the transformation of
Sterilpharma GmbH (
Gesellschaft mit beschränkter
Haftung
), a limited liability company under German law
incorporated in 1975, into a stock corporation under German law
(
Aktiengesellschaft
). A shareholders meeting on
April 15, 1996 adopted the resolutions for this
transformation and the commercial register registered the
transformation on August 5, 1996.
On September 30, 1996, we completed a series of
transactions to consummate an Agreement and Plan of
Reorganization entered into on February 4, 1996 by
Fresenius SE (then Fresenius AG) and W.R. Grace which we refer
to as the Merger elsewhere in this report. Pursuant
to that agreement, Fresenius SE contributed Fresenius Worldwide
Dialysis, its global dialysis business, including its
controlling interest in Fresenius USA, Inc., in exchange for
105,630,000 FMC-AG Ordinary shares. Thereafter, we acquired:
|
|
|
|
|
all of the outstanding common stock of W.R. Grace &
Co., whose sole business at the time of the transaction
consisted of National Medical Care, Inc., its global dialysis
business, in exchange for 94,080,000 Ordinary shares; and
|
|
|
|
the publicly-held minority interest in Fresenius USA, Inc., in
exchange for 10,290,000 Ordinary shares.
|
Effective October 1, 1996, we contributed all our shares in
Fresenius USA, Inc., to Fresenius Medical Care Holdings, Inc.,
which conducts business under the trade name Fresenius Medical
Care North America, and which is the managing company for all of
our operations in the U.S., Canada and Mexico.
On February 10, 2006, the Company completed the
transformation of its legal form under German law as approved by
its shareholders during the Extraordinary General Meeting
(EGM) held on August 30, 2005. Upon
registration of the transformation of legal form in the
commercial register of the local court in Hof an der Saale, on
February 10, 2006, Fresenius Medical Care AGs legal
form was changed from a stock corporation
(
Aktiengesellschaft
) to a partnership limited by shares
(
Kommanditgesellschaft auf Aktien
) with the name
Fresenius Medical Care AG & Co. KGaA. The Company as a
KGaA is the same legal entity under German law, rather than a
successor to the stock corporation. Fresenius Medical Care
Management AG (Management AG), a subsidiary of
Fresenius AG (now Fresenius SE & Co. KGaA), the
majority voting shareholder of FMC-AG prior to the
11
transformation, is the general partner of FMC-AG & Co.
KGaA. Shareholders in FMC-AG & Co. KGaA participate in
all economic respects, including profits and capital, to the
same extent and (except as modified by the share conversion
described below) with the same number of ordinary and preference
shares in FMC-AG & Co. KGaA as they held in FMC-AG
prior to the transformation. Upon effectiveness of the
transformation of legal form, the share capital of FMC-AG became
the share capital of FMC-AG & Co. KGaA, and persons
who were shareholders of FMC-AG became shareholders of the
Company in its new legal form.
Prior to the effectiveness of the transformation, and as
approved by the EGM and by a separate vote of the Companys
preference shareholders, the Company offered holders of its
non-voting preference shares (including preference shares
represented by American Depositary Shares (ADSs)) the
opportunity to convert their shares into ordinary shares, which
was accepted by the holders of approximately 96% of the
outstanding preference shares. Preference shares that were not
converted remained outstanding and became preference shares of
FMC-AG & Co. KGaA in the transformation.
On March 31, 2006, the Company completed the acquisition of
RCG (the RCG Acquisition), a Delaware corporation
with principal offices in Nashville, Tennessee, for an all cash
purchase price, net of cash acquired, of approximately
$4.2 billion including the concurrent repayment of
approximately $657.8 million of indebtedness of RCG.
All share and per share amounts in this report for the years
2007 and 2006 have been restated to reflect our
three-for-one
share split completed June 15, 2007.
Capital
Expenditures
We invested, by business segment and geographical areas, the
amounts shown in the table below during the twelve month periods
ended December 31, 2010, 2009, and 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Actual
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(in millions)
|
|
|
Capital expenditures for property, plant and equipment
|
|
|
|
|
|
|
|
|
|
|
|
|
North America
|
|
$
|
288
|
|
|
$
|
299
|
|
|
$
|
385
|
|
International
|
|
|
235
|
|
|
|
275
|
|
|
|
302
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Capital Expenditures
|
|
$
|
523
|
|
|
$
|
574
|
|
|
$
|
687
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisitions and Investments
|
|
|
|
|
|
|
|
|
|
|
|
|
North America
|
|
$
|
359
|
|
|
$
|
124
|
|
|
$
|
135
|
|
International
|
|
|
406
|
|
|
|
68
|
|
|
|
82
|
|
Corporate
|
|
|
157
|
|
|
|
|
|
|
|
107
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Acquisitions and Investments
|
|
$
|
922
|
|
|
$
|
192
|
|
|
$
|
324
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For additional information regarding our capital expenditures,
see Item 4. B, Business Overview
Acquisitions and Investments and Item 5.B,
Operating and Financial Review and Prospects
Liquidity Investing.
Our
Business
Based on publicly reported sales and number of patients treated,
we are the worlds largest kidney dialysis company,
operating in both the field of dialysis products and the field
of dialysis services. Our dialysis business is vertically
integrated, providing dialysis treatment at our own dialysis
clinics and supplying these clinics with a broad range of
products. In addition, we sell dialysis products to other
dialysis service providers. At December 31, 2010, we
provided dialysis treatment to 214,648 patients in 2,757
clinics worldwide located in more than 35 countries. In the
U.S. we also perform clinical laboratory testing and
provide inpatient dialysis services and other services under
contract to hospitals. In 2010, we provided
31,670,702 million dialysis treatments, an increase of
approximately 8% compared to 2009. We also develop and
manufacture a full range of equipment, systems and disposable
products, which we sell to customers in more than 120 countries.
For the year ended December 31, 2010, we had net revenues
of $12.1 billion, a 7% increase (7% in constant currency)
over 2009 revenues. We derived 67% of our revenues in 2010 from
our North America operations and 33% from our international
operations, which include our operations in Europe (21%), Latin
America (5%) and Asia-Pacific (7%). Our ordinary shares and our
preference shares are listed on the Frankfurt Stock Exchange and
American Depositary Receipts evidencing our
12
ordinary shares and our preference shares on the New York Stock
Exchange, and on February 18, 2011, we had a market
capitalization of $19.5 billion.
We use the insight we gain when treating patients in developing
new and improved products. We believe that our size, our
activities in both dialysis care and dialysis products and our
concentration in specific geographic areas allow us to operate
more cost-effectively than many of our competitors.
We estimate that in 2010, the value of the global dialysis
market was approximately $69 billion and grew at 4%,
adjusted for foreign currency translation effects. Approximately
$57 billion represents dialysis services, including the
administration of dialysis drugs, and approximately
$12 billion represents sales of dialysis products. The
following table summarizes net revenues for our North America
segment and our International segment in our major categories of
activity, dialysis care and dialysis products for the three
years ended December 31, 2010, 2009 and 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(in millions)
|
|
|
North America
|
|
|
|
|
|
|
|
|
|
|
|
|
Dialysis Care
|
|
$
|
7,303
|
|
|
$
|
6,794
|
|
|
$
|
6,247
|
|
Dialysis Products
|
|
|
827
|
|
|
|
818
|
|
|
|
758
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,130
|
|
|
|
7,612
|
|
|
|
7,005
|
|
International
|
|
|
|
|
|
|
|
|
|
|
|
|
Dialysis Care
|
|
|
1,767
|
|
|
|
1,556
|
|
|
|
1,490
|
|
Dialysis Products
|
|
|
2,156
|
|
|
|
2,079
|
|
|
|
2,117
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,923
|
|
|
|
3,635
|
|
|
|
3,607
|
|
Renal
Industry Overview
We offer life-maintaining and life-saving dialysis services and
products in a market which is characterized by favorable
demographic development. As a global market leader in dialysis
products and dialysis services, Fresenius Medical Care considers
it important to possess accurate and current information on the
status and development of the global, regional and national
markets.
To obtain and manage this information, Fresenius Medical Care
created an internal information tool called Market &
Competitor Survey (the MCS). The MCS is used within
the Company as a tool to collect, analyze and communicate
current, accurate and essential information on the dialysis
market, developing trends, the market position of Fresenius
Medical Care and those of its competitors. Country
by country surveys are performed at the end of each
calendar year which focus on the total number of patients
treated for ESRD, the treatment modality selected, products
used, treatment location and the structure of ESRD patient care
providers. The survey has been refined over the years to
facilitate access to more detailed information and to reflect
changes in the development of therapies and products as well as
changes to the structure of our competitive environment. The
questionnaires are distributed to professionals in the field of
dialysis who are in a position to provide ESRD-relevant country
specific information themselves or who can coordinate
appropriate input from contacts with the relevant know-how in
each country. The surveys are then centrally validated and
checked for consistency by cross-referencing them with the most
recent sources of national ESRD information (e.g. registry data
or publications if available) and with the results of surveys
performed in previous years. All information received is
consolidated at a global and regional level and analyzed and
reported together with publicly available information published
by our competitors.
Except as otherwise specified below, all patient and market data
in this Report have been derived using our MCS.
End-Stage
Renal Disease
ESRD is the stage of advanced chronic kidney disease
characterized by the irreversible loss of kidney function and
requires regular dialysis treatment or kidney transplantation to
sustain life. A normally functioning human kidney removes waste
products and excess water from the blood, which prevents toxin
buildup, water overload and the eventual poisoning of the body.
Most patients suffering from ESRD must rely on dialysis, which
is the removal of toxic waste products and excess fluids from
the body by artificial means. A number of conditions
diabetes, hypertension, glomerulonephritis and inherited
diseases can cause chronic kidney disease. The
majority of all people with ESRD acquire the disease as a
complication of one or more of these primary conditions.
There are currently only two methods for treating ESRD: dialysis
and kidney transplantation. Scarcity of compatible kidneys
limits transplants. Therefore, most patients suffering from ESRD
rely on dialysis.
13
We estimate that at the end of 2010, there were approximately
2.621 million ESRD patients worldwide, of which
approximately 592,000 kidney patients were living with a
transplanted kidney. For many years the number of donated organs
worldwide has continued to be significantly lower than the
number of patients on transplant waiting lists. Consequently,
less than one quarter of the global ESRD population lives with a
donor organ and the remainder receive renal replacement therapy
in the form of dialysis. Despite ongoing efforts by many
regional initiatives to increase awareness of and willingness
for kidney donation, the distribution of patients between the
various treatment modes has remained nearly unchanged over the
past ten years. In both the U.S. and Germany, approximately
30% of all ESRD patients live with a functioning kidney
transplant and approximately 70% require dialysis.
There are two major dialysis methods commonly used today,
hemodialysis (HD) and peritoneal dialysis
(PD). These are described below under Dialysis
Treatment Options for ESRD. Of the estimated
2.029 million dialysis patients treated in 2010,
approximately 1.810 million received HD and about 219,000
received PD. Generally, an ESRD patients physician, in
consultation with the patient, chooses the patient treatment
method, which is based on the patients medical conditions
and needs. The number of dialysis patients grew by approximately
7% in 2010.
The present annual patient growth rate in North America, the
largest dialysis market, is approximately 5% per year, while in
many developing countries we see annual growth rates of 10% or
more. We believe that worldwide growth will continue at around
6% per year. At the end of 2010, there were approximately
492,000 patients in North America (including Mexico),
approximately 322,000 dialysis patients in the 27 countries of
the European Union (E.U.), approximately 251,000 patients
in Europe (excluding the E.U. countries), the Middle East and
Africa, approximately 215,000 patients in Latin America
(excluding Mexico), and approximately 750,000 patients in
Asia (including 301,000 patients in Japan).
Dialysis patient growth rates vary significantly from region to
region. A below average increase in the number of patients is
experienced in the U.S. and Japan, as well as Western and
Central Europe, where patients with terminal kidney failure have
had readily available access to treatment, usually dialysis, for
many years. In contrast, growth rates in the economically weaker
regions were above average, reaching double digit figures in
some cases. This indicates that accessibility to treatment is
still somewhat limited in these countries, but is gradually
improving.
We estimate that about 20% of worldwide patients are treated in
the U.S., around 16% in E.U. and approximately 15% in Japan. The
remaining 49% of all dialysis patients are distributed
throughout approximately 120 countries in different geographical
regions.
We believe that the continuing growth in the number of dialysis
patients is principally attributable to:
|
|
|
|
|
increased general life expectancy and the overall aging of the
general population;
|
|
|
|
shortage of donor organs for kidney transplants;
|
|
|
|
improved dialysis technology that makes life-prolonging dialysis
available to a larger patient population;
|
|
|
|
greater access to treatment in developing countries; and
|
|
|
|
better treatment and survival of patients with hypertension,
diabetes and other illnesses that lead to ESRD.
|
Dialysis
Treatment Options for ESRD
Hemodialysis.
Hemodialysis removes toxins and
excess fluids from the blood in a process in which the blood
flows outside the body through plastic tubes known as bloodlines
into a specially designed filter, called a dialyzer. The
dialyzer separates waste products and excess water from the
blood. Dialysis solution flowing through the dialyzer carries
away the waste products and excess water, and supplements the
blood with solutes which must be added due to renal failure. The
treated blood is returned to the patient. The hemodialysis
machine pumps blood, adds anti-coagulants, regulates the
purification process and controls the mixing of dialysis
solution and the rate of its flow through the system. This
machine can also monitor and record the patients vital
signs.
Hemodialysis patients generally receive treatment three times
per week, typically for three to five hours per treatment. The
majority of hemodialysis patients receive treatment at
outpatient dialysis clinics, such as ours, where hemodialysis
treatments are performed with the assistance of a nurse or
dialysis technician under the general supervision of a physician.
Patients can receive treatment at a clinic run by (1) a
public center (government or government subsidiary owned/run),
(2) a healthcare organization (non-profit organizations for
public benefit purposes), (3) a private center (owned or
run by individual doctors or a group of doctors) or (4) a
company-owned clinic, including multi-clinic providers (owned or
run by a company such as Fresenius Medical Care). There were
approximately 5,600 Medicare-certified ESRD treatment
clinics in the U.S. in 2010 with only around 1% of patients
receiving
14
care in public centers. In 2010, there were approximately 5,100
dialysis clinics in the E.U. treating dialysis patients. Outside
of the U.S., approximately 46% of dialysis patients received
care through public centers, approximately 13% through centers
owned by healthcare organizations, approximately 22% through
private centers and approximately 19% through company-owned
clinics, such as ours. In Latin America, private centers and
company-owned clinics predominated, caring for over 83% of all
dialysis patients. In Japan, nephrologists (doctors who
specialize in the treatment of renal patients) cared for around
80% of the population in their private centers.
Among company-owned clinics, the two largest providers are
Fresenius Medical Care, caring for approximately
215,000 patients and DaVita, caring for approximately
126,000 patients at the end of 2010. All other
company-owned clinics care for less than 20,000 patients
each.
Of the approximately 2.029 million patients who received
dialysis care in 2010, more than 89% were treated with
hemodialysis. Hemodialysis patients represented about 93% of all
dialysis patients in the U.S., approximately 96% of all dialysis
patients in Japan, and, 91% in the E.U. and 85% in the rest of
the world. Within the 15 largest dialysis countries (measured by
number of patients) that account for approximately 75% of the
world dialysis population, hemodialysis is the predominant
treatment method in all countries, except Mexico. Based on these
data, it is clear that hemodialysis is the dominant therapy
method worldwide.
Peritoneal Dialysis.
Peritoneal dialysis
removes toxins from the blood using the peritoneum, the membrane
lining covering the internal organs located in the abdominal
area, as a filter. Most peritoneal dialysis patients administer
their own treatments in their own homes and workplaces, either
by a treatment known as continuous ambulatory peritoneal
dialysis or CAPD, or by a treatment known as continuous cycling
peritoneal dialysis or CCPD. In both of these treatments, a
surgically implanted catheter provides access to the peritoneal
cavity. Using this catheter, the patient introduces a sterile
dialysis solution from a solution bag through a tube into the
peritoneal cavity. The peritoneum operates as the filtering
membrane and, after a specified dwell time, the solution is
drained and disposed. A typical CAPD peritoneal dialysis program
involves the introduction and disposal of dialysis solution four
times a day. With CCPD, a machine pumps or cycles
solution to and from the patients peritoneal cavity while
the patient sleeps. During the day, one and a half to two liters
of dialysis solution remain in the abdominal cavity of the
patient. The human peritoneum can be used as a dialyzer only for
a limited period of time, ideally only if the kidneys are still
functioning to some extent.
Our
Strategy and Competitive Strengths
Growth
Objectives
Goal 10 was our long term growth strategy for 2005 through 2010.
Our annual progress toward achieving those objectives, which
were met or exceeded, was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual Progress
|
|
|
2005
|
|
2006
|
|
2007
|
|
2008
|
|
2009
|
|
2010
|
|
Revenue ($ million)
|
|
$
|
6,772
|
|
|
$
|
8,499
|
|
|
$
|
9,720
|
|
|
$
|
10,612
|
|
|
$
|
11,247
|
|
|
$
|
12,053
|
|
Annual revenue growth
|
|
|
8%
|
|
|
|
25%
|
|
|
|
12%
|
|
|
|
8%
|
|
|
|
9%
|
|
|
|
7%
|
|
Share of dialysis market*
|
|
|
13%
|
|
|
|
16%
|
|
|
|
16%
|
|
|
|
16%
|
|
|
|
17%
|
|
|
|
18%
|
|
Market volume* ($ in billion)
|
|
$
|
~52.5
|
|
|
$
|
~55
|
|
|
$
|
~61.5
|
|
|
$
|
~65
|
|
|
$
|
~65
|
|
|
$
|
~69
|
|
Annual net income attributable to FMC-AG & Co. KGaA
growth percentage**
|
|
|
17%
|
|
|
|
24%
|
|
|
|
25%
|
|
|
|
14%
|
|
|
|
9%
|
|
|
|
10%
|
|
Compound Annual Growth (Basis 2003)
|
|
|
19%
|
|
|
|
21%
|
|
|
|
21%
|
|
|
|
20%
|
|
|
|
18%
|
|
|
|
17%
|
|
|
|
*
|
Company estimates
|
|
**
|
2005 excluding one-time effects, 2006 excluding one-time effects
and impact of FAS 123(R) and 2007 excluding one-time effects
|
Goal 13 is our long-term strategy for sustained growth through
2013. Goal 13 includes the following annual objectives for the
years 2011, 2012 and 2013:
|
|
|
Annual revenue growth*
|
|
6-8%
|
Annual average interest rate
|
|
6.0-6.5%
|
Net income attributable to FMC AG & Co. KGaA (growth
in %)
|
|
High single to low double digits
|
Earnings per share (growth in %)
|
|
High single to low double digits
|
Cash flow from operations**
|
|
> 10%
|
Capital expenditures and acquisitions**
|
|
> 7%
|
|
|
*
|
in constant currency
|
|
**
|
As a percent of revenue.
|
15
Growth
Paths
We have established four paths that the Company continues to
follow in order to perform successfully in a broader spectrum of
the global dialysis market and to achieve our growth and
profitability objectives:
Path 1:
Organic Growth
For this path, we will continue to offer integrated, innovative
treatment concepts such as
UltraCare
®
,
NephroCare and our recently introduced Protect, Preserve and
Prolong (P3) comprehensive PD therapy program as
well as Cardioprotective Hemodialysis, which uses our Body
Composition Monitor to measure patient water levels, a major
factor in the cardiovascular health of dialysis patients (see
Business Research and Development) and
combine these treatments, for example, with our dialysis drugs.
With these measures, we want our portfolio of services to stand
out from those of our competitors. In addition, we plan to
increase our growth in revenue by opening
100-120
new
dialysis clinics annually over the next three years and to
further increase the number of patients whose treatments are
covered by private health insurance.
We also intend to continue to innovate with dialysis products.
High-quality products such as our recently introduced 2008T and
4008S classic HD machines and the 5008 therapy system in
addition to cost-effective manufacturing are intended to
contribute significantly to the further growth of our dialysis
products sector.
Path 2:
Acquisitions
We intend to make attractive, targeted acquisitions broadening
our network of dialysis clinics. In North America we want to
expand our clinic network in particularly attractive regions.
The acquisition of Renal Care Group is an excellent example of
this type of expansion although subsequent acquisitions have had
and future acquisitions in North America will have a smaller
financial scope.
Outside North America, we intend to participate in the
privatization process of healthcare systems and seek to achieve
above-average growth in Eastern Europe and Asia; acquisitions
will support these activities. We have entered into a long-term,
10-year
exclusive distribution agreement with Japanese-based Nikkiso Co.
Ltd. for distribution of hemodialysis and peritoneal dialysis
products in Japan and we have acquired Nikkiso Medical Korea Co.
Ltd., a wholly owned subsidiary of Nikkiso Co. Ltd. In our
clinic network outside North America, we continue to focus on
improving our strategic position in selected markets. In July
2010, we completed a significant expansion of our activities in
the field of dialysis services in the Asia-Pacific region
through the acquisition of Asia Renal Care Ltd., the second
largest provider of dialysis and related services in the
Asia-Pacific region (behind Fresenius Medical Care), with more
than 80 clinics throughout Asia treating about
5,300 patients. In June 2010, we announced an agreement to
acquire KNC (Kraevoy Nefrologocheskiy Centr), a private operator
of dialysis clinics in Russias Krasnodar region treating
approximately 1,000 patients in five clinics, and in
December 2010, we acquired Gambro ABs worldwide peritoneal
dialysis (PD) business, which serves over 4,000 PD patients in
more than 25 countries, expanding our activities in the home
dialysis market, especially in Europe and Asia-Pacific. In
January 2011, we entered into a definitive agreement to acquire
International Dialysis Centers (IDC), the dialysis
service business of Euromedic International, for
485 million (approximately $650 million at
December 31, 2010). IDC currently treats over 8,200
hemodialysis patients predominantly in Central and Eastern
Europe and operates a total of 70 clinics in nine countries. The
transaction is subject to necessary regulatory approvals by the
relevant anti-trust authorities and we expect to close the
acquisition in the first half of 2011.
Path 3:
Horizontal Expansion
We plan on opening up new growth opportunities in the dialysis
market by expanding our product portfolio beyond patient care
and dialysis products. To this end, beginning in 2006 we
increased our activities in some areas of dialysis medication
and will continue to do so in the future. Initially, we focused
on drugs regulating patients mineral and blood levels,
including phosphate binders, iron and Vitamin D supplements and
calcimimetics. High phosphate levels in the blood can lead to
medium-term damage to patients bones and blood vessels. In
2006, we acquired the
PhosLo
®
phosphate binder business of Nabi Biopharmaceuticals, and in
2008 we entered into license and distribution agreements to
market and distribute intravenous iron products such as
Venofer
®
and
Ferinject
®
for dialysis treatment. In December 2010, we expanded upon those
agreements by forming a new renal pharmaceutical company, Vifor
Fresenius Medical Care Renal Pharma Ltd., with Galenica Ltd.
(subject to final anti-trust approval in certain regions),
designed to develop and distribute products to treat iron
deficiency anemia and bone mineral metabolism for pre-dialysis
and dialysis patients. We own 45% of the new company. See the
discussion of Renal Pharmaceuticals below.
16
Path 4:
Home Therapies
Around 11% of all dialysis patients perform dialysis at home,
principally PD, with the remaining 89% treated in clinics.
Still, we aim to achieve a long-term leading global position in
the relatively small field of home therapies, including
peritoneal dialysis and home hemodialysis. To achieve this goal,
we can combine our comprehensive and innovative product
portfolio with our expertise in patient care. In 2007 we
acquired Renal Solutions, Inc. which owns technology that can be
utilized to significantly reduce water volumes used in
hemodialysis, an important step in advancing home hemodialysis,
and in March 2010, a subsidiary of FMCH purchased substantially
all the assets of Xcorporeal, Inc. (Xcorporeal) and
National Quality Care, Inc. (NQCI). Xcorporeal,
under license from NQCI, has completed functional prototypes of
a portable artificial kidney for attended and home dialysis care
and has demonstrated a feasibility prototype of a wearable
artificial kidney.
We expect these strategic steps, expansion of our product
portfolio horizontally through an increase of our dialysis drug
activities (Path 3), further development of our home therapies
(Path 4) and organic growth (Path 1), to produce average
annual revenue growth of about 6% to 8% through 2013. Between
2011 and 2013, we expect annual net income and earnings per
share growth, in percent, in the high single to low double
digits.
Our
Competitive Strengths
We believe that we are well positioned to meet our strategic
objectives. Our competitive strengths include:
Our
Leading Market Position
Based on publicly reported sales and number of patients treated,
we are the worlds largest kidney dialysis company,
operating in both the field of dialysis products and the field
of dialysis services. We use the insight we gain when treating
patients in developing new and improved products. We believe
that our size, our activities in both dialysis care and dialysis
products and our concentration in specific geographic areas
allow us to operate more cost-effectively than many of our
competitors.
Our Full
Spectrum of Dialysis and Laboratory Services
We provide expanded and enhanced patient services, including
renal pharmaceutical products and in the United States,
laboratory services, to both our own clinics and those of third
parties. We have developed disease state management
methodologies, which involve the coordination of holistic
patient care for ESRD patients and which we believe are
attractive to managed care payors. We provide ESRD and chronic
kidney disease management programs to about 4,000 patients.
In the United States, we also operate a surgical center for the
management and care of vascular access for ESRD patients, which
can decrease hospitalization.
Differentiated
Patient Care Programs from those of our Competitors
We believe that our
UltraCare
®
Patient Care program offered at our North American dialysis
facilities distinguishes and differentiates our patient care
from that of our competitors.
UltraCare
®
represents our commitment to deliver excellent care to patients
through innovative programs, the latest technology, continuous
quality improvement and a focus on superior customer service.
Our
Reputation for High Standards of Patient Care and Quality
Products and our Extensive Clinic Network
We believe that our reputation for providing high standards of
patient care is a competitive advantage. With our large patient
population, we have developed proprietary patient statistical
databases which enable us to improve dialysis treatment outcomes
and further improve the quality and effectiveness of dialysis
products. Our extensive network of dialysis clinics enables
physicians to refer their patients to conveniently located
clinics.
Our
Position as an Innovator in Product and Process
Technology
We are committed to technological leadership in both
hemodialysis and peritoneal dialysis products. Our research and
development teams focus on offering patients new products and
therapies in the area of dialysis and other extracorporeal
therapies to improve their quality of life and increase their
life expectancy. We believe that our extensive expertise in
patient treatment and clinical data will further enhance our
ability to develop more effective products and treatment
methodologies. Our ability to manufacture dialysis products on a
cost-effective and competitive basis results in large part from
our process technologies. Over the past several years, we have
reduced manufacturing costs per unit through development of
proprietary manufacturing technologies that have streamlined and
automated our production processes.
17
Our
Complete Dialysis Product Lines with Recurring Disposable
Products Revenue Streams
We offer broad and competitive hemodialysis and peritoneal
dialysis product lines. These product lines enjoy broad market
acceptance and enable us to serve as our customers single
source for all of their dialysis machines, systems and
disposable products.
Our
Worldwide Manufacturing Facilities
We operate
state-of-the-art
production facilities in all major regions North
America, Europe, Latin America and Asia Pacific to
meet the demand for our dialysis products, including dialysis
machines, dialyzers, and other equipment and disposables. We
have invested significantly in developing proprietary processes,
technologies and manufacturing equipment which we believe
provides a competitive advantage in manufacturing our products.
Our decentralized manufacturing structure adds to our economies
of scale by reducing transportation costs.
Dialysis
Care
Dialysis
Services
We provide dialysis treatment and related laboratory and
diagnostic services through our network of 2,757 outpatient
dialysis clinics, 1,823 of which are in North America (including
Mexico) and 934 of which are in more than 35 countries outside
of North America. Our operations within North America generated
81% of our 2010 dialysis care revenue and our operations outside
North America generated 19%. Our dialysis clinics are generally
concentrated in areas of high population density. In 2010, we
acquired a total of 168 existing clinics, opened 90 new clinics
and sold or consolidated 54 clinics. The number of patients we
treat at our clinics worldwide increased by about 10%, from
195,651 at December 31, 2009 to 214,648 at
December 31, 2010. For 2010, dialysis services accounted
for 75% of our total revenue.
With our large patient population, we have developed proprietary
patient statistical databases which enable us to improve
dialysis treatment outcomes, and further improve the quality and
effectiveness of dialysis products. We believe that local
physicians, hospitals and managed care plans refer their ESRD
patients to our clinics for treatment due to:
|
|
|
|
|
our reputation for quality patient care and treatment;
|
|
|
|
our extensive network of dialysis clinics, which enables
physicians to refer their patients to conveniently located
clinics; and
|
|
|
|
our reputation for technologically advanced products for
dialysis treatment.
|
At our clinics, we provide hemodialysis treatments at individual
stations through the use of dialysis machines and disposable
products. A nurse attaches the necessary tubing to the patient
and the dialysis machine and monitors the dialysis equipment and
the patients vital signs. The capacity of a clinic is a
function of the number of stations and such factors as type of
treatment, patient requirements, length of time per treatment,
and local operating practices and ordinances regulating hours of
operation.
Each of our dialysis clinics is under the general supervision of
a physician medical director. (See Patients, Physician and
Other Relationships.) Each dialysis clinic also has an
administrator or clinical manager who supervises the
day-to-day
operations of the facility and the staff. The staff typically
consists of registered nurses and licensed practical nurses. Our
North America clinics also employ patient care technicians, a
social worker, a registered dietician, a unit clerk and
biomedical technicians, while in some countries within our
International segment, the staff also includes technicians,
social workers and dieticians.
As part of the dialysis therapy, we provide a variety of
services to ESRD patients at our dialysis clinics in the U.S..
These services include administering EPO, a synthetic engineered
hormone that stimulates the production of red blood cells. EPO
is used to treat anemia, a medical complication that ESRD
patients frequently experience. We administer EPO to most of our
patients in the U.S. Revenues from EPO accounted for
approximately 19% of our total dialysis care revenue in our
North America segment for the year ended December 31, 2010.
We receive a substantial majority of this revenue as
reimbursements through the Medicare and Medicaid programs. Amgen
Inc. is the sole manufacturer of EPO in U.S. and any
interruption of supply could materially adversely affect our
business, financial condition and results of operations. Our
current contract with Amgen covers the period from October 2006
to December 2011. As of January 1, 2011, Medicare no longer
separately pays for EPO, which is now included in the PPS
bundled rate. See Regulatory and Legal
Matters Reimbursement U.S.
Erythropoietin stimulating agents and ESRD
PPS.
18
Our clinics also offer services for home dialysis patients, the
majority of whom receive peritoneal dialysis treatment. For
those patients, we provide materials, training and patient
support services, including clinical monitoring,
follow-up
assistance and arranging for delivery of the supplies to the
patients residence. (See Regulatory and
Legal Matters Reimbursement U.S.
for a discussion of billing for these products and services.)
We also provide dialysis services under contract to hospitals in
the U.S. on an as needed basis for hospitalized
ESRD patients and for patients suffering from acute kidney
failure. Acute kidney failure can result from trauma or similar
causes, and requires dialysis until the patients kidneys
recover their normal function. We service these patients either
at their bedside, using portable dialysis equipment, or at the
hospitals dialysis site. Contracts with hospitals provide
for payment at negotiated rates that are generally higher than
the Medicare reimbursement rates for chronic in-clinic
outpatient treatments.
We employ a centralized approach with respect to certain
administrative functions common to our operations. For example,
each dialysis clinic uses our proprietary manuals containing our
standardized operating and billing procedures. We believe that
centralizing and standardizing these functions enhance our
ability to perform services on a cost-effective basis.
The manner in which each clinic conducts its business depends,
in large part, upon applicable laws, rules and regulations of
the jurisdiction in which the clinic is located, as well as our
clinical policies. However, a patients attending
physician, who may be the clinics medical director or an
unaffiliated physician with staff privileges at the clinic, has
medical discretion to prescribe the particular treatment
modality and medications for that patient. Similarly, the
attending physician has discretion in prescribing particular
medical products, although the clinic typically purchases
equipment, regardless of brand, in consultation with its medical
director.
In the more than 35 countries outside North America in which we
currently operate or manage dialysis clinics we face legal,
regulatory and economic environments varying significantly from
country to country. These individual environments can affect all
aspects of providing dialysis services including our legal
status, the extent to which we can provide dialysis services,
the way we have to organize these services and the system under
which we are reimbursed. (See Regulatory and
Legal Matters Reimbursement
International (Including Germany and Other
Non-U.S.)
for further discussion of reimbursement.) Our approach to
managing this complexity utilizes local management to ensure the
strict adherence to the individual country rules and regulations
and international functional departments supporting country
management with processes and guidelines enabling the delivery
of the highest possible quality level of dialysis treatment. We
believe that with this bi-dimensional organization we will be
able to provide superior care to dialysis patients under the
varying local frameworks leading to improved patient well-being
and to lower social cost.
Fresenius
UltraCare
®
Program
The
UltraCare
®
program of our North America dialysis services group represents
our commitment to deliver excellent care to patients through
innovative programs,
state-of-the
art technology, continuous quality improvement and a focus on
superior patient service. It combines our latest product
technology with our highly trained and skilled staff to offer
our patients what we believe is a superior level of care. The
basis for this form of treatment is the
Optiflux
®
polysulfone single-use dialyzer.
Optiflux
®
single use dialyzers are combined with our
2008
tm
Hemodialysis Delivery System series, which has advanced online
patient monitoring and Ultra Pure Dialysate, all of which we
feel improve mortality rates and increase the quality of patient
care.
UltraCare
®
program also utilizes several systems to allow the tailoring of
treatment to meet individual patient needs. Among the other
capabilities of this system, staff will be alerted if toxin
clearance is less than the target prescribed for the patient,
and treatment can be adjusted accordingly. The
Ultracare
®
program also includes an annual training program for staff
recertification. In 2008 we launched UltraCare
at Home
tm
which emphasizes patient-centered care: offering the full range
of treatment modalities coupled with superior customer service
for patients desiring care in the home setting.
Laboratory
Services
We provide laboratory testing and marketing services in the
U.S. through Spectra Laboratories (Spectra).
Spectra provides blood, urine and other bodily fluid testing
services to determine the appropriate individual dialysis
therapy for a patient and to assist physicians in determining
whether a dialysis patients therapy regimen, diet and
medicines remain optimal. Spectra, the leading renal clinical
laboratory provider in North America, provides testing for
dialysis related treatments in its two operating laboratories
located in New Jersey and Northern California. During the year
ended December 31, 2010, Spectra performed more than
60 million tests for approximately 171,000 dialysis
patients in over 2,500 clinics across the U.S., including
clinics that we own or operate.
19
Acquisitions
and Investments
A significant factor in the growth in our revenue and operating
earnings in prior years has been our ability to acquire health
care businesses, particularly dialysis clinics, on reasonable
terms. Worldwide, physicians own many dialysis clinics that are
potential acquisition candidates for us. In the U.S., doctors
might decide to sell their clinics to obtain relief from
day-to-day
administrative responsibilities and changing governmental
regulations, to focus on patient care and to realize a return on
their investment. Outside of the U.S., doctors might determine
to sell to us
and/or
enter
into joint ventures or other relationships with us to achieve
the same goals and to gain a partner with extensive expertise in
dialysis products and services. Privatization of health care in
Eastern Europe and Asia could present additional acquisition
opportunities.
During 2010 and 2009, we had total acquisitions and investments
of $922 million and $192 million, respectively. Of the
total 2010 acquisitions and investments, the cash consideration
amounted to approximately $764 million, primarily for
acquisitions of dialysis clinics, the formation of a new renal
pharmaceutical company with Galenica, Ltd., pharmaceutical
licenses, the acquisition of Gambros peritoneal dialysis
business outside the United States and a 100 million
short term investment with banks. In 2009, the cash
consideration amounted to $188 million, primarily for
acquisitions of dialysis clinics and pharmaceutical licenses. We
continued to enhance our presence outside the U.S. in 2010.
We significantly expanded our dialysis services and home
dialysis businesses in Asia Pacific and in Europe in 2010
through acquisitions of dialysis service providers in those
regions and entered into a definitive agreement for a
significant acquisition in Eastern Europe in January 2011. We
also acquired individual or small groups of dialysis clinics in
selected markets, expanded existing clinics and opened new
clinics. For further discussion of our 2010 acquisitions and
investments, see -Our Strategy and Competitive
Strengths-Growth Paths-Path
2-Acquisitions
and Path 3-Horizontal Expansion and Renal
Pharmaceuticals below.
Quality
Assurance and Quality Management in Dialysis Care
In order to evaluate the quality of our dialysis treatments in
our worldwide operations, we make use of quality parameters that
are recognized by the dialysis industry, such as hemoglobin
values, phosphate levels, Kt/V values (the ratio of treatment
length to toxic molecule filtration), albumin levels for
assessment of nutritional condition and the rate of patients
dialyzed with a catheter. The number of days a patient spends
hospitalized is also an important indicator of treatment
quality. We also monitor the Standardized Mortality Rate
(SMR).
In our European region (includes our EU, European non-EU, Middle
East and African operations), our quality management activities
are primarily focused on comprehensive development and
implementation of an Integrated Management System
(IMS) for quality management. Our goals in this area
include not only meeting quality requirements for our dialysis
clinics and environmental concerns, but also managing the
quality of our dialysis care. This approach results in an IMS
structure that closely reflects existing corporate processes. We
are also able to use the IMS to fulfill many legal and normative
regulations covering service lines. In addition, the quality
management system standard offers a highly flexible structure
that allows us to adapt to future regulations. The most
important of these include, among others, ISO 9001:2008
requirements for quality management systems in combination with
the ISO 14001:2004 standard for environmental management
systems. Our IMS fulfils the ISO-Norm 9001:2008 requirements for
quality management systems and links it with the ISO-Norm
14001:2004 for environmental management systems. At the same
time, the IMS conforms to the medical devices requirements of
ISO-Norm 13485:2003.
Our dialysis clinics processes and documentation are
continuously inspected by internal auditors and external
parties. The underlying quality management system is certified
and found to be in compliance with relevant regulations,
requirements and company policies. We introduced our quality
management system in 45 dialysis clinics in 2010. Currently, 73%
of our European region clinics in 18 countries meet quality
management standard ISO 9001:2008.
Additionally, in 2010 in our European region, the NephroCare
Excellence Program, which aims to optimize the benefits of our
dialysis care for all stakeholders, was developed and
implemented. NephroCare seeks to improve knowledge, performance
and satisfaction for our patients, our employees, our
shareholders, and the community through the employment of highly
skilled and motivated staff, innovative and efficient programs,
the use of cutting edge technology, and process of continuing
improvement through research and optimisation.
At each of our North America dialysis clinics, a quality
assurance committee is responsible for reviewing quality of care
data, setting goals for quality enhancement and monitoring the
progress of quality assurance initiatives. We believe that we
enjoy a reputation of providing high quality care to dialysis
patients. In 2010, the Company continued to develop and
implement programs to assist in achieving our quality goals. Our
Access
20
Intervention Management Program detects and corrects
arteriovenous access failure in hemodialysis treatment and the
percentage of patients who use catheters, which is the major
cause of hospitalization and morbidity.
Our principal focus of our research and development activities
is the development of new products, technologies and treatment
concepts to optimize treatment quality for dialysis patients.
See Item 5.C, Operating and Financial Review and
Prospects Research and Development.
Sources
of U.S. Dialysis Care Net Revenue
The following table provides information for the years ended
December 31, 2010, 2009 and 2008 regarding the percentage
of our U.S. dialysis treatment services net revenues from
(a) the Medicare ESRD program, (b) private/alternative
payors, such as commercial insurance and private funds,
(c) Medicaid and other government sources and
(d) hospitals.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Medicare ESRD program
|
|
|
49.4
|
%
|
|
|
50.0
|
%
|
|
|
53.2
|
%
|
Private / alternative payors
|
|
|
42.3
|
%
|
|
|
41.1
|
%
|
|
|
37.4
|
%
|
Medicaid and other government sources
|
|
|
3.4
|
%
|
|
|
3.6
|
%
|
|
|
3.8
|
%
|
Hospitals
|
|
|
4.9
|
%
|
|
|
5.3
|
%
|
|
|
5.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
100.0
|
%
|
|
|
100.0
|
%
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Under the Medicare ESRD program, Medicare reimburses dialysis
providers for the treatment of certain individuals who are
diagnosed as having ESRD, regardless of age or financial
circumstances. See Regulatory and Legal
Matters Reimbursement.
Patient,
Physician and Other Relationships
We believe that our success in establishing and maintaining
dialysis clinics, both in the U.S. and in other countries,
depends significantly on our ability to obtain the acceptance of
and referrals from local physicians, hospitals and managed care
plans. In nearly all our dialysis clinics, local doctors, who
specialize in the treatment of renal patients (nephrologists)
act as practitioners. A dialysis patient generally seeks
treatment at a conveniently located clinic at which the
patients nephrologist has staff privileges. Our ability to
provide high-quality dialysis care and to fulfill the
requirements of patients and doctors depends significantly on
our ability to enlist nephrologists for our dialysis clinics and
receive referrals from nephrologists, hospitals and general
practitioners.
Medicare ESRD program reimbursement regulations require that a
medical director generally supervise treatment at a dialysis
clinic. Generally, the medical director must be board certified
or board eligible in internal medicine or pediatrics, have
completed a board-approved training program in nephrology and
have at least twelve months of experience providing care to
patients undergoing dialysis. Our medical directors also
generally maintain their own private practices. We have entered
into written agreements with physicians who serve as medical
directors in our clinics. In North America these agreements
generally have an initial term between five to ten years. The
compensation of our medical directors and other contracted
physicians is negotiated individually and depends in general on
local factors such as competition, the professional
qualification of the physician, their experience and their tasks
as well as the size and the offered services of the clinic. The
total annual compensation of the medical directors and the other
contracted physicians is stipulated at least one year in advance
and the medical directors agree to seek to continue to improve
efficiency and quality. We believe that the compensation of our
medical directors is in line with the market.
Almost all contracts we enter into with our medical directors in
the United States as well as the typical contracts which we
obtain when acquiring existing clinics, contain non-competition
clauses concerning certain activities in defined areas for a
defined period to time. These clauses do not enjoin the
physicians from performing patient services directly at other
locations/areas. As prescribed by law we do not require
physicians to send patients to us or to specific clinics or to
purchase or use specific medical products or ancillary services.
Competition
Dialysis Services.
Our largest competitors in
the North America segment are DaVita, Inc., Dialysis Clinic
Inc., Renal Advantage Inc. and Diversified Specialty Institutes,
Inc. and, in our International segment, our largest competitors
are Kuratorium für Heimdialyse and Diaverum (formerly the
non-U.S. dialysis
services business of Gambro AB) in Europe, Showa-Kai and
Zenjin-Kai in Asia Pacific, and Baxter International Inc. and
Diaverum in Latin America. Ownership of dialysis clinics in the
U.S. consists of a large number of company-owned clinic
21
providers, each owning ten or fewer clinics and a small number
of larger company-owned, multi-clinic providers who own the
majority of U.S. clinics, of which we are the largest. Over
the last decade the dialysis industry has been characterized by
ongoing consolidations. Internationally, the dialysis services
market is much more fragmented, with a higher degree of public
ownership in many countries.
Many of our dialysis clinics are in urban areas, where there
frequently are many competing clinics in proximity to our
clinics. We experience direct competition from time to time from
former medical directors, former employees or referring
physicians who establish their own clinics. Furthermore, other
health care providers or product manufacturers, some of which
have significant operations, may decide to enter the dialysis
business in the future.
Because in the U.S., government programs are the primary source
of reimbursement for services to the majority of patients,
competition for patients in the U.S. is based primarily on
quality and accessibility of service and the ability to obtain
admissions from physicians with privileges at the facilities.
However, the extension of periods during which commercial
insurers are primarily responsible for reimbursement and the
growth of managed care have placed greater emphasis on service
costs for patients insured with private insurance.
In most countries other than the U.S., we compete primarily
against individual freestanding clinics and hospital-based
clinics. In many of these countries, especially the developed
countries, governments directly or indirectly regulate prices
and the opening of new clinics. Providers compete in all
countries primarily on the basis of quality and availability of
service and the development and maintenance of relationships
with referring physicians.
Laboratory Services.
Spectra competes in the
U.S. with large nationwide laboratories, dedicated dialysis
laboratories and numerous local and regional laboratories,
including hospital laboratories. In the laboratory services
market, companies compete on the basis of performance, including
quality of laboratory testing, timeliness of reporting test
results and cost-effectiveness. We believe that our services are
competitive in these areas.
Dialysis
Products
Based on internal estimates prepared using our MCS, publicly
available market data and our data of significant competitors,
we are the worlds largest manufacturer and distributor of
equipment and related products for hemodialysis and the second
largest manufacturer and distributer of peritoneal dialysis
products, measured by publicly reported revenues. We sell our
dialysis products directly and through distributors in over 120
countries. Most of our customers are dialysis clinics. For the
year 2010, dialysis products accounted for 25% of our total
revenue.
We produce a wide range of machines and disposables for HD, PD
and acute dialysis:
|
|
|
|
|
HD machines and PD cyclers
|
|
|
|
Dialyzers, our largest product group
|
|
|
|
PD solutions in flexible bags
|
|
|
|
HD concentrates, solutions and granulates
|
|
|
|
Bloodlines
|
|
|
|
Systems for water treatment
|
Our product business also includes adsorbers, which are
specialized filters used in other extracorporeal therapies. In
addition we sell products from other producers, including
specific instruments for vascular access as well as other
supplies, such as bandages, clamps and injections. We also
include our
PhosLo
®
and
Venofer
®
iron products and sales of other renal pharmaceutical products
as part of our dialysis product revenues.
The markets in which we sell our dialysis products are highly
competitive. The three largest manufacturers of dialysis
products accounted for approximately 67% of the worldwide market
in 2010. As the market leader in this segment, we had
approximately a 33% market share. We estimate that in 2010, we
supplied approximately 45% of global dialyzer production and
approximately 55% of all HD machines sold worldwide. In 2010,
our market share for PD products sold worldwide was 17%. Our
acquisition of Gambros PD business closed in December
2010; as a result, our market share for PD products increased to
19%.
22
Overview
The following table shows the breakdown of our dialysis product
revenues into sales of hemodialysis products, peritoneal
dialysis products and other dialysis products.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
Total
|
|
|
|
|
|
Total
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
Product
|
|
|
% of
|
|
|
Product
|
|
|
% of
|
|
|
Product
|
|
|
% of
|
|
|
|
Revenues
|
|
|
Total
|
|
|
Revenues
|
|
|
Total
|
|
|
Revenues
|
|
|
Total
|
|
|
|
(in millions)
|
|
|
Hemodialysis Products
|
|
$
|
2,348
|
|
|
|
79
|
|
|
$
|
2,263
|
|
|
|
78
|
|
|
$
|
2,292
|
|
|
|
80
|
|
Peritoneal Dialysis Products
|
|
|
329
|
|
|
|
11
|
|
|
|
320
|
|
|
|
11
|
|
|
|
346
|
|
|
|
12
|
|
Other
|
|
|
306
|
|
|
|
10
|
|
|
|
314
|
|
|
|
11
|
|
|
|
237
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
2,983
|
|
|
|
100
|
|
|
$
|
2,897
|
|
|
|
100
|
|
|
$
|
2,875
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hemodialysis
Products
We offer a comprehensive hemodialysis product line, including HD
machines, modular components for dialysis machines, polysulfone
dialyzers, bloodlines, HD solutions and concentrates, needles,
connectors, machines for water treatment, data administration
systems, dialysis chairs,
PhosLo
®
and
Venofer
®
iron products, and other renal drug products. We continually
strive to expand and improve the capabilities of our
hemodialysis systems to offer an advanced treatment mode at
reasonable cost.
Dialysis Machines.
We sell our 4008 and 5008
Series HD dialysis machines in our International segment.
In North America, we sell our
2008
®
Series machines, modeled on the 4008 Series. The 4008/2008
series is the most widely sold machine for hemodialysis
treatment. In our International segment in 2009, we introduced
our 4008S classic machine which is a basic dialysis machine for
performing conventional HD treatments with limited therapy
options for budget-focused customers. Following the successful
launch of the 5008 series in 2005, we concentrated on the
continued improvement of the reliable operation of our model
5008 dialysis machine in clinical use and under increasingly
varied conditions in international applications during 2010.
These efforts for improvement have taken into account
considerable feedback from our own dialysis clinics as well as
from other customers while focusing on therapeutic, technical,
and economic aspects of the machine. The 5008 series is intended
to gradually replace most of the 4008 series in the coming
years. The successor 5008 contains a number of newly developed
technical components for revised and improved dialysis processes
and is offering the most efficient therapy modality,
Online-Hemodiafilitration, as a standard feature. Significant
advances in the field of electronics enable highly complex
treatment procedures to be controlled and monitored safely and
clearly through dedicated interfaces. In 2010 in North America,
we introduced our 2008T hemodialysis machine featuring Fresenius
Clinical Data Exchange software.
Our dialysis machines offer the following features and
advantages:
|
|
|
|
|
Volumetric dialysate balancing and ultrafiltration control
system. This system, which we introduced in 1977, provides for
safe and more efficient use of highly permeable dialyzers,
permitting efficient dialysis with controlled rates of fluid
removal;
|
|
|
|
Proven hydraulic systems, providing reliable operation and
servicing flexibility;
|
|
|
|
Compatibility with all manufacturers dialyzers and a
variety of bloodlines and dialysis solutions, permitting maximum
flexibility in both treatment and disposable products usage;
|
|
|
|
Modular design, which permits us to offer dialysis clinics a
broad range of options to meet specific patient or regional
treatment requirements and specialized modules that provide
monitoring and response capability for selected biophysical
patient parameters, such as body temperature and relative blood
volume. Modular design also allows upgrading through module
substitution without replacing the entire machine;
|
|
|
|
Sophisticated microprocessor controls, touchscreen interfaces,
displays
and/or
readout panels that are adaptable to local language requirements;
|
|
|
|
Battery backup, which continues operation of the blood circuit
and all protective systems up to 20 minutes following a power
failure;
|
23
|
|
|
|
|
Online clearance, measurement of dialyzer clearance for quality
assurance with On-Line Clearance Monitoring, providing immediate
effective clearance information, real time treatment outcome
monitoring, and therapy adjustment during dialysis without
requiring invasive procedures or blood samples;
|
|
|
|
In the series 5008 and 4008H, the most efficient therapy
mode Online-Hemodiafilitration as standard;
|
|
|
|
Online data collection capabilities and computer interfacing
with our TDMS
and/or
FDS08
systems. Our systems enable us to:
|
|
|
|
|
|
monitor and assess prescribed therapy;
|
|
|
|
connect a large number of hemodialysis machines and peripheral
devices, such as patient scales, blood chemistry analyzers and
blood pressure monitors, to a computer network;
|
|
|
|
enter nursing records automatically at bedside;
|
|
|
|
adapt to new data processing devices and trends;
|
|
|
|
perform home hemodialysis with remote monitoring by a staff
caregiver; and
|
|
|
|
record and analyze trends in medical outcome factors in
hemodialysis patients.
|
Dialyzers.
We manufacture our F-Series and FX
premium series of dialyzers using hollow fiber Fresenius
Polysulfone
®
and Helixone membranes from synthetic materials, including our
Optiflux
®
polysulfone single-use dialyzer. We estimate that we are the
leading worldwide producer of polysulfone dialyzers. We believe
that polysulfone offers the following superior performance
characteristics compared to other materials used in dialyzers:
|
|
|
|
|
higher biological compatibility, resulting in reduced incidence
of adverse reactions to the fibers;
|
|
|
|
greater capacity to clear uremic toxins from patient blood
during dialysis, permitting more thorough, more rapid dialysis,
resulting in shorter treatment time; and
|
|
|
|
a complete range of permeability or membrane pore size, which
permits dialysis at prescribed rates high flux and
low flux, as well as ultra flux for acute dialysis and allows
tailoring of dialysis therapy to individual patients.
|
Other
Hemodialysis Products
We manufacture and distribute arterial, venous, single needle
and pediatric bloodlines. We produce both liquid and dry
dialysate concentrates. Liquid dialysate concentrate is mixed
with purified water by the hemodialysis machine to produce
dialysis solution, which removes the toxins and excess water
from the patients blood during dialysis. Dry concentrate,
developed more recently, is less labor-intensive to use,
requires less storage space and may be less prone to bacterial
growth than liquid solutions. We also produce dialysis solutions
in bags, including solutions for priming and rinsing
hemodialysis bloodlines, as well as connection systems for
central concentrate supplies and devices for mixing dialysis
solutions and supplying them to hemodialysis machines. Other
products include solutions for disinfecting and decalcifying
hemodialysis machines, fistula needles, hemodialysis catheters,
and products for acute renal treatment.
Peritoneal
Dialysis Products
We offer a full line of peritoneal dialysis systems and
solutions which include both continuous ambulatory peritoneal
dialysis (CAPD) and continuous cycling peritoneal
dialysis (CCPD) also called automated peritoneal dialysis
(APD). In 2008, we introduced our Body Composition
Monitor for home dialysis, which determines a patients
body composition (water, body mass and fat) which assesses a
patients hydration state to assist in determining the
patients therapy. See Item 5.C, Operating and
Financial Review and Prospects Research and
Development.
CAPD Therapy:
We manufacture both systems and
solutions for CAPD therapy. Our product range offers the
following advantages for patients including:
|
|
|
|
|
Fewer possibilities for touch
contamination.
Our unique PIN and DISC technology
was designed to reduce the number of steps in the fluid exchange
process and by doing so has lessened the risk of infection,
particularly in the disconnection step in which the patient
connector is closed automatically without the need for manual
intervention.
|
24
|
|
|
|
|
Optimal biocompatibility.
Our PD balance and
bicaVera
®
solutions are pH neutral and have very low glucose degradation
products providing greater protection for the peritoneal
membrane and allowing for the protection of the residual renal
function of the PD patients.
|
|
|
|
Environmentally friendly material:
Our
staysafe
®
system is made of
Biofine
®
,
a material, developed by Fresenius, which upon combustion is
reduced to carbon dioxide and water and does not contain any
plasticizers.
|
APD Therapy:
We have been at the forefront of
the development of automated peritoneal dialysis machines since
1980. APD therapy differs from that of CAPD in that fluid is
infused into the patients peritoneal cavity while the
patient sleeps. The effectiveness of the therapy is dependant on
the dwell time, the composition of the solution used, the volume
of solution and the time of the treatment, usually 8
10 hours. APD offers a number of benefits to patients:
|
|
|
|
|
Improved quality of life.
The patient is
treated at night and can lead a more normal life during the day
without fluid exchange every few hours.
|
|
|
|
Improved adequacy of dialysis.
By adjusting
the parameters of treatment it is possible to provide more
dialysis to the patient compared to conventional CAPD therapy.
This therapy offers important options to physicians such as
improving the delivered dose of dialysis for certain patients.
|
Our automated peritoneal dialysis equipment incorporates
microprocessor technology. This offers physicians the
opportunity to program specific prescriptions for individual
patients. Our APD equipment product line includes:
|
|
|
|
|
sleepsafe:
The sleepsafe machine
has been used since 1999. It has automated connection technology
thus further reducing the risk on touch contamination. Another
key safety feature is the barcode recognition system for the
types of solution bags used. This improves compliance and
ensures that the prescribed dosage is administered to the
patient. There is also a pediatric option for the treatment of
infants. The sleepsafe machine allows for innovative and
simple ways of individualizing APD prescriptions to achieve
better treatment results. One of these is Adapted APD therapy in
which, by using the same treatment volume and total treatment
time but changing the profile of the cycles, better clearance
and ultrafiltration are achieved.
|
|
|
|
North American cycler portfolio:
This
includes: (a) the new
Liberty
®
cycler introduced in 2008 incorporating many new operational and
safety features with an innovative piston driven pumping
cassette design, (b) the
Freedom
®
and
90/2
®
cyclers for pediatric and acute markets, (c) the
Freedom
®
Cycler PD+ with IQ
card
tm
and (d) the Newton
IQ
®
Cycler. The credit card-sized
IQcard
tm
can provide actual treatment details and results for compliance
monitoring to the physician and, when used with the Newton
IQ
®
Cycler, can upload the patients prescription into the
machine. The Newton
IQ
®
Cycler also pumps waste dialysate directly into a receptacle.
|
|
|
|
Patient Management Software:
We have developed
specific patient management software tools to support both CAPD
and APD therapies in the different regions of the world. These
include: PatientOnLine,
Pack-PD
®
and
Finesse
®
.
These tools can be used by physicians and nurses to design and
monitor treatment protocols thus ensuring that therapy is
optimized and that patient care is maximized.
|
In December 2010, we acquired the global PD business of Gambro
AB, which serves over 4,000 patients in more than 25
countries (although acquisition of the Serbian business is
subject to final approval by antitrust authorities). This
acquisition expands our activities in the area of home dialysis,
particularly in the European and Asia-Pacific regions.
Renal
Pharmaceuticals
We acquired the rights to
PhosLo
®
from Nabi Pharmaceuticals in November 2006. During 2007, we
applied for approval of
PhosLo
®
in selected European countries and of OsvaRen, another phosphate
binder that supports bone health, in most EU member states. In
October 2008, a competitors generic phosphate binder that
competes with
PhosLo
®
was introduced in the U.S. market. See Item 5,
Operating and Financial Review and Prospects
Results of Operations Year Ended December 31,
2009 Compared to Year Ended December 31, 2008. In
October 2009, we launched a competing authorized generic version
of the
PhosLo
®
existing gelcap formulation in the U.S. In July 2009, a new
drug application for
Phoslyra
tm
,
the liquid formulation of
PhosLo
®
,
was submitted to the FDA.
In 2008, we entered into two separate and independent license
and distribution agreements, one for the U.S. (with
Galenica Ltd. and Luitpold Pharmaceuticals Inc.) and one for
certain countries in Europe and the Middle
25
East (with Galenica AG and Vifor (International) AG), to market
and distribute intravenous iron products, such as
Venofer
®
(iron sucrose) and
Ferinject
®
(ferric carboxymaltose). Both drugs are used to treat iron
deficiency anemia experienced by dialysis patients.
Venofer
®
is the leading intravenous iron product worldwide. The agreement
concerns all commercialization activities for these intravenous
iron products in the field of dialysis and became effective on
January 1, 2009. In North America, a separate license
agreement effective November 1, 2008 provides our
subsidiary FUSA Manufacturing Inc. (FMI) with
exclusive rights to manufacture and distribute
Venofer
®
to freestanding (non-hospital based) U.S. dialysis
facilities and, in addition, grants FMI similar rights for
certain new formulations of the drug. The U.S. license
agreement has a term of ten years and includes FMI extension
options. The international agreement has a term of 20 years.
In December 2010, we announced the extension of our agreements
with Galenica, Ltd. (Galenica) by forming a new
renal pharmaceutical company, Vifor Fresenius Medical Care Renal
Pharma Ltd., to develop and distribute products to treat iron
deficiency anemia and bone mineral metabolism for pre-dialysis
and dialysis patients. Galenica will contribute licenses (or the
commercial benefit in the U.S.) to the new company its
Venofer
®
and
Ferinject
®
products for use in the dialysis and pre-dialysis market
(Chronic Kidney Disease (CKD) stages III to V).
Commercialization of both of these products outside the field of
CKD stages III to V will remain fully the responsibility of
Galenica and its existing key partners. Galenica will also
contribute to the new company exclusive worldwide rights for
PA21, a novel iron-based phosphate binder currently in
preparation for phase III clinical studies, but will
maintain a recently announced agreement to develop and market
this product in Japan through another partner. Fresenius Medical
Care owns 45% of the new company which is headquartered in
Switzerland.
We estimate that the worldwide market for dialysis drugs used to
treat CKD (currently vitamin D, iron, potassium binders and
phosphate binders) in 2010 was more than $2.7 billion. As
part of our horizontal expansion growth path, we intend to
continue to integrate the use of dialysis drugs with our
existing product technology, dialysis treatment and laboratory
services.
Customers,
Marketing, Distribution and Service
We sell most of our products to clinics, hospitals and
specialized treatment clinics. With our comprehensive product
line and years of experience in dialysis, we believe that we
have been able to establish and maintain very close
relationships with our clinic customer base on a global basis.
Close interaction between our Sales & Marketing and
Research and Development (R&D) personnel
enables us to integrate concepts and ideas that originate in the
field into product development. We maintain a direct sales force
of trained salespersons engaged in the sale of both hemodialysis
and peritoneal dialysis products. Sales & Marketing
engages in direct promotional efforts, including visits to
physicians, clinical specialists, hospitals, clinics and
dialysis clinics, and represents us at industry trade shows. We
also sponsor medical conferences and scientific symposia as a
means for disseminating scientific or technical information. Our
clinical nurses provide clinical support, training and
assistance to customers and assist our sales force. We also use
outside distributors to provide sales coverage in countries that
our internal sales force does not service.
In our basic distribution system, we ship products from
factories to central warehouses which are frequently located
near the factories. From these central warehouses, we distribute
our dialysis products to regional warehouses. We distribute
peritoneal dialysis products to the patient at home, and ship
hemodialysis products directly to dialysis clinics and other
customers. Local sales forces, independent distributors, dealers
and sales agents sell all our products. In the U.S., products
are sold at the customers request.
In 2009, we consolidated our German warehouses in Gernsheim and
Darmstadt into a new central distribution center in Biebesheim
and all warehouse activities and business have been transferred,
resulting in one distribution center servicing customers in
approximately 140 countries worldwide. Through this
consolidation, we have been able to increase service level,
quality and responsiveness to customer demands, as well as
decrease stock levels and lower costs.
We offer customer service, training and education in the
applicable local language, and technical support such as field
service, repair shops, maintenance, and warranty regulation for
each country in which we sell dialysis products. We provide
training sessions on our equipment at our facilities in
Schweinfurt, Germany, Waukegan, Illinois, Coppell, Texas and
Manila, Philippines and we also maintain regional service
centers that are responsible for
day-to-day
international service support.
26
Manufacturing
Operations
We operate
state-of-the-art
production facilities worldwide to meet the demand for machines,
cyclers, dialyzers, solutions, concentrates, mixes, bloodlines,
and disposable tubing assemblies and equipment for water
treatment in dialysis clinics. We have invested significantly in
developing proprietary processes, technologies and manufacturing
equipment which we believe provide a competitive advantage in
manufacturing our products. Our strategically located production
and distribution centers help to reduce transport costs. We are
using our facilities in St. Wendel, Germany and Ogden, Utah as
centers of competence for development and manufacturing. For
example, in St. Wendel we developed in-house an automatic
bundling machine for processing polysulfone fibers. The machine
automatically carries out all steps required to convert hollow
fibers for dialyzer production and to create bundles with a
fixed number of fibers the core of the dialyzer. We
integrated the first automatic bundling machine into production
in 2008 and as of the end of 2010, we had four spinning lines
equipped with bundling machines.
We produce and assemble hemodialysis machines and CCPD cyclers
in our Schweinfurt, Germany and our Walnut Creek, California
facilities. We also maintain facilities at our service and local
distribution centers in Argentina, Egypt, France, Italy, The
Netherlands, China, Brazil and Russia for testing and
calibrating dialysis machines manufactured or assembled
elsewhere, to meet local end user market needs. We manufacture
and assemble dialyzers and polysulfone membranes in our St.
Wendel, Germany, LArbresle, France, Vrsac, Serbia and
Inukai and Buzen, Japan facilities and at production facilities
of our joint ventures in Belarus, Saudi Arabia and Japan. At our
Ogden, Utah facilities, we manufacture and assemble dialyzers
and polysulfone membranes and manufacture PD solutions. We
manufacture hemodialysis concentrate at various facilities
worldwide, including Italy, Great Britain, Spain, Turkey,
Serbia, Morocco, Argentina, Brazil, Columbia, Australia,
Germany, Canada, Mexico and the U.S. Our PD products are
manufactured in North America, Europe, Latin America, and Asia,
with two of our largest plants for production of PD products in
Germany and the U.S. Our plant in Reynosa, Mexico is the
worlds largest (by volume) bloodline manufacturing
facility. In 2009, our facility in Jiangsu, China, which
produces bloodlines, received approval from health authorities
to produce peritoneal dialysis solutions, and we are in a
position to start the second and final phase of the process for
obtaining pharmaceutical and medical product approval. We are
also pursing the approval process for manufacture of
hemodialysis concentrate and dialyzers in Jiangsu. Our
facilities are inspected on a regular basis by national
and/or
international authorities.
To meet the ever-growing demand for dialyzers from Fresenius
Medical Care, we put into operation in May 2008 a
38 million expansion of our production capacity for
FX-class premium dialyzers in Germany. With this expansion, our
installed dialyzer capacity has increased by almost 50% from
25 million to 37 million F- and FX-class dialyzers. We
have also expanded our dialyzer production capacities in the
U.S. (Ogden, Utah), from 35 million to
37 million, and a new assembly line scheduled to commence
production in 2011 will further increase capacity to
approximately 46 million dialyzers. In the coming years,
our Ogden site will implement two additional production lines
for polysulfone fiber bundles.
Due to strong demand for our HD dialysis machines, we have kept
our production of these machines for the U.S. market on an
increased level since 2008. In 2010, production of
series 5008 machines for our International segment rose by
11.8% compared to 2009, due to new sales of the series 5008
machines as well as replacement sales for the series 4008
machines. Total machine production quantities in 2010 rose by
approximately 11% over 2009.
We operate a comprehensive quality management system in our
production facilities. Raw materials delivered for the
production of solutions are subjected to infra-red and
ultra-violet testing as well as physical and chemical analysis
to ensure their quality and consistency. During the production
cycle, sampling and testing take place in accordance with
applicable quality control measures to assure sterility, safety
and effectiveness of the finished products. The pressure,
temperature and time required for the various processes are
monitored to ensure consistency of unfinished products during
the production process. Through monitoring of environmental
conditions, particle and bacterial content are kept below
permitted limits. We provide regular ongoing training for our
employees in the areas of quality control and proper production
practice. In North America, we are gearing our manufacturing
processes to the Lean Six Sigma management system
which is also utilized in our Schweinfurt facility. The focus of
Lean Six Sigma is to achieve a very low error rate which would
result in better quality production results while shortening the
time it takes to manufacture our products. IMS fulfills ISO
9001:2000 requirements for quality control systems in
combination with the ISO norm 14001:2004 for environmental
control systems. At the same time, IMS conforms to the
requirements for medical devices of ISO norm 13485:2003. We have
implemented our IMS in all our European production sites. (see
also Item 4. Regulatory and Legal Matters
Facilities and Operational Regulations.) At our production
facilities in North America, we received a total of five
comprehensive FDA facility inspections during 2010. Three of
these were concluded without any citations, while two required
remedial activities to address issues identified in the
FDAs Observation Report. Additionally, all of our
production
27
facilities have undergone annual ISO 13485:2003 Quality Systems
inspections, maintaining all certifications, with no major
non-conformances to the standard being noted.
Environmental
Management
We have integrated environmental protection targets into our
operations. To reach these goals, our IMS has been in use at our
production facilities as well as at a number of dialysis
clinics. IMS fulfills the requirements of quality management
systems as well as environmental management. Environmental goals
are set, adhered to and monitored during all stages of the lives
of our products, from their development to their disposal.
We continually seek to improve our production processes for
environmental compatibility, which frequently generates cost
savings. Our European region production plants, dialysis clinics
and research and development participate in the Corporate
Environment Program, the purpose of which is to improve
environmental awareness and ecological efficiency, comply with
new environmental regulations and expand the number of units
certified under the environmental management standard ISO
14001:2004.
In 2010, we continued the efficiency initiative Energy
squeeze in our main European production plants. The target
is to save 5% of energy consumption annually. In 2010, the
implementation of the environmental management system was
successfully completed in the production plants in
Ober-Erlenbach, Germany and Vrsac, Serbia. Both plants have been
audited externally and achieved the environmental certification
in accordance with ISO 14001:2004.
In our dialysis facilities, we establish, depending on the
facility and situation concerned, a priority environmental
protection target on which our dialysis clinics concentrate for
at least one year. Environmental performance in other dialysis
facilities is used as the basis for comparisons and targets.
Improvements are implemented on a
site-by-site
basis after evaluation of the sites performance. We
introduced our environmental management system in 55 dialysis
clinics in 2010 and increased the proportion of our European
region dialysis clinics that meet environmental management
standard ISO 14001:2004 to 52%. We continued to roll out the
integrated software solution
e-con
5 for
the management of eco-controlling data in over 300 clinics. This
software is intended to reduce the working time effort while
increasing the eco-controlling data quality and possibilities
for data analysis at the place of origin.
In our North America dialysis clinics, we have been able to
reduce fresh water consumption by one third by means of a new
system of production of purified water and to reduce electricity
consumption, and have implemented recycling programs for
corrugated materials and hemodialysis machines. Use of heat
exchangers enables us to obtain residual heat from water used
for industrial purposes, which we use to heat fresh water used
for dialysis treatment. Our clinics in North America commenced a
reusable sharp containers program in 2009. Targeted
environmental performance criteria in other locations include
fresh water consumption and improved separation of waste.
Sources
of Supply
Our purchasing policy combines worldwide sourcing of
high-quality materials with the establishment of long-term
relationships with our suppliers. Additionally, we carefully
assess the reliability of all materials purchased to ensure that
they comply with the rigorous quality and safety standards
required for our dialysis products and we outsource only if we
believe that a supplier can exceed our own quality standards. An
interactive information system links all our global projects to
ensure that they are standardized and constantly monitored.
We focus on further optimizing procurement logistics and
reducing purchasing costs. Supplemental raw material contracts
for all manufacturers of semi-finished goods will enable us to
improve purchasing terms for our complete network. We also plan
to intensify, where appropriate, our use of internet-based
procurement tools by purchasing raw materials through special
on-line auctions. Our sophisticated routing software enables us
to distribute our supplies to best accommodate customer requests
while maintaining operational efficiency.
New
Product Introductions
The field of dialysis products is mainly characterized by
constant development and refinement of existing product groups
and less by break-through innovations. In 2010, we introduced
the 2008T HD machine featuring Fresenius Clinical Data Exchange
software for the U.S. market, which we launched in
November. The 2008T is the first approved HD machine in the
U.S. market with an integrated software platform for
entering and managing clinical treatment data directly at the
treatment couch. It is designed to assist physicians and clinic
staff in efficiently and promptly recording the data required by
the authorities for billing services pursuant to the new ESRD
PPS requirements. In addition, we continued research to further
improve treatment quality both in the clinical and home
environment and are continuing to research ways to reduce water
consumption per treatment. Actual expenditures on research and
development in 2010 were $97 million. See Item 5.C,
Operating and Financial Review and Prospects
Research and Development.
28
Patents
and Licenses
As the owner of patents or licensee under patents throughout the
world, we currently hold rights in about 3,600 patents and
patent applications in major markets. Patented technologies that
relate to dialyzers include our generation of
DiaSafe
plus
®
filters and
FX
®
dialyzers which are the subject of patents and pending patent
applications.
The connector-container system for our biBag bicarbonate
concentrate powder container for the 4008 dialysis equipment
series has been patented in the United States, Norway, Japan and
Europe. The German part of the European patent has been the
subject of invalidity proceedings. A final court decision in
2009 confirmed the validity of the patent. For information
regarding patent infringement claims made against us, see
Note 18 of the Notes to Consolidated Financial Statements,
Legal Proceedings Commercial Litigation.
A number of patents and pending patent applications relate to
components of the more recent 5008 dialysis equipment series,
including, for example, the pump technology, extracorporeal
blood pressure measurement and connector system for a modified
biBag bicarbonate concentrate container. A number of new
applications are pending for the newly introduced North American
2008T HD machine including, for example, the CDX system for the
display of medical information directly on the 2008T screen, a
new wireless wet detector for sensing line disconnect and a
U.S. version of the biBag filling system. New applications
are also pending relating to our new
Liberty
®
peritoneal dialysis cycler which has a number of innovative
attributes such as its multi-channel disposable cassette, dual
piston pump and pneumatically locking door. Finally, a large
number of new patent applications have been filed related to our
new table top portable HD machine and wearable kidney devices in
development.
In 2007 we acquired Renal Solutions Inc. and its substantial
portfolio of patents and applications for renal sorbent
technology. Many of the patents and applications represent new
technology that the Company hopes to utilize in future products.
We recently filed several new patent applications for improved
sorbent designs/formulations developed since the acquisition as
well as for future dialysis devices that utilize the acquired
technology.
One of our more significant patents, the in-line sterilization
method patent, expired in 2010 in Germany, the United States and
other countries. The patent for the 4008 biBag connector expires
in 2013 in Germany, the United States, and other countries.
The dates given represent the maximum patent life of the
corresponding patents. We believe that even after the expiration
of some of our patents, our proprietary know how for the
manufacture of our products and our continuous efforts in
obtaining targeted patent protection for newly developed
upgraded products will continue to provide us with a competitive
advantage.
For PD, we hold protective rights for our polyolefine film,
Biofine
®
,
which is suitable for packaging intravenous and peritoneal
dialysis fluids. Patents have been granted in Australia, Brazil,
Canada, Germany, Europe, South Korea, Belarus and the United
States. A Japanese patent was revoked as a result of opposition
proceedings. A further patent family describes and claims a
special film for a peelable, non-PVC, multi chamber bag for
peritoneal dialysis solutions. These patents have been granted
in Brazil, Europe, Germany, Japan, South Korea and the United
States. However, proceedings against the registration of this
patent in Europe are currently pending.
We believe that our success will continue to depend
significantly on our technology. As a standard practice, we
obtain the legal protections we believe are appropriate for our
intellectual property. Nevertheless, we are in a position to
successfully market a material number of products for which
patent protection has lapsed or where only particular features
have been patented. From time to time our patents may be
infringed by third parties and in such case we will assert our
rights. Initially registered patents may also be subject to
invalidation claims made by competitors in formal proceedings
(oppositions, trials, re-examinations, etc.) either in part or
in whole. In addition, technological developments could suddenly
and unexpectedly reduce the value of some of our existing
intellectual property.
Trademarks
Our principal trademarks are the name Fresenius and
the F logo, for which we hold a perpetual,
royalty-free license from Fresenius SE, our major shareholder
and the sole shareholder of our general partner. See
Item 7.B, Related Party Transactions
Trademarks.
Competition
Our competitors in the sale of hemodialysis and peritoneal
dialysis products include Gambro AB, Baxter International Inc.,
Asahi Kasei Kuraray Medical Co. Ltd., Bellco S.r.l., B. Braun
Melsungen AG, Nipro Corporation Ltd., Nikkiso Co., Ltd., NxStage
Medical, Inc., Terumo Corporation, Kawasumi Laboratories Inc.,
Fuso Pharmaceuticals Industries Ltd., and Toray Industries, Inc.
29
Risk
Management
We see risk management as the ongoing task of assessing,
analyzing and evaluating the spectrum of possible and actual
developments and, if necessary, taking corrective measures. Our
far-reaching risk management system enables management to
identify and reduce risks that could threaten our going concern
or growth at an early stage and minimize their impact as much as
possible.
Risk management is part of our integrated management information
system and is based upon group-wide controlling as well as an
internal monitoring system. Regional monitoring systems form the
backbone of our risk management system and watch over all
inherent industry- and market-specific risks. Our management
board receives status reports from the responsible risk managers
twice yearly and immediate information regarding anticipated
risks as the information is developed. These reports include
qualitative and quantitative appraisals of the likelihood of
risks that have been identified as potentially harmful to us as
well as the potential extent of damage. Efficient reporting is
essential for controlling and monitoring risks as well as for
taking preventative measures. Management receives information on
a monthly and quarterly basis about the state of the health care
industry and our operative and non-operative business, as well
as analyses of our asset, financial and earnings position.
Our risk management system is strengthened by the internal audit
department. The department operates in compliance with the
Institute of Internal Auditors (IIA) standards and is
independent of the regions. Annual worldwide audit assignments
are selected based on a risk assessment model. The audit plan is
reviewed by the Management Board and approved by the Audit and
Corporate Governance Committee of the Supervisory Board. This
plan includes financial audits of individual units as well as
full-scope audits of all business processes of a subsidiary or
business unit. All audit reports resulting from the audit plan
are sent to the Management Board and our external auditor. The
internal audit department also monitors the implementation of
measures documented in the audit reports. The Management Board
is regularly informed about the implementation status. In
addition, the Audit and Corporate Governance Committee of the
Supervisory Board is informed about the audit results.
Since May 2009, we have been subject to the German Act on
the Modernisation of Accounting Law (BilMoG). The
act contains a number of provisions intended to enhance and
improve the corporate governance of companies participating in
the capital markets. Management has taken BilMoG as an
opportunity for additional review and, if necessary, improvement
of the existing internal reporting and control processes.
As a company required to file reports under the Securities
Exchange Act of 1934, we are subject to the provisions of the
Sarbanes-Oxley Act of 2002 and related listing rules of the New
York Stock Exchange applicable to foreign private issuers. For
further information on this requirement, see Items 15.A.
and 15.B, Disclosure Controls and Procedures and
Managements annual report on internal control over
financial reporting.
Regulatory
and Legal Matters
Regulatory
Overview
Our operations are subject to extensive governmental regulation
by virtually every country in which we operate including, most
notably, in the U.S., at the federal, state and local levels.
Although these regulations differ from country to country, in
general,
non-U.S. regulations
are designed to accomplish the same objectives as
U.S. regulations governing the operation of dialysis
clinics, laboratories and manufacturing facilities, the
provision of high quality health care for patients, compliance
with labor and employment laws, the maintenance of occupational,
health, safety and environmental standards and the provision of
accurate reporting and billing for governmental payments
and/or
reimbursement. In the U.S., some states establish regulatory
processes that must be satisfied prior to the establishment of
new dialysis clinics. Outside the U.S., each country has its own
payment and reimbursement rules and procedures, and some
countries prohibit ownership of healthcare providers or
establish other regulatory barriers to direct ownership by
foreign companies. In such jurisdictions, we may establish
alternative contractual arrangements to provide services to
those facilities.
Any of the following matters could have a material adverse
effect on our business, financial condition and results of
operations:
|
|
|
|
|
failure to receive required licenses, certifications or other
approvals for new facilities or products or significant delays
in such receipt;
|
|
|
|
complete or partial loss of various federal certifications,
licenses, or other permits required under the laws of any state
or other governmental authority by withdrawal, revocation,
suspension, or termination or restrictions of such certificates
and licenses by the imposition of additional requirements or
conditions, or the initiation of proceedings possibly leading to
such restrictions or the partial or complete loss of the
required certificates, licenses or permits;
|
30
|
|
|
|
|
a non-appealable finding of material violations of
U.S. healthcare laws; and
|
|
|
|
changes resulting from healthcare reform or other government
actions that reduce reimbursement or reduce or eliminate
coverage for particular services we provide.
|
We must comply with all U.S., German and other legal and
regulatory requirements under which we operate, including the
U.S. federal Medicare and Medicaid Fraud and Abuse
Amendments of 1977, as amended, generally referred to as the
Anti-Kickback Statute, the federal False Claims Act,
the federal restrictions on certain physician referrals,
commonly known as the Stark Law, U.S. federal
rules under the Health Insurance Portability and Accountability
Act of 1996 that protect the privacy and security of patient
medical records and prohibit inducements to patients to select a
particular healthcare provider, commonly known as
HIPAA, and other fraud and abuse laws and similar
state statutes, as well as similar laws in other countries. ACA
expanded the reach of many of these laws and expanded federal
enforcement authority. Moreover, there can be no assurance that
applicable laws, or the regulations thereunder, will not be
amended, or that enforcement agencies or the courts will not
make interpretations inconsistent with our own, any one of which
could have a material adverse effect on our business,
reputation, financial condition and operating results. Sanctions
for violations of these statutes may include criminal or civil
penalties, such as imprisonment, fines or forfeitures, denial of
payments, and suspension or exclusion from the Medicare and
Medicaid programs. In the U.S., some of these laws have been
broadly interpreted by a number of courts, and significant
government funds and personnel have been devoted to their
enforcement because such enforcement has become a high priority
for the federal government and some states. Our company, and the
healthcare industry in general, will continue to be subject to
extensive federal, state and foreign regulation, the full scope
of which cannot be predicted. In addition, the
U.S. Congress and federal and state regulatory agencies
continue to consider modifications to healthcare laws that may
create further restrictions.
We maintain a comprehensive worldwide compliance program under
the overall supervision of our general partners Member of
the Management Board responsible for, amongst others, Legal, who
is also our general counsel and chief compliance officer. The
program includes a compliance staff, a written code of conduct
applicable worldwide, training programs, regulatory compliance
policies and procedures, provisions for anonymous reporting of
suspected violations of applicable laws or Company policies and
periodic internal audits of our compliance procedures.
Nevertheless, we operate many facilities throughout the United
States and other countries in which we do business. In such a
decentralized system, it is often difficult to maintain the
desired level of oversight and control over the thousands of
individuals employed by many affiliated companies. We rely on
our management structure, regulatory and legal resources, and
the effective operation of our compliance program to direct,
manage and monitor the activities of these employees. If our
employees, deliberately or inadvertently, were to submit
inadequate or incorrect billings to any federally-funded
healthcare program, or engage in impermissible conduct with
physicians or other referral sources or vendors with which we do
business, the actions of such persons could subject us and our
subsidiaries to liability under the Anti-Kickback Statute, the
Stark Statute or the False Claims Act, among other laws. See
Note 18, Legal Proceedings Other
Litigation and Potential Exposures of the Notes to our
audited consolidated financial statements.
Product
Regulation
U.S.
In the U.S. numerous regulatory bodies, including the Food
and Drug Administration (FDA) and comparable state
regulatory agencies impose requirements on certain of our
subsidiaries as a manufacturer and a seller of medical products
and supplies under their jurisdiction. We are required to
register with the FDA as a device manufacturer. As a result, we
are subject to periodic inspection by the FDA for compliance
with the FDAs Quality System Regulation (21 C.F.R.
Part 820) requirements and other regulations. These
regulations require us to manufacture products in accordance
with current Good Manufacturing Practices (GMP) and
that we comply with FDA requirements regarding the design,
safety, labeling, record keeping and distribution of our
products. Further, we are required to comply with various FDA
and other agency requirements for labeling and promotion. The
medical device reporting regulations require that we provide
information to the FDA whenever there is evidence to reasonably
suggest that a device may have caused or contributed to a death
or serious injury. In addition, the FDA prohibits us from
promoting a product for unapproved indications.
If the FDA believes that a company is not in compliance with
applicable regulations, it can pursue enforcement action
including, for example, issuing a warning letter such as the
letter issued to the Company on September 15, 2010, in
response to which the Company has since taken corrective action
and is awaiting a reinspection by the FDA. Other FDA action may
include issuing a recall order, instituting proceedings to
detain or seize products, imposing operating restrictions,
enjoining future violations and assessing civil penalties
against a company, its officers or its employees. The agency can
also recommend criminal prosecution to the Department of
Justice. In
31
addition, companies may initiate voluntary recalls. For example,
on January 14, 2011, the Company announced a voluntary
Class l recall of certain blood tubing sets sold in the
U.S. and Canada due to reports of arterial line kinks.
In order to clinically test, produce and market certain medical
products and other disposables (including hemodialysis and
peritoneal dialysis equipment, dialyzers, bloodlines and other
disposables) for human use, we must also satisfy mandatory
procedures and safety and efficacy requirements established by
the FDA or comparable foreign governmental agencies. After
approval or clearance to market is given, the FDA, upon the
occurrence of certain events, has the power to withdraw the
approval or clearance or require changes to a device, its
manufacturing process, or its labeling or may require additional
proof that regulatory requirements have been met. Such rules
generally require that products be approved or cleared by the
FDA as safe and effective for their intended use prior to being
marketed.
We cannot assure that all necessary regulatory approvals,
including approvals for new products or product improvements,
will be granted on a timely basis, if at all. Delays in or
failure to receive approval, product recalls or warnings and
other regulatory actions and penalties can materially affect
operating results.
Some of our products including our peritoneal
dialysis solutions,
PhosLo
®
,
and
Venofer
®
are designated as drugs by the FDA and, as such, are subject to
additional regulation under the Food, Drug, and Cosmetic Act of
1938, as amended. Many of these requirements are similar to
those for devices. Thus, we are required to register with the
FDA and are required to comply with regulatory requirements
regarding drug manufacturing, labeling, distribution, and
recordkeeping. Our drug products must be manufactured in
accordance with cGMP (21 C.F.R. Part 211), and we are
required to provide information to the FDA whenever we become
aware of a report of an adverse drug experience associated with
the use of one of our drug products that is both serious and
unexpected, as defined in FDA regulations. In addition, as with
our medical devices, our drug products must satisfy mandatory
procedures and safety and efficacy requirements before they can
be marketed and the FDA prohibits us from promoting a
pharmaceutical product for unapproved indications. Finally, if
the FDA believes that a company is not in compliance with
applicable drug regulations, it has similar enforcement
authorities as those discussed above with respect to medical
devices.
International
(Including Germany and Other Non-U.S)
Most countries maintain different regulatory regimes for
medicinal products and for medical devices. In almost every
country, there are rules regarding the quality, effectiveness,
and safety of products and regulating their testing, production,
and distribution. Treaties or other international law and
standards and guidelines under treaties or laws may supplement
or supersede individual country regulations.
Drugs.
Some of our products, such as
peritoneal dialysis solutions and
PhosLo
®
,
are considered medicinal products and are, therefore subject to
the specific drug law provisions in the various countries. The
European Union has issued a directive on medicinal products,
No. 65/65/EWG (January 26, 1965), as amended. Each
member of the European Union is responsible for conforming its
law to comply with this directive. In Germany the German Drug
Law (Arzneimittelgesetz) (AMG), which implements
European Union requirements, is the primary regulation
applicable to medicinal products.
The provisions of the German Drug Law are comparable with the
legal standards in other European countries. As in many other
countries, the AMG provides that a medicinal product may only be
placed on the market if it has been granted a corresponding
marketing authorization. Such marketing authorization is granted
by the competent licensing authorities only if the quality,
efficacy and safety of the medicinal product has been
scientifically proven. Medicinal products marketed on the basis
of a corresponding marketing authorization are subject to
ongoing control by the competent authorities. The marketing
authorization may also be subsequently restricted or made
subject to specific requirements. It may be withdrawn or revoked
if there was a reason for the refusal of the marketing
authorization upon its grant or such a reason arises
subsequently, or if the medicinal product is not an effective
therapy or its therapeutic effect has been insufficiently proven
according to the relevant state of scientific knowledge. Such a
reason for refusal is, inter alia, found to exist if there is a
well-founded suspicion that the medicinal product has not been
sufficiently examined in accordance with the current state of
scientific knowledge, that the medicinal product does not show
the appropriate quality, or that the medicinal product, when
properly used as intended, produces detrimental effects going
beyond the extent justifiable according to the current state of
knowledge of medicinal science. The marketing authorization can
also be withdrawn or revoked in the case of incorrect or
incomplete information supplied in the authorization documents,
if the quality checks prescribed for the medicinal product were
insufficient or have not been sufficiently carried out, or if
the withdrawal or revocation is required to comply with a
decision made by the European Commission or the Council of the
European Union. Instead of a withdrawal or revocation, the
suspension of the marketing authorization may be ordered for a
limited period.
32
The provisions of the AMG and a statutory order, Arzneimittel-
und Wirkstoffherstellungsverordnung, also contain special
requirements for the manufacture of medicinal products. The
production of medicinal products requires a corresponding
manufacturing license which is granted by the competent
authorities of the relevant Member State for a specific
manufacturing facility and for specific medicinal products and
forms of medicinal products. The manufacturing license is
granted only if the manufacturing facility, production
techniques and production processes comply with the national
drug law requirements, with the principles and guidelines of
EU-good
manufacturing practice (EU-GMP) as well as the terms
of the particular marketing authorization. A manufacturer of
medicinal products must, inter alia, employ pharmacists,
chemists, biologists, or physicians responsible for the quality,
safety and efficacy of the medicinal products. The manufacturer
must name several responsible persons: a Qualified Person (QP)
for the release of the medicinal product into the market
possessing the expert knowledge specified by the AMG, a head of
production, a head of quality control, and, if the manufacturer
markets the medicinal products itself, a commissioner for the
so-called graduated plan (Stufenplanbeauftragter for Germany, a
Qualified Person for Pharmacovigilance (QPP) for the European
Union) and an information officer. It is the responsibility of
the QP to ensure that each batch of the medicinal products is
produced and examined in compliance with the statutory
provisions of the AMG. The QPP must, among other things, collect
and assess any reported risks associated with the medicinal
products and coordinate any necessary measures according to
German Drug Law. The QPP, residing within the European Economic
Area, is responsible for pharmacovigilance and the establishment
of a system for handling of all suspected adverse reactions that
need to be reported. The information officer is in charge of the
scientific information relating to the medicinal products. All
these persons may be held personally liable under German
criminal law for any breach of the AMG.
International guidelines also govern the manufacture of
medicinal products and, in many cases, overlap with national
requirements. Material regulations concerning manufacture and
registration related to medicinal products have been issued by
the European Commission and the International Conference on
Harmonization of Technical Requirements for Human Use
(ICH). In particular, the Pharmaceutical Inspection
Co-operation Scheme
(PIC/S)
an international treaty, contains rules binding many countries
in which medicinal products are manufactured. Among other
things, the European Commission, PIC/S and ICH establish
requirements for GMP which are then adopted at the national
level. Another international standard, which is non-binding for
medicinal products, is the ISO9001:2000 system for assuring
quality management system requirements. This system has a
broader platform than EU-GMP, which is more detailed and is
primarily acknowledged outside the field of medicinal products,
e.g., with respect to medical devices.
Medical Devices.
In the past, medical devices
were subject to less stringent regulation than medicinal
products in some countries. In the last decade, however,
statutory requirements have been increased. In the EU, the
requirements to be satisfied by medical devices are laid down in
three European directives to be observed by all Member States
and all Member States of the European Economic Area
(EEA), as well as all future accession states:
(1) Directive 90/385/EEC of June 20, 1990 relating to
active implantable medical devices (AIMDs), as last
amended (AIMD Directive), (2) Directive
93/42/EEC of June 14, 1993 relating to medical devices, as
last amended (MD Directive), and (3) Directive
98/79/EC of October 27, 1998 relating to in vitro
diagnostic medical devices as last amended (IVD
Directive). In addition, Directive 2001/95/EC of
December 3, 2001, as last amended, concerning product
safety should be noted. With regard to the MD Directive, the
Commission submitted an amendment, 2007/47/EC, intended to
achieve improvements, for instance in the following areas:
clinical assessment by specification of the requirements in more
detail; monitoring of the devices after their placing on the
market; and decision making by enabling the Commission to make
binding decisions in case of contradictory opinions of states
regarding the classification of a product as a medical device.
Member States had to incorporate the new Directive into national
law by December 31, 2008 and all manufacturers had to come
into compliance by March 21, 2010.
According to the directives relating to medical devices, the CE
mark (the abbreviation of Conformité Européenne
signifying that the device complies with all applicable
requirements) shall serve as a general product passport for all
Member States of the EU and the EEA. Upon receipt of a CE
certificate for a product according to the applicable conformity
assessment procedure, e.g. a certified full quality management
system for medical devices according to ISO13485:2003 and
AC2009, and the documented declaration and proof of conformity
of our products to the harmonized European norms (Declaration of
Conformity), we as the legal manufacturer are able to mark
products as being in compliance with the European Community
(EC) requirements. If able to do so, the
manufacturer has to put a CE mark on the products.
Medical devices that do not bear the CE mark cannot
be imported, sold or distributed within the EC.
The right to affix the CE mark is granted to any manufacturer
who has observed the conformity assessment procedure prescribed
for the relevant medical device and submitted the EC declaration
of conformity before placing the medical device on the market.
The conformity assessment procedures were standardized by
Council Decision
33
93/465/EEC of July 22, 1993, which established modules for
the various phases of the conformity assessment procedures
intended to be used in the technical harmonization norms and the
rules for the affixing and use of the CE conformity mark. The
conformity assessment modules to be used differ depending on the
risk class of the medical device to be placed on the market. The
classification rules for medical devices are, as a general rule,
based upon the potential risk of causing harm to the human body.
Annex IX to the MD Directive (making a distinction between
four product classes I, IIa, IIb, and
III) and Annex II to the IVD Directive (including a
list of the products from lists A and B) contain
classification criteria for products and product lists that are,
in turn, assigned to specific conformity assessment modules.
AIMDs represent a product class of their own and are subject to
the separate AIMD Directive. Special rules apply, for example,
to custom-made medical devices, medical devices manufactured
in-house, medical devices intended for clinical investigation or
in vitro diagnostic medical devices intended for
performance evaluation, as well as for diagnostic medical
devices for in-house use (lay use), combination
devices and accessories to medical devices.
The conformity assessment procedures for Class I devices
with a low degree of invasiveness in the human body (e.g.
devices without a measuring function that are not subject to any
sterilization requirements), can be made under the sole
responsibility of the manufacturer by submitting an EC
declaration of conformity (a self-certification or
self-declaration). For Class IIa devices, the participation
of a Notified Body is binding for the production
phase. Devices of classes IIb and III involving a high
risk potential are subject to inspection by the Notified Body
not only in relation to their manufacture (as for class IIa
devices), but also in relation to their specifications and
design. Class III is reserved for the most critical devices
the marketing of which is subject to an explicit prior
authorization with regard to their conformity. In risk
categories IIa, IIb and III, the manufacturer can make use
of several different conformity assessment modules.
To maintain the high quality standards and performance of our
operations, we have subjected our entire European business to
the most comprehensive procedural module, which is also the
fastest way to launch a new product in the European Union. This
module requires the certification of a full quality management
system by a Notified Body charged with supervising the quality
management system from design, manufacture, and distribution, to
after sales service.
Our Series 4008 dialysis machines and their therapy
modifications, our 5008 dialysis machine and its accessories and
devices, our PD-NIGHT cycler, our Sleep-safe cycler for
automated PD treatment, the multiFiltrate system, and our other
active medical devices distributed in the European market, as
well as our dialysis filters and dialysis tubing systems and
accessories, all bear the CE mark. We expect to
continue to obtain additional certificates for newly developed
products or product groups.
Environmental
Regulation
We are subject to a broad range of federal, foreign, state and
local laws and regulations relating to pollution and the
protection of the environment. These laws regulate, among other
things, the discharge of materials into the environment, the
handling and disposal of wastes, remediation of contaminated
sites and other matters relating to worker and consumer health,
and safety and to the protection of the environment.
Noncompliance with these regulations can result in significant
fines or penalties or limitations on our operations. The
applicable environmental, health and safety laws and
regulations, and any changes to them or their enforcement, may
require us to make material expenditures with respect to ongoing
compliance with or remediation under these laws and regulations
or require that we modify our products or processes in a manner
that increases our costs or reduces revenues.
In addition, the Company uses substances regulated under
U.S. and European environmental laws, primarily in
manufacturing and sterilization processes. While it is difficult
to quantify, we believe the ongoing impact of compliance with
environmental protection laws, rules and regulations will not
have a material impact on the Companys financial position
or results of operations.
An Environmental Management System (EMS) based on
ISO 14001:2004 has been established in the main production
plants and in a high number of dialysis clinics in the European
region. Compliance with environmental regulations is an
essential requirement of our EMS. Internal and external audits
are organized and performed to ensure that EMS requirements are
fulfilled.
Facilities
and Operational Regulation
U.S.
The Clinical Laboratory Improvement Amendments of 1988
(CLIA) subjects virtually all clinical laboratory
testing facilities, including ours, to the jurisdiction of the
Department of Health and Human Services (HHS).
34
CLIA establishes national standards for assuring the quality of
laboratories based upon the complexity of testing performed by a
laboratory. Certain of our operations are also subject to
federal laws governing the repackaging and dispensing of drugs
and the maintenance and tracking of certain life sustaining and
life-supporting equipment.
Our operations are subject to various U.S. Department of
Transportation, Nuclear Regulatory Commission, Environmental
Protection Agency, and Occupational Safety and Health
Administration (OSHA) requirements and other
federal, state and local hazardous and medical waste disposal
laws. As currently in effect, laws governing the disposal of
hazardous waste do not classify most of the waste produced in
connection with the provision of dialysis, or laboratory
services as hazardous, although disposal of nonhazardous medical
waste is subject to specific state regulation. Our operations
are also subject to various air emission and wastewater
discharge regulations.
Federal, state and local regulations require us to meet various
standards relating to, among other things, the management of
facilities, personnel qualifications and licensing, maintenance
of proper records, equipment, quality assurance programs, the
operation of pharmacies, and dispensing of controlled
substances. All of our operations in the U.S. are subject
to periodic inspection by federal and state agencies and other
governmental authorities to determine if the operations,
premises, equipment, personnel and patient care meet applicable
standards. To receive Medicare reimbursement, our dialysis
centers, renal diagnostic support business and laboratories must
be certified by CMS, an agency within HHS. All of our dialysis
centers, and laboratories that furnish Medicare or Medicaid
services have the required certification.
Certain of our facilities and certain of their employees are
also subject to state licensing statutes and regulations. These
statutes and regulations are in addition to federal and state
rules and standards that must be met to qualify for payments
under Medicare, Medicaid and other government reimbursement
programs. Licenses and approvals to operate these centers and
conduct certain professional activities are customarily subject
to periodic renewal and to revocation upon failure to comply
with the conditions under which they were granted.
OSHA regulations require employers to provide employees who work
with blood or other potentially infectious materials with
prescribed protections against blood-borne and air-borne
pathogens. The regulatory requirements apply to all healthcare
facilities, including dialysis centers, vascular access centers
and laboratories, and require employers to make a determination
as to which employees may be exposed to blood or other
potentially infectious materials and to have in effect a written
exposure control plan. In addition, employers are required to
provide hepatitis B vaccinations, personal protective equipment,
blood-borne pathogens training, post-exposure evaluation and
follow-up,
waste disposal techniques and procedures, engineering and work
practice controls and other OSHA-mandated programs for
blood-borne and air-borne pathogens.
Some states in which we operate have certificate of need
(CON) laws that require any person or entity seeking
to establish a new healthcare service or to expand an existing
service to apply for and receive an administrative determination
that the service is needed. We currently operate in several
states, as well as the District of Columbia and Puerto Rico that
have CON laws applicable to dialysis centers. These requirements
could, as a result of a states internal determination of
its dialysis services needs, prevent entry to new companies
seeking to provide services in these states, and could constrain
our ability to expand our operations in these states.
International
(Including Germany and Other
Non-U.S.)
Most countries outside of the U.S. regulate operating
conditions of dialysis clinics and hospitals and the
manufacturing of dialysis products, medicinal products and
medical devices.
We are subject to a broad spectrum of regulation in almost all
countries. Our operations must comply with various environmental
and transportation regulations in the various countries in which
we operate. Our manufacturing facilities and dialysis clinics
are also subject to various standards relating to, among other
things, facilities, management, personnel qualifications and
licensing, maintenance of proper records, equipment, quality
assurance programs, the operation of pharmacies, the protection
of workers from blood-borne diseases and the dispensing of
controlled substances. All of our operations are subject to
periodic inspection by various governmental authorities to
determine if the operations, premises, equipment, personnel and
patient care meet applicable standards. Our dialysis clinic
operations and our related activities generally require
licenses, which are subject to periodic renewal and may be
revoked for violation of applicable regulatory requirements.
In addition, many countries impose various investment
restrictions on foreign companies. For instance, government
approval may be required to enter into a joint venture with a
local partner. Some countries do not permit foreign investors to
own a majority interest in local companies or require that
companies organized under their laws have at least one local
shareholder. Investment restrictions therefore affect the
corporate structure, operating procedures and other
characteristics of our subsidiaries and joint ventures in these
and other countries.
35
We believe our facilities are currently in compliance in all
material respects with the applicable national and local
requirements in the jurisdictions in which they operate.
Reimbursement
As a global dialysis care provider and supplier of dialysis
services and products, we are represented in more than 120
countries throughout the world. Consequently, we face the
challenge of meeting the needs of a wide variety of patients and
customers in very different economic environments and healthcare
systems.
The healthcare systems and rules for the reimbursement of the
treatment of patients suffering from ESRD vary in the individual
countries. In general, the government, in some countries in
coordination with private insurers, is responsible for financing
the healthcare system through tax payments and other sources of
income, social security contributions or a combination of such
sources.
However, in a large number of developing countries, the
government or charitable institutions grant only minor aid so
that dialysis patients must bear all or a large part of their
treatment expenses themselves. In some countries, dialysis
patients do not receive treatment on a regular basis, but only
if and to the extent available funds so allow.
U.S.
Dialysis Services.
Our dialysis centers
provide outpatient hemodialysis treatment and related services
for ESRD patients. In addition, some of the Companys
centers offer services for the provision of peritoneal dialysis
and hemodialysis treatment at home, and dialysis for
hospitalized patients.
The Medicare program is the largest single source of dialysis
services revenues from dialysis treatment. Approximately 53% of
North America dialysis services revenues for 2010 were provided
by Medicares ESRD program and Medicaid. As a preliminary
matter, in order to be eligible for reimbursement by Medicare,
ESRD facilities must meet conditions for coverage established by
CMS. New conditions for coverage became effective in October of
2008, with the exception of two provisions relating to physical
environment and infection control which became effective in
February of 2009. We believe we have made the necessary
modifications to meet these requirements.
Medicare reimbursed our dialysis centers for certain products
and services delivered prior to January 1, 2011 in
accordance with a basic case-mix adjusted prospective
payment system, which provided a fixed payment for each
dialysis treatment, comprised of a composite rate component, a
drug add-on adjustment component, case-mix adjustments and a
regional wage index adjustment. The payment rates under this
system were subject to adjustment from time to time through
changes in the Medicare statute (in the case of basic services
included in the composite rate) or through annual
adjustments (in the case of a portion of the payment referred to
as the drug add-on, case-mix and wage index adjustments).
Effective January 2011, Medicare introduced a new ESRD PPS,
which encompasses those services that were paid under the
composite rate as well as certain formerly separately payable
drugs and laboratory tests. The ESRD PPS is described in greater
detail below.
For calendar year 2009, CMS set the drug add-on adjustment at
$20.33 per treatment, or 15.2% of the total per-treatment
composite payment. For calendar year 2010, CMS kept the drug
add-on amount constant at the 2009 rate of $20.33 per treatment,
while it increased the base portion of the composite rate by 1%
pursuant to the requirement in MIPPA. As a result, the drug
add-on amount, constant in dollar terms, declined to 15% of the
total per-treatment payment in 2010 and 14.7% for 2011. The base
portion of the composite rate, unlike many other payment rates
in Medicare, had not been automatically updated each year. As a
result, this portion of the composite payment rate had not
received an annual update in the absence of a statutory change.
In MIPPA, Congress provided for a 1.0% increase in the base
portion of the composite rate in each of 2009 and 2010. Further,
Congress eliminated a provision that previously paid
hospital-based facilities slightly more than independent (or
free-standing) facilities. Thus, in 2009, all
facilities were paid at the 2008 independent facility rate
increased by 1.0%.
For 2010, the base composite rate was $135.15 for both
independent and hospital-based facilities, an increase of 1.0%
from the 2009 rate. CMS updated the wage index adjustment
applicable to ESRD facilities from the 25/75 blend between
adjustments based on old metropolitan statistical areas
(MSA) and those based on new core-based statistical
areas (CBSA) used in 2008. For 2009, CMS completed
the transition from the MSA definition to the CBSA definition,
and facilities are now paid according to the CBSA rate. For
2010, CMS reduced the wage index floor from 0.70 to 0.65.
Certain other items and services that we furnish at our dialysis
centers were not included in the composite rate and were
eligible for separate Medicare reimbursement. The most
significant of these items are drugs or biologicals, such as
erythropoietin-stimulating agents (ESAs), vitamin D
analogs, and iron, which were reimbursed at 106%
36
of the average sales price as reported to CMS by the
manufacturer. Products and support services furnished to ESRD
patients receiving dialysis treatment at home were also
reimbursed separately under a reimbursement structure comparable
to the in-center composite rate.
Any significant decreases in Medicare reimbursement rates could
have material adverse effects on our provider business and,
because the demand for products is affected by Medicare
reimbursement, on our products business. To the extent that
increases in operating costs that are affected by inflation,
such as labor and supply costs, are not fully reflected in a
compensating increase in reimbursement rates, our business and
results of operations may be adversely affected. For a
discussion of the rules CMS is using to implement recent
Medicare reimbursement rate changes including provisions for
implementation of an expanded bundled rate for
dialysis services provided on or after January 1, 2011, see
ESRD PPS, below.
Medicare pays as the primary insurer for Medicare-eligible
individuals under some circumstances. For details, see
Coordination of Benefits below. For
Medicare-primary patients, Medicare pays 80% of the prospective
payment amount for the ESRD PPS items and services. The
beneficiary or third-party insurance payors (including
employer-sponsored health insurance plans, commercial insurance
carriers and the Medicaid program) on behalf of the beneficiary
are responsible for paying the beneficiarys cost-sharing
obligations (typically the annual deductible and 20%
co-insurance), subject to the specific coverage policies of such
payors. Each third-party payor, including Medicaid, makes
payment under contractual or regulatory reimbursement provisions
that may or may not cover the full 20% co-payment or annual
deductible. Where the beneficiary has no third-party insurance
or the third-party insurance does not fully cover the co-payment
or deductible, the beneficiary is responsible for paying the
co-payments or the deductible, which we frequently do not fully
collect despite reasonable collection efforts. In some states,
Medicaid does not fully cover the cost-sharing obligations of
Medicare-Medicaid dually eligible individuals, and we are
precluded from collecting directly from these beneficiaries.
Under an advisory opinion from the Office of the Inspector
General of the Department of Health and Human Services, subject
to specified conditions, we and other similarly situated
providers may make contributions to a non-profit organization
that has agreed to make premium payments for supplemental
medical insurance
and/or
Medigap insurance on behalf of indigent ESRD
patients, including some of our patients.
Medicaid Rebate Program and Other Government Drug Pricing
Program Requirements.
Manufacturers of drugs that
are covered by the Medicaid program or that are reimbursed by
Part B of the Medicare program are subject to various price
determination and reporting requirements under federal statutes,
including the Medicaid and Medicare statutes as well as the
Public Health Service Act (PHSA) and the Veterans
Health Care Act (VHCA). Compliance with the Medicaid
rebate statute, the VHCA, the Medicare statute, and
Section 340B of the PHSA requires us to calculate
and/or
report a number of different pricing metrics (
e.g.
,
Average Manufacturer Price (AMP), Best Price
(BP), Average Sales Price (ASP), Federal
Ceiling Price (FCP), non-federal average
manufacturer price (Non-FAMP), and 340B ceiling
price) to federal authorities responsible for monitoring and
enforcing drug manufacturer compliance with federal law and
policy.
We participate in the federal Medicaid rebate program
established by the Omnibus Budget Reconciliation Act of 1990, as
well as several state supplemental rebate programs. We make our
pharmaceutical products available to authorized users of the
Federal Supply Schedule (FSS) of the General
Services Administration under an FSS contract negotiated by the
department of Veterans Affairs (VA). With the recent
acquisition of a license to market and distribute the IV
Iron product
Venofer
®
to freestanding dialysis clinics, we also are considered, for
statutory price reporting purposes, to be the manufacturer of
Venofer
®
which is reimbursed under Part B of the Medicare program.
Our products also are subject to a federal requirement that any
company participating in the Medicaid rebate or Medicare
Part B program extend discounts comparable to the rebates
paid to State Medicaid agencies to qualified purchasers under
the Public Health Services (PHS) pharmaceutical
pricing program managed by HHS (also known as the 340B
program by virtue of the section of the PHSA that created
the program). The PHS pricing program extends these deep
discounts on drugs to a variety of community health clinics and
other entities that receive health services grants from the PHS,
as well as hospitals that serve a disproportionate share of poor
Medicare and Medicaid beneficiaries. ACA expanded the 340B
program to include additional providers.
Under the Medicaid rebate program, we pay a rebate to each state
Medicaid program based upon sales of our pharmaceutical products
that are reimbursed by those programs. The ACA increased the
minimum federal Medicare rebate percentages, effective
January 1, 2010. Rebate calculations are complex and, in
certain respects, subject to interpretations of law, regulation,
or policy guidance by us, government or regulatory agencies and
the courts. The Medicaid rebate amount is computed each quarter
based on our submission to CMS of our current average
manufacturer price and best price for our pharmaceutical
products. The Veterans Health Care Act of 1992 imposes a
requirement that the prices we charge to certain federal
entities under the FSS must be no greater than a Federal Ceiling
Price determined by applying a statutory discount to the AMP
charged to non-federal customers (a
37
pricing metric referred to as Non-FAMP). Because the
amount the government pays to reimburse the cost of a drug under
Part B of the Medicare program is ordinarily based on the
ASP charged by the manufacturer to purchasers of the drug,
additional price calculation and reporting obligations are
imposed on the manufacturers of Part B drugs under that
program. Since
Venofer
®
is a Part B drug (
i.e
., one ordinarily administered
incident to a physician service), we are responsible for
compiling and utilizing a wide range of sales data elements to
determine the ASP of
Venofer
®
marketed under our labeler code, and reporting it to the CMS. We
are subject to specific ASP reporting obligations with respect
to our
Venofer
®
sales under a consent order issued by the Federal Trade
Commission in October 2008 (FTC File
No. 081-0146).
The ESRD PPS system incorporates payment for
Venofer
®
starting January 1, 2011. While many facilities will move
to the new system immediately, some facilities will transition
to the new system over a four-year period. The extent to which
Medicare pays for
Venofer
®
under the ASP-based system will thus diminish over this period.
Government agencies may make changes in program interpretations,
requirements or conditions of participation, and retain the
right to audit the accuracy of our computations of rebates and
pricing, some of which may have or result in implications (such
as recoupment) for amounts previously estimated or paid and may
have a material adverse effect on the Companys revenues,
profitability and financial condition.
Laboratory Tests.
Spectra obtains a
substantial portion of its net revenue from Medicare, which pays
for clinical laboratory services provided to dialysis patients
in two ways.
First, payment for most tests is included in the new ESRD PPS
bundled rate paid to dialysis centers. The centers obtain the
laboratory services from laboratories and pay the laboratories
for the services. In accordance with industry practice, Spectra
usually provides such testing services under capitation
agreements with its customers pursuant to which it bills a fixed
amount per patient per month to cover the laboratory tests
included in the composite rate at the designated frequencies.
Second, the few laboratory tests performed by Spectra for
Medicare beneficiaries that are not included in the ESRD PPS
bundled rate are billed separately directly to Medicare. Such
tests are paid at 100% of the Medicare clinical laboratory fee
schedule amounts, which vary to some extent across different
geographic areas but which cannot exceed national ceilings on
payment rates, called national limitation amounts
(NLAs). Medicare updates the payment rates to
reflect inflation by the change in consumer price index, subject
to certain reductions. The Affordable Care Act imposed a
1.75 percentage point reduction from the rate of change in
the consumer price index for calendar years 2011 to 2015
together with a productivity adjustment, expected to
be slightly above 1 percentage point, applicable (with some
restrictions) for years starting with 2011.
With the introduction of the new ESRD PPS, most laboratory tests
that have been separately paid are paid as part of the expanded
bundle.
Erythropoietin stimulating agents.
ESAs,
including
Epogen
®
and
Aranesp
®
are used for anemia management of patients with renal disease.
The administration of ESAs was separately billable under the
composite rate payment system program, and accounted for 19% and
21% of our North America segment dialysis care revenues for the
years ended December 31, 2010 and 2009, respectively.
Starting January 2011, ESAs are included in the expanded bundle
under the ESRD PPS.
The amount of ESA that is appropriate for a patient varies by
several factors, including the severity of the patients
anemia. Anemia severity is commonly monitored by measuring a
patients hematocrit, an indicator of the proportion of red
blood cells in a patients whole blood, or by evaluating a
patients hemoglobin level.
We believe our policies on billing for ESAs in effect when ESAs
were separately billable complied with CMS policies. We
recommend to our treating physicians that they review and
understand the package label insert and the K/DOQI guidelines as
they make their anemia management decisions.
Any of the following changes relating to ESAs could adversely
affect our business, and results of operations, possibly
materially:
|
|
|
|
|
future changes in the ESA reimbursement methodology
and/or
rate;
|
|
|
|
a material reduction in the typical dosage per administration;
|
|
|
|
increases in the cost of ESAs without offsetting increases in
the ESRD PPS reimbursement rate; or
|
|
|
|
reduction by the manufacturer of ESAs of the amount of overfill
in the ESA vials.
|
ESRD Prospective Payment System.
With the
enactment of MIPPA in 2008, Congress mandated the development of
an expanded ESRD bundled payment system for services furnished
on or after January 1, 2011. On July 26, 2010, CMS
published a final rule implementing the ESRD PPS for ESRD
dialysis facilities
38
in accordance with MIPPA. Under the ESRD PPS, CMS reimburses
dialysis facilities with a single payment for each dialysis
treatment, inclusive of (i) all items and services included
in the former composite rate, (ii) oral vitamin D
analogues, oral levocarnitine (an amino acid derivative) and all
ESAs and other pharmaceuticals (other than vaccines) furnished
to ESRD patients that were previously reimbursed separately
under Part B of the Medicare program, (iii) most
diagnostic laboratory tests and (iv) other items and
services furnished to individuals for the treatment of ESRD.
ESRD-related drugs with only an oral form will be reimbursed
under the ESRD PPS starting in January 2014 with an adjusted
payment amount to be determined by the Secretary of Health and
Human Services to reflect the additional cost to dialysis
facilities of providing these medications. The initial ESRD PPS
base reimbursement rate is set at $229.63 per dialysis
treatment. The base ESRD PPS payment is subject to case mix
adjustments that take into account individual patient
characteristics (e.g., age, body surface area, body mass, time
on dialysis) and certain co-morbidities. The base payment is
also adjusted for (i) certain high cost patient outliers
due to unusual variations in medically necessary care,
(ii) disparately high costs incurred by low volume
facilities relative to other facilities, (iii) provision of
home dialysis training and (iv) wage-related costs in the
geographic area in which the provider is located. As part of the
base payment for 2011, CMS has included a negative
3.1 percent adjustment for each facility in order to ensure
a budget-neutral transition, the Transition
Adjustor, based on its estimation that only 43% of
dialysis facilities would elect to participate fully in the
bundle in 2011.
Beginning in 2012, the ESRD PPS payment amount will be subject
to annual adjustment based on increases in the costs of a
market basket of certain healthcare items and
services less a productivity adjustment. The ESRD PPSs
QIP, initially focusing on anemia management and dialysis
adequacy, will become effective January 1, 2012. Dialysis
facilities that fail to achieve the established quality
standards will have payments reduced by up to 2%, based on
performance in 2010 as an initial performance period.
The ESRD PPS will be phased in over four years with full
implementation for all dialysis facilities on January 1,
2014. However, providers were required to elect in November 2010
whether to become fully subject to the new system starting in
January 2011 or to participate in the phase-in.
Although, based upon CMSs assessment, we think that the
ESRD PPS will result in a lower reimbursement rate on average as
a result of the above measures by CMS, nearly all of our
U.S. dialysis facilities have elected to be fully subject
to the ESRD PPS starting on January 1, 2011. Our plans to
mitigate the impact of the ESRD PPS include two broad measures.
First, we are working with medical directors and treating
physicians to make protocol changes used in treating patients
and are negotiating pharmaceutical acquisition cost savings. In
addition, we are seeking to achieve greater efficiencies and
better patient outcomes by introducing new initiatives to
improve patient care upon initiation of dialysis, increase the
percentage of patients using home therapies and achieve
additional cost reductions in our clinics. We are currently
evaluating the impact of ESRD PPS and the above mitigation plan
on our business.
Coordination of Benefits.
Medicare entitlement
begins for most patients in the fourth month after the
initiation of chronic dialysis treatment at a dialysis center.
During the first three months, considered to be a waiting
period, the patient or patients insurance, Medicaid or a
state renal program are responsible for payment.
Patients who are covered by Medicare and are also covered by an
employer group health plan (EGHP) are subject to a
30-month
coordination period during which the EGHP is the primary payor
and Medicare the secondary payor. During this coordination
period the EGHP pays a negotiated rate or in the absence of such
a rate, our standard rate or a rate defined by its plan
documents. The EGHP payments are generally higher than the
Medicare payment. EGHP insurance, when available, will therefore
generally cover as the primary payor a total of 33 months,
the
3-month
waiting period plus the
30-month
coordination period.
Possible Changes in Statutes or
Regulations.
Further legislation or regulations
may be enacted in the future that could substantially modify or
reduce the amounts paid for services and products offered by us
and our subsidiaries. It is also possible that statutes may be
adopted or regulations may be promulgated in the future that
impose additional eligibility requirements for participation in
the federal and state healthcare programs. Such new legislation
or regulations could, depending upon the detail of the
provisions, have positive or adverse effects, possibly material,
on our businesses and results of operations. See Risk
Factors Risks Relating to Litigation and Regulatory
Matters Proposals for healthcare reform could
decrease our revenues and operating profit, and
Healthcare Reform below.
International
(Including Germany and Other
Non-U.S.)
As a global company delivering dialysis care and dialysis
products in more than 120 countries worldwide, we face the
challenge of addressing the needs of dialysis patients and
customers in widely varying economic and healthcare environments.
39
Healthcare systems and reimbursement structures for ESRD
treatment vary by country. In general, the government pays for
health care and finances its payments through taxes and other
sources of government income, from social contributions, or a
combination of those sources. However, not all healthcare
systems provide for dialysis treatment. In many developing
countries, only limited subsidies from government or charitable
institutions are available, and dialysis patients must finance
all or substantially all of the cost of their treatment. In some
countries patients in need of dialysis do not receive treatment
on a regular basis but rather when the financial resources
allow it.
In the major European and British Commonwealth countries,
healthcare systems are generally based on one of two models. The
Bismarck system, is based on mandatory employer and
employee contributions dedicated to healthcare financing. The
Beveridge system, provides a national healthcare
system funded by taxes. Within these systems, provision for the
treatment of dialysis has been made either through allocation of
a national budget, a billing system reimbursing on a
fee-for-service
basis or by a weekly flat rate. The healthcare systems of
countries such as Germany, Japan, France, Belgium, Austria,
Czech Republic, Poland, Hungary, Turkey and the Netherlands are
based on the Bismarck-type system. Countries like the United
Kingdom, Canada, Denmark, Finland, Portugal, Sweden and Italy
established their national health services using the
Beveridge-type system. For information on the distribution of
clinic ownership in various countries in which we operate, see
Renal Industry Overview Dialysis Treatment
Options for ESRD, above.
Financing policies for ESRD treatment also differ from
country-to-country.
There are three main types of reimbursement modalities: budget
transfer, fee for service and flat rate. In some cases, the
reimbursement modality varies within the same country depending
on the type of provider (public or private). Budget transfer is
a reimbursement modality used mainly for public providers in
most of the European countries where the funding is based on
taxation and in some of the countries where it is based on
social security. Fee for service is the most common
reimbursement modality for private providers in all European
countries (with exceptions, such as Germany, where reimbursement
to private providers is based on a weekly flat rate) and for
public providers in countries where the funding system is based
on social security payments.
In 2008, the Portuguese Ministry of Health and Anadial, the
national association of privately run dialysis centers, agreed
on a new reimbursement model for ambulatory care to hemodialysis
patients in Portugal. The new model Comprehensive Price
Payment is an integrated and quality-driven approach that
bundles a variety of dialysis related services and products. It
requires the implementation and functioning of an integrated
disease management model in order to achieve, simultaneously,
health benefits, quality improvement and system rationalization.
The Comprehensive Price Payment model includes all core
necessary dialysis services, the deployment of dialysis-related
products, laboratory services and other complementary medical
tests and the administration of renal drugs for anemia
management, bone management, blood pressure and cardiovascular
control as well as vitamins. The new reimbursement structure
provides for an outcome-oriented flat-rate payment of a national
reimbursement rate per week per patient. The main characteristic
is that the amount of this reimbursement will directly depend on
the fulfillment of certain treatment results and quality control
parameters with the dialysis services provided. The therapeutic
goals include, among others, the adequacy of dialysis, targets
for hemoglobin levels, bone metabolism status, water quality as
well as outcome measures such as mortality rate and
hospitalization days. These goals mirror the good practices
guidelines, both national and international, for dialysis care
to patients, which will serve as support for contractual
monitoring. The establishment of auditing, information,
monitoring, attendance and evaluation mechanisms is a
pre-requisite for a participating dialysis provider. We treat
approximately 4,300 patients in 34 dialysis clinics in
Portugal. In January 2011, we announced that we had entered into
a cooperation agreement with the public health authorities in
the Murcia region of Spain for that countrys first
comprehensive dialysis care and performance-oriented
reimbursement model. Under this agreement, we will provide
dialysis therapy to approximately 200 renal patients in the
region with reimbursement on an all-inclusive
bundled rate tied to our quality performance,
pursuant to the Portuguese system.
Treatment components included in the base reimbursement may vary
from
country-to-country
or even within countries, depending on the structure and cost
allocation principles. In the highly integrated reimbursement
models for dialysis, also often referred to as a bundled
reimbursement, (applied e.g., in Poland, Romania and Portugal as
noted above) the dialysis reimbursement rate covers
all or almost all directly and
indirectly treatment-related components. Countries with a
relatively low integration of the treatment components in the
base reimbursement (such as Czech Republic, UK or Germany)
dedicate correspondently diverse additional payments for
services rendered to dialysis patients arising from different
budgets (or payment streams), depending on the national
healthcare regulations.
Where treatment is reimbursed on a
fee-for-service
basis, reimbursement rates are sometimes allocated in accordance
with the type of treatment performed. We believe that it is not
appropriate to calculate a global reimbursement amount because
the services and costs for which reimbursement is provided in
any such global amount would likely bear little relation to the
actual reimbursement system in any one country. Generally, in
40
European countries with established dialysis programs,
reimbursements range from $100 to more than $300 per treatment.
However, a comparison from country to country would not be
meaningful if made in the absence of a detailed analysis of the
cost components reimbursed, services rendered and the structure
of the dialysis clinic in each country being compared.
Healthcare expenditures are consuming an ever-increasing portion
of gross domestic product worldwide. In the developed economies
of Europe, Asia and Latin America, healthcare spending is in the
range of 5%-15% of gross domestic product. In many countries,
dialysis costs consume a disproportionately high amount of
healthcare spending and these costs may be considered a target
for implementation of cost containment measures. Today, there is
increasing awareness of the correlation between the quality of
care delivered in the dialysis unit and the total healthcare
expenses incurred by the dialysis patient. Accordingly,
developments in reimbursement policies might include higher
reimbursement rates for practices which are believed to improve
the overall state of health of the ESRD patient and reduce the
need for additional medical treatment.
Anti-Kickback Statutes, False Claims Act, Health Insurance
Portability and Accountability Act of 1996, Civil Monetary
Penalties Law, Stark Law and Other Fraud and Abuse Laws in the
United States
Some of our operations are subject to federal and state statutes
and regulations governing financial relationships between
healthcare providers and potential referral sources and
reimbursement for services and items provided to Medicare and
Medicaid patients. Such laws include the Anti-Kickback Statute,
the False Claims Act, the Stark Law, and other federal
healthcare fraud and abuse laws and similar state laws.
The U.S. Government, many individual states and private
third-party risk insurers have devoted increasing resources to
combat fraud, waste, and abuse in the healthcare sector. The
Office of the Inspector General of HHS (OIG), state
Medicaid fraud control units, and other enforcement agencies
have dedicated substantial resources to their efforts to detect
agreements between physicians and service providers that may
violate fraud and abuse laws. In its most recent Work Plan for
Fiscal Year 2011, the OIG has scheduled an ESRD-related review
in the coming year on: (i) claims for ESRD beneficiaries
who are entitled to Medicare coverage only because of special
circumstances (e.g., beneficiaries who receive 36 months of
coverage after a kidney transplant or 12 months after
dialysis is terminated for beneficiaries who no longer require
dialysis and (ii) the availability of dialysis services at
Indian Health Service and tribal facilities.
Recent health reform legislation has also enhanced the
governments ability to pursue actions against potential
violators, by expanding the governments investigative
authority, expanding criminal and administrative penalties, and
providing the government with expanded opportunities to pursue
actions under the federal Anti-Kickback Statute, the False
Claims Act, and the Stark Law. For example, ACA narrowed the
public disclosure bar under the False Claims Act, allowing
increased opportunities for whistleblower litigation. In
addition, the legislation modified the intent standard under the
federal Anti-Kickback Statute, making it easier for prosecutors
to prove that alleged violators had met the requisite knowledge
requirement. Also, recent sunshine legislation will
require pharmaceutical and medical device manufacturers to
record any payments made to physicians and hospitals beginning
in 2012, with disclosures due in 2013.
Anti-Kickback
Statutes
The federal Anti-Kickback Statute establishes criminal
prohibitions against and civil penalties for the knowing and
willful solicitation, receipt, offer or payment of any
remuneration, whether direct or indirect, in return for or to
induce the referral of patients or the ordering or purchasing of
items or services payable in whole or in part under Medicare,
Medicaid or other federal healthcare programs. Sanctions for
violations of the Anti-Kickback Statute include criminal and
civil penalties, such as imprisonment
and/or
criminal fines of up to $25,000 per violation, and civil
penalties of up to $50,000 per violation and up to three times
the amount received from the healthcare program, and exclusion
from the Medicare or Medicaid programs and other federal
programs.
The OIG has the authority to promulgate regulations referred to
as safe harbors that define certain business
relationships and arrangements that would not be subject to
civil sanction or criminal enforcement under the Anti-Kickback
Statute. Failure to comply with a safe harbor provision does not
make the activity illegal. Rather, the safe harbors set forth
specific criteria that, if fully met, will assure the entities
involved of not being prosecuted criminally or civilly for the
arrangement under the Anti-Kickback Statute.
Many states also have enacted statutes similar to the
Anti-Kickback Statute, which may include criminal penalties,
applicable to referrals of patients regardless of payor source,
and may contain exceptions different from state to state and
from those contained in the federal Anti-Kickback Statute.
41
False
Claims Act and Related Criminal Provisions
The federal False Claims Act (the False Claims Act)
imposes civil penalties for knowingly making or causing to be
made false claims with respect to governmental programs, such as
Medicare and Medicaid, for services billed but not rendered, or
for misrepresenting actual services rendered, in order to obtain
higher reimbursement. Under the interpretation of certain
courts, claims submitted for services furnished in violation of
the Anti-Kickback Statute or Stark Law could also violate the
False Claims Act. Moreover, private individuals may bring qui
tam or whistle blower suits against providers under
the False Claims Act, which authorizes the payment of
15-30%
of
any recovery to the individual bringing suit. Such actions are
initially required to be filed under seal pending their review
by the Department of Justice. The False Claims Act generally
provides for the imposition of civil penalties of $5,500 to
$11,000 per claim and for treble damages, resulting in the
possibility of substantial financial penalties for small billing
errors that are replicated in a large number of claims, as each
individual claim could be deemed to be a separate violation of
the False Claims Act. Some states also have enacted statutes
similar to the False Claims Act which may include criminal
penalties, substantial fines, and treble damages. Effective,
January 1, 2007, section 1909 of the Social Security
Act (enacted by section 6031 of the Deficit Reduction Act
of 2005) provides a financial incentive for states to enact
false claims acts that establish liability to the state for the
submission of false or fraudulent claims to the states
Medicaid program. If a state false claims act is determined to
meet certain enumerated requirements, the state is entitled to
an increase in the amounts recovered under a state action
brought under such law. The OIG, in consultation with the
Attorney General of the United States and the Department of
Justice, determines whether a state false claims act meets these
enumerated requirements to qualify for the added financial
incentive. As of November 2010, the OIG had reviewed and
approved state false claims acts promulgated by California,
Georgia, Hawaii, Illinois, Indiana, Massachusetts, Michigan,
Nevada, New York, Rhode Island, Tennessee, Texas, Virginia,
and Wisconsin.
The
Health Insurance Portability and Accountability Act of 1996
(HIPAA)
HIPAA was enacted in August 1996 and expanded federal fraud and
abuse laws by increasing their reach to all federal healthcare
programs, establishing new bases for exclusions and mandating
minimum exclusion terms, creating an additional statutory
exception to the Anti-Kickback Statute for risk-sharing
arrangements, requiring the Secretary of Health and Human
Services to issue advisory opinions, increasing civil money
penalties to $10,000 (formerly $2,000) per item or service and
assessments to three times (formerly twice) the amount claimed,
creating a specific healthcare fraud offense and related health
fraud crimes, and expanding investigative authority and
sanctions applicable to healthcare fraud. It also prohibits a
provider from offering anything of value which the provider
knows or should know would be likely to induce a federal
healthcare program beneficiary to select or continue with the
provider.
HIPAA included a healthcare fraud provision which prohibits
knowingly and willfully executing a scheme or artifice to
defraud any health care benefit program, which
includes any public or private plan or contract affecting
commerce under which any medical benefit, item, or service is
provided to any individual, and includes any individual or
entity who is providing a medical benefit, item, or service for
which payment may be made under the plan or contract. Penalties
for violating this statute include criminal penalties, exclusion
from the Medicare and Medicaid programs, freezing of assets and
forfeiture of property traceable to commission of a healthcare
fraud.
HIPAA regulations establish national standards for certain
electronic healthcare transactions, the use and disclosure of
certain individually identifiable patient health information,
and the security of the electronic systems maintaining this
information. These are commonly known as the HIPAA Privacy and
Security Rules. Health insurance payers and healthcare providers
like us must comply with the HIPAA regulations. Violations of
these HIPAA regulations may include civil money penalties and
potential criminal sanctions.
Many U.S. states also have enacted state healthcare privacy
and data security breach laws governing patient information,
medical records and personal information, including sensitive
information such as financial and identity data. The HIPAA
Privacy Rule establishes a minimum U.S. federal standard
for protecting privacy and preempts all contrary U.S. state
privacy laws. The Privacy Rule does not, however, preempt
U.S. state privacy laws that are more stringent or more
protective. In such instances, we would need to comply with the
U.S. state privacy law. In addition, almost all
U.S. states now regulate data breaches (unless the data is
effectively encrypted) by requiring burdensome reporting and
notification requirements, with significant financial penalties
for noncompliance.
The Health Information Technology for Economic and Clinical
Health Act (HITECH Act), pursuant to the American
Recovery and Reinvestment Act of 2009 (ARRA), makes
sweeping changes to the health information privacy and security
regulations of HIPAA by expanding the scope and application of
the statute. These changes include, among other things,
(i) establishing an affirmative obligation to provide
patient data breach notification in
42
the event of the unauthorized acquisition, access, use or
disclosure of unsecured protected health information
(PHI); (ii) defining the minimum
necessary information that a covered entity may use,
disclose or request in the event the disclosure of a limited
data set (partially de-identified data) is insufficient to
accomplish the appropriate objectives; (iii) restricting
the use of PHI for marketing purposes (expanding definition of
marketing activities requiring authorization);
(iv) prohibiting the sale of PHI; (v) establishing an
affirmative obligation to provide an accounting of disclosures
made for payment, treatment and healthcare operations (up to
3 years); (vi) permitting individual requests to
restrict disclosure in certain circumstances;
(vii) applying the privacy and security rules to business
associates; and (viii) limiting application of the
amendments to personal health records vendors. The
U.S. government has promulgated interim final regulations,
effective September 23, 2009, that address the obligation
to provide patient data breach notifications, which subjects the
Company to additional administrative requirements in the
U.S. The Company cannot estimate the overall effect of the
remaining regulatory changes until adoption of final regulations
implementing those statutory provisions.
Civil
Monetary Penalties Law
Individuals or entities who have either (1) directly
submitted, or caused to be submitted, claims which are improper
or false; (2) arranged or contracted with an individual or
entity that the person knows or should know is excluded from
participation in federal healthcare programs; or
(3) offered or received kickbacks may also be subject to
monetary penalties or exclusion under the Civil Monetary
Penalties Law (CMPL) at the discretion of the OIG.
Penalties are generally not more than $10,000 for each item or
service. However, under the CMPL, violators of the federal
Anti-Kickback Statute provisions may also be subject to
additional civil money penalties of $50,000 per violation.
Violators are also subject to an assessment of up to three times
the amount claimed for each item or service in lieu of damages
sustained by the United States or a state agency because of such
claim, or damages of up to three times the total amount of
remuneration offered, paid, solicited, or received. In addition,
any person or entity who violates this section may be excluded
from participation in the federal or state healthcare programs.
Stark
Law
The original Ethics in Patient Referrals Act of 1989 (commonly
referred to as the Stark Law) was enacted as part of
the Omnibus Budget Reconciliation Act (OBRA) of
1989, and prohibited a physician from referring Medicare
patients for clinical laboratory services to entities with which
the physician (or an immediate family member) has a financial
relationship, unless an exception applies. Sanctions for
violations of the Stark Law may include denial of payment,
refund obligations, civil monetary penalties and exclusion of
the provider from the Medicare and Medicaid programs. In
addition, the Stark Law prohibits the entity receiving the
referral from filing a claim or billing for services arising out
of the prohibited referral.
Provisions of OBRA 1993, known as Stark II, amended
the Stark Law to revise and expand upon various statutory
exceptions, expanded the services regulated by the statute to a
list of Designated Health Services, and expanded the
reach of the statute to the Medicaid program. The provisions of
Stark II generally became effective on January 1,
1995. The additional Designated Health Services, in addition to
clinical laboratory services, include: physical therapy,
occupational therapy and speech language pathology services;
radiology and certain other imaging services; radiation therapy
services and supplies; durable medical equipment and supplies;
parenteral and enteral nutrients, equipment and supplies;
prosthetics, orthotics, and prosthetic devices and supplies;
home health services; outpatient prescription drugs; and
inpatient and outpatient hospital services. The first phase of
Stark regulations was finalized on January 4, 2001. Most
portions of the first phase regulations became effective in
2002. The first phase of the final regulations implementing the
Stark Law (the Phase I regulations) contains an
exception for
Epogen
®
and certain other dialysis-related outpatient prescription drugs
furnished in or by an ESRD facility under many circumstances. In
addition, the regulations made clear that services reimbursed by
Medicare to a dialysis facility under the ESRD composite rate do
not implicate the Stark Law. Further, the final Phase I
regulations also adopted a definition of durable medical
equipment which effectively excludes ESRD equipment and supplies
from the category of Designated Health Services. Phase II
of the Stark regulations was published on March 26, 2004,
and became effective on July 26, 2004. This phase of the
regulations finalized all of the compensation exceptions to the
Stark Law, including those for personal services
arrangements and indirect compensation
arrangements. In addition, Phase II revised the
exception for
Epogen
®
and certain other dialysis-related outpatient prescription drugs
furnished in or by an ESRD facility to include certain
additional drugs.
On September 5, 2007, CMS published Phase III of the
Stark regulations. While this rulemaking was intended to be the
final phase of the Stark rulemaking process, CMS continuee to
address the Stark Law as part of its annual rulemaking process
for reimbursement under the Medicare Part B Physician Fee
Schedule or under the Inpatient Prospective Payment System.
43
Finally, it should be noted that many states in which we operate
have enacted self-referral statutes similar to the Stark Law.
Such state self-referral laws may apply to referrals of patients
regardless of payor source and may contain exceptions different
from each other and from those contained in the Stark Law.
Other
Fraud and Abuse Laws
Our operations are also subject to a variety of other federal
and state fraud and abuse laws, principally designed to ensure
that claims for payment to be made with public funds are
complete, accurate and fully comply with all applicable program
rules.
Healthcare
Reform
ACA contains broad healthcare system reforms, including
(i) provisions to facilitate access to affordable health
insurance for all Americans, (ii) expansion of the Medicaid
program, (iii) an industry fee on pharmaceutical companies
starting in 2011 based on sales of brand name pharmaceuticals to
government healthcare programs, (iv) a 2.3% excise tax on
manufacturers medical device sales starting in 2013,
(v) increases in Medicaid prescription drug rebates
effective January 1, 2010, (vi) commercial insurance
market reforms that protect consumers, such as bans on lifetime
and annual limits, coverage of pre-existing conditions, and
limits on waiting periods, (vii) provisions encouraging
integrated care, efficiency and coordination among providers and
(viii) provisions for reduction of healthcare program waste
and fraud. ACAs medical device excise tax, Medicaid drug
rebate increases and annual pharmaceutical industry fees will
adversely impact our product business earnings and cash flows.
We expect modest favorable impact from ACAs integrated
care and commercial insurance consumer protection provisions.
There are many lawsuits challenging the constitutionality of
ACA, some of which have upheld it with others declaring it a
violation of the U.S. Constitution, although none of the
orders purporting to declare ACA void have enjoined its
operation. A recent effort to repeal ACA was approved by the
House of Representatives but was rejected by the Senate. Several
members of Congress have also expressed interest in repealing
certain ACA provisions. It is difficult to predict at this time
what the eventual outcome of the lawsuits will be once appeals
have been exhausted or which proposals, if any, will be adopted
or, if any lawsuit is successful or if any proposals are
adopted, what the effect would be.
Effective February 15, 2011, the Department of Veterans
Affairs (VA) adopted payment rules which reduce its
payment rates for non-contracted dialysis services to coincide
with those of the Medicare program. As a result of the enactment
of these new rules, we expect to experience variability in our
aggregated VA reimbursement rates for contracted and
non-contracted services. In addition, we may also experience
reductions in the volume of VA patients treated in our
facilities.
44
|
|
C.
|
Organizational
Structure
|
The following chart shows our organizational structure and our
significant subsidiaries. Fresenius Medical Care Holdings, Inc.
conducts its business as Fresenius Medical Care North
America.
|
|
D.
|
Property,
plant and equipment
|
Property
The table below describes our principal facilities. We do not
own the land and buildings comprising our principal facilities
in Germany. Rather, we lease those facilities on a long-term
basis from Fresenius SE or one of its affiliates. These leases
are described under Item 7.B. Related Party
Transactions Real Property Lease.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Currently
|
|
|
|
|
|
|
|
|
Owned or
|
|
|
|
|
|
|
Floor Area
|
|
Leased by
|
|
|
|
|
|
|
(Approximate
|
|
Fresenius
|
|
Lease
|
|
|
Location
|
|
Square Meters)
|
|
Medical Care
|
|
Expiration
|
|
Use
|
|
Bad Homburg, Germany
|
|
|
18,300
|
|
|
leased
|
|
December 2016
|
|
Corporate headquarters and administration
|
Bad Homburg, Germany
|
|
|
4,556
|
|
|
leased
|
|
December 2011
|
|
Administration Building FMC GmbH Central Europe
|
St. Wendel, Germany
|
|
|
58,767
|
|
|
leased
|
|
December 2016
|
|
Manufacture of polysulfone membranes, dialyzers and peritoneal
dialysis solutions; research and development
|
Biebesheim, Germany
|
|
|
30,000
|
|
|
leased
|
|
December 2023
|
|
Central distribution Europe, Asia Pacific and Latin America
|
Schweinfurt, Germany
|
|
|
38,100
|
|
|
leased
|
|
December 2016
|
|
Manufacture of hemodialysis machines and peritoneal dialysis
cyclers; research and development
|
45
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Currently
|
|
|
|
|
|
|
|
|
Owned or
|
|
|
|
|
|
|
Floor Area
|
|
Leased by
|
|
|
|
|
|
|
(Approximate
|
|
Fresenius
|
|
Lease
|
|
|
Location
|
|
Square Meters)
|
|
Medical Care
|
|
Expiration
|
|
Use
|
|
Bad Homburg (OE), Germany
|
|
|
10,304
|
|
|
leased
|
|
December 2016
|
|
Manufacture of hemodialysis concentrate solutions / Technical
Services / Logistics services
|
Stollberg, Germany
|
|
|
3,600
|
|
|
leased
|
|
July 2028
|
|
Manufacture of sub-assemblies for hemodialysis machines
|
Palazzo Pignano, Italy
|
|
|
19,990
|
|
|
owned
|
|
|
|
Manufacture of bloodlines and tubing, Office
|
LArbresle, France
|
|
|
13,524
|
|
|
owned
|
|
|
|
Manufacture of polysulfone dialyzers, special filters and dry
hemodialysis concentrates
|
Nottinghamshire, UK
|
|
|
5,110
|
|
|
leased
|
|
June 2025
|
|
Manufacture of hemodialysis concentrate solutions
|
Vrsac, Serbia
|
|
|
3,331
|
|
|
owned
|
|
|
|
Production area, laboratory, maintenance, administration,
logistics
|
Barcelona, Spain
|
|
|
2,000
|
|
|
owned
|
|
|
|
Manufacture of hemodialysis concentrate solutions
|
Antalya, Turkey
|
|
|
12,031
|
|
|
leased
|
|
December 2037
|
|
Manufacture of bloodlines
|
Casablanca, Morocco
|
|
|
2,823
|
|
|
owned
|
|
|
|
Manufacture of hemodialysis concentrate solutions
|
Guadalajara, México
|
|
|
26,984
|
|
|
owned
|
|
|
|
Manufacture of peritoneal dialysis bags
|
Buenos Aires, Argentina
|
|
|
20,000
|
|
|
owned
|
|
|
|
Manufacture of hemodialysis concentrate solutions, dry
hemodialysis concentrates, bloodlines and disinfectants
|
São Paulo, Brazil
|
|
|
8,615
|
|
|
owned
|
|
|
|
Manufacture of hemodialysis concentrate solutions, dry
hemodialysis concentrates, peritoneal dialysis bags, intravenous
solutions bags, peritoneal dialysis and blood lines sets
|
São Paulo, Brazil
|
|
|
5,430
|
|
|
leased
|
|
October 2011
|
|
Warehouse and Technical Service Office
|
Rio de Janeiro, Brazil
|
|
|
2,185
|
|
|
leased
|
|
July 2011
|
|
Head Office
|
Bogotá, Colombia
|
|
|
18,947
|
|
|
owned
|
|
|
|
Manufacture of hemodialysis concentrate solutions, peritoneal
dialysis bags, intravenous solutions, administration
|
Valencia, Venezuela
|
|
|
3,562
|
|
|
leased
|
|
February 2011
|
|
Head Office and Warehouse
|
Hong Kong
|
|
|
1,770
|
|
|
leased
|
|
February 2012
|
|
Warehouse
|
Suzhou, China (Changshu Plant)
|
|
|
25,168
|
|
|
owned
|
|
|
|
Manufacture of hemodialysis bloodline sets / AV Fistula set
|
Smithfield NSW, Australia
|
|
|
5,350
|
|
|
owned
|
|
|
|
Manufacture of hemodialysis concentrate & Warehouse
|
Scoresby, Australia
|
|
|
6,263
|
|
|
leased
|
|
December 2019
|
|
VIC Warehouse / Seating & Packs / Production
|
Auckland, New Zealand
|
|
|
2,170
|
|
|
leased
|
|
May 2030
|
|
Warehouse/Office
|
Selangor, Malaysia
|
|
|
3,149
|
|
|
leased
|
|
May 2012
|
|
Administration / Warehouse
|
Yongin, South Korea
|
|
|
1,650
|
|
|
leased
|
|
June 2011
|
|
Warehouse
|
Seoul, South Korea
|
|
|
1,905
|
|
|
leased
|
|
January 2012
|
|
Administration
|
Sooncheon, South Korea
|
|
|
5,112
|
|
|
owned
|
|
|
|
Clinic
|
Oita, Japan (Inukai Plant)
|
|
|
3,065
|
|
|
owned
|
|
|
|
Manufacture of polysulfone filters
|
Fukuoka, Japan (Buzen Plant)
|
|
|
37,092
|
|
|
owned
|
|
|
|
Manufacture of peritoneal dialysis bags and dialyzers
|
46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Currently
|
|
|
|
|
|
|
|
|
Owned or
|
|
|
|
|
|
|
Floor Area
|
|
Leased by
|
|
|
|
|
|
|
(Approximate
|
|
Fresenius
|
|
Lease
|
|
|
Location
|
|
Square Meters)
|
|
Medical Care
|
|
Expiration
|
|
Use
|
|
Fukuoka, Japan (Buzen Plant) - Site Area for future expansion
|
|
|
27,943
|
|
|
owned
|
|
|
|
Manufacture of peritoneal dialysis bags and dialyzers
|
Saga, Japan
|
|
|
3,306
|
|
|
leased
|
|
July 2011
|
|
Warehouse
|
Ibaragi, Japan
|
|
|
7,111
|
|
|
leased
|
|
August 2013
|
|
Clinic
|
Waltham, Massachusetts
|
|
|
25,588
|
|
|
leased
|
|
April 2017 - July 2017 with a 10 year and a second
5 year renewal option
|
|
North American corporate headquarters
|
Lexington, Massachusetts
|
|
|
6,425
|
|
|
leased
|
|
April 2017
|
|
IT headquarters and administration -North America
|
Nashville, Tennessee
|
|
|
4,487
|
|
|
leased
|
|
August 2012
|
|
IT administration / payroll administration
|
Walnut Creek, California
|
|
|
7,897
|
|
|
leased
|
|
June 2012 with 5 year renewal option
|
|
Manufacture of hemodialysis machines and peritoneal
|
Pittsburg, California
|
|
|
7,135
|
|
|
leased
|
|
July 2012 with 5 year renewal option
|
|
Warehouse
|
Ogden, Utah
|
|
|
74,322
|
|
|
owned
|
|
|
|
Manufacture polysulfone membranes and dialyzers and peritoneal
dialysis solutions; research and development
|
Ogden, Utah
|
|
|
9,755
|
|
|
leased
|
|
July 2033
|
|
Plant expansion, manufacturing operations
|
Ogden, Utah
|
|
|
24,452
|
|
|
leased
|
|
December 2011
|
|
Warehouse
|
Ogden, Utah
|
|
|
8,933
|
|
|
leased
|
|
December 2011
|
|
Warehouse
|
Ogden, Utah
|
|
|
2,072
|
|
|
leased
|
|
year-to-year lease
|
|
Warehouse
|
Oregon, Ohio
|
|
|
13,934
|
|
|
leased
|
|
April 2019
|
|
Manufacture of liquid hemodialysis concentrate solutions
|
Livingston, California
|
|
|
7,885
|
|
|
leased
|
|
December 2011 with 5-year renewal option
|
|
Manufacture of liquid hemodialysis concentrates and resupply
|
Milpitas, California
|
|
|
8,670
|
|
|
leased
|
|
December 2015 with 5-year renewal option
|
|
Clinical laboratory testing
|
Rockleigh, New Jersey
|
|
|
9,812
|
|
|
leased
|
|
May 2012
|
|
Clinical laboratory testing
|
Irving, Texas
|
|
|
8,374
|
|
|
leased
|
|
February 2014
|
|
Manufacture of liquid hemodialysis solution
|
Reynosa, Mexico
|
|
|
13,936
|
|
|
leased
|
|
June 2013
|
|
Manufacture of bloodlines
|
Reynosa, Mexico
|
|
|
7,079
|
|
|
leased
|
|
June 2013
|
|
Warehouse
|
Reynosa, Mexico
|
|
|
4,645
|
|
|
owned
|
|
|
|
Warehouse
|
Lachine, Canada
|
|
|
3,601
|
|
|
leased
|
|
March 2011
|
|
Warehouse
|
Montreal, Canada
|
|
|
4,036
|
|
|
leased
|
|
September 2020
|
|
Warehouse
|
Richmond, Canada
|
|
|
2,286
|
|
|
leased
|
|
April 2014
|
|
Warehouse
|
Richmond Hill, Canada
|
|
|
5,948
|
|
|
leased
|
|
November 2016
|
|
Warehouse and administrative offices
|
Warrendale, Pennsylvania
|
|
|
2,366
|
|
|
leased
|
|
April 2013
|
|
RSI administration and research facility
|
Oklahoma City, OK
|
|
|
3,665
|
|
|
leased
|
|
October 2015
|
|
Manufacture of sorbent cartridges
|
We lease most of our dialysis clinics, manufacturing,
laboratory, warehousing and distribution and administrative and
sales facilities in the U.S. and other countries on terms
which we believe are customary in the industry. We own those
dialysis clinics and manufacturing facilities that we do not
lease.
For information regarding plans to expand our facilities and
related capital expenditures, see Item 4.A. History
and Development of the Company Capital
Expenditures.
47
|
|
Item 4A.
|
Unresolved
Staff Comments
|
Not applicable.
|
|
Item 5.
|
Operating
and Financial Review and Prospects
|
You should read the following discussion and analysis of the
results of operations of Fresenius Medical Care AG &
Co. KGaA and its subsidiaries in conjunction with our historical
consolidated financial statements and related notes contained
elsewhere in this report. Some of the statements contained
below, including those concerning future revenue, costs and
capital expenditures and possible changes in our industry and
competitive and financial conditions include forward-looking
statements. We made these forward-looking statements based on
the expectations and beliefs of the management of the
Companys General Partner concerning future events which
may affect us, but we cannot assure that such events will occur
or that the results will be as anticipated. Because such
statements involve risks and uncertainties, actual results may
differ materially from the results which the forward-looking
statements express or imply. Such statements include the matters
and are subject to the uncertainties that we described in the
discussion in this report entitled
Introduction Forward-Looking Statements.
See also Item 3.D., Key Information Risk
Factors.
Our business is also subject to other risks and uncertainties
that we describe from time to time in our public filings.
Developments in any of these areas could cause our results to
differ materially from the results that we or others have
projected or may project.
Critical
Accounting Policies
The Companys reported financial condition and results of
operations are sensitive to accounting methods, assumptions and
estimates that are the basis for our financial statements. The
critical accounting policies, the judgments made in the creation
and application of these policies, and the sensitivities of
reported results to changes in accounting policies, assumptions
and estimates are factors to be considered along with the
Companys financial statements, and the discussion below in
Results of Operations.
Recoverability
of Goodwill and Intangible Assets
The growth of our business through acquisitions has created a
significant amount of intangible assets, including goodwill,
trade names and management contracts. At December 31, 2010,
the carrying amount of goodwill amounted to $8,140 million
and
non-amortizable
intangible assets amounted to $215 million representing in
total approximately 49% of our total assets.
In accordance with current accounting standards
,
we
perform an impairment test of goodwill and
non-amortizable
intangible assets at least once a year for each reporting unit,
or if we become aware of events that occur or if circumstances
change that would indicate the carrying value might be impaired.
See also Note 1f) in the Notes to Consolidated Financial
Statements.
To comply with the provisions of the current accounting
standards for the impairment testing, the fair value of the
reporting unit is compared to the reporting units carrying
amount. We estimate the fair value of each reporting unit using
estimated future cash flows for the unit discounted by a
weighted average cost of capital (WACC) specific to
that reporting unit. Estimating the discounted future cash flows
involves significant assumptions, especially regarding future
reimbursement rates and sales prices, treatments and sales
volumes and costs. In determining discounted cash flows, the
Company utilizes for every reporting unit, its three-year
budget, projections for years 4 to 10 and a corresponding growth
rate for all remaining years. Projections for up to ten years
are possible due to the stability of the Companys business
which, due to the non-discretionary nature of the healthcare
services we provide, the need for products utilized to provide
such services and the availability of government reimbursement
for a substantial portion of our services, has been largely
independent from the economic cycle. The Companys weighted
average cost of capital consisted of a basic rate of 6.38% for
2010. This basic rate is then adjusted by a country specific
risk rate within each reporting unit.
If the fair value of the reporting unit is less than its
carrying value, a second step is performed which compares the
fair value of the reporting units goodwill to the carrying
value of its goodwill. If the fair value of the goodwill is less
than its carrying value, the difference is recorded as an
impairment.
A prolonged downturn in the healthcare industry with lower than
expected increases in reimbursement rates
and/or
higher than expected costs for providing healthcare services and
for procuring and selling products could adversely affect our
estimated future cash flows. Future adverse changes in a
reporting units economic environment could affect the
discount rate. A decrease in our estimated future cash flows
and/or
a
decline in a reporting units economic environment could
result in impairment charges to goodwill and other intangible
assets which could materially and adversely affect our future
financial position and operating results.
48
Legal
Contingencies
We are party to litigation and subject to investigations
relating to a number of matters as described in Note 18 of
the Notes to Consolidated Financial Statements, Legal
Proceedings. The outcome of these matters may have a
material effect on our financial position, results of operations
or cash flows.
We regularly analyze current information including, as
applicable, our defenses and we provide accruals for probable
contingent losses including the estimated legal expenses to
resolve the matters. We use the resources of our internal legal
department as well as external lawyers for the assessment. In
making the decision regarding the need for loss accrual, we
consider the degree of probability of an unfavorable outcome and
our ability to make a reasonable estimate of the amount of loss.
The filing of a suit or formal assertion of a claim or
assessment, or the disclosure of any such suit or assertion,
does not automatically indicate that accrual of a loss may be
appropriate.
Accounts
Receivable and Allowance for Doubtful Accounts
Trade accounts receivable are a significant asset of ours and
the allowance for doubtful accounts is a significant estimate
made by management. Trade accounts receivable were
$2,573 million and $2,286 million at December 31,
2010 and 2009, respectively, net of allowances for doubtful
accounts of $277 million and $266 million at
December 31, 2010 and 2009, respectively. Approximately
half of our receivables relates to business in our North America
segment.
Dialysis care revenues are recognized and billed at amounts
estimated to be receivable under reimbursement arrangements with
third party payors. Medicare and Medicaid programs are billed at
pre-determined net realizable rates per treatment that are
established by statute or regulation. Revenues for
non-governmental payors where we have contracts or letters of
agreement in place are recognized at the prevailing contract
rates. The remaining non-governmental payors are billed at our
standard rates for services and, in our North America segment, a
contractual adjustment is recorded to recognize revenues based
on historic reimbursement experience with those payors for which
contracted rates are not predetermined. The contractual
adjustment and the allowance for doubtful accounts are reviewed
quarterly for their adequacy. No material changes in estimates
were recorded for the contractual allowance in the periods
presented.
The allowance for doubtful accounts is based on local payment
and collection experience. We sell dialysis products directly or
through distributors in over 120 countries and dialysis services
in more than 35 countries through owned or managed clinics. Most
payors are government institutions or government-sponsored
programs with significant variations between the countries and
even between payors within one country in local payment and
collection practices. Specifically, public health institutions
in a number of countries outside the U.S. require a
significant amount of time until payment is made. Payment
differences are mainly due to the timing of the funding by the
local, state or federal government to the agency that is
sponsoring the program that purchases our services or products.
The collection of accounts receivable from product sales to
dialysis clinics is affected by the same underlying causes,
since these buyers of our products are reimbursed as well by
government institutions or government sponsored programs.
In our U.S. operations, the collection process is usually
initiated 30 days after service is provided or upon the
expiration of the time provided by contract. For Medicare and
Medicaid, once the services are approved for payment, the
collection process begins upon the expiration of a period of
time based upon experience with Medicare and Medicaid. In all
cases where co-payment is required the collection process
usually begins within 30 days after service has been
provided. In those cases where claims are approved for amounts
less than anticipated or if claims are denied, the collection
process usually begins upon notice of approval of the lesser
amounts or upon denial of the claim. The collection process can
be confined to internal efforts, including the accounting and
sales staffs and, where appropriate, local management staff. If
appropriate, external collection agencies may be engaged.
For our international operations, a significant number of payors
are government entities whose payments are often determined by
local laws and regulations. Depending on local facts and
circumstances, the period of time to collect can be quite
lengthy. In those instances where there are commercial payors,
the same type of collection process is initiated as in the U.S.
Due to the number of our subsidiaries and different countries
that we operate in, our policy of determining when a valuation
allowance is required considers the appropriate local facts and
circumstances that apply to an account. While payment and
collection practices vary significantly between countries and
even agencies within one country, government payors usually
represent low credit risks. Accordingly, the length of time to
collect does not, in and of itself, indicate an increased credit
risk and it is our policy to determine when receivables should
be classified
49
as bad debt on a local basis taking into account local
practices. In all instances, local review of accounts receivable
is performed on a regular basis, generally monthly. When all
efforts to collect a receivable, including the use of outside
sources where required and allowed, have been exhausted, and
after appropriate management review, a receivable deemed to be
uncollectible is considered a bad debt and written off.
Estimates for the allowances for doubtful accounts receivable
from the dialysis service business are mainly based on local
payment and past collection history. Specifically, the
allowances for the North American operations are based on an
analysis of collection experience, recognizing the differences
between payors and aging of accounts receivable. From time to
time, accounts receivable are reviewed for changes from the
historic collection experience to ensure the appropriateness of
the allowances. The allowances in the International segment and
the products business are also based on estimates and consider
various factors, including aging, creditor and past collection
history. Write offs are taken on a claim by claim basis when the
collection efforts are exhausted. Due to the fact that a large
portion of our reimbursement is provided by public health care
organizations and private insurers, we expect that most of our
accounts receivables will be collectable, albeit potentially
more slowly in the International segment in the immediate
future, particularly in countries which continue to be severely
affected by the global financial crisis. See B. Liquidity
and Capital Resources Operations, below, for a
discussion of unfavorable days sales outstanding developments in
2010. A significant change in our collection experience, a
deterioration in the aging of receivables and collection
difficulties could require that we increase our estimate of the
allowance for doubtful accounts. Any such additional bad debt
charges could materially and adversely affect our future
operating results.
If, in addition to our existing allowances, 1% of the gross
amount of our trade accounts receivable as of December 31,
2010 were uncollectible through either a change in our estimated
contractual adjustment or as bad debt, our operating income for
2010 would have been reduced by approximately 1.5%.
The following tables show the portion and aging of trade
accounts receivable of major debtors or debtor groups at
December 31, 2010 and 2009. No single debtor other than
U.S. Medicaid and Medicare accounted for more than 5% of
total trade accounts receivable in either year. Trade accounts
receivable in the International segment are for a large part due
from government or government-sponsored organizations that are
established in the various countries within which we operate.
Amounts pending approval from third party payors represent less
than 3% at December 31, 2010.
Aging of Net Trade Accounts Receivable by Major Payor Groups:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2010
|
|
|
|
|
|
|
|
|
|
overdue
|
|
|
overdue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
overdue
|
|
|
more than
|
|
|
more than
|
|
|
overdue
|
|
|
|
|
|
% of
|
|
|
|
|
|
|
by
|
|
|
3 months
|
|
|
6 months
|
|
|
by
|
|
|
|
|
|
net
|
|
|
|
|
|
|
up to
|
|
|
up to
|
|
|
up to
|
|
|
more than
|
|
|
|
|
|
trade
|
|
|
|
current
|
|
|
3 months
|
|
|
6 months
|
|
|
1 year
|
|
|
1 year
|
|
|
Total
|
|
|
A/R
|
|
|
|
(in millions)
|
|
|
U.S. Medicare and Medicaid Programs
|
|
$
|
372
|
|
|
$
|
85
|
|
|
$
|
41
|
|
|
$
|
28
|
|
|
$
|
20
|
|
|
$
|
546
|
|
|
|
21
|
|
U.S. Commercial Payors
|
|
|
270
|
|
|
|
152
|
|
|
|
48
|
|
|
|
39
|
|
|
|
22
|
|
|
|
531
|
|
|
|
21
|
|
U.S. Hospitals
|
|
|
88
|
|
|
|
28
|
|
|
|
3
|
|
|
|
2
|
|
|
|
3
|
|
|
|
124
|
|
|
|
5
|
|
Self-Pay of U.S. patients
|
|
|
|
|
|
|
3
|
|
|
|
3
|
|
|
|
1
|
|
|
|
|
|
|
|
7
|
|
|
|
|
|
Other North America
|
|
|
1
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
International product customers and dialysis payors
|
|
|
777
|
|
|
|
227
|
|
|
|
116
|
|
|
|
112
|
|
|
|
131
|
|
|
|
1,363
|
|
|
|
53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,508
|
|
|
$
|
496
|
|
|
$
|
211
|
|
|
$
|
182
|
|
|
$
|
176
|
|
|
$
|
2,573
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2009
|
|
|
|
|
|
|
|
|
|
overdue
|
|
|
overdue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
overdue
|
|
|
more than
|
|
|
more than
|
|
|
overdue
|
|
|
|
|
|
% of
|
|
|
|
|
|
|
by
|
|
|
3 months
|
|
|
6 months
|
|
|
by
|
|
|
|
|
|
net
|
|
|
|
|
|
|
up to
|
|
|
up to
|
|
|
up to
|
|
|
more than
|
|
|
|
|
|
trade
|
|
|
|
current
|
|
|
3 months
|
|
|
6 months
|
|
|
1 year
|
|
|
1 year
|
|
|
Total
|
|
|
A/R
|
|
|
|
(in millions)
|
|
|
U.S. Medicare and Medicaid Programs
|
|
$
|
287
|
|
|
$
|
74
|
|
|
$
|
32
|
|
|
$
|
22
|
|
|
$
|
22
|
|
|
$
|
437
|
|
|
|
19
|
|
U.S. Commercial Payors
|
|
|
256
|
|
|
|
140
|
|
|
|
52
|
|
|
|
40
|
|
|
|
30
|
|
|
|
518
|
|
|
|
23
|
|
U.S. Hospitals
|
|
|
88
|
|
|
|
19
|
|
|
|
3
|
|
|
|
2
|
|
|
|
2
|
|
|
|
114
|
|
|
|
5
|
|
Self-Pay of U.S. patients
|
|
|
2
|
|
|
|
6
|
|
|
|
6
|
|
|
|
3
|
|
|
|
1
|
|
|
|
18
|
|
|
|
1
|
|
Other North America
|
|
|
2
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3
|
|
|
|
|
|
International product customers and dialysis payors
|
|
|
699
|
|
|
|
232
|
|
|
|
106
|
|
|
|
86
|
|
|
|
73
|
|
|
|
1,196
|
|
|
|
52
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,334
|
|
|
$
|
472
|
|
|
$
|
199
|
|
|
$
|
153
|
|
|
$
|
128
|
|
|
$
|
2,286
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50
Self-Insurance
Programs
Under the insurance programs for professional, product and
general liability, auto liability and workers compensation
claims, FMCH, our largest subsidiary, is partially self-insured
for professional liability claims. For all other coverages we
assume responsibility for incurred claims up to predetermined
amounts above which third party insurance applies. Reported
liabilities for the year represent estimated future payments of
the anticipated expense for claims incurred (both reported and
incurred but not reported) based on historical experience and
existing claim activity. This experience includes both the rate
of claims incidence (number) and claim severity (cost) and is
combined with individual claim expectations to estimate the
reported amounts.
Financial
Condition and Results of Operations
Overview
We are engaged primarily in providing dialysis services and
manufacturing and distributing products and equipment for the
treatment of end-stage renal disease (ESRD). In the
U.S., we also perform clinical laboratory testing. We estimate
that providing dialysis services and distributing dialysis
products and equipment represents an over $69 billion
worldwide market with expected annual worldwide value growth of
around 6%. Patient growth results from factors such as the aging
population and increased life expectancies; shortage of donor
organs for kidney transplants, increasing incidence and better
treatment of and survival of patients with diabetes and
hypertension, which frequently precede the onset of ESRD;
improvements in treatment quality, which prolong patient life;
and improving standards of living in developing countries, which
make life-saving dialysis treatment available. Key to continued
growth in revenue is our ability to attract new patients in
order to increase the number of treatments performed each year.
For that reason, we believe the number of treatments performed
each year is a strong indicator of continued revenue growth and
success. In addition, the reimbursement and ancillary services
utilization environment significantly influences our business.
In the past we experienced and also expect in the future
generally stable reimbursements for dialysis services. This
includes the balancing of unfavorable reimbursement changes in
certain countries with favorable changes in other countries. The
majority of treatments are paid for by governmental institutions
such as Medicare in the United States. As a consequence of the
pressure to decrease healthcare costs, reimbursement rate
increases have historically been limited. Our ability to
influence the pricing of our services is limited.
A majority of our U.S. dialysis services is paid for by the
Medicare program. Medicare payments for dialysis services
provided before January 1, 2011 were based on a composite
rate, which included a drug add-on adjustment, case-mix
adjustments, and a regional wage index adjustment. The drug
add-on adjustment was established under the Medicare
Prescription Drug, Improvement and Modernization Act of 2003
(MMA) to account for differences in Medicare
reimbursement for separately billable pharmaceuticals
pre-MMA
and
the new average sales price reimbursement system established by
the MMA.
For calendar year 2010, the Centers for CMS kept the drug add-on
amount constant at the calendar year 2009 rate of $20.33 per
treatment, while it increased the base portion of the composite
rate by 1% pursuant to the requirement in MIPPA. As a result,
the drug add-on amount, constant in dollar terms, declined to
15% of the total per-treatment payment in 2010 and for 2011 it
is 14.7%. The base portion of the composite rate, unlike many
other payment rates in Medicare, has not been automatically
updated each year. As a result, this portion of the composite
payment rate has not received an annual update in the absence of
a statutory change. In MIPPA, Congress provided for a 1.0%
increase in the base portion of the composite rate in 2010.
Further, Congress eliminated a provision that previously paid
hospital-based facilities slightly more than independent (or
free-standing) facilities. For 2010, the base
composite rate was $135.15 for both independent and
hospital-based facilities, an increase of 1.0% from the 2009
rate. CMS updated the wage index adjustment applicable to ESRD
facilities from the
25
/
75
blend between adjustments based on old metropolitan statistical
areas (MSAs) and those based on new core-based
statistical areas (CBSAs) used in 2008. In 2009, CMS
completed the transition from the MSA definition to the CBSA
definition, and facilities are now paid according to the CBSA
rate. For 2010, CMS reduced the wage index floor from 0.70 to
0.65. For a discussion of the composite rate for reimbursement
of dialysis treatments, see Business
Regulatory and Legal Matters Reimbursement.
Until January 1, 2011 certain other items and services that
we furnish at our dialysis centers were included in the
composite rate and were eligible for separate Medicare
reimbursement. The most significant of these items are drugs or
biologicals, such as erythropoietin-stimulating agents
(ESAs), vitamin D analogs, and iron, which were
reimbursed at 106% of the average sales price as reported to CMS
by the manufacturer. Products and support services furnished to
ESRD patients receiving dialysis treatment at home were also
reimbursed separately under a reimbursement structure comparable
to the in-center composite rate.
51
With the enactment of MIPPA in 2008, Congress mandated the
development of an expanded ESRD bundled payment system for
services furnished on or after January 1, 2011. On
July 26, 2010, CMS issued a final rule implementing the
case-mix adjusted bundled prospective payment system (ESRD
PPS) for ESRD dialysis facilities in accordance with
MIPPA. Under the ESRD PPS, CMS reimburses dialysis facilities
with a single payment for each dialysis treatment, inclusive of
(i) all items and services included in the composite rate,
(ii) oral vitamin D analogues, oral levocarnitine (an amino
acid derivative) and all ESAs and other pharmaceuticals (other
than vaccines) furnished to ESRD patients that were previously
reimbursed separately under Part B of the Medicare program,
(iii) most diagnostic laboratory tests and (iv) other
items and services furnished to individuals for the treatment of
ESRD. ESRD-related drugs with only an oral form will be
reimbursed under the ESRD PPS starting in January 2014 with an
adjusted payment amount to be determined by the Secretary of
Health and Human Services to reflect the additional cost to
dialysis facilities of providing these medications. The initial
ESRD PPS base reimbursement rate is set at $229.63 per dialysis
treatment (representing 98% of the estimated 2011 Medicare
program costs of dialysis care as calculated under the current
reimbursement system). The base ESRD PPS payment is subject to
case mix adjustments that take into account individual patient
characteristics (e.g., age, body surface area, body mass, time
on dialysis) and certain co-morbidities. The base payment is
also adjusted for (i) certain high cost patient outliers
due to unusual variations in medically necessary care,
(ii) disparately high costs incurred by low volume
facilities relative to other facilities, (iii) provision of
home dialysis training, (iv) wage-related costs in the
geographic area in which the provider is located and
(v) the Transition Adjustor.
Beginning in 2012, the ESRD PPS payment amount will be subject
to annual adjustment based on increases in the costs of a
market basket of certain healthcare items and
services less a productivity adjustment. The ESRD PPSs
pay-for-performance
standards, also known as the quality improvement program or QIP,
focusing in the first year on anemia management and dialysis
adequacy, will be fully implemented effective January 1,
2012. Dialysis facilities that fail to achieve the established
quality standards will have payments reduced by up to 2%, based
on performance in 2010 as an initial performance period.
The ESRD PPS will be phased in over four years with full
implementation for all dialysis facilities on January 1,
2014. However, providers could elect in November 2010 to become
fully subject to the new system starting in January 2011.
Although, based upon CMSs assessment, we think that the
ESRD PPS will result in a lower reimbursement rate on average as
a result of the above measures by CMS, nearly all of our
U.S. dialysis facilities have elected to be fully subject
to the ESRD PPS starting on January 1, 2011. Our plans to
mitigate the impact of the ESRD PPS include two broad measures.
First, we are working with other providers, CMS and the
U.S. Congress toward favorably revising the calculation of
the Transition Adjustor for 2011. Second, we are also working
with medical directors and treating physicians to make protocol
changes used in treating patients and are negotiating
pharmaceutical acquisition cost savings. Finally, we are seeking
to achieve greater efficiencies and better patient outcomes by
introducing new initiatives to improve patient care upon
initiation of dialysis, increase the percentage of patients
using home therapies and achieve additional cost reductions in
our clinics. We are currently evaluating the impact of ESRD PPS
and the above mitigation plan on our business.
The Patient Protection and Affordable Care Act was enacted in
the United States on March 23, 2010 and subsequently
amended by the Health Care and Educational Affordability
Reconciliation Act (as amended, ACA). ACA will
implement broad healthcare system reforms, including
(i) provisions to facilitate access to affordable health
insurance for all Americans, (ii) expansion of the Medicaid
program, (iii) an industry fee on pharmaceutical companies
starting in 2011 based on sales of brand name pharmaceuticals to
government healthcare programs, (iv) a 2.3% excise tax on
manufacturers medical device sales starting in 2013,
(v) increases in Medicaid prescription drug rebates
effective January 1, 2010, (vi) commercial insurance
market reforms that protect consumers, such as bans on lifetime
and annual limits, coverage of pre-existing conditions, limits
on administrative costs, and limits on waiting periods,
(vii) provisions encouraging integrated care, efficiency
and coordination among providers and (viii) provisions for
reduction of healthcare program waste and fraud. ACAs
medical device excise tax, Medicaid drug rebate increases and
annual pharmaceutical industry fees will adversely impact our
product business earnings and cash flows. We expect modest
favorable impact from ACAs integrated care and commercial
insurance consumer protection provisions.
Effective February 15, 2011, the VA adopted payment rules
which reduce its payment rates for non-contracted dialysis
services to coincide with those of the Medicare program. As a
result of the enactment of these new rules, we expect to
experience variability in our aggregated VA reimbursement rates
for contracted and non-contracted services. In addition, we may
also experience reductions in the volume of VA patients treated
in our facilities.
We have identified three operating segments, North America,
International, and Asia-Pacific. For reporting purposes, we have
aggregated the International and Asia-Pacific segments as
International. We aggregated these
52
segments due to their similar economic characteristics. These
characteristics include same services provided and same products
sold, same type patient population, similar methods of
distribution of products and services and similar economic
environments. The general partners Management Board member
responsible for the profitability and cash flow of each
segments various businesses supervises the management of
each operating segment. The accounting policies of the operating
segments are the same as those we apply in preparing our
consolidated financial statements under accounting principles
generally accepted in the United States
(U.S. GAAP). Our management evaluates each
segment using a measure that reflects all of the segments
controllable revenues and expenses.
With respect to the performance of our business operations, our
management believes the most appropriate measure in this regard
is operating income which measures our source of earnings.
Financing is a corporate function which segments do not control.
Therefore, we do not include interest expense relating to
financing as a segment measurement. We also regard income taxes
to be outside the segments control. Similarly, we do not
allocate corporate costs, which relate primarily to
certain headquarters overhead charges, including accounting and
finance, professional services, etc. because we believe that
these costs are also not within the control of the individual
segments. In addition, certain acquisitions and intangible
assets are not allocated to a segment but are accounted for as
corporate. Accordingly, all of these items are
excluded from our analysis of segment results and are discussed
below in the discussion of our consolidated results of
operations.
The following tables summarize our financial performance and
certain operating results by principal business segment for the
periods indicated. Inter-segment sales primarily reflect sales
of medical equipment and supplies from the International segment
to the North America segment. We prepared the information using
a management approach, consistent with the basis and manner in
which our management internally disaggregates financial
information to assist in making internal operating decisions and
evaluating management performance.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
(in millions)
|
|
|
Total revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America
|
|
$
|
8,135
|
|
|
$
|
7,615
|
|
|
$
|
7,007
|
|
|
|
|
|
International
|
|
|
4,012
|
|
|
|
3,713
|
|
|
|
3,688
|
|
|
|
|
|
Corporate
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Totals
|
|
|
12,147
|
|
|
|
11,328
|
|
|
|
10,696
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inter-segment revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America
|
|
|
5
|
|
|
|
3
|
|
|
|
2
|
|
|
|
|
|
International
|
|
|
89
|
|
|
|
78
|
|
|
|
82
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Totals
|
|
|
94
|
|
|
|
81
|
|
|
|
84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America
|
|
|
8,130
|
|
|
|
7,612
|
|
|
|
7,005
|
|
|
|
|
|
International
|
|
|
3,923
|
|
|
|
3,635
|
|
|
|
3,606
|
|
|
|
|
|
Corporate
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Totals
|
|
|
12,053
|
|
|
|
11,247
|
|
|
|
10,612
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America
|
|
|
287
|
|
|
|
265
|
|
|
|
238
|
|
|
|
|
|
International
|
|
|
207
|
|
|
|
183
|
|
|
|
171
|
|
|
|
|
|
Corporate
|
|
|
9
|
|
|
|
9
|
|
|
|
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Totals
|
|
|
503
|
|
|
|
457
|
|
|
|
416
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America
|
|
|
1,386
|
|
|
|
1,250
|
|
|
|
1,168
|
|
|
|
|
|
International
|
|
|
678
|
|
|
|
637
|
|
|
|
616
|
|
|
|
|
|
Corporate
|
|
|
(140
|
)
|
|
|
(131
|
)
|
|
|
(112
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Totals
|
|
|
1,924
|
|
|
|
1,756
|
|
|
|
1,672
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
25
|
|
|
|
21
|
|
|
|
25
|
|
|
|
|
|
Interest expense
|
|
|
(305
|
)
|
|
|
(321
|
)
|
|
|
(361
|
)
|
|
|
|
|
Income tax expense
|
|
|
(578
|
)
|
|
|
(491
|
)
|
|
|
(476
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income
|
|
|
1,066
|
|
|
|
965
|
|
|
|
860
|
|
|
|
|
|
Less: Net Income attributable to Noncontrolling interests
|
|
|
87
|
|
|
|
74
|
|
|
|
42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income attributable to FMC-AG & Co. KGaA
|
|
$
|
979
|
|
|
$
|
891
|
|
|
$
|
818
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
53
Year
ended December 31, 2010 compared to year ended
December 31, 2009
Highlights
Revenues increased by 7% to $12,053 million (7% at constant
rates) mainly due to organic growth of 6%.
Operating income (EBIT) increased 10%.
Net Income increased by 10%.
Consolidated
Financials
Key
Indicators for Consolidated Financials
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in %
|
|
|
|
|
|
|
|
|
|
|
|
|
at constant
|
|
|
|
2010
|
|
|
2009
|
|
|
as reported
|
|
|
exchange rates
|
|
|
Number of treatments
|
|
|
31,670,702
|
|
|
|
29,425,758
|
|
|
|
8
|
%
|
|
|
|
|
Same market treatment growth in %
|
|
|
4.6
|
%
|
|
|
4.1
|
%
|
|
|
|
|
|
|
|
|
Revenue in $ million
|
|
|
12,053
|
|
|
|
11,247
|
|
|
|
7
|
%
|
|
|
7
|
%
|
Gross profit in % of revenue
|
|
|
34.4
|
%
|
|
|
34.1
|
%
|
|
|
|
|
|
|
|
|
Selling, general and administrative costs in % of revenue
|
|
|
17.6
|
%
|
|
|
17.6
|
%
|
|
|
|
|
|
|
|
|
Net income attributable to FMC-AG & Co. KGaA in
$ million
|
|
|
979
|
|
|
|
891
|
|
|
|
10
|
%
|
|
|
|
|
Treatments increased by 8% for the year ended December 31,
2010 as compared to the same period in 2009. Same market
treatment growth contributed 5% and growth from acquisitions
contributed 4%, partially offset by the effect of closed or sold
clinics of 1%.
At December 31, 2010, we owned, operated or managed
(excluding those managed but not consolidated in the U.S.) 2,757
clinics compared to 2,553 clinics at December 31, 2009.
During 2010, we acquired 168 clinics, opened 90 clinics and
combined or closed 54 clinics. The number of patients treated in
clinics that we own, operate or manage (excluding patients of
clinics managed but not consolidated in the U.S.) increased by
10% to 214,648 at December 31, 2010 from 195,651 at
December 31, 2009. Including 30 clinics managed but not
consolidated in the U.S., the total number of patients was
216,286.
Net revenue increased by 7% (7% at constant exchange rates) for
the year ended December 31, 2010 over the comparable period
in 2009 due to growth in both dialysis care and dialysis
products revenues.
Dialysis care revenue grew by 9% to $9,070 million (9% at
constant exchange rates) for the year ended December 31,
2010 from $8,350 million in the same period of 2009, mainly
due to growth in same market treatments (5%), contributions from
acquisitions (3%) and increases in revenue per treatment (2%),
partially offset by the effect of closed or sold clinics (1%).
Dialysis product revenue increased by 3% to $2,983 million
(3% at constant exchange rates) from $2,897 million in the
same period of 2009, driven by increased sales of hemodialysis
products, especially of dialyzers, solutions and concentrates
and bloodlines as well as products for acute care treatments and
dialysis machines, partially offset by lower sales of renal
pharmaceuticals.
The increase in gross profit margin reflects an increase in
gross profit margin in North America, partially offset by a
decrease in the International segment. The increase in North
America was due to increased revenue per treatment and favorable
costs for pharmaceuticals. The decrease in International was due
to the positive effect of an inventory adjustment during the
same period of 2009 and lower gross profit margins of recently
acquired clinics, partially offset by favorable foreign exchange
effects in Europe and Asia-Pacific as well as growth in the
product business in China.
Selling, general and administrative (SG&A)
expenses increased to $2,124 million in the year ended
December 31, 2010 from $1,982 million in the same
period of 2009. SG&A expenses as a percentage of sales
remained unchanged at 17.6% for the year ended December 31,
2010 in comparison with the same period of 2009 as a result of
an increase in North America offset by a decrease in the
International segment. The increase in North America was
due to higher personnel expenses and donations to U.S. ESRD
patient assistance charities, partially offset by economies of
scale. The decrease in the International segment was mainly due
to economies of
54
scale and the effect of stronger growth in the dialysis care
business, which has lower SG&A margins, partially offset by
the one-time revaluation of the balance sheet of our operations
in Venezuela as a result of the devaluation of the Venezuelan
bolivar driven by hyperinflation. Bad debt expense for the year
ended December 31, 2010 was $218 million as compared
to $210 million for the same period of 2009, representing
1.8% and 1.9% of sales for the years ended December 31,
2010 and 2009, respectively.
R&D expenses increased to $97 million in the year
ended December 31, 2010 as compared to $94 million in
the same period in 2009.
Operating income increased to $1,924 million in the year
ended December 31, 2010 from $1,756 million for the
same period in 2009. Operating income margin increased to 16.0%
for the year ended December 31, 2010 from 15.6% for the
same period in 2009 as a result of the increase in gross profit
margin as noted above.
Interest expense decreased by 5% to $305 million for the
year ended December 31, 2010 from $321 million for the
same period in 2009 mainly as a result of decreased short-term
interest rates.
Income tax expense increased to $578 million for the year
ended December 31, 2010 from $491 million for the same
period in 2009. The effective tax rate increased to 35.2% from
33.7% for the same period of 2009, mainly due to higher
unrecognized tax benefits, lower tax effects related to internal
financing and the effect of non deductible losses in Venezuela
as a result of inflation accounting. This was partially offset
by the release of a valuation allowance in 2010 on deferred
taxes for net operating losses due to changes in activities of
the respective entities.
Net income attributable to FMC-AG & Co. KGaA for the
year ended December 31, 2010 increased to $979 million
from $891 million for the same period in 2009 as a result
of the combined effects of the items discussed above.
We employed 73,452 people (full-time equivalents) as of
December 31, 2010 compared to 67,988 as of
December 31, 2009, an increase of 8.0% primarily due to
overall growth in our business and acquisitions.
The following discussions pertain to our business segments and
the measures we use to manage these segments.
North
America Segment
Key
Indicators for North America Segment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
Change in %
|
|
|
Number of treatments
|
|
|
20,850,242
|
|
|
|
19,867,465
|
|
|
|
5
|
%
|
Same market treatment growth in %
|
|
|
4.3
|
%
|
|
|
3.5
|
%
|
|
|
|
|
Revenue in $ million
|
|
|
8,130
|
|
|
|
7,612
|
|
|
|
7
|
%
|
Depreciation and amortization in $ million
|
|
|
287
|
|
|
|
265
|
|
|
|
8
|
%
|
Operating income in $ million
|
|
|
1,386
|
|
|
|
1,250
|
|
|
|
11
|
%
|
Operating income margin in %
|
|
|
17.0
|
%
|
|
|
16.4
|
%
|
|
|
|
|
Revenue
Treatments increased by 5% for the year ended December 31,
2010 as compared to the same period in 2009 mostly due to same
market growth (4%) and contributions from acquisitions (2%),
partially offset by the effect of closed or sold clinics (1%).
At December 31, 2010, 137,689 patients (a 4% increase
over the same period in the prior year) were being treated in
the 1,823 clinics that we own or operate in the North America
segment, compared to 132,262 patients treated in 1,784
clinics at December 31, 2009. Average North America revenue
per treatment was $349 for the year ended December 31, 2010
and $341 in the same period in 2009. In the U.S., the average
revenue per treatment was $356 for the year ended
December 31, 2010 and $347 for the same period in 2009. The
increase was mainly attributable to increased commercial payor
revenue and improvements in the payor mix. In addition, there
was an increase of 1% to the 2010 Medicare composite rate.
Net revenue for the North America segment for the year ended
December 31, 2010 increased as a result of increases in
dialysis care revenue by 7% to $7,303 million from
$6,794 million in the same period of 2009 and in dialysis
product revenue by 1% to $827 million from
$818 million in the year ended December 31, 2009.
55
The dialysis care revenue increase was driven by same market
treatment growth (4%), increased revenue per treatment (3%) and
contributions from acquisitions (1%), partially offset by the
effect of closed or sold clinics (1%). The administration of EPO
represented approximately 19% and 21% of total North America
dialysis care revenue for the year ended December 31, 2010
and 2009, respectively.
The dialysis product revenue increase was driven mostly by
increased sales of bloodlines, solutions and concentrates as
well as dialysis machines, partially offset by lower sales of
renal pharmaceuticals.
Operating
Income
Operating income increased to $1,386 million for the year
ended December 31, 2010 from $1,250 million for the
same period in 2009. Operating income margin increased to 17.0%
for the year ended December 31, 2010 from 16.4% for the
same period in 2009, primarily due to higher revenue per
treatment and favorable costs for pharmaceuticals, partially
offset by an increase in cost per treatment to $285 for the year
ended December 31, 2010 from $283 in the same period of
2009 due to higher personnel expenses and donations to
U.S. ESRD patient assistance charities.
International
Segment
Key
Indicators for International Segment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in %
|
|
|
|
|
|
|
|
|
|
|
|
|
at constant
|
|
|
|
2010
|
|
|
2009
|
|
|
as reported
|
|
|
exchange rates
|
|
|
Number of treatments
|
|
|
10,820,460
|
|
|
|
9,558,293
|
|
|
|
13
|
%
|
|
|
|
|
Same market treatment growth in %
|
|
|
5.1
|
%
|
|
|
5.3
|
%
|
|
|
|
|
|
|
|
|
Revenue in $ million
|
|
|
3,923
|
|
|
|
3,635
|
|
|
|
8
|
%
|
|
|
8
|
%
|
Depreciation and amortization in $ million
|
|
|
207
|
|
|
|
183
|
|
|
|
13
|
%
|
|
|
|
|
Operating income in $ million
|
|
|
678
|
|
|
|
637
|
|
|
|
6
|
%
|
|
|
|
|
Operating income margin in %
|
|
|
17.3
|
%
|
|
|
17.5
|
%
|
|
|
|
|
|
|
|
|
Revenue
Treatments increased by 13% in the year ended December 31,
2010 over the same period in 2009 mainly due to contributions
from acquisitions (9%) and same market growth (5%), partially
offset by the effect of closed or sold clinics (1%). As of
December 31, 2010, 76,959 patients (a 21% increase
over the same period of the prior year) were being treated at
934 clinics that we own, operate or manage in the International
segment compared to 63,389 patients treated at 769 clinics
at December 31, 2009. Average revenue per treatment for the
year ended December 31, 2010 remained constant at $163 in
comparison with the same period of 2009.
Net revenues for the International segment for the year ended
December 31, 2010 increased by 8% (8% increase at constant
exchange rates) as compared to the same period in 2009 as a
result of increases in both dialysis care and dialysis product
revenues. Organic growth during the period was 5% and
acquisitions during the period contributed 4%, partially offset
by the effect of closed or sold clinics of 1%.
Including the effects of acquisitions, European region revenue
increased 3% (6% increase at constant exchange rates), Latin
America region revenue increased 16% (9% increase at constant
exchange rates), and Asia-Pacific region revenue increased 22%
(15% increase at constant exchange rates).
Total dialysis care revenue for the International segment
increased during the year ended December 31, 2010 by 14%
(13% increase at constant exchange rates) to $1,767 million
from $1,556 million in the same period of 2009. This
increase is a result of increase in contributions from
acquisitions (8%), same market treatment growth (5%), the
positive impact of increases in revenue per treatment (1%) and
the positive effect of exchange rate fluctuations (1%),
partially offset by the effect of closed or sold clinics (1%).
Total dialysis product revenue for the year ended
December 31, 2010 increased by 4% (4% increase at constant
exchange rates) to $2,156 million from $2,079 million
in the same period of 2009. The increase in product revenue was
driven by increased sales of dialyzers, hemodialysis solutions
and concentrates, dialysis machines, bloodlines and products for
acute care treatments, partially offset by lower sales of
pharmaceuticals.
56
Operating
Income
Operating income increased by 6% to $678 million for the
year ended December 31, 2010 from $637 million for the
same period in 2009. Operating income margin decreased to 17.3%
for the year ended December 31, 2010 from 17.5% for the
same period in 2009 due to the positive effect of an inventory
adjustment in the same period in 2009 and lower margins of
recently acquired clinics as well as the one-time revaluation of
the balance sheet of our operations in Venezuela which was
required as a result of the devaluation of the local currency
driven by hyperinflation, partially offset by economies of
scale, foreign exchange gains in Europe and Asia-Pacific and
growth in the dialysis products business in China.
Year
ended December 31, 2009 compared to year ended
December 31, 2008
Highlights
Revenues increased by 6% to $11,247 million (9% at constant
rates) mainly due to organic growth at 8% and acquisitions at 1%.
Operating income (EBIT) increased 5%.
Net Income increased by 9%.
Consolidated
Financials
Key
Indicators for Consolidated Financials
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in %
|
|
|
|
|
|
|
|
|
|
|
|
|
at constant
|
|
|
|
2009
|
|
|
2008
|
|
|
as reported
|
|
|
exchange rates
|
|
|
Number of treatments
|
|
|
29,425,758
|
|
|
|
27,866,573
|
|
|
|
6
|
%
|
|
|
|
|
Same market treatment growth in %
|
|
|
4.1
|
%
|
|
|
4.5
|
%
|
|
|
|
|
|
|
|
|
Revenue in $ million
|
|
|
11,247
|
|
|
|
10,612
|
|
|
|
6
|
%
|
|
|
9
|
%
|
Gross profit in % of revenue
|
|
|
34.1
|
%
|
|
|
34.2
|
%
|
|
|
|
|
|
|
|
|
Selling, general and administrative costs in % of revenue
|
|
|
17.6
|
%
|
|
|
17.7
|
%
|
|
|
|
|
|
|
|
|
Net income attributable to FMC-AG & Co. KGaA
in $ million
|
|
|
891
|
|
|
|
818
|
|
|
|
9
|
%
|
|
|
|
|
We provided 29,425,758 treatments during the year ended
December 31, 2009, an increase of 6% over the same period
in 2008. Same market treatment growth contributed 4% and growth
from acquisitions contributed 2%.
At December 31, 2009, we owned, operated or managed
(excluding those managed but not consolidated in the U.S.) 2,553
clinics compared to 2,388 clinics at December 31, 2008.
During 2009, we acquired 73 clinics, opened 118 clinics and
combined or closed 26 clinics. The number of patients treated in
clinics that we own, operate or manage (excluding patients of
clinics managed but not consolidated in the U.S.) increased by
6% to 195,651 at December 31, 2009 from 184,086 at
December 31, 2008. Including 30 clinics managed but not
consolidated in the U.S., the total number of patients was
197,358.
Net revenue increased by 6% (9% at constant exchange rates) for
the year ended December 31, 2009 over the comparable period
in 2008 due to growth in both dialysis care and dialysis
products revenues.
Dialysis care revenue grew by 8% to $8,350 million (10% at
constant exchange rates) in 2009 mainly due to growth in same
market treatments (4%), revenue per treatment (5%) and
acquisitions (1%), partially offset by exchange rate
fluctuations (2%).
Dialysis product revenue increased by 1% to $2,897 million
(increased by 6% at constant exchange rates) in the same period
driven by pharmaceutical sales, especially of the newly licensed
intravenous iron products and increased sales of dialyzers,
bloodlines, solutions and concentrates, as well as sales of
products for acute care treatments. These increases were
partially offset by decreased sales of our phosphate binding
drug
PhosLo
®
following a competitors launch of a generic version of the
drug in the U.S. in October 2008 and lower sales of
hemodialysis machines.
The slight decrease in gross profit margin reflects a decrease
in gross profit margin in North America, partially offset by an
increase in the International segment. North America was
impacted by cost increases for
57
pharmaceuticals as well as lower margin contribution from our
pharmaceutical business due to a competitors launch of a
generic version of
PhosLo
®
in the U.S. in October 2008, increased depreciation related
to recently acquired computer equipment and recently installed
leasehold improvements and higher personnel costs, partially
offset by increased revenue rates. The increase in International
was due to the positive effect of an inventory adjustment in the
first quarter of 2009, lower production costs caused by lower
prices for certain raw material and energy as well as economies
of scale, partially offset by unfavorable foreign exchange
transaction effects related to the purchase of products produced
in Europe and Japan due to the appreciation of the Euro and the
Yen against local currencies.
SG&A expenses increased to $1,982 million in 2009 from
$1,876 million in the same period of 2008. SG&A costs
as a percentage of sales decreased slightly to 17.6% in 2009
from 17.7% in the same period of 2008. The slight decrease was
due to a decrease in North America driven by economies of scale
and lower bad debt expenses partially offset by higher personnel
expenses. Bad debt expense for the year ended December 31,
2009 was $210 million as compared to $214 million in
2008, representing 1.9% of sales for the year ended
December 31, 2009, as compared to 2.0% for the same period
in 2008.
R&D expenses increased to $94 million in 2009 from
$80 million for the same period in 2008 due to additional
programs in the field of hemodialysis equipment and
extracorporeal critical care therapies.
Operating income increased to $1,756 million in 2009 from
$1,672 million for the same period in 2008. Operating
income margin decreased to 15.6% in 2009 as compared to 15.8%
for the same period in 2008 due to the decreased gross profit
margin as noted above partially offset by decreased SG&A
expenses as a percentage of sales as described above.
Interest expense decreased by 11% to $321 million in 2009
from $361 million for the same period in 2008 as a result
of decreased short-term interest rates.
Income tax expense increased to $491 million for the year
ended December 31, 2009 from $476 million for the same
period in 2008 as a result of higher earnings in 2009. The
effective tax rate for 2009 decreased to 33.7% from 35.6% in
2008 mainly as a result of an increase in non-taxable
noncontrolling interests in North America in 2009.
Net income attributable to FMC-AG & Co. KGaA for 2009
increased to $891 million from $818 million for the
same period in 2008 as a result of the combined effects of the
items discussed above.
We employed 67,988 people (full-time equivalents) as of
December 31, 2009 compared to 64,666 as of
December 31, 2008, an increase of 5.1% primarily due to
overall growth in our business.
The following discussions pertain to our business segments and
the measures we use to manage these segments.
North
America Segment
Key
Indicators for North America Segment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
|
2008
|
|
|
Change in %
|
|
|
Number of treatments
|
|
|
19,867,465
|
|
|
|
19,146,084
|
|
|
|
4
|
%
|
Same market treatment growth in %
|
|
|
3.5
|
%
|
|
|
2.9
|
%
|
|
|
|
|
Revenue in $ million
|
|
|
7,612
|
|
|
|
7,005
|
|
|
|
9
|
%
|
Depreciation and amortization in $ million
|
|
|
265
|
|
|
|
238
|
|
|
|
11
|
%
|
Operating income in $ million
|
|
|
1,250
|
|
|
|
1,168
|
|
|
|
7
|
%
|
Operating income margin in %
|
|
|
16.4
|
%
|
|
|
16.7
|
%
|
|
|
|
|
Revenue
Treatments increased by 4% for the year ended December 31,
2009 as compared to the same period in 2008 mostly due to same
market growth (4%) and acquisitions (1%), partially offset by
the effect of one less dialysis day of 1%. At December 31,
2009, 132,262 patients (a 5% increase over the same period
in the prior year) were being treated in the 1,784 clinics that
we own or operate in the North America segment, compared to
125,857 patients treated in 1,686 clinics at
December 31, 2008. Average North America revenue per
treatment was $341 for the year ended December 31, 2009 and
$326 in the same period in 2008. In the U.S., average revenue
per treatment was $347 for the year ended December 31, 2009
and $330 for the same period in 2008. The increase was mainly
attributable to a revenue per treatment increase, including
increased commercial payor revenue, increased utilization of
58
pharmaceuticals, including EPO, Medicare reimbursement increases
for pharmaceuticals (ASP+6%) and the 1% 2009 Medicare composite
rate increase.
Net revenue for the North America segment for 2009 increased as
a result of increases in dialysis care revenue by 9% to
$6,794 million from $6,247 million in the same period
of 2008 and in dialysis product revenue by 8% to
$818 million from $758 million in 2008.
The dialysis care revenue increase was driven by same market
treatment growth (4%), increased revenue per treatment (4%) and
acquisitions (1%). The administration of EPO represented
approximately 21% of total North America dialysis care
revenue for the year ended December 31, 2009 and 20% for
the year ended December 31, 2008.
The dialysis product revenue increase was driven mostly by a
higher pharmaceutical sales, especially of the newly licensed
intravenous iron products, partially offset by lower
PhosLo
®
revenues as a result of a competitors launch of a generic
version of
PhosLo
®
in the United States in October 2008.
Operating
Income
Operating income increased to $1,250 million for the year
ended December 31, 2009 from $1,168 million for the
same period in 2008. Operating income margin decreased to 16.4%
in 2009 from 16.7% in 2008 due to increased costs for
pharmaceuticals, lower margin contribution from our
pharmaceutical business due to a competitors launch of a
generic version of
PhosLo
®
in October 2008, higher personnel costs and increased
depreciation related to recently acquired computer equipment and
recently installed leasehold improvements, partially offset by
increased revenue per treatment as described above and decreased
bad debt expense. Cost per treatment increased to $283 in 2009
from $273 in 2008.
International
Segment
Key
Indicators for International Segment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in %
|
|
|
|
|
|
|
|
|
|
|
|
|
at constant
|
|
|
|
2009
|
|
|
2008
|
|
|
as reported
|
|
|
exchange rates
|
|
|
Number of treatments
|
|
|
9,558,293
|
|
|
|
8,720,489
|
|
|
|
10
|
%
|
|
|
|
|
Same market treatment growth in %
|
|
|
5.3
|
%
|
|
|
8.6
|
%
|
|
|
|
|
|
|
|
|
Revenue in $ million
|
|
|
3,635
|
|
|
|
3,606
|
|
|
|
1
|
%
|
|
|
9
|
%
|
Depreciation and amortization in $ million
|
|
|
183
|
|
|
|
171
|
|
|
|
8
|
%
|
|
|
|
|
Operating income in $ million
|
|
|
637
|
|
|
|
616
|
|
|
|
3
|
%
|
|
|
|
|
Operating income margin in %
|
|
|
17.5
|
%
|
|
|
17.1
|
%
|
|
|
|
|
|
|
|
|
Revenue
Treatments increased by 10% in 2009 over 2008 mainly due to same
market growth (5%) and acquisitions (5%). As of
December 31, 2009, 63,389 patients (a 9% increase over
the same period of the prior year) were being treated at 769
clinics that we own, operate or manage in the International
segment compared to 58,229 patients treated at 702 clinics
at December 31, 2008. Average revenue per treatment
decreased to $163 from $171 due to the weakening of local
currencies against the U.S. dollar ($15) partially offset
by increased reimbursement rates and changes in country mix ($7).
Net revenues for the International segment for the year ended
December 31, 2009 increased by 1% as compared to the same
period in 2008 as a result of an increase in dialysis care
revenue partially offset by a decrease in dialysis product
revenue. Organic growth during the period of 8% and a
contribution from acquisitions of approximately 2% were
partially offset by a negative impact of exchange rate
fluctuations of 8% as well as the effect of closed or sold
clinics of 1%.
Including the effects of acquisitions, European region revenue
decreased 1% (8% increase at constant exchange rates), Latin
America region revenue increased 5% (16% increase at constant
exchange rates), and Asia Pacific region revenue increased 6%
(8% increase at constant exchange rates).
Total dialysis care revenue for the International segment
increased during 2009 by 4% (14% increase at constant exchange
rates) to $1,556 million from $1,490 million in the
same period of 2008. This increase is a result of increases in
revenue per treatment of 6%, same market growth of 5% and a 4%
increase in contributions from
59
acquisitions, partially offset by of the negative impact of
exchange rate fluctuations of approximately 10% as well as the
effect of one less dialysis day of 1%.
Total dialysis product revenue for 2009 decreased by 2% (6%
increase at constant exchange rates) to $2,079 million.
Increased pharmaceutical sales especially related to newly
licensed intraveneous iron products, and increased sales of
dialyzers, bloodlines, hemodialysis solutions and concentrates
as well as sales of products for acute care treatment were more
than offset by the negative impact of exchange rate fluctuations
(8%) and lower sales of hemodialysis machines.
Operating
Income
Operating income increased by 3% to $637 million. Operating
income margin increased to 17.5% for the year ended
December 31, 2009 from 17.1% for the same period in 2008
due to lower production costs as a result of lower prices for
certain raw material and energy, economies of scale and the
positive effect of an inventory adjustment in the first quarter
of 2009, partially offset by unfavorable foreign currency
transaction effects related to the purchase of products produced
in Europe and Japan due to the appreciation of the Euro and Yen
against local currencies.
|
|
B.
|
Liquidity
and Capital Resources
|
Our primary sources of liquidity have historically been cash
from operations, cash from borrowings from third parties and
related parties, as well as cash from issuance of equity and
debt securities. We require this capital primarily to finance
working capital needs, to fund acquisitions and develop
free-standing renal dialysis centers, to purchase equipment for
existing or new renal dialysis centers and production sites, to
repay debt and to pay dividends.
At December 31, 2010, we had cash and cash equivalents of
$523 million. For information regarding utilization and
availability under our Amended 2006 Senior Credit Agreement, see
Note 9, Long-term Debt and Capital Lease
Obligations in our Consolidated Financial Statements
included in this Report.
Operations
In 2010, 2009 and 2008, we generated cash flows from operations
of $1,368 million, $1,339 million and
$1,016 million, respectively. Cash from operations is
impacted by the profitability of our business, the development
of our working capital, principally receivables, and cash
outflows that occur due to a number of singular specific items
(especially payments in relation to disallowed tax deductions
and legal proceedings). The increase in 2010 versus 2009 was
mainly a result of improvements in elements of working capital,
including decreased levels of inventory, and increased earnings,
partially offset by higher income tax payments. In addition,
there was unfavorable days sales outstanding (DSO)
development in 2010 as compared to 2009.
The profitability of our business depends significantly on
reimbursement rates. Approximately 75% of our revenues are
generated by providing dialysis treatment, a major portion of
which is reimbursed by either public health care organizations
or private insurers. For 2010, approximately 32% of our
consolidated revenues were attributable to U.S. federal
health care benefit programs, such as Medicare and Medicaid
reimbursement. Legislative changes could affect Medicare
reimbursement rates for a significant portion of the services we
provide, as well as the scope of Medicare coverage. A decrease
in reimbursement rates or the scope of coverage could have a
material adverse effect on our business, financial condition and
results of operations and thus on our capacity to generate cash
flow. In the past we experienced and, after the implementation
of the new ESRD PPS in the U.S., also expect in the future
generally stable reimbursements for our dialysis services. This
includes the balancing of unfavorable reimbursement changes in
certain countries with favorable changes in other countries. See
Overview above for a discussion of recent Medicare
reimbursement rate changes including provisions for
implementation of a bundled rate for dialysis
services provided after January 1, 2011.
Our working capital was $1,363 million at December 31,
2010 which decreased from $2,118 million at
December 31, 2009, mainly as a result of the
reclassification of the Trust Preferred Securities into
short-term debt, increased short-term borrowings under the
accounts receivable facility, an increase in accrued expenses
and other current liabilities and the recognition of the current
portion of long-term debt related to acquisitions, partially
offset by an increase in cash and cash equivalents, trade
accounts receivable and prepaid expenses and other current
assets. Our Trust Preferred Securities are due on
June 15, 2011 and as a result, $626 million
($656 million at December 31, 2009 exchange rates) was
reclassified as short-term debt during the second quarter of
2010. Our ratio of current assets to current liabilities was 1.4
at December 31, 2010.
Our financing activities are focused on the transition of our
debt portfolio to single tier and on lengthening the average
maturity of our debt. Furthermore, we intend to maintain
sufficient financial resources in the coming years.
60
We obtained long-term financing during the current financial
year through the issuance of 250 million principal
amount of senior notes and through the amendment and extension
of our 2006 Senior Credit Agreement, see Financing
below. We have sufficient financial resources, consisting of
only partly drawn credit facilities and our accounts receivable
facility, which was recently renewed and increased from
$650 million to $700 million. By obtaining additional
financing such as the proceeds from the $1,050 million bond
offering closed on February 3, 2011 see
Financing below, we aim to preserve financial
resources with a minimum of $300 to $500 million of
committed and unutilized credit facilities.
Cash from operations depends on the collection of accounts
receivable. Customers and governments generally have different
payment cycles. A lengthening of their payment cycles could have
a material adverse effect on our capacity to generate cash flow.
In addition, we could face difficulties in enforcing and
collecting accounts receivable under some countries legal
systems. Accounts receivable balances at December 31, 2010
and December 31, 2009, net of valuation allowances,
represented DSO of approximately 76 and 72, respectively.
The development of DSO by operating segment is shown in the
table below:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
North America days sales outstanding
|
|
|
54
|
|
|
|
52
|
|
|
|
|
|
|
|
|
|
|
International days sales outstanding
|
|
|
116
|
|
|
|
110
|
|
|
|
|
|
|
|
|
|
|
FMC AG & Co. KGaA average days sales outstanding
|
|
|
76
|
|
|
|
72
|
|
|
|
|
|
|
|
|
|
|
DSO performance in the North America segment continued to be
strong between December 31, 2009 and 2010. The increase in
DSO for the International segment mainly reflects average
payment delays, mostly in Europe, by government and private
entities most recently impacted by the worldwide financial
crises. Due to the fact that a large portion of our
reimbursement is provided by public health care organizations
and private insurers, we expect that most of our accounts
receivables will be collectable, albeit potentially more slowly
in the International segment in the immediate future,
particularly in countries which continue to be severely affected
by the global financial crisis. Interest and income tax payments
also have a significant impact on our cash from operations. We
anticipate a slight increase in DSO in the North America segment
in 2011 as a result of the implementation of the ESRD PPS for
dialysis services provided after January 1, 2011 due to the
coordination of insurance coverage between the U.S. federal
and state governments.
There are a number of tax and other items we have identified
that will or could impact our cash flows from operations in the
immediate future as follows:
We filed claims for refunds contesting the Internal Revenue
Services (IRS) disallowance of FMCHs
civil settlement payment deductions taken by Fresenius Medical
Care Holdings, Inc. (FMCH) in prior year tax
returns. As a result of a settlement agreement with the IRS, we
received a partial refund in September 2008 of $37 million,
inclusive of interest and preserved our right to pursue claims
in the United States Courts for refunds of all other disallowed
deductions. On December 22, 2008, we filed a complaint for
complete refund in the United States District Court for the
District of Massachusetts, styled as Fresenius Medical Care
Holdings, Inc. v. United States. On June 24, 2010, the
court denied FMCHs motion for summary judgment and the
litigation is proceeding towards trial.
For the tax year 1997, we recognized an impairment of one of our
subsidiaries which the German tax authorities disallowed in 2003
at the conclusion of its audit for the years 1996 and 1997. We
have filed a complaint with the appropriate German court to
challenge the tax authoritys decision. In January 2011, we
reached an agreement with the tax authorities, estimated to be
slightly more favorable than the tax benefit recognized
previously. The additional benefit will be recognized in 2011.
The IRS tax audits of FMCH for the years 2002 through 2006 have
been completed. The IRS has disallowed all deductions taken
during these audit periods related to intercompany mandatorily
redeemable preferred shares. We have protested the disallowed
deductions and will avail ourselves of all remedies. An adverse
determination with respect to the disallowed deductions related
to intercompany mandatorily redeemable preferred shares could
have a material adverse effect on our results of operations and
liquidity. In addition, the IRS proposed other adjustments which
have been recognized in our financial statements.
We are subject to ongoing and future tax audits in the U.S.,
Germany and other jurisdictions. We have received notices of
unfavorable adjustments and disallowances in connection with
certain of the audits, including those described above. We are
contesting, including appealing, certain of these unfavorable
determinations. If our objections and any final audit appeals
are unsuccessful, we could be required to make additional tax
payments,
61
including payments to state tax authorities reflecting the
adjustments made in our federal tax returns in the
U.S. With respect to other potential adjustments and
disallowances of tax matters currently under review, where
tentative agreement has been reached, we do not anticipate that
an unfavorable ruling could have a material impact on our
results of operations. We are not currently able to determine
the timing of these potential additional tax payments.
W.R. Grace & Co. and certain of its subsidiaries filed
for reorganization under Chapter 11 of the
U.S. Bankruptcy Code (the Grace Chapter 11
Proceedings) on April 2, 2001. The settlement
agreement with the asbestos creditors committees on behalf of
the W.R. Grace & Co. bankruptcy estate (see
Note 18 of the Notes to Consolidated Financial Statements,
Commitments and Contingencies Legal
Proceedings Commercial Litigation) provides
for payment by the Company of $115 million upon approval of
the settlement agreement by the U.S. District Court, which
has occurred, and confirmation of a W.R. Grace & Co.
bankruptcy reorganization plan that includes the settlement. On
January 31, 2011, the U.S. Bankruptcy Court approved W.R.
Grace & Co.s plan of reorganization, including the
settlement agreement, and recommended approval of the plan to
the U.S. District Court. The $115 million obligation
was included in the special charge we recorded in 2001 to
address 1996 merger-related legal matters. The payment
obligation is not interest-bearing.
If the potential additional tax payments discussed above and the
Grace Chapter 11 Proceedings settlement payment were to
occur contemporaneously, there could be a material adverse
impact on our operating cash flow in the relevant reporting
period. Nonetheless, we anticipate that cash from operations
and, if required, our senior credit agreement and other sources
of liquidity will be sufficient to satisfy all such obligations
if and when they come due.
Investing
We used net cash of $1,125 million, $698 million and
$891 million in investing activities in 2010, 2009 and
2008, respectively.
Capital expenditures for property, plant and equipment, net of
disposals were $507 million in 2010, $562 million in
2009 and $673 million in 2008. In 2010, capital
expenditures were $286 million in the North America segment
and $221 million for the International segment. Capital
expenditures in 2009 were $295 million in the North America
segment and $267 million for the International segment. In
2008, capital expenditures were $384 million in the North
America segment and $289 for the International segment. The
majority of our capital expenditures was used for maintaining
existing clinics, equipping new clinics, maintenance and
expansion of production facilities primarily in North America
and Germany and capitalization of machines provided to our
customers, primarily in the International segment. Capital
expenditures were approximately 4%, 5% and 6% of total revenue
for 2010, 2009 and 2008, respectively.
We invested approximately $632 million cash in 2010,
primarily for acquisitions of dialysis clinics, the formation of
a new renal pharmaceutical company with Galenica, Ltd. (subject
to final anti-trust approval in certain regions), the
acquisition of licenses, and the acquisition of Gambros
peritoneal dialysis business outside the United States
($237 million in the North America segment,
$373 million in the International segment and
$22 million at Corporate), as compared to $188 million
cash in 2009 ($124 million in the North America segment and
$64 million in the International segment) and
$227 million cash in 2008 ($113 million in the North
America segment, $57 million in the International segment
and $57 million at Corporate). In addition, we invested
100 million ($133 million at September 30,
2010) in short-term investments with banks during 2010,
which were divested during the fourth quarter of 2010. We also
received $14 million, $2 million and $59 million
in conjunction with divestitures in 2010, 2009 and 2008,
respectively. In 2008, we granted a loan of $50 million to
Fresenius SE, our parent, which they repaid on April 30,
2009.
We anticipate capital expenditures of approximately 5% of
revenues and expect to make acquisitions of approximately
$1,200 million in 2011, including the
485 million acquisition of International Dialysis
Centers, the dialysis service business of Euromedic
International, which we announced on January 4, 2011. See
Outlook below.
Financing
Net cash used in financing was $15 million in 2010 compared
to net cash used in financing of $558 million and
$156 million in 2009 and 2008, respectively.
In 2010, cash was used to reduce borrowings under our credit
facilities and to pay dividends. This was partially offset by
the issuance of 5.5% Senior Notes in January 2010, drawings
under our accounts receivable facility and other short term
borrowings. In 2009, cash was mainly used for the repayment of
the current portion of long-term debt including the Euro Notes
in the amount of $279 million (200 million) that
were due and repaid on July 27, 2009, reducing the amount
outstanding under our accounts receivable securitization
facility (A/R Facility), and the
62
payment of dividends partially offset by the issuance of
long-term debt and borrowings under other existing long-term
debt facilities. In 2008, cash was mainly used for redemption of
trust preferred securities ($678 million), the payment of
dividends ($252 million) and the payment in November 2008
of the remaining financial liability relating to the 2007 RSI
Acquisition ($56 million); we raised cash from our A/R
Facility and other existing long-term credit facilities.
For further discussion of our 2010 acquisitions and investments,
see Item 4.B., Business Overview Our
Strategy and Competitive Strengths Growth
Paths Path 2 Acquisitions and
Path 3 Horizontal
Expansion.
The following table summarizes the Companys available
sources of liquidity at December 31, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
Available Sources of Liquidity
|
|
|
|
|
Expiration per period of
|
|
in millions
|
|
Total
|
|
|
1 Year
|
|
|
2-5 Years
|
|
|
Accounts receivable
facility
(a)
|
|
$
|
190
|
|
|
$
|
190
|
|
|
$
|
|
|
Amended 2006 Senior Credit Agreement
|
|
|
997
|
|
|
|
|
|
|
|
997
|
|
Other Unused Lines of Credit
|
|
|
234
|
|
|
|
234
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,421
|
|
|
$
|
424
|
|
|
$
|
997
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
Subject to availability of sufficient accounts receivable
meeting funding criteria.
|
The amount of guarantees and other commercial commitments at
December 31, 2010 is not significant.
At December 31, 2010, we have short-term borrowings,
excluding the current portion of long-term debt, of
$671 million.
The following table summarizes, as of December 31, 2010,
our obligations and commitments to make future payments under
our long-term debt, trust preferred securities and other
long-term obligations, and our commitments and obligations under
lines of credit and letters of credit.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contractual Obligations and Commitments
|
|
|
|
|
Payments due by period of
|
|
in millions
|
|
Total
|
|
|
1 Year
|
|
|
2-5 Years
|
|
|
Over 5 Years
|
|
|
Trust Preferred Securities
|
|
$
|
650
|
|
|
$
|
650
|
|
|
$
|
|
|
|
$
|
|
|
Long Term
Debt
(a)(b)
|
|
|
5,142
|
|
|
|
435
|
|
|
|
3,770
|
|
|
|
937
|
|
Capital Lease Obligations
|
|
|
16
|
|
|
|
5
|
|
|
|
8
|
|
|
|
3
|
|
Operating Leases
|
|
|
2,796
|
|
|
|
490
|
|
|
|
1,396
|
|
|
|
910
|
|
Unconditional Purchase Obligations
|
|
|
2,164
|
|
|
|
374
|
|
|
|
1,071
|
|
|
|
719
|
|
Other Long-term Obligations
|
|
|
33
|
|
|
|
24
|
|
|
|
9
|
|
|
|
|
|
Letters of Credit
|
|
|
122
|
|
|
|
|
|
|
|
122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
10,923
|
|
|
$
|
1,978
|
|
|
$
|
6,376
|
|
|
$
|
2,569
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
Includes expected interest payments which are based upon the
principal repayment schedules and fixed interest rates or
estimated variable interest rates considering the applicable
interest rates (e.g. Libor, Prime), the applicable margins, and
the effects of related interest rate swaps.
|
|
(b)
|
Excludes our 5.75% and 5.25% Senior Notes due 2021 issued
on February 3, 2011 (5.75% Senior Notes
and 5.25% Senior Notes ).
|
Our obligations under the Amended 2006 Senior Credit Agreement
are secured by pledges of capital stock of certain material
subsidiaries, including FMCH and D-GmbH, in favor of the
lenders. Our Amended 2006 Senior Credit Agreement, EIB
agreements, Euro Notes, Senior Notes and the indentures relating
to our Trust Preferred Securities include covenants that
require us to maintain certain financial ratios or meet other
financial tests. Under our Amended 2006 Senior Credit Agreement,
we are obligated to maintain a minimum consolidated fixed charge
ratio (ratio of consolidated EBITDAR (sum of EBITDA plus Rent
expense under operation leases) to Consolidated Fixed Charges as
these terms are defined in the 2006 Senior Credit Agreement) and
a maximum consolidated leverage ratio (ratio of consolidated
funded debt to consolidated EBITDA as these terms are defined in
the Amended 2006 Senior Credit Agreement). Other covenants in
one or more of each of these agreements restrict or have the
effect of restricting our ability to dispose of assets, incur
debt, pay dividends and make other restricted payments, create
liens or engage in sale-lease backs.
The breach of any of the covenants in any of the instruments or
agreements governing our long-term debt the Amended
2006 Senior Credit Agreement, the EIB agreements, the Euro
Notes, the Senior Notes or the notes
63
underlying our Trust Preferred Securities
could, in turn, create additional defaults under one or more of
the other instruments or agreements. In default, the outstanding
balance under the Amended 2006 Senior Credit Agreement becomes
due at the option of the lenders under that agreement, and the
cross default provisions in our other long-term debt
permit the lenders to accelerate the maturity of the debt upon
such a default as well. As of December 31, 2010, we are in
compliance with all covenants under the Amended 2006 Senior
Credit Agreement and our other financing agreements. For
information regarding our Amended 2006 Senior Credit Agreement,
EIB agreements, Euro Notes, Senior Notes and the indentures
relating to our Trust Preferred Securities, see Note 9
and Note 11 of the Notes to Consolidated Financial
Statements, Long-Term Debt and Capital Lease
Obligations and Mandatorily Redeemable
Trust Preferred Securities.
Although we are not immune from the global financial crisis, we
believe that we are well positioned to continue to grow our
business while meeting our financial obligations as they come
due. Our business is generally not cyclical. A substantial
portion of our accounts receivable are generated by governmental
payers. While payment and collection practices vary
significantly between countries and even between agencies within
one country, government payors usually represent low credit
risks. However, limited or expensive access to capital could
make it more difficult for our customers to do business with us,
or to do business generally, which could adversely affect our
business by causing our customers to reduce or delay their
purchases of our dialysis products. See Results of
Operations above. If the current conditions in the credit
and equity markets continue, or worsen, they could also increase
our financing costs and limit our financial flexibility.
Following our earnings-driven dividend policy, our General
Partners Management Board will propose to the shareholders
at the Annual General meeting on May 12, 2011, a dividend
with respect to 2010 and payable in 2011, of 0.65 per
ordinary share (for 2009 paid in 2010: 0.61) and
0.67 per preference share (for 2009 paid in 2010:
0.63). The total expected dividend payment is
approximately 197 million (approximately
$263 million based upon the December 31, 2010 spot
rate) compared to dividends of 183 million
($232 million) paid in 2010 with respect to 2009. Our
Amended 2006 Senior Credit Agreement limits disbursements for
dividends and other payments for the acquisition of our equity
securities (and rights to acquire them, such as options or
warrants) during 2011 to $330 million in total.
On February 3, 2011, our wholly owned subsidiaries,
Fresenius Medical Care US Finance, Inc. and FMC Finance VII
S.A., issued $650 million and 300 million
(approximately $412 million at the date of issuance) of
5.75% Senior Notes and 5.25% Senior Notes,
respectively. The 5.75% Senior Notes had an issue price of
99.060% and have a yield to maturity of 5.875%. The
5.25% Senior Notes were issued at par. Both the
5.75% Senior Notes and the 5.25% Senior Notes are due
February 15, 2021. Net proceeds were or will be used to
repay indebtedness outstanding under our A/R Facility and the
revolving credit facility of the Amended 2006 Senior Credit
Agreement, for acquisitions, including payments under our recent
acquisition of International Dialysis Centers announced on
January 4, 2011, and for general corporate purposes to
support our renal dialysis products and services business. Both
the 5.75% and the 5.25% Senior Notes are guaranteed on a
senior basis jointly and severally by us, FMCH and Fresenius
Medical Care Deutschland GmbH (D-GmbH).
On September 29, 2010, we amended and extended the 2006
Senior Credit Agreement (as amended to-date and as it may be
further modified or amended, our Amended 2006 Senior
Credit Agreement). The significant changes are as follows:
|
|
|
|
|
The $1,000 million revolving credit facility has been
increased to $1,200 million and is now due and payable on
March 31, 2013, an extension from the original due date of
March 31, 2011.
|
|
|
|
The Term Loan A facility was increased by $50 million to
$1,365 million and its maturity extended from
March 31, 2011 to March 31, 2013, and will be repaid
in quarterly payments of $30 million which started on
December 31, 2010, with the remaining balance due and
payable in full on March 31, 2013.
|
|
|
|
The early repayment requirement for the Term Loan B, which
stipulated that Term Loan B was subject to early retirement if
the Trust Preferred Securities due June 15, 2011 were
not paid, refinanced or extended prior to March 1, 2011,
has been removed.
|
|
|
|
The definition of the Companys Consolidated Leverage
Ratio, which is used to determine the applicable margin, was
amended to allow for the reduction of up to $250 million
(increased from $30 million) of cash and cash equivalents
from Consolidated Funded Debt, as defined in the initial 2006
Senior Credit Agreement. The applicable margin is then added to
LIBOR to determine the interest rate for the appropriate period.
In addition, the Amended 2006 Senior Credit Agreement includes
increases in certain types of permitted borrowings outside of
the Amended 2006 Senior Credit Agreement and provides further
flexibility for certain types of investments.
|
64
|
|
|
|
|
The limitation on dividends and other restricted payments
($300 million for dividends in 2010 under the 2006 Senior
Credit Agreement) has been set for up to $330 million in
2011 and increases by $30 million each year through 2013.
|
On September 28, 2010, we renewed our accounts receivable
facility and increased available borrowings under the facility
from $650 million to $700 million.
On February 17, 2010, a 50 million
($67 million at December 31, 2010) loan was
disbursed from our 2009 agreement with the European Investment
Bank (EIB). The loan is due in 2014. In addition, on
March 15, 2010, we drew down the remaining
$80.8 million available on our 2005 revolving credit
agreement with the EIB, maturing in 2013. Both loans bear
variable interest rates which are based on EURIBOR or LIBOR, as
applicable, plus an applicable margin. These interest rates
change every three months.
On January 20, 2010, our wholly owned subsidiary, FMC
Finance VI S.A., issued 250 million
($353.3 million at date of issuance) aggregate principal
amount of 5.50% Senior Notes at an issue price of 98.6636%
of the principal amount. The 5.50% Senior Notes had a yield
to maturity of 5.75% and are due July 15, 2016. Proceeds
were used to repay short-term indebtedness and for general
corporate purposes. The 5.50% Senior Notes are guaranteed
on a senior basis jointly and severally by us, FMCH and D-GmbH.
In addition to the annual renewal of our accounts receivable
facility described above, our 2011 financing needs are limited
to the 485 million payment for our acquisition of
International Dialysis Centers, which we announced on
January 4, 2011, the dividend payment of approximately
$263 million in May 2011, which is expected to be covered
by cash flow from operations and from existing credit
facilities, and the amount due upon maturity of our
Trust Preferred Securities in June 2011 (See Note 11
of the Notes to Consolidated Financial Statements,
Mandatorily Redeemable Trust Preferred
Securities) of approximately $626 million at
December 31, 2010, which we expect to meet by entering into
diverse capital market transactions. We currently have
sufficient flexibility under our debt covenants to meet our
financing needs in the near future. Generally, we believe that
we will have sufficient financing to achieve our goals in the
future and to continue to promote our growth.
Outlook
Below is a table showing our growth outlook for 2011 and 2012:
|
|
|
|
|
|
|
2011
|
|
2012
|
|
Revenue
|
|
$12.8- $13.0
billion
|
|
|
Revenue growth*
|
|
6-8%
|
|
6-8%
|
Net Income attributable to FMC-AG & Co. KGaA
|
|
$1,035- $1,055
million
|
|
> revenue growth
|
Dividends
|
|
based on
development of
earnings
|
|
based on
development of
earnings
|
Capital Expenditures in % of revenue
|
|
~
5%
|
|
|
Acquisitions
|
|
~
$1,200 million
|
|
|
Capital Expenditures and Acquisitions in % of revenue
|
|
14%
|
|
~
7%
|
Tax Rate
|
|
34.5-35%
|
|
35-36%
|
Debt/EBITDA Ratio
|
|
£
2.8
|
|
£
2.8
|
Debt
covenant disclosure EBITDA
EBITDA (earnings before interest, tax, depreciation and
amortization expenses) was approximately $2,427 million,
20.1% of revenues for 2010, $2,213 million, 19.7% of
revenues for 2009 and $2,088 million, 19.7% of revenues for
2008. EBITDA is the basis for determining compliance with
certain covenants contained in our Amended 2006 Senior Credit
Agreement, Euro Notes, EIB, and the indentures relating to our
Senior Notes and our outstanding Trust Preferred
Securities. You should not consider EBITDA to be an alternative
to net earnings determined in accordance with U.S. GAAP or
to cash flow from operations, investing activities or financing
activities. In addition, not all funds depicted by EBITDA are
available for managements discretionary use. For example,
a substantial portion of such funds are subject to contractual
restrictions and functional requirements for debt service, to
fund necessary capital expenditures and to meet other
commitments from time to time as described in more detail
elsewhere in this report. EBITDA, as calculated, may not be
comparable to similarly titled measures
65
reported by other companies. A reconciliation of EBITDA to cash
flow provided by operating activities, which we believe to be
the most directly comparable U.S. GAAP financial measure,
is calculated as follows:
Reconciliation
of measures for consolidated totals
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the years ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(in thousands)
|
|
|
Total EBITDA
|
|
$
|
2,427,029
|
|
|
$
|
2,212,681
|
|
|
$
|
2,088,103
|
|
Interest expense (net of interest income)
|
|
|
(280,064
|
)
|
|
|
(299,963
|
)
|
|
|
(336,742
|
)
|
Income tax expense, net
|
|
|
(578,345
|
)
|
|
|
(490,413
|
)
|
|
|
(475,702
|
)
|
Change in deferred taxes, net
|
|
|
14,687
|
|
|
|
22,002
|
|
|
|
133,047
|
|
Changes in operating assets and liabilities
|
|
|
(236,647
|
)
|
|
|
(139,494
|
)
|
|
|
(403,123
|
)
|
Stock Compensation expense
|
|
|
27,981
|
|
|
|
33,746
|
|
|
|
31,879
|
|
Other items, net
|
|
|
(6,516
|
)
|
|
|
58
|
|
|
|
(21,064
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
$
|
1,368,125
|
|
|
$
|
1,338,617
|
|
|
$
|
1,016,398
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recently
Issued and Implemented Accounting Standards
For a discussion of recently issued and implemented accounting
standards, see Note 1 of the Notes to Consolidated
Financial Statements The Company, Basis of Presentation,
Health Care Reform and Summary of Significant Accounting
Policies Summary of Significant Accounting
Policies t) Recent Pronouncements.
|
|
C.
|
Research
and Development
|
As a leading global dialysis company, we focus our R&D
strategy on three essential objectives: first, to continuously
enhance the quality of life of patients with chronic kidney
disease using innovative products and treatment concepts;
second, to offer our customers high-quality services while
keeping our prices as low as possible; and third, to continue to
expand our position as the dialysis market leader. Due to our
vertical integration, our research and development department
can apply our experience as the worlds largest provider of
dialysis treatments to product development, and our technical
department benefits from our daily practical experience as a
provider of dialysis treatment and being directly in-touch with
doctors, nurses and patients to keep track of and meet customer
and patient needs. In addition, our research and development
units are usually located at production sites, enabling direct
exchange of ideas with our production staff. We conduct annual
internal R&D conferences which our employees attend every
year. In addition, our employees visit research events worldwide
and participate actively in scientific discourse. This not only
enables them to inject new concepts into their work, but also
strengthens our reputation in the international professional
community. We also maintain close contacts with universities and
research institutions. We are cooperating closely with the
University of Michigan (on a longitudinal study of chronic
kidney patients), Danube University Krems in Krems, Austria (on
extracorporeal methods), and the Renal Research Institute
(RRI) in the United States. RRI was founded in 1997
as a joint venture between Fresenius Medical Care North America
and the Beth Israel Medical Center, a hospital in New York.
Together, we are researching the fundamental issues of dialysis
treatment, including the causes that lead to kidney failure, the
particular features of treating children with ESRD, and issues
such as the mineralization of dialysis patients bones or
the effects of kidney diseases on the natural acid-base balance
in the human body.
The task of our research and development group, which employs
approximately 503 full time equivalents, is to continually
develop and improve our products and treatments. Our largest
research and development department is R&D International
with 335 employees, most of whom work at our Schweinfurt
and Bad Homburg locations. Smaller teams also work in St. Wendel
and in Romania, where an R&D competency center specializing
in software development has been established. In September 2010,
we opened a new research lab in Krems, which specializes in
sorbent technology. Apart from R&D International, we have
research and development departments in the North America and
the Asia Pacific regions. All of these units are closely
connected and cooperate on many projects.
Research and development expenditures amounted to
$97 million in 2010, compared to $94 million and
$80 million in 2009 and 2008, respectively. Our 2010
expenditures focused on continuously enhancing and improving our
products and treatment concepts for our patients and users, on
membrane development in connection with our work on a wearable
artificial kidney, on dialysis patient overhydration, on
software for enhanced patient safety during unattended dialysis
and data management for dialysis clinics, and on an
extracorporeal hepatic (liver) assist device. A discussion of
each of these activities follows below.
66
Home
Dialysis and Wearable Artificial Kidney
In HD, a dialyzer outside of the body filters the blood.
Traditionally, 120 to 200 liters of water are needed for each
treatment. For this reason, among others, PD is presently the
home therapy of choice. However, we are researching ways of
reducing water consumption per treatment, which would enable
widespread use of HD as a therapy outside of dialysis clinics.
In 2007, we acquired Renal Solutions, Inc. (RSI),
which is continuing to do intensive research in the field of
sorbent-based technology, helping to create a potential platform
for the eventual development of a wearable artificial kidney. In
2010, we acquired medical technology company Xcorporeal, which
is working on sorbent-based solutions for mobile and wearable
dialysis machines for both clinical and home use. Sorbents are
substances that bind toxins in liquids so that they can be
removed. These sorbents can be used to recycle dialysis
solution, which absorbs toxins during HD or PD treatment that
have been filtered out of the patients blood. By cleansing
and then recycling the dialysate with the help of sorbents, the
amount of water typically needed during dialysis treatment can
be reduced from 120 to 200 liters to approximately six to ten
liters. This innovative sorbent technology is particularly
important for our wearable kidney project, as a
device of this kind must be able to function with a
substantially smaller amount of liquid to be light and small
enough to be worn on the body.
During 2010, we also worked on the development of
ion-rejecting membranes. This two-layer membrane
allows transport of urea while at the same time inhibiting the
transport of electrolytes. Such membranes, combined with the use
of sorbents to regenerate (rather than remove and replace)
peritoneal dialysis solution, may provide the potential for a
wearable dialysis system in a PD-based wearable artificial
kidney. We have applied for a number of patents relating to our
ion-rejecting membrane.
Body
Composition Monitor (BCM)
We originally introduced our Body Composition Monitor in
selected markets in 2008 and successfully launched in additional
markets in 2009. The BCM can precisely measure the composition
of the human body and its fluids (body water, fat and fat-free
body mass). This provides doctors with information on the
patients general health, such as the constitution of their
blood vessels, and helps them to determine to what extent a
patient may be suffering from overhydration. Such information
can substantially improve the treatment quality of dialysis, as
heart and vascular diseases as a result of overhydration are
frequent causes of death for dialysis patients. The BCM and the
clinical analysis methods we developed made it possible for the
first time to demonstrate conclusively that overhydration beyond
a specified threshold carries a significant mortality risk for
dialysis patients and that correction of this condition
significantly improves a patients survival chances. While
these findings were expected in HD patients, our recent research
has demonstrated that this silent risk of
overhydration is even more prevalent in PD patients and that PD
patients can also benefit immensely from professional
fluid management, a regular check of their fluid
status with the treatment adjusted accordingly. Going forward,
we plan to use the BCM for acute dialysis patients and also as a
central monitoring element for the management of patient
hydration balance as well as for management of ESA
(erythropoiesis-stimulating agent) use, because overhydration
tends to diminish the effectiveness of EPO and other ESAs.
Software
Development
One of the most severe hazards during kidney dialysis and other
extracorporeal blood purification treatments is blood loss due
to technical or human error, which can occur suddenly, be
dangerously high and lead to death in a short time. This risk is
especially significant during dialysis performed while the
patient sleeps. Because dialysis treatment while the patient
sleeps is typically of longer duration, such treatment can be
especially effective, but reducing the risk of blood loss during
such unattended treatment is essential. Wetness
detectors built into dialysis machines can monitor the
patients vascular access and set off an alarm if leakage
is detected. During 2010, we successfully tested a
software-based method of blood loss prevention
Venous Needle Disconnect, or VND. The software uses
intelligent signal analysis in the area of extracorporeal
pressure to detect dangerous conditions in the bloodline system,
including needle disconnects at the point of vascular access,
leakage, and bent tubing. Based on a mathematical algorithm that
accounts for normal disturbances and pressure deviations (such
as those resulting from patient arm movement), the software
detects pressure drops due to leakage or needle slip, sets off
an alarm and turns off the blood pump and closes the venous
clamp automatically. We have scheduled the market launch of VND
for 2011. It will be integrated into the monitors in our 4008
and 5008 Series dialysis machines as part of our regular
software updates for both clinical and home use. Combined with
wetness detectors, VND is expected to significantly reduce blood
loss risk during dialysis.
During 2010, we also continued work on the creation of an
integrated data management system for dialysis clinics
reflecting the entire work flow and data base of these complex
clinical units, enabling staff to have fast and efficient access
to all required information from any point within the system.
67
Hepatic
Assist
During 2010, we also conducted research on treatment of
hepatorenal syndrome, or HRS, a life-threatening rapid
deterioration in kidney function in patients with cirrhosis or
liver failure. HRS is usually fatal unless a liver transplant is
performed, but donor organs are in short supply. In some cases,
the liver can recover its function, and research has explored
extracorporeal treatment for liver failure i.e.,
taking over a damaged livers functions in a manner
comparable to renal dialysis for kidney failure. We have
developed Prometheus, which removes toxins from the liver
through fractionated plasma separation (apheresis) and
adsorption. Although the HELIOS study of the Prometheus device,
presented in 2010, did not show any significant overall
difference in survival for patients treated with Prometheus and
those treated with standard therapy, among patients having the
most severe liver disease and the lowest life expectancy, the
group treated with Prometheus showed a probability of survival
that was 36% greater than the group receiving standard
treatment. This offers some encouragement inasmuch as the longer
a patient survives, the greater the chance that the liver will
regenerate or that a suitable organ for transplant will become
available.
Outlook
We intend to continue investing in developing and improving
life-sustaining products and treatment concepts in the years to
come, thus improving the quality of life for as many patients as
possible with financially viable, environmentally-friendly
innovations based on strategic technology platforms. We plan to
spend approximately $105 million and $112 million on
research and development in 2011 and 2012, respectively.
Our focus of R&D in the coming years will be to develop
innovations that incorporate additional treatment elements into
our products or to help better align them, with the goal of
improving the quality, safety and cost efficiency of treatment.
In addition, we will continue to focus our software development
efforts on developing integrated system solutions for clinical
quality data management in order to enable a larger volume of
data to be captured faster and more easily, enhance the quality
of the data and thus improve treatment. In general, we will
continue to look into the issue of how new scientific and
technological findings can be used to further improve the
quality of life of patients with chronic kidney failure, such as
through innovations in home therapies. Over the long term, we
are conducting research in the transferability of the
blood-cleansing dialysis process to other illnesses, such as
liver disease or certain autoimmune and metabolic disorders. We
are also researching new approaches to treating severe kidney
and liver disease through regenerative medicine, through
cooperations with scientific institutes and universities that
conduct research on adult liver and kidney stem cells. Finally,
we want to provide people in developing countries and emerging
markets with more access to higher-quality dialysis treatment
and to reduce the environmental impact of our products and
services.
For information regarding significant trends in our business see
Item 5.A, Operating Financial Review and
Prospects.
|
|
F.
|
Tabular
Disclosure of contractual obligations
|
The information required by this item may be found under
Item 5B, Liquidity and Capital
Resources Financing.
|
|
Item 6.
|
Directors,
Senior Management and Employees
|
|
|
A.
|
Directors
and senior management
|
General
As a partnership limited by shares, under the German Stock
Corporation Act (
Aktiengesetz
), our corporate bodies are
our general partner, our supervisory board and our general
meeting of shareholders. Our sole general partner is Fresenius
Medical Care Management AG (Management AG), a
wholly-owned subsidiary of Fresenius SE & Co. KGaA.
Management AG is required to devote itself exclusively to the
management of Fresenius Medical Care AG & Co. KGaA.
For a detailed discussion of the legal and management structure
of Fresenius Medical Care AG & Co. KGaA, including the
more limited powers and functions of the supervisory board
compared to those of the general partner, see Item 16.G,
below, Governance The Legal Structure of
Fresenius Medical Care AG & Co. KGaA.
68
Our general partner has a Supervisory Board and a Management
Board. These two boards are separate and no individual may
simultaneously be a member of both boards. A person may,
however, serve on both the supervisory board of our general
partner and on our supervisory board.
The
General Partners Supervisory Board
The Supervisory Board of Management AG consists of six members
who are elected by Fresenius SE & Co. KGaA (acting
through its general partner, Fresenius Management SE) as the
sole shareholder of Management AG. Pursuant to pooling
agreements for the benefit of the public holders of our ordinary
shares and the holders of our preference shares, at least
one-third (but no fewer than two) of the members of the general
partners Supervisory Board are required to be independent
directors as defined in the pooling agreements, i.e., persons
with no substantial business or professional relationship with
us, Fresenius SE & Co. KGaA, the general partner, or
any affiliate of any of them.
Unless resolved otherwise by the general meeting of
shareholders, the terms of each of the members of the
Supervisory Board of Management AG will expire at the end of the
general meeting of shareholders in which the shareholders
discharge the Supervisory Board for the fourth fiscal year
following the year in which the Management AG supervisory board
member was elected by Fresenius SE, but not counting the fiscal
year in which such members term begins. Members of the
general partners Supervisory Board may be removed only by
a resolution of Fresenius SE in its capacity as sole shareholder
of the general partner. Neither our shareholders nor the
separate supervisory board of FMC AG & Co. KGaA has
any influence on the appointment of the Supervisory Board of the
general partner.
The general partners Supervisory Board ordinarily acts by
simple majority vote and the Chairman has a tie-breaking vote in
case of any deadlock. The principal function of the general
partners Supervisory Board is to appoint and to supervise
the general partners Management Board in its management of
the Company, and to approve mid-term planning, dividend payments
and matters which are not in the ordinary course of business and
are of fundamental importance to us.
The table below provides the names of the members of the
Supervisory Board of Management AG and their ages as of
December 31, 2010.
|
|
|
|
|
|
|
Age as of
|
|
|
December 31,
|
Name
|
|
2010
|
|
Dr. Ulf M. Schneider,
Chairman
(1)
|
|
|
45
|
|
Dr. Dieter Schenk, Vice
Chairman
(4)
|
|
|
58
|
|
Dr. Gerd
Krick
(1)(2)
|
|
|
72
|
|
Dr. Walter L.
Weisman
(1)(2)(3)
|
|
|
75
|
|
Mr. John G.
Kringel
(3)(4)
|
|
|
71
|
|
Mr. William P.
Johnston
(1)(2)(3)(4)
|
|
|
66
|
|
|
|
(1)
|
Members of the Human Resources Committee of the Supervisory
Board of Management AG
|
|
(2)
|
Members of the Audit and Corporate Governance Committee of
FMC-AG & Co. KGaA
|
|
(3)
|
Independent director for purposes of our pooling agreement
|
|
(4)
|
Member of the Regulatory and Reimbursement Assessment Committee
of the Supervisory Board of Management AG
|
DR. ULF M. SCHNEIDER has been Chairman of the Supervisory Board
of Management AG since April 15, 2005. He was a member of
the Fresenius Medical Care AG Supervisory Board from May 2004
and Chairman of its Supervisory Board until the effective date
of the transformation when he resigned upon the Companys
transformation to a KGaA. He was Chief Financial Officer of
FMC-AG from November 2001 until May 2003. On March 7, 2003,
Dr. Schneider announced his resignation from the FMC-AG
Management Board to become Chairman of the Management Board of
Fresenius SE, effective May 28, 2003 and, effective
January 28, 2011, he is Chairman of the Management Board of
Fresenius Management SE, the general partner of Fresenius
SE & Co. KGaA. Previously he was Group Finance
Director for Gehe UK plc., a pharmaceutical wholesale and retail
distributor, in Coventry, United Kingdom. He has held several
senior executive and financial positions since 1989 with
Gehes majority shareholder, Franz Haniel & Cie.
GmbH, Duisburg, a diversified German multinational company.
Dr. Schneider is Chairman of the Supervisory Boards of
Fresenius Kabi AG, HELIOS Kliniken GmbH and Fresenius Medical
Care Groupe France S.A.S., France. Dr. Schneider is a member of
the Supervisory Boards of Fresenius Kabi España S.A., Spain
and Fresenius HemoCare Netherlands B.V., the Netherlands. He was
member of the Supervisory Board of Fresenius Kabi Austria GmbH,
Austria, until June 30, 2010. Dr. Schneider is a
member of the Board of Directors of APP
69
Pharmaceuticals, Inc., USA. He remains a member of the Board of
Directors of Fresenius Kabi Pharmaceuticals Holding, Inc., USA
and is a member of the Board of Directors of FHC (Holdings),
Ltd., Great Britain.
DR. DIETER SCHENK has been a member of the Supervisory
Board of Management AG since April 8, 2005 and Vice
Chairman of the Supervisory Board of Management AG since
April 15, 2005. He was Vice Chairman of the Supervisory
Board of FMC-AG from 1996 until the transformation of legal form
to a KGaA. He is also Vice Chairman of the Supervisory Board of
FMC-AG & Co. KGaA. He is an attorney and tax advisor
and has been a partner in the law firm of Noerr LLP (formerly
Nörr Stiefenhofer Lutz) since 1986. Dr. Schenk is also
Vice Chairman of the Supervisory Board of Fresenius Management
SE and Chairman of the Advisory Board of
Else-Kröner-Fresenius-Stiftung, which owns approximately
28.9% of the shares of Fresenius SE & Co. KGaA. He was
Vice Chairman of the Supervisory Board of Fresenius SE until
January 28, 2011. He also serves as the Chairman of the
Supervisory Board of Gabor Shoes AG and TOPTICA Photonics AG and
as a Vice-Chairman of the Supervisory Board of Greiffenberger
AG. Dr. Schenk was Chairman of the Supervisory Board of NSL
Consulting AG until September 2008.
DR. GERD KRICK has been a member of the Supervisory Board
of Management AG since December 28, 2005 and was Chairman
of the Supervisory Board of FMC-AG from January 1, 1998
until the transformation of legal form to a KGaA. He is also
Chairman of the Supervisory Boards of FMC AG & Co.
KGaA and Fresenius Management SE. He was Chairman of the
Fresenius AG Management Board from 1992 to May 2003 at which
time he became chairman of its Supervisory Board. He was
Chairman of the Supervisory Board of Fresenius SE and effective
January 28, 2011, he is the Chairman of the Supervisory
Board of Fresenius Management SE and a member of the
supervisory Board of Fresenius SE & Co. KGaA. Prior to
1992, he was a Director of the Medical Systems Division of
Fresenius AG and Vice-Chairman of the Fresenius AG Management
Board. From September 1996 until December 1997, Dr. Krick
was Chairman of the Management Board of FMC-AG. Dr. Krick
was a member of the Advisory Board of HDI Haftpflichtverband der
deutschen Industrie V.a.G until December 31, 2008. He is
also the Chairman of the Supervisory Board of Vamed AG, Austria
and was a member of the Supervisory Board of Allianz Private
Krankenversicherungs-AG until April 16, 2008.
MR. JOHN G. KRINGEL has been a member of the Supervisory
Board of Management AG since December 28, 2005 and was a
member of the Supervisory Board of FMC-AG from October 20,
2004, when his appointment to fill a vacancy was approved by the
local court, until the transformation of legal form to a KGaA.
His election to the Supervisory Board was subsequently approved
by the shareholders of FMC-AG at the Annual General Meeting held
May 24, 2005. He is also a member of the Supervisory Board
of FMC-AG & Co. KGaA. He has the following other
mandates: Natures View, LLC, Alpenglow Development, LLC,
Justice, LLC, and River Walk, LLC. Formerly he was also an
Advisory Board member of Visionary Medical Device Fund.
Mr. Kringel spent 18 years with Abbott Laboratories
prior to his retirement as Senior Vice President, Hospital
Products, in 1998. Prior to Abbott Laboratories, he spent three
years as Executive Vice President of American Optical
Corporation, a subsidiary of Warner Lambert Co. and ten years in
the U.S. Medical Division of Corning Glassworks.
DR. WALTER L. WEISMAN has been a member of the Supervisory
Board of Management AG since December 28, 2005 and was a
member of the Supervisory Board of FMC-AG from 1996 until the
transformation of legal form to a KGaA. He is also a member of
the Supervisory Board of FMC-AG & Co. KGaA. He is a
private investor and a former President and Chief Executive
Officer of American Medical International, Inc., and is a member
of the Board of Directors of Occidental Petroleum Corporation.
He is Senior Trustee of the Board of Trustees for the California
Institute of Technology, a Life Trustee of the Board of Trustees
of the Los Angeles County Museum of Art, and Chairman of the
Board of Trustees of the Sundance Institute. Dr. Weisman
was Vice-Chairman and Lead Director of Maguire Properties, Inc.
until September 1, 2008 and was Vice-Chairman of the Board
of Trustees of the Samuel H. Kress Foundation until
November 1, 2008.
MR. WILLIAM P. JOHNSTON was elected to the Supervisory
Board of Management AG on August 30, 2006. He has been a
member of the Supervisory Board of FMC-AG & Co. KGaA
since May 2006. He was the former Chairman of the Board of
Directors of Renal Care Group, Inc. Mr. Johnston has been a
Senior Advisor of The Carlyle Group since June 2006. He is also
a member of the Board of Directors of The Hartford Mutual Funds,
Inc., HCR-Manor Care, Inc. and LifeCare Holdings, Inc.
Mr. Johnston is a member of the Board of Directors of the
Georgia OKeeffe Museum.
The
General Partners Management Board
Each member of the Management Board of Management AG is
appointed by the Supervisory Board of Management AG for a
maximum term of five years and is eligible for reappointment
thereafter. Their terms of office expire in the years listed
below.
70
The table below provides names, positions and terms of office of
the members of the Management Board of Management AG and their
ages as of December 31, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
Age as of
|
|
|
|
|
|
|
Jan. 1,
|
|
|
|
Year term
|
Name
|
|
2011
|
|
Position
|
|
expires
|
|
Dr. Ben J. Lipps
|
|
|
70
|
|
|
Chairman of the Management Board, Chief Executive Officer of
FMC-AG & Co. KGaA
|
|
|
2012
|
|
Rice Powell
|
|
|
55
|
|
|
Deputy Chairman of the Management Board and Chief Executive
Officer, Fresenius Medical Care North America
|
|
|
2014
|
|
Michael Brosnan
|
|
|
55
|
|
|
Chief Financial Offier of FMC-AG & Co. KGaA
|
|
|
2012
|
|
Roberto Fusté
|
|
|
58
|
|
|
Chief Executive Officer for Asia Pacific
|
|
|
2011
|
|
Dr. Emanuele Gatti
|
|
|
55
|
|
|
Chief Executive Officer for Europe, Middle East, Africa and
Latin America and Chief Strategist for FMC-AG & Co. KGaA
|
|
|
2012
|
|
Dr. Rainer Runte
|
|
|
51
|
|
|
Chief Administrative Officer for Global Law, Compliance,
Intellectual Property and Corporate Business Development and
Labor Relations Director for Germany
|
|
|
2015
|
|
Kent Wanzek
|
|
|
51
|
|
|
Head of Global Manufacturing Operations
|
|
|
2012
|
|
DR. BEN J. LIPPS became Chairman and Chief Executive
Officer of the Management Board of Management AG on
December 21, 2005. He served as acting Chief Financial
Officer from September 1, 2009 until December 31,
2009. He was Chairman and Chief Executive Officer of the
Management Board of FMC-AG from May 1, 1999 until the
transformation of legal form to a KGaA and was Vice Chairman of
the Management Board until May 1999. He was Chief Executive
Officer of Fresenius Medical Care North America until February
2004. He was President, Chief Executive Officer, Chief Operating
Officer and a director of Fresenius USA from October 1989
through February 2004, and served in various capacities with
Fresenius USAs predecessor from 1985 through 1989. He is a
member of the management board of Fresenius Management SE.
Dr. Lipps is a member of the Board of Administration of
Vifor Fresenius Medical Care Renal Pharma Ltd., Switzerland. He
has been active in the field of dialysis for more than
40 years. After earning his masters and doctoral
degrees at the Massachusetts Institute of Technology in chemical
engineering, Dr. Lipps led the research team that developed
the first commercial hollow fiber artificial kidney at the end
of the 1960s. Before joining the Fresenius Group in 1985,
Dr. Lipps held several research management positions in
various companies, among them with DOW Chemical.
RICE POWELL became Deputy Chairman of the Management Board and
Chief Executive Officer of Fresenius Medical Care North America
effective January 1, 2010. He was a member of the
Management Board of FMC-AG from February 2004 until the
transformation of legal form and was Co-Chief Executive Officer
of Fresenius Medical Care North America and CEO of Renal Therapy
Group of Fresenius Medical Care North America. He is the Deputy
Chairman of the Board of Administration of Vifor Fresenius
Medical Care Renal Pharma Ltd., Switzerland. He has over
30 years of experience in the healthcare industry. From
1978 to 1996 he held various positions within Baxter
International Inc. (USA), Biogen Inc. (USA) and Ergo Sciences
Inc. (USA).
MICHAEL BROSNAN became a member of the Management Board of
Management AG and Chief Financial Officer on January 1,
2010. Previously, he served as Chief Financial Officer and
member of the Board of Directors of Fresenius Medical Care North
America for seven years. He is a member of the Board of
Administration of Vifor Fresenius Medical Care Renal Pharma
Ltd., Switzerland. Mr. Brosnan joined the Company in 1998
as Vice President of Finance and Administration for Spectra
Renal Management, the Companys laboratory services
organization. Since then, he has held several executive
positions in North America. Prior to joining Fresenius Medical
Care, Mr. Brosnan held senior financial positions at
Polaroid Corporation and was an audit partner at KPMG.
DR. EMANUELE GATTI became a member of the Management Board
of Management AG and Chief Executive Officer for Europe, Latin
America, Middle East and Africa on December 21, 2005. He
held such positions in FMC-AG from May 1997 until the
transformation of legal form. He became Chief Strategist
effective January 1, 2010. After completing his studies in
bioengineering, Dr. Gatti lectured at several biomedical
institutions. He continues to be involved in comprehensive
research and development activities focusing on dialysis and
blood purification, biomedical signal analysis, medical device
safety and health care economics.
71
Dr. Gatti has been with the company since 1989. Before
being appointed to the Management Board in 1997, he was
responsible for the Companys dialysis business in Southern
Europe.
ROBERTO FUSTÉ became a member of the Management Board of
Management AG and Chief Executive Officer for Asia Pacific on
December 21, 2005. He held such positions in FMC-AG from
January 1, 1999 until the transformation of legal form.
After finishing his studies in economic sciences at the
University of Valencia, he founded the company Nephrocontrol
S.A. in 1983. In 1991, Nephrocontrol was acquired by the
Fresenius Group, where Mr. Fusté has since worked.
Before being appointed to the Management Board of FMC-AG in
1999, Mr. Fusté held several senior positions within
the Company in Europe and the Asia Pacific region.
DR. RAINER RUNTE is the Companys Chief Administrative
Officer for Global Law, Compliance, Intellectual Property and
Corporate Business Development and Labor Relations Director for
Germany. He has been a member of the Management Board of
Management AG since December 2005. He became Chief
Administrative Officer including, among other responsibilities,
Labor Relations Director for Germany, effective January 1,
2010. He was a member of the Management Board responsible for
Law, Compliance and Intellectual Property of FMC-AG from
January 1, 2004 until the transformation of legal form to a
KGaA. Dr. Runte is a member of the Board of Administration
of Vifor Fresenius Medical Care Renal Pharma Ltd., Switzerland.
He has worked for the Fresenius group for 20 years.
Previously he served as scientific assistant to the law
department of the Johann Wolfgang Goethe University in Frankfurt
and as an attorney in a law firm specialized in economic law.
Dr. Runte took the position as Senior Vice President for
Law of Fresenius Medical Care in 1997 and was appointed as
deputy member of the Management Board in 2002.
KENT WANZEK became a member of the Management Board of
Management AG effective January 1, 2010, with
responsibility for Global Manufacturing Operations. Previously,
Mr. Wanzek was in charge of North American Operations for
the Renal Therapies Group at Fresenius Medical Care North
America since 2004. Prior to joining the Company in 2003,
Mr. Wanzek held several senior executive positions with
companies in the health care industry, including Philips Medical
Systems, Perkin-Elmer, Inc. and Baxter Healthcare Corporation.
The business address of all members of our Management Board and
Supervisory Board is Else-Kröner-Strasse 1, 61352 Bad
Homburg, Germany.
The
Supervisory Board of FMC-AG & Co. KGaA
The Supervisory Board of FMC-AG & Co. KGaA consists of
six members who are elected by the shareholders of
FMC-AG & Co. KGaA in a general meeting. Fresenius
SE & Co. KGaA, as the sole shareholder of Management
AG, the general partner, is barred from voting for election of
the Supervisory Board of FMC-AG & Co. KGaA but,
nevertheless has and will retain significant influence over the
membership of the FMC-AG & Co. KGaA Supervisory Board
in the foreseeable future. See Item 16.G, below,
Governance The Legal Structure of
FMC-AG & Co. KGaA.
The current Supervisory Board of FMC-AG & Co. KGaA
consists of six persons, five of whom
Messrs. Schenk, Krick, Kringel, Weisman and
Johnston are also members of the Supervisory Board
of our General Partner. For information regarding the names,
ages, terms of office and business experience of those members
of the Supervisory Board of FMC-AG & Co. KGaA, see
The General Partners Supervisory Board, above.
The sixth member of the Supervisory Board of FMC-AG &
Co. KGaA is Prof. Dr. Bernd Fahrholz. Information regarding
his age, term of office and business experience is as follows:
PROF. DR. BERND FAHRHOLZ, age 63, was a member of the
Supervisory Board of Management AG from April 8, 2005 until
August 30, 2006 and was a member of the Supervisory Board
of FMC-AG from 1998 until the transformation of legal form to a
KGaA and a member of the Supervisory Board of FMC-AG &
Co. KGaA following the transformation. He is a member of our
Audit and Corporate Governance Committee. He is partner in the
law firm of Dewey & LeBoeuf, LLP, and from 2004 until
September 30, 2005 was a partner in the law firm of
Nörr Stiefenhofer Lutz (now Noerr LLP). He was a member of
the Management Board of Dresdner Bank AG beginning in 1998 and
was Chairman from April 2000 until he resigned in March of 2003.
He also served as the vice-chairman of the Management Board of
Allianz AG and chairman of the Supervisory Board of Advance
Holding AG until March 25, 2003. He served on the
Supervisory Boards of BMW AG until May 13, 2004 and
Heidelberg Cement AG until May 6, 2004. Prof.
Dr. Fahrholz is Chairman of the Supervisory Board of
SMARTRAC N.V.
The terms of office of the aforesaid members of the Supervisory
Board of FMC-AG & Co. KGaA will expire at the end of
the general meeting of shareholders of FMC-AG & Co.
KGaA, in which the shareholders discharge the Supervisory Board
for the fourth fiscal year following the year in which they were
elected, but not counting the fiscal year in which such
members term begins. Members of the FMC-AG & Co.
KGaA Supervisory Board may be
72
removed only by a resolution of the shareholders of
FMC-AG & Co. KGaA with a majority of three quarters of
the votes cast at such general meeting. Fresenius SE &
Co. KGaA is barred from voting on such resolutions. The
Supervisory Board of FMC-AG & Co. KGaA ordinarily acts
by simple majority vote and the Chairman has a tie-breaking vote
in case of any deadlock.
The principal function of the Supervisory Board of
FMC-AG & Co. KGaA is to oversee the management of the
Company but, in this function, the supervisory board of a
partnership limited by shares has less power and scope for
influence than the supervisory board of a stock corporation. The
Supervisory Board of FMC-AG & Co. KGaA is not entitled
to appoint the general partner or its executive bodies, nor may
it subject the general partners management measures to its
consent or issue rules of procedure for the general partner.
Only the Supervisory Board of Management AG, elected solely by
Fresenius SE & Co. KGaA, has the authority to appoint
or remove members of the general partners Management
Board. See Item 16.G, below, Governance
The Legal Structure of FMC-AG & Co. KGaA. Among
other matters, the Supervisory Board of FMC-AG & Co.
KGaA will, together with the general partner, fix the agenda for
the annual general meeting and make recommendations with respect
to approval of the companys annual financial statements
and dividend proposals. The Supervisory Board of
FMC-AG & Co. KGaA will also propose nominees for
election as members of its Supervisory Board and propose the
Companys auditors for approval by shareholders.
Report
of the Management Board of Management AG, our General
Partner
The compensation report of Fresenius Medical Care AG &
Co. KGaA summarizes the main elements of the compensation system
for the members of the Management Board of Fresenius Medical
Care Management AG as general partner of Fresenius Medical
AG & Co. KGaA and in this regard notably explains the
amounts and structure of the compensation paid to the Management
Board. The compensation report is part of the group management
report. The compensation report is prepared on the basis of the
recommendations made by the German Corporate Governance Code and
also includes the disclosures as required pursuant to the
applicable statutory regulations, notably in accordance with the
German Commercial Code (HGB).
Compensation
of the Management Board
The entire Supervisory Board of Fresenius Medical Care
Management AG is responsible for determining the compensation of
the Management Board. The Supervisory Board is assisted in this
task by a personnel committee, the Human Resources Committee.
For fiscal year 2010, the Human Resources Committee was composed
of Dr Ulf M. Schneider, Dr Gerd Krick, William P.
Johnston and Dr Walter Weisman.
In fiscal year 2010, the compensation of the Management Board of
Fresenius Medical Care Management AG already took into account
the newly worded requirements in accordance with the German Act
on the Appropriateness of Executive Board Compensation
(
Gesetz zur Angemessenheit der
Vorstandsvergütung VorstAG
), which entered
into force on August 5, 2009. The Management Board
compensation system was reviewed by an independent external
compensation expert at the beginning of fiscal year 2010 and
later submitted to Fresenius Medical Care AG & Co.
KGaAs shareholders meeting for approval. On
May 11, 2010 the shareholders meeting approved of the
Management Board compensation system with a majority of 99.26%
of the votes cast.
The objective of the compensation system is to enable the
members of the Management Board to participate reasonably in the
sustainable development of the Companys business with the
compensation paid and to reward them based on their duties and
performance as well as their success in managing the
Companys economic and financial position while giving due
regard to the peer environment.
The compensation of the Management Board is, as a whole,
performance-oriented and was composed of three elements in
fiscal year 2010:
|
|
|
|
|
performance-unrelated compensation (basic salary)
|
|
|
|
performance-related compensation (variable bonus)
|
|
|
|
components with long-term incentive effects (stock options and
share-based compensation with cash settlement)
|
The individual components are designed on the basis of the
following criteria:
In fiscal year 2010, the performance-unrelated compensation was
paid in twelve monthly instalments as basic salary. Moreover,
the members of the Management Board received additional benefits
consisting mainly of insurance premiums, the private use of
company cars, special payments such as foreign supplements, rent
73
supplements, reimbursement of fees for the preparation of tax
returns and reimbursement of certain other charges and
additional contributions to pension and health insurance. The
performance-related compensation will also be granted for the
fiscal year 2010 as a short-term cash component (annual bonus)
and a longer-term share-based compensation component (stock
options, share-based compensation with cash settlement). The
amount of the performance-related compensation component in each
case depends on the achievement of individual and common targets:
The targets for the members of the Management Board are measured
by reference to operating profit margin, growth of Group-wide
after-tax earnings (EAT growth) as well as the development of
free cash flow (cash flow before acquisitions). All values are
derived from the comparison of targeted and actually achieved
figures. Furthermore, targets are divided into Group level
targets and those to be achieved in individual regions. Lastly,
the various target parameters are weighted differently by their
relative share in the aggregate amount of variable compensation
depending on the respective (regional) areas of responsibility
assumed by the members of the Management Board.
Variable compensation was based upon EAT growth of at least 6%
and capped at 15%. Furthermore, the members of the Management
Board assuming Group functions and the members of the Management
Board with regional responsibilities were evaluated in terms of
the development of the respective free cash flow within the
Group or in the relevant regions during the period under review,
with the targets subject to compensation being within a range of
rates between 3% and 6% of the respective free cash flow with
reference to the turnover. The regional operating profit margins
achieved during 2010 were moreover compensated for the
respective Board members with regional responsibilities, in each
case, within a target range between 13% and 18.5%.
As a rule, EAT growth for members of the Management Board with
Group functions -these are Messrs. Dr. Ben Lipps,
Michael Brosnan and Dr. Rainer Runte are
compensated at a share of 80% in variable compensation and are
thus weighted higher than for Board members having
responsibility for regional earnings (these are
Messrs. Roberto Fusté, Dr. Emanuele Gatti and
Rice Powell) or in the Global Manufacturing Operations division
(Mr. Kent Wanzek), where the share is 60%. The achievement
of the target for free cash flow is assessed at the uniform rate
of 20% of variable compensation for all members of the
Management Board; likewise, the valuation of operating profit
margins in the regions is weighted at 20% of the variable
compensation component.
In fiscal year 2010, the bonus components to be paid via cash
payment consisted proportionately of a short-term annual bonus
and a further share-based compensation component (long-term), to
be paid by way of cash settlement based on the performance of
the stock exchange price of the ordinary shares of Fresenius
Medical Care AG & Co. KGaA. Once the annual targets
were or are achieved, the cash was or will be paid after the end
of the respective fiscal year in which the target is achieved.
The share-based compensation also to be granted yearly in case
of achievement of the yearly targets is subject to a three-year
vesting period, although a shorter period may apply in special
cases (e.g. professional incapacity, entry into retirement,
non-renewal by the company of expired service agreements). The
amount of cash payment of this share-based compensation
corresponds to the share price of Fresenius Medical Care
AG & Co. KGaA ordinary shares upon exercise after the
three-year vesting period. Therefore, the share-based
compensation is attributed to the long-term incentive
compensation components. The annual targets of the
aforementioned and respectively applicable key data is valued at
a maximum of 120% and subject to a fixed multiplier, thereby
limiting the variable compensation. In determining the variable
compensation, care was taken that the share of the long-term
compensation components (including the stock option components
described below) constitutes at least 50% of the total variable
components. Should this not be the case mathematically, the
Management Board members contracts provide that the share
of the short-term annual bonus be reduced and the share of the
long-term share-based cash components be correspondingly
increased, in order to meet this quota. For the total
performance-based compensation, the amount of the maximum
achievable bonus for each of the members of the Management Board
is respectively capped. The share-based compensation components
also contain a limitation for cases of extraordinary
developments. Furthermore, the Supervisory Board may grant a
discretionary bonus for extraordinary performance.
In addition, a special bonus component applied in some cases for
fiscal years 2006, 2007 and 2008 which was linked to the
achievement of targets as measured only over this three-year
period but whose payment to a certain extent is also subject to
a vesting period of several years and consequently will take
place up to 2012. This bonus component also included special
components linked to the achievement of extraordinary financial
targets related to special integration measures (e.g. in
connection with the acquisition of Renal Care Group in the U.S.)
and thus required the achievement of an extraordinary increase
in earnings. The present report also reflects those payments
based on this earlier bonus component but exercised and paid
only in the year under review.
74
For fiscal years 2010 and 2009 the amount of cash payments of
the Management Board of Fresenius Medical Care Management AG
without long-term incentive components consisted of the
following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Compensation
|
|
|
|
Non-Performance Related
|
|
|
|
|
|
|
|
|
(without long-term
|
|
|
|
Compensation
|
|
|
Performance Related Compensation
|
|
|
Incentive Components)
|
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
|
in thousands
|
|
|
in thousands
|
|
|
in thousands
|
|
|
in thousands
|
|
|
Dr. Ben Lipps
|
|
$
|
1,200
|
|
|
$
|
1,200
|
|
|
$
|
469
|
|
|
$
|
350
|
|
|
$
|
1,554
|
|
|
$
|
1,674
|
|
|
$
|
3,223
|
|
|
$
|
3,224
|
|
Michael Brosnan
|
|
|
650
|
|
|
|
|
|
|
|
183
|
|
|
|
|
|
|
|
821
|
|
|
|
|
|
|
|
1,654
|
|
|
|
|
|
Roberto Fusté
|
|
|
597
|
|
|
|
558
|
|
|
|
245
|
|
|
|
258
|
|
|
|
740
|
|
|
|
724
|
|
|
|
1,582
|
|
|
|
1,540
|
|
Dr. Emanuele Gatti
|
|
|
862
|
|
|
|
767
|
|
|
|
139
|
|
|
|
155
|
|
|
|
1,086
|
|
|
|
1,021
|
|
|
|
2,087
|
|
|
|
1,943
|
|
Rice Powell
|
|
|
950
|
|
|
|
750
|
|
|
|
36
|
|
|
|
39
|
|
|
|
1,319
|
|
|
|
1,210
|
|
|
|
2,305
|
|
|
|
1,999
|
|
Dr. Rainer Runte
|
|
|
564
|
|
|
|
530
|
|
|
|
47
|
|
|
|
42
|
|
|
|
729
|
|
|
|
629
|
|
|
|
1,340
|
|
|
|
1,201
|
|
Kent Wanzek
|
|
|
500
|
|
|
|
|
|
|
|
25
|
|
|
|
|
|
|
|
727
|
|
|
|
|
|
|
|
1,252
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
5,323
|
|
|
$
|
3,805
|
|
|
$
|
1,144
|
|
|
$
|
844
|
|
|
$
|
6,976
|
|
|
$
|
5,258
|
|
|
$
|
13,443
|
|
|
$
|
9,907
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1)
|
Includes insurance premiums, private use of company cars, rent
supplements, contributions to pension and health insureance and
other benefits.
|
In addition to the aforementioned share-based compensation
component with cash settlement, stock options under Stock Option
Plan 2006 were granted as (further) components with long-term
incentive effects in fiscal year 2010. The principles of Stock
Option Plan 2006 are described in more detail in the Notes under
the header Conditional Capital VI.
As of January 1, 2010, the Company still had three
additional Employee Participation Programs secured by
conditional capital which entitled their participants to
convertible bonds or stock options, and from which, however, in
fiscal year 2010 no further options could be issued. In
continuation with these successful employee participation
programs of the past fiscal years, Fresenius Medical Care
AG & Co. KGaA implemented the Stock Option Plan 2006
approved by resolution of the general meeting on May 9,
2006 and amended by resolution of the general meeting of
May 15, 2007 (reflecting the share split 1: 3).
During 2010, a total of 2,817,879 (2009: 2,585,196) stock
options were granted under this Stock Option Plan of which
423,300 (2009: 348,600) were granted to the members of the
Management Board.
For fiscal years 2010 and 2009 the number and value of stock
options issued and the value of other share-based compensation
with cash settlement is shown individually in the following
table.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Components with Long-term Incentive Effect
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Compensation with Cash
|
|
|
|
|
|
|
|
|
|
|
|
|
Settlement
|
|
|
Total
|
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
|
Number
|
|
|
in thousands
|
|
|
in thousands
|
|
|
in thousands
|
|
|
Dr. Ben Lipps
|
|
|
99,600
|
|
|
|
99,600
|
|
|
$
|
1,040
|
|
|
$
|
1,086
|
|
|
$
|
518
|
|
|
$
|
475
|
|
|
$
|
1,558
|
|
|
$
|
1,561
|
|
Michael Brosnan
|
|
|
49,800
|
|
|
|
|
|
|
|
520
|
|
|
|
|
|
|
|
301
|
|
|
|
|
|
|
|
821
|
|
|
|
|
|
Roberto Fusté
|
|
|
49,800
|
|
|
|
49,800
|
|
|
|
520
|
|
|
|
543
|
|
|
|
207
|
|
|
|
176
|
|
|
|
727
|
|
|
|
719
|
|
Dr. Emanuele Gatti
|
|
|
49,800
|
|
|
|
49,800
|
|
|
|
520
|
|
|
|
543
|
|
|
|
553
|
|
|
|
340
|
|
|
|
1,073
|
|
|
|
883
|
|
Rice Powell
|
|
|
74,700
|
|
|
|
49,800
|
|
|
|
780
|
|
|
|
543
|
|
|
|
539
|
|
|
|
337
|
|
|
|
1,319
|
|
|
|
880
|
|
Dr. Rainer Runte
|
|
|
49,800
|
|
|
|
49,800
|
|
|
|
520
|
|
|
|
543
|
|
|
|
243
|
|
|
|
209
|
|
|
|
763
|
|
|
|
752
|
|
Kent Wanzek
|
|
|
49,800
|
|
|
|
|
|
|
|
520
|
|
|
|
|
|
|
|
242
|
|
|
|
|
|
|
|
762
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
423,300
|
|
|
|
298,800
|
|
|
$
|
4,420
|
|
|
$
|
3,258
|
|
|
$
|
2,603
|
|
|
$
|
1,537
|
|
|
$
|
7,023
|
|
|
$
|
4,795
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The stated values of the stock options granted to the members of
the Management Board in fiscal year 2010 correspond to their
fair value at the time of being granted, namely a value of
$10.44 (8.07) (2009: $10.90/7.64) per stock option.
The exercise price for the stock options granted is $55.19
(42.68) (2009: $45.62/31.97).
At the end of fiscal year 2010, the members of the Management
Board held a total of 2,178,699 stock options (2009: 2,041,121
stock options).
75
The development and status of stock options of the members of
the Management Board in fiscal year 2010 are shown in more
detail in the following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr. Ben
|
|
|
Michael
|
|
|
Roberto
|
|
|
Dr. Emanuele
|
|
|
Rice
|
|
|
Dr. Rainer
|
|
|
Kent
|
|
|
|
|
|
|
Lipps
|
|
|
Brosnan
|
|
|
Fusté
|
|
|
Gatti
|
|
|
Powell
|
|
|
Runte
|
|
|
Wanzek
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding at January 1, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
703,416
|
|
|
|
230,481
|
|
|
|
316,076
|
|
|
|
326,076
|
|
|
|
226,977
|
|
|
|
257,553
|
|
|
|
56,526
|
|
|
|
2,117,105
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average exercise price in $
|
|
|
38.00
|
|
|
|
37.43
|
|
|
|
36.38
|
|
|
|
34.94
|
|
|
|
40.93
|
|
|
|
40.10
|
|
|
|
44.48
|
|
|
|
37.81
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options granted during the fiscal year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
99,600
|
|
|
|
49,800
|
|
|
|
49,800
|
|
|
|
49,800
|
|
|
|
74,700
|
|
|
|
49,800
|
|
|
|
49,800
|
|
|
|
423,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average exercise price in $
|
|
|
57.03
|
|
|
|
57.03
|
|
|
|
57.03
|
|
|
|
47.03
|
|
|
|
57.03
|
|
|
|
57.03
|
|
|
|
57.03
|
|
|
|
57.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercised during the fiscal year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
204,146
|
|
|
|
10,683
|
|
|
|
25,890
|
|
|
|
|
|
|
|
77,577
|
|
|
|
22,884
|
|
|
|
20,526
|
|
|
|
361,706
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average exercise price in $
|
|
|
32.72
|
|
|
|
36.42
|
|
|
|
17.53
|
|
|
|
|
|
|
|
32.79
|
|
|
|
29.93
|
|
|
|
43.44
|
|
|
|
32.19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average share price in $
|
|
|
57.64
|
|
|
|
59.94
|
|
|
|
54.90
|
|
|
|
|
|
|
|
57.58
|
|
|
|
57.59
|
|
|
|
59.30
|
|
|
|
57.59
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options forfeited during the fiscal year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average exercise price in $
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding at December 31, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
598,870
|
|
|
|
269,598
|
|
|
|
339,986
|
|
|
|
375,876
|
|
|
|
224,100
|
|
|
|
284,469
|
|
|
|
85,800
|
|
|
|
2,178,699
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average exercise price in $
|
|
|
42.96
|
|
|
|
41.09
|
|
|
|
39.91
|
|
|
|
37.87
|
|
|
|
49.11
|
|
|
|
43.88
|
|
|
|
52.00
|
|
|
|
42.48
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average remaining contractual life in years
|
|
|
4.4
|
|
|
|
4.5
|
|
|
|
4.1
|
|
|
|
3.9
|
|
|
|
5.2
|
|
|
|
4.4
|
|
|
|
5.9
|
|
|
|
4.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Range of exercise price in $
|
|
|
19.33 - 57.03
|
|
|
|
15.26 - 57.03
|
|
|
|
15.26 - 57.03
|
|
|
|
15.26 -57.03
|
|
|
|
42.72 - 57.03
|
|
|
|
19.33 - 57.03
|
|
|
|
42.72 - 57.03
|
|
|
|
15.26 - 57.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercisable at December 31, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
300,070
|
|
|
|
153,798
|
|
|
|
190,586
|
|
|
|
226,476
|
|
|
|
49,800
|
|
|
|
135,069
|
|
|
|
|
|
|
|
1,055,799
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average exercise price in $
|
|
|
36.89
|
|
|
|
34.22
|
|
|
|
32.74
|
|
|
|
30.49
|
|
|
|
45.31
|
|
|
|
38.16
|
|
|
|
|
|
|
|
34.94
|
|
Based on the targets achieved in fiscal year 2010, additional
rights for share-based compensation with cash settlement
totalling $2.603 million (2009: $1.537 million) were
earned, on the basis of which the number of share-based
compensation rights is distributed. Since the actual
distribution will not take place until March 2011, the specific
number of shares of such share-based compensation rights will be
determined by the Supervisory Board at that time by reference to
the then current price of the ordinary shares of Fresenius
Medical Care AG & Co. KGaA. Such number of shares will
then serve as a basis and multiplier for calculating of the
payment after the three-year vesting period.
The amount of the total compensation of the Management Board of
Fresenius Medical Care Management AG for fiscal years 2010 and
2009 is shown in the following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Components with
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
long-term
|
|
|
|
|
|
|
|
|
|
Cash Compensation (without long-term Incentive components)
|
|
|
Incentive Effect
|
|
|
Total Compensation (including long-term Incentive
Components)
|
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
|
in thousands
|
|
|
in thousands
|
|
|
in thousands
|
|
|
Dr. Ben Lipps
|
|
$
|
3,223
|
|
|
$
|
3,224
|
|
|
$
|
1,558
|
|
|
$
|
1,561
|
|
|
$
|
4,781
|
|
|
$
|
4,785
|
|
Michael Brosnan
|
|
|
1,654
|
|
|
|
|
|
|
|
821
|
|
|
|
|
|
|
|
2,475
|
|
|
|
|
|
Roberto Fusté
|
|
|
1,582
|
|
|
|
1,540
|
|
|
|
727
|
|
|
|
719
|
|
|
|
2,309
|
|
|
|
2,259
|
|
Dr. Emanuele Gatti
|
|
|
2,087
|
|
|
|
1,943
|
|
|
|
1,073
|
|
|
|
883
|
|
|
|
3,160
|
|
|
|
2,826
|
|
Rice Powell
|
|
|
2,305
|
|
|
|
1,999
|
|
|
|
1,319
|
|
|
|
880
|
|
|
|
3,624
|
|
|
|
2,879
|
|
Dr. Rainer Runte
|
|
|
1,340
|
|
|
|
1,201
|
|
|
|
763
|
|
|
|
752
|
|
|
|
2,103
|
|
|
|
1,953
|
|
Kent Wanzek
|
|
|
1,252
|
|
|
|
|
|
|
|
762
|
|
|
|
|
|
|
|
2,014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
13,443
|
|
|
$
|
9,907
|
|
|
$
|
7,023
|
|
|
$
|
4,795
|
|
|
$
|
20,466
|
|
|
$
|
14,702
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Compensation components with long-term incentive effects, i.e.
stock options as well as share-based compensation with cash
settlement, can be exercised only after the expiry of the
specified vesting period. Their
76
value is recognized over the vesting period as expense in the
respective fiscal year of the vesting period. Share-based
compensation expenses attributable to fiscal years 2010 and 2009
are shown in the following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expense
|
|
|
|
|
|
|
Expense
|
|
|
for Long-term
|
|
|
|
|
|
|
for Long-term
|
|
|
Incentive Components
|
|
|
Total Expense
|
|
|
|
Incentive Components
|
|
|
by Share-based
|
|
|
for
|
|
|
|
with Equity
|
|
|
Compensation with
|
|
|
Share-based
|
|
|
|
Instruments
|
|
|
Cash Settlement
|
|
|
Compensation
|
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
|
in thousands
|
|
|
in thousands
|
|
|
in thousands
|
|
|
Dr. Ben Lipps
|
|
$
|
1,165
|
|
|
$
|
1,318
|
|
|
$
|
1,140
|
|
|
$
|
1,272
|
|
|
$
|
2,305
|
|
|
$
|
2,590
|
|
Michael Brosnan
|
|
|
74
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
74
|
|
|
|
|
|
Roberto Fusté
|
|
|
583
|
|
|
|
659
|
|
|
|
61
|
|
|
|
|
|
|
|
644
|
|
|
|
659
|
|
Dr. Emanuele Gatti
|
|
|
583
|
|
|
|
659
|
|
|
|
426
|
|
|
|
424
|
|
|
|
1,009
|
|
|
|
1,083
|
|
Rice Powell
|
|
|
620
|
|
|
|
659
|
|
|
|
713
|
|
|
|
805
|
|
|
|
1,333
|
|
|
|
1,464
|
|
Dr. Rainer Runte
|
|
|
583
|
|
|
|
659
|
|
|
|
502
|
|
|
|
508
|
|
|
|
1,085
|
|
|
|
1,167
|
|
Kent Wanzek
|
|
|
74
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
74
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
3,682
|
|
|
$
|
3,954
|
|
|
$
|
2,842
|
|
|
$
|
3,009
|
|
|
$
|
6,524
|
|
|
$
|
6,963
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitments
to Members of the Management Board for the Event of the
Termination of their Appointment
There are individual contractual pension commitments for the
Management Board members Roberto Fusté, Dr Emanuele
Gatti and Dr Rainer Runte. Under these commitments, Fresenius
Medical Care as of December 31, 2010 has pension
obligations of $8.098 million (as of December 31,
2009: $4.231 million).
Each of the pension commitments provides for a pension and
survivor benefit as of the time of conclusively ending active
work, at age 65 at the earliest, however, depending on the
amount of the recipients most recent basic salary. The
pension commitment for Management Board member Dr Emanuele Gatti
was amended, effective for the 2010 fiscal year, in that the
earliest age at which retirement benefits may be received was
reduced from 65 to 60. The present value of the pension
commitments has increased by $1.999 million due to this
amendment.
With regard to the retirement pension, the starting percentage
of 30% from the last base salary increases with every complete
year of service by 1.5 percentage points up to a maximum of
45%. Current pensions increase according to legal requirements
(Sec. 16 to the German law to improve company pension plans,
BetrAVG). 30% of the gross amount of any later
income from an activity of the Management Board member is set
off against the pension obligation. Any amounts to which the
Management Board members or their surviving dependants,
respectively, are entitled from other company pension rights of
the Management Board member, even from service agreements with
other companies are to be set off. If a Management Board member
dies, the widow receives a pension amounting to 60% of the
resulting pension claim at that time. Furthermore, the deceased
Management Board members own legitimate children
(
leibliche eheliche Kinder
) receive an orphans
pension amounting to 20% of the resulting pension claim at that
time, until the completion of their education or they reach
25 years of age, at the latest. All orphans pensions
and the widow pension together reach a maximum of 90% of the
Management Board members pension, however. If a Management
Board member leaves the Management Board of Fresenius Medical
Care Management AG before he reaches 65 or (in the case of Dr
Gatti) 60, except in the event of a disability (
Berufs- oder
Erwerbsunfähigkeit
), the rights to the aforementioned
benefits remain, although the pension to be paid for a covered
event is reduced in proportion to the ratio of the actual years
of service as a Management Board member to the potential years
of service until reaching 65 or (in the case of Dr Gatti)
60 years of age.
With the Chairman of the Management Board, Dr Ben Lipps, there
is an individual agreement instead of a pension provision, to
the effect that, taking account of a non-compete covenant upon
termination of his employment contract/service agreement with
Fresenius Medical Care Management AG, he will be retained to
render consulting services to the Company for a period of
10 years. The annual consideration for such services would
amount to approximately 33% of the non-performance-linked
compensation components paid to him in fiscal year 2010. The
present value of this agreement amounted to $2.877 million
as of December 31, 2010.
Management Board members Rice Powell, Michael Brosnan and Kent
Wanzek participated in the
U.S.-based
401(k) savings plan in 2010. This plan generally allows
employees in the U.S. to invest a portion of their gross
salaries in retirement pension programs. The company supports
this investment, for permanent employees with at least one year
of service, via 50% of the investment made, up to a limit of 6%
of income whereupon the allowance paid by the
Company is limited to 3% of the income or a maximum
of $0.0165 million ($0.022 million
77
for employees 50 years of age or older). The aforementioned
Management Board members were each contractually enabled to
participate in this plan: in the past fiscal year the company
paid out U.S.$9,383.50 respectively in this regard.
Furthermore, the Management Board members Dr. Ben Lipps,
Rice Powell and Michael Brosnan have acquired non-forfeitable
benefits from participation in employee pension plans of
Fresenius Medical Care North America, which provide payment of
pensions as of the age of 65 and the payment of reduced benefits
as of the age of 55. Due to plan cuts in March 2002, the rights
to receive benefits from the pension plans have been frozen at
the level then applicable.
Additions to pension obligations in fiscal year 2010 amounted to
$3.945 million (2009: $1.497 million). The pension
commitments are shown in the following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of January 1,
|
|
|
|
|
|
As of December 31,
|
|
|
|
2010
|
|
|
increase
|
|
|
2010
|
|
|
|
in thousands
|
|
|
Dr. Ben Lipps
|
|
$
|
491
|
|
|
$
|
45
|
|
|
$
|
536
|
|
Michael Brosnan
|
|
|
57
|
|
|
|
11
|
|
|
|
68
|
|
Roberto Fusté
|
|
|
1,747
|
|
|
|
651
|
|
|
|
2,398
|
|
Dr. Emanuele Gatti
|
|
|
1,764
|
|
|
|
2,855
|
|
|
|
4,619
|
|
Rice Powell
|
|
|
109
|
|
|
|
22
|
|
|
|
131
|
|
Dr. Rainer Runte
|
|
|
720
|
|
|
|
361
|
|
|
|
1,081
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
4,888
|
|
|
$
|
3,945
|
|
|
$
|
8,833
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A post-employment non-competition covenant was agreed upon with
all Management Board members. If such covenant becomes
applicable, the Management Board members receive compensation
amounting to half their annual base salaries for each year of
respective application of the non-competition covenant, up to a
maximum of two years. The employment contracts of the Management
Board members contain no express provisions for the case of a
change of control.
With Mr Mats Wahlstrom, who resigned from the Management Board
on December 31, 2009 it was agreed that all outstanding
cash-settled share-based compensation related to the special
bonus component from the years 2006 to 2008 became vested at the
time of his resignation from the Board on December 31,
2009. Mr Wahlstrom completely exercised these rights, as agreed,
in the amount of $2.324 million in February 2010.
All members of the Management Board have received individual
contractual commitments for the continuation of their payments
in cases of sickness for a maximum of 12 months, although
as of six months of sick leave, insurance benefits may be
set off therewith. If a Management Board member dies, the
surviving dependants will be paid three more monthly amounts
after the month of death, until the end of the respective
service agreement at the longest, however.
Miscellaneous
In fiscal year 2010, no loans or advance payments of future
compensation components were made to members of the Management
Board of Fresenius Medical Care Management AG.
The payments to Management Board members Michael Brosnan and
Kent Wanzek were paid in part in U.S. dollars and in part
in euro. The part paid in Germany was agreed in net amounts, so
that varying tax rates in both countries may retroactively
change the gross amounts. Since the actual tax burden can only
be calculated later in the context of the tax returns,
subsequent adjustments may have to be made, which will then be
retroactively covered in future compensation reports.
To the extent permitted by law, Fresenius Medical Care
Management AG undertook to indemnify the members of the
Management Board from claims against them arising out of their
work for the Company and its affiliates, if such claims exceed
their liability under German law. To secure such obligations,
the Company has obtained Directors & Officers
liability insurance with an excess, which complies with the
requirements of the German Act on the Appropriateness of
Executive Board Compensation (VorstAG). The indemnity applies
for the time in which each member of the Management Board is in
office and for claims in this connection after termination of
membership on the Management Board in each case.
78
Former members of the Management Board did not receive any
compensation in fiscal year 2010 other than that mentioned under
point II. Pensions obligations for this group exist in an amount
of $0.666 million (2009: $0.545 million).
Further
Adjustments to System of Compensation of Members of the
Management Board
Since the expiry of fiscal year 2010, no further stock options
can be granted to Management Board members or employees out of
the Stock Option Plan 2006 of Fresenius Medical Care. However,
allotments from the existing Stock Option Plan form a
significant element of the compensation component with long-term
incentive effect. It is intended to implement a new program with
long-term compensation components covering the next five years
in fiscal year 2011.
The new compensation concept with long-term incentive effect is
based on a combination plan, which includes, on the one hand, a
stock option program which is backed by conditional capital. The
additional component of the compensation concept is a likewise
long-term oriented and share-based component with cash
settlement.
The structure of the stock option plan backed by a conditional
capital is oriented mainly on the parameters of the existing
Stock Option Plan 2006. The plan also complies with the amended
requirements of the VorstAG, in particular with regard to the
waiting periods prolonged to four years, and further requires
the achievement of demanding targets. The new stock option plan
requires, for its introduction, the approval of the shareholders
at the ordinary General Meeting of Fresenius Medical Care
AG & Co. KGaA.
The further element of the new long-term compensation system is
an additional, independent, long-term oriented and share-based
compensation component with cash settlement. The granting of
this compensation component is now also intended to be subject
to a four-year waiting period and to require the achievement of
demanding targets. The amount of the cash payment under the
terms of this share-based compensation component will then be
guided by the stock exchange price of the Fresenius Medical Care
AG & Co. KGaA ordinary shares at the time of exercise
after the expiry of the four-year waiting period.
Compared to the Stock Option Plan 2006, the total number of
stock options to be granted is intended to be smaller in view of
the additionally planned long-term oriented share-based
compensation component with cash settlement.
The granting of stock options or the share-based compensation
with cash settlement, respectively, is intended to be available
to management board members as well as to other leading
executives. In compliance with the corporate law allocation of
powers and responsibilities, the supervisory board shall make
the allocations to the Management Board members which will make
the allocations to other leading executives.
Compensation
of the Supervisory Board of Fresenius Medical Care &
Co KGaA and Supervisory Board of Management AG
Our supervisory board consists of six members, five of whom are
also members of the supervisory board of Management AG, our
general partner. Management AG has one additional supervisory
board member who is not a member of our supervisory board. Each
member of our supervisory board is paid an annual retainer fee
of $80,000. The Chairman is paid twice that amount and the
Vice-Chairman 150% of that amount. Supervisory Board members are
reimbursed for their reasonable travel and accommodation
expenses, including value added tax, incurred with respect to
their duties as Supervisory Board members. Supervisory board
members who serve on committees of Fresenius Medical Care
AG & Co. KGaA receive an additional retainer of
$30,000 per year ($50,000 per year in the case of committee
chairs). In accordance with our by-laws, we pay 50% of the fees
directly to the board member for the five supervisory board
members who are also members of the Management AG board and 100%
of the sixth (unaffiliated) members compensation directly
to him. In addition, under the management agreement with our
general partner, the general partner pays the remaining 50% of
the retainer fees of five members of our supervisory board and
100% of the fees payable to the general partners sixth
board member (who has no position with FMC-AG & Co.
KGaA or its Supervisory Board). By agreement, we reimburse
Management AG for 100% of all fees it incurs (including
compensation paid to the general partners supervisory
board). The aggregate compensation reported does not include
amounts paid as fees for services rendered by certain business
or professional entities with which some of the Supervisory
Board members are associated.
79
For the years 2010 and 2009 the
compensation
1)
for the members of the supervisory boards were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed
|
|
|
Fixed
|
|
|
|
|
|
|
|
|
|
|
|
|
compensation for
|
|
|
compensation for
|
|
|
Compensation for
|
|
|
Compensation for
|
|
|
|
|
|
|
Supervisory Board
|
|
|
Supervisory Board
|
|
|
committee services
|
|
|
committee services
|
|
|
|
|
|
|
at FMC
|
|
|
at FMC-AG
|
|
|
at FMC
|
|
|
at FMC-AG
|
|
|
Total
|
|
|
|
Management AG
|
|
|
& Co. KGaA
|
|
|
Management AG
|
|
|
& Co. KGaA
|
|
|
compensation
|
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
|
in thousand
|
|
|
in thousand
|
|
|
in thousand
|
|
|
in thousand
|
|
|
in thousand
|
|
Dr. Gerd Krick
|
|
$
|
40
|
|
|
$
|
40
|
|
|
$
|
120
|
|
|
$
|
120
|
|
|
$
|
60
|
|
|
$
|
40
|
|
|
$
|
30
|
|
|
$
|
30
|
|
|
$
|
250
|
|
|
$
|
230
|
|
Dr. Dieter Schenk
|
|
|
60
|
|
|
|
60
|
|
|
|
60
|
|
|
|
60
|
|
|
|
50
|
|
|
|
30
|
|
|
|
|
|
|
|
|
|
|
|
170
|
|
|
|
150
|
|
Dr. Ulf M.
Schneider
2)
|
|
|
160
|
|
|
|
160
|
|
|
|
|
|
|
|
|
|
|
|
70
|
|
|
|
50
|
|
|
|
|
|
|
|
|
|
|
|
230
|
|
|
|
210
|
|
Dr. Walter L. Weisman
|
|
|
40
|
|
|
|
40
|
|
|
|
40
|
|
|
|
40
|
|
|
|
50
|
|
|
|
30
|
|
|
|
50
|
|
|
|
50
|
|
|
|
180
|
|
|
|
160
|
|
John Gerhard
Kringel
4)
|
|
|
40
|
|
|
|
40
|
|
|
|
40
|
|
|
|
40
|
|
|
|
60
|
|
|
|
40
|
|
|
|
|
|
|
|
10
|
|
|
|
140
|
|
|
|
130
|
|
William P. Johnston
|
|
|
40
|
|
|
|
40
|
|
|
|
40
|
|
|
|
40
|
|
|
|
120
|
|
|
|
80
|
|
|
|
30
|
|
|
|
30
|
|
|
|
230
|
|
|
|
190
|
|
Prof. Dr. Bernd
Fahrholz
3)
|
|
|
|
|
|
|
|
|
|
|
80
|
|
|
|
80
|
|
|
|
|
|
|
|
|
|
|
|
30
|
|
|
|
30
|
|
|
|
110
|
|
|
|
110
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
380
|
|
|
$
|
380
|
|
|
$
|
380
|
|
|
$
|
380
|
|
|
$
|
410
|
|
|
$
|
270
|
|
|
$
|
140
|
|
|
$
|
150
|
|
|
$
|
1,310
|
|
|
$
|
1,180
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1)
|
|
Shown without VAT and withholding
tax
|
|
2)
|
|
Chairman of the supervisory board
of FMC Management AG, but not member of the supervisory board of
FMC-AG & Co. KGaA; fixed compensation paid by FMC
Management AG
|
|
3)
|
|
Member of the supervisory board of
FMC-AG & Co. KGaA, but not member of the supervisory
board of FMC Management AG; fixed compensation paid by
FMC-AG & Co. KGaA
|
|
4)
|
|
Member of committee of
FMC-AG & Co. KGaA until Q2 2009
|
For information relating to the terms of office of the
Management Board and the Supervisory Board of the general
partner, Fresenius Medical Care Management AG, and of the
Supervisory Board of FMC-AG & Co. KGaA, and the
periods in which the members of those bodies have served in
office, see Item 6.A, Directors, Senior Management
and Employees Directors and Senior Management,
above. For information regarding certain compensation payable to
certain members of the general partners management board
after termination of employment, see Item 6.B,
Directors, Senior Management and Employees
Compensation Commitments to Members of Management
for the Event of the Termination of their Employment,
above. The functions usually performed by a remuneration
committee, particularly evaluation and assessment of the
compensation of the members of the general partners
Management Board, are performed by the Human Resources Committee
of the general partners Supervisory Board, the members of
which are Dr. Ulf M. Schneider (Chairman), Dr. Gerd
Krick, Mr. William P. Johnston and Dr. Walter L.
Weisman. Determination of the compensation system and of the
compensation to be granted is to be made by the full Supervisory
Board of Management AG. In 2010, the Audit and Corporate
Governance Committee of FMC-AG & Co. KGaA consisted of
Dr. Gerd Krick, Prof. Dr. Bernd Fahrholz,
Dr. Walter L. Weisman (Chairman) and Mr. William P.
Johnston, all of whom are independent directors for purposes of
SEC
Rule 10A-3.
The primary function of the Audit and Corporate Governance
Committee is to assist FMC-AG & Co. KGaAs
supervisory board in fulfilling its oversight responsibilities,
primarily through:
|
|
|
|
|
overseeing managements conduct of our financial reporting
process and the internal accounting and financial control
systems and auditing of our financial statements;
|
|
|
|
monitoring our internal controls risk program;
|
|
|
|
monitoring our corporate governance performance according to the
German corporate governance codex;
|
|
|
|
monitoring the independence and performance of our outside
auditors;
|
|
|
|
providing an avenue of communication among the outside auditors,
management and the Supervisory Board;
|
|
|
|
reviewing the report of our general partner on relations with
related parties and for reporting to the overall supervisory
board thereon;
|
|
|
|
recommending the appointment of our independent auditors to
audit our German statutory financial statements (subject to the
approval by our shareholders at our Annual General Meeting) and
approval of their fees;
|
|
|
|
retaining the services of our independent auditors to audit our
U.S. GAAP financial statements and approval of their
fees; and
|
|
|
|
pre-approval of all audit and non-audit services performed by
KPMG, our independent auditors.
|
80
In connection with the settlement of the shareholder proceedings
contesting the resolutions of the Extraordinary General Meeting
(EGM) held August 30, 2005 that approved the
transformation, the conversion of our preference shares into
ordinary shares and related matters, we established a joint
committee (the Joint Committee) (gemeinsamer
Ausschuss) of the supervisory boards of Management AG and
FMC-AG & Co. KGaA consisting of two members designated
by each supervisory board to advise and decide on certain
extraordinary management measures, including:
|
|
|
|
|
transactions between us and Fresenius SE with a value in excess
of 0.25% of our consolidated revenue, and
|
|
|
|
acquisitions and sales of significant participations and parts
of our business, the spin-off of significant parts of our
business, initial public offerings of significant subsidiaries
and similar matters. A matter is significant for
purposes of this approval requirement if 40% of our consolidated
revenues, our consolidated balance sheet total assets or
consolidated profits, determined by reference to the arithmetic
average of the said amounts shown in our audited consolidated
accounts for the previous three fiscal years, are affected by
the matter.
|
Furthermore, a nomination committee prepares candidate proposals
for the Supervisory Board and suggests suitable candidates to
the Companys Supervisory Board and for its
nomination prospects to the General Meeting. In 2010, the
nomination committee consisted of Dr. Gerd Krick
(Chairman), Dr. Walter G. Weisman and Dr. Dieter
Schenk.
The supervisory board of our general partner, Management AG, is
supported by a Regulatory and Reimbursement Assessment Committee
(the RRAC) whose members are Mr. William P.
Johnston (Chairman), Mr. John Gerhard Kringel and
Dr. Dieter Schenk. The primary function of the RRAC is to
assist and to represent the board in fulfilling its
responsibilities, primarily through assessing the Companys
affairs in the area of its regulatory obligations and
reimbursement structures for dialysis services. In the United
States, these reimbursement regulations are mandated by the HHS
and CMS for dialysis services. Similar regulatory agencies exist
country by country in the International regions to address the
conditions for payment of dialysis treatments. Furthermore, the
Supervisory Board of Management has its own nomination
committee, which consisted of Dr. Ulf. M. Schneider
(Chairman), Dr. Gerd Krick and Dr. Walter G. Weisman
in 2010.
At December 31, 2010, we had 73,452 employees
(full-time equivalents) as compared to 67,988 at
December 31, 2009, and 64,666 at December 31, 2008.
The 8.0% increase in 2010 was mainly due to the overall growth
in our business and acquisitions. The following table shows the
number of employees by our major category of activities for the
last three fiscal years.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
North America
|
|
|
|
|
|
|
|
|
|
|
|
|
Dialysis Care
|
|
|
36,488
|
|
|
|
35,188
|
|
|
|
33,694
|
|
Dialysis Products
|
|
|
7,557
|
|
|
|
6,916
|
|
|
|
6,752
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
44,045
|
|
|
|
42,104
|
|
|
|
40,446
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
International
|
|
|
|
|
|
|
|
|
|
|
|
|
Dialysis Care
|
|
|
19,647
|
|
|
|
16,413
|
|
|
|
15,180
|
|
Dialysis Products
|
|
|
9,584
|
|
|
|
9,312
|
|
|
|
8,903
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29,231
|
|
|
|
25,725
|
|
|
|
24,083
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate
|
|
|
176
|
|
|
|
159
|
|
|
|
137
|
|
Total Company
|
|
|
73,452
|
|
|
|
67,988
|
|
|
|
64,666
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We are members of the Chemical Industry Employers Association
for most sites in Germany and we are bound by union agreements
negotiated with the respective union representatives. We
generally apply the principles of the association and the
related union agreements for those sites where we are not
members. We are also party to additional shop agreements
negotiated with works councils at individual facilities that
relate to those facilities. In addition, approximately 4% of our
U.S. employees are covered by collective bargaining
agreements. During the last three fiscal years, we have not
suffered any labor-related work disruptions.
As of December 31, 2010, no member of the Supervisory Board
or the Management Board beneficially owned 1% or more of our
outstanding Ordinary shares or our outstanding Preference
shares. At December 31, 2010,
81
Management Board members of the General Partner held options to
acquire 2,178,699 ordinary shares of which options to purchase
1,055,799 ordinary shares were exercisable at a weighted average
exercise price of 26.15 ($34.94). See Item 6.B,
Directors, Senior Management and Employees
Compensation. Those options expire at various dates
between 2012 and 2017.
Options
to Purchase Our Securities
Stock
Option and Other Share Based Plans
Incentive
plan
In 2010, Management Board members were eligible for
performance related compensation that depended upon
achievement of targets. The targets are measured by reference to
operating profit margin, growth of group-wide after-tax earnings
(EAT growth) as well as the development of free cash flow (cash
flow before acquisitions), and are derived from the comparison
of targeted and actually achieved figures. Targets are divided
into Group level targets and those to be achieved in individual
regions. For detailed information relating to targets and
calculation of bonus payments, see Item 6.B above.
The bonus for fiscal year 2010 will consist proportionately of
a cash component and a share-based component which will be paid
in cash. Upon meeting the annual targets, the cash component was
or will be paid after the end of 2010. The share-based component
is subject to a three-year vesting period, although a shorter
period may apply in special cases. The amount of cash payment
relating to the share-based component will correspond to the
share price of Fresenius Medical Care AG & Co. KGaA
ordinary shares upon exercise after the three-year vesting
period. The amount of the maximum achievable bonus for each of
the members of the Management Board is capped.
In 2006, Fresenius Medical Care Management AG adopted a
performance related compensation plan for the members of its
management board in the form of a variable bonus. A special
bonus component (award) for some of the management board members
consists in equal parts of cash payments and share-based
compensation based on the development of the stock price of
Fresenius Medical Care AG & Co. KGaAs ordinary
shares. The amount of the award in each case depends on the
achievement of certain performance targets. The targets are
measured by reference to revenue growth, operating income,
consolidated net income and cash flow development. These
performance targets relate to a three-year period comprising the
fiscal years 2007, 2008 and 2009 only. Annual targets have been
achieved and the cash portion of the award has been paid after
the end of the respective fiscal year. The share-based
compensation portion has been granted but subject to a
three-year vesting period. The amount of cash payment of the
share-based compensation portion corresponds to the share price
of Fresenius Medical Care AG & Co. KGaAs
ordinary shares on exercise, i.e. at the end of the vesting
period, and is also made in cash.
The share-based compensation incurred under these plans for
years 2010, 2009 and 2008 was $2,603, $1,537 and $2,189,
respectively. Such share-based compensation paid to the members
of the general partners management board is included in
the amounts shown in the table entitled Components with
Long-Term Incentive Effect in Item 6.B, Directors,
Senior Management and Employees
Compensation Compensation of the Management
Board.
Fresenius
Medical Care AG & Co. KGaA Stock Option Plan
2006
On May 9, 2006, as amended on May 15, 2007 for a
three-for-one
share split (the Share Split), the Fresenius Medical
Care AG & Co. KGaA Stock Option Plan 2006 (the
Amended 2006 Plan) was established by resolution of
our annual general meeting with a conditional capital increase
up to 15,000,000 subject to the issue of up to fifteen
million no par value bearer ordinary shares with a nominal value
of 1.00 each. Under the Amended 2006 Plan, up to fifteen
million options can be issued, each of which can be exercised to
obtain one ordinary share, with up to three million options
designated for members of the Management Board of the General
Partner, up to three million options designated for members of
management boards of direct or indirect subsidiaries of the
Company and up to nine million options designated for managerial
staff members of the Company and such subsidiaries. With respect
to participants who are members of the General Partners
Management Board, the general partners Supervisory Board
has sole authority to grant stock options and exercise other
decision making powers under the Amended 2006 Plan (including
decisions regarding certain adjustments and forfeitures). The
General Partners Management Board has such authority with
respect to all other participants in the Amended 2006 Plan.
Options under the Amended 2006 Plan can be granted the last
Monday in July
and/or
the
first Monday in December. The exercise price of options granted
under the Amended 2006 Plan shall be the average closing price
on the Frankfurt Stock Exchange of our ordinary shares during
the 30 calendar days immediately prior to each grant date.
Options granted under the Amended 2006 Plan have a seven-year
term but can be exercised only after a three-year vesting
period. The vesting of options granted is subject to achievement
of performance targets, measured over
82
a three-year period from the grant date. For each such year, the
performance target is achieved if our adjusted basic income per
ordinary share (EPS), as calculated in accordance
with the Amended 2006 Plan, increases by at least 8% year over
year during the vesting period, beginning with EPS for the year
of grant as compared to EPS for the year preceding such grant.
Calculation of EPS under the Amended 2006 Plan excludes, among
other items, the costs of the transformation of our legal form
to a KGaA and the conversion of preference shares into ordinary
shares. For each grant, one-third of the options granted are
forfeited for each year in which EPS does not meet or exceed the
8% target. The performance targets for 2010, 2009, and 2008 were
met but the options that vested will not be exercisable until
expiration of the full
3-year
vesting period of each years grants. Vesting of the
portion or portions of a grant for a year or years in which the
performance target is met does not occur until completion of the
entire three-year vesting period. During 2010, we awarded
2,817,879 options, including 423,300 to members of the
Management Board of the General Partner, at a weighted average
exercise price of $57.07 (42.71), a weighted average fair
value of $10.47 each and a total fair value of approximately
$29.5 million which will be amortized on a straight line
basis over the three-year vesting period. The last grant under
the Amended 2006 Plan took place on December 6, 2010. No
further grants are possible under the Amended 2006 Plan. For
information regarding options granted to each member of the
general partners management board, see Item 6.B,
- Compensation of the Management Board above.
Options granted under the Amended 2006 Plan to
U.S. participants are non-qualified stock options under the
United States Internal Revenue Code of 1986, as amended. Options
under the Amended 2006 Plan are not transferable by a
participant or a participants heirs, and may not be
pledged, assigned, or otherwise disposed of.
At December 31, 2010, we had awards outstanding under the
terms of various prior stock-based compensation plans, including
the 2001 plan. Under the 2001 plan, convertible bonds with a
principal of up to 10,240,000 were issued to the members
of the Management Board and other employees of the Company
representing grants for up to 4 million non-voting
Preference shares. Following the Share Split, the convertible
bonds have a par value of 0.85 and bear interest at a rate
of 5.5%. Except for the members of the Management Board,
eligible employees were able to purchase the bonds by issuing a
non-recourse note with terms corresponding to the terms of and
secured by the bond. We have the right to offset our obligation
on a bond against the employees obligation on the related
note; therefore, the convertible bond obligations and employee
note receivables represent stock options we issued and are not
reflected in the consolidated financial statements. The options
expire in ten years and one third of each grant can be exercised
beginning after two, three or four years from the date of the
grant. Bonds issued to Board members who did not issue a note to
us are recognized as a liability on our balance sheet.
Upon issuance of the option, the employees had the right to
choose options with or without a stock price target. The
conversion price of options subject to a stock price target
becomes the stock exchange quoted price of the shares upon the
first time the stock exchange quoted price exceeds the initial
value by at least 25%. The initial value (Initial
Value) is the average price of the shares during the last
30 trading days prior to the date of grant. In the case of
options not subject to a stock price target, the number of
convertible bonds awarded to the eligible employee would be 15%
less than if the employee elected options subject to the stock
price target. The conversion price of the options without a
stock price target is the Initial Value, as adjusted in
accordance to the Share Split. Each option entitles the holder
thereof, upon payment the respective conversion price, to
acquire one share. Up to 20% of the total amount available for
the issuance of awards under the 2001 plan could be issued each
year through May 22, 2006. Effective May 2006, no further
grants could be issued under the 2001 plan.
During 1998, we adopted two stock incentive plans (FMC98
Plan 1 and FMC98 Plan 2) for our key
management and executive employees. These stock incentive plans
were replaced by the 2001 plan and no options have been granted
since 2001. Under these plans eligible employees had the right
to acquire our shares. Options granted under these plans have a
ten-year term, and one third of them vest on each of the second,
third and fourth anniversaries of the award date. Each option
can be exercised for one share.
At December 31, 2010, the Management Board members of the
General Partner held 2,178,699 stock options for ordinary shares
and employees of the Company held 9,973,409 stock options for
ordinary shares with an average remaining contractual life of
4.8 years and 58,663 stock options for preference shares
with an average remaining contractual life of 3.38 years
with 58,663 exercisable preference options at a weighted average
exercise price of $25.65 and 4,316,450 exercisable ordinary
options at a weighted average exercise price of $37.40.
83
|
|
Item 7.
|
Major
Shareholders and Related Party Transactions
|
Security
Ownership of Certain Beneficial Owners of Fresenius Medical
Care
Our outstanding share capital consists of Ordinary shares and
non-voting Preference shares that are issued only in bearer
form. Accordingly, unless we receive information regarding
acquisitions of our shares through a filing with the Securities
and Exchange Commission or through the German statutory
requirements referred to below, or except as described below
with respect to our shares held in American Depository Receipt
(ADR) form, we face difficulties precisely
determining who our shareholders are at any specified time or
how many shares any particular shareholder owns. Because we are
a foreign private issuer under the rules of the Securities and
Exchange Commission, our directors and officers are not required
to report their ownership of our equity securities or their
transactions in our equity securities pursuant to
Section 16 of the Exchange Act. However, persons who become
beneficial owners of more than 5% of our ordinary
shares are required to report their beneficial ownership
pursuant to Section 13(d) of the Exchange Act. In addition,
under the German Securities Trading Act
(
Wertpapierhandelsgesetz
), persons who discharge
managerial responsibilities within an issuer of shares are
obliged to notify the issuer and the German Federal Financial
Supervisory Authority of their own transactions in shares of the
issuer. This obligation also applies to persons who are closely
associated with the persons discharging managerial
responsibility. Additionally, holders of voting securities of a
German company listed on the Regulated Market (Regulierter
Markt) of a German stock exchange or a corresponding trading
segment of a stock exchange within the European Union are
obligated to notify the company of the level of their holding
whenever such holding reaches, exceeds or falls below certain
thresholds, which have been set at 3%, 5%, 10%, 15%, 20%, 25%,
30%, 50% and 75% of a companys outstanding voting rights.
Such notification obligations will also apply to option
agreements (excluding the 3% threshold).
We have been informed that as of December 31, 2010,
Fresenius SE owned approximately 35.7% of our Ordinary shares.
In August 2008, an indirect wholly-owned subsidiary of Fresenius
SE issued 554.4 million aggregate principal amount of
Mandatory Exchangeable Bonds due 2011 with each bond having a
nominal value of 50,000 (the FSE Bonds).
Fresenius SE may redeem the FSE Bonds at or prior to maturity
solely by delivery of our Ordinary shares. The actual number of
ordinary shares deliverable by Fresenius SE upon redemption of
the FSE Bonds will depend upon the exchange ratio for the FSE
Bonds at the time of exchange, subject to an adjusted minimum
exchange price of 31.83 and an adjusted maximum exchange
price of 37.56. Upon maturity of the FSE Bonds, Fresenius
SEs holding of our Ordinary shares could decrease to
between approximately 31% at the maximum exchange price and 30%
at the minimum exchange price.
All of our ordinary shares have the same voting rights. However,
as the sole shareholder of our general partner, Fresenius SE is
barred from voting its ordinary shares on certain matters. See
Item 16.G, Corporate Governance
Supervisory Board.
Bank of New York Mellon, our ADR depositary, informed us, that
as of December 31, 2010, 17,702,065 Ordinary ADSs, each
representing one Ordinary share, were held of record by 4,571
U.S. holders and there were 86,191 Preference ADSs, each
representing one Preference share, held of record by 1
U.S. holder. For more information regarding ADRs and ADSs
see Item 10.B, Memorandum and Articles of
Association Description of American Depositary
Receipts.
Security
Ownership of Certain Beneficial Owners of Fresenius
SE
Following the change of its legal form, Fresenius SEs
share capital consists solely of ordinary shares, issued only in
bearer form. Accordingly, Fresenius SE & Co. KGaA has
difficulties precisely determining who its shareholders are at
any specified time or how many shares any particular shareholder
owns. However, under the German Securities Trading Act, holders
of voting securities of a German company listed on the Regulated
Market (Regulierter Markt) of a German stock exchange or a
corresponding trading segment of a stock exchange within the
European Union are obligated to notify the company of certain
levels of holdings, as described above.
The Else-Kröner-Fresenius Stiftung is the sole shareholder
of Fresenius Management SE, the general partner of Fresenius SE,
and has sole power to elect the supervisory board of Fresenius
Management SE. In addition, based on the most recent information
available, Else-Kröner-Fresenius Stiftung owns
approximately 28.9% of the Fresenius SE Ordinary shares,
(reduced from approximately 58% as a result of the change of
Fresenius SEs legal form, in which all of Fresenius
SEs preference shares were converted into Fresenius SE
ordinary shares). See Item 7.B, Related party
transactions Other interests, below. According
to Allianz SE, they hold, indirectly, approximately 4.26% of the
Fresenius SE Ordinary shares.
84
|
|
B.
|
Related
party transactions
|
In connection with the formation of FMC-AG, and the combination
of the dialysis businesses of Fresenius SE and W.R.
Grace & Co. in the second half 1996, Fresenius SE and
its affiliates and Fresenius Medical Care and its affiliates
entered into several agreements for the purpose of giving effect
to the Merger and defining our ongoing relationship. Fresenius
SE and W.R. Grace & Co. negotiated these agreements.
The information below summarizes the material aspects of certain
agreements, arrangements and transactions between Fresenius
Medical Care and Fresenius SE and their affiliates. The
following descriptions are not complete and are qualified in
their entirety by reference to those agreements, which have been
filed with the Securities and Exchange Commission and the New
York Stock Exchange. We believe that the leases, the supply
agreements and the service agreements are no less favorable to
us and no more favorable to Fresenius SE than would have been
obtained in arms-length bargaining between independent
parties. The trademark and other intellectual property
agreements summarized below were negotiated by Fresenius SE and
W.R. Grace & Co., and, taken independently, are not
necessarily indicative of market terms.
Dr. Gerd Krick, Chairman of our Supervisory Board, is also
a member of the Supervisory Board of our general partner as well
as of the supervisory Board of Fresenius SE & Co. KGaA and
Chairman of the Supervisory Board of its general partner,
Fresenius Management SE. Dr. Dieter Schenk, Vice Chairman
of the Supervisory Board of our general partner and of the
Supervisory Board of FMC-AG & Co. KGaA, is also Vice
Chairman of the Supervisory Board of the general partner of
Fresenius SE, and Dr. Ulf M. Schneider, Chairman of the
Supervisory Board of our general partner and a former member of
the Supervisory Board of FMC-AG, is Chairman of the Management
Board of Fresenius SE & Co. KGaAs general partner and
was the CEO of Fresenius SE (until change of legal form on
January 28, 2011). Dr. Ben J. Lipps of the Management Board
of our general partner, is a member of the Management Board of
the general partner of Fresenius SE. Each of Mr. John G.
Kringel, Dr. Walter L. Weisman and Mr. William P.
Johnston is a member of both our Supervisory Board and our
general partners Supervisory Board.
In the discussion below regarding our contractual and other
relationships with Fresenius SE:
|
|
|
|
|
the term we (or us) and our affiliates refers only
to Fresenius Medical Care AG & Co. KGaA and its
subsidiaries; and
|
|
|
|
the term Fresenius SE and its affiliates refers only
to Fresenius SE and affiliates of Fresenius SE other than
Fresenius Medical Care AG & Co. KGaA and its
subsidiaries.
|
Real
Property Lease
We did not acquire the land and buildings in Germany that
Fresenius Worldwide Dialysis used when we were formed in the
second half of 1996. Fresenius SE or its affiliates have leased
part of the real property to us, directly, and transferred the
remainder of that real property to two limited partnerships.
Fresenius SE is the sole limited partner of each partnership,
and the sole shareholder of the general partner of each
partnership. These limited partnerships, as landlords, have
leased the properties to us and to our affiliates, as
applicable, for use in our respective businesses. The aggregate
annual rent payable by us under these leases is approximately
18.0 million, which was approximately
$23.8 million as of December 31, 2010, exclusive of
maintenance and other costs, and is subject to escalation, based
upon development of the German consumer-price-index determined
by the Federal Statistical Office. The leases for manufacturing
facilities have a ten-year term, followed by two successive
optional renewal terms of ten years each at our election. In
December 2006, the Company exercised its option to renew the
lease for manufacturing facilities and the other leases were
amended to extend their terms and add renewal options. The
leases for the other facilities have a term of ten years. In
December 2007, we amended the lease for the Schweinfurt, Germany
facility, to add additional manufacturing capacity. Based upon
an appraisal, we believe that the rents under the leases
represent fair market value for such properties. For information
with respect to our principal properties in Germany, see
Item 4.D. Property, plants and equipment.
Trademarks
Fresenius SE continues to own the name and mark
Fresenius and its F logo. Fresenius SE
and Fresenius Medical Care Deutschland GmbH, one of our German
subsidiaries, have entered into agreements containing the
following provisions. Fresenius SE has granted to our German
subsidiary, for our benefit and that of our affiliates, an
exclusive, worldwide, royalty-free, perpetual license to use
Fresenius Medical Care in our company names, and to
use the Fresenius marks, including some combination marks
containing the Fresenius name that were used by the worldwide
dialysis business of Fresenius SE, and the Fresenius Medical
Care name as a trade name, in all
85
aspects of the renal business. Our German subsidiary, for our
benefit and that of our affiliates, has also been granted a
worldwide, royalty-free, perpetual license:
|
|
|
|
|
to use the Fresenius Medical Care mark in the then
current National Medical Care non-renal business if it is used
as part of Fresenius Medical Care together with one
or more descriptive words, such as Fresenius Medical Care
Home Care or Fresenius Medical Care
Diagnostics;
|
|
|
|
to use the F logo mark in the National Medical Care
non-renal business, with the consent of Fresenius SE. That
consent will not be unreasonably withheld if the mark using the
logo includes one or more additional descriptive words or
symbols; and
|
|
|
|
to use Fresenius Medical Care as a trade name in the
renal business
|
We and our affiliates have the right to use Fresenius
Medical Care as a trade name in other medical businesses
only with the consent of Fresenius SE. Fresenius SE may not
unreasonably withhold its consent. In the U.S. and Canada,
Fresenius SE will not use Fresenius or the
F logo as a trademark or service mark, except that
it is permitted to use Fresenius in combination with
one or more additional words such as Pharma Home
Care as a service mark in connection with its home care
business and may use the F logo as a service mark
with the consent of our principal German subsidiary. Our
subsidiary will not unreasonably withhold its consent if the
service mark includes one or more additional descriptive words
or symbols. Similarly, in the U.S. and Canada, Fresenius SE
has the right to use Fresenius as a trade name, but
not as a mark, only in connection with its home care and other
medical businesses other than the renal business and only in
combination with one or more other descriptive words, provided
that the name used by Fresenius SE is not confusingly similar to
our marks and trade names. Fresenius SEs ten-year covenant
not to compete with us, granted in 1996, has expired, and
Fresenius SE may use Fresenius in its corporate
names if it is used in combination with one or more additional
distinctive word or words, provided that the name used by
Fresenius SE is not confusingly similar to the Fresenius Medical
Care marks or corporate or trade names.
Other
Intellectual Property
Some of the patents, patent applications, inventions, know-how
and trade secrets that Fresenius Worldwide Dialysis used prior
to our formation were also used by other divisions of Fresenius
SE. For
Biofine
®
,
the polyvinyl chloride-free packaging material, Fresenius SE has
granted to our principal German subsidiary, for our benefit and
for the benefit of our affiliates, an exclusive license for the
renal business and a non-exclusive license for all other fields
except other non-renal medical businesses. Our German subsidiary
and Fresenius SE share equally any royalties from licenses of
the
Biofine
®
intellectual property by either our German subsidiary or by
Fresenius SE to third parties outside the renal business and the
other non-renal medical businesses. In addition, Fresenius SE
transferred to our German subsidiary the other patents, patent
applications, inventions, know-how and trade secrets that were
used predominantly in Fresenius SEs dialysis business. In
certain cases Fresenius Worldwide Dialysis and the other
Fresenius SE divisions as a whole each paid a significant part
of the development costs for patents, patent applications,
inventions, know-how and trade secrets that were used by both
prior to the Merger. Where our German subsidiary acquired those
jointly funded patents, patent applications, inventions,
know-how and trade secrets, our subsidiary licensed them back to
Fresenius SE exclusively in the other non-renal medical
businesses and non-exclusively in all other fields. Where
Fresenius SE retained the jointly funded patents, patent
applications, inventions, know-how and trade secrets, Fresenius
SE licensed them to our German subsidiary exclusively in the
renal business and non-exclusively in all other fields.
Supply
Agreements and Arrangements
We produce most of our products in our own facilities. However,
Fresenius Kabi AG, a subsidiary of Fresenius SE, manufactures
some of our products for us, principally dialysis concentrates
and other solutions, at facilities located in Germany, Brazil,
France and South Africa. Conversely, our facilities in Germany
and Italy produce products for Fresenius Kabi AG.
Our local subsidiaries and those of Fresenius SE have entered
into supply agreements for the purchase and sale of products
from the above facilities. Prices under the supply agreements
are determined by good-faith negotiation. During 2010, we sold
products to Fresenius SE in the amount of $15.4 million. In
2010, we made purchases from Fresenius SE in the amount of
$43.5 million.
The parties may modify existing or enter into additional supply
agreements, arrangements and transactions. Any future
modifications, agreements, arrangements and transactions will be
negotiated between the parties and will be subject to the
approval provisions of the pooling agreements and the regulatory
provisions of German law regarding dominating enterprises.
86
On September 10, 2008, Fresenius Kabi AG, a wholly-owned
subsidiary of Fresenius SE, acquired APP Pharmaceuticals Inc.
(APP Inc.), which manufactures and sells sodium
heparin. Heparin is a blood thinning drug that is widely and
routinely used in the treatment of dialysis patients to prevent
life-threatening blood clots. FMCH currently purchases heparin
supplied by APP Inc. through MedAssets, Inc. MedAssets Inc. is a
publicly-traded U.S. corporation that provides inventory
purchasing services to healthcare providers through a group
purchasing organization (GPO) structure. A GPO is an
organization that endeavors to manage supply and service costs
for hospitals and health care providers by negotiating
discounted prices with manufacturers, distributors and other
vendors. Vendors discount their prices and pay administrative
fees to GPOs because GPOs provide access to a large customer
base, thus reducing vendors sales and marketing costs and
overhead. FMCH is one of many U.S. healthcare providers
that participate in the MedAssets GPO. FMCH purchases
pharmaceuticals and supplies used in its dialysis services
business through the MedAssets GPO contract. During 2010, we
acquired $30.7 million of heparin from APP Inc. through the
GPO.
We were party to a German consolidated trade tax return with
Fresenius SE and certain of its German subsidiaries for the
fiscal years
1997-2001.
During the second quarter of 2009, we reclassified an account
payable in the amount of 77.7 million
($110 million at June 30, 2009) to Fresenius SE
to short-term borrowings from related parties. The amount
represents taxes payable by the Company arising from the period
1997-2001
during which German trade taxes were paid by Fresenius SE on
behalf of the Company. Of this amount, 5.75 million
($7.7 million at December 31, 2010) will be
repaid in 2011 at an interest rate of 6%.
Services
Agreement
We obtain administrative and other services from Fresenius SE
headquarters and from other divisions and subsidiaries of
Fresenius SE. These services relate to, among other things,
administrative services, management information services,
employee benefit administration, insurance, IT services, tax
services and treasury services. For 2010, Fresenius SE and its
affiliates charged us approximately $59.5 million for these
services. Conversely, we have provided certain services to other
divisions and subsidiaries of Fresenius SE relating to research
and development, central purchasing and warehousing. For 2010 we
charged approximately $6.1 million to Fresenius SE and its
subsidiaries for services we rendered to them.
We and Fresenius SE may modify existing or enter into additional
services agreements, arrangements and transactions. Any such
future modifications, agreements, arrangements and transactions
will be negotiated between the parties and will be subject to
the approval provisions of the pooling agreements and the
regulations of German law regarding dominating enterprises.
Financing
We are party to an Amended and Restated Subordinated Loan Note
with Fresenius SE under which we or our subsidiaries may request
and receive one or more advances up to an aggregate amount of
$400 million during the period ending March 31, 2013.
See Note 8 of the Notes to Consolidated Financial
Statements, Short-Term Borrowings, Other Financial
Liabilities and Short-Term Borrowings from Related
Parties Short-Term Borrowings from Related
Parties. During 2010, we received advances between
10.0 million and 86.5 million which
carried interest at rates between 0.968% and 1.879% per annum.
On December 31, 2010, the Company had no advances
outstanding due to Fresenius SE. On August 19, 2009, the
Company borrowed $2.2 million from the general partner at
1.335%. The balance, originally due on August 19, 2010, was
extended until August 19, 2011 at an interest rate of
1.421%.
Other
Interests
Dr. Gerd Krick, chairman of the Supervisory Board of
FMC-AG & Co. KGaA and member of the supervisory board
of Management AG, was a member of the administration board of
Dresdner Bank, Luxembourg, S.A., a subsidiary of Dresdner Bank
AG. See Security Ownership of Certain
Beneficial Owners of Fresenius SE. Dresdner Bank AG,
through its New York and Cayman branches, was a documentation
agent and was one of the joint lead arrangers and book managers
under our senior credit agreement in effect prior to our 2006
Senior Credit Agreement in effect prior to 2006 and our current
Amended 2006 Senior Credit Agreement. Dr. Dieter Schenk,
Vice Chairman of the Supervisory Boards of Management AG and of
FMC-AG Co. KGaA and a member of the Supervisory Board of
Fresenius Management SE, the general partner of Fresenius SE
& Co. KGaA, is a partner in the law firm of Noerr LLP
(formerly Nörr Stiefenhofer Lutz Partnerschaft), which has
provided legal services to Fresenius Medical Care. The portion
of said legal services to Fresenius Medical Care for the period
January 1, 2010 through September 30, 2010, has been
approved by the supervisory board, with Dr. Schenk
abstaining from the vote. Services for the fourth quarter of
2010 will be reviewed in the first quarter of 2011 and are
subject to approval by the supervisory board. During 2010, Noerr
LLP was paid approximately $1.6 million for these services
by Fresenius
87
Medical Care. Dr. Schenk is one of the executors of the
estate of the late Mrs. Else Kröner. Else
Kröner-Fresenius-Stiftung, a charitable foundation
established under the will of the late Mrs. Kröner, is
the sole shareholder of the general partner of Fresenius SE
& Co. KGaA and owns approximately 28.9% of the voting
shares of Fresenius SE & Co. KGaA. Dr. Schenk is also
the Chairman of the advisory board of
Else-Kröner-Fresenius-Stiftung. See
Security Ownership of Certain Beneficial
Owners of Fresenius SE.
Under the articles of association of FMC AG & Co.
KGaA, we will pay Fresenius SE a guaranteed return on its
capital investment in our general partner. See Item 1.6G,
Corporate Governance The Legal Structure of
FMC AG & Co. KGaA, below.
General
Partner Reimbursement
Management AG, the Companys general partner, is a 100%
wholly-owned subsidiary of Fresenius SE. The Companys
Articles of Association provide that the general partner shall
be reimbursed for any and all expenses in connection with
management of the Companys business, including
compensation of the members of the general partners
supervisory board and the general partners management
board. The aggregate amount reimbursed to Management AG for 2010
was approximately $16.1 million for its management services
during 2010 including $0.08 million as compensation for its
exposure to risk as general partner. The Companys Articles
of Association fix this compensation as a guaranteed return of
4% of the amount of the General Partners invested capital
(1.5 million). See Item 16.G
Governance The Legal Structure of
FMC-AG & Co. KGaA below.
|
|
Item 8.
|
Financial
information
|
The information called for by parts 8.A.1 through 8.A.6 of this
item is in the section beginning on
Page F-1.
8.A.7. Legal
Proceedings
The information in Note 18 of the Notes to Consolidated
Financial Statements, Legal Proceedings, in
Part III, Item 18 of this report is incorporated by
this reference in response to this item. For information
regarding certain tax audits and related claims, see
Note 16 of the Notes to Consolidated Financial Statements,
Income Taxes.
8.A.8. Dividend
Policy
We generally pay annual dividends on both our preference shares
and our ordinary shares in amounts that we determine on the
basis of Fresenius Medical Care AG & Co. KGaAs
prior year unconsolidated earnings as shown in the statutory
financial statements that we prepare under German law on the
basis of the accounting principles of the German Commercial Code
(
Handelsgesetzbuch
or
HGB
), subject to
authorization by a resolution to be passed at our general
meeting of shareholders. Under our articles of association, the
minimum dividend payable on the preference shares is 0.04
per share and, if we declare dividends, holders of our
preference shares must receive 0.02 per share more than
the dividend on an ordinary share. Under German law, we must, in
all cases, pay the annual dividend declared on our preference
shares before we pay dividends declared on our ordinary shares.
The general partner and our Supervisory Board propose dividends
and the shareholders approve dividends for payment in respect of
a fiscal year at the Annual General Meeting in the following
year. Since all of our shares are in bearer form, we remit
dividends to the depositary bank (
Depotbank
) on behalf of
the shareholders.
Our Amended 2006 Senior Credit Agreement and outstanding euro
notes, as well as the senior subordinated indentures relating to
our trust preferred securities, restrict our ability to pay
dividends. Item 5.B, Operating and Financial Review
and Prospects Liquidity and Capital Resources
and the notes to our consolidated financial statements appearing
elsewhere in this report discuss this restriction.
The table below provides information regarding the annual
dividend per share that we paid on our Preference shares and
Ordinary shares. These payments were paid in the years shown for
the results of operations in the year preceding the payment.
|
|
|
|
|
|
|
|
|
|
|
|
|
Per Share Amount
|
|
2010
|
|
2009
|
|
2008
|
|
Preference share
|
|
|
0.63
|
|
|
|
0.60
|
|
|
|
0.56
|
|
Ordinary share
|
|
|
0.61
|
|
|
|
0.58
|
|
|
|
0.54
|
|
We have announced that the general partners Management
Board and our Supervisory Board have proposed dividends for 2010
payable in 2011 of 0.67 per preference share and
0.65 per ordinary share. These dividends are subject to
approval by our shareholders at our Annual General Meeting to be
held on May 12, 2011.
88
Except as described herein, holders of ADSs will be entitled to
receive dividends on the ordinary shares and the preference
shares represented by the respective ADSs. We will pay any cash
dividends payable to such holders to the depositary in euros
and, subject to certain exceptions, the depositary will convert
the dividends into U.S. dollars and distribute the
dividends to ADS holders. See Item 10, Additional
Information Description of American Depositary
Receipts Share Dividends and Other
Distributions. Fluctuations in the exchange rate between
the U.S. dollar and the euro will affect the amount of
dividends that ADS holders receive. Dividends paid on the
preference shares and dividends paid to holders and beneficial
holders of the ADSs will be subject to deduction of German
withholding tax. You can find a discussion of German withholding
tax below in Item 10.E. Taxation.
|
|
Item 9.
|
The
Offer and Listing Details
|
A.4. and
C. Information regarding the trading markets for price history
of our stock
Trading
Markets
The principal trading market for our ordinary shares and the
preference shares is the Frankfurt Stock Exchange
(FWB
®
Frankfurter Wertpapierbörse). All ordinary shares and
preference shares have been issued in bearer form. Accordingly,
we face difficulties determining precisely who our holders of
ordinary and preference shares are or how many shares any
particular shareholder owns, with the exception of the number of
shares held in ADR form in the United States. For more
information regarding ADRs see Item 10.B. Memorandum
and articles of association Description of American
Depositary Receipts. However, under the German Securities
Trading Act, holders of voting securities of a German company
listed on a stock exchange within the EU are obligated to notify
the company of certain levels of holdings as described in
Item 7.A. Major Shareholders. Additionally,
persons discharging managerial responsibilities and affiliated
persons are obliged to notify the supervising authority and the
Company of trades in their shares in excess of 5,000 in
any year. The ordinary shares of Fresenius Medical Care AG had
been listed on the Frankfurt Stock Exchange since
October 2, 1996, the preference shares since
November 25, 1996. Trading in the ordinary shares and
preference shares of FMC-AG & Co. KGaA on the
Frankfurt Stock Exchange commenced on February 13, 2006.
Our shares have been listed on the Official Market (Amtlicher
Markt) of the Frankfurt Stock Exchange, which has been combined
with another market and renamed as the Regulated Market
(Regulierter Markt) as of November 1, 2007, and on the
sub-segment
Prime Standard of the Regulated Market. The Prime Standard is a
sub-segment
of the Regulated Market with additional post-admission
obligations. Admission to the Prime Standard requires the
fulfillment of the following transparency criteria: publication
of quarterly reports; preparation of financial statements in
accordance with international accounting standards (IFRS or
U.S. GAAP); publication of a company calendar; convening of
at least one analyst conference per year; and publication of
ad-hoc messages (i.e., certain announcements of material
developments and events) in English. Companies aiming to be
listed in this segment have to apply for admission. Listing in
the Prime Standard is a prerequisite for inclusion of shares in
the selection indices of the Frankfurt Stock Exchange, such as
the
DAX
®
,
the index of 30 major German stocks.
Since October 1, 1996, ADSs each originally representing
one-third of an Ordinary share and, commencing June 15,
2007, each representing one Ordinary share (the Ordinary
ADSs), have been listed and traded on the New York
Stock Exchange (NYSE) under the symbol FMS. Since
November 25, 1996, ADSs, each originally representing
one-third of a Preference share and, commencing June 15,
2007, each representing one Preference share (the
Preference ADSs), have been listed and traded on the
NYSE under the symbol FMS/P. At December 31, 2010, there
were 84,341 preference ADSs outstanding. Accordingly, while the
preference ADSs remain listed on the New York Stock Exchange,
the trading market for the preference ADSs is highly illiquid.
In addition, in connection with the New Your Stock Exchange
listing of our ADSs upon consummation of our transformation and
the related conversion offer, the New York Stock Exchange
advised us that if the number of publicly held preference ADSs
falls below 100,000, which has occurred, the preference ADSs
could be delisted. The Depositary for both the Ordinary ADSs and
the Preference ADSs is Bank of New York Mellon (the
Depositary).
Trading
on the Frankfurt Stock Exchange
Deutsche Börse AG operates the Frankfurt Stock Exchange,
which is the most significant of the six German stock exchanges.
As of December 2009, the most recent figures available, the
shares of more than 10,000 companies traded on the Regulated
Market and the Regulated Unofficial Market of the Frankfurt
Stock Exchange.
Trading on the floor of the Frankfurt Stock Exchange begins
every business day at 9:00 a.m. and ends at 8:00 p.m.,
Central European Time (CET). In floor trading, lead
brokers are responsible for price determination and quotation
for the shares supported by them. The order book in which all
buy and sell orders are compiled serves
89
as their basis. Thereby, only one lead broker is in charge of
each security. A performance measurement for price determination
on the floor includes minimum requirements and therefore ensures
|
|
|
|
|
permanent quotation during trading hours
|
|
|
|
best price execution (in terms of spread and speed)
|
|
|
|
full execution.
|
Our shares are traded on
Xetra
®
,
the electronic trading system of the Deutsche Börse, in
addition to being traded on the Frankfurt floor. The trading
hours for Xetra are between 9:00 a.m. and 5:30 p.m.
CET. Only brokers and banks that have been admitted to Xetra by
the Frankfurt Stock Exchange have direct access to the system
and may trade on it. Private investors can trade on Xetra
through their banks and brokers.
Deutsche Börse AG publishes information for all traded
securities on the Internet,
http://www.deutsche-boerse.com.
Transactions on Xetra and the Frankfurt Stock Exchange settle on
the second business day following the trade except for trades
executed on Xetra International Markets, the European Blue Chip
segment of Deutsche Börse AG, which settle on the third
business day following a trade. The Frankfurt Stock Exchange can
suspend a quotation if orderly trading is temporarily endangered
or if a suspension is deemed to be necessary to protect the
public.
The Hessian Stock Exchange Supervisory Authority (Hessische
Börsenaufsicht) and the Trading Monitoring Unit of the
Frankfurt Stock Exchange (HÜST
Handelssüberwachungsstelle) both monitor trading on the
Frankfurt Stock Exchange.
The Federal Financial Supervisory Authority (
Bundesanstalt
für Finanzdienstleistungsaufsicht
), an independent
federal authority, is responsible for the general supervision of
securities trading pursuant to provisions of the German
Securities Trading Act (
Wertpapierhandelsgesetz
) and
other laws.
The table below sets forth for the periods indicated, the high
and low closing sales prices in euro for the Ordinary shares and
the Preference shares on the Frankfurt Stock Exchange, as
reported by the Frankfurt Stock Exchange Xetra system. Since
January 4, 1999, all shares on German stock exchanges trade
in euro. All share prices have been adjusted to reflect our
one-for-three
share splits in June 2007.
As of February 18, 2011, the share prices for the Ordinary and
Preference shares traded on the Frankfurt Stock Exchange were
47.23 and 40.01, respectively.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Price per
|
|
Price per
|
|
|
|
|
ordinary share ()
|
|
preference share ()
|
|
|
|
|
High
|
|
Low
|
|
High
|
|
Low
|
|
|
2011
|
|
|
January
|
|
|
43.51
|
|
|
|
41.11
|
|
|
|
36.38
|
|
|
|
34.48
|
|
|
2010
|
|
|
December
|
|
|
45.78
|
|
|
|
43.01
|
|
|
|
36.40
|
|
|
|
33.50
|
|
|
|
|
|
November
|
|
|
45.65
|
|
|
|
45.33
|
|
|
|
37.90
|
|
|
|
34.80
|
|
|
|
|
|
October
|
|
|
45.79
|
|
|
|
44.36
|
|
|
|
38.00
|
|
|
|
36.39
|
|
|
|
|
|
September
|
|
|
45.51
|
|
|
|
43.53
|
|
|
|
37.96
|
|
|
|
36.10
|
|
|
|
|
|
August
|
|
|
45.41
|
|
|
|
42.12
|
|
|
|
37.89
|
|
|
|
35.51
|
|
|
2010
|
|
|
Fourth Quarter
|
|
|
45.79
|
|
|
|
43.01
|
|
|
|
38.00
|
|
|
|
33.50
|
|
|
|
|
|
Third Quarter
|
|
|
45.51
|
|
|
|
41.13
|
|
|
|
38.00
|
|
|
|
35.00
|
|
|
|
|
|
Second Quarter
|
|
|
44.71
|
|
|
|
38.21
|
|
|
|
38.50
|
|
|
|
32.35
|
|
|
|
|
|
First Quarter
|
|
|
41.78
|
|
|
|
36.10
|
|
|
|
35.87
|
|
|
|
28.20
|
|
|
2009
|
|
|
Fourth Quarter
|
|
|
37.71
|
|
|
|
31.86
|
|
|
|
33.46
|
|
|
|
30.50
|
|
|
|
|
|
Third Quarter
|
|
|
34.20
|
|
|
|
30.03
|
|
|
|
34.00
|
|
|
|
28.72
|
|
|
|
|
|
Second Quarter
|
|
|
32.19
|
|
|
|
27.64
|
|
|
|
30.00
|
|
|
|
25.24
|
|
|
|
|
|
First Quarter
|
|
|
35.48
|
|
|
|
27.07
|
|
|
|
35.30
|
|
|
|
25.60
|
|
|
2010
|
|
|
Annual
|
|
|
45.79
|
|
|
|
36.10
|
|
|
|
38.50
|
|
|
|
28.20
|
|
|
2009
|
|
|
Annual
|
|
|
37.71
|
|
|
|
26.07
|
|
|
|
35.30
|
|
|
|
25.24
|
|
|
2008
|
|
|
Annual
|
|
|
39.10
|
|
|
|
29.73
|
|
|
|
37.60
|
|
|
|
28.31
|
|
|
2007
|
|
|
Annual
|
|
|
38.67
|
|
|
|
33.05
|
|
|
|
36.78
|
|
|
|
31.32
|
|
|
2006
|
|
|
Annual
|
|
|
36.30
|
|
|
|
27.50
|
|
|
|
33.83
|
|
|
|
25.03
|
|
The average daily trading volume of the Ordinary shares and the
Preference shares traded on the Frankfurt Stock Exchange during
2010 was 824,535 shares and 1,230 shares,
respectively. The foregoing figures are based on total yearly
turnover statistics supplied by the Frankfurt Stock Exchange.
90
Trading
on the New York Stock Exchange
As of February 18, 2011, the share prices for the Ordinary ADSs
and Preference ADSs traded on the NYSE were $64.32 and $52.69,
respectively.
The table below sets forth, for the periods indicated, the high
and low closing sales prices for the Ordinary ADSs and the
Preference ADSs on the NYSE:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Price per
|
|
Price per
|
|
|
|
|
ordinary ADS ($)
|
|
preference ADS ($)
|
|
|
|
|
High
|
|
Low
|
|
High
|
|
Low
|
|
|
2011
|
|
|
January
|
|
|
58.32
|
|
|
|
55.75
|
|
|
|
48.00
|
|
|
|
46.00
|
|
|
2010
|
|
|
December
|
|
|
60.65
|
|
|
|
56.53
|
|
|
|
50.00
|
|
|
|
48.00
|
|
|
|
|
|
November
|
|
|
63.48
|
|
|
|
57.98
|
|
|
|
53.11
|
|
|
|
50.00
|
|
|
|
|
|
October
|
|
|
64.01
|
|
|
|
61.46
|
|
|
|
53.11
|
|
|
|
52.00
|
|
|
|
|
|
September
|
|
|
61.80
|
|
|
|
55.99
|
|
|
|
49.00
|
|
|
|
45.04
|
|
|
|
|
|
August
|
|
|
57.76
|
|
|
|
55.12
|
|
|
|
48.00
|
|
|
|
45.31
|
|
|
2010
|
|
|
Fourth Quarter
|
|
|
64.01
|
|
|
|
56.53
|
|
|
|
53.11
|
|
|
|
48.00
|
|
|
|
|
|
Third Quarter
|
|
|
61.80
|
|
|
|
52.17
|
|
|
|
49.00
|
|
|
|
45.00
|
|
|
|
|
|
Second Quarter
|
|
|
56.70
|
|
|
|
47.57
|
|
|
|
49.70
|
|
|
|
38.88
|
|
|
|
|
|
First Quarter
|
|
|
56.20
|
|
|
|
49.62
|
|
|
|
50.72
|
|
|
|
42.70
|
|
|
2009
|
|
|
Fourth Quarter
|
|
|
54.96
|
|
|
|
47.57
|
|
|
|
49.60
|
|
|
|
44.75
|
|
|
|
|
|
Third Quarter
|
|
|
50.29
|
|
|
|
42.31
|
|
|
|
49.18
|
|
|
|
40.00
|
|
|
|
|
|
Second Quarter
|
|
|
45.04
|
|
|
|
36.94
|
|
|
|
50.00
|
|
|
|
32.00
|
|
|
|
|
|
First Quarter
|
|
|
47.67
|
|
|
|
35.66
|
|
|
|
43.00
|
|
|
|
35.00
|
|
|
2010
|
|
|
Annual
|
|
|
64.01
|
|
|
|
47.57
|
|
|
|
53.11
|
|
|
|
38.88
|
|
|
2009
|
|
|
Annual
|
|
|
54.96
|
|
|
|
35.66
|
|
|
|
50.00
|
|
|
|
32.00
|
|
|
2008
|
|
|
Annual
|
|
|
59.01
|
|
|
|
39.84
|
|
|
|
55.00
|
|
|
|
28.87
|
|
|
2007
|
|
|
Annual
|
|
|
56.70
|
|
|
|
43.69
|
|
|
|
53.50
|
|
|
|
40.00
|
|
|
2006
|
|
|
Annual
|
|
|
47.60
|
|
|
|
34.50
|
|
|
|
40.00
|
|
|
|
31.00
|
|
|
|
Item 10.
|
Additional
information
|
|
|
B.
|
Articles
of Association
|
FMC-AG & Co. KGaA is a partnership limited by shares
(
Kommanditgesellschaft auf Aktien
) organized under the
laws of Germany. FMC-AG & Co. KGaA is registered with
the commercial register of the local court
(Amtsgericht)
of Hof an der Saale, Germany under HRB 4019. Our registered
office
(Sitz)
is Hof an der Saale, Germany. Our business
address is Else-Kröner-Strasse 1, 61352 Bad Homburg,
Germany, telephone +49-6172-609-0.
The following summary of the material provisions of our articles
of association is qualified in its entirety by reference to the
complete text of our articles of association. An English
convenience translation of our articles of association has been
filed with the Securities and Exchange Commission and can also
be found on our website under
www.fmc-ag.com
. For a
summary of certain other provisions of our Articles of
Association relating to management by our general partner and
required ownership of our share capital by the shareholder of
our general partner, See Item 16.G,
Governance the Articles of Association of
FMC-AG & Co. KGaA above.
Corporate
Purposes
Under our articles of association, our business purposes are:
|
|
|
|
|
the development, production and distribution of as well as the
trading in health care products, systems and procedures,
including dialysis;
|
|
|
|
the projecting, planning, establishment, acquisition and
operation of health care businesses, including dialysis centers,
also in separate enterprises or through third parties as well as
the participation in such dialysis centers;
|
|
|
|
the development, production and distribution of other
pharmaceutical products and the provision of services in this
field;
|
|
|
|
the provision of advice in the medical and pharmaceutical areas
as well as scientific information and documentation;
|
|
|
|
the provision of laboratory services for dialysis and
non-dialysis patients and homecare medical services.
|
91
We conduct our business directly and through subsidiaries within
and outside Germany.
General
Information Regarding Our Share Capital
As of February 18, 2011, our share capital consists of
302,242,075, divided into 298,284,907 bearer ordinary
shares without par value (
Stückaktien
) and 3,957,168
bearer non-voting preference shares without par value
(
Stückaktien
). Our share capital has been fully paid
in.
All shares of FMC-AG & Co. KGaA are in bearer form.
Our shares are deposited as share certificates in global form
(
Sammelurkunden
) with Clearstream Banking AG, Frankfurt
am Main. Shareholders are not entitled to have their
shareholdings issued in certificated form. All shares of
FMC-AG & Co. KGaA are freely transferable, subject to
any restrictions imposed by applicable securities laws.
General
provisions on Increasing the Capital of Stock Corporations and
Partnerships Limited by Shares
Under the German Stock Corporation Act (
Aktiengesetz
),
the capital of a stock corporation or of a partnership limited
by shares may be increased by a resolution of the general
meeting, passed with a majority of three quarters of the capital
represented at the vote, unless the articles of association of
the stock corporation or the partnership limited by shares
provide for a different majority.
In addition, the general meeting of a stock corporation or a
partnership limited by shares may create authorized capital
(also called approved capital) (
genehmigtes Kapital
). The
resolution creating authorized capital requires the affirmative
vote of a majority of three quarters of the capital represented
at the vote and may authorize the management board to issue
shares up to a stated amount for a period of up to five years.
The nominal value of the authorized capital may not exceed half
of the share capital at the time of the authorization.
In addition, the general meeting of a stock corporation or of a
partnership limited by shares may create conditional capital
(
bedingtes Kapital
) for the purpose of issuing
(i) shares to holders of convertible bonds or other
securities which grant a right to shares, (ii) shares as
consideration to prepare a merger with another company, or
(iii) shares offered to members of the management board or
employees of the company or of an affiliated company. In each
case, the authorizing resolution requires the affirmative vote
of a majority of three quarters of the capital represented at
the vote. The nominal value of the conditional capital may not
exceed half or, in the case of conditional capital created for
the purpose of issuing shares to members of the management board
and employees, 10% of the companys share capital at the
time of the resolution.
In a partnership limited by shares all resolutions increasing
the capital of the partnership limited by shares also require
the consent of the general partner for their effectiveness.
Authorized
Capital
By resolution of the Annual General Meeting (AGM) of
shareholders on May 11, 2010, Management AG was authorized,
with the approval of the supervisory board, to increase, on one
or more occasions, the Companys share capital until
May 10, 2015 up to a total of 35,000 through issue of
new bearer ordinary shares for cash contributions,
Authorized Capital 2010/I. The General Partner is
entitled, subject to the approval of the supervisory board, to
exclude the pre-emption rights of the shareholders. However,
such an exclusion of pre-emption rights will be permissible for
fractional amounts. Additionally, the newly issued shares may be
taken up by financial institutions nominated by the General
Partner with the obligation to offer them to the shareholders of
the company (indirect pre-emption rights). No Authorized Capital
2010/I has been issued as of December 31, 2010.
In addition, by resolution of the AGM of shareholders on
May 11, 2010, the General Partner was authorized, with the
approval of the supervisory board, to increase, on one or more
occasions, the share capital of the Company until May 10,
2015 up to a total of 25,000 through the issue of new
bearer ordinary shares for cash contributions or contributions
in kind, Authorized Capital 2010/II. The General
Partner is entitled, subject to the approval of the supervisory
board, to exclude the pre-emption rights of the shareholders.
However, such exclusion of pre-emption rights will be
permissible only if (i) in case of a capital increase
against cash contributions, the nominal value of the issued
shares does not exceed 10% of the nominal share value of the
Companys share capital and the issue price for the new
shares is at the time of the determination by the General
Partner not significantly lower than the stock price in Germany
of the existing listed shares of the same class and with the
same rights or, (ii) in case of a capital increase against
contributions in kind, the purpose of such increase is to
acquire an enterprise, parts of an enterprise or an interest in
an enterprise. No Authorized Capital 2010/II has been issued as
of December 31, 2010.
Authorized Capital 2010/I and Authorized Capital 2010/II became
effective upon registration with the commercial register of the
local court in Hof an der Saale on May 25, 2010.
92
Conditional
Capital
By resolution of the Companys Annual General Meeting of
shareholders (AGM) on May 9, 2006, as amended
by the AGM on May 15, 2007, resolving a
three-for-one
share split, the Companys share capital was conditionally
increased by up to 15,000 corresponding to 15 million
ordinary shares with no par value and a nominal value of
1.00. This Conditional Capital increase can only be
effected by the exercise of stock options under the
Companys Stock Option Plan 2006 with each stock option
awarded exercisable for one ordinary share (see Note 15).
The Company has the right to deliver ordinary shares that it
owns or purchases in the market in place of increasing capital
by issuing new shares.
Voting
Rights
Each ordinary share entitles the holder thereof to one vote at
general meetings of shareholders of FMC-AG & Co. KGaA.
Resolutions are passed at an ordinary general or an
extraordinary general meeting of our shareholders by a majority
of the votes cast, unless a higher vote is required by law or
our articles of association. By statute, Fresenius SE as
shareholder of the general partner is not entitled to vote its
ordinary shares in the election or removal of members of the
supervisory board of FMC-AG & Co. KGaA, the
ratification of the acts of the general partners and members of
the supervisory board, the appointment of special auditors, the
assertion of compensation claims against members of the
executive bodies arising out of the management of the Company,
the waiver of compensation claims and the appointment of
auditors. In the case of resolutions regarding such matters
Fresenius SEs voting rights may not be exercised by any
other person.
Our preference shares do not have any voting rights, except as
otherwise regulated by law. If we do not pay the minimum annual
dividend payable on the preference shares for any year in the
following year, and we do not pay both the dividend arrearage
and the dividend payable on the preference shares for such
following year in full in the next following year, then the
preference shares shall have the same voting rights as the
ordinary shares (one vote for each share held or for each ADS
held) until all preference share dividend arrearages are fully
paid up. In addition, holders of preference shares are entitled
to vote on most matters affecting their preferential rights,
such as changes in the rate of the preferential dividend. Any
such vote requires the affirmative vote of 75% of the votes cast
in a meeting of holders of preference shares.
Dividend
Rights
The general partner and our supervisory board will propose any
dividends for approval at the annual general meeting of
shareholders. Usually, shareholders vote on a recommendation
made by management (i.e., the general partner) and the
supervisory board as to the amount of dividends to be paid. Any
dividends are paid once a year, generally, immediately following
our annual general meeting.
Under German law, dividends may only be paid from our balance
sheet profits (
Bilanzgewinn
) as determined by our
unconsolidated annual financial statements as approved by our
annual general meeting of shareholders and the general partner.
Unlike our consolidated annual financial statements, which are
prepared on the basis of accounting principles generally
accepted in the United States of America (U.S. GAAP), the
unconsolidated annual financial statements referred to above are
prepared on the basis of the accounting principles of the German
Commercial Code (
Handelsgesetzbuch
or
HGB
). Since
our ordinary shares and our preference shares that are entitled
to dividend payments are held in a clearing system, the
dividends will be distributed in accordance with the rules of
the individual clearing system. We will publish notice of the
dividends paid and the appointment of the paying agent or agents
for this purpose in the electronic version of the German Federal
Gazette (
elektronischer Bundesanzeiger
). If dividends are
declared, preference shareholders will receive 0.02 per
share more than the dividend payable on our ordinary shares, but
not less than 0.04 per share, according to our articles of
association. Under German law, we must pay the annual dividend
for our preference shares prior to paying any dividends on the
ordinary shares. If the profit shown on the balance sheet in one
or more fiscal years is not adequate to permit distribution of a
dividend of 0.04 per preference share, the shortfall
without interest must be made good out of the profit on the
balance sheet in the following fiscal year or years after
distribution of the minimum dividend on the preference shares
for that year or years and prior to the distribution of a
dividend on the ordinary shares. The right to this payment is an
integral part of the profit share of the fiscal year from which
the shortfall in the preference share dividend is made good.
In the case of holders of ADRs, the depositary will receive all
cash dividends and distributions on all deposited securities and
will, as promptly as practicable, distribute the dividends and
distributions to the holders of ADRs entitled to the dividend.
See Description of American Depositary
Receipts Share Dividends and Other
Distributions.
93
Liquidation
Rights
Our company may be dissolved by a resolution of our general
shareholders meeting passed with a majority of three
quarters of our share capital represented at such general
meeting and the approval of the general partner. In accordance
with the German Stock Corporation Act (
Aktiengesetz
), in
such a case, any liquidation proceeds remaining after paying all
of our liabilities will be distributed among our shareholders in
proportion to the total number of shares held by each
shareholder. Our preference shares are not entitled to a
preference in liquidation.
Pre-emption
Rights
Under the German Stock Corporation Act, each shareholder in a
stock corporation or partnership limited by shares has a
preferential right to subscribe for any issue by that company of
shares, debt instruments convertible into shares, e.g.
convertible bonds or option bonds, and participating debt
instruments, e.g. profit participation rights or participating
certificates, in proportion to the number of shares held by that
shareholder in the existing share capital of the company. Such
pre-emption rights are freely assignable. These rights may also
be traded on German stock exchanges within a specified period of
time prior to the expiration of the subscription period. Our
general shareholders meeting may exclude pre-emption
rights by passing a resolution with a majority of at least three
quarters of our share capital represented at the general meeting
at which the resolution to exclude the pre-emption rights is
passed. In addition, an exclusion of pre-emption rights requires
a report by the general partner justifying the exclusion by
explaining why the interest of FMC-AG & Co. KGaA in
excluding the pre-emption rights outweighs our
shareholders interests in receiving such rights. However,
such justification is not required for any issue of new shares
if:
|
|
|
|
|
we increase our share capital against contributions in cash;
|
|
|
|
the amount of the capital increase does not exceed 10% of our
existing share capital; and
|
|
|
|
the issue price of the new shares is not significantly lower
than the price for the shares quoted on a stock exchange.
|
Exclusion
of Minority Shareholders
Under the provisions of Sections 327a et seq. of the German
Stock Corporation Act concerning squeeze-outs, a shareholder who
owns 95% of the issued share capital (a principal
shareholder) may request that the annual
shareholders meeting of a stock corporation or a
partnership limited by shares resolve to transfer the shares of
the other minority shareholders to the principal shareholder in
return for adequate cash compensation. In a partnership limited
by shares, the consent of the general partner(s) is not
necessary for the effectiveness of the resolution. The amount of
cash compensation to be paid to the minority shareholders must
take account of the issuers financial condition at the
time the resolution is passed. The full value of the issuer,
which is normally calculated using the capitalization of
earnings method (
Ertragswertmethode
), is decisive for
determining the compensation amount.
In addition to the provisions for squeeze-outs of minority
shareholders, Sections 319 et seq. of the German Stock
Corporation Act provides for the integration of stock
corporations. In contrast to the squeeze-out of minority
shareholders, integration is only possible when the future
principal company is a stock corporation with a stated domicile
in Germany. A partnership limited by shares can not be
integrated into another company.
General
Meeting
Our annual general meeting must be held within the first eight
months of each fiscal year at the location of FMC-AG &
Co. KGaAs registered office, or in a German city where a
stock exchange is situated or at the location of a registered
office of a domestic affiliated company. To attend the general
meeting and exercise voting rights, shareholders must register
for the general meeting and prove ownership of shares. The
relevant reporting date is the beginning of the 21st day
prior to the general meeting.
Amendments
to the Articles of Association
An amendment to our articles of association requires both a
voting majority of 75% of the shares entitled to vote
represented at the general meeting and the approval of the
general partner.
94
Description
of American Depositary Receipts
General
The Bank of New York Mellon, a New York banking corporation, is
the depositary representing our ordinary shares and preference
shares. Each American Depositary Share (ADS) represents an
ownership interest in one ordinary share or one preference
share. The deposited shares are deposited with a custodian, as
agent of the depositary, under the deposit agreements among
ourselves, the depositary and all of the holders and owners of
ADSs of the applicable class from time to time (who become bound
by the deposit agreement by their acceptance of American
Depositary Receipts, or ADRs, evidencing their ADSs). Each ADS
also represents any securities, cash or other property deposited
with the depositary but not distributed by it directly to ADS
holders. The ADSs may be evidenced by certificates or may also
be uncertificated. If ADSs are issued in uncertificated form,
owners holding ADSs in book-entry form will receive periodic
statements from the depositary showing their ownership of ADSs.
In the case of beneficial holders of ADSs, owners will receive
these periodic statements through their brokers.
The depositarys office is located at 101 Barclay Street,
New York, NY 10286, U.S.A.
An investor may hold ADSs either directly or indirectly through
a broker or other financial institution. Investors who hold ADSs
directly, by having ADSs registered in their names on the books
of the depositary, are ADS holders. This description assumes an
investor holds ADSs directly. Investors who hold ADSs through
their brokers or financial institution nominees must rely on the
procedures of their brokers or financial institutions to assert
the rights of an ADS holder described in this section. Investors
should consult with their brokers or financial institutions to
find out what those procedures are.
As an ADS holder, we will not treat you as one of our
shareholders and you will not have shareholder rights. German
law governs shareholder rights. The depositary will be the
holder of the shares underlying your ADSs. As a registered
holder of ADSs, you will have ADS holder rights. The applicable
deposit agreement sets out ADS holder rights as well as the
rights and obligations of the depositary. New York law governs
the deposit agreements and the ADSs.
As of December 31, 2010, we had 86,191 preference share
ADSs outstanding. Accordingly, while the preference share ADSs
remain listed on the New York Stock Exchange, the trading market
for the preference share ADSs is highly illiquid. In addition,
the New York Stock Exchange has advised us that if the number of
publicly held preference share ADSs falls below 100,000
preference share ADSs could be delisted.
The following is a summary of the material terms of the deposit
agreements. Because it is a summary, it does not contain all the
information that may be important to investors. Except as
specifically noted, the description covers both ordinary share
ADSs and preference share ADSs. For more complete information,
investors should read the entire applicable deposit agreement
and the form of ADR of the relevant class which contains the
terms of the ADSs. Investors may obtain a copy of the deposit
agreements at the SECs Public Reference Room, located at
100 F Street N.E., Washington, D.C. 20549.
Electronic copies of the deposit agreements are also available
on the website maintained by the SEC,
www.sec.gov
.
Share
Dividends and Other Distributions
We may make different types of distributions with respect to our
ordinary shares and our preference shares. The depositary has
agreed to pay to investors the cash dividends or other
distributions it or the custodian receives on the shares or
other deposited securities, after deducting its fees and
expenses. Investors will receive these distributions in
proportion to the number of underlying shares of the applicable
class their ADSs represent.
Except as stated below, to the extent the depositary is legally
permitted it will deliver distributions to ADS holders in
proportion to their interests in the following manner:
|
|
|
|
|
Cash.
The depositary shall convert cash
distributions from foreign currency to U.S. dollars if this
is permissible and can be done on a reasonable basis. The
depositary will endeavor to distribute cash in a practicable
manner, and may deduct any taxes or other governmental charges
required to be withheld, any expenses of converting foreign
currency and transferring funds to the United States, and
certain other fees and expenses. In addition, before making a
distribution the depositary will deduct any taxes withheld. If
exchange rates fluctuate during a time when the depositary
cannot convert a foreign currency, investors may lose some or
all of the value of the distribution.
|
|
|
|
Shares.
If we make a distribution in shares,
the depositary may deliver additional ADSs to represent the
distributed shares, unless the number of ordinary shares or
preference shares represented by our ADSs is adjusted in
connection with the distribution. Only whole ADSs will be
issued. Any shares which would
|
95
|
|
|
|
|
result in fractional ADSs will be sold and the net proceeds will
be distributed to the ADS holders otherwise entitled to receive
fractional ADSs.
|
|
|
|
|
|
Rights to receive additional shares.
In the
case of a distribution of pre-emption rights to subscribe for
ordinary shares or preference shares, or other subscription
rights, if we provide satisfactory evidence that the depositary
may lawfully distribute the rights, the depositary may arrange
for ADS holders to instruct the depositary as to the exercise of
the rights. However, if we do not furnish the required evidence
or if the depositary determines it is not practical to
distribute the rights, the depositary may:
|
|
|
|
|
|
allow the rights to lapse, in which case ADS holders will
receive nothing, or
|
|
|
|
sell the rights if practicable and distribute the net proceeds
as cash.
|
We have no obligation to file a registration statement under the
U.S. Securities Act of 1933, as amended (the
Securities Act) in order to make any rights
available to ADS holders.
|
|
|
|
|
Other Distributions.
If we make a distribution
of securities or property other than those described above, the
depositary may either:
|
|
|
|
|
|
distribute the securities or property in any manner it deems
fair and equitable;
|
|
|
|
sell the securities or property and distribute any net proceeds
in the same way it distributes cash; or
|
|
|
|
hold the distributed property in which case the ADSs will also
represent the distributed property.
|
Any U.S. dollars will be distributed by checks drawn on a
bank in the United States for whole dollars and cents
(fractional cents will be rounded to the nearest whole cent).
Registered holders will receive the checks directly, while the
checks for beneficial owners will be first sent to the brokers,
who will then distribute the checks to the rightful owners.
The depositary may choose any practical method of distribution
for any specific ADS holder, including the distribution of
foreign currency, securities or property, or it may retain the
items, without paying interest on or investing them, on behalf
of the ADS holder as deposited securities.
The depositary is not responsible if it decides that it is
unlawful or impractical to make a distribution available to any
ADS holders.
There can be no assurance that the depositary will be able to
convert any currency at a specified exchange rate or sell any
property, rights, shares or other securities at a specified
price, or that any of these transactions can be completed within
a specified time period.
Deposit,
Withdrawal and Cancellation
The depositary will deliver ADSs if an investor or his broker
deposits ordinary shares or preference shares or evidence of
rights to receive ordinary shares or preference shares with the
custodian. Shares deposited with the custodian must be
accompanied by certain documents, including instruments showing
that such shares have been properly transferred or endorsed to
the person on whose behalf the deposit is being made.
The custodian will hold all deposited shares for the account of
the depositary. ADS holders thus have no direct ownership
interest in the shares and only have the rights that are
contained in the deposit agreements. The custodian will also
hold any additional securities, property and cash received on or
in substitution for the deposited shares. The deposited shares
and any additional items are referred to as deposited
securities.
Upon each deposit of shares, receipt of related delivery
documentation and compliance with the other provisions of the
deposit agreement, including the payment of the fees and charges
of the depositary and any taxes or other fees or charges owing,
the depositary will deliver ADSs of the applicable class in the
name of the person entitled to them.
All ADSs issued will, unless specifically requested to the
contrary, be delivered through the book-entry settlement system
of The Depository Trust Company, also referred to as DTC,
or be uncertificated and held through the depositarys
book-entry direct registration system (DRS), and a
registered holder will receive periodic statements from the
depositary which will show the number of ADSs registered in the
holders name. An ADS holder can request that the ADSs not
be held through the depositarys DRS and that an ADR be
issued to evidence those ADSs. ADRs will be delivered at the
depositarys principal New York office or any other
location that it may designate as its transfer office.
96
Profile is a required feature of DRS which allows a participant
in DTC, claiming to act on behalf of a registered holder of
ADSs, to direct the depositary to register a transfer of those
ADSs to DTC or its nominee and to deliver those ADSs to the DTC
account of that DTC participant without receipt by the
depositary of prior authorization from the ADS registered holder
to register that transfer.
In connection with and in accordance with the arrangements and
procedures relating to DRS/Profile, the parties to the deposit
agreements understand that the depositary will not verify,
determine or otherwise ascertain that the DTC participant which
is claiming to be acting on behalf of an ADS registered holder
in requesting registration of transfer and delivery described in
the paragraph above has the actual authority to act on behalf of
the ADS registered holder (notwithstanding any requirements
under the Uniform Commercial Code). In the deposit agreements,
the parties agree that the depositarys reliance on and
compliance with instructions received by the depositary through
the DRS/Profile System and in accordance with the deposit
agreement, shall not constitute negligence or bad faith on the
part of the depositary.
When an investor surrenders ADSs at the depositarys
office, the depositary will, upon payment of certain applicable
fees, charges and taxes, and upon receipt of proper
instructions, deliver the whole number of ordinary shares or
preference shares represented by the ADSs turned in to the
account the investor directs within Clearstream Banking AG, the
central German clearing firm.
The depositary may restrict the withdrawal of deposited
securities only in connection with:
|
|
|
|
|
temporary delays caused by closing our transfer books or those
of the depositary, or the deposit of shares in connection with
voting at a shareholders meeting, or the payment of
dividends,
|
|
|
|
the payment of fees, taxes and similar charges, or
|
|
|
|
compliance with any U.S. or foreign laws or governmental
regulations relating to the ADRs.
|
This right of withdrawal may not be limited by any other
provision of the applicable deposit agreement.
Voting
Rights
You may instruct the depositary to vote the number of shares
your ADSs represent. The depositary will notify you of
shareholders meetings and arrange to deliver our voting
materials to you if we ask it to. Those materials will describe
the matters to be voted on and explain how you may instruct the
depositary how to vote. For instructions to be valid, they must
reach the depositary by a date set by the depositary.
The depositary will try, as far as practical, subject to German
law and the provisions of our constitutive documents, to vote
the number of shares or other deposited securities represented
by your ADSs as you instruct. The depositary will only vote or
attempt to vote as you instruct or as described below.
We cannot ensure that you will receive voting materials or
otherwise learn of an upcoming shareholders meeting in
time to ensure that you can instruct the depositary to vote your
shares. In addition, the depositary and its agents are not
responsible for failing to carry out voting instructions or for
the manner of carrying out voting instructions. This means that
you may not be able to vote and there may be nothing you can do
if your shares are not voted as you requested.
If (i) we timely asked the depositary to solicit your
voting instructions, (ii) the depositary receives a
recommendation as to how to vote from the custodian pursuant to
the German Stock Corporation Act before it mails voting
materials to ADS holders and (iii) the depositary does not
receive voting instructions from you by the specified date, it
will consider you to have authorized and directed it to give a
discretionary proxy to the custodian to vote the number of
deposited securities represented by your ADSs in accordance with
the custodians recommendation. The depositary will give a
discretionary proxy in those circumstances with respect to each
question covered by the recommendation unless we notify the
depositary that:
|
|
|
|
|
we do not wish a discretionary proxy to be given;
|
|
|
|
we think there is substantial shareholder opposition to the
particular question; or
|
|
|
|
we think the particular question would have an adverse impact on
our shareholders.
|
Fees and
Expenses
For information regarding fees and expenses payable by holders
of ADSs and amounts payable by the Depository to the Company,
see Item 12.D, American Depositary Shares.
97
Payment
of Taxes
ADS holders must pay any tax or other governmental charge
payable by the custodian or the depositary on any ADS or ADR,
deposited security or distribution. If an ADS holder owes any
tax or other governmental charge, the depositary may
(i) deduct the amount thereof from any cash distributions,
or (ii) sell deposited securities and deduct the amount
owing from the net proceeds of such sale. In either case the ADS
holder remains liable for any shortfall. Additionally, if any
tax or governmental charge is unpaid, the depositary may also
refuse to effect any registration, registration of transfer,
split-up
or
combination of deposited securities or withdrawal of deposited
securities (except under limited circumstances mandated by
securities regulations). If any tax or governmental charge is
required to be withheld on any non-cash distribution, the
depositary may sell the distributed property or securities to
pay such taxes and distribute any remaining net proceeds to the
ADS holders entitled thereto.
Limitations
on Obligations and Liability
Limits on
our Obligations and the Obligations of the Depositary; Limits on
Liability to Holders of ADSs
The deposit agreements expressly limit our obligations and the
obligations of the depositary. They also limit our liability and
the liability of the depositary. We and the depositary:
|
|
|
|
|
are only obligated to take the actions specifically set forth in
the applicable deposit agreement without negligence or bad faith;
|
|
|
|
are not liable if we are or it is prevented or delayed by law or
circumstances beyond our control from performing our or its
obligations under the applicable deposit agreement;
|
|
|
|
are not liable if we or it exercises discretion permitted under
the applicable deposit agreement;
|
|
|
|
have no obligation to become involved in a lawsuit or other
proceeding related to the ADSs or the applicable deposit
agreement on your behalf or on behalf of any other
person; and
|
|
|
|
may rely upon any documents we believe or it believes in good
faith to be genuine and to have been signed or presented by the
proper person.
|
In the deposit agreements, we and the depositary agree to
indemnify each other under certain circumstances.
Requirements
for Depositary Actions
Before the depositary will deliver or register a transfer of an
ADS, make a distribution on an ADS, or permit withdrawal of
shares, the depositary may require:
|
|
|
|
|
payment of stock transfer or other taxes or other governmental
charges and transfer or registration fees charged by third
parties for the transfer of any shares or other deposited
securities;
|
|
|
|
satisfactory proof of the identity and genuineness of any
signature or other information it deems necessary; and
|
|
|
|
compliance with regulations it may establish, from time to time,
consistent with the deposit agreement, including presentation of
transfer documents.
|
The depositary may refuse to deliver ADSs or register transfers
of ADSs generally when the transfer books of the depositary or
our transfer books are closed or at any time if the depositary
or we think it advisable to do so.
Shareholder
Communications; Inspection of Register of Holders of
ADSs
The depositary will make available for your inspection at its
office all communications that it receives from us as a holder
of deposited securities that we make generally available to
holders of deposited securities. The depositary will send you
copies of those communications if we ask it to. You have a right
to inspect the register of holders of ADSs, but not for the
purpose of contacting those holders about a matter unrelated to
our business or the ADSs.
Description
of the Pooling Arrangements
Prior to the transformation of legal form of FMC-AG to
FMC-AG & Co. KGaA, FMC-AG, Fresenius SE and the
independent directors (as defined in the pooling agreements
referred to below) of FMC-AG were parties to two pooling
agreements for the benefit of the holders of our ordinary shares
and the holders of our preference shares (other than Fresenius
SE and its affiliates). Upon consummation of the conversion and
the transformation, we entered into pooling arrangements that we
believe provide similar benefits for the holders of the ordinary
shares and preference shares of FMC-AG & Co. KGaA. The
following is a summary of the material provisions of the pooling
arrangements which we have entered into with Fresenius SE and
our independent directors.
98
General
The pooling arrangements have been entered into for the benefit
of all persons who, from time to time, beneficially own our
ordinary shares, including owners of ADSs evidencing our
ordinary shares, other than Fresenius SE and its affiliates or
their agents and representatives, and persons from time to time
beneficially owning our preference shares, including (if the
preference ADSs are eligible for listing on the New York Stock
Exchange), ADSs evidencing our preference shares, other than
Fresenius SE and its affiliates or their agents and
representatives. Beneficial ownership is determined in
accordance with the beneficial ownership rules of the SEC.
Independent
Directors
Under the pooling arrangements, no less than one-third of the
supervisory board of Management AG, the general partner of
FMC-AG & Co. KGaA, must be independent directors, and
there must be at least two independent directors. Independent
directors are persons without a substantial business or
professional relationship with us, Fresenius SE, or any
affiliate of either, other than as a member of the supervisory
board of FMC-AG & Co. KGaA or as a member of the
supervisory board of Management AG. If an independent director
resigns, is removed, or is otherwise unable or unwilling to
serve in that capacity, a new person shall be appointed to serve
as an independent director in accordance with the provisions of
the articles of association of the general partner, and the
pooling arrangements, if as a result of the resignation or
removal the number of independent directors falls below the
required minimum. The provisions of the pooling agreement
relating to independent directors are in addition to the
functions of the joint committee established in connection with
the transformation of our legal form and conversion of our
preference shares, and are also in addition to the requirement
of
Rule 10A-3
under the Securities Exchange Act of 1934 that our audit
committee be composed solely of independent directors as defined
in that rule. We have identified the members of Management
AGs supervisory board who are independent for purposes of
our pooling arrangements in Item 6.B., Directors,
Senior Management and Employees The General
Partners Supervisory Board.
Extraordinary
Transactions
Under the pooling arrangements, we and our affiliates on the one
hand, and Management AG and Fresenius SE and their affiliates on
the other hand, must comply with all provisions of German law
regarding: any merger, consolidation, sale of all or
substantially all assets, recapitalization, other business
combination, liquidation or other similar action not in the
ordinary course of our business, any issuance of shares of our
voting capital stock representing more than 10% of our total
voting capital stock outstanding, and any amendment to our
articles of association which adversely affects any holder of
ordinary shares or preference shares, as applicable.
Interested
Transactions
We and Management AG and Fresenius SE have agreed that while the
pooling arrangements are in effect, a majority of the
independent directors must approve any transaction or contract,
or any series of related transactions or contracts, between
Fresenius SE, Management AG or any of their affiliates (other
than us or our controlled affiliates), on the one hand, and us
or our controlled affiliates, on the other hand, which involves
aggregate payments in any calendar year in excess of
5 million for each individual transaction or
contract, or a related series of transactions or contracts.
However, approval is not required if the transaction or
contract, or series of related transactions or contracts, has
been described in a business plan or budget that a majority of
the independent directors has previously approved. In any year
in which the aggregate amount of transactions that require
approval (or that would have required approval in that calendar
year but for the fact that such payment or other consideration
did not exceed 5 million) has exceeded
25 million, a majority of the independent directors
must approve all further interested transactions involving more
than 2.5 million. However, approval is not required
if the transaction or contract, or series of related
transactions or contracts, has been described in a business plan
or budget that a majority of independent directors has
previously approved.
Listing
of American Depositary Shares; SEC Filings
During the term of the pooling agreement, Fresenius SE has
agreed to use its best efforts to exercise its rights as the
direct or indirect holder of the general partner interest in
Fresenius Medical Care AG & Co. KGaA to cause us to,
and we have agreed to:
|
|
|
|
|
maintain the effectiveness of (i) the deposit agreement for
the ordinary shares, or a similar agreement, and to assure that
the ADSs evidencing the ordinary shares are listed on either the
New York Stock Exchange or the Nasdaq Stock Market and (ii),
while the preference ADSs are eligible for listing on the New
York Exchange or the Nasdaq Stock Market, the deposit agreement
for the preference shares, or a similar agreement, and to assure
that, if eligible for such listing, the ADSs evidencing the
preference shares are listed on either the New York Stock
Exchange or the Nasdaq Stock Market;
|
99
|
|
|
|
|
file all reports, required by the New York Stock Exchange or the
Nasdaq Stock Market, as applicable, the Securities Act, the
Securities Exchange Act of 1934, as amended, and all other
applicable laws;
|
|
|
|
prepare all financial statements required for any filing in
accordance with generally accepted accounting principles of the
U.S. (U.S. GAAP);
|
|
|
|
on an annual basis, prepare audited consolidated financial
statements in accordance with U.S. GAAP, and, on a
quarterly basis, prepare and furnish to the SEC consolidated
financial statements prepared in accordance with U.S. GAAP
under cover of
form 6-K
or a comparable successor form;
|
|
|
|
furnish materials with the SEC with respect to annual and
special shareholder meetings under cover of
Form 6-K
and make the materials available to the depositary for
distribution to holders of ordinary share ADSs and, if we
maintain a preference share ADS facility, to holders of
preference share ADSs at any time that holders of preference
shares are entitled to voting rights; and
|
|
|
|
make available to the depositary for distribution to holders of
ADSs representing our ordinary shares and, if we maintain a
preference share ADS facility, ADSs representing our preference
shares on an annual basis, a copy of any report prepared by the
supervisory board or the supervisory board of the general
partner and provided to our shareholders generally pursuant to
Section 314(2) of the German Stock Corporation Act, or any
successor provision. These reports concern the results of the
supervisory boards examination of the managing
boards report on our relation with affiliated enterprises.
|
Term
The pooling arrangements will terminate if:
|
|
|
|
|
Fresenius SE or its affiliates acquire all our voting shares;
|
|
|
|
Fresenius SEs beneficial ownership of our outstanding
share capital is reduced to less than 25%;
|
|
|
|
Fresenius SE or an affiliate of Fresenius SE ceases to own the
general partner interest in FMC-AG & Co. KGaA; or
|
|
|
|
we no longer meet the minimum threshold for obligatory
registration of the ordinary shares or ADSs representing our
ordinary shares and the preference shares or ADSs representing
our preference shares, as applicable, under
Section 12(g)(1) of the Securities Exchange Act of 1934, as
amended, and
Rule 12g-1
thereunder.
|
Amendment
Fresenius SE and a majority of the independent directors may
amend the pooling arrangements, provided, that beneficial owners
of 75% of the ordinary shares held by shareholders other than
Fresenius SE and its affiliates at a general meeting of
shareholders and 75% of the preference shares at a general
meeting of preference shareholders, as applicable, approve such
amendment.
Enforcement;
Governing Law
The pooling arrangements are governed by New York law and may be
enforced in the state and federal courts of New York. The
Company and Fresenius SE have confirmed their intention to abide
by the terms of the pooling arrangements as described above.
Directors
and Officers Insurance
Subject to any mandatory restrictions imposed by German law,
FMC-AG has obtained and FMC-AG & Co. KGaA will
continue to maintain directors and officers insurance in respect
of all liabilities arising from or relating to the service of
the members of the supervisory board and our officers, subject
to legally mandated deductibles. We believe that our acquisition
of that insurance is in accordance with customary and usual
policies followed by public corporations in the U.S.
For information regarding certain of our material contracts, see
Item 7.B. Major Shareholders and Related Party
Transactions Related Party Transactions. For a
description of our stock option plans, see Item 6.E.
Directors, Senior Management and Employees Share
Ownership Options to Purchase our Securities.
For a description of our Amended 2006 Senior Credit Agreement
and our agreements relating to our long-term and short-term
indebtedness, see Notes 8 and 9 of the Notes to
Consolidated Financial Statements.
100
Our material agreements include the settlement agreement that
we, FMCH and NMC entered into with the Official Committee of
Asbestos Injury Claimants, and the Official Committee of
Asbestos Property Damage Claimants of W.R. Grace &
Co., a description of which appears in Note 18 of the Notes
to Consolidated Financial Statements, Legal
Proceedings, and the Merger agreement among us, FMCH and
RCG. For a description of our license and distribution
agreements for injectable iron products, see Note 6 of the
Notes to Consolidated Financial Statements, Intangible
Assets and Goodwill.
Exchange
Controls and Other Limitations Affecting Security
Holders.
At the present time, Germany does not restrict the export or
import of capital, except for certain restrictions on
transactions based on international embargo or terror prevention
resolutions concerning for example Iraq, Iran, the Democratic
Republic of Korea, Myanmar, or Sudan. However, the Federal
Ministry of Economics and Technology (
Bundesministerium
für Wirtschaft und Technologie
) may in
exceptional cases review and prohibit the direct or
indirect acquisition of 25% or more of the shares or voting
rights in a German company by a person or company resident
outside of the European Union or the European Free Trade Area if
such acquisition constitutes a material threat to the public
security or order. Further, for statistical purposes only, every
resident individual or corporation residing in Germany must
report to the German Federal Bank (Deutsche Bundesbank), subject
only to certain immaterial exceptions, any payment received from
or made to an individual or a corporation resident outside of
Germany if such payment exceeds 12,500. In addition,
residents must report any claims against, or any liabilities
payable to, non-residents individuals or corporations, if such
claims or liabilities, in the aggregate exceed
5 million at the end of any month.
There are no limitations imposed by German law or our articles
of association (
Satzung
) on the right of a non-resident
to hold the Preference shares or Ordinary shares or the ADSs
evidencing Preference shares or Ordinary shares.
U.S. and
German Tax Consequences of Holding ADSs
The discussion below is not a complete analysis of all of the
potential U.S. federal and German tax consequences of
holding ADSs of FMC-AG & Co. KGaA. In addition, the
U.S. federal and German tax consequences to particular
U.S. holders, such as insurance companies, tax-exempt
entities, investors holding ADSs through partnerships or other
fiscally transparent entities, investors liable for the
alternative minimum tax, investors that hold ADSs as part of a
straddle or a hedge, investors whose functional currency is not
the U.S. dollar, financial institutions and dealers in
securities, and to
non-U.S. holders
may be different from that discussed herein.
Germany and the United States of America have agreed on a
Protocol amending the existing Income Tax Treaty. On
December 28, 2007, the Protocol entered into force. The
Protocol is effective in respect of withholding taxes for
amounts paid on or after January 1, 2007. Changes related
to other taxes on income became effective on January 1,
2008.
Investors should consult their tax advisors with respect to the
particular United States federal and German tax consequences
applicable to holding ADSs of FMC-AG & Co.KGaA.
Tax
Treatment of Dividends
German corporations are required to withhold tax on dividends
paid to resident and non-resident shareholders. The German
Business Tax Reform 2008 increased the withholding tax rate on
dividends to 25% (plus solidarity surcharges) starting
January 1, 2009. Also effective January 1, 2009 for
corporate non-German holders, forty percent (40%) of the
withheld and remitted withholding tax may be refunded upon
application at the German Federal Tax Office (at the address
noted below), which would generally result in a net withholding
of 15% (plus solidarity surcharge). The entitlement of corporate
non-German holders to further reductions of the withholding tax
under an applicable income tax treaty remains unaffected. A
partial refund of this withholding tax can be obtained by
U.S. holders under the
U.S.-German
Tax Treaty (Treaty). For U.S. federal income
tax purposes, U.S. holders are taxable on dividends paid by
German corporations subject to a foreign tax credit for certain
German income taxes paid. The amount of the refund of German
withholding tax and the determination of the foreign tax credit
allowable against U.S. federal income tax depend on whether
the U.S. holder is a corporation owning at least 10% of the
voting stock of the German corporation (Holder 1).
101
In the case of any U.S. holder (Holder 2) other
than a Holder 1, the German withholding tax is partially
refunded under the Treaty to reduce the withholding tax to 15%
of the gross amount of the dividend. In this case, for each $100
of gross dividend that we pay to a Holder 2, the dividend is
subject to withholding tax of $26.38, $11.38 which is refunded,
resulting in a net tax of $15. For U.S. foreign tax credit
purposes, the U.S. holder would report dividend income of
$100 (to the extent paid out of current and accumulated earnings
and profits) and foreign taxes paid of $15, for purposes of
calculating the foreign tax credit or the deduction for taxes
paid.
Subject to certain exceptions, dividends received by a
non-corporate U.S. holder will be subject to a maximum
U.S. federal income tax rate of 15%. The lower rate applies
to dividends only if the ADSs in respect of which such dividend
is paid have been held for at least 61 days during the
121 day period beginning 60 days before the
ex-dividend date. Periods during which you hedge a position in
our ADSs or related property may not count for purposes of the
holding period test. The dividends would also not be eligible
for the lower rate if you elect to take dividends into account
as investment income for purposes of limitations on deductions
for investment income. U.S. holders should consult their
own tax advisors regarding the availability of the reduced
dividend rate in light of their own particular circumstances.
In the case of a Holder 1, the 26.375% German withholding tax is
reduced under the Treaty to 5% of the gross amount of the
dividend. Such a holder may, therefore, apply for a refund of
German withholding tax in the amount of 21.375% of the gross
amount of the dividends. A corporate U.S. holder will
generally not be eligible for the dividends-received deduction
generally allowed to U.S. corporations in respect of
dividends received from other U.S. corporations.
Subject to certain complex limitations, a U.S. holder is
generally entitled to a foreign tax credit equal to the portion
of the withholding tax that cannot be refunded under the Treaty.
Dividends paid in Euros to a U.S. holder of ADSs will be
included in income in a dollar amount calculated by reference to
the exchange rate in effect on the date the dividends, including
the deemed refund of German withholding tax, are included in
income by such a U.S. holder. If dividends paid in Euros
are converted into dollars on the date included in income,
U.S. holders generally should not be required to recognize
foreign currency gain or loss in respect of the dividend income.
Under the Treaty the refund of German tax, including the
withholding tax, Treaty payment and solidarity surcharge, will
not be granted when the ADSs are part of the business property
of a U.S. holders permanent establishment located in
Germany or are part of the assets of an individual
U.S. holders fixed base located in Germany and used
for the performance of independent personal services. In this
case, however, withholding tax and solidarity surcharge may be
credited against German income tax liability.
Refund
Procedures
To claim a refund under the Treaty, the U.S. holder must
submit a claim for refund to the German tax authorities, with
the original bank voucher, or certified copy thereof issued by
the paying entity documenting the tax withheld within four years
from the end of the calendar year in which the dividend is
received. Claims for refund are made on a special German claim
for refund form, which must be filed with the German Federal Tax
Office: Bundeszentralamt für Steuern, An der Küppe 1,
D-53225 Bonn, Germany. The claim refund forms may be obtained
from the German Federal Tax Office at the same address where the
applications are filed, or from the Embassy of the Federal
Republic of Germany, 4645 Reservoir Road, N.W.,
Washington, D.C.
20007-1998,
or from the Office of International Operations, Internal Revenue
Service, 1325 K Street, N.W., Washington, D.C.
20225, Attention: Taxpayer Service Division, Room 900 or
can be downloaded from the homepage of the Bundeszentralamt
für Steuern (www.bzst.bund.de).
U.S. holders must also submit to the German tax authorities
certification of their last filed U.S. federal income tax
return. Certification is obtained from the office of the
Director of the Internal Revenue Service Center by filing a
request for certification with the Internal Revenue Service
Center, Foreign Certificate Request, P.O. Box 16347,
Philadelphia, PA
19114-0447.
Requests for certification are to be made in writing and must
include the U.S. holders name, address, phone number,
social security number or employer identification number, tax
return form number and tax period for which certification is
requested. The Internal Revenue Service will send the
certification back to the U.S. holder for filing with the
German tax authorities.
U.S. holders of ADSs who receive a refund attributable to
reduced withholding taxes under the Treaty may be required to
recognize foreign currency gain or loss, which will be treated
as ordinary income or loss, to the extent that the dollar value
of the refund received by the U.S. holders differs from the
dollar equivalent of the refund on the date the dividend on
which such withholding taxes were imposed was received by the
depositary or the U.S. holder, as the case may be.
102
Taxation
of Capital Gains
Under the Treaty, a U.S. holder who is not a resident of
Germany for German tax purposes will not be liable for German
tax on capital gains realized or accrued on the sale or other
disposition of ADSs unless the ADSs are part of the business
property of a permanent establishment located in Germany or are
part of the assets of a fixed base of an individual located in
Germany and used for the performance of independent personal
services.
Upon a sale or other disposition of the ADSs, a U.S. holder
will recognize gain or loss for U.S. federal income tax
purposes in an amount equal to the difference between the amount
realized and the U.S. holders tax basis in the ADSs.
Such gain or loss will generally be capital gain or loss if the
ADSs are held by the U.S. holder as a capital asset, and
will be long-term capital gain or loss if the
U.S. holders holding period for the ADSs exceeds one
year. Individual U.S. holders are generally taxed at a
maximum 15% rate on net long-term capital gains.
Gift and
Inheritance Taxes
The
U.S.-Germany
estate, inheritance and gift tax treaty provides that an
individual whose domicile is determined to be in the
U.S. for purposes of such treaty will not be subject to
German inheritance and gift tax, the equivalent of the
U.S. federal estate and gift tax, on the individuals
death or making of a gift unless the ADSs are part of the
business property of a permanent establishment located in
Germany or are part of the assets of a fixed base of an
individual located in Germany and used for the performance of
independent personal services. An individuals domicile in
the U.S., however, does not prevent imposition of German
inheritance and gift tax with respect to an heir, donee, or
other beneficiary who is domiciled in Germany at the time the
individual died or the gift was made.
Such treaty also provides a credit against U.S. federal
estate and gift tax liability for the amount of inheritance and
gift tax paid in Germany, subject to certain limitations, in a
case where ADSs are subject to German inheritance or gift tax
and U.S. federal estate or gift tax.
Other
German Taxes
There are no German transfer, stamp or other similar taxes that
would apply to U.S. holders who purchase or sell ADSs.
United
States Information Reporting and Backup Withholding
Dividends and payments of the proceeds on a sale of ADSs, paid
within the United States or through
U.S.-related
financial intermediaries are subject to information reporting
and may be subject to backup withholding unless you (1) are
a corporation or other exempt recipient or (2) provide a
taxpayer identification number and certify (on Internal Revenue
Service
Form W-9)
that no loss of exemption from backup withholding has occurred.
Non-U.S. shareholders
are not U.S. persons generally subject to information
reporting or backup withholding. However, a
non-U.S. holder
may be required to provide a certification (generally on
Internal Revenue Service
Form W-8BEN)
of its
non-U.S. status
in connection with payments received in the United States or
through a
U.S.-related
financial intermediary.
We file periodic reports and information with the Securities and
Exchange Commission and the New York Stock Exchange. You may
inspect a copy of these reports without charge at the Public
Reference Room of the Securities and Exchange Commission at
100 F Street N.E., Washington, D.C. 20549 or at
the Securities and Exchange Commissions regional offices
233 Broadway, New York, New York 10279 and 500 West
Madison Street, Suite 1400, Chicago, Illinois 60661. The
public may obtain information on the operation of the Public
Reference Room by calling the Securities and Exchange Commission
at
1-800-SEC-0330.
The Securities and Exchange Commission also maintains an
Internet site that contains reports, proxy and information
statements and other information regarding registrants that file
electronically with the Securities and Exchange Commission. The
Securities and Exchange Commissions World Wide Web address
is
http://www.sec.gov.
The New York Stock Exchange currently lists American Depositary
Shares representing our Preference shares and American
Depositary Shares representing our Ordinary shares. As a result,
we are subject to the periodic reporting requirements of the
Securities Exchange Act of 1934, as amended, and we file reports
and other information with the Securities and Exchange
Commission. These reports, proxy statements and other
information and the registration statement and exhibits and
schedules thereto may be inspected without charge at, and copies
thereof may be obtained at prescribed rates from, the public
reference facilities of the Securities and Exchange Commission
and the electronic
103
sources listed in the preceding paragraph. In addition, these
materials are available for inspection and copying at the
offices of the New York Stock Exchange, 20 Broad Street,
New York, New York 10005, USA.
We prepare annual and quarterly reports. Our annual reports
contain financial statements examined and reported upon, with
opinions expressed by our independent auditors. Our consolidated
financial statements included in these annual reports are
prepared in conformity with U.S. GAAP. Our annual and
quarterly reports to our shareholders are posted under
Publications on the Investor Relations
page of our website at
http://www.fmc-ag.com.
In furnishing our web site address in this report, however, we
do not intend to incorporate any information on our web site
into this report, and any information on our web site should not
be considered to be part of this report.
We will also furnish the depositary with all notices of
shareholder meetings and other reports and communications that
are made generally available to our shareholders. The
depositary, to the extent permitted by law, shall arrange for
the transmittal to the registered holders of American Depositary
Receipts of all notices, reports and communications, together
with the governing instruments affecting our shares and any
amendments thereto. Such documents are also available for
inspection by registered holders of American Depositary Receipts
at the principal office of the depositary.
Documents referred to in this report which relate to us as well
as future annual and interim reports prepared by us may also be
inspected at our offices, Else-Kröner-Strasse 1, 61352 Bad
Homburg.
|
|
Item 11.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
Market
Risk
Our businesses operate in highly competitive markets and are
subject to changes in business, economic and competitive
conditions. Our business is subject to:
|
|
|
|
|
changes in reimbursement rates;
|
|
|
|
intense competition;
|
|
|
|
foreign exchange rate and interest rate fluctuations;
|
|
|
|
varying degrees of acceptance of new product introductions;
|
|
|
|
technological developments in our industry;
|
|
|
|
uncertainties in litigation or investigative proceedings and
regulatory developments in the health care sector; and
|
|
|
|
the availability of financing.
|
Our business is also subject to other risks and uncertainties
that we describe from time to time in our public filings. See
Item 3.D, Key Information Risk
Factors. Developments in any of these areas could cause
our results to differ materially from the results that we or
others have projected or may project.
Reimbursement
Rates
We obtained approximately 32% of our worldwide revenue for 2010
from sources subject to regulations under U.S. government
health care programs. In the past, U.S. budget deficit
reduction and health care reform measures have changed the
reimbursement rates under these programs, including the Medicare
composite rate, the reimbursement rate for EPO, and the
reimbursement rates for other dialysis and non-dialysis related
services and products, as well as other material aspects of
these programs, and they may change in the future. Effective
January 1, 2011, the Medicare reimbursement rate for
dialysis services is determined on the basis of a case-mix
adjusted blended prospective payment system for ESRD
dialysis facilities. See Item 4.B, Information on the
Company Business Overview Regulatory and
Legal Matters Reimbursement and
Health Care Reform.
We also obtain a significant portion of our net revenues from
reimbursement by non-government payors. Historically, these
payors reimbursement rates generally have been higher than
government program rates in their respective countries. However,
non-governmental payors are imposing cost containment measures
that are creating significant downward pressure on reimbursement
levels that we receive for our services and products.
104
Inflation
The effects of inflation during the periods covered by the
consolidated financial statements have not been significant to
our results of operations. However, a major portion of our net
revenues from dialysis care are subject to reimbursement rates
regulated by governmental authorities, and a significant portion
of other revenues, especially revenues from the U.S., is
received from customers whose revenues are subject to these
regulated reimbursement rates. Non-governmental payors are also
exerting downward pressure on reimbursement rates. Increased
operation costs that are subject to inflation, such as labor and
supply costs, may not be recoverable through price increases in
the absence of a compensating increase in reimbursement rates
payable to us and our customers, and could materially adversely
affect our business, financial condition and results of
operations.
Management
of Foreign Exchange and Interest Rate Risks
We are primarily exposed to market risk from changes in foreign
exchange rates and changes in interest rates. In order to manage
the risks from these foreign exchange rate and interest rate
fluctuations, we enter into various hedging transactions, as
authorized by the Management Board of the general partner, with
banks which generally have ratings in the A Category
or better. We do not use financial instruments for trading or
other speculative purposes.
Fresenius SE, as provided for under a service agreement,
conducts financial instrument activity for us and its other
subsidiaries under the control of a single centralized
department. Fresenius SE has established guidelines, that we
have agreed to, for risk assessment procedures and controls for
the use of financial instruments. They include a clear
segregation of duties with regard to execution on one side and
administration, accounting and controlling on the other.
Foreign
Exchange Risk
We conduct our business on a global basis in various currencies,
although our operations are located principally in the United
States and Germany. For financial reporting purposes, we have
chosen the U.S. dollar as our reporting currency.
Therefore, changes in the rate of exchange between the
U.S. dollar and the local currencies in which the financial
statements of our international operations are maintained,
affect our results of operations and financial position as
reported in our consolidated financial statements. We have
consolidated the balance sheets of our
non-U.S. dollar
denominated operations into U.S. dollars at the exchange
rates prevailing at the balance sheet date. Revenues and
expenses are translated at the average exchange rates for the
period.
Our exposure to market risk for changes in foreign exchange
rates relates to transactions such as sales and purchases. We
have significant amounts of sales of products invoiced in euro
from our European manufacturing facilities to our other
international operations. This exposes our subsidiaries to
fluctuations in the rate of exchange between the euro and the
currency in which their local operations are conducted. For the
purpose of hedging existing and foreseeable foreign exchange
transaction exposures we enter into foreign exchange forward
contracts and, on a small scale, foreign exchange options. Our
policy, which has been consistently followed, is that foreign
exchange rate derivatives be used only for purposes of hedging
foreign currency exposures. We have not used such instruments
for purposes other than hedging.
In connection with intercompany loans in foreign currency, we
normally use foreign exchange swaps thus assuring that no
foreign exchange risks arise from those loans.
The Company is exposed to potential losses in the event of
non-performance by counterparties to financial instruments. We
do not expect any counterparty to fail to meet its obligations.
The current credit exposure of foreign exchange derivatives is
represented by the fair value of those contracts with a positive
fair value at the reporting date. The table below provides
information about our foreign exchange forward contracts at
December 31, 2010. The information is provided in
U.S. dollar equivalent amounts. The table presents the
notional amounts by year of maturity, the fair values of the
contracts, which show the unrealized net gain (loss) on existing
contracts as of December 31, 2010, and the credit risk
inherent to those contracts with positive market values as of
December 31, 2010. All contracts expire within
59 months after the reporting date.
105
Foreign
Currency Risk Management
December 31, 2010
(USD in millions)
Nominal amount
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Credit
|
|
|
|
2011
|
|
|
2012
|
|
|
2013
|
|
|
2014
|
|
|
2015
|
|
|
Total
|
|
|
Fair value
|
|
|
risk
|
|
|
Purchase of EUR against US$
|
|
$
|
725
|
|
|
|
20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
745
|
|
|
$
|
(42
|
)
|
|
$
|
3
|
|
Sale of EUR against US$
|
|
|
421
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
421
|
|
|
|
(5
|
)
|
|
|
|
|
Purchase of EUR against others
|
|
|
781
|
|
|
|
102
|
|
|
|
33
|
|
|
|
31
|
|
|
|
29
|
|
|
|
976
|
|
|
|
(19
|
)
|
|
|
3
|
|
Sale of EUR against others
|
|
|
249
|
|
|
|
89
|
|
|
|
60
|
|
|
|
31
|
|
|
|
29
|
|
|
|
458
|
|
|
|
1
|
|
|
|
1
|
|
Others
|
|
|
33
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
2,209
|
|
|
|
212
|
|
|
|
93
|
|
|
|
62
|
|
|
|
58
|
|
|
$
|
2,634
|
|
|
$
|
(65
|
)
|
|
$
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A summary of the high and low exchange rates for the euro to
U.S. dollars and the average exchange rates for the last
five years is set forth below. The European Central Bank
(ECB) determines such rates (Reference
Rates) based on the regular daily averaging of rates
between central banks within and outside the European banking
system. The ECB normally publishes the Reference Rates daily at
2:15 p.m. (CET). In preparing our consolidated financial
statements and in converting certain U.S. dollar amounts in
this report, we have used the Years Average Reference Rate
of $1.3259 or Years Close Reference Rate of $1.3362 per
1.00.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years
|
|
Years
|
|
Years
|
|
Years
|
Year ending December 31,
|
|
High
|
|
Low
|
|
Average
|
|
Close
|
|
2006 US$ per EUR
|
|
|
1.3331
|
|
|
|
1.1826
|
|
|
|
1.2558
|
|
|
|
1.3170
|
|
2007 US$ per EUR
|
|
|
1.4874
|
|
|
|
1.2893
|
|
|
|
1.3705
|
|
|
|
1.4721
|
|
2008 US$ per EUR
|
|
|
1.5990
|
|
|
|
1.2460
|
|
|
|
1.4713
|
|
|
|
1.3917
|
|
2009 US$ per EUR
|
|
|
1.5120
|
|
|
|
1.2555
|
|
|
|
1.3948
|
|
|
|
1.4406
|
|
2010 US$ per EUR
|
|
|
1.4563
|
|
|
|
1.1942
|
|
|
|
1.3259
|
|
|
|
1.3362
|
|
|
The Reference Rate on February 18, 2011 was $1.3627 per
1.00.
|
Foreign
Exchange Sensitivity Analysis
In order to estimate and quantify the transaction risks from
foreign currencies, the Company considers the cash flows
reasonably expected for the three months following the reporting
date as the relevant assessment basis for a sensitivity
analysis. For this analysis, the Company assumes that all
foreign exchange rates in which the Company had unhedged
positions as of the reporting date would be negatively impacted
by 10%. By multiplying the calculated unhedged risk positions
with this factor, the maximum possible negative impact of the
foreign exchange transaction risks on the Companys results
of operations would be $13 million.
Interest
Rate Risk
We are exposed to changes in interest rates that affect our
variable-rate borrowings. We enter into debt obligations
including accounts receivable securitizations to support our
general corporate purposes such as capital expenditures and
working capital needs. Consequently, we enter into derivatives,
particularly interest rate swaps to protect interest rate
exposures arising from borrowings at floating rates by
effectively swapping them into fixed rates.
These interest rate derivatives are designated as cash flow
hedges. The majority of these interest rate swap agreements
effectively convert the major part of payments based on variable
interest rates applicable to the Companys Amended 2006
Senior Credit Agreement, denominated in U.S. dollars, into
payments at a fixed rate. The remaining interest rate swaps have
been entered into in anticipation of future debt issuances.
Swap agreements in notional amounts of $3,175 million
expire at various dates in 2011 and 2012 and bear an average
interest rate of 4.26%. Interest payable and interest receivable
under the swap agreements are accrued and recorded as an
adjustment to interest expense at each reporting date. At
December 31, 2010, the negative fair value of these
agreements is $125million.
The table below presents principal amounts and related weighted
average interest rates by year of maturity for interest rate
swaps and for our significant debt obligations.
106
Interest
Rate Exposure
December 31,
2010
(in
millions)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dec. 31,
|
|
|
|
2011
|
|
|
2012
|
|
|
2013
|
|
|
2014
|
|
|
2015
|
|
|
Thereafter
|
|
|
Totals
|
|
|
2010
|
|
|
FLOATING RATE US$ DEBT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal payments on Senior Credit Agreement
|
|
$
|
217
|
|
|
|
1,262
|
|
|
|
1,475
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
2,954
|
|
|
$
|
2,938
|
|
Variable interest rate = 1.77%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable securitization programs
|
|
$
|
510
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
510
|
|
|
$
|
510
|
|
Variable interest rate = 0.33%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EIB loans
|
|
$
|
|
|
|
|
|
|
|
|
165
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
165
|
|
|
$
|
165
|
|
Variable interest rate = 0.43%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FLOATING RATE DEBT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Euro Notes 2009/2012
|
|
$
|
|
|
|
|
160
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
160
|
|
|
$
|
162
|
|
Variable interest rate = 6.253%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Euro Notes 2009/2014
|
|
$
|
|
|
|
|
5
|
|
|
|
5
|
|
|
|
31
|
|
|
|
|
|
|
|
|
|
|
$
|
41
|
|
|
$
|
41
|
|
Variable interest rate = 6.753%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EIB loan
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
187
|
|
|
|
|
|
|
|
|
|
|
$
|
187
|
|
|
$
|
187
|
|
Variable interest rate = 1.8176%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FIXED RATE US$ DEBT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company obligated mandatorily redeemable preferred securities of
subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fresenius Medical Care Capital Trusts
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed interest rate = 7.375% / issued in 2001
|
|
$
|
225
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
225
|
|
|
$
|
229
|
|
Senior Notes 2007/2017; fixed interest rate = 6.875%
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
494
|
|
|
$
|
494
|
|
|
$
|
531
|
|
FIXED RATE DEBT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company obligated mandatorily redeemable preferred securities of
subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fresenius Medical Care Capital Trusts
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed interest rate = 7.375% / issued in 2001
|
|
$
|
401
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
401
|
|
|
$
|
415
|
|
Senior Notes 2007/2017; fixed interest rate = 6.875%
|
|
$
|
|
|
|
|
47
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
47
|
|
|
$
|
52
|
|
Fixed interest rate = 7.4065%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Euro Notes 2009/2014
|
|
$
|
|
|
|
|
2
|
|
|
|
2
|
|
|
|
15
|
|
|
|
|
|
|
|
|
|
|
$
|
19
|
|
|
$
|
22
|
|
Fixed interest rate = 8.3835%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior Notes 2010/2016
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330
|
|
|
$
|
330
|
|
|
$
|
349
|
|
Fixed interest rate = 5.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INTEREST RATE DERIVATIVES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US$ Payer Swaps Notional amount
|
|
$
|
1,650
|
|
|
|
1,525
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3,175
|
|
|
$
|
(125
|
)
|
Average fixed pay rate = 4.26%
|
|
|
4.08
|
%
|
|
|
4.45
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.26
|
%
|
|
|
|
|
Receive rate =
3-month
$LIBOR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All variable interest rates depicted above are as of
December 31, 2010
Interest
Rate Sensitivity Analysis
For purposes of analyzing the impact of changes in the relevant
reference interest rates on the Companys results of
operations, the Company calculates the portion of financial debt
which bears variable interest and which has not been hedged by
means of interest rate swaps or options against rising interest
rates. For this particular part of its liabilities, the Company
assumes an increase in the reference rates of 0.5% compared to
the actual rates as of reporting date. The corresponding
additional annual interest expense is then compared to the
Companys net income. This analysis shows that an increase
of 0.5% in the relevant reference rates would have an effect of
less than 1% on the consolidated net income of the Company.
|
|
Item 12.
|
Description
of Securities other than Equity Securities
|
|
|
D.
|
American
Depositary Shares
|
For a description of our American Depositary Shares, see
Item 10.B, Additional Information
Articles of Association Description of American
Depositary Receipts.
107
ADS holders will be charged a fee for each issuance of ADSs,
including issuances resulting from distributions of shares,
rights and other property, and for each surrender of ADSs in
exchange for deposited securities. The fee in each case is up to
$5.00 for each 100 ADSs (or any portion thereof) issued or
surrendered.
The following additional charges shall be incurred by the ADS
holders, by any party depositing or withdrawing shares or by any
party surrendering ADSs or to whom ADSs are issued (including,
without limitation, issuance pursuant to a stock dividend or
stock split declared by the Company or an exchange of stock
regarding the ADSs or the deposited securities or a distribution
of ADRs), whichever is applicable:
|
|
|
|
|
a fee of $0.02 or less per ADS (or portion thereof) for any cash
distribution made pursuant to the deposit agreement;
|
|
|
|
a fee of $0.02 per ADS (or portion thereof) per year for
services performed by the depositary in administering our ADS
program (which fee shall be assessed against holders of ADSs as
of the record date set by the depositary not more than once each
calendar year and shall be payable in the manner described in
the next succeeding provision);
|
|
|
|
any other charge payable by any of the depositary, any of the
depositarys agents, including, without limitation, the
custodian, or the agents of the depositarys agents in
connection with the servicing of our shares or other deposited
securities (which charge shall be assessed against registered
holders of our ADSs as of the record date or dates set by the
depositary and shall be payable at the sole discretion of the
depositary by billing such registered holders or by deducting
such charge from one or more cash dividends or other cash
distributions);
|
|
|
|
a fee for the distribution of securities (or the sale of
securities in connection with a distribution), such fee being in
an amount equal to the fee for the execution and delivery of
ADSs which would have been charged as a result of the deposit of
such securities (treating all such securities as if they were
shares) but which securities or the net cash proceeds from the
sale thereof are instead distributed by the depositary to those
holders entitled thereto;
|
|
|
|
stock transfer or other taxes and other governmental charges;
|
|
|
|
cable, telex and facsimile transmission and delivery charges
incurred at the request of holders of our shares;
|
|
|
|
transfer or registration fees for the registration of transfer
of deposited securities on any applicable register in connection
with the deposit or withdrawal of deposited securities; and
|
|
|
|
expenses of the depositary in connection with the conversion of
foreign currency into U.S. dollars.
|
We will pay all other charges and expenses of the depositary and
any agent of the depositary (except the custodian) pursuant to
agreements from time to time between us and the depositary. The
fees described above may be amended from time to time.
|
|
D.4.
|
Amounts
payable by the depositary to the Company
|
Fees
Incurred in Past Annual Period
Under the fee agreement between us and the depositary, the
depositary agrees to pay certain fees relating to the
maintenance of the ADRs. Certain fees we encounter related to
our ADRs are reimbursed to us by the depositary. For 2010, we
received from the depositary $0.26 million in aggregate
payments for continuing annual stock exchange listing fees,
standard
out-of-pocket
maintenance costs for the ADRs (consisting of the expenses of
postage and envelopes for mailing annual and interim financial
reports, printing and distributing dividend checks, electronic
filing of U.S. Federal tax information, mailing required
tax forms, stationary, postage, facsimile, and telephone calls),
any applicable performance indicators relating to the ADR
facility and legal fees.
Fees
to be Paid in the Future
The Bank of New York Mellon, as depositary, has agreed to
reimburse us for expenses we incur that are related to
establishment and maintenance expenses of the ADS program. The
depositary has agreed to reimburse us for its continuing annual
stock exchange listing fees. The depositary has also agreed to
pay the standard
out-of-pocket
maintenance costs for the ADRs, which consist of the expenses of
postage and envelopes for mailing annual and interim financial
statements, printing and distributing dividend checks,
electronic filing of U.S. Federal tax information, mailing
required tax forms, stationary, postage, facsimile, and
telephone calls. It has also agreed to reimburse us annually for
certain investor relations programs or special investor
relations promotion activities. In
108
certain instances, the depositary has agreed to provide
additional payments to us based on any applicable performance
indicators relating to the ADR facility. There are limits on the
amount of expenses for which the depositary will reimburse the
Company, but the amount of reimbursement available to us is not
necessarily tied to the amount of fees the depositary collects
from investors.
The depositary collects its fees for delivery and surrender of
ADSs directly from investors depositing shares or surrendering
ADSs for the purpose of withdrawal or from intermediaries acting
for them. The depositary collects fees from the amounts
distributed or by selling a portion of distributable property to
pay the fees. The depositary may collect its annual fee for
depositary services by deduction from cash distributions or by
directly billing investors or by charging the book-entry system
accounts of participants acting for them. The depositary may
generally refuse to provide fee-attracting services until its
fees for those services are paid.
PART II
|
|
Item 13.
|
Defaults,
Dividend Arrearages and Delinquencies
|
None
|
|
Item 14.
|
Material
Modifications to the Rights of Security Holders and Use of
Proceeds
|
Not applicable
|
|
Item 15A.
|
Disclosure
Controls and Procedures
|
The Companys management, including the members of the
Management Board of our general partner performing the functions
Chief Executive Officer and Chief Financial Officer, has
conducted an evaluation of the effectiveness of the design and
operation of the Companys disclosure controls and
procedures as of the end of the period covered by this report,
as contemplated by Securities Exchange Act
Rule 13a-15.
Based on that evaluation, the Chief Executive Officer of our
general partner and Chief Financial Officer of our general
partner concluded that the disclosure controls and procedures
were effective in ensuring that all material information
required to be filed in this annual report has been made known
to them in a timely fashion. There have been no significant
changes in internal controls, or in factors that could
significantly affect internal controls, subsequent to the date
the Chief Executive Officer and Chief Financial Officer
completed their evaluation.
|
|
Item 15B.
|
Managements
annual report on internal control over financial
reporting
|
Management of the Company is responsible for establishing and
maintaining adequate internal control over financial reporting,
as such term is defined in Exchange Act
Rules 13a-15(f).
The Companys internal control over financial reporting is
a process designed by or under the supervision of the Chief
Executive Officer of our general partner and Chief Financial
Officer of our general partner, to provide reasonable assurance
regarding the reliability of financial reporting and the
preparation of the Companys financial statements for
external reporting purposes in accordance with
U.S. generally accepted accounting principles.
As of December 31, 2010, management conducted an assessment
of the effectiveness of the Companys internal control over
financial reporting based on the criteria established in
Internal Control Integrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway Commission
(COSO). Based on this assessment, management has determined that
the Companys internal control over financial reporting as
of December 31, 2010 is effective.
The Companys internal control over financial reporting
includes policies and procedures that (1) pertain to the
maintenance of records that, in reasonable detail, accurately
and fairly reflect transactions and dispositions of our assets;
(2) provide reasonable assurances that the Companys
transactions are recorded as necessary to permit preparation of
financial statements in accordance with U.S. generally
accepted accounting principles, and that the Companys
receipts and expenditures are being made only in accordance with
authorizations of management; and (3) provide reasonable
assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the
Companys assets that could have a material effect on the
Companys financial statements.
Because of its inherent limitation, internal control over
financial reporting, no matter how well designed, cannot provide
absolute assurance of achieving financial reporting objectives
and may not prevent or detect misstatements. Therefore, even if
the internal control over financial reporting is determined to
be effective it can provide only reasonable assurance with
respect to financial statement preparation and presentation.
Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become
109
inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.
The effectiveness of our internal control over financial
reporting as of December 31, 2010, has been audited by
KPMG, an independent registered public accounting firm, as
stated in their report included on
page F-3.
|
|
Item 15C.
|
Attestation
report of the registered public accounting firm
|
The attestation report of KPMG with respect to Managements
Report on Internal Control Over Financial Reporting appears at
page F-4.
|
|
Item 15D.
|
Changes
in Internal Control over Financial Reporting
|
There have been no changes in the Companys internal
control over financial reporting that occurred during fiscal
year 2010, which have materially affected or are reasonably
likely to materially affect the Companys internal control
over financial reporting.
|
|
Item 16A.
|
Audit
Committee Financial Expert
|
Our Supervisory Board has determined that each of Prof.
Dr. Bernd Fahrholz, Dr. Walter L. Weisman and
Mr. William P. Johnston qualifies as an independent audit
committee financial expert and is independent as
defined in
Rule 10A-3
under the Exchange Act, in accordance with the provisions of
Item 16A of
Form 20-F.
In 2003, our Management Board adopted through our worldwide
compliance program a code of ethics, titled the
Code of
Business Conduct
, which as adopted applied to members of the
Management Board, including its chairman and the responsible
member for Finance & Controlling, other senior
officers and all Company employees. After the transformation of
legal form, our Code of Business Conduct applies to the members
of the Management Board of our general partner and all Company
employees, including senior officers. A copy of the
Companys Code of Business Conduct is available on our
website under Our Company Compliance at:
http://www.fmc-ag.com/Code_of_Conduct.htm
|
|
Item 16C.
|
Principal
Accountant Fees and Services.
|
In the annual general meeting held on May 11, 2010, our
shareholders approved the appointment of KPMG to serve as our
independent auditors for the 2010 fiscal year. KPMG billed the
following fees to us for professional services in each of the
last two years:
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
|
(in thousands)
|
|
|
Audit fees
|
|
$
|
10,433
|
|
|
$
|
9,838
|
|
Audit related fees
|
|
|
856
|
|
|
|
187
|
|
Tax fees
|
|
|
932
|
|
|
|
909
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
12,221
|
|
|
$
|
10,934
|
|
|
|
|
|
|
|
|
|
|
Audit Fees are the aggregate fees billed by KPMG for
the audit of our German statutory and U.S. GAAP
consolidated and annual financial statements, reviews of interim
financial statements and attestation services that are provided
in connection with statutory and regulatory filings or
engagements. Fees related to the audit of internal control are
included in Audit Fees. Audit-Related Fees are fees
charged by KPMG for assurance and related services that are
reasonably related to the performance of the audit or review of
our financial statements and are not reported under Audit
Fees. This category comprises fees billed for comfort
letters, consultation on accounting issues, the audit of
employee benefit plans and pension schemes,
agreed-upon
procedure engagements and other attestation services subject to
regulatory requirements. Tax Fees are fees for
professional services rendered by KPMG for tax compliance, tax
advice on implications for actual or contemplated transactions,
tax consulting associated with international transfer prices,
and expatriate employee tax services.
Audit
Committees pre-approval policies and procedures
As a German company, we prepare statutory financial statements
under German law on the basis of the accounting principles of
the German Commercial Code (
Handelsgesetzbuch
or
HGB
). Our supervisory board
110
engages our independent auditors to audit these financial
statements, in consultation with our Audit and Governance
Committee and subject to approval by our shareholders at our AGM
in accordance with German law.
We also prepare financial statements in accordance with
U.S. GAAP, which are included in registration statements
and reports that we file with the Securities and Exchange
Commission. Our Audit and Corporate Governance Committee engages
our independent auditors to audit these financial statements in
accordance with
rule 10A-3
under the Exchange Act and Rule 303A.06 of the NYSE
Governance Rules. See also the description in
Item 6C. Directors, Senior Management and Employees -
Board Practices.
In 2003, Fresenius Medical Care AGs audit committee also
adopted a policy requiring management to obtain the
committees approval before engaging our independent
auditors to provide any audit or permitted non-audit services to
us or our subsidiaries. Pursuant to this policy, which is
designed to assure that such engagements do not impair the
independence of our auditors, the Audit and Corporate Governance
Committee pre-approves annually a catalog of specific audit and
non-audit services in the categories Audit Services,
Audit-Related Services, Tax Services, and Other Services that
may be performed by our auditors as well as additional approval
requirements based on fee amount.
The general partners Chief Financial Officer reviews all
individual management requests to engage our auditors as a
service provider in accordance with this catalog and, if the
requested services are permitted pursuant to the catalog, fee
level, and fee structure, approves the request accordingly.
Services that are not included in the catalog, exceed applicable
fee levels or fee structure are passed on either to the chair of
the Audit and Corporate Governance Committee or to the full
committee, for approval on a case by case basis. Additionally we
inform the Audit and Corporate Governance Committee about all
approvals on an annual basis. Neither the chairman of our Audit
and Corporate Governance Committee nor the full committee is
permitted to approve any engagement of our auditors if the
services to be performed either fall into a category of services
that are not permitted by applicable law or the services would
be inconsistent with maintaining the auditors independence.
During 2010, the total fees paid to the Audit and Corporate
Governance Committee members for service on the committee were
$0.14 million.
|
|
Item 16D.
|
Exemptions
from the Listing Standards for Audit Committees
|
Not applicable
|
|
Item 16E.
|
Purchase
of Equity Securities by the Issuer and Affiliated
Purchasers
|
We did not purchase any of our equity securities during the
fiscal year covered by this report.
|
|
Item 16F.
|
Change
in Registrants Certifying Accountant
|
Not applicable
|
|
Item 16G.
|
Corporate
Governance
|
Introduction
American Depositary Shares representing our Ordinary shares and
our Preference shares are listed on the New York Stock
Exchange (NYSE). However, because we are a
foreign private issuer, as defined in the rules of
the Securities and Exchange Commission, we are exempt from
substantially all of the governance rules set forth in
Section 303A of the NYSEs Listed Companies Manual,
other than the obligation to maintain an audit committee in
accordance with
Rule 10A-3
under the Securities Exchange Act of 1934, as amended, the
obligation to notify the NYSE if any of our executive officers
becomes aware of any material non-compliance with any applicable
provisions of Section 303A, and the obligation to file
annual and interim written affirmations, on forms mandated by
the NYSE, relating to our compliance with applicable NYSE
governance rules. Instead, the rules of both the SEC and the
NYSE require that we disclose the significant ways in which our
corporate practices differ from those applicable to
U.S. domestic companies under NYSE listing standards.
As a German company FMC-AG & Co. KGaA follows German
Corporate Governance practices. German corporate governance
practices generally derive from the provisions of the German
Stock Corporation Act (
Aktiengesetz, AktG
)
including capital market related laws, the German
Codetermination Act (
Mitbestimmungsgesetz,
MitBestG
) and the German Corporate Governance
Code which was adopted in 2002 and revised periodically
thereafter by the German government commission, most recently in
May 2010. Our Articles of Association also include provisions
affecting our corporate governance. German standards differ from
the corporate governance listing standards applicable to
U.S. domestic companies which have been adopted by the
111
NYSE. The discussion below provides certain information
regarding our organizational structure, management arrangements
and governance, including information regarding the legal
structure of a partnership limited by shares, or KGaA,
management by our general partner, certain provisions of our
Articles of Association and the role of our supervisory board in
monitoring the management of our company by the general partner.
It includes a brief, general summary of the principal
differences between German and U.S. corporate governance
practices, together with, as appropriate, a comparison to
U.S. principles or practices.
The
Legal Structure of FMC-AG & Co. KGaA
A KGaA (
Kommanditgesellschaft auf Aktien
) is
a mixed form of entity under German corporate law, which has
elements of both a partnership and a corporation. Like a stock
corporation, the share capital of a KGaA is held by its
shareholders. A KGaA is similar to a limited partnership because
there are two groups of owners, the general partner on the one
hand, and the KGaA shareholders on the other hand. Our general
partner, Management AG, is a wholly-owned subsidiary of
Fresenius SE & Co. KGaA. KGaA and stock corporation
(
Aktiengesellschaft, AG
) are the only legal
forms provided by German law for entities whose shares trade on
a German stock exchange.
A KGaAs corporate bodies are its general partner, its
supervisory board and the general meeting of shareholders. A
KGaA may have one or more general partners who conduct the
business of the KGaA. However, unlike a stock corporation, in
which the supervisory board appoints the management board, the
supervisory board of a KGaA has no influence on appointment of
the managing body the general partner. Likewise, the
removal of the general partner from office is subject to very
strict conditions. General partners may, but are not required
to, purchase shares of the KGaA. General partners are personally
liable for the liabilities of the KGaA in relations with third
parties subject, in the case of corporate general partners, to
applicable limits on liability of corporations generally.
Management
and Oversight
The management structure of FMC-AG & Co. KGaA is
illustrated as follows (percentage ownership amounts refer to
ownership of the Companys total share capital of all
classes):
General
Partner
Management AG, a stock corporation and a wholly owned subsidiary
of Fresenius SE & Co. KGaA, is the sole general
partner of FMC-AG & Co. KGaA and will conduct its
business and represent it in external relations. Use of a stock
corporation as the legal form of the general partner enables the
Company to maintain a management structure substantially similar
to FMC-AGs management structure prior to the
transformation into a KGaA. The internal corporate governance
structure of the general partner is substantially similar to the
prior structure at FMC-AG. In particular, the general partner
has substantially the same provisions in its articles of
association concerning the relationship between the general
partners management board and the general partners
supervisory board and, subject to applicable statutory law,
substantially the same rules of procedure for its executive
bodies. Management AG was incorporated on April 8, 2005 and
registered with the commercial register in Hof an der Saale on
May 10, 2005. The registered share capital of Management AG
is 1.5 million.
112
The general partner has not made a capital contribution to the
Company and, therefore, will not participate in its assets or
its profits and losses. However, the general partner will be
compensated or reimbursed for all outlays in connection with
conducting the business of the Company, including the
remuneration of members of the general partners management
board and supervisory board. See The Articles of
Association of FMC-AG & Co. KGaA
Organization of the Company below and Item 7.B.,
Major Shareholders and Related Party Transactions.
FMC-AG &
Co. KGaA itself will bear all expenses of its administration.
Management AG will devote itself exclusively to the management
of FMC-AG & Co. KGaA. The general partner will receive
annual compensation amounting to 4% of its capital for assuming
the liability and the management of FMC-AG & Co.
AG & Co. KGaA. This payment of 60,000 per annum
constitutes a guaranteed return on Fresenius SEs
investment in the share capital of Management AG. This payment
is required for tax reasons, to avoid a constructive dividend by
the general partner to Fresenius SE in the amount of reasonable
compensation for undertaking liability for the obligations of
Fresenius Medical Care AG & Co. KGaA. FMC
AG & Co. KGaA will also reimburse the general partner
for the remuneration paid to the members of its management board
and its supervisory board.
The position of the general partner or partners in a KGaA is
stronger than that of the shareholders based on: (i) the
management powers of the general partners, (ii) the
existing de facto veto rights regarding material resolutions
adopted by the general meeting and (iii) the independence
of the general partner from the influence of the KGaA
shareholders as a collective body (See General
Meeting, below). Because Fresenius SE & Co. KGaA
is the sole shareholder of Management AG, the general partner,
Fresenius SE & Co. KGaA has the sole power to elect
the supervisory board of Management AG which appoints the
members of the management board of Management AG, who act on
behalf of the general partner in the conduct of the
companys business and in relations with third parties.
The statutory provisions governing a partnership, including a
KGaA, provide that the consent of the KGaA shareholders at a
general meeting is required for transactions that are not in the
ordinary course of business. However, as permitted by statute,
the articles of association of FMC-AG & Co. KGaA
permit such decisions to be made by Management AG as general
partner without the consent of the FMC-AG & Co. KGaA
shareholders. This negation of the statutory restrictions on the
authority of Management AG as general partner is intended to
replicate governance arrangements in FMC-AG, our corporate form
prior to transformation of legal form, by retaining for the
management board of the general partner the level of operating
flexibility that the
FMC-AG
management board possessed prior to the transformation. Prior to
the transformation of legal form, the shareholders of FMC-AG did
not have any such veto right regarding determinations of its
management board. This does not affect the general
meetings right of approval with regard to measures of
unusual significance, such as a spin-off of a substantial part
of a companys assets, as developed in German Federal
Supreme Court decisions.
The general partners supervisory board appoints the
members of the general partners management board and
supervises and advises them in managing the Company. The general
partners management board conducts the business activities
of our Company in accordance with the rules of procedure adopted
by the general partners supervisory board pursuant to the
German Corporate Governance Code. The relationship between the
Management AG supervisory board and the Management AG management
board is substantially similar to the governance provisions at
FMC-AG prior to the transformation. In particular, under the
articles of association of Management AG, the same transactions
are subject to the consent of the supervisory board of
Management AG as previously required the consent of the
supervisory board of FMC-AG. These transactions include, among
others:
|
|
|
|
|
The acquisition, disposal and encumbrance of real property if
the value or the amount to be secured exceeds a specified
threshold (5 million);
|
|
|
|
The acquisition, formation, disposal or encumbrance of an equity
participation in other enterprises if the value of the
transaction exceeds a specified threshold (5 million);
|
|
|
|
The adoption of new or the abandonment of existing lines of
business or establishments;
|
|
|
|
Conclusion, amendment and termination of affiliation
agreements; and
|
|
|
|
Certain inter-company transactions.
|
Five of the six members of the supervisory board of
FMC-AG & Co. KGaA are also members of the supervisory
board of Management AG. The Company and Fresenius SE have
entered into a pooling agreement requiring that at least
one-third (and not less than two) members of the general
partners supervisory board be independent
directors i.e., persons without a substantial
business or professional relationship with the Company,
Fresenius SE, or any affiliate of either, other than as a member
of the supervisory board of the Company or the general partner.
See Item 10.B, Additional Information
Articles of Association Description of the Pooling
Arrangements.
113
Fresenius SEs de facto control of the Company through
ownership of the general partner is conditioned upon its
ownership of a substantial amount of the Companys share
capital (See The Articles of Association of
FMC-AG & Co. KGaA Organization of the
Company, below).
Supervisory
Board
The supervisory board of a KGaA is similar in certain respects
to the supervisory board of a stock corporation. Like the
supervisory board of a stock corporation, the supervisory board
of a KGaA is under an obligation to oversee the management of
the business of the Company. The supervisory board is elected by
the KGaA shareholders at the general meeting. Shares in the KGaA
held by the general partner or its affiliated companies are not
entitled to vote for the election of the supervisory board
members of the KGaA. Accordingly, Fresenius SE is not entitled
to vote its shares for the election of FMC-AG & Co.
KGaAs supervisory board members.
Although Fresenius SE will not be able to vote in the election
of FMC-AG & Co. KGaAs supervisory board,
Fresenius SE will nevertheless retain influence on the
composition of the supervisory board of FMC-AG & Co. KGaA.
Because (i) four of the six former members of the FMC-AG
supervisory board continue to hold office as four of the six
current members of the supervisory board of FMC-AG &
Co. KGaA (except for Dr. Ulf M. Schneider and
Mr. William P. Johnston) and (ii) in the future, the
FMC-AG & Co. KGaA supervisory board will propose
future nominees for election to its supervisory board (subject
to the right of shareholders to make nominations), Fresenius SE
is likely to retain de facto influence over the selection of the
supervisory board of FMC-AG & Co. KGaA. However, under
our articles of association, a resolution for the election of
members of the supervisory board requires the affirmative vote
of 75% of the votes cast at the general meeting. Such a high
vote requirement could be difficult to achieve, which could
result in the need to apply for court appointment of members to
the supervisory board after the end of the terms of the members
in office.
The supervisory board of FMC-AG & Co. KGaA has less
power and scope for influence than the supervisory board of the
Company as a stock corporation. The supervisory board of
FMC-AG & Co. KGaA is not entitled to appoint the
general partner or its executive bodies. Nor may the supervisory
board subject the management measures of the general partner to
its consent, or issue rules of procedure for the general
partner. Management of the Company will be conducted by the
management board of the general partner and only the supervisory
board of the general partner (all of whose members will be
elected solely by Fresenius SE) has the authority to appoint or
remove them. FMC-AG & Co. KGaAs supervisory
board will represent FMC-AG & Co. KGaA in transactions
with the general partner.
FMC-AG & Co. KGaAs annual financial statements
are submitted to the Companys shareholders for approval at
the Companys general meeting. Except for making a
recommendation to the general meeting regarding such approval,
this matter is not within the competence of the supervisory
board.
Under certain conditions supervisory boards of large German
stock corporations will include both shareholder representatives
and a certain percentage of labor representatives, referred to
as co-determination. Depending on the companys
total number of employees, up to one half of the supervisory
board members are being elected by the companys employees.
In these cases traditionally the chairman is a representative of
the shareholders. In case of a tie vote, the supervisory board
chairman may cast the decisive tie-breaking vote. We are not
currently subject to German law co-determination requirements.
In recent history, there has been a trend towards selecting
shareholder representatives for supervisory boards from a wider
spectrum of candidates, including representatives from
non-German companies, in an effort to introduce a broader range
of experience and expertise and a larger degree of independence.
German regulations also have several rules applicable to
supervisory board members which are designed to ensure that the
supervisory board members as a group possess the knowledge,
ability and expert experience to properly complete their tasks
as well as to ensure a certain degree of independence of the
boards members. In addition to prohibiting members of the
management board from serving on the supervisory board, German
law requires members of the supervisory board to act in the best
interest of the company. They do not have to follow direction or
instruction from third parties. Any service, consulting or
similar agreements between the company and any of its
supervisory board members must be approved by the supervisory
board.
General
Meeting
The annual general meeting is the resolution body of the KGaA
shareholders. Shareholders can exercise their voting rights at
the general meeting themselves, by proxy via a representative of
their choice, or by a Company-nominated proxy acting on their
instructions. Among other matters, the general meeting of a KGaA
approves its annual financial statements. The internal procedure
of the general meeting corresponds to that of the general
114
meeting of a stock corporation. The agenda for the general
meeting is fixed by the general partner and the KGaA supervisory
board except that the general partner cannot propose nominees
for election as members of the KGaA supervisory board or
proposals for the Company auditors.
KGaA shareholders exercise influence in the general meeting
through their voting rights but, in contrast to a stock
corporation, the general partner of a KGaA has a de facto veto
right with regard to material resolutions. The members of the
supervisory board of a KGaA are elected by the general meeting
as in a stock corporation. Although Fresenius SE & Co.
KGaA, as sole shareholder of the general partner of the Company
is not entitled to vote its shares in the election of the
supervisory board of FMC-AG & Co. KGaA, Fresenius
SE & Co. KGaA retains a degree of influence on the
composition of the supervisory board of FMC-AG & Co.
KGaA due to the overlapping membership on the
FMC-AG &
Co. KGaA supervisory board and the Management AG supervisory
board (see The Supervisory Board, above).
Under German law, resolutions may be adopted by the vote of a
majority of the shares present at the meeting. Therefore, based
on Fresenius SEs ownership of approximately 35.7% of the
Companys voting ordinary shares, as long as less than
approximately 72.0% of the Companys ordinary shares
(including the ordinary shares held by Fresenius SE) are present
at a meeting, Fresenius SE & Co. KGaA will continue to
possess a controlling vote on most matters presented to the
shareholders, other than election of the supervisory board and
the matters subject to a ban on voting as set forth below, at
least until the Company would issue additional ordinary shares
in a capital increase in which Fresenius SE would not
participate.
Fresenius SE & Co. KGaA is subject to various bans on
voting at general meetings due to its ownership of the shares of
the general partner. Fresenius SE & Co. KGaA is banned
from voting on resolutions concerning the election to and
removal from office of the FMC-AG & Co. KGaA
supervisory board, ratification or discharge of the actions of
the general partner and members of the supervisory board, the
appointment of special auditors, the assertion of claims for
damages against members of the executive bodies, the waiver of
claims for damages, and the selection of auditors of the annual
financial statements.
Certain matters requiring a resolution at the general meeting
will also require the consent of the general partner, such as
amendments to the articles of association, dissolution of the
Company, mergers, a change in the legal form of the partnership
limited by shares and other fundamental changes. The general
partner therefore has a de facto veto right on these matters.
Annual financial statements are subject to approval by both the
KGaA shareholders and the general partner.
The
Articles of Association of FMC-AG & Co.
KGaA
The articles of association of FMC-AG & Co. KGaA are
based on the articles of association of FMC-AG formerly in
effect, particularly with respect to capital structure, the
supervisory board and the general meeting. Other provisions of
the articles of association, such as those dealing with
management of FMC-AG & Co. KGaA, have been adjusted to
the KGaA legal form. Certain material provisions of the articles
of association are explained below, especially variations from
the articles of association of FMC-AG. The following summary is
qualified in its entirety by reference to the complete form of
articles of association of FMC-AG & Co. KGaA, an
English translation of which is on file with the SEC. In
addition, it can be found on the Companys website under
www.fmc-ag.com
.
Organization
of the Company
The articles of association of FMC-AG & Co. KGaA
contain several provisions relating to the general partner of
FMC-AG & Co. KGaA.
Under the articles of association, possession of the power to
control management of the Company through ownership of the
general partner is conditioned upon ownership of a specific
minimum portion of the Companys share capital. Under
German law, Fresenius SE & Co. KGaA could
significantly reduce its holdings in the Companys share
capital while at the same time retaining its de facto control
over the Companys management through its ownership of the
shares of the general partner. Under the Companys prior
legal form as a stock corporation, a shareholder had to hold
more than 50% of the Companys voting ordinary shares to
exercise a controlling influence. If half the Companys
total share capital had been issued as preference shares (the
maximum permissible by law), such controlling interest would
represent more than 25% of the Companys total share
capital. This minimum threshold for control of more than 25% of
the total share capital of a stock corporation is the basis for
a provision in the articles of association of FMC-AG &
Co. KGaA requiring that a parent company within the group shall
hold an interest of more than 25% of the share capital of
FMC-AG & Co. KGaA. As a result, the general partner
will be required to withdraw from FMC-AG & Co. KGaA if
its shareholder no longer holds, directly or
115
indirectly, more than 25% of the Companys share capital.
The effect of this provision is that the parent company within
the group may not reduce its capital participation in
FMC-AG & Co. KGaA below such amount without causing
the withdrawal of the general partner. The articles of
association also permit a transfer of all shares in the general
partner to the Company, which would have the same effect as
withdrawal of the general partner.
The articles of association also provide that the general
partner must withdraw if the shares of the general partner are
acquired by a person who does not make an offer under the German
Securities Acquisition and Takeover Act to acquire the shares of
the Companys other shareholders within three months of the
acquisition of the general partner. The consideration to be
offered to shareholders must include any portion of the
consideration paid for the general partners shares in
excess of the general partners equity capital, even if the
parties to the sale allocate the premium solely to the general
partners shares. The Companys articles of
association provide that the general partner can be acquired
only by a purchaser who at the same time acquires more than 25%
of FMC-AG & Co. KGaAs share capital. These
provisions would therefore trigger a takeover offer at a lower
threshold than the German Securities Acquisition and Takeover
Act, which requires that a person who acquires at least 30% of a
companys shares make an offer to all shareholders. The
provisions will enable shareholders to participate in any
potential control premium payable for the shares of the general
partner, although the obligations to make the purchase offer and
extend the control premium to outside shareholders could also
discourage an acquisition of the general partner, thereby
discouraging a change of control.
In the event that the general partner withdraws from
FMC-AG & Co. KGaA as described above or for other
reasons, the articles of association provide for continuation of
the Company as a so-called unified KGaA
(Einheits-KGaA), i.e., a KGaA in which the general partner is a
wholly-owned subsidiary of the KGaA. Upon the coming into
existence of a unified KGaA, the shareholders of
FMC-AG & Co. KGaA would effectively be restored to the
status as shareholders in a stock corporation, since the control
over the general partner would be exercised by
FMC-AG & Co. KGaAs supervisory board pursuant to
the articles of association. If the KGaA is continued as a
unified KGaA, an extraordinary or the next ordinary
general meeting would vote on a change in the legal form of the
partnership limited by shares into a stock corporation. In such
a case, the change of legal form back to the stock corporation
would be facilitated by provisions of the articles of
association requiring only a simple majority vote and that the
general partner consent to the transformation of legal form.
The articles of association provide that to the extent legally
required, the general partner must declare or refuse its consent
to resolutions adopted by the meeting directly at the general
meeting.
The articles of association of a KGaA may be amended only
through a resolution of the general meeting adopted by a
qualified 75% majority and with the consent of the general
partner. Therefore, neither group (i.e., the KGaA shareholders
and the general partner(s)) can unilaterally amend the articles
of association without the consent of the other group. Fresenius
SE & Co. KGaA will, however, continue to be able to
exert significant influence over amendments to the articles of
association of FMC-AG & Co. KGaA through its ownership
of a significant percentage of the Companys ordinary
shares after the transformation, since such amendments require a
75% vote of the shares present at the meeting rather than three
quarters of the outstanding shares.
Annual
Financial Statement and Allocation of Profits
The articles of association of FMC AG & Co. KGaA on
rendering of accounts require that the annual financial
statement and allocation of profits of FMC-AG & Co.
KGaA be submitted for approval to the annual general meeting of
the Company.
Corresponding to the articles of FMC-AG, the articles of
association of FMC-AG & Co. KGaA provide that
Management AG is authorized to transfer up to a maximum of half
of the annual surplus of FMC-AG & Co. KGaA to other
retained earnings when setting up the annual financial
statements.
Articles
of Association of Management AG
As a separate corporation, FMC AG & Co. KGaAs
general partner, Management AG, has its own articles of
association.
The articles of association of Management AG are based
essentially on FMC-AGs articles of association formerly in
effect. In particular, the provisions of its articles of
association on relations between the management board and the
supervisory board have been incorporated into the articles of
association of Management AG. The amount of Management AGs
share capital is 1,500,000, issued as 1,500,000 registered
shares without par value. By law, notice of any transfer of
Management AGs shares must be provided to the management
board of Management AG in order for the transferee to be
recognized as a new shareholder by Management AG.
116
Directors
Share Dealings
According to article 15a of the German Securities Trading
Act (Wertpapierhandelsgesetz,), members of the Management and
Supervisory Boards or other employees in management positions
are required to inform the Company when buying or selling our
shares and related financial instruments if the volume exceeds
5,000 within a single year. We publish the information
received in these reports on our web site in accordance with the
regulations as well as in our Annual Report to Shareholders.
Comparison
with U.S. and NYSE Governance Standards and
Practices
The listing standards of the NYSE require that a
U.S. domestic listed company have a majority of independent
board members and that the independent directors meet in
regularly scheduled sessions without management.
U.S. listed companies also must adopt corporate governance
guidelines that address director qualification standards,
director responsibilities, director access to management and
independent advisors, director compensation, director
orientation and continuing education, management succession, and
an annual performance evaluation of the board. Although, as
noted above, we are exempt from these NYSE requirements, several
of these concepts are addressed (but not mandated) by the German
Corporate Governance Code (the Code) issued by the
German Federal Ministry of Justice. The most recent version of
the Code is dated May 26, 2010. While the Codes
governance rules applicable to German corporations are not
legally binding, companies failing to comply with the
Codes recommendations must disclose publicly how and for
what reason their practices differ from those recommended by the
Code. A convenience translation of our most recent annual
Declaration of Compliance under the Code, will be
posted on our web site,
www.fmc-ag.com
on the Investor
Relations page under Corporate Governance/Declaration of
Compliance together with our declarations for prior years.
Some of the Codes recommendations address the independence
and qualifications of supervisory board members. Specifically,
the Corporate Governance Code recommends that the supervisory
board should specify concrete objectives regarding its
composition which -inter alia- shall also take into account
potential conflicts of interest. Similarly, if a material
conflict of interest arises during the term of a member of the
supervisory board, the Corporate Governance Code recommends that
the term of that member be terminated. The Corporate Governance
Code further recommends that at any given time not more than two
former members of the management board should serve on the
supervisory board and that, generally, the supervisory board of
a stock corporation should have an adequate number of
independent members. Our general partners supervisory
board includes three members who serve on our Audit and
Governance Committee and are independent under SEC
Rule 10A-3
and NYSE Rule 303A.06 (the audit committee rules of the SEC
and the NYSE, respectively), and our pooling agreement requires
that at least one-third (but not less than two) members of the
general partners supervisory board be
independent within the meaning of that agreement.
See Item 6A, Directors, Senior Management and
Employees Directors and Senior
Management the General Partners Supervisory
Board and Item 10B, Additional
Information Description of the Pooling
Arrangements: The Supervisory Board must be composed of
members who have the required knowledge, abilities and expert
experience to properly complete their tasks. The only
recommendations with which we do not currently comply are the
requirement to agree severance payment caps with specified
limits in contracts with the members of the Management Board,
the imposition or specification of age limits for service on the
Supervisory Board and the Management Board, payment of
performance related compensation (including components based on
the enterprises long-term performance) to members of the
Supervisory Board and specification of concrete objectives in
terms of composition of the Supervisory Board, which shall be
published and taken into account in recommendations made by the
Supervisory Board to the competent election bodies. The
employment contracts with the members of the Management Board of
Management AG do not contain severance payment arrangements for
the case of premature termination of the contract without
serious cause and we believe that the agreement of such
severance payment caps would be contrary to our concept,
according to which, in line with the German Stock Corporation
Act, employment contracts are generally concluded for the period
of their appointment and hence, premature termination in
principle requires a serious cause. We further believe that the
composition of the Supervisory Board needs to be aligned to the
enterprises interest and has to ensure the effective
supervision and consultation of the Management Board. Hence, in
composing the Supervisory Board, knowledge, skills and expert
experience of each individual are of precedence. In contrast,
fixed diversity quotas and age limits would generally limit the
selection of qualified candidates. Furthermore, we currently pay
only fixed compensation to the members of the Supervisory Board;
however, the possible introduction of performance-related
compensation to the members of the Supervisory Board, linked to
the success of the Company, is still under review. The Corporate
Governance Code furthermore includes the suggestion that
supervisory board members meet without any representatives of
the management board attending, whenever necessary, a practice
followed by our supervisory board when appropriate. Deviations
from this recommendation are, however, not required to be
disclosed publicly.
117
As noted in the Introduction, as a company listed on the NYSE,
we are required to maintain an audit committee in accordance
with
Rule 10A-3
under the Securities Exchange Act of 1934. The NYSEs
listing standards applicable to U.S. domestic listed
companies require that such companies also maintain a nominating
committee to select nominees to the board of directors and a
compensation committee, each consisting solely of directors who
are independent as defined in the NYSEs
governance rules.
In contrast to U.S. practice, with one exception, German
corporate law does not mandate the creation of specific
supervisory board committees. In certain cases, German
corporations are required to establish what is called a
mediation committee with a charter to resolve any disputes among
the members of the supervisory board that may arise in
connection with the appointment or dismissal of members of the
management board. The German Stock Corporation Act provides that
the supervisory board may establish, and the German Corporate
Governance Code recommends that a supervisory board establish an
audit committee to handle the formal engagement of the
companys independent auditors once they have been approved
by the general meeting of shareholders. Under the Corporate
Governance Code, the audit committee would also address issues
of accounting, risk management and auditor independence and,
under the Stock Corporation Act, an audit committee should
supervise the effectiveness of the internal control system, the
risk management system and the internal audit function. Our
Audit and Corporate Governance Committee within the supervisory
board of FMC-AG & Co. KGaA functions in each of these
areas and also serves as our audit committee as required by
Rule 10A-3
under the Exchange Act and the NYSE rules. As sole shareholder
of our general partner, Fresenius SE elects the supervisory
board of our general partner (subject to the requirements of our
pooling agreement discussed above). In practice, many
supervisory boards have also constituted other committees to
facilitate the work of the supervisory board. For example, a
presidential committee is frequently constituted to deal with
executive compensation and nomination issues as well as service
agreements with members of the supervisory board. At the present
time, these functions are carried out by our general
partners supervisory board, as a whole assisted, with
respect to compensation matters, by its Human Resources
Committee. We have also established a joint committee (the
Joint Committee) (gemeinsamer Ausschuss) together
with Fresenius SE and our general partner, Management AG, of the
supervisory boards of Management AG and
FMC-AG &
Co. KGaA consisting of two members designated by each
supervisory board to advise and decide on certain extraordinary
management measures.
For information regarding the members of our Audit and Corporate
Governance Committee as well as the functions of the Audit and
Corporate Governance Committee, the Joint Committee, the
Nominating Committee, our general partners Regulatory and
Reimbursement Assessment Committee and our general
partners Human Resources Committee, see Item 6.C,
Directors, Senior Management and Employees
Board Practices.
PART III
|
|
Item 17.
|
Financial
Statements
|
Not applicable. See Item 18. Financial
Statements.
|
|
Item 18.
|
Financial
Statements
|
The information called for by this item commences on
Page F-1.
Pursuant to the provisions of the Instructions for the filings
of Exhibits to Annual Reports on
Form 20-F,
Fresenius Medical Care AG & Co. KGaA (the
Registrant) is filing the following exhibits
1.1 Articles of Association (Satzung) of the Registrant
(incorporated by reference to Exhibit 10.1 to the
Registrants Report on
Form 6-K
for the month of August 2010, filed August 3, 2010).
2.1 Amended and Restated Deposit Agreement dated as of
February 26, 2007 between The Bank of New York (now The
Bank of New York Mellon) and the Registrant relating to Ordinary
Share ADSs (incorporated by reference to Exhibit 1 to the
Registrants Registration Statement on
Form F-6,
Registration
No. 333-140664,
filed February 13, 2007).
2.2 Amended and Restated Deposit Agreement dated as of
February 26, 2007 between The Bank of New York (now The
Bank of New York Mellon) and the Registrant to Preference Share
ADSs (incorporated by reference to Exhibit 1 to the
Registration Statement on
Form F-6,
Registration
No. 333-140730,
filed February 15, 2007).
2.3 Pooling Agreement dated February 13, 2006 by and
between Fresenius AG, Fresenius Medical Care Management AG and
the individuals acting from time to time as Independent
Directors. (incorporated by reference
118
to Exhibit 2.3 to the Registrants Annual Report on
Form 20-F
for the year ended December 31, 2005, filed March 2,
2006).
2.4 Declaration of Trust of Fresenius Medical Care Capital
Trust IV dated February 12, 1998 (incorporated by
reference to Exhibit 4.41 to the Registration Statement on
Form F-4
of Fresenius Medical Care AG (FMC-AG) et al,
Registration
No. 333-66558,
filed August 2, 2001,).
2.5 First Amendment to Declaration of Trust of Fresenius
Medical Care Capital Trust IV dated June 5, 2001
(incorporated by reference to Exhibit No. 4.42 to the
Registration Statement on
Form F-4
of FMC AG et al, Registration
No. 333-66558,
filed August 2, 2001).
2.6 Declaration of Trust of Fresenius Medical Care Capital
Trust V dated June 1, 2001 (incorporated by reference
to Exhibit 4.43 to the Registration Statement on
Form F-4
of FMC-AG et al, Registration
No. 333-66558,
filed August 2, 2001).
2.8 Amended and Restated Declaration of Trust of Fresenius
Medical Care Capital Trust IV dated as of June 6, 2001
(incorporated by reference to Exhibit 4.44 to the
Registration Statement on
Form F-4
of FMC- AG et al, Registration
No. 333-66558,
filed August 2, 2001).
2.9 Amended and Restated Declaration of Trust of Fresenius
Medical Care Capital Trust V dated as of June 15, 2000
(incorporated by reference to Exhibit 4.45 to the
Registration Statement on
Form F-4
of FMC-AG et al, Registration
No. 333-66558,
filed August 2, 2001).
2.10 Senior Subordinated Indenture (U.S. Dollar
denominated) dated as of June 6, 2001 among FMC-AG, FMC
Trust Finance S.à.r.l. Luxembourg-III, State Street
Bank and Trust Company, as Trustee, and the Subsidiary
Guarantors named therein (incorporated by reference to
Exhibit 4.47 to the Registration Statement on
Form F-4
of FMC- AG et al, Registration
No. 333-66558,
filed August 2, 2001).
2.11 First Supplemental Indenture dated as of
December 23, 2004 among FMC-AG, FMC Trust Finance
S.à.r.l Luxembourg-III, US Bank, National Association,
successor to State Street Bank and Trust Company, as
Trustee, and the Subsidiary Guarantors named therein
(incorporated by reference to Exhibit 2.28 to the Annual
Report on
Form 20-F
of FMC-AG for the year ended December 31, 2004, filed
March 1, 2005).
2.12 Guarantee Agreement dated as of June 6, 2001
between FMC-AG and State Street Bank and Trust Company, as
Trustee, with respect to Fresenius Medical Care Capital
Trust IV (incorporated by reference to
Exhibit No. 4.48 to the Registration Statement on
Form F-4
of FMC-AG et al, Registration
No. 333-66558,
filed August 2, 2001).
2.13 Guarantee Agreement dated as of June 15, 2001
between FMC-AG and State Street Bank and Trust Company, as
Trustee, with respect to Fresenius Medical Care Capital
Trust V (incorporated by reference to Exhibit 4.49 to
the Registration Statement on
Form F-4
of FMC-AG et al, Registration
No. 333-66558,
filed August 2, 2001).
2.14 Agreement as to Expenses and Liabilities dated as of
June 6, 2001 between FMC-AG and Fresenius Medical Care
Capital Trust IV (incorporated by reference to
Exhibit 4.50 to the Registration Statement on
Form F-4
of FMC-AG et al, Registration
No. 333-66558,
filed August 2, 2001).
2.15 Agreement as to Expenses and Liabilities dated as of
June 15, 2001 between FMC-AG and Fresenius Medical Care
Capital Trust V (incorporated by reference to
Exhibit 4.51 to the Registration Statement on
Form F-4
of FMC-AG et al, Registration
No. 333-66558,
filed August 2, 2001).
2.16 Indenture (Euro denominated) dated as of July 2,
2007 by and among FMC Finance III S.A., the Registrant and
the other Guarantors party thereto and U.S. Bank National
Association, as Trustee, related to the
6
7
/
8
% Senior
Notes due 2017 of FMC Finance III S.A. (incorporated by
reference to Exhibit 4.3 to the Registrants Report on
Form 6-K
for the month of August 2007, furnished August 2, 2007).
2.17 Form of Note Guarantee for
6
7
/
8
% Senior
Notes due 2017 (Included in Exhibit 2.16) (incorporated by
reference to Exhibit 4.3 to the Registrants Report on
Form 6-K
for the month of August 2007, furnished August 2, 2007).
2.18 Indenture (Euro denominated) dated as of
January 20, 2010 by and among FMC Finance VI S.A., the
Registrant and the other Guarantors party thereto and
U.S. Bank National Association, as Trustee, and Deutsche
Bank Aktiengesellschaft, as Paying Agent, related to the
5.50% Senior Notes due 2016 of FMC Finance VI S.A.
(incorporated by reference to Exhibit 10.1 to the
Registrants Report on
Form 6-K
for the month of May 2010, furnished May 5, 2010).
119
2.19 Form of Note Guarantee for 5.50% Senior Notes due
2016 (Included in Exhibit 2.18) (incorporated by reference
to Exhibit 10.2 to the Registrants Report on
Form 6-K
for the month of May 2010, furnished May 5, 2010).
2.20 Indenture (Euro denominated) dated as of
February 2, 2011 by and among FMC Finance VII S.A., the
Registrant and the other Guarantors party thereto and
U.S. Bank National Association, as Trustee, and Deutsche
Bank Aktiengesellschaft, as Paying Agent, related to the
5.25% Senior Notes due 2021 of FMC Finance VII S.A. (filed
herewith).
2.21 Form of Note Guarantee for 5.25% Senior Notes due
2021 (included in Exhibit 2.20) (filed herewith).
2.22 Indenture (Dollar denominated) dated as of
February 2, 2011 by and among Fresenius Medical Care US
Finance, Inc., the Registrant and the other Guarantors party
thereto and U.S. Bank National Association, as Trustee,
related to the 5.75% Senior Notes due 2021 of Fresenius
Medical Care US Finance, Inc. (filed herewith).
2.23 Form of Note Guarantee for 5.75% Senior Notes due
2021 (included in Exhibit 2.22) (filed herewith).
2.24 Bank Credit Agreement dated as of March 31, 2006
among the Registrant, Fresenius Medical Care Holdings, Inc., and
certain subsidiaries of the Registrant as Borrowers and
Guarantors, Bank of America N.A., as Administrative Agent,
Deutsche Bank AG New York Branch, as Sole Syndication Agent, The
Bank of Nova Scotia, Credit Suisse, Cayman Islands Branch, and
JPMorgan Chase Bank, National Association, as Co-Documentation
Agents and the Lenders named therein (incorporated by reference
to Exhibit 4.1 to the Registrants Report on
Form 6-K
for the month of May 2006, furnished May 17,
2006).
(1)
2.25 Term Loan Credit Agreement dated as of March 31,
2006 among the Registrant, Fresenius Medical Care Holdings,
Inc., and certain subsidiaries of the Registrant as Borrowers
and Guarantors, Bank of America N.A., as Administrative Agent,
Deutsche Bank AG New York Branch, as Sole Syndication Agent, The
Bank of Nova Scotia, Credit Suisse, Cayman Islands Branch, and
JPMorgan Chase Bank, National Association, as Co-Documentation
Agents and the Lenders named therein (incorporated by reference
to Exhibit 4.2 to the Registrants Report on
Form 6-K
for the month of May 2006, furnished May 17,
2006).
(1)
2.26 Amendment No. 1 dated as of June 26, 2007 to
Bank Credit Agreement (incorporated by reference to
Exhibit 4.1 to the Registrants Report on
Form 6-K
for the month of August 2007, furnished August 2, 2007).
2.27 Amendment No. 1 dated as of June 26, 2007 to
Term Loan Credit (incorporated by reference to Exhibit 4.2
to the Registrants Report on
Form 6-K
for the month of August 2007, furnished on August 2, 2007).
2.28 Amendment No. 2 dated as of January 31, 2008
to Bank Credit Agreement (incorporated by reference to
Exhibit 2.24 to the Registrants Annual Report on
Form 20-F
for the year ended December 31, 2008, filed
February 20, 2009).
2.29 Amendment No. 2 dated as of January 31, 2008
to Term Loan Credit Agreement (incorporated by reference to
Exhibit 2.24 to the Registrants Annual Report on
Form 20-F
for the year ended December 31, 2008, filed
February 20, 2009).
2.30 Amendment No. 3 dated as of September 29,
2010 to Bank Credit Agreement and Term Loan Credit Agreement
(incorporated by reference to Exhibit 10.4 to the
Registrants Report on
Form 6-K
for the month of November 2010, furnished November 3,
2010).
(2)
2.31 Amendment No. 4 dated as of January 14, 2011
to Bank Credit Agreement and Term Loan Credit Agreement (filed
herewith).
2.32 Fifth Amended and Restated Transfer and Administration
Agreement dated as of November 17, 2009 by and among NMC
Funding Corporation, as Transferor, National Medical Care, Inc.,
as initial collection agent, Paradigm Funding LLC, and other
Conduit Investors party thereto, the financial institutions
party thereto, The Bank of Nova Scotia, Barclays Bank PLC,
Bayerische Landesbank, New York Branch, Calyon New York Branch
and Royal Bank of Canada, as administrative agents, and WestLB
AG, New York Branch, as Administrative Agent and as Agent
(incorporated by reference to Exhibit 2.20 to the
Registrants Annual Report on
Form 20-F
for the year ended December 31, 2009, filed
February 24, 2010).
2.33 Amendment No. 1 dated as of June 16, 2010 to
Fifth Amended and Restated Transfer and Administration Agreement
(incorporated by reference to Exhibit 10.1 to the
Registrants Report on
Form 6-K
for the month of November 2010, furnished November 3, 2010).
120
2.34 Amendment No. 2 dated as of September 28,
2010 to Fifth Amended and Restated Transfer and Administration
Agreement (incorporated by reference to Exhibit 10.2 to the
Registrants Report on
Form 6-K
for the month of November 2010, furnished November 3, 2010).
2.35 Amended and Restated Receivables Purchase Agreement
dated October 16, 2008 between National Medical Care, Inc.
and NMC Funding Corporation (incorporated by reference to
Exhibit 10.1 to the Registrants Amended Report on
Form 6-K/A
for the month of August 2009, furnished December 16,
2010).
(1)
2.36 Amendment No. 1 dated November 17, 2009 to
Amended and Restated Receivables Purchase Agreement
(incorporated by reference to Exhibit 2.21 to the
Registrants Annual Report on
Form 20-F
for the year ended December 31, 2009, filed
February 24, 2010).
2.37 Amendment No. 2 dated June 16, 2010 to
Amended and Restated Receivables Purchase Agreement
(incorporated by reference to Exhibit 10.3 to the
Registrants Report on
Form 6-K
for the month of November 2010, furnished November 3, 2010).
4.1 Agreement and Plan of Reorganization dated as of
February 4, 1996 between W.R. Grace & Co. and
Fresenius AG. (incorporated by reference to Appendix A to
the Joint Proxy Statement-Prospectus of FMC-AG, W.R.
Grace & Co. and Fresenius USA, Inc., dated
August 2, 1996).
4.2 Distribution Agreement dated as of February 4,
1996 by and among W.R. Grace & Co., W.R.,
Grace & Co. Conn. and Fresenius AG
(incorporated by reference to Appendix A to the Joint Proxy
Statement-Prospectus of FMC-AG, W.R. Grace & Co. and
Fresenius USA, Inc., dated August 2, 1996).
4.3 Contribution Agreement dated as of February 4,
1996 by and among Fresenius AG, Sterilpharma GmbH and W.R.
Grace & Co. Conn. (incorporated by
reference to Appendix E to the Joint Proxy
Statement-Prospectus of FMC-AG, W.R. Grace & Co. and
Fresenius USA, Inc., dated August 2, 1996).
4.4 Renewed Post-Closing Covenants Agreement effective
January 1, 2007 between Fresenius AG and Registrant
(incorporated by reference to Exhibit 4.4 to the
Registrants Amended Annual Report on
Form 20-F/A
for the year ended December 31, 2006, filed
February 26, 2007).
4.5 Lease Agreement for Office Buildings dated
September 30, 1996 by and between Fresenius AG and
Fresenius Medical Care Deutschland GmbH. (Incorporated by
reference to Exhibit 10.3 to the Registration Statement on
Form F-1
of FMC-AG, Registration
No. 333-05922,
filed November 18, 1996).
4.6 Amendment for Lease Agreement for Office Buildings
dated December 19, 2006 by and between Fresenius AG and
Fresenius Medical Care Deutschland GmbH (incorporated by
reference to Exhibit 4.5 to the Registrants Amended
Annual Report on
Form 20-F/A
for the year ended December 31, 2006, filed
February 26, 2007).
4.7 Lease Agreement for Manufacturing Facilities dated
September 30, 1996 by and between Fresenius
Immobilien-Verwaltungs-GmbH & Co. Objekt Schweinfurt
KG and Fresenius Medical Care Deutschland GmbH (incorporated by
reference to Exhibit 10.4.1 to the Registration Statement
on
Form F-1
of FMC-AG, Registration
No. 333-05922,
filed November 16, 1996).
4.8 Amendment for Lease Agreement for Manufacturing
Facilities dated December 19, 2006 by and between Fresenius
Immobilien-Verwaltungs-GmbH & Co. Objekt Schweinfurt
KG and Fresenius Medical Care Deutschland GmbH (incorporated by
reference to Exhibit 4.6 to the Registrants Amended
Annual Report on
Form 20-F/A
for the year ended December 31, 2006, filed on
February 26, 2007).
4.9 Schweinfurt facility rental agreement between Fresenius
Immobilien-Verwaltungs-GmbH & Co, Objekt Schweinfurt
KG, as Lessor, and Fresenius Medical Care Deutschland GmbH, as
Lessee, dated February 6, 2008 and effective
October 1, 2007, supplementing the Principal Lease dated
December 18, 2006 (incorporated by reference to
Exhibit 10.1 to the Report of
Form 6-K
for the month of April 2008, furnished April 30, 2008).
4.10 Lease Agreement for Manufacturing Facilities dated
September, 1996 by and between Fresenius
Immobilien-Verwaltungs-GmbH & Co. Objekt St. Wendel KG
and Fresenius Medical Care Deutschland GmbH (incorporated by
reference to Exhibit 10.4.2 to the Registration Statement
on
Form F-1
of FMC-AG, Registration
No. 333-05922,
filed November 16, 1996).
4.11 Amendment for Lease Agreement for Manufacturing
Facilities dated December 19, 2006 by and between Fresenius
Immobilien-Verwaltungs-GmbH & Co. Objekt St. Wendel KG
and Fresenius Medical Care Deutschland GmbH (incorporated by
reference to Exhibit 4.7 to the Registrants Amended
Annual Report on
Form 20-F/A
for the year ended December 31, 2006 filed on
February 26, 2007).
121
4.12 Lease Agreement for Manufacturing Facilities dated
September 30, 1996 by and between Fresenius AG and
Fresenius Medical Care Deutschland GmbH (Ober-Erlenbach)
(incorporated by reference to Exhibit 10.5 to the
Registration Statement on
Form F-1
of FMC-AG, Registration
No. 333-05922,
filed November 18, 1996).
4.13 Amendment for Lease Agreement for Manufacturing
Facilities dated December 19, 2006 by and between Fresenius
AG and Fresenius Medical Care Deutschland GmbH (Ober-Erlenbach)
(incorporated by reference to Exhibit 4.8 to the
Registrants Amended Annual Report on
Form 20-F/A
for the year ended December 31, 2006 filed on
February 26, 2007).
4.14 Trademark License Agreement dated September 27,
1996 by and between Fresenius AG and FMC-AG. (Incorporated by
reference to Exhibit 10.8 to FMC-AGs Registration
Statement on
Form F-1,
Registration
No. 333-05922,
filed November 16, 1996).
4.15 Technology License Agreement (Biofine) dated
September 27, 1996 by and between Fresenius AG and FMC-AG
(incorporated by reference to Exhibit 10.9 to the
Registration Statement on
Form F-1
of FMC-AG, Registration
No. 333-05922,
filed November 16, 1996).
4.16 Cross-License Agreement dated September 27, 1996
by and between Fresenius AG and FMC-AG (incorporated by
reference to Exhibit 10.10 to the Registration Statement on
Form F-1
of FMC-AG, Registration
No. 333-05922,
filed November 16, 1996).
4.17 Lease Agreement for Office Buildings dated
September 30, 1996 by and between Fresenius AG and
Fresenius Medical Care Deutschland GmbH (Daimler Str.)
(incorporated by reference to Exhibit 2.8 to the Annual
Report on
Form 20-F
of FMC-AG for the year ended December 31, 1996, filed
April 7, 1997).
4.18 Amendment for Lease Agreement for Office Buildings
dated December 19, 2006 by and between Fresenius AG and
Fresenius Medical Care Deutschland GmbH (Daimler Str.)
(incorporated by reference to Exhibit 4.12 to the
Registrants Amended Annual Report on
Form 20-F/A
for the year ended December 31, 2006, filed on
February 26, 2007).
4.19 FMC AG 1998 Stock Incentive Plan
adopted effective as of April 6, 1998 (incorporated by
reference to Exhibit 4.8 to the Report on
Form 6-K
of FMC-AG for the month of May 1998, furnished May 14,
1998).
4.20 FMC-AG Stock Option Plan of June 10, 1998 (for
non-North American employees) (incorporated by reference to
Exhibit 1.2 to the Annual Report on
Form 20-F
of FMC-AG, for the year ended December 31, 1998, filed
March 24, 1999).
4.21 Fresenius Medical Care Aktiengesellschaft 2001
International Stock Incentive Plan (incorporated by reference to
Exhibit 10.17 to the Registration Statement on
Form F-4
of FMC-AG et al, Registration
No. 333-66558,
filed August 2, 2001).
4.22 Stock Option Plan 2006 of Fresenius Medical Care
AG & Co. KGaA (incorporated by reference to
Exhibit 10.2 to the Registrants Amended Report on
Form 6-K/A
for the month of August 2006, furnished August 11, 2006).
4.23 Sourcing and Supply Agreement dated effective
October 1, 2006 by and among Amgen, Inc., Amgen USA, Inc.,
and Fresenius Medical Care Holdings, Inc. (incorporated by
reference to Exhibit 4.18 to the Registrants Amended
Annual Report on
Form 20-F/A
for the year ended December 31, 2006, filed on
February 26,
2007).
(1)
4.24 Amendment No. 1 to Sourcing and Supply Agreement
(incorporated by reference to Exhibit 10.2 to the
Registrants Report on
Form 6-K
for the month of August 2007, furnished August 2,
2007).
(1)
4.25 Amendment No. 2 to Sourcing and Supply Agreement
(incorporated by reference to Exhibit 10.3 to the
Registrants Report on
Form 6-K
for the month of August 2007, furnished August 2,
2007).
(1)
4.26 Amendment No. 3 to Sourcing and Supply agreement
(incorporated by reference to Exhibit 10.4 the
Registrants Report on
Form 6-K
for the month of August 2007, furnished August 2,
2007).
(1)
4.27 Amendment No. 4 to Sourcing and Supply Agreement
(incorporated by reference to Exhibit 10.5 to the
Registrants Report on
Form 6-K
for the month of August 2007, furnished August 2,
2007).
(1)
4.28 Settlement Agreement dated as of February 6, 2003
by and among FMC-AG, Fresenius Medical Care Holdings, National
Medical Care, Inc., the Official Committee of Asbestos Personal
Injury Claimants, and the Official Committee of Asbestos
Property Damage Claimants of W.R. Grace & Co.
(incorporated by reference to Exhibit 10.18 to the Annual
Report on
Form 10-K
of Fresenius Medical Care Holdings, Inc. for the year ended
December 31, 2002, filed March 17, 2002).
122
4.29 Amended and Restated Subordinated Loan Note dated as
of March 31, 2006, among National Medical Care, Inc. and
certain of its subsidiaries as Borrowers and Fresenius AG as
Lender (incorporated herein by reference to Exhibit 4.3 to
the Registrants Report on
Form 6-K
for the month of May 2006, furnished May 17,
2006).
(1)
4.30 Allonge dated September 29, 2010 to Amended and
Restated Subordinated Loan Note dated as of March 31, 2006
(incorporated by reference to Exhibit 10.5 to the
Registrants Report on
Form 6-K
for the month of November 2010, furnished November 3,
2010).
(2)
4.31 Agreement Containing Consent Orders, United States of
America before Federal Trade Commission, In the Matter of
Fresenius AG, File
No. 051-0154
(incorporated by reference to Exhibit 10.1 to the
Registrants Report on
Form 6-K
for the month of May 2006, furnished May 17, 2006).
4.32 Decision and Order, United States of America before
Federal Trade Commission, In the Matter of Fresenius AG
(incorporated by reference to Exhibit 10.3 to the
Registrants Report on
Form 6-K
for the month of May 2006, furnished May 17, 2006).
4.33 License, Distribution, Manufacturing and Supply
Agreement dated June 2008 by and between Luitpold
Pharmaceuticals, Inc., American Regent, Inc., and Fresenius USA
Manufacturing, Inc. (incorporated by reference to
Exhibit 10.1 to the Registrants Report of
Form 6-K
for the month of November 2008, furnished November 5,
2008).
(1)
4.34 First Amendment dated September 13, 2008 to the
License, Distribution, Manufacturing and Supply Agreement
(incorporated by reference to Exhibit 10.2 to the
Registrants Report of
Form 6-K
for the month of November 2008, furnished November 5,
2008).
(1)
8.1 List of Significant Subsidiaries. Our significant
subsidiaries are identified in Item 4.C. Information
on the Company Organizational Structure.
11.1 Code of Business Conduct. A copy of the
Registrants Code of Business Conduct is available on the
Registrants web site at:
http://www.fmc-ag.com/Code_of_Conduct.htm.
12.1 Certification of Chief Executive Officer of the
general partner of the Registrant Pursuant to Section 302
of the Sarbanes-Oxley Act of 2002 (filed herewith).
12.2 Certification of Chief Financial Officer of the
general partner of the Registrant Pursuant to Section 302
of the Sarbanes-Oxley Act of 2002 (filed herewith).
13.1 Certification of Chief Executive Officer and Chief
Financial Officer of the general partner of the Registrant
Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(furnished herewith). (This Exhibit is furnished herewith, but
not deemed filed for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise
subject to liability under that section. Such certification will
not be deemed to be incorporated by reference into any filing
under the Securities Act or the Exchange Act, except to the
extent that we explicitly incorporate it by reference.)
14.1 Consent of KPMG, independent registered public
accounting firm (filed herewith).
|
|
(1)
|
Confidential treatment has been granted as to certain portions
of this document in accordance with the applicable rules of the
Securities and Exchange Commission.
|
|
(2)
|
Portions of this exhibit have been omitted pursuant to a request
for confidential treatment and file separately with the
Securities and Exchange Commission.
|
123
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
DATE: February 23, 2011
Fresenius Medical Care
AG & Co. KG
aA
a partnership limited by shares, represented by:
fresenius medical care
management ag,
its general partner
Name: Dr. Ben J. Lipps
|
|
|
|
Title:
|
Chief Executive Officer and
|
Chairman of the Management Board
of the General Partner
Name: Michael Brosnan
|
|
|
|
Title:
|
Chief Financial Officer and Member
|
of the Management Board of the
General Partner
124
INDEX OF
FINANCIAL STATEMENTS
|
|
|
|
|
Audited Consolidated Financial Statements
|
|
|
|
|
|
|
|
F-2
|
|
|
|
|
F-3
|
|
|
|
|
F-4
|
|
|
|
|
F-5
|
|
|
|
|
F-6
|
|
|
|
|
F-7
|
|
|
|
|
F-8
|
|
|
|
|
F-9
|
|
|
|
|
F-10
|
|
|
|
|
S-II
|
|
F-1
MANAGEMENTS
ANNUAL REPORT ON INTERNAL CONTROL
OVER FINANCIAL REPORTING
Management of the Company is responsible for establishing and
maintaining adequate internal control over financial reporting,
as such term is defined in Exchange Act
Rule 13a-15(f).
The Companys internal control over financial reporting is
a process designed by or under the supervision of the
Companys chief executive officer and chief financial
officer to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of the
Companys financial statements for external reporting
purposes in accordance with U.S. generally accepted
accounting principles.
As of December 31, 2010, management conducted an assessment
of the effectiveness of the Companys internal control over
financial reporting based on the criteria established in
Internal Control Integrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway Commission
(COSO). Managements assessment follows the guidance for
management of the evaluation of internal controls over financial
reporting released by the Securities and Exchange Commission on
May 23, 2007. Based on this assessment, management has
determined that the Companys internal control over
financial reporting is effective as of December 31, 2010.
The Companys internal control over financial reporting
includes policies and procedures that (1) pertain to the
maintenance of records that in reasonable detail accurately and
fairly reflect transactions and dispositions of assets;
(2) provide reasonable assurance that the Companys
transactions are recorded as necessary to permit preparation of
financial statements in accordance with U.S. generally
accepted accounting principles, and that the Companys
receipts and expenditures are being made only in accordance with
authorizations of the Companys management and directors;
and (3) provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use or
disposition of the Companys assets that could have a
material effect on the Companys financial statements.
Because of its inherent limitation, internal control over
financial reporting, no matter how well designed, cannot provide
absolute assurance of achieving financial reporting objectives
and may not prevent or detect misstatements. Therefore, even if
the internal control over financial reporting is determined to
be effective it can provide only reasonable assurance with
respect to financial statement preparation and presentation.
Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.
The Companys internal control over financial reporting as
of December 31, 2010 has been audited by KPMG AG
Wirtschaftsprüfungsgesellschaft, an independent registered
public accounting firm, as stated in their report included on
page F-4.
Date: February 23, 2011
Fresenius Medical Care
AG & Co.
KGaA,
a partnership limited by shares, represented by:
fresenius medical care
management ag
, its
General Partner
By: /s/ DR. BEN LIPPS
Name: Dr. Ben Lipps
|
|
|
|
Title:
|
Chief Executive Officer and Chairman
|
of the Management Board of the
General Partner
By: /s/ MICHAEL BROSNAN
Name: Michael Brosnan
|
|
|
|
Title:
|
Chief Financial Officer and member
|
of the Management Board of the
General Partner
F-2
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Supervisory Board
Fresenius Medical Care AG & Co. KGaA:
We have audited the accompanying consolidated balance sheets of
Fresenius Medical Care AG & Co. KGaA and subsidiaries
(Fresenius Medical Care or the Company)
as of December 31, 2010 and 2009 and the related
consolidated statements of income, comprehensive income,
shareholders equity and cash flows for each of the years
in the three-year period ended December 31, 2010. In
connection with our audits of the consolidated financial
statements, we have also audited the financial statement
schedule as listed in the accompanying index. These consolidated
financial statements and the financial statement schedule are
the responsibility of the Companys management. Our
responsibility is to express an opinion on these consolidated
financial statements and the financial statement schedule based
on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by
management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the financial
position of Fresenius Medical Care as of December 31, 2010
and 2009, and the results of their operations and their cash
flows for each of the years in the three-year period ended
December 31, 2010, in conformity with U.S. generally
accepted accounting principles. Also in our opinion, the related
financial statement schedule, when considered in relation to the
consolidated financial statements taken as a whole, presents
fairly, in all material respects, the information set forth
therein.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States),
Fresenius Medical Cares internal control over financial
reporting as of December 31, 2010, based on criteria
established in Internal Control Integrated Framework
issued by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO), and our report dated
February 23, 2011 expressed an unqualified opinion on the
effectiveness of the Companys internal control over
financial reporting.
Frankfurt am Main, Germany
February 23, 2011
/s/ KPMG AG
Wirtschaftsprüfungsgesellschaft
F-3
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
ON INTERNAL CONTROL OVER FINANCIAL REPORTING
The Supervisory Board
Fresenius Medical Care AG & Co. KGaA:
We have audited the internal control over financial reporting of
Fresenius Medical Care AG & Co. KGaA and subsidiaries
(Fresenius Medical Care or the Company)
as of December 31, 2010, based on criteria established in
Internal Control-Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (COSO).
Fresenius Medical Cares management is responsible for
maintaining effective internal control over financial reporting
and its assessment of the effectiveness of internal control over
financial reporting included in the accompanying
Managements Annual Report on Internal Control over
Financial Reporting. Our responsibility is to express an opinion
on the Companys internal control over financial reporting
based on our audit.
We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control
over financial reporting was maintained in all material
respects. Our audit included obtaining an understanding of
internal control over financial reporting, assessing the risk
that a material weakness exists, and testing and evaluating the
design and operating effectiveness of internal control based on
the assessed risk. Our audit also included performing such other
procedures as we considered necessary in the circumstances. We
believe that our audit provides a reasonable basis for our
opinion.
A companys internal control over financial reporting is a
process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles. A companys
internal control over financial reporting includes those
policies and procedures that (1) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the
company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company
are being made only in accordance with authorizations of
management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the
companys assets that could have a material effect on the
financial statements.
Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.
In our opinion, Fresenius Medical Care maintained, in all
material respects, effective internal control over financial
reporting as of December 31, 2010, based on criteria
established in Internal Control-Integrated Framework issued by
the Committee of Sponsoring Organizations of the Treadway
Commission (COSO).
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
consolidated balance sheets of Fresenius Medical Care as of
December 31, 2010 and 2009, and the related consolidated
statements of income, comprehensive income, shareholders
equity and cash flows for each of the years in the three-year
period ended December 31, 2010, and our report dated
February 23, 2011 expressed an unqualified opinion on those
consolidated financial statements.
Frankfurt am Main, Germany
February 23, 2011
/s/ KPMG AG
Wirtschaftsprüfungsgesellschaft
F-4
FRESENIUS
MEDICAL CARE AG & Co. KGaA
For the years ended December 31,
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Net revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
Dialysis Care
|
|
$
|
9,070,546
|
|
|
$
|
8,350,233
|
|
|
$
|
7,737,498
|
|
Dialysis Products
|
|
|
2,982,944
|
|
|
|
2,897,244
|
|
|
|
2,874,825
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,053,490
|
|
|
|
11,247,477
|
|
|
|
10,612,323
|
|
Costs of revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
Dialysis Care
|
|
|
6,345,135
|
|
|
|
5,945,724
|
|
|
|
5,547,615
|
|
Dialysis Products
|
|
|
1,563,634
|
|
|
|
1,470,241
|
|
|
|
1,435,860
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,908,769
|
|
|
|
7,415,965
|
|
|
|
6,983,475
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
4,144,721
|
|
|
|
3,831,512
|
|
|
|
3,628,848
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
2,124,384
|
|
|
|
1,982,106
|
|
|
|
1,876,177
|
|
Research and development
|
|
|
96,532
|
|
|
|
93,810
|
|
|
|
80,239
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
1,923,805
|
|
|
|
1,755,596
|
|
|
|
1,672,432
|
|
Other (income) expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
(25,409
|
)
|
|
|
(21,397
|
)
|
|
|
(24,811
|
)
|
Interest expense
|
|
|
305,473
|
|
|
|
321,360
|
|
|
|
361,553
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
1,643,741
|
|
|
|
1,455,633
|
|
|
|
1,335,690
|
|
Income tax expense
|
|
|
578,345
|
|
|
|
490,413
|
|
|
|
475,702
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
1,065,396
|
|
|
|
965,220
|
|
|
|
859,988
|
|
Less: Net income attributable to Noncontrolling interests
|
|
|
86,879
|
|
|
|
74,082
|
|
|
|
42,381
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to FMC-AG & Co. KGaA
|
|
$
|
978,517
|
|
|
$
|
891,138
|
|
|
$
|
817,607
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income per ordinary share
|
|
$
|
3.25
|
|
|
$
|
2.99
|
|
|
$
|
2.75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fully diluted income per ordinary share
|
|
$
|
3.24
|
|
|
$
|
2.99
|
|
|
$
|
2.74
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
F-5
FRESENIUS
MEDICAL CARE AG & Co. KGaA
For the years ended December 31,
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Net Income
|
|
$
|
1,065,396
|
|
|
$
|
965,220
|
|
|
$
|
859,988
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) gain related to cash flow hedges
|
|
|
(8,109
|
)
|
|
|
30,082
|
|
|
|
(108,240
|
)
|
Actuarial (loss) gain on defined benefit pension plans
|
|
|
(35,654
|
)
|
|
|
9,708
|
|
|
|
(28,551
|
)
|
(Loss) gain related to foreign currency translation
|
|
|
(110,888
|
)
|
|
|
82,545
|
|
|
|
(170,748
|
)
|
Income tax benefit (expense) related to components of other
comprehensive income
|
|
|
12,821
|
|
|
|
(18,971
|
)
|
|
|
55,692
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive (loss) income, net of tax
|
|
|
(141,830
|
)
|
|
|
103,364
|
|
|
|
(251,847
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income
|
|
$
|
923,566
|
|
|
$
|
1,068,584
|
|
|
$
|
608,141
|
|
Comprehensive income attributable to Noncontrolling interests
|
|
|
89,370
|
|
|
|
75,886
|
|
|
|
42,696
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income attributable to FMC-AG & Co. KGaA
|
|
$
|
834,196
|
|
|
$
|
992,698
|
|
|
$
|
565,445
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
F-6
FRESENIUS
MEDICAL CARE AG & Co. KGaA
Consolidated
Balance Sheets
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
522,870
|
|
|
$
|
301,225
|
|
Trade accounts receivable less allowance for doubtful accounts
of $277,139 in 2010 and $266,449 in 2009
|
|
|
2,573,258
|
|
|
|
2,285,909
|
|
Accounts receivable from related parties
|
|
|
113,976
|
|
|
|
272,886
|
|
Inventories
|
|
|
809,097
|
|
|
|
821,654
|
|
Prepaid expenses and other current assets
|
|
|
783,231
|
|
|
|
729,306
|
|
Deferred taxes
|
|
|
350,162
|
|
|
|
316,820
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
5,152,594
|
|
|
|
4,727,800
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
2,527,292
|
|
|
|
2,419,570
|
|
Intangible assets
|
|
|
692,544
|
|
|
|
859,195
|
|
Goodwill
|
|
|
8,140,468
|
|
|
|
7,511,434
|
|
Deferred taxes
|
|
|
93,168
|
|
|
|
64,749
|
|
Investment in equity method investees
|
|
|
250,373
|
|
|
|
5,795
|
|
Other assets
|
|
|
238,222
|
|
|
|
232,772
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
17,094,661
|
|
|
$
|
15,821,315
|
|
|
|
|
|
|
|
|
|
|
Liabilities and shareholders equity
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
420,637
|
|
|
$
|
362,407
|
|
Accounts payable to related parties
|
|
|
121,887
|
|
|
|
277,429
|
|
Accrued expenses and other current liabilities
|
|
|
1,537,423
|
|
|
|
1,335,553
|
|
Short-term borrowings and other financial liabilities
|
|
|
670,671
|
|
|
|
316,344
|
|
Short-term borrowings from related parties
|
|
|
9,683
|
|
|
|
10,440
|
|
Current portion of long-term debt and capital lease obligations
|
|
|
263,982
|
|
|
|
157,634
|
|
Company-obligated mandatorily redeemable preferred securities of
subsidiary Fresenius Medical Care Capital Trusts holding solely
Company-guaranteed debentures of subsidiaries
current portion
|
|
|
625,549
|
|
|
|
|
|
Income tax payable
|
|
|
117,542
|
|
|
|
116,978
|
|
Deferred taxes
|
|
|
22,349
|
|
|
|
32,930
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
3,789,723
|
|
|
|
2,609,715
|
|
|
|
|
|
|
|
|
|
|
Long-term debt and capital lease obligations, less current
portion
|
|
|
4,309,676
|
|
|
|
4,427,921
|
|
Other liabilities
|
|
|
294,015
|
|
|
|
307,112
|
|
Pension liabilities
|
|
|
190,150
|
|
|
|
147,327
|
|
Income tax payable
|
|
|
200,581
|
|
|
|
215,921
|
|
Deferred taxes
|
|
|
506,896
|
|
|
|
427,530
|
|
Company-obligated mandatorily redeemable preferred securities of
subsidiary Fresenius Medical Care Capital Trusts holding solely
Company-guaranteed debentures of subsidiaries
|
|
|
|
|
|
|
656,096
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
9,291,041
|
|
|
|
8,791,622
|
|
Noncontrolling interests subject to put provisions
|
|
|
279,709
|
|
|
|
231,303
|
|
Shareholders equity:
|
|
|
|
|
|
|
|
|
Preference shares, no par value, 1.00 nominal value,
12,356,880 shares authorized, 3,957,168 issued and
outstanding
|
|
|
4,440
|
|
|
|
4,343
|
|
Ordinary shares, no par value, 1.00 nominal value,
373,436,220 shares authorized, 298,279,001 issued and
outstanding
|
|
|
369,002
|
|
|
|
365,672
|
|
Additional paid-in capital
|
|
|
3,339,781
|
|
|
|
3,243,466
|
|
Retained earnings
|
|
|
3,858,080
|
|
|
|
3,111,530
|
|
Accumulated other comprehensive (loss) income
|
|
|
(194,045
|
)
|
|
|
(49,724
|
)
|
|
|
|
|
|
|
|
|
|
Total FMC-AG & Co. KGaA shareholders equity
|
|
|
7,377,258
|
|
|
|
6,675,287
|
|
|
|
|
|
|
|
|
|
|
Noncontrolling interests not subject to put provisions
|
|
|
146,653
|
|
|
|
123,103
|
|
Total equity
|
|
|
7,523,911
|
|
|
|
6,798,390
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and equity
|
|
$
|
17,094,661
|
|
|
$
|
15,821,315
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
F-7
FRESENIUS
MEDICAL CARE AG & Co. KGaA
For the years ended December 31,
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Operating Activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1,065,396
|
|
|
$
|
965,220
|
|
|
|
859,988
|
|
Adjustments to reconcile net income to net cash
|
|
|
|
|
|
|
|
|
|
|
|
|
provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
503,224
|
|
|
|
457,085
|
|
|
|
415,671
|
|
Change in deferred taxes, net
|
|
|
14,687
|
|
|
|
22,002
|
|
|
|
133,047
|
|
Gain on sale of investments
|
|
|
(5,888
|
)
|
|
|
(1,250
|
)
|
|
|
(24,049
|
)
|
(Gain) loss on sale of fixed assets
|
|
|
(628
|
)
|
|
|
1,308
|
|
|
|
2,985
|
|
Compensation expense related to stock options
|
|
|
27,981
|
|
|
|
33,746
|
|
|
|
31,879
|
|
Changes in assets and liabilities, net of amounts from
businesses acquired:
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade accounts receivable, net
|
|
|
(300,274
|
)
|
|
|
(41,994
|
)
|
|
|
(241,967
|
)
|
Inventories
|
|
|
18,326
|
|
|
|
(88,933
|
)
|
|
|
(94,112
|
)
|
Prepaid expenses, other current and non-current assets
|
|
|
(60,305
|
)
|
|
|
(147,105
|
)
|
|
|
(84,089
|
)
|
Accounts receivable from related parties
|
|
|
125,962
|
|
|
|
(144,224
|
)
|
|
|
(32,747
|
)
|
Accounts payable to related parties
|
|
|
(135,001
|
)
|
|
|
138,506
|
|
|
|
64,999
|
|
Accounts payable, accrued expenses and other current and
non-current liabilities
|
|
|
124,279
|
|
|
|
71,092
|
|
|
|
(17,040
|
)
|
Income tax payable
|
|
|
(9,634
|
)
|
|
|
73,164
|
|
|
|
1,833
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
1,368,125
|
|
|
|
1,338,617
|
|
|
|
1,016,398
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing Activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases of property, plant and equipment
|
|
|
(523,629
|
)
|
|
|
(573,606
|
)
|
|
|
(687,356
|
)
|
Proceeds from sale of property, plant and equipment
|
|
|
16,108
|
|
|
|
11,730
|
|
|
|
13,846
|
|
Acquisitions and investments, net of cash acquired, and net
purchases of intangible assets
|
|
|
(764,338
|
)
|
|
|
(188,113
|
)
|
|
|
(276,473
|
)
|
Proceeds from divestitures
|
|
|
146,835
|
|
|
|
51,965
|
|
|
|
58,582
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) investing activities
|
|
|
(1,125,024
|
)
|
|
|
(698,024
|
)
|
|
|
(891,401
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing Activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from short-term borrowings and other financial
liabilities
|
|
|
281,022
|
|
|
|
107,192
|
|
|
|
176,104
|
|
Repayments of short-term borrowings and other financial
liabilities
|
|
|
(258,561
|
)
|
|
|
(169,175
|
)
|
|
|
(183,210
|
)
|
Proceeds from short-term borrowings from related parties
|
|
|
|
|
|
|
18,830
|
|
|
|
168,641
|
|
Repayments of short-term borrowings from related parties
|
|
|
|
|
|
|
(118,422
|
)
|
|
|
(169,573
|
)
|
Proceeds from long-term debt and capital lease obligations (net
of debt issuance costs of $31,458 in 2010)
|
|
|
947,346
|
|
|
|
709,540
|
|
|
|
458,951
|
|
Repayments of long-term debt and capital lease obligations
|
|
|
(1,072,941
|
)
|
|
|
(566,241
|
)
|
|
|
(135,492
|
)
|
Redemption of trust preferred securities
|
|
|
|
|
|
|
|
|
|
|
(678,379
|
)
|
Increase (decrease) of accounts receivable securitization program
|
|
|
296,000
|
|
|
|
(325,000
|
)
|
|
|
454,000
|
|
Proceeds from exercise of stock options
|
|
|
109,518
|
|
|
|
72,394
|
|
|
|
43,887
|
|
Dividends paid
|
|
|
(231,967
|
)
|
|
|
(231,940
|
)
|
|
|
(252,395
|
)
|
Distributions to Noncontrolling interests
|
|
|
(111,550
|
)
|
|
|
(68,004
|
)
|
|
|
(38,592
|
)
|
Contributions from Noncontrolling interests
|
|
|
26,416
|
|
|
|
12,699
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) financing activities
|
|
|
(14,717
|
)
|
|
|
(558,127
|
)
|
|
|
(156,058
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
(6,739
|
)
|
|
|
(2,825
|
)
|
|
|
7,955
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
221,645
|
|
|
|
79,641
|
|
|
|
(23,106
|
)
|
Cash and cash equivalents at beginning of period
|
|
|
301,225
|
|
|
|
221,584
|
|
|
|
244,690
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
522,870
|
|
|
$
|
301,225
|
|
|
|
221,584
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
F-8
FRESENIUS
MEDICAL CARE AG & Co. KGaA
For the years ended December 31, 2010, 2009 and 2008
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
FMC-AG &
|
|
|
Noncontrolling
|
|
|
|
|
|
|
Preference Shares
|
|
|
Ordinary Shares
|
|
|
Additional
|
|
|
|
|
|
Other
|
|
|
Co. KGaA
|
|
|
interests not
|
|
|
|
|
|
|
Number of
|
|
|
No par
|
|
|
Number of
|
|
|
No par
|
|
|
paid in
|
|
|
Retained
|
|
|
comprehensive
|
|
|
shareholders
|
|
|
subject to put
|
|
|
Total
|
|
|
|
shares
|
|
|
value
|
|
|
shares
|
|
|
value
|
|
|
capital
|
|
|
earnings
|
|
|
income (loss)
|
|
|
equity
|
|
|
provisions
|
|
|
Equity
|
|
|
Balance at December 31, 2007
|
|
|
3,778,087
|
|
|
$
|
4,191
|
|
|
|
292,786,583
|
|
|
$
|
361,384
|
|
|
$
|
3,140,073
|
|
|
$
|
1,887,120
|
|
|
$
|
100,878
|
|
|
$
|
5,493,646
|
|
|
$
|
73,258
|
|
|
$
|
5,566,904
|
|
Proceeds from exercise of options and related tax effects
|
|
|
32,453
|
|
|
|
49
|
|
|
|
1,145,453
|
|
|
|
1,692
|
|
|
|
40,395
|
|
|
|
|
|
|
|
|
|
|
|
42,136
|
|
|
|
|
|
|
|
42,136
|
|
Compensation expense related to stock options
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,879
|
|
|
|
|
|
|
|
|
|
|
|
31,879
|
|
|
|
|
|
|
|
31,879
|
|
Dividends paid
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(252,395
|
)
|
|
|
|
|
|
|
(252,395
|
)
|
|
|
(24,098
|
)
|
|
|
(276,493
|
)
|
Purchase/ sale of Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,852
|
|
|
|
21,852
|
|
Contributions from Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,105
|
|
|
|
4,105
|
|
Changes in fair value of Noncontrolling interests subject to put
provisions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(24,258
|
)
|
|
|
|
|
|
|
|
|
|
|
(24,258
|
)
|
|
|
|
|
|
|
(24,258
|
)
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
817,607
|
|
|
|
|
|
|
|
817,607
|
|
|
|
28,735
|
|
|
|
846,342
|
|
Other comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(252,162
|
)
|
|
|
(252,162
|
)
|
|
|
315
|
|
|
|
(251,847
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
565,445
|
|
|
|
29,050
|
|
|
|
594,495
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2008
|
|
|
3,810,540
|
|
|
$
|
4,240
|
|
|
|
293,932,036
|
|
|
$
|
363,076
|
|
|
$
|
3,188,089
|
|
|
$
|
2,452,332
|
|
|
$
|
(151,284
|
)
|
|
$
|
5,856,453
|
|
|
$
|
104,167
|
|
|
$
|
5,960,620
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from exercise of options and related tax effects
|
|
|
73,788
|
|
|
|
103
|
|
|
|
1,814,599
|
|
|
|
2,596
|
|
|
|
64,585
|
|
|
|
|
|
|
|
|
|
|
|
67,284
|
|
|
|
|
|
|
|
67,284
|
|
Compensation expense related to stock options
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
33,746
|
|
|
|
|
|
|
|
|
|
|
|
33,746
|
|
|
|
|
|
|
|
33,746
|
|
Dividends paid
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(231,940
|
)
|
|
|
|
|
|
|
(231,940
|
)
|
|
|
(44,569
|
)
|
|
|
(276,509
|
)
|
Purchase/ sale of Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,138
|
)
|
|
|
|
|
|
|
|
|
|
|
(3,138
|
)
|
|
|
12,929
|
|
|
|
9,791
|
|
Contributions from Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,285
|
|
|
|
3,285
|
|
Changes in fair value of Noncontrolling interests subject to put
provisions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(39,816
|
)
|
|
|
|
|
|
|
|
|
|
|
(39,816
|
)
|
|
|
|
|
|
|
(39,816
|
)
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
891,138
|
|
|
|
|
|
|
|
891,138
|
|
|
|
45,487
|
|
|
|
936,625
|
|
Other comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101,560
|
|
|
|
101,560
|
|
|
|
1,804
|
|
|
|
103,364
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
992,698
|
|
|
|
47,291
|
|
|
|
1,039,989
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2009
|
|
|
3,884,328
|
|
|
$
|
4,343
|
|
|
|
295,746,635
|
|
|
$
|
365,672
|
|
|
$
|
3,243,466
|
|
|
$
|
3,111,530
|
|
|
$
|
(49,724
|
)
|
|
$
|
6,675,287
|
|
|
$
|
123,103
|
|
|
$
|
6,798,390
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from exercise of options and related tax effects
|
|
|
72,840
|
|
|
|
97
|
|
|
|
2,532,366
|
|
|
|
3,330
|
|
|
|
98,819
|
|
|
|
|
|
|
|
|
|
|
|
102,246
|
|
|
|
|
|
|
|
102,246
|
|
Compensation expense related to stock options
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27,981
|
|
|
|
|
|
|
|
|
|
|
|
27,981
|
|
|
|
|
|
|
|
27,981
|
|
Dividends paid
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(231,967
|
)
|
|
|
|
|
|
|
(231,967
|
)
|
|
|
(58,617
|
)
|
|
|
(290,584
|
)
|
Purchase/ sale of Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,263
|
)
|
|
|
|
|
|
|
|
|
|
|
(6,263
|
)
|
|
|
17,295
|
|
|
|
11,032
|
|
Contributions from Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,392
|
|
|
|
4,392
|
|
Changes in fair value of Noncontrolling interests subject to put
provisions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(24,222
|
)
|
|
|
|
|
|
|
|
|
|
|
(24,222
|
)
|
|
|
|
|
|
|
(24,222
|
)
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
978,517
|
|
|
|
|
|
|
|
978,517
|
|
|
|
58,040
|
|
|
|
1,036,557
|
|
Other comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(144,321
|
)
|
|
|
(144,321
|
)
|
|
|
2,440
|
|
|
|
(141,881
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
834,196
|
|
|
|
60,480
|
|
|
|
894,676
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2010
|
|
|
3,957,168
|
|
|
$
|
4,440
|
|
|
|
298,279,001
|
|
|
$
|
369,002
|
|
|
$
|
3,339,781
|
|
|
$
|
3,858,080
|
|
|
$
|
(194,045
|
)
|
|
$
|
7,377,258
|
|
|
$
|
146,653
|
|
|
$
|
7,523,911
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
F-9
|
|
1.
|
The
Company, Basis of Presentation, Healthcare Reform and Summary of
Significant Accounting Policies
|
The
Company
Fresenius Medical Care AG & Co. KGaA
(FMC-AG & Co. KGaA or the
Company, we, us or
our and together with its subsidiaries on a
consolidated basis, as the context requires), a German
partnership limited by shares (
Kommanditgesellschaft auf
Aktien
), is the worlds largest kidney dialysis
company, operating in both the field of dialysis services and
the field of dialysis products for the treatment of end-stage
renal disease (ESRD). The Companys dialysis
business is vertically integrated, providing dialysis treatment
at dialysis clinics it owns or operates and supplying these
clinics with a broad range of products. In addition, the Company
sells dialysis products to other dialysis service providers. In
the United States, the Company also performs clinical laboratory
testing and provides inpatient dialysis services and other
services under contract to hospitals.
Basis of
Presentation
The accompanying consolidated financial statements have been
prepared in accordance with accounting principles generally
accepted in the United States of America
(U.S. GAAP).
Income tax expense in the amount of $13,440 for the year ended
December 31, 2008 in the prior years comparative
consolidated financial statements has been reclassified to
income attributable to noncontrolling interests to conform with
the current years presentation.
The Company has reclassified and revalued noncontrolling
interests subject to put provisions in the Consolidated Balance
Sheets. As a result, at December 31, 2009, 2008, and 2007,
the Company reclassified $85,658, $56,337, and $32,556
respectively, from Noncontrolling interests and
$145,645, $105,829, and $81,571 respectively, from
Additional paid in capital to Noncontrolling
interests subject to put provisions. The Company has also
renamed the remaining balance of Noncontrolling
interests as Noncontrolling interests not subject to
put provisions. The Consolidated Statement of
Shareholders Equity has been adjusted accordingly. There
is no impact on the Consolidated Statements of Income.
Certain other items in the prior years comparative
consolidated financial statements have been reclassified to
conform to the current years presentation.
United
States Healthcare Reform
The Patient Protection and Affordable Care Act was enacted in
the United States on March 23, 2010 and subsequently
amended by the Health Care and Educational Affordability
Reconciliation Act (as amended, ACA). ACA will
implement broad healthcare system reforms, including
(i) provisions to facilitate access to affordable health
insurance for all Americans, (ii) expansion of the Medicaid
program, (iii) an industry fee on pharmaceutical companies
starting in 2011 based on sales of brand name pharmaceuticals to
government healthcare programs, (iv) a 2.3% excise tax on
manufacturers medical device sales starting in 2013,
(v) increases in Medicaid prescription drug rebates
effective January 1, 2010, (vi) commercial insurance
market reforms that protect consumers, such as bans on lifetime
and annual limits, coverage of pre-existing conditions, limits
on administrative costs, and limits on waiting periods,
(vii) provisions encouraging integrated care, efficiency
and coordination among providers and (viii) provisions for
reduction of healthcare program waste and fraud. ACAs
medical device excise tax, Medicaid drug rebate increases and
annual pharmaceutical industry fees will adversely impact the
Companys product business earnings and cash flows. The
Company expects modest favorable impact from ACAs
integrated care and commercial insurance consumer protection
provisions.
Summary
of Significant Accounting Policies
a) Principles
of Consolidation
The consolidated financial statements include all companies in
which the Company has legal or effective control. In addition,
the Company consolidates variable interest entities
(VIEs) for which it is deemed the primary
beneficiary. In accordance with current accounting principles,
the Company also consolidates certain clinics that it manages
and financially controls. The equity method of accounting is
used for investments in associated companies (20% to 50% owned).
Noncontrolling interests represent the proportionate equity
interests of owners in the
F-10
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
Companys consolidated entities that are not wholly owned.
All significant intercompany transactions and balances have been
eliminated.
The Company entered into various arrangements with certain
dialysis clinics and a dialysis product distributor to provide
management services, financing and product supply. The dialysis
clinics and the dialysis product distributor have either
negative equity or are unable to provide their own funding and
operations. Therefore, the Company has agreed to fund their
operations through loans. The compensation for the funding can
carry interest, exclusive product supply agreements or the
Company is entitled to a pro rata share of profits, if any, and
has a right of first refusal in the event the owners sell the
business or assets. These clinics and the dialysis product
distributor are VIEs in which the Company has been determined to
be the primary beneficiary and which therefore have been fully
consolidated. They generated approximately $132,697, $112,573
and $111,854 in revenue in 2010, 2009, and 2008, respectively.
The Company provided funding to these VIEs through loans and
accounts receivable of $110,600 and $42,300 in 2010 and 2009,
respectively. The table below shows the carrying amounts of the
assets and liabilities of these VIEs at December 31, 2010
and 2009:
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
2009
|
|
Trade accounts receivable, net
|
|
$
|
60,070
|
|
|
$
|
50,730
|
|
Other current assets
|
|
|
26,981
|
|
|
|
20,029
|
|
Property, plant and equipment, intangible assets &
other non-current assets
|
|
|
29,597
|
|
|
|
13,841
|
|
Goodwill
|
|
|
56,883
|
|
|
|
21,606
|
|
Accounts payable, accrued expenses and other liabilities
|
|
|
(105,662
|
)
|
|
|
(42,931
|
)
|
Non-current loans to related parties
|
|
|
(12,998
|
)
|
|
|
(17,016
|
)
|
Equity
|
|
|
(54,870
|
)
|
|
|
(46,258
|
)
|
b) Cash
and Cash Equivalents
Cash and cash equivalents comprise cash funds and all
short-term, liquid investments with original maturities of up to
three months.
c) Allowance
for Doubtful Accounts
Estimates for the allowances for accounts receivable from the
dialysis care business are based mainly on past collection
history. Specifically, the allowances for the North America
services division are based on an analysis of collection
experience, recognizing the differences between payors and aging
of accounts receivable. From time to time, accounts receivable
are reviewed for changes from the historic collection experience
to ensure the appropriateness of the allowances. The allowances
in the International Segment and the products business are based
on estimates and consider various factors, including aging,
debtor and past collection history.
d) Inventories
Inventories are stated at the lower of cost (determined by using
the average or
first-in,
first-out method) or market value (see Note 4). Costs
included in inventories are based on invoiced costs
and/or
production costs as applicable. Included in production costs are
material, direct labor and production overhead, including
depreciation charges.
e) Property,
Plant and Equipment
Property, plant, and equipment are stated at cost less
accumulated depreciation (see Note 5). Significant
improvements are capitalized; repairs and maintenance costs that
do not extend the useful lives of the assets are charged to
expense as incurred. Property and equipment under capital leases
are stated at the present value of future minimum lease payments
at the inception of the lease, less accumulated depreciation.
Depreciation on property, plant and equipment is calculated
using the straight-line method over the estimated useful lives
of the assets ranging from 5 to 50 years for buildings and
improvements with a weighted average life of 12 years and 3
to 15 years for machinery and equipment with a weighted
average life of 10 years. Equipment held under capital
leases and leasehold improvements are amortized using the
straight-line method over the shorter of the lease term or the
estimated useful life of the asset. Internal use platform
software that is integral to the computer equipment it supports
is included in property, plant and equipment. The Company
capitalizes interest on borrowed funds during
F-11
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
construction periods. Interest capitalized during 2010, 2009,
and 2008 was $5,918, $10,395 and $8,723, respectively.
f) Intangible
Assets and Goodwill
Intangible assets such as non-compete agreements, technology,
distribution rights, patents, licenses to treat, licenses to
manufacture, distribute and sell pharmaceutical drugs, trade
names, management contracts, application software, acute care
agreements, lease agreements, and licenses acquired in an
acquisition method business combination are recognized and
reported apart from goodwill (see Note 6).
Goodwill and identifiable intangibles with indefinite useful
lives are not amortized but tested for impairment annually or
when an event becomes known that could trigger an impairment.
The Company identified trade names and certain qualified
management contracts as intangible assets with indefinite useful
lives because, based on an analysis of all of the relevant
factors, there is no foreseeable limit to the period over which
those assets are expected to generate net cash inflows for the
Company. Intangible assets with finite useful lives are
amortized over their respective useful lives to their residual
values. The Company amortizes non-compete agreements over their
average useful life of 8 years. Technology is amortized
over its useful life of 15 years. Licenses to manufacture,
distribute and sell pharmaceutical drugs are amortized over
their average useful life of 13 years. All other intangible
assets are amortized over their weighted average useful lives of
6 years. The average useful life of all amortizable
intangible assets is 11 years. Intangible assets with
finite useful lives are evaluated for impairment when events
have occurred that may give rise to an impairment.
To perform the annual impairment test of goodwill, the Company
identified its reporting units and determined their carrying
value by assigning the assets and liabilities, including the
existing goodwill and intangible assets, to those reporting
units. A reporting unit is usually defined one level below the
segment level based on regions or legal entities. Two reporting
units were identified in the segment North America (Renal
Therapy Group and Fresenius Medical Services). The segment
International is divided into two reporting units (Europe and
Latin America), while only one reporting unit exists in the
segment Asia Pacific.
In a first step, the Company compares the fair value of a
reporting unit to its carrying amount. Fair value is determined
using estimated future cash flows for the unit discounted by an
after-tax weighted average cost of capital (WACC)
specific to that reporting unit. Estimating the discounted
future cash flows involves significant assumptions, especially
regarding future reimbursement rates and sales prices, number of
treatments, sales volumes and costs. In determining discounted
cash flows, the Company utilizes for every reporting unit, its
three-year budget, projections for years 4 to 10 and a
corresponding growth rate for all remaining years. Projections
for up to ten years are possible due to the stability of the
Companys business which, due to the non-discretionary
nature of the healthcare services we provide, the need for
products utilized to provide such services and the availability
of government reimbursement for a substantial portion of our
services, has been largely independent of the economic cycle.
The reporting units respective expected growth rates for
the period beyond ten years are: Renal Therapy Group 1%,
Fresenius Medical Services 1%, Europe 0%, Latin America 4%, and
Asia Pacific 4%. The discount factor is determined by the WACC
of the respective reporting unit. The Companys WACC
consists of a basic rate of 6.38% for 2010. The basic rate is
then adjusted by a country-specific risk rate within each
reporting unit. In 2010, WACCs for the reporting units ranged
from 6.38% to 13.56%.
In the case that the fair value of the reporting unit is less
than its book value, a second step is performed which compares
the fair value of the reporting units goodwill to the
carrying value of its goodwill. If the fair value of the
goodwill is less than the book value, the difference is recorded
as an impairment.
To evaluate the recoverability of intangible assets with
indefinite useful lives, the Company compares the fair values of
intangible assets with their carrying values. An intangible
assets fair value is determined using a discounted cash
flow approach or other methods, if appropriate.
g) Derivative
Financial Instruments
Derivative financial instruments which primarily include foreign
currency forward contracts and interest rate swaps are
recognized as assets or liabilities at fair value in the balance
sheet (see Note 19). Changes in the fair value of
derivative financial instruments classified as fair value hedges
and in the corresponding underlyings are recognized periodically
in earnings. The effective portion of changes in fair value of
cash flow hedges is recognized
F-12
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
in accumulated other comprehensive income (loss) in
shareholders equity. The ineffective portion of cash flow
hedges is recognized in current net earnings. The change in fair
value of derivatives that do not qualify for hedge accounting
are recorded in the income statement and usually offset the
changes in value recorded in the income statement for the
underlying asset or liability.
h) Foreign
Currency Translation
For purposes of these consolidated financial statements, the
U.S. dollar is the reporting currency. Substantially all
assets and liabilities of the parent company and all
non-U.S. subsidiaries
are translated at year-end exchange rates, while revenues and
expenses are translated at average exchange rates. Adjustments
for foreign currency translation fluctuations are excluded from
net earnings and are reported in accumulated other comprehensive
income (loss). In addition, the translation adjustments of
certain intercompany borrowings, which are considered foreign
equity investments, are reported in accumulated other
comprehensive income (loss).
i) Revenue
Recognition Policy
Dialysis care revenues are recognized on the date services and
related products are provided and the payor is obligated to pay
at amounts estimated to be received under reimbursement
arrangements with third party payors. Medicare and Medicaid in
North America and programs involving other government payors in
the International Segment are billed at pre-determined rates per
treatment that are established by statute or regulation. Most
non-governmental payors are billed at our standard rates for
services net of contractual allowances to reflect the estimated
amounts to be received under reimbursement arrangements with
these payors.
Dialysis product revenues are recognized when title to the
product passes to the customers either at the time of shipment,
upon receipt by the customer or upon any other terms that
clearly define passage of title. As product returns are not
typical, no return allowances are established. In the event a
return is required, the appropriate reductions to sales,
accounts receivables and cost of sales are made. Sales are
stated net of discounts and rebates.
A minor portion of International Segment product revenues is
generated from arrangements which give the customer, typically a
health care provider, the right to use dialysis machines. In the
same contract the customer agrees to purchase the related
treatment disposables at a price marked up from the standard
price list. In this type of contract, FMC-AG & Co.
KGaA does not recognize revenue upon delivery of the dialysis
machine but recognizes revenue on the sale of disposables. In
certain other contracts of this type, the contract is structured
as a sales type lease whereby ownership of the dialysis machine
is transferred to the user upon installation of the dialysis
machine at the customer site. In this type of contract, revenue
is recognized in accordance with the accounting principles for
sales type leases.
Any tax assessed by a governmental authority that is incurred as
a result of a revenue transaction (e.g. sales tax) is excluded
from revenues and the related revenue is reported on a net basis.
j) Research
and Development expenses
Research and development expenses are expensed as incurred.
k) Income
Taxes
The Company recognizes deferred tax assets and liabilities for
future consequences attributable to temporary differences
between the financial statement carrying amounts of existing
assets and liabilities and their respective tax basis as well as
on consolidation procedures affecting net income and tax loss
carryforwards which are more likely than not to be utilized.
Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered
or settled. The recognition of deferred tax assets from net
operating losses and their utilization is based on the budget
planning of the Company and implemented tax strategies. A
valuation allowance is recorded to reduce the carrying amount of
the deferred tax assets unless it is more likely than not that
such assets will be realized (see Note 16).
It is the Companys policy to recognize interest and
penalties related to its tax positions as income tax expense.
F-13
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
l) Impairment
The Company reviews the carrying value of its long-lived assets
or asset groups with definite useful lives to be held and used
for impairment whenever events or changes in circumstances
indicate that the carrying value of these assets may not be
recoverable. Recoverability of these assets is measured by a
comparison of the carrying value of an asset to the future net
cash flows directly associated with the asset. If assets are
considered to be impaired, the impairment recognized is the
amount by which the carrying value exceeds the fair value of the
asset. The Company uses a discounted cash flow approach or other
methods, if appropriate, to assess fair value.
Long-lived assets to be disposed of by sale are reported at the
lower of carrying value or fair value less cost to sell and
depreciation is ceased. Long-lived assets to be disposed of
other than by sale are considered to be held and used until
disposal.
For the Companys policy related to goodwill impairment,
see 1f) above.
m) Debt
Issuance Costs
Costs related to the issuance of debt are amortized over the
term of the related obligation (see Note 9).
n) Self-Insurance
Programs
Under the insurance programs for professional, product and
general liability, auto liability and workers compensation
claims, the Companys largest subsidiary is partially
self-insured for professional liability claims. For all other
coverages, the Company assumes responsibility for incurred
claims up to predetermined amounts above which third party
insurance applies. Reported liabilities for the year represent
estimated future payments of the anticipated expense for claims
incurred (both reported and incurred but not reported) based on
historical experience and existing claim activity. This
experience includes both the rate of claims incidence (number)
and claim severity (cost) and is combined with individual claim
expectations to estimate the reported amounts.
o) Use
of Estimates
The preparation of consolidated financial statements in
conformity with U.S. GAAP requires management to make
estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and
liabilities at the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those
estimates.
p) Concentration
of Risk
The Company is engaged in the manufacture and sale of products
for all forms of kidney dialysis, principally to health care
providers throughout the world, and in providing kidney dialysis
treatment, clinical laboratory testing, and other medical
ancillary services. The Company performs ongoing evaluations of
its customers financial condition and, generally, requires
no collateral.
Approximately 32%, 33% and 35% of the Companys worldwide
revenues were earned and subject to regulations under Medicare
and Medicaid, governmental health care programs administered by
the United States government in 2010, 2009, and 2008,
respectively.
See Note 4 for concentration of supplier risks.
q) Legal
Contingencies
From time to time, during the ordinary course of the
Companys operations, the Company is party to litigation
and arbitration and is subject to investigations relating to
various aspects of its business (see Note 18). The Company
regularly analyzes current information about such claims for
probable losses and provides accruals for such matters,
including the estimated legal expenses and consulting services
in connection with these matters, as appropriate. The Company
utilizes its internal legal department as well as external
resources for these assessments. In making the decision
regarding the need for loss accrual, the Company considers the
degree of probability of an unfavorable outcome and its ability
to make a reasonable estimate of the amount of loss.
F-14
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
The filing of a suit or formal assertion of a claim or
assessment, or the disclosure of any such suit or assertion,
does not necessarily indicate that accrual of a loss is
appropriate.
r) Earnings
per Ordinary share and Preference share
Basic earnings per ordinary share and basic earnings per
preference share for all years presented have been calculated
using the two-class method based upon the weighted average
number of ordinary and preference shares outstanding. Basic
earnings per share is computed by dividing net income less
preference amounts by the weighted average number of ordinary
shares and preference shares outstanding during the year. Basic
earnings per preference share is derived by adding the
preference per preference share to the basic earnings per share.
Diluted earnings per share include the effect of all potentially
dilutive instruments on ordinary shares and preference shares
that would have been outstanding during the year.
The awards granted under the Companys stock incentive
plans (see Note 15), are potentially dilutive equity
instruments.
s) Employee
Benefit Plans
The Company recognizes the underfunded status of its defined
benefit plans, measured as the difference between plan assets at
fair value and the benefit obligation, as a liability. Changes
in the funded status of a plan, net of tax, resulting from
actuarial gains or losses and prior service costs or credits
that are not recognized as components of the net periodic
benefit cost will be recognized through accumulated other
comprehensive income in the year in which they occur. Actuarial
gains or losses and prior service costs are subsequently
recognized as components of net periodic benefit cost when
realized. The Company uses December 31 as the measurement date
when measuring the funded status of all plans.
t) Recent
Pronouncements
Recently
Implemented Accounting Statements
In July 2010, the Financial Accounting Standards Board
(FASB) issued
Accounting Standards Update
2010-20
(ASU
2010-20),
Disclosures about the Credit Quality of Financing Receivables
and the Allowance for Credit Losses
. ASU
2010-20
is
an update of Accounting Standards Codification Topic 310,
Receivables.
This update requires enhanced disclosures on
a disaggregated basis about:
|
|
|
|
|
The nature of the credit risk inherent in the portfolio of
financing receivables,
|
|
|
|
How that risk is analyzed and assessed in arriving at the
allowance for credit losses and
|
|
|
|
The changes and reasons for those changes in the allowance for
credit losses.
|
The disclosures required under ASU
2010-20
as
of the end of a reporting period are effective for interim and
annual reporting periods ending on or after December 15,
2010. Disclosures about activity that occurs during a reporting
period are effective for interim and annual reporting periods
beginning on or after December 15, 2010. The Company
adopted the provisions of ASU
2010-20
as
of December 31, 2010.
In June 2009, the FASB issued
Accounting Standards Update
2009-17
(ASU
2009-17)
(originally issued as FASB Statement No. 167),
ASC 810,
Consolidations- Improvements to Financial
Reporting by Enterprises Involved with Variable Interest
Entities
. ASU
2009-17
requires reporting entities to evaluate former Qualifying
Special Purpose Entities (QSPE) for consolidation
and changes the approach to determining a VIEs primary
beneficiary from a quantitative assessment to a qualitative
assessment designed to identify a controlling financial
interest. In addition, ASU
2009-17
increases the frequency of required reassessments to determine
whether a company is the primary beneficiary of a VIE. It also
clarifies, but does not significantly change, the
characteristics that identify a VIE. ASU
2009-17
also
requires additional year-end and interim disclosures about risks
related to continuing involvement in transferred financial
assets.
The amendments contained in ASU
2009-17
are
effective as of the beginning of a companys first fiscal
year that begins after November 15, 2009 and for subsequent
interim and annual reporting periods. All former QSPEs and other
variable interest entities needed to be reevaluated under the
amended consolidation requirements as of the
F-15
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
beginning of the first annual reporting period that began after
November 15, 2009. Early adoption was prohibited. The
Company implemented the amendments prescribed by ASU
2009-17
as
of January 1, 2010.
In June 2009, the FASB issued
Accounting Standards Update
2009-16
(ASU
2009-16)
(originally issued as FASB Statement No. 166),
ASC 860,
Transfers and Servicing Accounting
for Transfers of Financial Assets
. ASU
2009-16
eliminates the QSPE concept, creates more stringent conditions
for reporting a transfer of a portion of a financial asset as a
sale, clarifies the derecognition criteria, revises how retained
interests are initially measured, and removes the guaranteed
mortgage securitization recharacterization provisions. ASU
2009-16
also
requires additional year-end and interim disclosures about risks
related to variable interest entities.
ASU
2009-16
is effective as of the beginning of a companys first
fiscal year that begins after November 15, 2009, and for
subsequent interim and annual reporting periods. ASU
2009-16s
disclosure requirements must be applied to transfers that
occurred before and after its effective date. Early adoption is
prohibited. The Company adopted provisions of ASU
2009-16
as
of January 1, 2010.
On February 3, 2011, Fresenius Medical Care US Finance,
Inc. (US Finance), a wholly-owned subsidiary of the
Company, issued $650,000 aggregate principal amount of senior
unsecured notes with a coupon of 5.75% (the
5.75% Senior Notes) at an issue price of
99.060% and FMC Finance VII S.A. (Finance VII), a
wholly-owned subsidiary of the Company, issued 300,000
aggregate principal amount ($412,350 at date of issuance) of
senior unsecured notes with a coupon 5.25% (the
5.25% Senior Notes) at par. The
5.75% Senior Notes have a yield to maturity of 5.875% and
are due February 15, 2021. The 5.25% Senior Notes are
due February 15, 2021. US Finance and Finance VII may
redeem the 5.75% Senior Notes and 5.25% Senior Notes,
respectively, at any time at 100% of principal plus accrued
interest and a premium calculated pursuant to the terms of the
applicable indenture. The holders of the 5.75% Senior Notes
and the 5.25% Senior Notes have a right to request that the
respective issuers of the notes repurchase the applicable issue
of notes at 101% of principal plus accrued interest upon the
occurrence of a change of control of the Company followed by a
decline in the rating of the respective notes. The Company used
or will use the net proceeds of approximately $1,035,000 to
repay indebtedness outstanding under its A/R Facility and the
revolving credit facility of the Amended 2006 Senior Credit
Agreement, for acquisitions, including payments under our recent
acquisition of International Dialysis Centers announced on
January 4, 2011 (see below), and for general corporate
purposes to support our renal dialysis products and services
business. The 5.75% Senior Notes and the 5.25% Senior
Notes are guaranteed on a senior basis jointly and severally by
the Company, Fresenius Medical Care Holdings, Inc. and Fresenius
Medical Care Deutschland GmbH.
On January 4, 2011, the Company announced the signing of a
purchase agreement to acquire International Dialysis Centers
(IDC), Euromedic Internationals
(Euromedic) dialysis service business for
485,000 (approximately $650,000 as of January 4,
2011). IDC currently treats over 8,200 hemodialysis patients
predominantly in Central and Eastern Europe and operates a total
of 70 clinics in nine countries. Closing is subject to necessary
regulatory approvals by the relevant anti-trust authorities and
is expected to occur in the first half of 2011.
|
|
3.
|
Related
Party Transactions
|
a) Service
and Lease Agreements
The Companys parent, Fresenius SE & Co. KGaA, is
a German partnership limited by shares resulting from the change
of legal form effective January 28, 2011, from Fresenius
SE, a European Company (Societas Europaea), and which, prior to
July 13, 2007, was called Fresenius AG, a German stock
corporation. In these Consolidated Financial Statements,
Fresenius SE refers to that company as a partnership limited by
shares, effective on and after January 28, 2011, as well as
both before and after the conversion of Fresenius AG from a
stock corporation into a European Company. Fresenius SE owns
100% of the share capital of Fresenius Medical Care Management
AG (Management AG), the Companys general
partner and is the Companys largest shareholder owning
approximately 35.7% of the Companys voting shares as of
December 31, 2010.
The Company is party to service agreements with Fresenius
SE & Co. KGaA and certain of its affiliates
(collectively the Fresenius SE Companies) to receive
services, including, but not limited to: administrative
services, management information services, employee benefit
administration, insurance, IT services, tax services
F-16
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
and treasury management services. During 2010, 2009 and 2008,
amounts charged by Fresenius SE to the Company under the terms
of these agreements were $59,501, $68,234 and $59,038,
respectively. The Company also provides certain services to the
Fresenius SE Companies, including research and development,
central purchasing and warehousing. The Company charged $6,115,
$13,540 and $9,798 for services rendered to the Fresenius SE
Companies during year of 2010, 2009 and 2008, respectively.
Under operating lease agreements for real estate entered into
with the Fresenius SE Companies, which are leases for the
corporate headquarters in Bad Homburg, Germany and production
sites in Schweinfurt and St. Wendel, Germany, the Company paid
the Fresenius SE Companies $23,807, $23,109 and $23,485 during
2010, 2009 and 2008, respectively. The majority of the leases
expire in 2016 and contain renewal options.
The Companys Articles of Association provide that the
General Partner shall be reimbursed for any and all expenses in
connection with management of the Companys business,
including remuneration of the members of the General
Partners supervisory board and the General Partners
management board. The aggregate amount reimbursed to the General
Partner for 2010, 2009 and 2008 was $16,123, $7,783 and $9,230,
respectively, for its management services during the years and
included $80, $84 and $88 as compensation for their exposure to
risk as General Partner for 2010, 2009, and 2008, respectively.
The Companys Articles of Association set the annual
compensation for assuming unlimited liability at 4% of the
amount of the General Partners invested capital
(1,500).
b) Products
For 2010, 2009 and 2008, the Company sold products to the
Fresenius SE Companies for $15,413, $13,601 and $36,704,
respectively. During 2010, 2009 and 2008, the Company made
purchases from the Fresenius SE Companies in the amount of
$43,474, $43,320 and $45,084, respectively.
In addition to the purchases noted above, the Company currently
purchases heparin supplied by APP Pharmaceuticals Inc.
(APP Inc.), through an independent group purchasing
organization (GPO). In September 2008, Fresenius
Kabi AG, a wholly-owned subsidiary of Fresenius SE, acquired
100% of APP Inc. The Company has no direct supply agreement with
APP Inc. and does not submit purchase orders directly to APP
Inc. During 2010, 2009 and 2008, Fresenius Medical Care
Holdings, Inc. (FMCH) acquired approximately
$30,703, $31,300 and $19,564, respectively, of heparin from APP
Inc. through the GPO contract, which was negotiated by the GPO
at arms length on behalf of all members of the GPO.
c) Financing
Provided by and to Fresenius SE and the General
Partner
Throughout 2010, the Company, under its cash pooling agreement,
made cash advances to Fresenius SE. The balance outstanding at
December 31, 2010 of 24,600 ($32,871 as of
December 31, 2010) was fully repaid on January 3,
2011 at an interest rate of 1.942%.
On August 19, 2009, the Company borrowed 1,500
($2,004 as of December 31, 2010) from the General
Partner at 1.335%. The loan repayment, originally due on
August 19, 2010, was extended until August 19, 2011.
During the second quarter of 2009, the Company reclassified an
account payable to Fresenius SE in the amount of 77,745
($109,885 at June 30, 2009) from accounts payable to
related parties to short-term borrowings from related parties.
The amount represents taxes payable by the Company arising from
the period
1997-2001
during which German trade taxes were paid by Fresenius SE on
behalf of the Company. Of this amount, 5,747 ($7,679 at
December 31, 2010) was outstanding at
December 31, 2010 at an interest rate of 6% and will be
repaid in 2011.
The Company is party to an Amended and Restated Subordinated
Loan Note with Fresenius SE under which the Company or its
subsidiaries may request and receive one or more advances up to
an aggregate amount of $400,000 during the period ending
March 31, 2013. See Note 8. During 2010, we received
advances between 10,000 and 86,547 which carried
interest at rates between 0.968% and 1.879% per annum. On
December 31, 2010, the Company had no advances outstanding
due to Fresenius SE.
d) Other
During the third quarter of 2009, the Company acquired
production lines from the Fresenius SE Companies for a purchase
price of $3,416, net or value added tax (VAT).
F-17
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
The Chairman of the Companys Supervisory Board is also the
Chairman of the Supervisory Board of Fresenius SE. He is also a
member of the Supervisory Board of the Companys General
Partner.
The Vice Chairman of the Companys Supervisory Board is a
member of the Supervisory Board of the general partner of
Fresenius SE and Vice Chairman of the Supervisory Board of the
Companys General Partner. He is also a partner in a law
firm which provided services to the Company and certain of its
subsidiaries. The Company and certain of its subsidiaries paid
the law firm approximately $1,601, $1,445 and $1,098 in 2010,
2009, and 2008, respectively. Five of the six members of the
Companys Supervisory Board, including the Chairman and
Vice Chairman, are also members of the Supervisory Board of the
Companys General Partner.
As of December 31, 2010 and 2009, inventories consisted of
the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
|
|
|
Raw materials and purchased components
|
|
$
|
158,163
|
|
|
$
|
154,599
|
|
|
|
|
|
Work in process
|
|
|
56,345
|
|
|
|
63,683
|
|
|
|
|
|
Finished goods
|
|
|
475,641
|
|
|
|
481,047
|
|
|
|
|
|
Health care supplies
|
|
|
118,948
|
|
|
|
122,325
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inventories
|
|
$
|
809,097
|
|
|
$
|
821,654
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Under the terms of certain unconditional purchase agreements,
the Company is obligated to purchase approximately $2,164,532 of
materials, of which $374,083 is committed at December 31,
2010 for 2011. The terms of these agreements run 1 to
8 years. At December 31, 2009, the Company was
obligated to purchase approximately $2,414,214 of materials, of
which $407,889 was committed at that date for 2010. At
December 31, 2008, the Company was obligated to purchase
approximately $2,556,603 of materials, of which $385,283 was
committed as of that date for 2009. The Company has a contingent
liability of up to $60,400, subject to renegotiation of certain
supply contracts.
Inventories as of December 31, 2010 and 2009 include
$32,987 and $34,788, respectively, of Erythropoietin
(EPO), which is supplied by a single source supplier
in the United States. In October 2006, the Company entered into
a five-year exclusive sourcing and supply agreement with its EPO
supplier. Revenues from administration of EPO accounted for
approximately 19%, 21% and 20% of total dialysis care revenue in
the North America segment for 2010, 2009 and 2008, respectively.
Delays, stoppages, or interruptions in the supply of EPO could
adversely affect the operating results of the Company.
|
|
5.
|
Property,
Plant and Equipment
|
As of December 31, 2010 and 2009, property, plant and
equipment consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
Land and improvements
|
|
$
|
50,505
|
|
|
$
|
44,837
|
|
Buildings and improvements
|
|
|
1,856,968
|
|
|
|
1,727,681
|
|
Machinery and equipment
|
|
|
2,893,643
|
|
|
|
2,630,925
|
|
Machinery, equipment and rental equipment under capitalized
leases
|
|
|
28,406
|
|
|
|
29,557
|
|
Construction in progress
|
|
|
238,812
|
|
|
|
259,711
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,068,334
|
|
|
|
4,692,711
|
|
Accumulated depreciation
|
|
|
(2,541,042
|
)
|
|
|
(2,273,141
|
)
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
$
|
2,527,292
|
|
|
$
|
2,419,570
|
|
|
|
|
|
|
|
|
|
|
Depreciation expense for property, plant and equipment amounted
to $432,930, $396,860 and $368,300 for the years ended
December 31, 2010, 2009, and 2008, respectively.
Included in property, plant and equipment as of
December 31, 2010 and 2009 were $416,392 and $364,118,
respectively, of peritoneal dialysis cycler machines which the
Company leases to customers with end-stage renal
F-18
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
disease on a
month-to-month
basis and hemodialysis machines which the Company leases to
physicians under operating leases.
Accumulated depreciation related to machinery, equipment and
rental equipment under capital leases was $14,966 and $14,010 at
December 31, 2010 and 2009, respectively.
|
|
6.
|
Intangible
Assets and Goodwill
|
As of December 31, 2010 and 2009, the carrying value and
accumulated amortization of intangible assets other than
goodwill consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
|
Gross
|
|
|
|
|
|
Gross
|
|
|
|
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
|
Amount
|
|
|
Amortization
|
|
|
Amount
|
|
|
Amortization
|
|
|
Amortizable Intangible Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-compete Agreements
|
|
$
|
243,575
|
|
|
$
|
(167,801
|
)
|
|
$
|
224,579
|
|
|
$
|
(157,717
|
)
|
Technology
|
|
|
110,850
|
|
|
|
(25,346
|
)
|
|
|
100,016
|
|
|
|
(18,109
|
)
|
License and distribution agreements
|
|
|
233,460
|
|
|
|
(70,189
|
)
|
|
|
184,219
|
|
|
|
(59,677
|
)
|
Self-developed Software
|
|
|
46,955
|
|
|
|
(21,861
|
)
|
|
|
31,230
|
|
|
|
(9,405
|
)
|
Other
|
|
|
286,021
|
|
|
|
(214,382
|
)
|
|
|
277,468
|
|
|
|
(210,484
|
)
|
Construction in progress
|
|
|
55,781
|
|
|
|
|
|
|
|
67,113
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
976,642
|
|
|
$
|
(499,579
|
)
|
|
$
|
884,625
|
|
|
$
|
(455,392
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2010 and 2009 the carrying value of
non-amortizable
intangible assets other than goodwill consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
|
Carrying Amount
|
|
|
Carrying Amount
|
|
|
Non-amortizable
Intangible Assets
|
|
|
|
|
|
|
|
|
Tradename
|
|
$
|
210,424
|
|
|
$
|
210,348
|
|
Management contracts
|
|
|
5,057
|
|
|
|
219,614
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
215,481
|
|
|
$
|
429,962
|
|
|
|
|
|
|
|
|
|
|
Total Intangible Assets
|
|
$
|
692,544
|
|
|
$
|
859,195
|
|
|
|
|
|
|
|
|
|
|
The tables below show the amortization expense related to the
amortizable intangible assets for the years presented and the
estimated amortization expense of these assets for the following
five years.
|
|
|
|
|
Amortization Expense
|
|
|
|
2008
|
|
$
|
47,384
|
|
2009
|
|
$
|
60,225
|
|
2010
|
|
$
|
70,294
|
|
|
|
|
|
|
Estimated Amortization
Expense
|
|
|
|
2011
|
|
$
|
67,585
|
|
2012
|
|
$
|
61,644
|
|
2013
|
|
$
|
58,389
|
|
2014
|
|
$
|
57,353
|
|
2015
|
|
$
|
53,260
|
|
Goodwill
A change in New York state regulations allowed for the direct
ownership of facilities in that state, which had previously been
prohibited by state law. Due to this prohibition, the Company
had historically used a combination of administrative service
contracts, stock option agreements, and asset acquisitions to
qualify for consolidation of such
F-19
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
facilities under guidance originally issued as Emerging Issues
Task Force
97-2,
Application of FASB Statement No. 94 and APB Opinion
No. 16 to Physicians Practice Management Entities and
Certain Other Entities with Contractual Management Arrangements
which is now included within FASB Accounting Standards
Codification Topic
810-10,
Consolidation: Overall
. In such qualifying transactions,
a portion of the purchase price was allocated to identifiable
intangible assets with the remainder classified as an
Administrative Services Agreement intangible asset
that was accounted for in the same manner as goodwill and was
shown on our Balance Sheet at December 31, 2009, under the
category Management Contracts within Intangible Assets. With the
regulatory approval gained on April 1, 2010, the Company
obtained the full ownership of these facilities and reclassified
the $214,706 of Administrative Services Agreement intangible
asset to goodwill within our North America segment, effective
April 1, 2010, to be consistent with other clinic
acquisitions where the Company obtained control via legal
ownership.
Other than the above, changes in the carrying amount of goodwill
are mainly a result of acquisitions and the impact of foreign
currency translations. During 2010 and 2009, the Companys
acquisitions consisted primarily of clinics in the normal course
of operations and the acquisition of Gambros worldwide
peritoneal dialysis business. The segment detail is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North
|
|
|
|
|
|
|
|
|
|
|
|
|
America
|
|
|
International
|
|
|
Corporate
|
|
|
Total
|
|
|
Balance as of January 1, 2009
|
|
$
|
6,571,411
|
|
|
$
|
578,682
|
|
|
$
|
159,817
|
|
|
$
|
7,309,910
|
|
Goodwill acquired
|
|
|
123,303
|
|
|
|
52,011
|
|
|
|
|
|
|
|
175,314
|
|
Reclassifications
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign Currency Translation Adjustment
|
|
|
(3
|
)
|
|
|
26,213
|
|
|
|
|
|
|
|
26,210
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2009
|
|
$
|
6,694,711
|
|
|
$
|
656,906
|
|
|
$
|
159,817
|
|
|
$
|
7,511,434
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill acquired
|
|
|
115,040
|
|
|
|
314,338
|
|
|
|
132
|
|
|
|
429,510
|
|
Reclassifications
|
|
|
214,706
|
|
|
|
|
|
|
|
|
|
|
|
214,706
|
|
Foreign Currency Translation Adjustment
|
|
|
288
|
|
|
|
(15,470
|
)
|
|
|
|
|
|
|
(15,182
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2010
|
|
$
|
7,024,745
|
|
|
$
|
955,774
|
|
|
$
|
159,949
|
|
|
$
|
8,140,468
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7.
|
Accrued
Expenses and Other Current Liabilities
|
At December 31, 2010 and 2009, accrued expenses and other
current liabilities consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
Accrued salaries, wages and incentive plan compensations
|
|
$
|
389,434
|
|
|
$
|
334,227
|
|
Unapplied cash and receivable credits
|
|
|
169,657
|
|
|
|
192,626
|
|
Accrued insurance
|
|
|
163,240
|
|
|
|
169,866
|
|
Derivative financial instruments
|
|
|
124,171
|
|
|
|
15,773
|
|
Special charge for legal matters
|
|
|
115,000
|
|
|
|
115,000
|
|
Other
|
|
|
575,921
|
|
|
|
508,061
|
|
|
|
|
|
|
|
|
|
|
Total accrued expenses and other current liabilities
|
|
$
|
1,537,423
|
|
|
$
|
1,335,553
|
|
|
|
|
|
|
|
|
|
|
In 2001, the Company recorded a $258,159 special charge to
address legal matters relating to transactions pursuant to the
Agreement and Plan of Reorganization dated as of
February 4, 1996 by and between W.R. Grace & Co.
and Fresenius SE (the Merger), estimated liabilities
and legal expenses arising in connection with the W.R.
Grace & Co. Chapter 11 proceedings (the
Grace Chapter 11 Proceedings) and the cost of
resolving pending litigation and other disputes with certain
commercial insurers. During the second quarter of 2003, the
court supervising the Grace Chapter 11 Proceedings approved
a definitive settlement agreement entered into among the
Company, the committees representing the asbestos creditors and
W.R. Grace & Co. Under the settlement agreement, the
Company will pay $115,000, without interest, upon plan
confirmation (see Note 18). With the exception of the
proposed $115,000 payment under the Settlement Agreement, all
other matters included in the special charge have been resolved.
F-20
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
The other item in the table above includes accruals for
operating expenses, interest, withholding tax, value added tax,
legal and compliance costs, physician compensation, commissions,
short-term portion of pension liabilities, bonuses and rebates,
and accrued rents.
|
|
8.
|
Short-Term
Borrowings and Other Financial Liabilities, and Short-Term
Borrowings from Related Parties
|
As of December 31, 2010 and 2009, short-term borrowings,
other financial liabilities and short-term borrowings from
related parties consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
Borrowings under lines of credit
|
|
$
|
131,791
|
|
|
$
|
95,720
|
|
Accounts receivable facility
|
|
|
510,000
|
|
|
|
214,000
|
|
Other financial liabilities
|
|
|
28,880
|
|
|
|
6,624
|
|
|
|
|
|
|
|
|
|
|
Short-term borrowings and other financial liabilities
|
|
|
670,671
|
|
|
|
316,344
|
|
Short-term borrowings from related parties (See Note 2.c.)
|
|
|
9,683
|
|
|
|
10,440
|
|
|
|
|
|
|
|
|
|
|
Short-term borrowings, Other financial liabilities and
Short-term borrowings from related parties
|
|
$
|
680,354
|
|
|
$
|
326,784
|
|
|
|
|
|
|
|
|
|
|
Short-term
Borrowings and Other Financial Liabilities
Lines of
Credit
Short-term borrowings of $131,791 and $95,720 at
December 31, 2010 and 2009, respectively, represented
amounts borrowed by the Company and certain of its subsidiaries
under lines of credit with commercial banks. The average
interest rates on these borrowings at December 31, 2010 and
2009 were 4.19% and 2.94%, respectively.
Excluding amounts available under the Amended 2006 Senior Credit
Agreement (see Note 9 below), at December 31, 2010 and
2009, the Company had $234,370 and $208,952 available under
other commercial bank agreements. In some instances, lines of
credit are secured by assets of the Companys subsidiary
that is party to the agreement or may require the Companys
guarantee. In certain circumstances, the subsidiary may be
required to meet certain covenants.
Accounts
Receivable Facility
The Company has an asset securitization facility (the A/R
Facility) which is typically renewed in October of each
year and was most recently renewed and increased from $650,000
to $700,000 on September 28, 2010. Under the A/R Facility,
certain receivables are sold to NMC Funding Corporation
(NMC Funding), a wholly-owned subsidiary. NMC
Funding then assigns percentage ownership interests in the
accounts receivable to certain bank investors. Under the terms
of the A/R Facility, NMC Funding retains the right, at any time,
to recall all the then outstanding transferred interests in the
accounts receivable. Consequently, the receivables remain on the
Companys Consolidated Balance Sheet and the proceeds from
the transfer of percentage ownership interests are recorded as
short-term borrowings.
At December 31, 2010 there are outstanding short-term
borrowings under the A/R Facility of $510,000. NMC Funding pays
interest to the bank investors calculated based on the
commercial paper rates for the particular tranches selected. The
average interest rate during 2010 was 1.86%. Annual refinancing
fees, which include legal costs and bank fees, are amortized
over the term of the facility.
Other
Financial Liabilities
At December 31, 2010 and 2009, the Company had $28,880 and
$6,624 of other financial liabilities which were mainly related
to the Companys purchase of noncontrolling interests and
to the signing of licensing and distribution agreements for
Venofer
®
(See Note 9 Other below).
F-21
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
Short-term
Borrowings from related parties
From time to time during each of the years presented, the
Company received advances under the existing loan agreements
with Fresenius SE for those years. During the year ended
December 31, 2010, the Company received advances ranging
from 10,000 to 86,547 with interest rates ranging
from 0.968% to 1.879%. During the year ended December 31,
2009, the Company received advances ranging from 1,300 to
72,000 with interest rates ranging from 1.05% to 2.05%. On
December 31, 2010 and 2009, the Company had advances
outstanding with Fresenius SE in the amount of $7,679
(5,747) and $8,279 (5,747) with an interest rate of
6%. Furthermore, the Company had advances outstanding with the
Companys general partner in the amount of $2,004
(1,500) and $2,161 (1,500) with an interest rate of
1.421% and 1.335% on December 31, 2010 and 2009,
respectively. Annual interest expense on the borrowings during
the years presented was $179, $188 and $3,388 for the years
2010, 2009 and 2008, respectively.
|
|
9.
|
Long-term
Debt and Capital Lease Obligations
|
As of December 31, 2010 and 2009, long-term debt and
capital lease obligations consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
Amended 2006 Senior Credit Agreement
|
|
$
|
2,953,890
|
|
|
$
|
3,522,040
|
|
Senior Notes
|
|
|
824,446
|
|
|
|
493,344
|
|
Euro Notes
|
|
|
267,240
|
|
|
|
288,120
|
|
EIB Agreements
|
|
|
351,686
|
|
|
|
213,460
|
|
Capital lease obligations
|
|
|
15,439
|
|
|
|
17,600
|
|
Other
|
|
|
160,957
|
|
|
|
50,991
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,573,658
|
|
|
|
4,585,555
|
|
Less current maturities
|
|
|
(263,982
|
)
|
|
|
(157,634
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
4,309,676
|
|
|
$
|
4,427,921
|
|
|
|
|
|
|
|
|
|
|
Senior
Debt
The Companys senior debt consists mainly of borrowings
related to its Amended 2006 Senior Credit Agreement, its Senior
Notes, its Euro Notes and borrowings under its European
Investment Bank Agreements as follows:
Amended
2006 Senior Credit Agreement
The Company, FMCH, and certain other subsidiaries of the Company
that are borrowers
and/or
guarantors thereunder, including Fresenius Medical Care
Deutschland GmbH (D-GmbH), entered into a $4,600,000
syndicated credit facility (the 2006 Senior Credit
Agreement) with Bank of America, N.A.; Deutsche Bank AG
New York Branch; The Bank of Nova Scotia, Credit Suisse, Cayman
Islands Branch; JPMorgan Chase Bank, National Association; and
certain other lenders (collectively, the Lenders) on
March 31, 2006 which replaced its prior credit agreement.
Since entering into the 2006 Senior Credit Agreement, the
Company arranged several amendments with the lenders and
effected voluntary prepayments of the term loans, which led to a
change in the total amount available under this facility.
Pursuant to an amendment together with an extension arranged on
September 29, 2010 the revolving facility was increased
from $1,000,000 to $1,200,000 and the Term Loan A facility by
$50,000 to $1,365,000. The maturity for both tranches was
extended from March 31, 2011 to March 31, 2013 (a
2 year extension). Additionally, the early repayment
requirement for the Term Loan B, which stipulated that Term Loan
B was subject to early retirement if the Trust Preferred
Securities due June 15, 2011 were not paid, refinanced or
extended prior to March 1, 2011, has been removed. The
definition of the Companys Consolidated Leverage Ratio,
which is used to determine the applicable margin, was amended to
allow for the reduction of up to $250,000 (increased from
$30,000) of cash and cash equivalents from Consolidated Funded
Debt, as defined in the initial 2006 Senior Credit Agreement. In
addition, the amendment includes increases in certain types of
permitted borrowings outside of the Amended 2006 Senior Credit
Agreement and provides further flexibility for certain types
F-22
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
of investments. Furthermore, the parties agreed to change the
limitation on dividends and other restricted payments for up to
$330,000 in 2011. Thereafter, these limitations increase by
$30,000 each year through 2013.
As of December 31, 2010, the Amended 2006 Senior Credit
Agreement consists of:
|
|
|
|
|
a $1,200,000 revolving credit facility (of which up to $400,000
is available for letters of credit, up to $400,000 is available
for borrowings in certain
non-U.S. currencies,
up to $150,000 is available as swing line loans in
U.S. dollars, up to $250,000 is available as a competitive
loan facility and up to $50,000 is available as swing line loans
in certain
non-U.S. currencies,
the total of which cannot exceed $1,200,000) which will be due
and payable on March 31, 2013.
|
|
|
|
a term loan facility (Term Loan A) of $1,335,000,
also scheduled to mature on March 31, 2013. Quarterly
repayments of $30,000 are required at the end of each quarter
with the remaining balance outstanding due on March 31,
2013.
|
|
|
|
a term loan facility (Term Loan B) of $1,537,764
scheduled to mature on March 31, 2013 with 5 quarterly
repayments of $4,036 followed by 4 quarterly repayments of
$379,396 each due at the end of its respective quarter.
|
Interest on these facilities will be, at the Companys
option, depending on the interest periods chosen, at a rate
equal to either (i) LIBOR plus an applicable margin or
(ii) the higher of (a) BofAs prime rate or
(b) the Federal Funds rate plus 0.5%, plus an applicable
margin.
The applicable margin is variable and depends on the
Companys Consolidated Leverage Ratio which is a ratio of
its Consolidated Funded Debt less up to $250,000 cash and cash
equivalents to Consolidated EBITDA (as these terms are defined
in the Amended 2006 Senior Credit Agreement).
In addition to scheduled principal payments, indebtedness
outstanding under the Amended 2006 Senior Credit Agreement will
be reduced by mandatory prepayments utilizing portions of the
net cash proceeds from certain sales of assets, securitization
transactions other than the Companys existing A/R
Facility, the issuance of subordinated debt other than certain
intercompany transactions, certain issuances of equity and
excess cash flow.
Obligations under the Amended 2006 Senior Credit Agreement are
secured by pledges of capital stock of certain material
subsidiaries in favor of the lenders. The Amended 2006 Senior
Credit Agreement contains affirmative and negative covenants
with respect to the Company and its subsidiaries and other
payment restrictions. Certain of the covenants limit
indebtedness of the Company and investments by the Company, and
require the Company to maintain certain financial ratios defined
in the agreement. Additionally, the Amended 2006 Senior Credit
Agreement provides for a limitation on dividends and other
restricted payments which is $330,000 for dividends in 2011, and
increases by $30,000 in each of the subsequent years. The
Company paid dividends of $231,967 in May of 2010 which was in
compliance with the restrictions set forth in the 2006 Senior
Credit Agreement. In default, the outstanding balance under the
Amended 2006 Senior Credit Agreement becomes immediately due and
payable at the option of the Lenders. As of December 31,
2010, the Company is in compliance with all covenants under the
Amended 2006 Senior Credit Agreement.
The Company incurred fees of approximately $85,828 in
conjunction with the 2006 Senior Credit Agreement and fees of
approximately $21,115 in conjunction with the Amended 2006
Senior Credit Agreement which are being amortized over the life
of this agreement.
The following table shows the available and outstanding amounts
under the Amended 2006 Senior Credit Agreement at
December 31, 2010 and 2009, respectively:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum Amount Available
|
|
|
Balance Outstanding
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
Revolving Credit
|
|
$
|
1,200,000
|
|
|
$
|
1,000,000
|
|
|
$
|
81,126
|
|
|
$
|
594,714
|
|
Term Loan A
|
|
|
1,335,000
|
|
|
|
1,373,418
|
|
|
|
1,335,000
|
|
|
|
1,373,418
|
|
Term Loan B
|
|
|
1,537,764
|
|
|
|
1,553,908
|
|
|
|
1,537,764
|
|
|
|
1,553,908
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
4,072,764
|
|
|
$
|
3,927,326
|
|
|
$
|
2,953,890
|
|
|
$
|
3,522,040
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-23
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
In addition, at December 31, 2010 and 2009, respectively,
$121,518 and $97,287 were utilized as letters of credit which
are not included as part of the balances outstanding at those
dates.
Senior
Notes
As of December 31, 2010, the Companys Senior Notes
consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notional
|
|
|
|
|
|
|
|
|
|
|
Issuer/Transaction
|
|
Amount
|
|
|
Maturity
|
|
|
Coupon
|
|
|
Book value
|
|
|
FMC Finance III S.A. 2007/2017
|
|
|
$500,000
|
|
|
|
July 15, 2017
|
|
|
|
6
7
/
8
|
%
|
|
$
|
494,231
|
|
FMC Finance VI S.A. 2010/2016
|
|
|
250,000
|
|
|
|
July 15, 2016
|
|
|
|
5.50
|
%
|
|
$
|
330,215
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
824,446
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In January 2010, 250,000 ($353,300 at date of issuance) of
senior notes was issued with a coupon of 5.50% at an issue price
of 98.6636%. These Senior Notes had a yield to maturity of 5.75%
and are due July 15, 2016. Proceeds were used to repay
short-term indebtedness and for general corporate purposes.
In July 2007, $500,000 of senior notes was issued with a coupon
of
6
7
/
8
%
at discount, resulting in an effective interest rate of
7
1
/
8
%.
All Senior Notes are unsecured and guaranteed on a senior basis
jointly and severally by the Company and its subsidiaries, FMCH
and D-GmbH. The issuers may redeem the Senior Notes at any time
at 100% of principal plus accrued interest and a premium
calculated pursuant to the terms of the indenture. The holders
have the right to request that the issuers repurchase the Senior
Notes at 101% of principal plus accrued interest upon the
occurrence of a change of control followed by a decline in the
credit agency ratings of the respective Senior Notes.
The Company has agreed to a number of covenants to provide
protection to the holders which, under certain circumstances,
limit the ability of the Company and its subsidiaries to, among
other things, incur debt, incur liens, engage in sale-leaseback
transactions and merge or consolidate with other companies or
sell assets. As of December 31, 2010, the Company was in
compliance with all of its covenants under the Senior Notes.
Euro
Notes
On April 27, 2009, the Company issued euro denominated
notes (Euro Notes) totaling 200,000 ($267,240
at December 31, 2010), which are senior, unsecured and
guaranteed by FMCH and D-GmbH, consisting of 4 tranches having
terms of 3.5 and 5.5 years with floating and fixed interest
rate tranches. Proceeds were used to retire the 2005 Euro Notes.
European
Investment Bank Agreements
The Company entered into various credit agreements with the
European Investment Bank (EIB) in 2005, 2006 and
2009. The EIB is a
not-for-profit
long-term lending institution of the European Union and lends
funds at favourable rates for the purpose of capital investment
and R&D projects, normally for up to half of the funds
required for such projects.
The borrowings under the four EIB credit facilities available at
December 31, 2010 and 2009 are shown below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum amount
|
|
|
|
|
|
|
|
|
|
available
|
|
|
Balance outstanding
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
Maturity
|
|
|
2010
|
|
|
2009
|
|
|
2010
|
|
|
2009
|
|
|
Revolving Credit
|
|
|
2013
|
|
|
|
90,000
|
|
|
|
90,000
|
|
|
$
|
115,812
|
|
|
$
|
35,000
|
|
Loan 2005
|
|
|
2013
|
|
|
|
41,000
|
|
|
|
41,000
|
|
|
|
48,806
|
|
|
|
48,806
|
|
Loan 2006
|
|
|
2014
|
|
|
|
90,000
|
|
|
|
90,000
|
|
|
|
120,258
|
|
|
|
129,654
|
|
Loan 2009
|
|
|
2014
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
66,810
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
271,000
|
|
|
|
271,000
|
|
|
$
|
351,686
|
|
|
$
|
213,460
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-24
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
The borrowings under the Revolving Credit and Loan 2005 are
denominated in U.S. dollars while the borrowings under Loan
2006 and Loan 2009 are denominated in euro.
In December 2009, the Company entered into a 50,000
term-loan agreement with the EIB. The disbursement took place on
February 17, 2010. The loan has a four-year term and is
guaranteed by FMCH and D-GmbH.
On March 15, 2010, the Company drew down the remaining
available balance of $80,812 on the 2005 Revolving Credit
Facility. Under the terms of the agreement, the Company could
effect borrowings under this facility only until March 15,
2010 and could drawdown only up to 90,000 in total, which
at the time of the initial borrowing equaled $115,800.
Loan 2006 was fully drawn down in February 2008 and Loan 2005
was fully drawn down in September 2005.
All agreements with the EIB have variable interest rates that
change quarterly. The Companys U.S. dollar borrowings
had an interest rate of 0.432% and 0.384%, and the euro
borrowings had interest rates of 1.018% and 3.257% at
December 31, 2010 and 0.695% at December 31, 2009.
All EIB facilities were fully utilized at December 31,
2010. Borrowings under the 2005 and 2006 agreements are secured
by bank guarantees while the 2009 agreement is guaranteed by
FMCH and D-GmbH. All EIB agreements have customary covenants. As
of December 31, 2010, the Company is in compliance with the
respective covenants.
Other
In conjunction with certain acquisitions and investments entered
into in 2010, including the joint venture with Galenica, Ltd.
(Galenica), the Company incurred debt totaling
approximately $139,277 of which $119,090 was classified as the
current portion of long-term debt at December 31, 2010. The
Galenica joint venture, announced in December 2010, is intended
to expand on our agreements with Galenica by forming a new renal
pharmaceutical company, Vifor Fresenius Medical Care Renal
Pharma Ltd., to develop and distribute products to treat iron
deficiency anemia and bone mineral metabolism for pre-dialysis
and dialysis patients. Galenica will contribute a licenses (or
the commercial benefit in the U.S.) to the new company for its
Venofer
®
and
Ferinject
®
products for use in the dialysis and pre-dialysis market
(Chronic Kidney Disease (CKD) stages III to V).
Commercialization of both of these products outside the field of
CKD stages III to V will remain fully the responsibility of
Galenica and its existing key partners. Galenica will also
contribute to the new company exclusive worldwide rights for
PA21, a novel iron-based phosphate binder currently in
preparation for phase III clinical studies, but will
maintain a recently announced agreement to develop and market
this product in Japan through another partner. Fresenius Medical
Care owns 45% of the new company which is headquartered in
Switzerland.
Annual
Payments
Aggregate annual payments applicable to the Amended 2006 Senior
Credit Agreement, Senior Notes, Euro Notes, EIB agreements,
capital leases and other borrowings (excluding the
Companys trust preferred securities, see
Note 11) for the five years subsequent to
December 31, 2010 are:
|
|
|
|
|
2011
|
|
$
|
263,982
|
|
2012
|
|
|
1,500,184
|
|
2013
|
|
|
1,734,568
|
|
2014
|
|
|
236,368
|
|
2015
|
|
|
1,631
|
|
Thereafter
|
|
|
846,528
|
|
|
|
|
|
|
|
|
$
|
4,583,261
|
|
|
|
|
|
|
|
|
10.
|
Employee
Benefit Plans
|
General
FMC-AG & Co. KGaA recognizes pension costs and related
pension liabilities for current and future benefits to qualified
current and former employees of the Company. The Companys
pension plans are structured differently
F-25
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
according to the legal, economic and fiscal circumstances in
each country. The Company currently has two types of plans,
defined benefit and defined contribution plans. In general, plan
benefits in defined benefit plans are based on all or a portion
of the employees years of services and final salary. Plan
benefits in defined contribution plans are determined by the
amount of contribution by the employee and the employer, both of
which may be limited by legislation, and the returns earned on
the investment of those contributions.
Upon retirement under defined benefit plans, the Company is
required to pay defined benefits to former employees when the
defined benefits become due. Defined benefit plans may be funded
or unfunded. The Company has two major defined benefit plans,
one funded plan in North America and an unfunded plan in Germany.
Actuarial assumptions generally determine benefit obligations
under defined benefit plans. The actuarial calculations require
the use of estimates. The main factors used in the actuarial
calculations affecting the level of the benefit obligations are:
assumptions on life expectancy, the discount rate and future
salary and benefit levels. Under the Companys funded
plans, assets are set aside to meet future payment obligations.
An estimated return on the plan assets is recognized as income
in the respective period. Actuarial gains and losses are
generated when there are variations in the actuarial assumptions
and differences between the actual and the estimated return on
plan assets for that year. The companys pension liability
is impacted by these actuarial gains or losses.
In the case of the Companys funded plan, the defined
benefit obligation is offset against the fair value of plan
assets. A pension liability is recognized in the balance sheet
if the defined benefit obligation exceeds the fair value of plan
assets. A pension asset is recognized (and reported under other
assets in the balance sheet) if the fair value of plan assets
exceeds the defined benefit obligation and if the Company has a
right of reimbursement against the fund or a right to reduce
future payments to the fund.
Under defined contribution plans, the Company pays defined
contributions during the employees service life which
satisfies all obligations of the Company to the employee. The
Company has a defined contribution plan in North America.
Defined
Benefit Pension Plans
During the first quarter of 2002, FMCH, the Companys North
America subsidiary, curtailed its defined benefit and
supplemental executive retirement plans. Under the curtailment
amendment for substantially all employees eligible to
participate in the plan, benefits have been frozen as of the
curtailment date and no additional defined benefits for future
services will be earned. The Company has retained all employee
benefit obligations as of the curtailment date. Each year FMCH
contributes at least the minimum amount required by the Employee
Retirement Income Security Act of 1974, as amended. There was no
minimum funding requirement for FMCH for the defined benefit
plan in 2010. FMCH voluntarily contributed $600 during 2010.
Expected funding for 2011 is $661.
The benefit obligation for all defined benefit plans at
December 31, 2010, is $425,472 (2009: $386,852) which
consists of the benefit obligation of $282,792 (2009: $261,282)
for the North America plan, which is funded by plan assets, and
the benefit obligation of $142,680 (2009: $125,570) for the
German unfunded plan.
F-26
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
The following table shows the changes in benefit obligations,
the changes in plan assets, and the funded status of the pension
plans. Benefits paid as shown in the changes in benefit
obligations represent payments made from both the funded and
unfunded plans while the benefits paid as shown in the changes
in plan assets include only benefit payments from the
Companys funded benefit plan.
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
Change in benefit obligation:
|
|
|
|
|
|
|
|
|
Benefit obligation at beginning of year
|
|
$
|
386,852
|
|
|
$
|
353,961
|
|
Foreign currency translation
|
|
|
(8,898
|
)
|
|
|
4,235
|
|
Service cost
|
|
|
7,982
|
|
|
|
7,500
|
|
Interest cost
|
|
|
22,615
|
|
|
|
21,397
|
|
Transfer of plan participants
|
|
|
181
|
|
|
|
96
|
|
Actuarial (gain) loss
|
|
|
26,655
|
|
|
|
13,216
|
|
Benefits paid
|
|
|
(9,915
|
)
|
|
|
(7,560
|
)
|
Curtailments and settlements
|
|
|
|
|
|
|
(5,993
|
)
|
|
|
|
|
|
|
|
|
|
Benefit obligation at end of year
|
|
$
|
425,472
|
|
|
$
|
386,852
|
|
|
|
|
|
|
|
|
|
|
Change in plan assets:
|
|
|
|
|
|
|
|
|
Fair value of plan assets at beginning of year
|
|
$
|
236,633
|
|
|
$
|
214,616
|
|
Actual return on plan assets
|
|
|
3,191
|
|
|
|
29,382
|
|
Employer contributions
|
|
|
600
|
|
|
|
759
|
|
Benefits paid
|
|
|
(8,099
|
)
|
|
|
(6,063
|
)
|
Settlements
|
|
|
|
|
|
|
(2,061
|
)
|
|
|
|
|
|
|
|
|
|
Fair value of plan assets at end of year
|
|
$
|
232,325
|
|
|
$
|
236,633
|
|
|
|
|
|
|
|
|
|
|
Funded status at end of year
|
|
$
|
193,147
|
|
|
$
|
150,219
|
|
|
|
|
|
|
|
|
|
|
The Company had a pension liability of $193,147 and $150,219 at
December 31, 2010 and 2009, respectively. The pension
liability consists of a current portion of $2,997 (2009: $2,892)
which is recognized as a current liability in the line item
accrued expenses and other current liabilities in
the balance sheet. The non-current portion of $190,150 (2009:
$147,327) is recorded as non-current pension liability in the
balance sheet. Approximately 85% of the beneficiaries are
located in North America with the majority of the remaining 15%
located in Germany.
The accumulated benefit obligation for all defined benefit
pension plans was $394,276 and $367,182 at December 31,
2010 and 2009, respectively. The accumulated benefit obligation
for all defined benefit pension plans with an obligation in
excess of plan assets was $394,276 and $367,182 at
December 31, 2010 and 2009, respectively; the related plan
assets had a fair value of $232,325 and $236,633 at
December 31, 2010 and 2009, respectively.
F-27
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
The pre-tax changes in the table below reflect actuarial losses
(gains) in other comprehensive income relating to pension
liabilities. As of December 31, 2010, there are no
cumulative effects of prior service costs included in other
comprehensive income.
|
|
|
|
|
|
|
Actuarial
|
|
|
|
losses (gains)
|
|
|
Adjustments related to pensions at January 1, 2009
|
|
$
|
76,926
|
|
Additions
|
|
|
(4,331
|
)
|
Releases
|
|
|
(5,404
|
)
|
Foreign currency translation adjustment
|
|
|
27
|
|
|
|
|
|
|
Adjustments related to pensions at December 31, 2009
|
|
$
|
67,218
|
|
|
|
|
|
|
Additions
|
|
|
40,917
|
|
Releases
|
|
|
(5,313
|
)
|
Foreign currency translation adjustment
|
|
|
50
|
|
|
|
|
|
|
Adjustments related to pensions at December 31, 2010
|
|
$
|
102,872
|
|
|
|
|
|
|
The actuarial loss expected to be amortized from other
comprehensive income into net periodic pension cost over the
next year is $8,086.
The discount rates for all plans are based upon yields of
portfolios of equity and highly rated debt instruments with
maturities that mirror the plans benefit obligation. The
Companys discount rate is the weighted average of these
plans based upon their benefit obligations at December 31,
2010. The following weighted-average assumptions were utilized
in determining benefit obligations as of December 31:
|
|
|
|
|
|
|
|
|
in %
|
|
2010
|
|
2009
|
|
Discount rate
|
|
|
5.70
|
|
|
|
6.00
|
|
Rate of compensation increase
|
|
|
4.00
|
|
|
|
4.01
|
|
The defined benefit pension plans net periodic benefit
costs are comprised of the following components for each of the
years ended December 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
Components of net periodic benefit cost:
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Service cost
|
|
$
|
7,982
|
|
|
$
|
7,500
|
|
|
$
|
8,357
|
|
Interest cost
|
|
|
22,615
|
|
|
|
21,397
|
|
|
|
20,393
|
|
Expected return on plan assets
|
|
|
(17,453
|
)
|
|
|
(15,767
|
)
|
|
|
(16,931
|
)
|
Amortization of unrealized losses
|
|
|
5,313
|
|
|
|
4,592
|
|
|
|
1,944
|
|
Settlement loss
|
|
|
|
|
|
|
812
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic benefit costs
|
|
$
|
18,457
|
|
|
$
|
18,534
|
|
|
$
|
13,763
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following weighted-average assumptions were used in
determining net periodic benefit cost for the year ended
December 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
in %
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Discount rate
|
|
|
6.00
|
|
|
|
6.15
|
|
|
|
6.16
|
|
Expected return of plan assets
|
|
|
7.50
|
|
|
|
7.50
|
|
|
|
7.50
|
|
Rate of compensation increase
|
|
|
4.01
|
|
|
|
4.19
|
|
|
|
4.16
|
|
F-28
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
Expected benefit payments for the next five years and in the
aggregate for the five years thereafter are as follows:
|
|
|
|
|
2011
|
|
$
|
11,224
|
|
2012
|
|
|
12,489
|
|
2013
|
|
|
13,462
|
|
2014
|
|
|
14,796
|
|
2015
|
|
|
16,304
|
|
2016-2020
|
|
|
108,387
|
|
Plan
Assets
The following table presents the fair values of the
Companys pension plan assets at December 31, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements at December 31, 2010
|
|
|
|
|
|
Fair Value Measurements at December 31, 2009
|
|
|
|
|
|
|
Quoted Prices in
|
|
|
Significant
|
|
|
|
|
|
Quoted Prices in
|
|
|
Significant
|
|
|
|
|
|
|
Active Markets
|
|
|
Observable
|
|
|
|
|
|
Active Markets
|
|
|
Observable
|
|
|
|
|
|
|
for Identical Assets
|
|
|
Inputs
|
|
|
|
|
|
for Identical Assets
|
|
|
Inputs
|
|
Asset Category
|
|
Total
|
|
|
(Level 1)
|
|
|
(Level 2)
|
|
|
Total
|
|
|
(Level 1)
|
|
|
(Level 2)
|
|
|
Equity Investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stocks
|
|
$
|
2,565
|
|
|
$
|
2,565
|
|
|
$
|
|
|
|
$
|
5,904
|
|
|
$
|
5,904
|
|
|
$
|
|
|
Index
Funds
1
|
|
|
65,621
|
|
|
|
|
|
|
|
65,621
|
|
|
|
71,406
|
|
|
|
|
|
|
|
71,406
|
|
Fixed Income Investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Government
Securities
2
|
|
|
4,479
|
|
|
|
1,967
|
|
|
|
2,512
|
|
|
|
3,655
|
|
|
|
394
|
|
|
|
3,261
|
|
Corporate
Bonds
3
|
|
|
152,564
|
|
|
|
|
|
|
|
152,564
|
|
|
|
149,367
|
|
|
|
|
|
|
|
149,367
|
|
Other
Bonds
4
|
|
|
2,442
|
|
|
|
|
|
|
|
2,442
|
|
|
|
163
|
|
|
|
|
|
|
|
163
|
|
U.S. Treasury Money Market
Funds
5
|
|
|
4,232
|
|
|
|
4,232
|
|
|
|
|
|
|
|
5,776
|
|
|
|
5,776
|
|
|
|
|
|
Other types of investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash, Money Market and Mutual
Funds
6
|
|
|
422
|
|
|
|
422
|
|
|
|
|
|
|
|
362
|
|
|
|
362
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
232,325
|
|
|
$
|
9,186
|
|
|
$
|
223,139
|
|
|
$
|
236,633
|
|
|
$
|
12,436
|
|
|
$
|
224,197
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
This Category comprises low-cost
equity index funds not actively managed that track the S&P
500, S&P 400, Russell 2000, the MSCI EAFE Index and the
MSCI Emerging Markets Index for both 2010 and 2009 as well as
the Barclays Capital Long Corporate Index in 2009
|
2
|
|
This Category primarily comprises
fixed income investments by the U.S. government and government
sponsored entities
|
3
|
|
This Category primarily represents
investment grade bonds of U.S. issuers from diverse industries
|
4
|
|
This Category comprises private
placement bonds as well as collateralized mortgage obligations
|
5
|
|
This Category represents funds that
invest in treasury obligations directly or in treasury backed
obligations
|
6
|
|
This Category represents cash,
money market funds as well as mutual funds comprised of high
grade corporate bonds
|
The methods and inputs used to measure the fair value of plan
assets are as follows:
Common stocks are valued at their market prices as of the
balance sheet date.
Index funds are valued based on market quotes.
The majority of the fair values of the government bonds are
measured based on market quotes. The remaining government bonds
are valued at their market prices.
Corporate bonds and other bonds are valued based on market
quotes as of the balance sheet date.
Cash is stated at nominal value which equals the fair value.
US Treasury money market funds as well as other money market and
mutual funds are valued at their market price.
F-29
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
Plan
Investment Policy and Strategy
For the North America funded plan, the Company periodically
reviews the assumption for long-term expected return on pension
plan assets. As part of the assumptions review, a range of
reasonable expected investment returns for the pension plan as a
whole was determined based on an analysis of expected future
returns for each asset class weighted by the allocation of the
assets. The range of returns developed relies both on forecasts,
which include the actuarial firms expected long-term rates
of return for each significant asset class or economic
indicator, and on broad-market historical benchmarks for
expected return, correlation, and volatility for each asset
class. As a result, the Companys expected rate of return
on pension plan assets was 7.50% for 2010.
The Companys overall investment strategy is to achieve a
mix of approximately 98% of investments for long-term growth and
2% for near-term benefit payments with a wide diversification of
asset types, fund strategies and fund managers.
The investment policy, utilizing a revised target investment
allocation of 35% equity and 65% long-term U.S. bonds,
considers that there will be a time horizon for invested funds
of more than 5 years. The total portfolio will be measured
against a policy index that reflects the asset class benchmarks
and the target asset allocation. The Plan policy does not allow
investments in securities of the Company or other related party
securities. The performance benchmarks for the separate asset
classes include: S&P 500 Index, S&P 400 Index, Russell
2000 Growth Index, MSCI EAFE Index, MSCI Emerging Markets Index,
Barclays Capital Long Term Government Index and Barclays Capital
20 Year US Treasury Strip Index.
Defined
Contribution Plans
Most FMCH employees are eligible to join a 401(k) savings plan.
Employees can deposit up to 75% of their pay up to a maximum of
$16.5 if under 50 years old ($22.00 if 50 or over) under
this savings plan. The Company will match 50% of the employee
deposit up to a maximum Company contribution of 3% of the
employees pay. The Companys total expense under this
defined contribution plan for the years ended December 31,
2010, 2009, and 2008, was $31,583, $28,567 and $26,096,
respectively.
|
|
11.
|
Mandatorily
Redeemable Trust Preferred Securities
|
In June 2001, the Company issued Trust Preferred Securities
through Fresenius Medical Care Capital Trusts, statutory trusts
organized under the laws of the State of Delaware.
FMC-AG & Co. KGaA owns all of the common securities of
these trusts. The sole asset of each trust is a senior
subordinated note of FMC-AG & Co. KGaA or a
wholly-owned subsidiary of FMC-AG & Co. KGaA.
FMC-AG & Co. KGaA, D-GmbH and FMCH have guaranteed
payment and performance of the senior subordinated notes to the
respective Fresenius Medical Care Capital Trusts. The
Trust Preferred Securities are guaranteed by
FMC-AG & Co. KGaA through a series of undertakings by
the Company, FMCH and D-GmbH.
The Trust Preferred Securities entitle the holders to
distributions at a fixed annual rate of the stated amount and
are mandatorily redeemable after 10 years, which is
scheduled to occur on June 15, 2011. Earlier redemption at
the option of the holders may also occur upon a change of
control followed by a rating decline or defined events of
default including a failure to pay interest. Upon liquidation of
the trusts, the holders of Trust Preferred Securities are
entitled to a distribution equal to the stated amount. The
Trust Preferred Securities do not hold voting rights in the
trust except under limited circumstances.
The indentures governing the notes held by the Fresenius Medical
Care Capital Trusts contain affirmative and negative covenants
with respect to the Company and its subsidiaries and other
payment restrictions. Some of the covenants limit the
Companys indebtedness and its investments, and require the
Company to maintain certain ratios defined in the indentures. As
of December 31, 2010, the Company is in compliance with all
financial covenants under all Trust Preferred Securities
agreements.
F-30
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
The Trust Preferred Securities outstanding as of
December 31, 2010 and 2009 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mandatory
|
|
|
|
|
|
|
|
|
|
Year
|
|
|
Stated
|
|
|
Interest
|
|
|
Redemption
|
|
|
|
|
|
|
|
|
|
Issued
|
|
|
Amount
|
|
|
Rate
|
|
|
Date
|
|
|
2010
|
|
|
2009
|
|
|
Fresenius Medical Care Capital Trust IV
|
|
|
2001
|
|
|
|
$225,000
|
|
|
|
7
7
/
8
|
%
|
|
|
June 15, 2011
|
|
|
$
|
224,835
|
|
|
$
|
224,451
|
|
Fresenius Medical Care Capital Trust V
|
|
|
2001
|
|
|
|
300,000
|
|
|
|
7
3
/
8
|
%
|
|
|
June 15, 2011
|
|
|
|
400,714
|
|
|
|
431,645
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
625,549
|
|
|
$
|
656,096
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.
|
Noncontrolling
Interests Subject to Put Provisions
|
The Company has potential obligations to purchase the
noncontrolling interests held by third parties in certain of its
consolidated subsidiaries. These obligations are in the form of
put provisions and are exercisable at the third-party
owners discretion within specified periods as outlined in
each specific put provision. If these put provisions were
exercised, the Company would be required to purchase all or part
of third-party owners noncontrolling interests at the
appraised fair value. The methodology the Company uses to
estimate the fair values of the noncontrolling interest subject
to put provisions assumes the greater of net book value or a
multiple of earnings, based on historical earnings, development
stage of the underlying business and other factors. The
estimated fair values of the noncontrolling interests subject to
these put provisions can also fluctuate and the implicit
multiple of earnings at which these noncontrolling interest
obligations may ultimately be settled could vary significantly
from our current estimates depending upon market conditions.
As of December 31, 2010 and 2009 the Companys
potential obligations under these put options are $279,709 and
$231,303, respectively, of which, at December 31, 2010,
$95,159 were exercisable. In the last three fiscal years ending
December 31, 2010, three puts have been exercised for a
total consideration of $6,535.
During 2008, the Company received cash contributions from
holders of noncontrolling interests in the amount of $17,174.
This amount was recorded in net cash provided by operating
activities in the cash flow statement.
Following is a roll forward of noncontrolling interests subject
to put provisions for the years ended December 31,:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Beginning balance
|
|
$
|
231,303
|
|
|
$
|
162,166
|
|
|
$
|
116,539
|
|
Dividends paid
|
|
|
(38,964
|
)
|
|
|
(16,930
|
)
|
|
|
(14,494
|
)
|
Purchase/ sale of Noncontrolling interests
|
|
|
28,969
|
|
|
|
12,548
|
|
|
|
9,148
|
|
Contributions from Noncontrolling interests
|
|
|
5,289
|
|
|
|
5,108
|
|
|
|
13,069
|
|
Changes in fair value of Noncontrolling interests
|
|
|
24,222
|
|
|
|
39,816
|
|
|
|
24,258
|
|
Net income
|
|
|
28,839
|
|
|
|
28,595
|
|
|
|
13,646
|
|
Other comprehensive income (loss)
|
|
|
51
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending balance
|
|
$
|
279,709
|
|
|
$
|
231,303
|
|
|
$
|
162,166
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital
Stock
The General Partner has no equity interest in the Company and,
therefore, does not participate in either the assets or the
profits and losses of the Company. However, the General Partner
is compensated for all outlays in connection with conducting the
Companys business, including the remuneration of members
of the management board and the supervisory board (see
Note 3).
The general meeting of a partnership limited by shares may
approve Authorized Capital (
genehmigtes Kapital
). The
resolution creating Authorized Capital requires the affirmative
vote of a majority of three quarters of the capital represented
at the vote and may authorize the management board to issue
shares up to a stated amount for a period of up to five years.
The nominal value of the Authorized Capital may not exceed half
of the issued capital stock at the time of the authorization.
In addition, the general meeting of a partnership limited by
shares may create Conditional Capital (
bedingtes Kapital
)
for the purpose of issuing (i) shares to holders of
convertible bonds or other securities which grant a right to
F-31
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
shares, (ii) shares as the consideration in a merger with
another company, or (iii) shares offered to management or
employees. In each case, the authorizing resolution requires the
affirmative vote of a majority of three quarters of the capital
represented at the vote. The nominal value of the Conditional
Capital may not exceed half or, in the case of Conditional
Capital created for the purpose of issuing shares to management
and employees, 10% of the companys issued capital at the
time of the resolution.
All resolutions increasing the capital of a partnership limited
by shares also require the consent of the General Partner for
their effectiveness.
Authorized
Capital
By resolution of the Annual General Meeting (AGM) of
shareholders on May 11, 2010, Management AG was authorized,
with the approval of the supervisory board, to increase, on one
or more occasions, the Companys share capital until
May 10, 2015 up to a total of 35,000 through issue of
new bearer ordinary shares for cash contributions,
Authorized Capital 2010/I. The General Partner is
entitled, subject to the approval of the supervisory board, to
exclude the pre-emption rights of the shareholders. However,
such an exclusion of pre-emption rights will be permissible for
fractional amounts. Additionally, the newly issued shares may be
taken up by financial institutions nominated by the General
Partner with the obligation to offer them to the shareholders of
the company (indirect pre-emption rights). A further resolution
of the AGM also cancelled Authorized Capital I which was
approved by resolution of the AGM of shareholders on
August 30, 2005. No Authorized Capital 2010/I has been
issued as of December 31, 2010.
In addition, by resolution of the AGM of shareholders on
May 11, 2010, the General Partner was authorized, with the
approval of the supervisory board, to increase, on one or more
occasions, the share capital of the Company until May 10,
2015 up to a total of 25,000 through the issue of new
bearer ordinary shares for cash contributions or contributions
in kind, Authorized Capital 2010/II. The General
Partner is entitled, subject to the approval of the supervisory
board, to exclude the pre-emption rights of the shareholders.
However, such exclusion of pre-emption rights will be
permissible only if (i) in case of a capital increase
against cash contributions, the nominal value of the issued
shares does not exceed 10% of the nominal share value of the
Companys share capital and the issue price for the new
shares is at the time of the determination by the General
Partner not significantly lower than the stock price in Germany
of the existing listed shares of the same class and with the
same rights or, (ii) in case of a capital increase against
contributions in kind, the purpose of such increase is to
acquire an enterprise, parts of an enterprise or an interest in
an enterprise. A further resolution of the AGM also cancelled
Authorized Capital II which was approved by resolution of
the AGM of shareholders on August 30, 2005. No Authorized
Capital 2010/II has been issued as of December 31, 2010.
Authorized Capital 2010/I and Authorized Capital 2010/II became
effective upon registration with the commercial register of the
local court in Hof an der Saale on May 25, 2010.
Conditional
Capital
By resolution of the Companys Annual General Meeting of
shareholders (AGM) on May 9, 2006, as amended
by the AGM on May 15, 2007, resolving a
three-for-one
share split, the Companys share capital was conditionally
increased by up to 15,000 corresponding to 15 million
ordinary shares with no par value and a nominal value of
1.00. This Conditional Capital increase can only be
effected by the exercise of stock options under the
Companys Stock Option Plan 2006 with each stock option
awarded exercisable for one ordinary share (see Note 15).
The Company has the right to deliver ordinary shares that it
owns or purchases in the market in place of increasing capital
by issuing new shares.
Through the Companys other employee participation
programs, the Company has issued convertible bonds and stock
option/subscription rights (
Bezugsrechte
) to employees
and the members of the Management Board of the General Partner
and employees and members of management of affiliated companies
that entitle these persons to receive preference shares or,
following the conversion offer in 2005, ordinary shares. At
December 31, 2010, 58,663 convertible bonds or options for
preference shares remained outstanding with a remaining average
term of 3.38 years and 12,152,108 convertible bonds or
options for ordinary shares remained outstanding with a
remaining average term of 4.8 years under these programs.
For the year ending December 31, 2010, 72,840 options for
preference shares and 2,532,366 options for ordinary shares had
been exercised under these employee participation plans (see
Note 15).
F-32
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
As the result of the Companys
three-for-one
stock split for both preference and ordinary shares on
June 15, 2007, and with the approval of the shareholders as
the AGM on May 15, 2007, the Companys Conditional
Capital was increased by $6,557 (4,454). Conditional
Capital available for all programs at December 31, 2010 is
$31,477 (23,557) which includes $17,476 (13,079) for
the 2006 Plan and $14,001 (10,478) for all other plans.
Dividends
Under German law, the amount of dividends available for
distribution to shareholders is based upon the unconsolidated
retained earnings of Fresenius Medical Care AG & Co.
KGaA as reported in its balance sheet determined in accordance
with the German Commercial Code (
Handelsgesetzbuch
).
If no dividends on the Companys preference shares are
declared for two consecutive years after the year for which the
preference shares are entitled to dividends, then the holders of
such preference shares would be entitled to the same voting
rights as holders of ordinary shares until all arrearages are
paid. In addition, the payment of dividends by
FMC-AG & Co. KGaA is subject to limitations under the
Amended 2006 Senior Credit Agreement (see Note 9).
Cash dividends of $231,967 for 2009 in the amount of 0.63
per preference share and 0.61 per ordinary share were paid
on May 12, 2010.
Cash dividends of $231,940 for 2008 in the amount of 0.60
per preference share and 0.58 per ordinary share were paid
on May 8, 2009.
Cash dividends of $252,395 for 2007 in the amount of 0.56
per preference share and 0.54 per ordinary share were paid
on May 21, 2008.
The following table contains reconciliations of the numerators
and denominators of the basic and diluted earnings per share
computations for 2010 and 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Numerators:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to FMC-AG & Co. KGaA
|
|
$
|
978,517
|
|
|
$
|
891,138
|
|
|
$
|
817,607
|
|
less:
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividend preference on Preference shares
|
|
|
104
|
|
|
|
107
|
|
|
|
112
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income available to all classes of shares
|
|
$
|
978,413
|
|
|
$
|
891,031
|
|
|
$
|
817,495
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominators:
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of:
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares outstanding
|
|
|
296,808,978
|
|
|
|
294,418,795
|
|
|
|
293,233,477
|
|
Preference shares outstanding
|
|
|
3,912,348
|
|
|
|
3,842,586
|
|
|
|
3,795,248
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total weighted average shares outstanding
|
|
|
300,721,326
|
|
|
|
298,261,381
|
|
|
|
297,028,725
|
|
Potentially dilutive Ordinary shares
|
|
|
1,311,042
|
|
|
|
|
|
|
|
777,848
|
|
Potentially dilutive Preference shares
|
|
|
35,481
|
|
|
|
66,314
|
|
|
|
98,060
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total weighted average Ordinary shares outstanding assuming
dilution
|
|
|
298,120,020
|
|
|
|
294,418,795
|
|
|
|
294,011,325
|
|
Total weighted average Preference shares outstanding assuming
dilution
|
|
|
3,947,829
|
|
|
|
3,908,900
|
|
|
|
3,893,308
|
|
Basic income per Ordinary share
|
|
$
|
3.25
|
|
|
$
|
2.99
|
|
|
$
|
2.75
|
|
Plus preference per Preference share
|
|
|
0.03
|
|
|
|
0.03
|
|
|
|
0.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income per Preference Share
|
|
$
|
3.28
|
|
|
$
|
3.02
|
|
|
$
|
2.78
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fully diluted income per Ordinary share
|
|
$
|
3.24
|
|
|
$
|
2.99
|
|
|
$
|
2.74
|
|
Plus preference per Preference share
|
|
|
0.03
|
|
|
|
0.03
|
|
|
|
0.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fully diluted income per Preference share
|
|
$
|
3.27
|
|
|
$
|
3.02
|
|
|
$
|
2.77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-33
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
In connection with its stock option program, the Company
incurred compensation expense of $27,981, $33,746 and $31,879
for the years ending December 31, 2010, 2009, and 2008,
respectively. There were no capitalized compensation costs in
any of the three years presented. The Company also recorded a
related deferred income tax of $8,020, $9,740 and $9,158 for the
years ending December 31, 2010, 2009, and 2008,
respectively.
Stock
Options and other Share-Based Plans
At December 31, 2010, the Company has awards outstanding
under various stock-based compensation plans.
Incentive
plan
In 2010, Management Board members were eligible for
performance related compensation that depended upon
achievement of targets. The targets are measured by reference to
operating profit margin, growth of group-wide after-tax earnings
(EAT growth) as well as the development of free cash flow (cash
flow before acquisitions), and are derived from the comparison
of targeted and actually achieved current year figures. Targets
are divided into Group level targets and those to be achieved in
individual regions.
The bonus for fiscal year 2010 will consist proportionately of a
cash component and a share-based component which will be paid in
cash. Upon meeting the annual targets, the cash component was or
will be paid after the end of 2010. The share-based component is
subject to a three-year vesting period, although a shorter
period may apply in special cases. The amount of cash payment
relating to the share-based component will correspond to the
share price of Fresenius Medical Care AG & Co. KGaA
ordinary shares upon exercise after the three-year vesting
period. The amount of the maximum achievable bonus for each of
the members of the Management Board is capped.
In 2006, Fresenius Medical Care Management AG adopted a
three-year performance related compensation plan for fiscal
years 2008, 2007 and 2006, for the members of its management
board in the form of a variable bonus. A special bonus component
(award) for some of the management board members consists in
equal parts of cash payments and a share-based compensation
based on development of the share price of Fresenius Medical
Care AG & Co. KGaAs ordinary shares. The amount
of the award in each case depends on the achievement of certain
performance targets. The targets are measured by reference to
revenue growth, operating income, consolidated net income, and
cash flow development. Annual targets have been achieved, the
cash portion of the award has been paid after the end of the
respective fiscal year. The share-based compensation portion of
the award has been granted but subject to a three-year vesting
period beginning after the respective fiscal year in which the
target has been met and is amortized over the same three-year
vesting period. The payment of the share-based compensation
portion corresponds to the share price of Fresenius Medical Care
AG & Co. KGaAs ordinary shares on exercise, i.e.
at the end of the vesting period, and is also made in cash. The
share-based compensation is revalued each reporting period
during the vesting period to reflect the market value of the
stock as of the reporting date with any changes in value
recorded in the reporting period.
The share-based compensation incurred under these plans for
years 2010, 2009 and 2008 was $2,603, $1,537 and $2,189,
respectively.
Fresenius
Medical Care AG & Co. KGaA Stock Option Plan
2006
On May 9, 2006, as amended on May 15, 2007, the
Fresenius Medical Care AG & Co. KGaA Stock Option Plan
2006 (the Amended 2006 Plan) was established by
resolution of the Companys AGM with a conditional capital
increase up to 15,000 subject to the issue of up to
fifteen million no par value bearer ordinary shares with a
nominal value of 1.00 each. Under the Amended 2006 Plan,
up to fifteen million options can be issued, each of which can
be exercised to obtain one ordinary share, with up to three
million options designated for members of the Management Board
of the General Partner, up to three million options designated
for members of management boards of direct or indirect
subsidiaries of the Company and up to nine million options
designated for managerial staff members of the Company and such
subsidiaries. With respect to participants who are members of
the General Partners Management Board, the general
partners Supervisory Board has sole authority to grant
stock options and exercise other decision making powers under
the Amended 2006 Plan (including decisions regarding certain
adjustments and forfeitures). The General Partner has such
authority with respect to all other participants in the Amended
2006 Plan.
F-34
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
Options under the Amended 2006 Plan can be granted the last
Monday in July
and/or
the
first Monday in December. The exercise price of options granted
under the Amended 2006 Plan shall be the average closing price
on the Frankfurt Stock Exchange of the Companys ordinary
shares during the 30 calendar days immediately prior to each
grant date. Options granted under the Amended 2006 Plan have a
seven-year term but can be exercised only after a three-year
vesting period. The vesting of options granted is subject to
achievement of performance targets measured over a three-year
period from the grant date. For each such year, the performance
target is achieved if the Companys adjusted basic income
per ordinary share (EPS), as calculated in
accordance with the Amended 2006 Plan, increases by at least 8%
year over year during the vesting period, beginning with EPS for
the year of grant as compared to EPS for the year preceding such
grant. Calculation of EPS under the Amended 2006 Plan excluded,
among other items, the costs of the transformation of the
Companys legal form and the conversion of preference
shares into ordinary shares. For each grant, one-third of the
options granted are forfeited for each year in which EPS does
not meet or exceed the 8% target. The performance targets for
2010, 2009 and 2008 were met. Vesting of the portion or portions
of a grant for a year or years in which the performance target
is met does not occur until completion of the entire three-year
vesting period.
During 2010, the Company awarded 2,817,879 options under the
Amended 2006 Plan, including 423,300 options granted to members
of the Management Board of Fresenius Medical Care Management AG,
the Companys general partner, at a weighted average
exercise price of $57.07 (42.71), a weighted average fair
value of $10.47 each and a total fair value of $29,515 which
will be amortized over the three year vesting period. As of
December 2010, no further grants will be issued under the
Amended 2006 Plan.
During 2009, the Company awarded 2,585,196 options under the
Amended 2006 Plan, including 348,600 options granted to members
of the Management Board of Fresenius Medical Care Management AG,
the Companys general partner, at a weighted average
exercise price of $46.22 (32.08), a weighted average fair
value of $10.95 each and a total fair value of $28,318 which
will be amortized over the three year vesting period.
During 2008, the Company awarded 2,523,729 options under the
Amended 2006 Plan, including 398,400 options granted to members
of the Management Board of the General Partner, at a weighted
average exercise price of $49.38 (35.48), a weighted
average fair value of $15.37 each and a total fair value of
$38,788, which will be amortized on a straight line basis over
the three-year vesting period.
Options granted under the Amended 2006 Plan to US participants
are non-qualified stock options under the United States Internal
Revenue Code of 1986, as amended. Options under the Amended 2006
Plan are not transferable by a participant or a
participants heirs, and may not be pledged, assigned, or
otherwise disposed of.
Fresenius
Medical Care 2001 International Stock Option Plan
Under the Fresenius Medical Care 2001 International Stock
Incentive Plan (the 2001 Plan), options in the form
of convertible bonds with a principal of up to 10,240 were
issued to the members of the Management Board and other
employees of the Company representing grants for up to
4 million non-voting preference shares. The convertible
bonds originally had a par value of 2.56 and bear interest
at a rate of 5.5%. In connection with the share split effected
in 2007, the principal amount was adjusted in the same
proportion as the share capital out of the capital increase and
the par value of the convertible bonds was adjusted to
0.85 without affecting the interest rate. Except for the
members of the Management Board, eligible employees may purchase
the bonds by issuing a non-recourse note with terms
corresponding to the terms of and secured by the bond. The
Company has the right to offset its obligation on a bond against
the employees obligation on the related note; therefore,
the convertible bond obligations and employee note receivables
represent stock options issued by the Company and are not
reflected in the Consolidated Financial Statements. The options
expire ten years from issuance and can be exercised beginning
two, three or four years after issuance. Compensation costs
related to awards granted under this plan are amortized on a
straight-line basis over the vesting period for each separately
vesting portion of the awards. Bonds issued to Management Board
members who did not issue a note to the Company are recognized
as a liability on the Companys balance sheet.
Upon issuance of the option, the employees had the right to
choose options with or without a stock price target. The
conversion price of options subject to a stock price target
corresponds to the stock exchange quoted price of the preference
shares upon the first time the stock exchange quoted price
exceeds the initial value by at least 25%. The initial value
(Initial Value) is the average price of the
preference shares during the last 30 trading days prior to the
date of grant. In the case of options not subject to a stock
price target, the number of convertible bonds awarded to
F-35
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
the eligible employee would be 15% less than if the employee
elected options subject to the stock price target. The
conversion price of the options without a stock price target is
the Initial Value. Each option entitles the holder thereof, upon
payment of the respective conversion price, to acquire one
preference share. Effective May 2006, no further grants can be
issued under the 2001 Plan and no options were granted under the
2001 Plan after 2005.
At December 31, 2010, the Management Board members of the
General Partner held 2,178,699 stock options for ordinary shares
and employees of the Company held 9,973,409 stock options for
ordinary shares and 58,663 stock options for preference shares,
under the various stock-based compensation plans of the Company.
The Table below provides reconciliations for options outstanding
at December 31, 2010, as compared to December 31, 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
Weighted
|
|
|
|
|
|
|
average
|
|
|
average
|
|
|
|
Options
|
|
|
exercise
|
|
|
exercise
|
|
|
|
(in thousands)
|
|
|
price
|
|
|
price
|
|
|
|
|
|
|
|
|
|
$
|
|
|
Ordinary shares
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2009
|
|
|
11,894
|
|
|
|
30.50
|
|
|
|
40.75
|
|
Granted
|
|
|
2,818
|
|
|
|
42.71
|
|
|
|
57.07
|
|
Exercised
|
|
|
2,532
|
|
|
|
28.38
|
|
|
|
37.92
|
|
Forfeited
|
|
|
28
|
|
|
|
30.35
|
|
|
|
40.55
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2010
|
|
|
12,152
|
|
|
|
33.78
|
|
|
|
45.14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preference shares
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2009
|
|
|
147
|
|
|
|
18.35
|
|
|
|
24.52
|
|
Exercised
|
|
|
73
|
|
|
|
18.57
|
|
|
|
24.81
|
|
Forfeited
|
|
|
15
|
|
|
|
13.95
|
|
|
|
18.64
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2010
|
|
|
59
|
|
|
|
19.19
|
|
|
|
25.64
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table provides a summary of fully vested options
outstanding and exercisable for both preference and ordinary
shares at December 31, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fully Vested Outstanding and Exercisable Options
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
|
|
|
|
average
|
|
Weighted
|
|
Weighted
|
|
|
|
|
|
|
Number
|
|
remaining
|
|
average
|
|
average
|
|
Aggregate
|
|
Aggregate
|
|
|
of
|
|
contractual
|
|
exercise
|
|
exercise
|
|
intrinsic
|
|
intrinsic
|
|
|
Options
|
|
life in years
|
|
price
|
|
price
|
|
value
|
|
value
|
|
|
(in thousands)
|
|
|
|
|
|
US$
|
|
|
|
US$
|
|
Options for preference shares
|
|
|
59
|
|
|
|
3.38
|
|
|
|
19.19
|
|
|
|
25.65
|
|
|
|
940
|
|
|
|
1,255
|
|
Options for ordinary shares
|
|
|
4,316
|
|
|
|
3.29
|
|
|
|
27.99
|
|
|
|
37.40
|
|
|
|
65,785
|
|
|
|
87,902
|
|
At December 31, 2010, there was $43,604 of total
unrecognized compensation costs related to non-vested options
granted under all plans. These costs are expected to be
recognized over a weighted-average period of 1.6 years.
During the years ended December 31, 2010, 2009, and 2008,
the company received cash of $96,204, $64,271 and $36,755,
respectively, from the exercise of stock options (see Note 13).
The intrinsic value of options exercised for the twelve-month
periods ending December 31, 2010, 2009, and 2008 was
$50,921, $28,170 and $27,135, respectively. The Company recorded
a related tax benefit of $13,313, $8,123 and $7,132 for the
years ending December 31, 2010, 2009, and 2008,
respectively.
Fair
Value Information
The Company used a binomial option-pricing model in determining
the fair value of the awards under the 2006 Plan. Option
valuation models require the input of highly subjective
assumptions including expected stock price volatility. The
Companys assumptions are based upon its past experiences,
market trends and the experiences of other entities of the same
size and in similar industries. Expected volatility is based on
historical volatility of the
F-36
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
Companys shares. To incorporate the effects of expected
early exercise in the model, an early exercise of vested options
was assumed as soon as the share price exceeds 155% of the
exercise price. The Companys stock options have
characteristics that vary significantly from traded options and
changes in subjective assumptions can materially affect the fair
value of the option. The assumptions used to determine the fair
value of the 2010 and 2009 grants are as follows:
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
Expected dividend yield
|
|
|
1.98%
|
|
|
|
2.39%
|
|
Risk-free interest rate
|
|
|
2.28%
|
|
|
|
3.11%
|
|
Expected volatility
|
|
|
22.92%
|
|
|
|
25.85%
|
|
Expected life of options
|
|
|
7 years
|
|
|
|
7 years
|
|
Weighted average exercise price (in )
|
|
|
42.71
|
|
|
|
32.08
|
|
Weighted average exercise price (in US-$)
|
|
|
57.07
|
|
|
|
46.22
|
|
Income before income taxes is attributable to the following
geographic locations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Germany
|
|
$
|
303,954
|
|
|
$
|
296,326
|
|
|
$
|
372,174
|
|
United States
|
|
|
1,084,756
|
|
|
|
904,083
|
|
|
|
773,089
|
|
Other
|
|
|
255,031
|
|
|
|
255,224
|
|
|
|
190,427
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,643,741
|
|
|
$
|
1,455,633
|
|
|
$
|
1,335,690
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense (benefit) for the years ended
December 31, 2010, 2009, and 2008, consisted of the
following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Current:
|
|
|
|
|
|
|
|
|
|
|
|
|
Germany
|
|
$
|
100,635
|
|
|
$
|
68,442
|
|
|
$
|
62,609
|
|
United States
|
|
|
355,739
|
|
|
|
318,589
|
|
|
|
198,763
|
|
Other
|
|
|
101,206
|
|
|
|
81,236
|
|
|
|
77,134
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
557,580
|
|
|
|
468,267
|
|
|
|
338,506
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred:
|
|
|
|
|
|
|
|
|
|
|
|
|
Germany
|
|
|
(16,479
|
)
|
|
|
5,041
|
|
|
|
43,593
|
|
United States
|
|
|
52,648
|
|
|
|
22,498
|
|
|
|
105,152
|
|
Other
|
|
|
(15,404
|
)
|
|
|
(5,393
|
)
|
|
|
(11,549
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,765
|
|
|
|
22,146
|
|
|
|
137,196
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
578,345
|
|
|
$
|
490,413
|
|
|
$
|
475,702
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In 2010, 2009 and 2008, the Company is subject to German federal
corporation income tax at a base rate of 15% plus a solidarity
surcharge of 5.5% on federal corporation taxes payable.
A reconciliation between the expected and actual income tax
expense is shown below. The expected corporate income tax
expense is computed by applying the German corporation tax rate
(including the solidarity surcharge) and the effective trade tax
rate on income before income taxes. The respective combined tax
rates are 28.71%, 29.13% and 29.58% for the fiscal years ended
December 31, 2010, 2009, and 2008, respectively.
F-37
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Expected corporate income tax expense
|
|
$
|
471,836
|
|
|
$
|
423,953
|
|
|
$
|
395,097
|
|
Tax free income
|
|
|
(24,088
|
)
|
|
|
(33,284
|
)
|
|
|
(49,309
|
)
|
Tax rate differentials
|
|
|
117,946
|
|
|
|
96,237
|
|
|
|
93,877
|
|
Non-deductible expenses
|
|
|
6,934
|
|
|
|
3,947
|
|
|
|
5,494
|
|
Taxes for prior years
|
|
|
11,994
|
|
|
|
6,663
|
|
|
|
21,371
|
|
Change in valuation allowance
|
|
|
(2,259
|
)
|
|
|
8,950
|
|
|
|
4,168
|
|
Noncontrolling partnership interests
|
|
|
(26,870
|
)
|
|
|
(26,876
|
)
|
|
|
(13,440
|
)
|
Other
|
|
|
22,852
|
|
|
|
10,823
|
|
|
|
18,444
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Actual income tax expense
|
|
$
|
578,345
|
|
|
$
|
490,413
|
|
|
$
|
475,702
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax rate
|
|
|
35.2
|
%
|
|
|
33.7
|
%
|
|
|
35.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The tax effects of the temporary differences that give rise to
deferred tax assets and liabilities at December 31, 2010
and 2009, are presented below:
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Accounts receivable, primarily due to allowance for doubtful
accounts
|
|
$
|
28,538
|
|
|
$
|
37,571
|
|
Inventory, primarily due to additional costs capitalized for tax
purposes, and inventory reserve accounts
|
|
|
35,172
|
|
|
|
33,798
|
|
Plant, equipment, intangible assets and other non current
assets, principally due to differences in depreciation and
amortization
|
|
|
79,244
|
|
|
|
50,925
|
|
Accrued expenses and other liabilities for financial accounting
purposes, not currently tax deductible
|
|
|
310,730
|
|
|
|
291,767
|
|
Net operating loss carryforwards, tax credit carryforwards and
interest carryforwards
|
|
|
93,165
|
|
|
|
78,730
|
|
Derivatives
|
|
|
60,199
|
|
|
|
52,283
|
|
Stock-based compensation expense
|
|
|
24,112
|
|
|
|
22,981
|
|
Other
|
|
|
12,626
|
|
|
|
21,530
|
|
|
|
|
|
|
|
|
|
|
Total deferred tax assets
|
|
$
|
643,786
|
|
|
$
|
589,585
|
|
Less: valuation allowance
|
|
|
(71,799
|
)
|
|
|
(63,497
|
)
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
$
|
571,987
|
|
|
$
|
526,088
|
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
$
|
12,549
|
|
|
$
|
10,670
|
|
Inventory, primarily due to inventory reserve accounts for tax
purposes
|
|
|
7,730
|
|
|
|
9,643
|
|
Accrued expenses and other liabilities deductible for tax prior
to financial accounting recognition
|
|
|
45,370
|
|
|
|
14,941
|
|
Plant, equipment and intangible assets, principally due to
differences in depreciation and amortization
|
|
|
510,284
|
|
|
|
513,254
|
|
Derivatives
|
|
|
|
|
|
|
3,128
|
|
Other
|
|
|
81,969
|
|
|
|
53,343
|
|
|
|
|
|
|
|
|
|
|
Total deferred tax liabilities
|
|
|
657,902
|
|
|
|
604,979
|
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets (liabilities)
|
|
$
|
(85,915
|
)
|
|
$
|
(78,891
|
)
|
|
|
|
|
|
|
|
|
|
The valuation allowance increased by $8,302 in 2010 and by
$7,328 in 2009.
F-38
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
The expiration of net operating losses is as follows:
|
|
|
|
|
2011
|
|
$
|
6,919
|
|
2012
|
|
|
17,067
|
|
2013
|
|
|
13,949
|
|
2014
|
|
|
19,539
|
|
2015
|
|
|
20,078
|
|
2016
|
|
|
27,730
|
|
2017
|
|
|
9,444
|
|
2018
|
|
|
13,201
|
|
2019
|
|
|
4,507
|
|
2020 and thereafter
|
|
|
5,476
|
|
Without expiration date
|
|
|
155,064
|
|
|
|
|
|
|
Total
|
|
$
|
292,974
|
|
|
|
|
|
|
In assessing the realizability of deferred taxes, management
considers whether it is more-likely-than-not that some portion
or all of a deferred tax asset will be realized or whether
deferred tax liabilities will be reversed. The ultimate
realization of deferred tax assets is dependent upon the
generation of future taxable income during the periods in which
those temporary differences become deductible. Management
considers the scheduled reversal of deferred tax liabilities and
projected future taxable income in making this assessment. Based
upon the level of historical taxable income and projections for
future taxable income over the periods in which the deferred tax
assets are deductible, management believes it is
more-likely-than-not the Company will realize the benefits of
these deductible differences, net of the existing valuation
allowances at December 31, 2010.
The Company provides for income taxes on the cumulative earnings
of foreign subsidiaries that will not be reinvested. At
December 31, 2010, the Company provided for $11,603 of
deferred tax liabilities associated with earnings that are
likely to be distributed in 2011 and the following years.
Provision has not been made for additional taxes on $3,411,518
undistributed earnings of foreign subsidiaries as these earnings
are considered permanently reinvested. The earnings could become
subject to additional tax if remitted or deemed remitted as
dividends; however calculation of such additional tax is not
practical. These taxes would predominantly comprise foreign
withholding tax on dividends of foreign subsidiaries, and German
income tax of approx 1.4 percent on all dividends and
capital gains.
FMC-AG & Co. KGaA companies are subject to tax audits
in Germany and the U.S. on a regular basis and on-going tax
audits in other jurisdictions.
In Germany, the tax audit for the years 1998 until 2001 has been
finalized. The Company recognized and recorded the results of
the audit in 2006 and thereafter paid all amounts due to the tax
authorities. Fiscal years 2002 through 2005 are currently under
audit. As of December 31, 2010, all proposed adjustments
are deemed immaterial and have been recognized in the financial
statements. Fiscal years 2006, 2007, 2008, 2009 and 2010 are
open to audit.
For the tax year 1997, the Company recognized an impairment of
one of its subsidiaries which the German tax authorities
disallowed in 2003 at the conclusion of its audit for the years
1996 and 1997. The Company filed a complaint with the
appropriate German court to challenge the tax authoritys
decision. In January 2011, the Company reached an agreement with
the tax authorities, estimated to be slightly more favorable
than the tax benefit recognized previously. The additional
benefit will be recognized in 2011.
In the U.S., the Company filed claims for refunds contesting the
Internal Revenue Services (IRS) disallowance
of FMCHs civil settlement payment deductions taken by FMCH
in prior year tax returns. As a result of a settlement agreement
with the IRS, the Company received a partial refund in September
2008 of $37,000, inclusive of interest and preserved the right
to continue to pursue claims in the United States Courts for
refunds of all other disallowed deductions. On December 22,
2008, we filed a complaint for a complete refund in the United
States District Court for the District of Massachusetts, styled
as FMCH v. United States. On June 24, 2010, the court
denied FMCHs motion for summary judgment and the
litigation is proceeding towards trial. The unrecognized tax
benefit relating to these deductions is included in the total
unrecognized tax benefit noted below.
The IRS tax audits of FMCH for the years 2002 through 2006 have
been completed. The IRS has disallowed all deductions taken
during these audit periods related to intercompany mandatorily
redeemable preferred shares. The Company has protested the
disallowed deductions and will avail itself of all remedies. An
adverse determination
F-39
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
with respect to the disallowed deductions related to the
intercompany mandatorily redeemable preferred shares could have
a material adverse effect on the results of operations and
liquidity. In addition, the IRS proposed other adjustments which
have been recognized in the financial statements.
Fiscal years 2007 and 2008 are currently under audit and 2009
and 2010 are open to audit. There are a number of state audits
in progress and various years are open to audit in various
states. All expected results have been recognized in the
financial statements.
Subsidiaries of FMC-AG & Co. KGaA in a number of
countries outside of Germany and the U.S. are also subject
to tax audits. The Company estimates that the effects of such
tax audits are not material to these consolidated financial
statements.
The following table shows the reconciliation of the beginning
and ending amounts of unrecognized tax benefits:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Unrecognized tax benefits (net of interest)
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at January 1, 2010
|
|
$
|
410,016
|
|
|
$
|
379,327
|
|
|
$
|
354,050
|
|
Increases in unrecognized tax benefits prior periods
|
|
|
12,782
|
|
|
|
59,833
|
|
|
|
24,074
|
|
Decreases in unrecognized tax benefits prior periods
|
|
|
(11,429
|
)
|
|
|
(13,911
|
)
|
|
|
(36,334
|
)
|
Increases in unrecognized tax benefits current period
|
|
|
13,588
|
|
|
|
7,587
|
|
|
|
20,180
|
|
Changes related to settlements with tax authorities
|
|
|
(34,410
|
)
|
|
|
(8,599
|
)
|
|
|
(2,042
|
)
|
Reductions as a result of a lapse of the statute of limitations
|
|
|
(129
|
)
|
|
|
|
|
|
|
|
|
Foreign currency translation
|
|
|
(14,518
|
)
|
|
|
(14,221
|
)
|
|
|
19,399
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2010
|
|
$
|
375,900
|
|
|
$
|
410,016
|
|
|
$
|
379,327
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included in the balance at December 31, 2010 are $347,081
of unrecognized tax benefits which would affect the effective
tax rate if recognized. As a result of the settlement agreement
for 1997 noted above, the Company estimates that the
unrecognized tax benefits at December 31, 2010 could be
reduced by approximately $196,000 in 2011 with a small portion
of the reduction being realized as an additional tax benefit in
2011. The Company is currently not in a position to forecast the
timing and magnitude of changes in other unrecognized tax
benefits.
During the year ended December 31, 2010 the Company
recognized $10,650 in interest and penalties. The Company had a
total accrual of $57,378 of tax related interest and penalties
at December 31, 2010.
The Company leases buildings and machinery and equipment under
various lease agreements expiring on dates through 2034. Rental
expense recorded for operating leases for the years ended
December 31, 2010, 2009 and 2008 was $563,182, $532,465 and
$497,875, respectively. For information regarding intercompany
operating leases, see Note 3 a).
Future minimum rental payments under noncancelable operating
leases for the five years succeeding December 31, 2010 and
thereafter are:
|
|
|
|
|
2011
|
|
$
|
489,481
|
|
2012
|
|
|
427,901
|
|
2013
|
|
|
376,255
|
|
2014
|
|
|
319,724
|
|
2015
|
|
|
272,369
|
|
Thereafter
|
|
|
910,381
|
|
|
|
|
|
|
|
|
|
2,796,111
|
|
|
|
|
|
|
F-40
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
|
|
18.
|
Commitments
and Contingencies
|
Legal
Proceedings
The Company is routinely involved in numerous claims, lawsuits,
regulatory and tax audits, investigations and other legal
matters arising, for the most part, in the ordinary course of
its business of providing healthcare services and products. The
outcome of litigation and other legal matters is always
difficult to accurately predict and outcomes that are not
consistent with the Companys view of the merits can occur.
The Company believes that it has valid defenses to the legal
matters pending against it and is defending itself vigorously.
Nevertheless, it is possible that the resolution of one or more
of the legal matters currently pending or threatened could have
a material adverse effect on its business, results of operations
and financial condition.
Commercial
Litigation
The Company was originally formed as a result of a series of
transactions it completed pursuant to the Agreement and Plan of
Reorganization dated as of February 4, 1996, by and between
W.R. Grace & Co. and Fresenius SE (the
Merger). At the time of the Merger, a W.R.
Grace & Co. subsidiary known as W.R. Grace &
Co.-Conn. had, and continues to have, significant liabilities
arising out of product-liability related litigation (including
asbestos-related actions), pre-Merger tax claims and other
claims unrelated to National Medical Care, Inc.
(NMC), which was W.R. Grace & Co.s
dialysis business prior to the Merger. In connection with the
Merger, W.R. Grace & Co.-Conn. agreed to indemnify the
Company, FMCH, and NMC against all liabilities of W.R.
Grace & Co., whether relating to events occurring
before or after the Merger, other than liabilities arising from
or relating to NMCs operations. W.R. Grace & Co.
and certain of its subsidiaries filed for reorganization under
Chapter 11 of the U.S. Bankruptcy Code (the
Grace Chapter 11 Proceedings) on April 2,
2001.
Prior to and after the commencement of the Grace Chapter 11
Proceedings, class action complaints were filed against W.R.
Grace & Co. and FMCH by plaintiffs claiming to be
creditors of W.R. Grace & Co.-Conn., and by the
asbestos creditors committees on behalf of the W.R.
Grace & Co. bankruptcy estate in the Grace
Chapter 11 Proceedings, alleging among other things that
the Merger was a fraudulent conveyance, violated the uniform
fraudulent transfer act and constituted a conspiracy. All such
cases have been stayed and transferred to or are pending before
the U.S. District Court as part of the Grace
Chapter 11 Proceedings.
In 2003, the Company reached agreement with the asbestos
creditors committees on behalf of the W.R.
Grace & Co. bankruptcy estate and W.R.
Grace & Co. in the matters pending in the Grace
Chapter 11 Proceedings for the settlement of all fraudulent
conveyance and tax claims against it and other claims related to
the Company that arise out of the bankruptcy of W.R.
Grace & Co. Under the terms of the settlement
agreement as amended (the Settlement Agreement),
fraudulent conveyance and other claims raised on behalf of
asbestos claimants will be dismissed with prejudice and the
Company will receive protection against existing and potential
future W.R. Grace & Co. related claims, including
fraudulent conveyance and asbestos claims, and indemnification
against income tax claims related to the non-NMC members of the
W.R. Grace & Co. consolidated tax group upon
confirmation of a W.R. Grace & Co. bankruptcy
reorganization plan that contains such provisions. Under the
Settlement Agreement, the Company will pay a total of $115,000
without interest to the W.R. Grace & Co. bankruptcy
estate, or as otherwise directed by the Court, upon plan
confirmation. No admission of liability has been or will be
made. The Settlement Agreement has been approved by the
U.S. District Court. On January 31, 2011, the U.S.
Bankruptcy Court approved W.R. Grace & Co.s plan of
reorganization, including the Settlement Agreement, and
recommended approval of the plan to the U.S. District Court.
Subsequent to the Merger, W.R. Grace & Co. was
involved in a multi-step transaction involving Sealed Air
Corporation (Sealed Air, formerly known as Grace
Holding, Inc.). The Company is engaged in litigation with Sealed
Air to confirm its entitlement to indemnification from Sealed
Air for all losses and expenses incurred by the Company relating
to pre-Merger tax liabilities and Merger-related claims. Under
the Settlement Agreement, upon final confirmation of a plan of
reorganization that satisfies the conditions of the
Companys payment obligation, this litigation will be
dismissed with prejudice.
On April 4, 2003, FMCH filed a suit in the
U.S. District Court for the Northern District of
California, styled Fresenius USA, Inc., et al., v. Baxter
International Inc., et al., Case No. C
03-1431,
seeking a declaratory judgment that FMCH does not infringe
patents held by Baxter International Inc. and its subsidiaries
and affiliates (Baxter), that the patents are
invalid, and that Baxter is without right or authority to
threaten or maintain suit against FMCH for alleged infringement
of Baxters patents. In general, the asserted patents
concern the use of touch screen interfaces for hemodialysis
machines. Baxter filed counterclaims against FMCH seeking more
than $140,000 in
F-41
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
monetary damages and injunctive relief, and alleging that FMCH
willfully infringed on Baxters patents. On July 17,
2006, the court entered judgment on a jury verdict in favor of
FMCH finding that all the asserted claims of the Baxter patents
are invalid as obvious
and/or
anticipated in light of prior art.
On February 13, 2007, the court granted Baxters
motion to set aside the jurys verdict in favor of FMCH and
reinstated the patents and entered judgment of infringement.
Following a trial on damages, the court entered judgment on
November 6, 2007 in favor of Baxter on a jury award of
$14,300. On April 4, 2008, the court denied Baxters
motion for a new trial, established a royalty payable to Baxter
of 10% of the sales price for continuing sales of FMCHs
2008K hemodialysis machines and 7% of the sales price of related
disposables, parts and service beginning November 7, 2007,
and enjoined sales of the touchscreen-equipped 2008K machine
effective January 1, 2009. The Company appealed the
courts rulings to the United States Court of Appeals for
the Federal Circuit (Federal Circuit). In October
2008, the Company completed design modifications to the 2008K
machine that eliminate any incremental hemodialysis machine
royalty payment exposure under the original District Court
order. On September 10, 2009, the Federal Circuit reversed
the district courts decision and determined that the
asserted claims in two of the three patents at issue are
invalid. As to the third patent, the Federal Circuit affirmed
the district courts decision; however, the Court also
vacated the injunction and award of damages. These issues were
remanded to the District Court for reconsideration in light of
the invalidity ruling on most of the claims. As a result, FMCH
is no longer required to fund the court-approved escrow account
set up to hold the royalty payments ordered by the district
court, although funds already contributed will remain in escrow
until the case is finally concluded. On March 18, 2010, the
U.S. Patent and Trademark Office (USPTO) and the Board of
Patent Appeals and Interferences ruled in reexamination that the
remaining Baxter patent is invalid. On October 5, 2010,
Baxter appealed the Boards ruling to the Federal Circuit.
On April 28, 2008, Baxter filed suit in the
U.S. District Court for the Northern District of Illinois,
Eastern Division (Chicago), styled Baxter International, Inc.
and Baxter Healthcare Corporation v. Fresenius Medical Care
Holdings, Inc. and Fresenius USA, Inc., Case No. CV 2389,
asserting that FMCHs hemodialysis machines infringe four
patents issued in 2007 and 2008, all of which are based on one
of the patents at issue in the April 2003 Baxter case described
above. The new patents expire in April 2011 and relate to trend
charts shown on touch screen interfaces and the entry of
ultrafiltration profiles (ultrafiltration is the removing of
liquid from a patients body using osmotic pressure). This
case is currently stayed pursuant to court order. The Company
believes that its hemodialysis machines do not infringe any
valid claims of the Baxter patents at issue. All the asserted
patents now stand rejected in an ongoing reexamination at the
USPTO.
On October 17, 2006, Baxter and DEKA Products Limited
Partnership (DEKA) filed suit in the U.S. District Court
for the Eastern District of Texas which was subsequently
transferred to the Northern District of California, styled
Baxter Healthcare Corporation and DEKA Products Limited
Partnership v. Fresenius Medical Care Holdings, Inc. d/b/a
Fresenius Medical Care North America and Fresenius USA, Inc.,
Case No. CV 438 TJW. The complaint alleged that FMCHs
Liberty
tm
cycler infringes nine patents owned by or licensed to Baxter.
During and after discovery, seven of the asserted patents were
dropped from the suit. On July 28, 2010, at the conclusion
of the trial, the jury returned a verdict in favor of FMCH
finding that the
Liberty
tm
cycler does not infringe any of the asserted claims of the
Baxter patents. Baxter has asked the District Court to overturn
the jury verdict.
A patent infringement action had been pending in Germany between
Gambro Industries (Gambro) on the one side and
D-GmbH and FMC-AG & Co. KGaA on the other side
(hereinafter collectively Fresenius Medical Care).
Fresenius Medical Care and Gambro have resolved this and other
current patent infringement lawsuits between the parties by
entering into respective settlements and a series of patent
licenses between the parties.
Other
Litigation and Potential Exposures
Renal Care Group, Inc. (RCG) is named as a nominal
defendant in a complaint originally filed September 13,
2006 in the Chancery Court for the State of Tennessee Twentieth
Judicial District at Nashville styled Indiana State District
Council of Laborers and Hod Carriers Pension Fund v. Gary
Brukardt et al. Following the trial courts dismissal of
the complaint, plaintiffs appeal in part, and reversal in
part by the appellate court, the cause of action purports to be
a class action on behalf of former shareholders of RCG and seeks
monetary damages only against the individual former directors of
RCG. The individual defendants, however, may have claims for
indemnification and reimbursement of expenses against the
Company. The Company expects to continue as a defendant in the
litigation, which is proceeding toward trial in the Chancery
Court, and believes that defendants will prevail.
F-42
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
On July 17, 2007, resulting from an investigation begun in
2005, the United States Attorney filed a civil complaint in the
United States District Court for the Eastern District of
Missouri (St. Louis) against Renal Care Group, Inc., its
subsidiary RCG Supply Company, and FMCH in its capacity as
RCGs current corporate parent. The complaint seeks
monetary damages and penalties with respect to issues arising
out of the operation of RCGs Method II supply company
through 2005, prior to FMCHs acquisition of RCG in 2006.
The complaint is styled United States of America ex rel. Julie
Williams et al. vs. Renal Care Group, Renal Care Group Supply
Company and FMCH. On August 11, 2009, the Missouri District
Court granted RCGs motion to transfer venue to the United
States District Court for the Middle District of Tennessee
(Nashville). On March 22, 2010, the Tennessee District
Court entered judgment against defendants for approximately
$23,000 in damages and interest under the unjust enrichment
count of the complaint but denied all relief under the six False
Claims Act counts of the complaint. The Company appealed the
Tennessee District Courts decision to the United States
Court of Appeals for the Sixth Circuit and secured a stay of
enforcement of the judgment pending appeal. The United States
Attorney filed a cross appeal, but also asked the Tennessee
District Court for an indicative or supplemental ruling. On
June 23, 2010, the Tennessee District Court issued an
indicative ruling to the effect that, if the case were remanded
to the District Court, it would expect to enter a judgment under
the False Claims Act against the Company for approximately
$104,000. On September 23, 2010, the Court of Appeals
remanded the case to the Tennessee District Court to permit
revision or supplementation of the original judgment, after
which the Company may pursue its appeals to the Court of
Appeals. The Company believes that RCGs operation of its
Method II supply company was in compliance with applicable
law, that no relief is due to the United States, and that its
position in the litigation will ultimately be sustained.
On November 27, 2007, the United States District Court for
the Western District of Texas (El Paso) unsealed and
permitted service of two complaints previously filed under seal
by a qui tam relator, a former FMCH local clinic employee. The
first complaint alleged that a nephrologist unlawfully employed
in his practice an assistant to perform patient care tasks that
the assistant was not licensed to perform and that Medicare
billings by the nephrologist and FMCH therefore violated the
False Claims Act. The second complaint alleged that FMCH
unlawfully retaliated against the relator by discharging her
from employment constructively. The United States Attorney for
the Western District of Texas declined to intervene and to
prosecute on behalf of the United States. On March 30,
2010, the District Court issued final judgment in favor of
defendants on all counts based on a jury verdict rendered on
February 25, 2010 and on rulings of law made by the Court
during the trial. The plaintiff has appealed from the District
Court judgment.
The Company filed claims for refunds contesting the Internal
Revenue Services (IRS) disallowance of
FMCHs civil settlement payment deductions taken by FMCH in
prior year tax returns. As a result of a settlement agreement
with the IRS, the Company received a partial refund in September
2008 of $37,000, inclusive of interest and preserved our right
to pursue claims in the United States Courts for refunds of all
other disallowed deductions. On December 22, 2008, the
Company filed a complaint for complete refund in the United
States District Court for the District of Massachusetts, styled
as Fresenius Medical Care Holdings, Inc. v United States. On
June 24, 2010, the court denied FMCHs motion for
summary judgment and the litigation is proceeding towards trial.
For the tax year 1997, the Company recognized an impairment of
one of our subsidiaries which the German tax authorities
disallowed in 2003 at the conclusion of its audit for the years
1996 and 1997. The Company has filed a complaint with the
appropriate German court to challenge the tax authoritys
decision. In January 2011, the Company reached an agreement with
the tax authorities, estimated to be slightly more favorable
than the tax benefit recognized previously. The additional
benefit will be recognized in 2011.
The IRS tax audits of FMCH for the years 2002 through 2006 have
been completed. The IRS has disallowed all deductions taken
during these audit periods related to intercompany mandatorily
redeemable preferred shares. The Company has protested the
disallowed deductions and will avail itself of all remedies. An
adverse determination with respect to the disallowed deductions
related to intercompany mandatorily redeemable preferred shares
could have a material adverse effect on our results of
operations and liquidity. In addition, the IRS proposed other
adjustments which have been recognized in the financial
statements.
From time to time, the Company is a party to or may be
threatened with other litigation or arbitration, claims or
assessments arising in the ordinary course of its business.
Management regularly analyzes current information including, as
applicable, the Companys defenses and insurance coverage
and, as necessary, provides accruals for probable liabilities
for the eventual disposition of these matters.
F-43
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
The Company, like other health care providers, conducts its
operations under intense government regulation and scrutiny. It
must comply with regulations which relate to or govern the
safety and efficacy of medical products and supplies, the
operation of manufacturing facilities, laboratories and dialysis
clinics, and environmental and occupational health and safety.
The Company must also comply with the Anti-Kickback Statute, the
False Claims Act, the Stark Law, and other federal and state
fraud and abuse laws. Applicable laws or regulations may be
amended, or enforcement agencies or courts may make
interpretations that differ from the Companys
interpretations or the manner in which it conducts its business.
Enforcement has become a high priority for the federal
government and some states.
In addition, the provisions of the False Claims Act authorizing
payment of a portion of any recovery to the party bringing the
suit encourage private plaintiffs to commence whistle
blower actions. In May 2009, the scope of the False Claims
Act was expanded and additional protections for whistle blowers
and procedural provisions to aid whistle blowers ability
to proceed in a False Claims Act case were added. By virtue of
this regulatory environment, the Companys business
activities and practices are subject to extensive review by
regulatory authorities and private parties, and continuing
audits, investigative demands, subpoenas, other inquiries,
claims and litigation relating to the Companys compliance
with applicable laws and regulations. The Company may not always
be aware that an inquiry or action has begun, particularly in
the case of whistle blower actions, which are
initially filed under court seal.
The Company operates many facilities throughout the United
States. In such a decentralized system, it is often difficult to
maintain the desired level of oversight and control over the
thousands of individuals employed by many affiliated companies.
The Company relies upon its management structure, regulatory and
legal resources, and the effective operation of its compliance
program to direct, manage and monitor the activities of these
employees. On occasion, the Company may identify instances where
employees, deliberately or inadvertently, have submitted
inadequate or false billings. The actions of such persons may
subject the Company and its subsidiaries to liability under the
Anti-Kickback Statute, the Stark Law and the False Claims Act,
among other laws.
Physicians, hospitals and other participants in the health care
industry are also subject to a large number of lawsuits alleging
professional negligence, malpractice, product liability,
workers compensation or related claims, many of which
involve large claims and significant defense costs. The Company
has been and is currently subject to these suits due to the
nature of its business and expects that those types of lawsuits
may continue. Although the Company maintains insurance at a
level which it believes to be prudent, it cannot assure that the
coverage limits will be adequate or that insurance will cover
all asserted claims. A successful claim against the Company or
any of its subsidiaries in excess of insurance coverage could
have a material adverse effect upon it and the results of its
operations. Any claims, regardless of their merit or eventual
outcome, could have a material adverse effect on the
Companys reputation and business.
The Company has also had claims asserted against it and has had
lawsuits filed against it relating to alleged patent
infringements or businesses that it has acquired or divested.
These claims and suits relate both to operation of the
businesses and to the acquisition and divestiture transactions.
The Company has, when appropriate, asserted its own claims, and
claims for indemnification. A successful claim against the
Company or any of its subsidiaries could have a material adverse
effect upon its business, financial condition, and the results
of its operations. Any claims, regardless of their merit or
eventual outcome, could have a material adverse effect on the
Companys reputation and business.
Accrued
Special Charge for Legal Matters
At December 31, 2001, the Company recorded a pre-tax
special charge of $258,159 to reflect anticipated expenses
associated with the defense and resolution of pre-Merger tax
claims, Merger-related claims, and commercial insurer claims.
The costs associated with the Settlement Agreement and
settlements with insurers have been charged against this
accrual. With the exception of the proposed $115,000 payment
under the Settlement Agreement in the Grace Chapter 11
Proceedings, all other matters included in the special charge
have been resolved. While the Company believes that its
remaining accrual reasonably estimates its currently anticipated
costs related to the continued defense and resolution of this
matter, no assurances can be given that its actual costs
incurred will not exceed the amount of this accrual.
F-44
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
|
|
19.
|
Financial
Instruments
|
As a global supplier of dialysis services and products in more
than 120 countries throughout the world, the Company is faced
with a concentration of credit risks due to the nature of the
reimbursement systems which are often provided by the
governments of the countries in which the Company operates.
Changes in reimbursement rates or the scope of coverage could
have a material adverse effect on the Companys business,
financial condition and results of operations and thus on its
capacity to generate cash flow. In the past we experienced and,
after the implementation of the new bundled reimbursement system
in the U.S., also expect in the future generally stable
reimbursements for our dialysis services. This includes the
balancing of unfavorable reimbursement changes in certain
countries with favorable changes in other countries. Due to the
fact that a large portion of the Companys reimbursement is
provided by public health care organizations and private
insurers, the Company expects that most of its accounts
receivables will be collectable, albeit somewhat more slowly in
the International segment in the immediate future, particularly
in countries which continue to be severely affected by the
global financial crisis.
Non-derivative
Financial Instruments
The following table presents the carrying amounts and fair
values of the Companys non-derivative financial
instruments at December 31, 2010, and December 31,
2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
|
Carrying
|
|
|
Fair
|
|
|
Carrying
|
|
|
Fair
|
|
|
|
Amount
|
|
|
Value
|
|
|
Amount
|
|
|
Value
|
|
|
Non-derivatives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
522,870
|
|
|
$
|
522,870
|
|
|
$
|
301,225
|
|
|
$
|
301,225
|
|
Accounts Receivable
|
|
|
2,687,234
|
|
|
|
2,687,234
|
|
|
|
2,558,795
|
|
|
|
2,558,795
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
|
542,524
|
|
|
|
542,524
|
|
|
|
639,836
|
|
|
|
639,836
|
|
Short-term borrowings
|
|
|
670,671
|
|
|
|
670,671
|
|
|
|
316,344
|
|
|
|
316,344
|
|
Short-term borrowings from related parties
|
|
|
9,683
|
|
|
|
9,683
|
|
|
|
10,440
|
|
|
|
10,440
|
|
Long term debt, excluding Amended 2006 Senior Credit Agreement,
Euro Notes and Senior Notes
|
|
|
528,082
|
|
|
|
528,082
|
|
|
|
282,051
|
|
|
|
282,051
|
|
Amended 2006 Senior Credit Agreement
|
|
|
2,953,890
|
|
|
|
2,937,504
|
|
|
|
3,522,040
|
|
|
|
3,429,470
|
|
Euro Notes
|
|
|
267,240
|
|
|
|
276,756
|
|
|
|
288,120
|
|
|
|
299,621
|
|
Senior Notes
|
|
|
824,446
|
|
|
|
880,366
|
|
|
|
493,344
|
|
|
|
498,750
|
|
Trust Preferred Securities
|
|
|
625,549
|
|
|
|
643,828
|
|
|
|
656,096
|
|
|
|
688,026
|
|
Noncontrolling interests subject to put provisions
|
|
|
279,709
|
|
|
|
279,709
|
|
|
|
231,303
|
|
|
|
231,303
|
|
The carrying amounts in the table are included in the
consolidated balance sheet under the indicated captions or in
the case of long-term debt, as noted in the captions shown in
Note 9.
The significant methods and assumptions used in estimating the
fair values of non-derivative financial instruments are as
follows:
Cash and cash equivalents are stated at nominal value which
equals the fair value.
Short-term financial instruments such as accounts receivable,
accounts payable and short-term borrowings are valued at their
carrying amounts, which are reasonable estimates of the fair
value due to the relatively short period to maturity of these
instruments.
The fair values of the major long-term financial liabilities are
calculated on the basis of market information. Instruments for
which market quotes are available are measured using these
quotes. The fair values of the other long-term financial
liabilities are calculated at the present value of the
respective future cash flows. To determine these present values,
the prevailing interest rates and credit spreads for the Company
as of the balance sheet date are used.
The valuation of the noncontrolling interests subject to put
provisions is determined using significant unobservable inputs
(Level 3). See Note 12 for a discussion of the
Companys methodology for estimating the fair value of
these noncontrolling interests subject to put obligations.
F-45
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
The credit risk exposure related to the companys financing
receivables is insignificant and any impact on our operating
results from allowances on credit losses of financing
receivables can be considered immaterial.
Derivative
Financial Instruments
The Company is exposed to market risk from changes in interest
rates and foreign exchange rates. In order to manage the risk of
interest rate and currency exchange rate fluctuations, the
Company enters into various hedging transactions by means of
derivative instruments with highly rated financial institutions
as authorized by the Companys General Partner. On a
quarterly basis the Company performs an assessment of its
counterparty credit risk. The Company currently considers this
risk to be low. The Companys policy, which has been
consistently followed, is that financial derivatives be used
only for the purpose of hedging foreign currency and interest
rate exposure.
In certain instances, the Company enters into derivative
contracts that do not qualify for hedge accounting but are
utilized for economic purposes (economic hedges).
The Company does not use financial instruments for trading
purposes.
The Company established guidelines for risk assessment
procedures and controls for the use of financial instruments.
They include a clear segregation of duties with regard to
execution on one side and administration, accounting and
controlling on the other.
Foreign
Exchange Risk Management
The Company conducts business on a global basis in various
currencies, though its operations are mainly in Germany and the
United States. For financial reporting purposes, the Company has
chosen the U.S. dollar as its reporting currency.
Therefore, changes in the rate of exchange between the
U.S. dollar and the local currencies in which the financial
statements of the Companys international operations are
maintained affect its results of operations and financial
position as reported in its consolidated financial statements.
The Companys exposure to market risk for changes in
foreign exchange rates relates to transactions such as sales and
purchases. The Company has significant amounts of sales of
products invoiced in euro from its European manufacturing
facilities to its other international operations and, to a
lesser extent, sales of products invoiced in other
non-functional currencies. This exposes the subsidiaries to
fluctuations in the rate of exchange between the euro and the
currency in which their local operations are conducted. For the
purpose of hedging existing and foreseeable foreign exchange
transaction exposures the Company enters into foreign exchange
forward contracts and, on a small scale, foreign exchange
options. As of December 31, 2010 the Company had no foreign
exchange options.
Changes in the fair value of the effective portion of foreign
exchange forward contracts designated and qualifying as cash
flow hedges of forecasted product purchases and sales are
reported in accumulated other comprehensive income (loss)
(AOCI). Additionally, in connection with
intercompany loans in foreign currency, the Company uses foreign
exchange swaps thus assuring that no foreign exchange risks
arise from those loans, which, if they qualify for cash flow
hedge accounting, are also reported in AOCI. These amounts
recorded in AOCI are subsequently reclassified into earnings as
a component of cost of revenues for those contracts that hedge
product purchases or SG&A for those contracts that hedge
loans, in the same period in which the hedged transaction
affects earnings. The notional amounts of foreign exchange
contracts in place that are designated and qualify as cash flow
hedges totaled $1,026,937 and $1,076,217 at December 31,
2010 and December 31, 2009, respectively.
The Company also enters into derivative contracts for forecasted
product purchases and sales and for intercompany loans in
foreign currency that do not qualify for hedge accounting but
are utilized for economic hedges as defined above. In these
cases, the change in value of the economic hedge is recorded in
the income statement and usually offsets the change in value
recorded in the income statement for the underlying asset or
liability. The notional amounts of economic hedges that do not
qualify for hedge accounting totaled $1,607,312 and $750,812 at
December 31, 2010 and December 31, 2009, respectively.
Interest
Rate Risk Management
The Company enters into derivatives, particularly interest rate
swaps and to a certain extent, interest rate options, to protect
against the risk of changes in interest rates. These interest
rate derivatives are designated as cash
F-46
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
flow hedges. The majority of the interest rate swap agreements
effectively convert the major part of payments based on variable
interest rates applicable to the Companys Amended 2006
Senior Credit Agreement denominated in U.S. dollars into
payments at a fixed interest rate. The remaining interest rate
swaps have been entered into in anticipation of future debt
issuances. The swap agreements, all of which expire at various
dates in 2011 and 2012, bear an average interest rate of 4.26%.
Interest payable and receivable under the swap agreements is
accrued and recorded as an adjustment to interest expense.
As of December 31, 2010 and 2009, the notional amounts of
interest rate swaps in place were $3,175,000 and $2,400,000,
respectively.
Derivative
Financial Instruments Valuation
The following table shows the Companys derivatives at
December 31, 2010 and December 31, 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2010
|
|
|
December 31, 2009
|
|
|
|
Assets
(2)
|
|
|
Liabilities
(2)
|
|
|
Assets
(2)
|
|
|
Liabilities
(2)
|
|
|
Derivatives in cash flow hedging
relationships
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts
|
|
|
3,703
|
|
|
|
(51,816
|
)
|
|
|
8,899
|
|
|
|
(9,251
|
)
|
Interest rate contracts (Dollar)
|
|
|
|
|
|
|
(51,604
|
)
|
|
|
|
|
|
|
(305
|
)
|
Interest rate contracts (Yen)
|
|
|
|
|
|
|
(0
|
)
|
|
|
|
|
|
|
|
|
Noncurrent
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts
|
|
|
810
|
|
|
|
(486
|
)
|
|
|
5,284
|
|
|
|
(830
|
)
|
Interest rate contracts (Dollar)
|
|
|
|
|
|
|
(73,221
|
)
|
|
|
|
|
|
|
(105,810
|
)
|
Interest rate contracts (Yen)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
4,513
|
|
|
$
|
(177,127
|
)
|
|
$
|
14,183
|
|
|
$
|
(116,199
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivatives not designated as hedging
instruments
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts
|
|
|
3,517
|
|
|
|
(20,751
|
)
|
|
|
7,696
|
|
|
|
(6,217
|
)
|
Non-current
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts
|
|
|
509
|
|
|
|
(213
|
)
|
|
|
9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
4,026
|
|
|
$
|
(20,964
|
)
|
|
$
|
7,705
|
|
|
$
|
(6,217
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
As of December 31, 2010 and
December 31, 2009, the valuation of the Companys
derivatives was determined using Significant Other Observable
Inputs (Level 2) in accordance with the fair value
hierarchy levels established in the Codification.
|
|
(2)
|
|
Derivative instruments are marked
to market each reporting period resulting in carrying amounts
being equal to fair values at the reporting date.
|
The carrying amounts for the current portion of derivatives
indicated as assets in the table above are included in Prepaid
expenses and other current assets in the Consolidated Balance
Sheets while the current portion of those indicated as
liabilities are included in Accrued expenses and other current
liabilities. The non-current portions indicated as assets or
liabilities are included in the Consolidated Balance Sheets in
Other assets or Other liabilities, respectively.
The significant methods and assumptions used in estimating the
fair values of derivative financial instruments are as follows:
The fair value of interest rate swaps is calculated by
discounting the future cash flows on the basis of the market
interest rates applicable for the remaining term of the contract
as of the balance sheet date. To determine the fair value of
foreign exchange forward contracts, the contracted forward rate
is compared to the current forward rate for the remaining term
of the contract as of the balance sheet date. The result is then
discounted on the basis of the market interest rates prevailing
at the balance sheet date for the applicable currency.
The Company includes its own credit risk for financial
instruments deemed liabilities and counterparty-credit risks for
financial instruments deemed assets when measuring the fair
value of derivative financial instruments.
F-47
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
The
Effect of Derivatives on the Consolidated Financial
Statements
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of (Gain)
|
|
|
|
Amount of Gain or
|
|
|
|
|
or Loss Reclassified
|
|
|
|
(Loss) Recognized in
|
|
|
|
|
from AOCI in
|
|
|
|
OCI on Derivatives
|
|
|
|
|
Income (Effective
|
|
|
|
(Effective Portion)
|
|
|
Location of (Gain)
|
|
Portion) for the
|
|
|
|
for the year ended
|
|
|
or Loss Reclassified
|
|
year ended
|
|
Derivatives in Cash Flow
|
|
December 31,
|
|
|
from AOCI in Income
|
|
December 31,
|
|
Hedging Relationships
|
|
2010
|
|
|
2009
|
|
|
(Effective Portion)
|
|
2010
|
|
|
2009
|
|
|
Interest rate contracts (Dollar)
|
|
$
|
(18,710
|
)
|
|
$
|
42,832
|
|
|
Interest income/expense
|
|
$
|
|
|
|
$
|
(33
|
)
|
Interest rate contracts (Yen)
|
|
|
2
|
|
|
|
6
|
|
|
Interest income/expense
|
|
|
|
|
|
|
|
|
Foreign exchange contracts
|
|
|
3,046
|
|
|
|
(6,785
|
)
|
|
Costs of Revenue
|
|
|
7,553
|
|
|
|
(5,938
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(15,662
|
)
|
|
$
|
36,053
|
|
|
|
|
$
|
7,553
|
|
|
$
|
(5,971
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of (Gain) or Loss Recognized in
|
|
|
|
|
|
Location of (Gain) or
|
|
Income on Derivatives
|
|
|
|
Derivatives not Designated as
|
|
Loss Recognized in
|
|
for the year ended December 31,
|
|
|
|
Hedging Instruments
|
|
Income on Derivative
|
|
2010
|
|
|
2009
|
|
|
|
|
Foreign exchange contracts
|
|
Selling, general and
administrative expense
|
|
$
|
72,454
|
|
|
$
|
(3,309
|
)
|
|
|
|
|
Interest income/expense
|
|
|
(8,622
|
)
|
|
|
3,883
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
63,832
|
|
|
$
|
574
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For foreign exchange derivatives, the Company expects to
recognize $3,745 of losses deferred in accumulated other
comprehensive income at December 31, 2010, in earnings
during the next twelve months.
The Company expects to incur additional interest expense of
$63,812 over the next twelve months which is currently deferred
in accumulated other comprehensive income. This amount reflects
the current fair value at December 31, 2010, of expected
additional interest payments resulting from interest rate swaps
entered into to reduce the volatility of interest payments for
certain parts of the Amended 2006 Credit Agreement and for
future debt issuances.
As of December 31, 2010, the Company had foreign exchange
derivatives with maturities of up to 59 months and interest
rate swaps with maturities of up to 20 months.
|
|
20.
|
Other
Comprehensive Income (Loss)
|
The changes in the components of other comprehensive income
(loss) for the years ended December 31, 2010, 2009, and
2008 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, 2010
|
|
|
Year ended December 31, 2009
|
|
|
Year ended December 31, 2008
|
|
|
|
|
|
|
Tax
|
|
|
|
|
|
|
|
|
Tax
|
|
|
|
|
|
|
|
|
Tax
|
|
|
|
|
|
|
Pretax
|
|
|
Effect
|
|
|
Net
|
|
|
Pretax
|
|
|
Effect
|
|
|
Net
|
|
|
Pretax
|
|
|
Effect
|
|
|
Net
|
|
|
Other comprehensive income (loss) relating to cash flow hedges:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Changes in fair value of cash flow hedges during the period
|
|
|
(15,662
|
)
|
|
|
2,241
|
|
|
|
(13,421
|
)
|
|
|
36,053
|
|
|
|
(16,419
|
)
|
|
|
19,634
|
|
|
|
(107,316
|
)
|
|
|
42,764
|
|
|
|
(64,552
|
)
|
Reclassification adjustments
|
|
|
7,553
|
|
|
|
(1,928
|
)
|
|
|
5,625
|
|
|
|
(5,971
|
)
|
|
|
1,375
|
|
|
|
(4,596
|
)
|
|
|
(924
|
)
|
|
|
296
|
|
|
|
(628
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other comprehensive income (loss) relating to cash flow
hedges:
|
|
|
(8,109
|
)
|
|
|
313
|
|
|
|
(7,796
|
)
|
|
|
30,082
|
|
|
|
(15,044
|
)
|
|
|
15,038
|
|
|
|
(108,240
|
)
|
|
|
43,060
|
|
|
|
(65,180
|
)
|
Foreign-currency translation adjustment
|
|
|
(110,888
|
)
|
|
|
|
|
|
|
(110,888
|
)
|
|
|
82,545
|
|
|
|
|
|
|
|
82,545
|
|
|
|
(170,748
|
)
|
|
|
|
|
|
|
(170,748
|
)
|
Adjustments related to pension obligations
|
|
|
(35,654
|
)
|
|
|
12,508
|
|
|
|
(23,146
|
)
|
|
|
9,708
|
|
|
|
(3,927
|
)
|
|
|
5,781
|
|
|
|
(28,551
|
)
|
|
|
12,632
|
|
|
|
(15,919
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss)
|
|
$
|
(154,651
|
)
|
|
$
|
12,821
|
|
|
$
|
(141,830
|
)
|
|
$
|
122,335
|
|
|
$
|
(18,971
|
)
|
|
$
|
103,364
|
|
|
$
|
(307,539
|
)
|
|
$
|
55,692
|
|
|
$
|
(251,847
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-48
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
|
|
21.
|
Business
Segment Information
|
The Company has identified three business segments, North
America, International, and Asia Pacific, which were determined
based upon how the Company manages its businesses. All segments
are primarily engaged in providing dialysis services and
manufacturing and distributing products and equipment for the
treatment of end-stage renal disease. In the U.S., the Company
also engages in performing clinical laboratory testing and
providing inpatient dialysis services, and other services under
contract to hospitals. The Company has aggregated the
International and Asia Pacific operating segments as
International. The segments are aggregated due to
their similar economic characteristics. These characteristics
include the same services provided and the same products sold,
the same type patient population, similar methods of
distribution of products and services and similar economic
environments.
Management evaluates each segment using a measure that reflects
all of the segments controllable revenues and expenses.
Management believes that the most appropriate measure in this
regard is operating income which measures the Companys
source of earnings. Financing is a corporate function, which the
Companys segments do not control. Therefore, the Company
does not include interest expense relating to financing as a
segment measure. Similarly, the Company does not allocate
corporate costs which relate primarily to certain
headquarters overhead charges, including accounting and finance,
professional services, etc., because the Company believes that
these costs are also not within the control of the individual
segments. The Company also regards income taxes to be outside
the segments control. In addition, certain acquisitions
and intangible assets are not allocated to a segment but are
accounted for as corporate.
F-49
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North
|
|
|
|
|
|
Segment
|
|
|
|
|
|
|
|
|
|
America
|
|
|
International
|
|
|
Total
|
|
|
Corporate
|
|
|
Total
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue external customers
|
|
$
|
8,129,737
|
|
|
$
|
3,923,301
|
|
|
$
|
12,053,038
|
|
|
$
|
452
|
|
|
$
|
12,053,490
|
|
Inter-segment revenue
|
|
|
5,419
|
|
|
|
88,965
|
|
|
|
94,384
|
|
|
|
(94,384
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
|
8,135,156
|
|
|
|
4,012,266
|
|
|
|
12,147,422
|
|
|
|
(93,932
|
)
|
|
|
12,053,490
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
(287,062
|
)
|
|
|
(207,072
|
)
|
|
|
(494,134
|
)
|
|
|
(9,090
|
)
|
|
|
(503,224
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income
|
|
|
1,385,651
|
|
|
|
677,630
|
|
|
|
2,063,281
|
|
|
|
(139,476
|
)
|
|
|
1,923,805
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment assets
|
|
|
11,720,495
|
|
|
|
4,787,479
|
|
|
|
16,507,974
|
|
|
|
586,687
|
|
|
|
17,094,661
|
|
thereof investments in equity method investees
|
|
|
243,452
|
|
|
|
6,921
|
|
|
|
250,373
|
|
|
|
|
|
|
|
250,373
|
|
Capital expenditures, acquisitions and
investments
(1)
|
|
|
524,330
|
|
|
|
608,263
|
|
|
|
1,132,593
|
|
|
|
155,374
|
|
|
|
1,287,967
|
|
2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue external customers
|
|
$
|
7,611,500
|
|
|
$
|
3,635,373
|
|
|
$
|
11,246,873
|
|
|
$
|
604
|
|
|
$
|
11,247,477
|
|
Inter-segment revenue
|
|
|
2,752
|
|
|
|
77,856
|
|
|
|
80,608
|
|
|
|
(80,608
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
|
7,614,252
|
|
|
|
3,713,229
|
|
|
|
11,327,481
|
|
|
|
(80,004
|
)
|
|
|
11,247,477
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
(264,785
|
)
|
|
|
(183,405
|
)
|
|
|
(448,190
|
)
|
|
|
(8,895
|
)
|
|
|
(457,085
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income
|
|
|
1,249,769
|
|
|
|
636,665
|
|
|
|
1,886,434
|
|
|
|
(130,838
|
)
|
|
|
1,755,596
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment assets
|
|
|
11,202,999
|
|
|
|
4,253,058
|
|
|
|
15,456,057
|
|
|
|
365,258
|
|
|
|
15,821,315
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
thereof investments in equity method investees
|
|
|
|
|
|
|
5,795
|
|
|
|
5,795
|
|
|
|
|
|
|
|
5,795
|
|
Capital expenditures, acquisitions and
investments
(2)
|
|
|
422,537
|
|
|
|
338,000
|
|
|
|
760,537
|
|
|
|
1,182
|
|
|
|
761,719
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue external customers
|
|
$
|
7,005,401
|
|
|
$
|
3,606,270
|
|
|
$
|
10,611,671
|
|
|
$
|
652
|
|
|
$
|
10,612,323
|
|
Inter-segment revenue
|
|
|
2,100
|
|
|
|
82,283
|
|
|
|
84,383
|
|
|
|
(84,383
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
|
7,007,501
|
|
|
|
3,688,553
|
|
|
|
10,696,054
|
|
|
|
(83,731
|
)
|
|
|
10,612,323
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
(238,300
|
)
|
|
|
(169,999
|
)
|
|
|
(408,299
|
)
|
|
|
(7,372
|
)
|
|
|
(415,671
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income
|
|
|
1,168,173
|
|
|
|
616,034
|
|
|
|
1,784,207
|
|
|
|
(111,775
|
)
|
|
|
1,672,432
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment assets
|
|
|
10,960,264
|
|
|
|
3,557,247
|
|
|
|
14,517,511
|
|
|
|
402,165
|
|
|
|
14,919,676
|
|
thereof investments in equity method investees
|
|
|
|
|
|
|
4,396
|
|
|
|
4,396
|
|
|
|
|
|
|
|
4,396
|
|
Capital expenditures, acquisitions and
investments
(3)
|
|
|
497,612
|
|
|
|
358,930
|
|
|
|
856,542
|
|
|
|
107,287
|
|
|
|
963,829
|
|
|
|
|
(1)
|
|
North America, International and
Corporate acquisitions exclude $122,847, $32,935 and $2,125,
respectively, of non-cash acquisitions and investments for 2010.
|
|
(2)
|
|
International acquisitions exclude
$4,151 of non-cash acquisitions for 2009.
|
|
(3)
|
|
North America and International
acquisitions exclude $22,542 and $24,710, respectively, of
non-cash acquisitions and investments for 2008.
|
F-50
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
For the geographic presentation, revenues are attributed to
specific countries based on the end users location for
products and the country in which the service is provided.
Information with respect to the Companys geographic
operations is set forth in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North
|
|
|
Rest of
|
|
|
|
|
|
|
Germany
|
|
|
America
|
|
|
the World
|
|
|
Total
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
$
|
374,883
|
|
|
$
|
8,129,737
|
|
|
$
|
3,548,870
|
|
|
$
|
12,053,490
|
|
Long-lived assets
|
|
|
471,537
|
|
|
|
9,236,166
|
|
|
|
2,139,877
|
|
|
|
11,847,580
|
|
2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
$
|
358,060
|
|
|
$
|
7,611,500
|
|
|
$
|
3,277,917
|
|
|
$
|
11,247,477
|
|
Long-lived assets
|
|
|
350,194
|
|
|
|
8,864,165
|
|
|
|
1,809,114
|
|
|
|
11,023,473
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
$
|
350,995
|
|
|
$
|
7,005,401
|
|
|
$
|
3,255,927
|
|
|
$
|
10,612,323
|
|
Long-lived assets
|
|
|
306,963
|
|
|
|
8,706,790
|
|
|
|
1,597,576
|
|
|
|
10,611,329
|
|
|
|
22.
|
Supplementary
Cash Flow Information
|
The following additional information is provided with respect to
the consolidated statements of cash flows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Supplementary cash flow information:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
264,525
|
|
|
$
|
332,731
|
|
|
$
|
357,295
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for income
taxes
(1)
|
|
$
|
520,766
|
|
|
$
|
425,945
|
|
|
$
|
343,224
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash inflow for income taxes from stock option exercises
|
|
$
|
13,313
|
|
|
$
|
8,123
|
|
|
$
|
7,132
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures of cash flow information:
|
|
|
|
|
|
|
|
|
|
|
|
|
Details for acquisitions:
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets acquired
|
|
$
|
(668,198
|
)
|
|
$
|
(241,745
|
)
|
|
$
|
(129,711
|
)
|
Liabilities assumed
|
|
|
102,698
|
|
|
|
20,574
|
|
|
|
9,858
|
|
Noncontrolling interests
|
|
|
36,141
|
|
|
|
35,448
|
|
|
|
(3,706
|
)
|
Notes assumed in connection with acquisition
|
|
|
31,666
|
|
|
|
4,151
|
|
|
|
2,490
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid
|
|
|
(497,693
|
)
|
|
|
(181,572
|
)
|
|
|
(121,069
|
)
|
Less cash acquired
|
|
|
16,318
|
|
|
|
7,059
|
|
|
|
714
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash paid for acquisitions
|
|
$
|
(481,375
|
)
|
|
$
|
(174,513
|
)
|
|
$
|
(120,355
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.
|
Supplemental
Condensed Combining Information
|
In June 2001 FMC Trust Finance S.à.r.l.
Luxembourg III, a wholly-owned subsidiary of FMC-AG &
Co. KGaA, issued euro-denominated and
U.S. dollar-denominated senior subordinated debt
securities, fully and unconditionally guaranteed, jointly and
severally, on a senior subordinated basis, by FMC-AG &
Co. KGaA,
D-GmbH
and
FMCH (D-GmbH and FMCH being the Guarantor
Subsidiaries). The senior subordinated debt securities
were issued to Fresenius Medical Care Capital Trust IV and
Fresenius Medical Care Capital Trust V, statutory trusts
organized under the laws of the State of Delaware, which issued
trust preferred securities that were guaranteed by the Company
through a series of undertakings by the Company and the
Guarantor Subsidiaries, and the Company acquired all of the
common securities of the trusts. In December 2004, the Company
assumed the obligations of its wholly owned subsidiary as the
issuer of the euro-denominated senior subordinated notes held by
Capital Trust V.
F-51
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
In addition, FMC Finance III S.A., a wholly-owned
subsidiary of the Company, is the obligor on 6
7
/
8
% senior
notes which are fully and unconditionally guaranteed, jointly
and severally on a senior basis, by the Company and by the
Guarantor Subsidiaries and FMC Finance VI S.A., a wholly-owned
subsidiary of the Company, is the obligor on 5.50% senior
notes which are fully and unconditionally guaranteed, jointly
and severally on a senior basis, by the Company and by the
Guarantor Subsidiaries (see Note 9). The financial
statements in this report present the financial condition,
results of operations and cash flows of the Company, the obligor
on the above-mentioned euro-denominated senior subordinated
notes, on a consolidated basis as of December 31, 2010 and
2009 and for the years ended December 31, 2010 and 2009.
The following combining financial information for the Company is
as of December 31, 2010 and December 31, 2009 and for
the years ended December 31, 2010 and 2009, segregated
between FMC Finance III S.A. and FMC Finance VI S.A. as
issuers, the Company, D-GmbH and FMCH as guarantors, and each of
the Companys other businesses (the Non-Guarantor
Subsidiaries). For purposes of the condensed combining
information, the Company and the Guarantors carry their
investments under the equity method. Other (income) expense
includes income (loss) related to investments in consolidated
subsidiaries recorded under the equity method for purposes of
the condensed combining information. In addition, other (income)
expense includes income and losses from profit and loss transfer
agreements as well as dividends received.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2010
|
|
|
|
Issuer
|
|
|
Guarantors
|
|
|
|
|
|
|
|
|
|
|
|
|
FMC
|
|
|
FMC
|
|
|
FMC - AG &
|
|
|
|
|
|
|
|
|
Non-Guarantor
|
|
|
Combining
|
|
|
Combined
|
|
|
|
Finance III
|
|
|
Finance VI
|
|
|
Co. KGaA
|
|
|
D-GmbH
|
|
|
FMCH
|
|
|
Subsidiaries
|
|
|
Adjustment
|
|
|
Total
|
|
|
Net revenue
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
1,587,720
|
|
|
$
|
|
|
|
$
|
12,744,881
|
|
|
$
|
(2,279,111
|
)
|
|
$
|
12,053,490
|
|
Cost of revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,022,617
|
|
|
|
|
|
|
|
9,148,969
|
|
|
|
(2,262,817
|
)
|
|
|
7,908,769
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
565,103
|
|
|
|
|
|
|
|
3,595,912
|
|
|
|
(16,294
|
)
|
|
|
4,144,721
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses (income):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
31
|
|
|
|
39
|
|
|
|
113,176
|
|
|
|
158,538
|
|
|
|
20,158
|
|
|
|
1,843,202
|
|
|
|
(10,760
|
)
|
|
|
2,124,384
|
|
Research and development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
62,435
|
|
|
|
|
|
|
|
34,097
|
|
|
|
|
|
|
|
96,532
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income
|
|
|
(31
|
)
|
|
|
(39
|
)
|
|
|
(113,176
|
)
|
|
|
344,130
|
|
|
|
(20,158
|
)
|
|
|
1,718,613
|
|
|
|
(5,534
|
)
|
|
|
1,923,805
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (income) expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest, net
|
|
|
(719
|
)
|
|
|
(545
|
)
|
|
|
39,113
|
|
|
|
2,388
|
|
|
|
56,047
|
|
|
|
192,183
|
|
|
|
(8,403
|
)
|
|
|
280,064
|
|
Other, net
|
|
|
|
|
|
|
|
|
|
|
(1,200,299
|
)
|
|
|
210,649
|
|
|
|
(664,020
|
)
|
|
|
|
|
|
|
1,653,670
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes
|
|
|
688
|
|
|
|
506
|
|
|
|
1,048,010
|
|
|
|
131,093
|
|
|
|
587,815
|
|
|
|
1,526,430
|
|
|
|
(1,650,801
|
)
|
|
|
1,643,741
|
|
Income tax expense (benefit)
|
|
|
196
|
|
|
|
143
|
|
|
|
69,493
|
|
|
|
99,957
|
|
|
|
(30,025
|
)
|
|
|
634,911
|
|
|
|
(196,330
|
)
|
|
|
578,345
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
492
|
|
|
|
363
|
|
|
|
978,517
|
|
|
|
31,136
|
|
|
|
617,840
|
|
|
|
891,519
|
|
|
|
(1,454,471
|
)
|
|
|
1,065,396
|
|
Net income attributable to Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
86,879
|
|
|
|
86,879
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to FMC-AG & Co. KGaA
|
|
$
|
492
|
|
|
$
|
363
|
|
|
$
|
978,517
|
|
|
$
|
31,136
|
|
|
$
|
617,840
|
|
|
$
|
891,519
|
|
|
$
|
(1,541,350
|
)
|
|
$
|
978,517
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-52
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2009
|
|
|
|
Issuer
|
|
|
Guarantors
|
|
|
|
|
|
|
|
|
|
|
|
|
FMC
|
|
|
FMC - AG &
|
|
|
|
|
|
|
|
|
Non-Guarantor
|
|
|
Combining
|
|
|
Combined
|
|
|
|
Finance III
|
|
|
Co. KGaA
|
|
|
D-GmbH
|
|
|
FMCH
|
|
|
Subsidiaries
|
|
|
Adjustment
|
|
|
Total
|
|
|
Net revenue
|
|
$
|
|
|
|
$
|
|
|
|
$
|
1,521,831
|
|
|
$
|
|
|
|
$
|
12,041,002
|
|
|
$
|
(2,315,356
|
)
|
|
$
|
11,247,477
|
|
Cost of revenue
|
|
|
|
|
|
|
|
|
|
|
997,257
|
|
|
|
|
|
|
|
8,734,160
|
|
|
|
(2,315,452
|
)
|
|
|
7,415,965
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
|
|
|
|
|
|
|
|
524,574
|
|
|
|
|
|
|
|
3,306,842
|
|
|
|
96
|
|
|
|
3,831,512
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses (income):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
28
|
|
|
|
87,774
|
|
|
|
173,215
|
|
|
|
(19,877
|
)
|
|
|
1,753,586
|
|
|
|
(12,620
|
)
|
|
|
1,982,106
|
|
Research and development
|
|
|
|
|
|
|
|
|
|
|
64,911
|
|
|
|
|
|
|
|
28,899
|
|
|
|
|
|
|
|
93,810
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income
|
|
|
(28
|
)
|
|
|
(87,774
|
)
|
|
|
286,448
|
|
|
|
19,877
|
|
|
|
1,524,357
|
|
|
|
12,716
|
|
|
|
1,755,596
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (income) expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest, net
|
|
|
(720
|
)
|
|
|
35,184
|
|
|
|
6,070
|
|
|
|
56,269
|
|
|
|
231,559
|
|
|
|
(28,399
|
)
|
|
|
299,963
|
|
Other, net
|
|
|
|
|
|
|
(1,032,515
|
)
|
|
|
190,345
|
|
|
|
(560,286
|
)
|
|
|
|
|
|
|
1,402,456
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes
|
|
|
692
|
|
|
|
909,557
|
|
|
|
90,033
|
|
|
|
523,894
|
|
|
|
1,292,798
|
|
|
|
(1,361,341
|
)
|
|
|
1,455,633
|
|
Income tax expense (benefit)
|
|
|
197
|
|
|
|
18,419
|
|
|
|
86,728
|
|
|
|
(14,338
|
)
|
|
|
518,329
|
|
|
|
(118,922
|
)
|
|
|
490,413
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
495
|
|
|
|
891,138
|
|
|
|
3,305
|
|
|
|
538,232
|
|
|
|
774,469
|
|
|
|
(1,242,419
|
)
|
|
|
965,220
|
|
Net income attributable to Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
74,082
|
|
|
|
74,082
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to FMC-AG & Co. KGaA
|
|
$
|
495
|
|
|
$
|
891,138
|
|
|
$
|
3,305
|
|
|
$
|
538,232
|
|
|
$
|
774,469
|
|
|
$
|
(1,316,501
|
)
|
|
$
|
891,138
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2008
|
|
|
|
Issuer
|
|
|
Guarantors
|
|
|
|
|
|
|
|
|
|
|
|
|
FMC
|
|
|
FMC - AG &
|
|
|
|
|
|
|
|
|
Non-Guarantor
|
|
|
Combining
|
|
|
Combined
|
|
|
|
Finance III
|
|
|
Co. KGaA
|
|
|
D-GmbH
|
|
|
FMCH
|
|
|
Subsidiaries
|
|
|
Adjustment
|
|
|
Total
|
|
|
Net revenue
|
|
$
|
|
|
|
$
|
|
|
|
$
|
1,745,311
|
|
|
$
|
|
|
|
$
|
11,218,494
|
|
|
$
|
(2,351,482
|
)
|
|
$
|
10,612,323
|
|
Cost of revenue
|
|
|
|
|
|
|
|
|
|
|
1,082,077
|
|
|
|
|
|
|
|
8,215,977
|
|
|
|
(2,314,579
|
)
|
|
|
6,983,475
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
|
|
|
|
|
|
|
|
663,234
|
|
|
|
|
|
|
|
3,002,517
|
|
|
|
(36,903
|
)
|
|
|
3,628,848
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses (income):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
93
|
|
|
|
49,245
|
|
|
|
208,299
|
|
|
|
(5,503
|
)
|
|
|
1,600,385
|
|
|
|
23,658
|
|
|
|
1,876,177
|
|
Research and development
|
|
|
|
|
|
|
|
|
|
|
55,448
|
|
|
|
|
|
|
|
24,791
|
|
|
|
|
|
|
|
80,239
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income
|
|
|
(93
|
)
|
|
|
(49,245
|
)
|
|
|
399,487
|
|
|
|
5,503
|
|
|
|
1,377,341
|
|
|
|
(60,561
|
)
|
|
|
1,672,432
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (income) expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest, net
|
|
|
(721
|
)
|
|
|
13,597
|
|
|
|
14,565
|
|
|
|
79,688
|
|
|
|
260,600
|
|
|
|
(30,987
|
)
|
|
|
336,742
|
|
Other, net
|
|
|
|
|
|
|
(945,938
|
)
|
|
|
255,501
|
|
|
|
(568,804
|
)
|
|
|
|
|
|
|
1,259,241
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes
|
|
|
628
|
|
|
|
883,096
|
|
|
|
129,421
|
|
|
|
494,619
|
|
|
|
1,116,741
|
|
|
|
(1,288,815
|
)
|
|
|
1,335,690
|
|
Income tax expense (benefit)
|
|
|
185
|
|
|
|
65,489
|
|
|
|
114,279
|
|
|
|
(29,118
|
)
|
|
|
376,169
|
|
|
|
(51,302
|
)
|
|
|
475,702
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
443
|
|
|
|
817,607
|
|
|
|
15,142
|
|
|
|
523,737
|
|
|
|
740,572
|
|
|
|
(1,237,513
|
)
|
|
|
859,988
|
|
Net income attributable to Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42,381
|
|
|
|
42,381
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to FMC-AG & Co. KGaA
|
|
$
|
443
|
|
|
$
|
817,607
|
|
|
$
|
15,142
|
|
|
$
|
523,737
|
|
|
$
|
740,572
|
|
|
$
|
(1,279,894
|
)
|
|
$
|
817,607
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-53
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2010
|
|
|
|
Issuer
|
|
|
Guarantors
|
|
|
|
|
|
|
|
|
|
|
|
|
FMC
|
|
|
FMC
|
|
|
FMC - AG &
|
|
|
|
|
|
|
|
|
Non-Guarantor
|
|
|
Combining
|
|
|
Combined
|
|
|
|
Finance III
|
|
|
Finance VI
|
|
|
Co. KGaA
|
|
|
D-GmbH
|
|
|
FMCH
|
|
|
Subsidiaries
|
|
|
Adjustment
|
|
|
Total
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
123
|
|
|
$
|
7
|
|
|
$
|
147,177
|
|
|
$
|
225
|
|
|
$
|
|
|
|
$
|
342,394
|
|
|
$
|
32,944
|
|
|
$
|
522,870
|
|
Trade accounts receivable, less allowance for doubtful accounts
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
157,755
|
|
|
|
|
|
|
|
2,415,503
|
|
|
|
|
|
|
|
2,573,258
|
|
Accounts receivable from related parties
|
|
|
16,542
|
|
|
|
8,971
|
|
|
|
2,418,066
|
|
|
|
667,484
|
|
|
|
441,601
|
|
|
|
2,817,556
|
|
|
|
(6,256,244
|
)
|
|
|
113,976
|
|
Inventories
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
184,948
|
|
|
|
|
|
|
|
711,053
|
|
|
|
(86,904
|
)
|
|
|
809,097
|
|
Prepaid expenses and other current assets
|
|
|
1
|
|
|
|
1
|
|
|
|
111,594
|
|
|
|
11,341
|
|
|
|
50
|
|
|
|
662,187
|
|
|
|
(1,943
|
)
|
|
|
783,231
|
|
Deferred taxes
|
|
|
|
|
|
|
|
|
|
|
14,221
|
|
|
|
|
|
|
|
|
|
|
|
317,644
|
|
|
|
18,297
|
|
|
|
350,162
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
16,666
|
|
|
|
8,979
|
|
|
|
2,691,058
|
|
|
|
1,021,753
|
|
|
|
441,651
|
|
|
|
7,266,337
|
|
|
|
(6,293,850
|
)
|
|
|
5,152,594
|
|
Property, plant and equipment, net
|
|
|
|
|
|
|
|
|
|
|
390
|
|
|
|
168,939
|
|
|
|
|
|
|
|
2,458,364
|
|
|
|
(100,401
|
)
|
|
|
2,527,292
|
|
Intangible assets
|
|
|
|
|
|
|
|
|
|
|
428
|
|
|
|
65,684
|
|
|
|
|
|
|
|
626,432
|
|
|
|
|
|
|
|
692,544
|
|
Goodwill
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
65,315
|
|
|
|
|
|
|
|
8,075,153
|
|
|
|
|
|
|
|
8,140,468
|
|
Deferred taxes
|
|
|
|
|
|
|
|
|
|
|
9,463
|
|
|
|
4,693
|
|
|
|
|
|
|
|
121,875
|
|
|
|
(42,863
|
)
|
|
|
93,168
|
|
Other assets
|
|
|
494,231
|
|
|
|
330,215
|
|
|
|
7,201,295
|
|
|
|
644,523
|
|
|
|
9,320,731
|
|
|
|
(6,911,510
|
)
|
|
|
(10,590,890
|
)
|
|
|
488,595
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
510,897
|
|
|
$
|
339,194
|
|
|
$
|
9,902,634
|
|
|
$
|
1,970,907
|
|
|
$
|
9,762,382
|
|
|
$
|
11,636,651
|
|
|
$
|
(17,028,004
|
)
|
|
$
|
17,094,661
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
|
|
|
$
|
|
|
|
$
|
5,738
|
|
|
$
|
22,387
|
|
|
$
|
|
|
|
$
|
392,512
|
|
|
$
|
|
|
|
$
|
420,637
|
|
Accounts payable to related parties
|
|
|
229
|
|
|
|
|
|
|
|
952,141
|
|
|
|
670,613
|
|
|
|
1,538,658
|
|
|
|
3,210,393
|
|
|
|
(6,250,147
|
)
|
|
|
121,887
|
|
Accrued expenses and other current liabilities
|
|
|
15,866
|
|
|
|
8,457
|
|
|
|
122,000
|
|
|
|
94,978
|
|
|
|
2,054
|
|
|
|
1,284,105
|
|
|
|
9,963
|
|
|
|
1,537,423
|
|
Short-term borrowings
|
|
|
|
|
|
|
|
|
|
|
121
|
|
|
|
|
|
|
|
|
|
|
|
670,550
|
|
|
|
|
|
|
|
670,671
|
|
Short-term borrowings from related parties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,004
|
|
|
|
7,679
|
|
|
|
9,683
|
|
Current portion of long-term debt and capital lease obligations
|
|
|
|
|
|
|
|
|
|
|
106,862
|
|
|
|
|
|
|
|
101,145
|
|
|
|
55,975
|
|
|
|
|
|
|
|
263,982
|
|
Company obligated mandatorily redeemable preferred securities of
subsidiary Fresenius Medical Care Capital Trusts holding solely
Company-guaranteed debentures of subsidiaries-current portion
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
625,549
|
|
|
|
|
|
|
|
625,549
|
|
Income tax payable
|
|
|
24
|
|
|
|
144
|
|
|
|
54,366
|
|
|
|
|
|
|
|
|
|
|
|
62,360
|
|
|
|
648
|
|
|
|
117,542
|
|
Deferred taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,513
|
|
|
|
|
|
|
|
27,143
|
|
|
|
(10,307
|
)
|
|
|
22,349
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
16,119
|
|
|
|
8,601
|
|
|
|
1,241,228
|
|
|
|
793,491
|
|
|
|
1,641,857
|
|
|
|
6,330,591
|
|
|
|
(6,242,164
|
)
|
|
|
3,789,723
|
|
Long term debt and capital lease obligations, less current
portion
|
|
|
494,231
|
|
|
|
330,215
|
|
|
|
870,348
|
|
|
|
|
|
|
|
1,357,745
|
|
|
|
3,739,390
|
|
|
|
(2,482,253
|
)
|
|
|
4,309,676
|
|
Long term borrowings from related parties
|
|
|
|
|
|
|
|
|
|
|
334,428
|
|
|
|
208,368
|
|
|
|
494,231
|
|
|
|
400,883
|
|
|
|
(1,437,910
|
)
|
|
|
|
|
Other liabilities
|
|
|
|
|
|
|
|
|
|
|
73,382
|
|
|
|
11,241
|
|
|
|
|
|
|
|
184,542
|
|
|
|
24,850
|
|
|
|
294,015
|
|
Pension liabilities
|
|
|
|
|
|
|
|
|
|
|
4,933
|
|
|
|
143,362
|
|
|
|
|
|
|
|
41,855
|
|
|
|
|
|
|
|
190,150
|
|
Income tax payable
|
|
|
|
|
|
|
|
|
|
|
1,057
|
|
|
|
|
|
|
|
|
|
|
|
75,055
|
|
|
|
124,469
|
|
|
|
200,581
|
|
Deferred taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
522,521
|
|
|
|
(15,625
|
)
|
|
|
506,896
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
510,350
|
|
|
|
338,816
|
|
|
|
2,525,376
|
|
|
|
1,156,462
|
|
|
|
3,493,833
|
|
|
|
11,294,837
|
|
|
|
(10,028,633
|
)
|
|
|
9,291,041
|
|
Noncontrolling interests subject to put provisions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
279,709
|
|
|
|
|
|
|
|
279,709
|
|
Total FMC-AG & Co. KGaA shareholders equity
|
|
|
547
|
|
|
|
378
|
|
|
|
7,377,258
|
|
|
|
814,445
|
|
|
|
6,268,549
|
|
|
|
(84,548
|
)
|
|
|
(6,999,371
|
)
|
|
|
7,377,258
|
|
Noncontrolling interests not subject to put provisions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
146,653
|
|
|
|
|
|
|
|
146,653
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total equity
|
|
|
547
|
|
|
|
378
|
|
|
|
7,377,258
|
|
|
|
814,445
|
|
|
|
6,268,549
|
|
|
|
62,105
|
|
|
|
(6,999,371
|
)
|
|
|
7,523,911
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and equity
|
|
$
|
510,897
|
|
|
$
|
339,194
|
|
|
$
|
9,902,634
|
|
|
$
|
1,970,907
|
|
|
$
|
9,762,382
|
|
|
$
|
11,636,651
|
|
|
$
|
(17,028,004
|
)
|
|
$
|
17,094,661
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-54
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2009
|
|
|
|
Issuer
|
|
|
Guarantors
|
|
|
|
|
|
|
|
|
|
|
|
|
FMC
|
|
|
FMC - AG &
|
|
|
|
|
|
|
|
|
Non-Guarantor
|
|
|
Combining
|
|
|
Combined
|
|
|
|
Finance III
|
|
|
Co. KGaA
|
|
|
D-GmbH
|
|
|
FMCH
|
|
|
Subsidiaries
|
|
|
Adjustment
|
|
|
Total
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
108
|
|
|
$
|
24
|
|
|
$
|
194
|
|
|
$
|
|
|
|
$
|
286,205
|
|
|
$
|
14,694
|
|
|
$
|
301,225
|
|
Trade accounts receivable, less allowance for doubtful accounts
|
|
|
|
|
|
|
|
|
|
|
158,089
|
|
|
|
|
|
|
|
2,128,308
|
|
|
|
(488
|
)
|
|
|
2,285,909
|
|
Accounts receivable from related parties
|
|
|
16,543
|
|
|
|
1,837,748
|
|
|
|
628,819
|
|
|
|
539,867
|
|
|
|
2,600,656
|
|
|
|
(5,350,747
|
)
|
|
|
272,886
|
|
Inventories
|
|
|
|
|
|
|
|
|
|
|
202,837
|
|
|
|
|
|
|
|
701,429
|
|
|
|
(82,612
|
)
|
|
|
821,654
|
|
Prepaid expenses and other current assets
|
|
|
1
|
|
|
|
110,117
|
|
|
|
16,072
|
|
|
|
50
|
|
|
|
608,990
|
|
|
|
(5,924
|
)
|
|
|
729,306
|
|
Deferred taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
294,214
|
|
|
|
22,606
|
|
|
|
316,820
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
16,652
|
|
|
|
1,947,889
|
|
|
|
1,006,011
|
|
|
|
539,917
|
|
|
|
6,619,802
|
|
|
|
(5,402,471
|
)
|
|
|
4,727,800
|
|
Property, plant and equipment, net
|
|
|
|
|
|
|
266
|
|
|
|
191,445
|
|
|
|
|
|
|
|
2,322,145
|
|
|
|
(94,286
|
)
|
|
|
2,419,570
|
|
Intangible assets
|
|
|
|
|
|
|
622
|
|
|
|
50,263
|
|
|
|
|
|
|
|
808,310
|
|
|
|
|
|
|
|
859,195
|
|
Goodwill
|
|
|
|
|
|
|
|
|
|
|
3,508
|
|
|
|
|
|
|
|
7,507,926
|
|
|
|
|
|
|
|
7,511,434
|
|
Deferred taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
91,346
|
|
|
|
(26,597
|
)
|
|
|
64,749
|
|
Other assets
|
|
|
493,344
|
|
|
|
7,001,455
|
|
|
|
1,193,451
|
|
|
|
8,910,859
|
|
|
|
(6,023,422
|
)
|
|
|
(11,337,120
|
)
|
|
|
238,567
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
509,996
|
|
|
$
|
8,950,232
|
|
|
$
|
2,444,678
|
|
|
$
|
9,450,776
|
|
|
$
|
11,326,107
|
|
|
$
|
(16,860,474
|
)
|
|
$
|
15,821,315
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
4
|
|
|
$
|
217
|
|
|
$
|
19,131
|
|
|
$
|
|
|
|
$
|
343,055
|
|
|
$
|
|
|
|
$
|
362,407
|
|
Accounts payable to related parties
|
|
|
200
|
|
|
|
867,147
|
|
|
|
600,951
|
|
|
|
1,500,829
|
|
|
|
2,672,902
|
|
|
|
(5,364,600
|
)
|
|
|
277,429
|
|
Accrued expenses and other current liabilities
|
|
|
15,868
|
|
|
|
42,304
|
|
|
|
98,966
|
|
|
|
791
|
|
|
|
1,178,644
|
|
|
|
(1,020
|
)
|
|
|
1,335,553
|
|
Short-term borrowings
|
|
|
|
|
|
|
130
|
|
|
|
|
|
|
|
|
|
|
|
316,214
|
|
|
|
|
|
|
|
316,344
|
|
Short-term borrowings from related parties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,161
|
|
|
|
8,279
|
|
|
|
10,440
|
|
Current portion of long-term debt and capital lease obligations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133,866
|
|
|
|
23,768
|
|
|
|
|
|
|
|
157,634
|
|
Income tax payable
|
|
|
30
|
|
|
|
32,342
|
|
|
|
|
|
|
|
|
|
|
|
83,958
|
|
|
|
648
|
|
|
|
116,978
|
|
Deferred taxes
|
|
|
|
|
|
|
2,569
|
|
|
|
8,692
|
|
|
|
|
|
|
|
24,288
|
|
|
|
(2,619
|
)
|
|
|
32,930
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
16,102
|
|
|
|
944,709
|
|
|
|
727,740
|
|
|
|
1,635,486
|
|
|
|
4,644,990
|
|
|
|
(5,359,312
|
)
|
|
|
2,609,715
|
|
Long term debt and capital lease obligations, less current
portion
|
|
|
493,344
|
|
|
|
1,063,346
|
|
|
|
|
|
|
|
1,576,242
|
|
|
|
4,096,766
|
|
|
|
(2,801,777
|
)
|
|
|
4,427,921
|
|
Long term borrowings from related parties
|
|
|
|
|
|
|
4,543
|
|
|
|
226,936
|
|
|
|
493,344
|
|
|
|
430,743
|
|
|
|
(1,155,566
|
)
|
|
|
|
|
Other liabilities
|
|
|
|
|
|
|
105,810
|
|
|
|
7,693
|
|
|
|
|
|
|
|
170,121
|
|
|
|
23,488
|
|
|
|
307,112
|
|
Pension liabilities
|
|
|
|
|
|
|
3,702
|
|
|
|
114,666
|
|
|
|
|
|
|
|
28,959
|
|
|
|
|
|
|
|
147,327
|
|
Income tax payable
|
|
|
|
|
|
|
1,139
|
|
|
|
|
|
|
|
|
|
|
|
100,917
|
|
|
|
113,865
|
|
|
|
215,921
|
|
Deferred taxes
|
|
|
|
|
|
|
6,051
|
|
|
|
3,110
|
|
|
|
|
|
|
|
428,448
|
|
|
|
(10,079
|
)
|
|
|
427,530
|
|
Company obligated mandatorily redeemable preferred securities of
subsidiary Fresenius Medical Care Capital Trusts holding solely
Company-guaranteed debentures of subsidiary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
656,096
|
|
|
|
|
|
|
|
656,096
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
509,446
|
|
|
|
2,129,300
|
|
|
|
1,080,145
|
|
|
|
3,705,072
|
|
|
|
10,557,040
|
|
|
|
(9,189,381
|
)
|
|
|
8,791,622
|
|
Noncontrolling interests subject to put provisions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
231,303
|
|
|
|
|
|
|
|
231,303
|
|
Total FMC-AG & Co. KGaA shareholders equity
|
|
|
550
|
|
|
|
6,820,932
|
|
|
|
1,364,533
|
|
|
|
5,745,704
|
|
|
|
414,661
|
|
|
|
(7,671,093
|
)
|
|
|
6,675,287
|
|
Noncontrolling interests not subject to put provisions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
123,103
|
|
|
|
|
|
|
|
123,103
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total equity
|
|
|
550
|
|
|
|
6,820,932
|
|
|
|
1,364,533
|
|
|
|
5,745,704
|
|
|
|
537,764
|
|
|
|
(7,671,093
|
)
|
|
|
6,798,390
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and equity
|
|
$
|
509,996
|
|
|
$
|
8,950,232
|
|
|
$
|
2,444,678
|
|
|
$
|
9,450,776
|
|
|
$
|
11,326,107
|
|
|
$
|
(16,860,474
|
)
|
|
$
|
15,821,315
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-55
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2010
|
|
|
|
Issuer
|
|
|
Guarantors
|
|
|
|
|
|
|
|
|
|
|
|
|
FMC
|
|
|
FMC
|
|
|
FMC - AG &
|
|
|
|
|
|
|
|
|
Non-Guarantor
|
|
|
Combining
|
|
|
Combined
|
|
|
|
Finance III
|
|
|
Finance VI
|
|
|
Co. KGaA
|
|
|
D-GmbH
|
|
|
FMCH
|
|
|
Subsidiaries
|
|
|
Adjustment
|
|
|
Total
|
|
|
Operating Activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
492
|
|
|
$
|
363
|
|
|
$
|
978,517
|
|
|
$
|
31,136
|
|
|
$
|
617,840
|
|
|
$
|
891,519
|
|
|
$
|
(1,454,471
|
)
|
|
$
|
1,065,396
|
|
Adjustments to reconcile net income to net cash provided by
(used in) operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity affiliate income
|
|
|
|
|
|
|
|
|
|
|
(683,735
|
)
|
|
|
|
|
|
|
(664,020
|
)
|
|
|
|
|
|
|
1,347,755
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
|
1,452
|
|
|
|
47,161
|
|
|
|
888
|
|
|
|
476,647
|
|
|
|
(22,924
|
)
|
|
|
503,224
|
|
Change in deferred taxes, net
|
|
|
|
|
|
|
|
|
|
|
(9,645
|
)
|
|
|
(2,636
|
)
|
|
|
|
|
|
|
30,710
|
|
|
|
(3,742
|
)
|
|
|
14,687
|
|
(Gain) loss on sale of fixed assets and investments
|
|
|
|
|
|
|
|
|
|
|
(18
|
)
|
|
|
155
|
|
|
|
|
|
|
|
(6,653
|
)
|
|
|
|
|
|
|
(6,516
|
)
|
Loss (gain) on investments
|
|
|
|
|
|
|
|
|
|
|
883
|
|
|
|
28
|
|
|
|
|
|
|
|
225
|
|
|
|
(1,136
|
)
|
|
|
|
|
Compensation expense related to stock options
|
|
|
|
|
|
|
|
|
|
|
27,981
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27,981
|
|
Changes in assets and liabilities, net of amounts from
businesses acquired:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade accounts receivable, net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(11,037
|
)
|
|
|
|
|
|
|
(289,237
|
)
|
|
|
|
|
|
|
(300,274
|
)
|
Inventories
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,063
|
|
|
|
|
|
|
|
7,082
|
|
|
|
5,181
|
|
|
|
18,326
|
|
Prepaid expenses and other current and non-current assets
|
|
|
|
|
|
|
|
|
|
|
(355
|
)
|
|
|
804
|
|
|
|
10,725
|
|
|
|
(70,862
|
)
|
|
|
(617
|
)
|
|
|
(60,305
|
)
|
Accounts receivable from / payable to related parties
|
|
|
30
|
|
|
|
(8,901
|
)
|
|
|
76,758
|
|
|
|
105,072
|
|
|
|
34,394
|
|
|
|
(319,995
|
)
|
|
|
103,603
|
|
|
|
(9,039
|
)
|
Accounts payable, accrued expenses and other current and
non-current liabilities
|
|
|
(6
|
)
|
|
|
8,365
|
|
|
|
31,784
|
|
|
|
22,268
|
|
|
|
1,263
|
|
|
|
56,439
|
|
|
|
4,166
|
|
|
|
124,279
|
|
Income tax payable
|
|
|
(6
|
)
|
|
|
143
|
|
|
|
24,179
|
|
|
|
|
|
|
|
(30,025
|
)
|
|
|
(21,344
|
)
|
|
|
17,419
|
|
|
|
(9,634
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities
|
|
|
510
|
|
|
|
(30
|
)
|
|
|
447,801
|
|
|
|
199,014
|
|
|
|
(28,935
|
)
|
|
|
754,531
|
|
|
|
(4,766
|
)
|
|
|
1,368,125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing Activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases of property, plant and equipment
|
|
|
|
|
|
|
|
|
|
|
(340
|
)
|
|
|
(31,749
|
)
|
|
|
|
|
|
|
(522,514
|
)
|
|
|
30,974
|
|
|
|
(523,629
|
)
|
Proceeds from sale of property, plant and equipment
|
|
|
|
|
|
|
|
|
|
|
30
|
|
|
|
1,099
|
|
|
|
|
|
|
|
14,979
|
|
|
|
|
|
|
|
16,108
|
|
Disbursement of loans to related parties
|
|
|
|
|
|
|
(327,045
|
)
|
|
|
227,151
|
|
|
|
180
|
|
|
|
314,665
|
|
|
|
|
|
|
|
(214,951
|
)
|
|
|
|
|
Acquisitions and investments, net of cash acquired, and net
purchases of intangible assets
|
|
|
|
|
|
|
|
|
|
|
(273,710
|
)
|
|
|
(19,881
|
)
|
|
|
|
|
|
|
(614,049
|
)
|
|
|
143,302
|
|
|
|
(764,338
|
)
|
Proceeds from divestitures
|
|
|
|
|
|
|
|
|
|
|
132,823
|
|
|
|
|
|
|
|
|
|
|
|
14,245
|
|
|
|
(233
|
)
|
|
|
146,835
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by investing activities
|
|
|
|
|
|
|
(327,045
|
)
|
|
|
85,954
|
|
|
|
(50,351
|
)
|
|
|
314,665
|
|
|
|
(1,107,339
|
)
|
|
|
(40,908
|
)
|
|
|
(1,125,024
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing Activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term borrowings, net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(148,617
|
)
|
|
|
|
|
|
|
171,078
|
|
|
|
|
|
|
|
22,461
|
|
Long-term debt and capital lease obligations, net
|
|
|
|
|
|
|
327,045
|
|
|
|
(146,443
|
)
|
|
|
|
|
|
|
(285,730
|
)
|
|
|
(235,418
|
)
|
|
|
214,951
|
|
|
|
(125,595
|
)
|
(Decrease) increase of accounts receivable securitization program
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
296,000
|
|
|
|
|
|
|
|
296,000
|
|
Proceeds from exercise of stock options
|
|
|
|
|
|
|
|
|
|
|
96,204
|
|
|
|
|
|
|
|
|
|
|
|
13,314
|
|
|
|
|
|
|
|
109,518
|
|
Dividends paid
|
|
|
(495
|
)
|
|
|
|
|
|
|
(231,967
|
)
|
|
|
|
|
|
|
|
|
|
|
(6,193
|
)
|
|
|
6,688
|
|
|
|
(231,967
|
)
|
Capital increase (decrease)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
143,069
|
|
|
|
(143,069
|
)
|
|
|
|
|
Distributions to Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(111,550
|
)
|
|
|
|
|
|
|
(111,550
|
)
|
Contributions from Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,416
|
|
|
|
|
|
|
|
26,416
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by financing activities
|
|
|
(495
|
)
|
|
|
327,045
|
|
|
|
(282,206
|
)
|
|
|
(148,617
|
)
|
|
|
(285,730
|
)
|
|
|
296,716
|
|
|
|
78,570
|
|
|
|
(14,717
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
|
|
|
|
(4
|
)
|
|
|
(104,396
|
)
|
|
|
(15
|
)
|
|
|
|
|
|
|
97,628
|
|
|
|
48
|
|
|
|
(6,739
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
15
|
|
|
|
(34
|
)
|
|
|
147,153
|
|
|
|
31
|
|
|
|
|
|
|
|
41,536
|
|
|
|
32,944
|
|
|
|
221,645
|
|
Cash and cash equivalents at beginning of period
|
|
|
108
|
|
|
|
41
|
|
|
|
24
|
|
|
|
194
|
|
|
|
|
|
|
|
300,858
|
|
|
|
|
|
|
|
301,225
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
123
|
|
|
|
7
|
|
|
$
|
147,177
|
|
|
$
|
225
|
|
|
$
|
|
|
|
$
|
342,394
|
|
|
$
|
32,944
|
|
|
$
|
522,870
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-56
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2009
|
|
|
|
Issuer
|
|
|
Guarantors
|
|
|
|
|
|
|
|
|
|
|
|
|
FMC
|
|
|
FMC - AG &
|
|
|
|
|
|
|
|
|
Non-Guarantor
|
|
|
Combining
|
|
|
Combined
|
|
|
|
Finance III
|
|
|
Co. KGaA
|
|
|
D-GmbH
|
|
|
FMCH
|
|
|
Subsidiaries
|
|
|
Adjustment
|
|
|
Total
|
|
|
Operating Activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
495
|
|
|
$
|
891,138
|
|
|
$
|
3,305
|
|
|
$
|
538,232
|
|
|
$
|
774,469
|
|
|
$
|
(1,242,419
|
)
|
|
$
|
965,220
|
|
Adjustments to reconcile net income to net cash provided by
(used in) operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity affiliate income
|
|
|
|
|
|
|
(635,395
|
)
|
|
|
|
|
|
|
(560,286
|
)
|
|
|
|
|
|
|
1,195,681
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
1,470
|
|
|
|
38,029
|
|
|
|
888
|
|
|
|
439,196
|
|
|
|
(22,498
|
)
|
|
|
457,085
|
|
Change in deferred taxes, net
|
|
|
|
|
|
|
23,191
|
|
|
|
4,707
|
|
|
|
|
|
|
|
(15,491
|
)
|
|
|
9,595
|
|
|
|
22,002
|
|
Loss (gain) on sale of fixed assets and investments
|
|
|
|
|
|
|
|
|
|
|
411
|
|
|
|
|
|
|
|
(353
|
)
|
|
|
|
|
|
|
58
|
|
Loss (gain) on investments
|
|
|
|
|
|
|
7,063
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,063
|
)
|
|
|
|
|
Write-off of loans from related parties
|
|
|
|
|
|
|
50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(50
|
)
|
|
|
|
|
Compensation expense related to stock options
|
|
|
|
|
|
|
33,746
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
33,746
|
|
Changes in assets and liabilities, net of amounts from
businesses acquired:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade accounts receivable, net
|
|
|
|
|
|
|
|
|
|
|
(13,874
|
)
|
|
|
|
|
|
|
(28,120
|
)
|
|
|
|
|
|
|
(41,994
|
)
|
Inventories
|
|
|
|
|
|
|
|
|
|
|
(27,435
|
)
|
|
|
|
|
|
|
(49,213
|
)
|
|
|
(12,285
|
)
|
|
|
(88,933
|
)
|
Prepaid expenses and other current and non-current assets
|
|
|
|
|
|
|
(37,138
|
)
|
|
|
9,921
|
|
|
|
(18,344
|
)
|
|
|
(93,954
|
)
|
|
|
(7,590
|
)
|
|
|
(147,105
|
)
|
Accounts receivable from / payable to related parties
|
|
|
208
|
|
|
|
(388,546
|
)
|
|
|
7,308
|
|
|
|
39,091
|
|
|
|
256,906
|
|
|
|
79,315
|
|
|
|
(5,718
|
)
|
Accounts payable, accrued expenses and other current and
non-current liabilities
|
|
|
(15
|
)
|
|
|
16,210
|
|
|
|
12,731
|
|
|
|
(1,149
|
)
|
|
|
38,065
|
|
|
|
5,250
|
|
|
|
71,092
|
|
Income tax payable
|
|
|
(160
|
)
|
|
|
(23,961
|
)
|
|
|
|
|
|
|
(14,338
|
)
|
|
|
71,931
|
|
|
|
39,692
|
|
|
|
73,164
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities
|
|
|
528
|
|
|
|
(112,172
|
)
|
|
|
35,103
|
|
|
|
(15,906
|
)
|
|
|
1,393,436
|
|
|
|
37,628
|
|
|
|
1,338,617
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing Activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases of property, plant and equipment
|
|
|
|
|
|
|
(152
|
)
|
|
|
(65,684
|
)
|
|
|
|
|
|
|
(537,167
|
)
|
|
|
29,397
|
|
|
|
(573,606
|
)
|
Proceeds from sale of property, plant and equipment
|
|
|
|
|
|
|
|
|
|
|
731
|
|
|
|
|
|
|
|
10,999
|
|
|
|
|
|
|
|
11,730
|
|
Disbursement of loans to related parties
|
|
|
|
|
|
|
(7,270
|
)
|
|
|
178
|
|
|
|
17,240
|
|
|
|
|
|
|
|
(10,148
|
)
|
|
|
|
|
Acquisitions and investments, net of cash acquired, and net
purchases of intangible assets
|
|
|
|
|
|
|
(11,841
|
)
|
|
|
(1,900
|
)
|
|
|
|
|
|
|
(185,878
|
)
|
|
|
11,506
|
|
|
|
(188,113
|
)
|
Proceeds from divestitures
|
|
|
|
|
|
|
13,380
|
|
|
|
|
|
|
|
|
|
|
|
1,965
|
|
|
|
36,620
|
|
|
|
51,965
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by investing activities
|
|
|
|
|
|
|
(5,883
|
)
|
|
|
(66,675
|
)
|
|
|
17,240
|
|
|
|
(710,081
|
)
|
|
|
67,375
|
|
|
|
(698,024
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing Activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term borrowings, net
|
|
|
|
|
|
|
(95,795
|
)
|
|
|
31,716
|
|
|
|
|
|
|
|
10,943
|
|
|
|
(108,439
|
)
|
|
|
(161,575
|
)
|
Long-term debt and capital lease obligations, net
|
|
|
|
|
|
|
396,013
|
|
|
|
|
|
|
|
(1,334
|
)
|
|
|
(261,528
|
)
|
|
|
10,148
|
|
|
|
143,299
|
|
(Decrease) increase of accounts receivable securitization program
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(325,000
|
)
|
|
|
|
|
|
|
(325,000
|
)
|
Proceeds from exercise of stock options
|
|
|
|
|
|
|
64,271
|
|
|
|
|
|
|
|
|
|
|
|
8,123
|
|
|
|
|
|
|
|
72,394
|
|
Dividends paid
|
|
|
(443
|
)
|
|
|
(231,940
|
)
|
|
|
|
|
|
|
|
|
|
|
(5,321
|
)
|
|
|
5,764
|
|
|
|
(231,940
|
)
|
Capital increase (decrease)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,874
|
)
|
|
|
1,874
|
|
|
|
|
|
Distributions to Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(68,004
|
)
|
|
|
|
|
|
|
(68,004
|
)
|
Contributions from Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,699
|
|
|
|
|
|
|
|
12,699
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by financing activities
|
|
|
(443
|
)
|
|
|
132,549
|
|
|
|
31,716
|
|
|
|
(1,334
|
)
|
|
|
(629,962
|
)
|
|
|
(90,653
|
)
|
|
|
(558,127
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
|
|
|
|
(14,470
|
)
|
|
|
6
|
|
|
|
|
|
|
|
11,590
|
|
|
|
49
|
|
|
|
(2,825
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
85
|
|
|
|
24
|
|
|
|
150
|
|
|
|
|
|
|
|
64,983
|
|
|
|
14,399
|
|
|
|
79,641
|
|
Cash and cash equivalents at beginning of period
|
|
|
23
|
|
|
|
|
|
|
|
44
|
|
|
|
|
|
|
|
221,517
|
|
|
|
|
|
|
|
221,584
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
108
|
|
|
$
|
24
|
|
|
$
|
194
|
|
|
$
|
|
|
|
$
|
286,500
|
|
|
$
|
14,399
|
|
|
$
|
301,225
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-57
FRESENIUS
MEDICAL CARE AG & Co. KGaA
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
(in thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2008
|
|
|
|
Issuer
|
|
|
Guarantors
|
|
|
|
|
|
|
|
|
|
|
|
|
FMC
|
|
|
FMC - AG &
|
|
|
|
|
|
|
|
|
Non-Guarantor
|
|
|
Combining
|
|
|
Combined
|
|
|
|
Finance III
|
|
|
Co. KGaA
|
|
|
D-GmbH
|
|
|
FMCH
|
|
|
Subsidiaries
|
|
|
Adjustment
|
|
|
Total
|
|
|
Operating Activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
443
|
|
|
$
|
817,607
|
|
|
$
|
15,142
|
|
|
$
|
523,737
|
|
|
$
|
740,572
|
|
|
$
|
(1,237,513
|
)
|
|
$
|
859,988
|
|
Adjustments to reconcile net income to net cash provided by
(used in) operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity affiliate income
|
|
|
|
|
|
|
(462,412
|
)
|
|
|
|
|
|
|
(568,804
|
)
|
|
|
|
|
|
|
1,031,216
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
1,472
|
|
|
|
40,895
|
|
|
|
888
|
|
|
|
393,558
|
|
|
|
(21,142
|
)
|
|
|
415,671
|
|
Change in deferred taxes, net
|
|
|
|
|
|
|
(7,951
|
)
|
|
|
3,169
|
|
|
|
|
|
|
|
97,726
|
|
|
|
40,103
|
|
|
|
133,047
|
|
(Gain) loss on sale of fixed assets and investments
|
|
|
|
|
|
|
(422
|
)
|
|
|
(55
|
)
|
|
|
|
|
|
|
(21,009
|
)
|
|
|
422
|
|
|
|
(21,064
|
)
|
Write-up
of
loans from related parties
|
|
|
|
|
|
|
(17,727
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17,727
|
|
|
|
|
|
Compensation expense related to stock options
|
|
|
|
|
|
|
31,879
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,879
|
|
Changes in assets and liabilities, net of amounts from
businesses acquired:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade accounts receivable, net
|
|
|
|
|
|
|
|
|
|
|
(34,889
|
)
|
|
|
|
|
|
|
(207,078
|
)
|
|
|
|
|
|
|
(241,967
|
)
|
Inventories
|
|
|
|
|
|
|
|
|
|
|
(27,549
|
)
|
|
|
|
|
|
|
(82,328
|
)
|
|
|
15,765
|
|
|
|
(94,112
|
)
|
Prepaid expenses and other current and non-current assets
|
|
|
|
|
|
|
(32,757
|
)
|
|
|
(25,384
|
)
|
|
|
(3,964
|
)
|
|
|
(30,156
|
)
|
|
|
8,172
|
|
|
|
(84,089
|
)
|
Accounts receivable from / payable to related parties
|
|
|
899
|
|
|
|
(318,373
|
)
|
|
|
43,853
|
|
|
|
34,620
|
|
|
|
104,895
|
|
|
|
166,358
|
|
|
|
32,252
|
|
Accounts payable, accrued expenses and other current and
non-current liabilities
|
|
|
(1,237
|
)
|
|
|
1,140
|
|
|
|
22,438
|
|
|
|
(4,538
|
)
|
|
|
(38,463
|
)
|
|
|
3,620
|
|
|
|
(17,040
|
)
|
Income tax payable
|
|
|
96
|
|
|
|
(49,994
|
)
|
|
|
|
|
|
|
(29,118
|
)
|
|
|
91,779
|
|
|
|
(10,930
|
)
|
|
|
1,833
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities
|
|
|
201
|
|
|
|
(37,538
|
)
|
|
|
37,620
|
|
|
|
(47,179
|
)
|
|
|
1,049,496
|
|
|
|
13,798
|
|
|
|
1,016,398
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing Activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases of property, plant and equipment
|
|
|
|
|
|
|
(186
|
)
|
|
|
(77,381
|
)
|
|
|
|
|
|
|
(646,396
|
)
|
|
|
36,607
|
|
|
|
(687,356
|
)
|
Proceeds from sale of property, plant and equipment
|
|
|
|
|
|
|
16
|
|
|
|
1,348
|
|
|
|
|
|
|
|
12,482
|
|
|
|
|
|
|
|
13,846
|
|
Disbursement of loans to related parties
|
|
|
|
|
|
|
(123,908
|
)
|
|
|
177
|
|
|
|
164,746
|
|
|
|
|
|
|
|
(41,015
|
)
|
|
|
|
|
Acquisitions and investments, net of cash acquired, and net
purchases of intangible assets
|
|
|
|
|
|
|
(36,148
|
)
|
|
|
(39,721
|
)
|
|
|
|
|
|
|
(186,477
|
)
|
|
|
(14,127
|
)
|
|
|
(276,473
|
)
|
Proceeds from divestitures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
58,582
|
|
|
|
|
|
|
|
58,582
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by investing activities
|
|
|
|
|
|
|
(160,226
|
)
|
|
|
(115,577
|
)
|
|
|
164,746
|
|
|
|
(761,809
|
)
|
|
|
(18,535
|
)
|
|
|
(891,401
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing Activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term borrowings, net
|
|
|
|
|
|
|
36,847
|
|
|
|
78,179
|
|
|
|
|
|
|
|
(123,064
|
)
|
|
|
|
|
|
|
(8,038
|
)
|
Long-term debt and capital lease obligations, net
|
|
|
|
|
|
|
366,231
|
|
|
|
(221
|
)
|
|
|
(117,567
|
)
|
|
|
(644,378
|
)
|
|
|
41,015
|
|
|
|
(354,920
|
)
|
Increase (decrease) of accounts receivable securitization program
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
454,000
|
|
|
|
|
|
|
|
454,000
|
|
Proceeds from exercise of stock options
|
|
|
|
|
|
|
36,755
|
|
|
|
|
|
|
|
|
|
|
|
7,132
|
|
|
|
|
|
|
|
43,887
|
|
Dividends paid
|
|
|
(222
|
)
|
|
|
(252,395
|
)
|
|
|
|
|
|
|
|
|
|
|
163
|
|
|
|
59
|
|
|
|
(252,395
|
)
|
Capital increase (decrease)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35,873
|
|
|
|
(35,873
|
)
|
|
|
|
|
Distributions to Noncontrolling interests
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(38,592
|
)
|
|
|
|
|
|
|
(38,592
|
)
|
Net cash (used in) provided by financing activities
|
|
|
(222
|
)
|
|
|
187,438
|
|
|
|
77,958
|
|
|
|
(117,567
|
)
|
|
|
(308,866
|
)
|
|
|
5,201
|
|
|
|
(156,058
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
|
|
|
|
10,326
|
|
|
|
(2
|
)
|
|
|
|
|
|
|
(2,419
|
)
|
|
|
50
|
|
|
|
7,955
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash and cash equivalents
|
|
|
(21
|
)
|
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
(23,598
|
)
|
|
|
514
|
|
|
|
(23,106
|
)
|
Cash and cash equivalents at beginning of period
|
|
|
44
|
|
|
|
|
|
|
|
45
|
|
|
|
|
|
|
|
244,601
|
|
|
|
|
|
|
|
244,690
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
23
|
|
|
$
|
|
|
|
$
|
44
|
|
|
$
|
|
|
|
$
|
221,003
|
|
|
$
|
514
|
|
|
$
|
221,584
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-58
FRESENIUS
MEDICAL CARE AG & Co. KGaA
Schedule II Valuation
and Qualifying Accounts
(in
thousands, except share data)
Development
of allowance for doubtful accounts
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Allowance for doubtful accounts as of January 1
|
|
$
|
266,449
|
|
|
$
|
262,836
|
|
|
$
|
247,800
|
|
Change in valuation allowances as recorded in the consolidated
statements of income
|
|
|
218,496
|
|
|
|
210,124
|
|
|
|
213,586
|
|
Write-offs and recoveries of amounts previously written-off
|
|
|
(205,666
|
)
|
|
|
(210,166
|
)
|
|
|
(192,626
|
)
|
Foreign currency translation
|
|
|
(2,140
|
)
|
|
|
3,656
|
|
|
|
(5,924
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts as of December 31
|
|
$
|
277,139
|
|
|
$
|
266,449
|
|
|
$
|
262,836
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S-II
Exhibit 2.20
FMC FINANCE VII S.A.
as Issuer
U.S. BANK NATIONAL ASSOCIATION
as Trustee
DEUTSCHE BANK
AKTIENGESELLSCHAFT
as Paying Agent
FRESENIUS MEDICAL CARE
AG & Co. KGaA,
FRESENIUS MEDICAL CARE HOLDINGS, INC. and
FRESENIUS MEDICAL CARE DEUTSCHLAND GmbH
as Guarantors
INDENTURE
DATED AS OF FEBRUARY 3, 2011
with respect to the issuance of
5.25% SENIOR NOTES DUE 2021
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
ARTICLE I
|
|
DEFINITIONS AND INCORPORATION BY REFERENCE
|
|
|
|
|
|
|
|
|
|
|
SECTION 1.1
|
|
|
Definitions
|
|
|
1
|
|
|
SECTION 1.2
|
|
|
Rules of Construction
|
|
|
21
|
|
|
SECTION 1.3
|
|
|
Incorporation by Reference of Trust Indenture Act
|
|
|
21
|
|
|
ARTICLE II
|
|
THE NOTES
|
|
|
|
|
|
|
|
|
|
|
SECTION 2.1
|
|
|
Form and Dating
|
|
|
21
|
|
|
SECTION 2.2
|
|
|
Execution and Authentication
|
|
|
23
|
|
|
SECTION 2.3
|
|
|
Registrar and Paying Agent
|
|
|
24
|
|
|
SECTION 2.4
|
|
|
Paying Agent To Hold Assets in Trust
|
|
|
24
|
|
|
SECTION 2.5
|
|
|
List of Holders
|
|
|
25
|
|
|
SECTION 2.6
|
|
|
Book-Entry Provisions for Global Notes
|
|
|
25
|
|
|
SECTION 2.7
|
|
|
Registration of Transfer and Exchange
|
|
|
26
|
|
|
SECTION 2.8
|
|
|
Replacement Notes
|
|
|
31
|
|
|
SECTION 2.9
|
|
|
Outstanding Notes
|
|
|
31
|
|
|
SECTION 2.10
|
|
|
Treasury Notes
|
|
|
31
|
|
|
SECTION 2.11
|
|
|
Temporary Notes
|
|
|
32
|
|
|
SECTION 2.12
|
|
|
Cancellation
|
|
|
32
|
|
|
SECTION 2.13
|
|
|
Defaulted Interest
|
|
|
32
|
|
|
SECTION 2.14
|
|
|
ISINs and Common Codes
|
|
|
32
|
|
|
SECTION 2.15
|
|
|
Deposit of Moneys
|
|
|
33
|
|
|
SECTION 2.16
|
|
|
Certain Matters Relating to Global Notes
|
|
|
33
|
|
|
SECTION 2.17
|
|
|
Record Date
|
|
|
33
|
|
|
ARTICLE III
|
|
REDEMPTION
|
|
|
|
|
|
|
|
|
|
|
SECTION 3.1
|
|
|
Optional Redemption
|
|
|
33
|
|
|
SECTION 3.2
|
|
|
Notices to Trustee
|
|
|
34
|
|
|
SECTION 3.3
|
|
|
Selection of Notes To Be Redeemed
|
|
|
34
|
|
|
SECTION 3.4
|
|
|
Notice of Redemption
|
|
|
34
|
|
|
SECTION 3.5
|
|
|
Effect of Notice of Redemption
|
|
|
36
|
|
|
SECTION 3.6
|
|
|
Deposit of Redemption Price
|
|
|
36
|
|
|
SECTION 3.7
|
|
|
Notes Redeemed in Part
|
|
|
36
|
|
|
SECTION 3.8
|
|
|
Special Tax Redemption
|
|
|
37
|
|
-i-
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
ARTICLE IV
|
|
COVENANTS
|
|
|
|
|
|
|
|
|
|
|
SECTION 4.1
|
|
|
Payment of Notes
|
|
|
37
|
|
|
SECTION 4.2
|
|
|
Maintenance of Office or Agency
|
|
|
38
|
|
|
SECTION 4.3
|
|
|
Limitation on Incurrence of Indebtedness
|
|
|
38
|
|
|
SECTION 4.4
|
|
|
Limitation on Liens
|
|
|
40
|
|
|
SECTION 4.5
|
|
|
Ownership of the Issuer
|
|
|
40
|
|
|
SECTION 4.6
|
|
|
Existence
|
|
|
40
|
|
|
SECTION 4.7
|
|
|
Maintenance of Properties
|
|
|
41
|
|
|
SECTION 4.8
|
|
|
Payment of Taxes and Other Claims
|
|
|
41
|
|
|
SECTION 4.9
|
|
|
Maintenance of Insurance
|
|
|
41
|
|
|
SECTION 4.10
|
|
|
Reports
|
|
|
41
|
|
|
SECTION 4.11
|
|
|
Change of Control
|
|
|
42
|
|
|
SECTION 4.12
|
|
|
Additional Amounts
|
|
|
44
|
|
|
SECTION 4.13
|
|
|
Compliance Certificate; Notice of Default
|
|
|
45
|
|
|
SECTION 4.14
|
|
|
Limitation on Sale and Leaseback Transactions
|
|
|
46
|
|
|
ARTICLE V
|
|
SUCCESSOR ISSUER OR GUARANTOR
|
|
|
|
|
|
|
|
|
|
|
SECTION 5.1
|
|
|
Limitation on Mergers and Sales of Assets
|
|
|
46
|
|
|
SECTION 5.2
|
|
|
Successor Entity Substituted
|
|
|
47
|
|
|
SECTION 5.3
|
|
|
Substitution of the Issuer
|
|
|
47
|
|
|
ARTICLE VI
|
|
DEFAULT AND REMEDIES
|
|
|
|
|
|
|
|
|
|
|
SECTION 6.1
|
|
|
Events of Default
|
|
|
48
|
|
|
SECTION 6.2
|
|
|
Acceleration
|
|
|
49
|
|
|
SECTION 6.3
|
|
|
Other Remedies
|
|
|
49
|
|
|
SECTION 6.4
|
|
|
The Trustee May Enforce Claims Without Possession of Notes
|
|
|
50
|
|
|
SECTION 6.5
|
|
|
Rights and Remedies Cumulative
|
|
|
50
|
|
|
SECTION 6.6
|
|
|
Delay or Omission Not Waiver
|
|
|
50
|
|
|
SECTION 6.7
|
|
|
Waiver of Past Defaults
|
|
|
50
|
|
|
SECTION 6.8
|
|
|
Control by Majority
|
|
|
50
|
|
|
SECTION 6.9
|
|
|
Limitation on Suits
|
|
|
51
|
|
|
SECTION 6.10
|
|
|
Rights of Holders To Receive Payment
|
|
|
51
|
|
|
SECTION 6.11
|
|
|
Collection Suit by Trustee
|
|
|
51
|
|
|
SECTION 6.12
|
|
|
Trustee May File Proofs of Claim
|
|
|
51
|
|
|
SECTION 6.13
|
|
|
Priorities
|
|
|
52
|
|
|
SECTION 6.14
|
|
|
Restoration of Rights and Remedies
|
|
|
52
|
|
|
SECTION 6.15
|
|
|
Undertaking for Costs
|
|
|
53
|
|
|
SECTION 6.16
|
|
|
Notices of Default
|
|
|
53
|
|
-ii-
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
ARTICLE VII
|
|
TRUSTEE
|
|
|
|
|
|
|
|
|
|
|
SECTION 7.1
|
|
|
Duties of Trustee
|
|
|
53
|
|
|
SECTION 7.2
|
|
|
Rights of Trustee
|
|
|
54
|
|
|
SECTION 7.3
|
|
|
Individual Rights of Trustee
|
|
|
55
|
|
|
SECTION 7.4
|
|
|
Trustees Disclaimer
|
|
|
55
|
|
|
SECTION 7.5
|
|
|
Notice of Default
|
|
|
55
|
|
|
SECTION 7.6
|
|
|
Reports by Trustee to Holders of the Notes
|
|
|
56
|
|
|
SECTION 7.7
|
|
|
Compensation and Indemnity
|
|
|
56
|
|
|
SECTION 7.8
|
|
|
Replacement of Trustee
|
|
|
57
|
|
|
SECTION 7.9
|
|
|
Successor Trustee by Merger, Etc
|
|
|
58
|
|
|
SECTION 7.10
|
|
|
Eligibility; Disqualification
|
|
|
59
|
|
|
SECTION 7.11
|
|
|
Preferential Collection of Claims Against the Company
|
|
|
59
|
|
|
ARTICLE VIII
|
|
SATISFACTION AND DISCHARGE OF INDENTURE
|
|
|
|
|
|
|
|
|
|
|
SECTION 8.1
|
|
|
Option To Effect Legal Defeasance or Covenant Defeasance
|
|
|
59
|
|
|
SECTION 8.2
|
|
|
Legal Defeasance and Discharge
|
|
|
59
|
|
|
SECTION 8.3
|
|
|
Covenant Defeasance
|
|
|
60
|
|
|
SECTION 8.4
|
|
|
Conditions to Legal or Covenant Defeasance
|
|
|
60
|
|
|
SECTION 8.5
|
|
|
Satisfaction and Discharge of Indenture
|
|
|
61
|
|
|
SECTION 8.6
|
|
|
Survival of Certain Obligations
|
|
|
62
|
|
|
SECTION 8.7
|
|
|
Acknowledgment of Discharge by Trustee
|
|
|
62
|
|
|
SECTION 8.8
|
|
|
Application of Trust Moneys
|
|
|
62
|
|
|
SECTION 8.9
|
|
|
Repayment to the Issuer; Unclaimed Money
|
|
|
62
|
|
|
SECTION 8.10
|
|
|
Reinstatement
|
|
|
63
|
|
|
ARTICLE IX
|
|
AMENDMENTS, SUPPLEMENTS AND WAIVERS
|
|
|
|
|
|
|
|
|
|
|
SECTION 9.1
|
|
|
Without Consent of Holders of Notes
|
|
|
64
|
|
|
SECTION 9.2
|
|
|
With Consent of Holders of Notes
|
|
|
64
|
|
|
SECTION 9.3
|
|
|
Notice of Amendment, Supplement or Waiver
|
|
|
65
|
|
|
SECTION 9.4
|
|
|
Revocation and Effect of Consents
|
|
|
65
|
|
|
SECTION 9.5
|
|
|
Notation on or Exchange of Notes
|
|
|
66
|
|
|
SECTION 9.6
|
|
|
Trustee To Sign Amendments, Etc
|
|
|
66
|
|
|
ARTICLE X
|
|
NOTE GUARANTEE
|
|
|
|
|
|
|
|
|
|
|
SECTION 10.1
|
|
|
Note Guarantee
|
|
|
66
|
|
-iii-
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
|
SECTION 10.2
|
|
|
Execution and Delivery of Note Guarantees
|
|
|
70
|
|
|
SECTION 10.3
|
|
|
Guarantors May Consolidate, Etc., On Certain Terms
|
|
|
70
|
|
|
SECTION 10.4
|
|
|
Release of Guarantors
|
|
|
70
|
|
|
ARTICLE XI
|
|
MISCELLANEOUS
|
|
|
|
|
|
|
|
|
|
|
SECTION 11.1
|
|
|
Notices
|
|
|
71
|
|
|
SECTION 11.2
|
|
|
Certificate and Opinion as to Conditions Precedent
|
|
|
73
|
|
|
SECTION 11.3
|
|
|
Statements Required in Certificate or Opinion
|
|
|
74
|
|
|
SECTION 11.4
|
|
|
Rules by Trustee, Paying Agent, Registrar
|
|
|
74
|
|
|
SECTION 11.5
|
|
|
Legal Holidays
|
|
|
74
|
|
|
SECTION 11.6
|
|
|
Governing Law
|
|
|
74
|
|
|
SECTION 11.7
|
|
|
Submission to Jurisdiction
|
|
|
74
|
|
|
SECTION 11.8
|
|
|
No Personal Liability of Directors, Officers, Employees and
Stockholders
|
|
|
75
|
|
|
SECTION 11.9
|
|
|
Successors
|
|
|
75
|
|
|
SECTION 11.10
|
|
|
Counterpart Originals
|
|
|
76
|
|
|
SECTION 11.11
|
|
|
Severability
|
|
|
76
|
|
|
SECTION 11.12
|
|
|
Table of Contents, Headings, etc
|
|
|
76
|
|
|
SECTION 11.13
|
|
|
Trust Indenture Act Controls
|
|
|
76
|
|
|
SECTION 11.14
|
|
|
Currency Indemnity
|
|
|
76
|
|
|
SECTION 11.15
|
|
|
Information
|
|
|
76
|
|
-iv-
|
|
|
|
|
EXHIBITS
|
|
|
|
|
Exhibit A
|
|
-
|
|
Form of Initial Global Note
|
Exhibit B
|
|
-
|
|
Form of Initial Definitive Note
|
Exhibit C
|
|
-
|
|
Form of Note Guarantee
|
Exhibit D
|
|
-
|
|
Form of Transfer Certificate for Transfer from Rule 144A
Global Note to Regulation S Global Note
|
Exhibit E
|
|
-
|
|
Form of Transfer Certificate for Transfer from Regulation S
Global Note to Rule 144A Global Note
|
NOTE: This Table of Contents shall not, for any purpose, be
deemed to be part of this Indenture.
-v-
INDENTURE dated as of February 3, 2011, among FMC FINANCE
VII S.A., a société anonyme organized under the laws
of Luxembourg (the Issuer), as Issuer, FRESENIUS
MEDICAL CARE AG & Co. KGaA, a partnership limited by
shares (Kommanditgesellschaft auf Aktien) organized under the
laws of the Federal Republic of Germany (the
Company), FRESENIUS MEDICAL CARE HOLDINGS, INC., a
New York corporation (FMCH) and FRESENIUS MEDICAL
CARE DEUTSCHLAND GmbH, a limited liability company organized
under the laws of the Federal Republic of Germany
(FMCD and, together with the Company and FMCH, the
Guarantors), U.S. BANK NATIONAL ASSOCIATION, a
national banking association, as trustee (the
Trustee) and DEUTSCHE BANK AKTIENGESELLSCHAFT, as
the paying agent (the Paying Agent).
The Issuer has duly authorized the creation and issuance of its
5.25% Senior Notes due 2021. The Notes consist of (i)
300,000,000 aggregate principal amount of notes issued on
the date hereof (the Initial Notes) and
(ii) Additional Notes (as defined herein) that may be
issued on any Issue Date (all such notes referred to in
clauses (i) and (ii) being referred to as the
Notes); and, to provide therefor, the Issuer has
duly authorized the execution and delivery of this Indenture.
The Notes will be guaranteed (the Note Guarantee) on
a senior unsecured basis by each Guarantor. Each of the Issuer
and the Guarantors has duly authorized the execution and
delivery of this Indenture. All things necessary to make the
Notes, when duly issued and executed by the Issuer and
authenticated and delivered by the Trustee hereunder, the valid
obligations of the Issuer, and the Note Guarantee, when executed
by each Guarantor and endorsed upon the Notes, the valid
obligation of each Guarantor and to make this Indenture a valid
agreement of the Issuer and each Guarantor, have been done.
Each party agrees as follows for the benefit of the other
parties and for the equal and ratable benefit of the Holders:
ARTICLE I
DEFINITIONS
AND INCORPORATION BY REFERENCE
SECTION 1.1
Definitions
. As
used in this Indenture, the following terms shall have the
following meanings:
Accounting Principles means U.S. GAAP, or, upon
adoption thereof by the Company and notice to the Trustee, IFRS
or any other accounting standards which are generally acceptable
in the jurisdiction of organization of the Company, approved by
the relevant regulatory or other accounting bodies in that
jurisdiction and internationally generally acceptable and, in
the case of IFRS or such other accounting standards, as in
effect from time to time.
Acquired Indebtedness means Indebtedness of a Person
existing at the time such Person becomes a Subsidiary or is
merged into or consolidated with any other Person or that is
assumed in connection with the acquisition of assets from such
Person and, in each case, not Incurred by such Person in
connection with, or in anticipation or contemplation of, such
Person becoming a Subsidiary or such merger, consolidation or
acquisition.
Additional Amounts shall have the meaning set forth
in Section 4.12 hereof.
Additional Notes means additional 5.25% Senior
Notes due 2021.
Additional Taxing Jurisdiction shall have the
meaning set forth in Section 4.12 hereof.
Affiliate of any specified Person means:
(1) any other Person, directly or
indirectly, controlling or controlled by, or
(2) under direct or indirect common
control with such specified Person.
For the purposes of this definition, control when
used with respect to any Person means the power to direct the
management and policies of such Person, directly or indirectly,
whether through the ownership of voting securities, by contract
or otherwise; and the terms controlling and
controlled have meanings correlative to the
foregoing.
Agent means the Paying Agent, any Registrar,
Authenticating Agent or co-Registrar.
Agent Members shall have the meaning set forth in
Section 2.16.
A/R Facility means the accounts receivable facility
established pursuant to the Fifth Amended and Restated Transfer
and Administration Agreement dated as of November 17, 2009
by and among NMC Funding Corporation, as transferor, National
Medical Care, Inc., as initial collection agent, Compass US
Acquisition LLC, and other conduit investors party thereto, the
financial institutions party thereto, The Bank of Nova Scotia,
Barclays Bank PLC, Credit Agricole Corporate and Investment
Bank, New York Branch and Royal Bank of Canada, as
administrative agents, and WestLB AG, New York Branch, as
administrative agent and as agent (as amended, modified,
renewed, refunded, replaced, restated or refinanced from time to
time).
Asset Disposition means any direct or indirect sale,
issuance, conveyance, transfer, lease (other than operating
leases entered into in the ordinary course of business),
assignment or other transfer for value by the Company or any of
its Subsidiaries (including any Sale and Leaseback Transaction)
to any Person other than the Company or a Wholly Owned
Subsidiary of the Company, including any disposition by means of
a merger, consolidation or similar transaction (each referred to
for the purposes of this definition as a
disposition), of:
(1) any shares of Capital Stock of
any Subsidiary (other than directors qualifying shares or
shares required by applicable law to be held by a Person other
than the Company or a Subsidiary),
(2) all or substantially all the
assets of any division or line of business of the Company or any
Subsidiary, or
(3) any other assets of the Company
or any Subsidiary outside of the ordinary course of business of
the Company or such Subsidiary,
other than, in the case of clauses (1), (2) and
(3) above,
-2-
(A) a disposition of assets or
issuance of Capital Stock by a Subsidiary to the Company or by
the Company or a Subsidiary to a Wholly Owned Subsidiary,
(B) transactions permitted under
Section 5.1, and
(C) dispositions in connection with
Permitted Liens, foreclosures on assets and any release of
claims which have been written down or written off.
Attributable Debt means, in respect of any Sale and
Leaseback Transaction, as of the time of determination, the
total obligation (discounted to present value at the rate per
annum equal to the discount rate which would be applicable to a
Capital Lease Obligation with the like term in accordance with
Accounting Principles) of the lessee for rental payments (other
than amounts required to be paid on account of property taxes,
maintenance, repairs, insurance, water rates and other items
which do not constitute payments for property rights) during the
remaining portion of the initial term of the lease included in
such Sale and Leaseback Transaction.
Authenticating Agent shall have the meaning set
forth in Section 2.2.
Average Life means, as of the date of determination,
with respect to any Indebtedness or Preferred Stock, the
quotient obtained by dividing:
(1) the sum of the products of
numbers of years from the date of determination to the dates of
each successive scheduled principal payment of such Indebtedness
or redemption or similar payment with respect to such Preferred
Stock multiplied by the amount of such payment by,
(2) the sum of all such payments.
Bankruptcy Law means (i) for purposes of the
Company and FMCD, any bankruptcy, insolvency, reorganization,
moratorium and other similar laws of general application
(including, without limitation, the German Insolvency Code
(Insolvenzordnung), (ii) for purposes of the
Issuer, any bankruptcy, insolvency or other similar statute
(including, without limitation, the Luxembourg Commercial Code
(Code de Commerce) and any similar statute), regulation or
provision of any jurisdiction in which the Issuer is organized
or conducting business (iii) for purposes of FMCH, any
bankruptcy, insolvency, reorganization, moratorium and other
similar laws of general application (including, without
limitation, 11 U.S.C. §101 et seq., as amended) and
(iv) for purposes of the Trustee, any bankruptcy,
insolvency or similar statute, regulation or provision of any
jurisdiction in which the Trustee is organized or conducting
business.
Board of Directors means, with respect to the Issuer
or any Guarantor, as the case may be, the Board of Directors (or
other body performing functions similar to any of those
performed by a Board of Directors including those performed, in
the case of a German stock corporation, by the management board
or, in the case of a KGaA, by the General Partner) of such
Person or any committee thereof duly authorized to act on behalf
of such Board (or other body).
Board Resolution means, with respect to the Issuer
or a Guarantor, a copy of a resolution certified by the
Secretary or an Assistant Secretary or a member of the Board of
Directors or Management Board of the Issuer or such Guarantor to
have been duly adopted by the
-3-
Board of Directors or the Management Board, or such committee of
the Board of Directors or the Management Board or officers of
the Issuer or such Guarantor to which authority to act on behalf
of the Board of Directors or the Management Board has been
delegated, and to be in full force and effect on the date of
such certification, and delivered to the Trustee by the Issuer
or the Guarantor, as the case may be, and the Trustee shall be
entitled to rely on such certification as conclusive evidence
thereof.
Bund Rate means the yield to maturity at the time of
computation of direct obligations of the Federal Republic of
Germany (Bund or Bundesanleihen) with a constant maturity (as
officially compiled and published in the most recent financial
statistics that have become publicly available at least two
Business Days (but not more than five Business Days) prior to
the redemption date (or, if such financial statistics are not so
published or available, any publicly available source of similar
market data selected by the Issuer in good faith)) most nearly
equal to the period from the redemption date to
February 15, 2021;
provided, however
that if the
period from the redemption date to February 15, 2021 is not
equal to the constant maturity of the direct obligations of the
Federal Republic of Germany for which a weekly average yield is
given, the Bund Rate shall be obtained by linear interpolation
(calculated to the nearest one-twelfth of a year) from the
weekly average yields of direct obligations of the Federal
Republic of Germany for which such yields are given, except that
if the period from such redemption date to February 15,
2021 is less than one year, the weekly average yield on actually
traded direct obligations of the Federal Republic of Germany
adjusted to a constant maturity of one year shall be used.
Business Day means any day other than:
(1) a Saturday or Sunday,
(2) a day on which banking
institutions in Frankfurt am Main or the jurisdiction of
organization of the Issuer or of the office of the Paying Agent
(other than the Trustee) are authorized or required by law or
executive order to remain closed, or
(3) except for purposes of payments
made on or in respect of the Notes by a Paying Agent other than
the Trustee, a day on which the Corporate Trust Office of
the Trustee is closed for business.
Capital Lease Obligations means an obligation that
is required to be classified and accounted for as a capital
lease for financial reporting purposes in accordance with
Accounting Principles, and the amount of Indebtedness
represented by such obligation shall be the capitalized amount
of such obligation determined in accordance with Accounting
Principles; and the Stated Maturity thereof shall be the date of
the last payment of rent or any other amount due under such
lease prior to the first date upon which such lease may be
terminated by the lessee without payment of a penalty.
Capital Stock of any Person means any and all
shares, interests, rights to purchase, warrants, options,
participations or other equivalents of or interests in (however
designated) equity of such Person, including any Preferred
Stock, but excluding any debt securities convertible into such
equity.
-4-
Cash Management Arrangements means the cash
management arrangements of the Company and its Affiliates
(including any Indebtedness arising thereunder) which
arrangements are in the ordinary course of business consistent
with past practice.
Change of Control means the occurrence of one or
more of the following events:
(1) so long as the Company is
organized as a KGaA, if the General Partner of the Company
charged with management of the Company shall at any time fail to
be a Subsidiary of Fresenius SE, or if Fresenius SE shall fail
at any time to own and control more than 25% of the capital
stock with ordinary voting power in the Company;
(2) if the Company is no longer
organized as a KGaA, any event the result of which is that
(A) any person or group (as such
terms are used in Sections 13(d) and 14(d) of the Exchange
Act), other than Fresenius SE, is or becomes the beneficial
owner (as defined in
Rules 13d-3
and
13d-5
under the Exchange Act, except that such Person or group shall
be deemed to have beneficial ownership of all shares
that any such Person or group has the right to acquire, whether
such right is exercisable immediately or only after the passage
of time), directly or indirectly, of more than 35% of the total
voting power of the Voting Stock of the Company and
(B) Fresenius SE does not beneficially own (as
defined in Rules
13d-3
and
13d-5
of the
Exchange Act), directly or indirectly, in the aggregate a
greater percentage of the total voting power of the Voting Stock
of the Company;
(3) any sale, lease, exchange or
other transfer (in one transaction or a series of related
transactions) of all or substantially all of the assets of the
Company to any Person or group of related Persons for purposes
of Section 13(d) of the Exchange Act (a Group),
together with any Affiliates thereof (whether or not otherwise
in compliance with the provisions herein).
Change of Control Triggering Event means the
occurrence of a Change of Control and a Ratings Decline.
Clearing Agency means one or more of Euroclear,
Clearstream, or the successor of either of them, in each case
acting directly, or through a custodian, nominee or depository,
as holder of the Global Notes.
Clearstream shall have the meaning set forth in
Section 2.6.
Closing Date means the date of this Indenture.
Code means the United States Internal Revenue Code
of 1986, as amended.
Company means the party named as such in this
Indenture until a successor replaces it pursuant to this
Indenture and thereafter means such successor.
Consolidated Coverage Ratio of any Person as of any
date of determination means the ratio of (x) the aggregate
amount of EBITDA for such Persons most recently ended
-5-
four full fiscal quarters for which internal financial
statements are available immediately preceding the date of such
determination to (y) Consolidated Interest Expense for such
four fiscal quarters;
provided
,
however
, that:
(1) if such Person or any of its
Subsidiaries has Incurred or repaid, repurchased, defeased or
otherwise discharged (in each case other than Indebtedness under
any revolving credit facility unless such Indebtedness has been
permanently repaid and any related commitment has been
terminated) any Indebtedness since the beginning of such period
that remains outstanding or discharged or if the transaction
giving rise to the need to calculate the Consolidated Coverage
Ratio is an Incurrence or discharge of Indebtedness, or both,
EBITDA and Consolidated Interest Expense for such period shall
be calculated after giving effect on a pro forma basis to such
Indebtedness as if such Indebtedness had been Incurred or
discharged on the first day of such period and the Incurrence or
discharge of any other Indebtedness as if such Incurrence or
discharge had occurred on the first day of such period,
(2) if since the beginning of such
period such Person or any of its Subsidiaries shall have made
any Asset Disposition, the EBITDA for such period shall be
reduced by an amount equal to the EBITDA (if positive) directly
attributable to the assets which are the subject of such Asset
Disposition for such period, or increased by an amount equal to
the EBITDA (if negative), directly attributable thereto for such
period and Consolidated Interest Expense for such period shall
be reduced by an amount equal to the Consolidated Interest
Expense directly attributable to any Indebtedness of such Person
or any of its Subsidiaries repaid, repurchased, defeased or
otherwise discharged with respect to such Person and its
continuing Subsidiaries in connection with such Asset
Disposition for such period (or, if the Capital Stock of any
Subsidiary is sold, the Consolidated Interest Expense for such
period of credit and directly attributable to the Indebtedness
of such Subsidiary to the extent such Person and its continuing
Subsidiaries are no longer liable for such Indebtedness after
such Asset Disposition),
(3) if since the beginning of such
period such Person or any of its Subsidiaries (by merger or
otherwise) shall have made an Investment in any Subsidiary (or
any Person which becomes a Subsidiary) or an acquisition of
assets, which constitutes all or substantially all of an
operating unit of a business, EBITDA and Consolidated Interest
Expense for such period shall be calculated after giving pro
forma effect thereto (including the Incurrence of any
Indebtedness) as if such Investment or acquisition occurred on
the first day of such period, and
(4) if since the beginning of such
period any Person (that subsequently became a Subsidiary or was
merged with or into such Person or any of its Subsidiaries since
the beginning of such period) shall have made any Asset
Disposition, any Investment or acquisition of assets that would
have required an adjustment pursuant to clause (2) or
(3) above if made by such Person or a Subsidiary of such
Person during such period, EBITDA and Consolidated Interest
Expense for such period shall be calculated after giving pro
forma effect thereto as if such Asset Disposition, Investment or
acquisition occurred on the first day of such period.
-6-
For purposes of this definition, whenever pro forma effect is to
be given to an acquisition of assets, the amount of income or
earnings relating thereto and the amount of Consolidated
Interest Expense associated with any Indebtedness Incurred in
connection therewith, the pro forma calculations shall be
determined in good faith by a responsible financial or
accounting officer of the Company, as applicable. If any
Indebtedness bears a floating rate of interest and is being
given pro forma effect, the interest of such Indebtedness shall
be calculated as if the rate in effect on the date of
determination had been the applicable rate for the entire period
(taking into account any Interest Rate Agreement applicable to
such Indebtedness if such Interest Rate Agreement has a
remaining term in excess of 12 months).
Consolidated Interest Expense means, with respect to
any Person for any period, the total interest expense of such
Person and its consolidated Subsidiaries, including the
amortization of debt discount and premium, the interest
component under capital leases and the implied interest
component (if any) under any Receivables Financing, in each case
on a consolidated basis determined in accordance with Accounting
Principles.
Consolidated Net Income means, with respect to any
Person for any period, the net income of such Person and its
consolidated Subsidiaries (including, for any period after
January 1, 2009, any net income attributable to
non-controlling interest of such Person and its consolidated
Subsidiaries), in each case as determined on a consolidated
basis in accordance with Accounting Principles;
provided
that extraordinary gains and losses shall be excluded from
Consolidated Net Income.
Consolidated Net Tangible Assets means, as of any
date of determination, the total amount of all assets of the
Company and its Subsidiaries, determined on a consolidated basis
in accordance with Accounting Principles, as of the end of the
most recent fiscal quarter for which the Companys
financial statements are available, less the sum of:
(1) the Companys consolidated
current liabilities as of such quarter end, determined on a
consolidated basis in accordance with Accounting
Principles; and
(2) the Companys consolidated
assets that are properly classified as intangible assets as of
such quarter end, determined on a consolidated basis in
accordance with Accounting Principles.
Corporate Trust Office means the address of the
Trustee specified in Section 11.1, or such other address as
to which the Trustee may, from time to time, give written notice
to the Company.
Covenant Defeasance shall have the meaning set forth
in Section 8.3.
Credit Facility means (i) the bank credit
agreement entered into as of March 31, 2006 among the
Company, FMCH, the other borrowers identified therein, the
guarantors identified therein, the lenders party thereto and
Bank of America, N.A., as administrative agent, as extended on
September 29, 2010 and as amended, modified, renewed,
refunded, replaced, restated or refinanced from time to time
(the Revolving Credit Facility) and (ii) the
term loan credit agreement entered into as of March 31,
2006 among the Company, FMCH, the other borrowers identified
therein, the guarantors identified therein, the lenders party
thereto and Bank of Ameri-
-7-
ca, N.A., as administrative agent, as extended on
September 29, 2010 and as amended, modified, renewed,
refunded, replaced, restated or refinanced from time to time.
Currency Agreement means any foreign currency
exchange contract, currency swap agreement or other similar
agreement or arrangement.
Custodian means any receiver, trustee, assignee,
liquidator, sequestration or similar official under any
Bankruptcy Law.
Default means any event that is, or after notice or
passage of time or both would be, an Event of Default (as
defined herein).
Default Interest Payment Date shall have the meaning
set forth in Section 2.13.
Defeasance Trust shall have the meaning set forth in
Section 8.4.
Definitive Notes means Notes in definitive
registered form substantially in the form of
Exhibit B
.
Designated Government Obligations means direct
non-callable and non-redeemable obligations (in each case, with
respect to the issuer thereof) of any member state of the
European Union that is a member of the European Union as of the
date of this Indenture or of the United States of America
(including, in each case, any agency or instrumentality
thereof), as the case may be, the payment of which is secured by
the full faith and credit of the applicable member state or of
the United States of America, as the case may be.
Disqualified Stock means, with respect to any
Person, any Capital Stock that by its terms (or by the terms of
any security into which it is convertible or for which it is
exchangeable) or upon the happening of any event:
(1) matures or is mandatorily
redeemable pursuant to a sinking fund obligation or otherwise;
(2) is convertible or exchangeable
for Indebtedness or Disqualified Stock; or
(3) is redeemable at the option of
the holder thereof, in whole or in part,
in each case on or prior to the first anniversary of the Stated
Maturity of the Notes;
provided
,
however
, that any
Capital Stock that would not constitute Disqualified Stock but
for provisions thereof giving holders thereof the right to
require such Person to repurchase or redeem such Capital Stock
upon the occurrence of an asset sale or change
of control occurring prior to the first anniversary of the
Stated Maturity of the Notes shall not constitute Disqualified
Stock if the asset sale or change of
control provisions applicable to such Capital Stock are
not more favorable to the holders of such Capital Stock than the
provisions of Section 4.11.
EBITDA for any Person for any period means the sum
of Consolidated Net Income of such Person, plus Consolidated
Interest Expense of such Person plus the following to the extent
deducted in calculating such Consolidated Net Income:
-8-
(1) all income tax expense of such
Person and its Subsidiaries,
(2) depreciation expense, and
(3) amortization expense, in each
case for such period.
Notwithstanding the foregoing, the provision for taxes based on
the income or profits of, and the depreciation and amortization
of, a Subsidiary that is not a Wholly Owned Subsidiary shall be
added to Consolidated Net Income to compute EBITDA only to the
extent (and in the same proportion) that the net income of such
Subsidiary was included in calculating Consolidated Net Income
and only if a corresponding amount would be permitted at the
date of determination to be dividended to such Person by such
Subsidiary without prior approval (that has not been obtained),
pursuant to the terms of its charter and all agreements,
instruments, judgments, decrees, orders, statutes, rules and
governmental regulations applicable to such Subsidiary or its
stockholders.
or euro means the single
currency of the Participating Member States.
Euroclear shall have the meaning set forth in
Section 2.6.
Event of Default shall have the meaning set forth in
Section 6.1.
Exchange Act means the United States Securities
Exchange Act of 1934, as amended.
Finance Subsidiary means any Wholly Owned Subsidiary
of the Company created for the sole purpose of issuing evidences
of Indebtedness and which is subject to similar restrictions on
its activities as the Issuer.
Fresenius SE means Fresenius SE & Co.
KGaA, a partnership limited by shares (
Kommanditgesellschaft
auf Aktien
) resulting from the change of legal form of
Fresenius SE, a European Company (Societas Europaea) previously
called Fresenius AG, a German stock corporation.
General Partner means Fresenius Medical Care
Management AG, a German stock corporation, including its
successors and assigns and other Persons, in each case who serve
as the general partner (
persönlich haftender
Gesellschafter
) of the Company from time to time.
Global Notes shall mean Notes in registered global
form substantially in the form of
Exhibit A
.
Guarantee means any obligation, contingent or
otherwise, of any Person directly or indirectly guaranteeing any
Indebtedness or other obligation of any Person (other than, in
the case of subsidiaries, obligations which would not constitute
Indebtedness) and any obligation, direct or indirect, contingent
or otherwise, of such Person:
(1) to purchase or pay (or advance
or supply funds for the purchase or payment of) such
Indebtedness or other obligation of such Person (whether arising
by virtue
-9-
of partnership arrangements, or by agreements to keep-well, to
purchase assets, goods, securities or services, to
take-or-pay
or to maintain financial statement conditions or
otherwise), or
(2) entered into for the purpose of
assuring in any other manner the obligee of such Indebtedness or
other obligation of the payment thereof or to protect such
obligee against loss in respect thereof (in whole or in part);
provided
,
however
, that the term
Guarantee shall not include endorsements for
collection or deposit in the ordinary course of business. The
term Guarantee used as a verb has a corresponding
meaning.
Guarantee Agreement means, in the context of a
consolidation, merger or sale of all or substantially all of the
assets of a Guarantor, an agreement by which the Surviving
Person from such a transaction expressly assumes all of the
obligations of such Guarantor under its Note Guarantee.
Guarantor means each of the Company, FMCH and FMCD
and any successor or additional Guarantor, unless released from
its obligations under its Note Guarantee in accordance with the
terms of this Indenture.
Hedging Obligations of any Person means the
obligations of such Person pursuant to any Interest Rate
Agreement or Currency Agreement.
Holder means a Person in whose name a Note is
registered on the Registrars books.
IFRS means international financial reporting
standards and interpretations issued by the International
Accounting Standards Board and adopted by the European
Commission, as in effect from time to time.
Incur means issue, assume, guarantee, incur or
otherwise become liable for;
provided
,
however
,
that any Indebtedness or Capital Stock of a Person existing at
the time such Person becomes a Subsidiary (whether by merger,
consolidation, acquisition or otherwise) shall be deemed to be
Incurred by such Subsidiary at the time it becomes a Subsidiary.
The term Incurrence when used as a noun shall have a
correlative meaning. The accretion of principal of a
non-interest bearing or other discount security shall be deemed
the Incurrence of Indebtedness.
Indebtedness means, with respect to any Person on
any date of determination (without duplication):
(1) the principal of and premium
(if any) in respect of (A) indebtedness of such Person for
money borrowed and (B) indebtedness evidenced by notes,
debentures, bonds or other similar instruments for the payment
of which such Person is responsible or liable,
(2) all Capital Lease Obligations
of such Person,
-10-
(3) all obligations of such Person
issued or assumed as the deferred purchase price of property or
services, all conditional sale obligations of such Person and
all obligations of such Person under any title retention
agreement (other than (x) customary reservations or
retentions of title under agreements with suppliers entered into
in the ordinary course of business, (y) trade debt Incurred
in the ordinary course of business and not overdue by
90 days or more and (z) obligations Incurred under a
pension, retirement or deferred compensation program or
arrangement regulated under the Employee Retirement Income
Security Act of 1974, as amended, or the laws of a foreign
government),
(4) all obligations of such Person
for the reimbursement of any obligor on any letter of credit,
bank guarantee, bankers acceptance or similar credit
transaction (except to the extent such reimbursement obligation
relates to trade debt in the ordinary course of business and
such reimbursement obligation is paid within 30 days after
payment of the trade debt),
(5) the amount of all obligations
of such Person with respect to the redemption, repayment or
other repurchase of any Disqualified Stock or, with respect to
any subsidiary of such Person, any Preferred Stock (but
excluding, in each case, any accrued dividends),
(6) all obligations of the type
referred to in clauses (1) through (5) of other
Persons and all dividends of other Persons for the payment of
which, in either case, such Person is responsible or liable,
directly or indirectly, as obligor, guarantor or otherwise,
including by means of any Guarantee,
(7) all obligations of the type
referred to in clauses (1) through (6) of other
Persons secured by any Lien on any property or asset of such
Person (whether or not such obligation is assumed by such
Person), the amount of such obligation being deemed to be the
lesser of the value of such property or assets or the amount of
the obligation so secured, and
(8) to the extent not otherwise
included in this definition, Hedging Obligations of such Person.
The amount of Indebtedness of any Person at any date shall be
the outstanding balance at such date of all unconditional
obligations as described above and the maximum liability, upon
the occurrence of the contingency giving rise to the obligation,
of any contingent obligations at such date. For the avoidance of
doubt, the following will not be treated as Indebtedness:
(1) Indebtedness Incurred in
respect of workers compensation claims, self insurance
obligations, performance, surety and similar bonds and
completion guarantees provided in this ordinary course of
business;
(2) Indebtedness arising from
agreements providing for indemnification, adjustment of purchase
price or similar obligations, in each case, Incurred or assumed
in connection with the disposition or acquisition of any
business, assets or Capital Stock of a Subsidiary,
provided
, that the maximum aggregate liability in respect
of all such Indebtedness (other than in respect of tax and
environmental indemnities) shall at no time ex-
-11-
ceed, in the case of a disposition, the gross proceeds actually
received by the Company and its Subsidiaries in connection with
such disposition and, in the case of an acquisition, the fair
market value of any business assets or Capital Stock acquired;
(3) Indebtedness arising from the
honoring by a bank or other financial institution of a check,
draft or similar instrument (except in the case of daylight
overdrafts) drawn against insufficient funds in the ordinary
course of business,
provided
that such Indebtedness is
extinguished within five Business Days of the Incurrence.
Indenture means this Indenture, as amended, modified
or supplemented from time to time in accordance with the terms
hereof.
Initial Notes shall have the meaning set forth in
the preamble to this Indenture.
Interest Rate Agreement means any interest rate swap
agreement, interest rate cap agreement or other similar
financial agreement or arrangement.
Investment in any Person means any direct or
indirect advance, loan (other than advances to customers in the
ordinary course of business that are recorded as accounts
receivable on the balance sheet of such Person) or other
extensions of credit (including by way of Guarantee or similar
arrangement) or capital contribution to (by means of any
transfer of cash or other property to others or any payment for
property or services for the account or use of others), or any
purchase or acquisition of Capital Stock, Indebtedness or other
similar instruments issued by such Person;
provided
,
however
, that advances, loans or other extensions of
credit arising under the Cash Management Arrangements shall not
be deemed Investments.
Investment Grade means a rating of BBB- or higher by
S&P and Baa3 or higher by Moodys or the equivalent of
such ratings by S&P or Moodys and the equivalent in
respect of Rating Categories of any Rating Agencies substituted
for S&P or Moodys.
Investment Grade Status exists as of any time if at
such time both (i) the rating assigned to the Notes by
Moodys is at least Baa3 (or the equivalent) or higher and
(ii) the rating assigned to the Notes by S&P is at
least BBB- (or the equivalent) or higher and the equivalent in
respect of Rating Categories of any Rating Agencies substituted
for S&P or Moodys.
Issue Date means the date on which any Notes are
issued.
Issuer means FMC Finance VII S.A. until a successor
replaces it pursuant to this Indenture and thereafter means such
successor.
Issuer Order means a written order or request signed
in the name of the Issuer by a Responsible Officer of the Issuer
and delivered to the Trustee by the Issuer.
KGaA means a German partnership limited by shares
(
Kommanditgesellschaft auf Aktien
).
Legal Defeasance shall have the meaning set forth in
Section 8.2.
-12-
Lien means any mortgage, pledge, security interest,
encumbrance, lien or charge of any kind (including any
conditional sale or other title retention agreement or lease in
the nature thereof).
Listing Agent means BNP Paribas Securities Services,
Luxembourg Branch.
Luxembourg Paying Agent shall have the meaning set
forth in Section 2.3.
Maturity Date means February 15, 2021.
Moodys means Moodys Investors Service,
Inc. and its successors.
Note Guarantee means the Guarantee by a Guarantor of
the Issuers obligations with respect to the Notes.
Notes shall have the meaning set forth in the
preamble of this Indenture.
Officers Certificate means a certificate
signed by two Responsible Officers of the Issuer or of any
Guarantor.
Opinion of Counsel means a written opinion from
legal counsel who is reasonably acceptable to the Trustee. The
counsel may be an employee of or counsel to the Issuer, a
Guarantor or the Trustee.
Participating Member State means a member state of
the European Union which has adopted or adopts the single
currency in accordance with the Treaty establishing the European
Community (as that Treaty is amended from time to time).
Paying Agent shall have the meaning set forth in
Section 2.3.
Permitted Liens means, with respect to any Person:
(1) pledges or deposits by such
Person under workmens compensation laws, unemployment
insurance laws or similar legislation, or good faith deposits in
connection with bids, tenders, contracts (other than for the
payment of Indebtedness) or leases to which such Person is a
party, or deposits to secure public or statutory obligations of
such Person or deposits or cash or Designated Government
Obligations to secure surety or appeal bonds to which such
Person is a party, or deposits as security for contested taxes
or import or customs duties or for the payment of rent, in each
case Incurred in the ordinary course of business;
(2) Liens imposed by law, including
carriers, warehousemens and mechanics Liens,
in each case for sums not yet due or being contested in good
faith if a reserve or other appropriate provisions, if any, as
are required by Accounting Principles have been made in respect
thereof;
(3) Liens for taxes, assessments or
other governmental charges not yet subject to penalties for
non-payment or which are being contested in good faith provided
appro-
-13-
priate reserves, if any, as are required by Accounting
Principles have been made in respect thereof;
(4) Liens in favor of issuers of
surety or performance bonds or letters of credit or
bankers acceptances issued pursuant to the request of and
for the account of such Person in the ordinary course of its
business;
(5) encumbrances, easements or
reservations of, or rights of others for, licenses, rights of
way, sewers, electric lines, telegraph and telephone lines and
other similar purposes, or zoning or other restrictions as to
the use of real properties or liens incidental to the conduct of
the business of such Person or to the ownership of its
properties which do not in the aggregate materially adversely
affect the value of said properties or materially impair their
use in the operation of the business of such Person;
(6) Liens securing Hedging
Obligations so long as the related Indebtedness is, and is
permitted to be, secured by a Lien on the same property securing
such Hedging Obligation or Interest Rate Agreement;
(7) leases, subleases and licenses
of real property which do not materially interfere with the
ordinary conduct of the business of the Company or any of its
Subsidiaries and leases, subleases and licenses of other assets
in the ordinary course of business;
(8) judgment Liens not giving rise
to an Event of Default so long as such Lien is adequately bonded
and any appropriate legal proceedings which may have been duly
initiated for the review of such judgment have not been finally
terminated or the period within which such proceedings may be
initiated has not expired;
(9) Liens for the purpose of
securing the payment (or the refinancing of the payment) of all
or a part of the purchase price of, or Capital Lease Obligations
with respect to, assets or property acquired or constructed in
the ordinary course of business;
provided
that:
(a) the aggregate principal amount
secured by such Liens does not exceed the cost of the assets or
property so acquired or constructed; and
(b) such Liens are created within
180 days of construction or acquisition of such assets or
property (or, upon a refinancing, replace Liens created within
such period) and do not encumber any other assets or property of
the Company or any Subsidiary other than such assets or property
and assets affixed or appurtenant thereto;
(10) Liens arising solely by virtue
of any statutory or common law provisions relating to
bankers Liens, rights of set-off or similar rights and
remedies as to deposit accounts or other funds maintained with a
depositary institution;
provided
that such deposit
account is not intended by the Company or any Subsidiary to
provide collateral to the depositary institution;
-14-
(11) Liens arising from United
States Uniform Commercial Code financing statement filings (or
similar filings in other applicable jurisdictions) regarding
operating leases entered into by the Company and its
Subsidiaries in the ordinary course of business;
(12) Liens existing on the Closing
Date (other than Liens under clause (19));
(13) Liens on property or shares of
stock of a Person at the time such Person becomes a Subsidiary;
provided
,
however
, that such Liens are not
created, Incurred or assumed in connection with, or in
contemplation of, such other Person becoming a Subsidiary;
provided further, however, that any such Lien may not extend to
any other property owned by the Company or any Subsidiary;
(14) Liens on property at the time
the Company or a Subsidiary acquired the property, including any
acquisition by means of a merger or consolidation with or into
the Company or any Subsidiary;
provided
,
however
,
that such Liens are not created, Incurred or assumed in
connection with, or in contemplation of, such acquisition;
provided further
,
however
, that such Liens may not
extend to any other property owned by the Company or any
Subsidiary;
(15) Liens securing Indebtedness or
other obligations of the Company to a Subsidiary or of a
Subsidiary owing to the Company or a Subsidiary;
(16) Liens securing the Notes and
all other Indebtedness which by its terms must be secured if the
Notes are secured;
(17) Liens securing Indebtedness
Incurred to refinance Indebtedness that was previously secured
(other than Liens under clause (19));
provided
, that such
Lien is limited to all or part of the same property or assets
that secured the Indebtedness refinanced;
(18) Liens arising by operation of
law or by agreement to the same effect in the ordinary course of
business;
(19) Liens securing Indebtedness
and other obligations under the Credit Facility in an aggregate
principal amount of Indebtedness secured thereby not to exceed
the greater of (x) $4.6 billion, the maximum amount of
Indebtedness that could be incurred under the Credit Facility as
of March 31, 2006, and (y) 2.5 times the
Companys aggregate EBITDA for the most recently ended four
full fiscal quarters for which internal financial statements are
available;
(20) Liens securing the A/R
Facility; and
(21) other Liens securing
Indebtedness having an aggregate principal amount, measured as
of the date of creation of any such Lien and the date of
Incurrence of any such Indebtedness, not to exceed 5% of the
Companys Consolidated Net Tangible Assets.
-15-
Person means any individual, corporation,
partnership, joint venture, association, joint-stock company,
trust, unincorporated organization, government or any agency,
instrumentality or political subdivision thereof, or any other
entity.
Preferred Stock, as applied to the Capital Stock of
any corporation, means Capital Stock of any class or classes
(however designated) which is preferred as to the payment of
dividends, or as to the distribution of assets upon any
voluntary or involuntary liquidation or dissolution of such
corporation, over shares of Capital Stock of any other class of
such corporation.
Private Placement Legend means the legend set forth
in Section 2.7(f).
Qualified Capital Stock means any Capital Stock
which is not Disqualified Stock.
Rating Agencies means:
(1) S&P and
(2) Moodys, or
(3) if S&P or Moodys or
both shall not make a rating of the Notes publicly available,
despite the Company using its commercially reasonable efforts to
obtain such a rating, a nationally recognized securities rating
agency or agencies, as the case may be, selected by the Company,
which shall be substituted for S&P or Moodys or both,
as the case may be.
Rating Category means:
(1) with respect to S&P, any
of the following categories: BB, B, CCC, CC, C and D (or
equivalent successor categories),
(2) with respect to Moodys,
any of the following categories: Ba, B, Caa, Ca, C and D (or
equivalent successor categories), and
(3) the equivalent of any such
category of S&P or Moodys used by another rating
agency. In determining whether the rating of the Notes has
decreased by one or more gradations, gradations within rating
categories (+ and - for S&P, 1, 2 and 3 for Moodys;
or the equivalent gradations for another rating agency) shall be
taken into account (
e.g
., with respect to S&P, a
decline in a rating from BB+ to BB, as well as from BB- to B+,
which constitute a decrease of one gradation).
Rating Date means the date which is 90 days
prior to the earlier of (1) a Change of Control and
(2) public notice of the occurrence of a Change of Control
or of the intention by the Company or any Person to effect a
Change of Control.
Ratings Decline means the occurrence on or within
90 days after the date of the first public notice of either
the occurrence of a Change of Control or of a transaction which
will effect a Change of Control, whichever is earlier (which
period shall be extended so long as any
-16-
Rating Agency has publicly announced that it is considering a
possible downgrade of the Notes) of (1) in the event the
Notes are rated by either Moodys or S&P on the Rating
Date as Investment Grade, a decrease in the rating of the Notes
by both Rating Agencies to a rating that is below Investment
Grade, or (2) in the event the Notes are rated below
Investment Grade by both Rating Agencies on the Rating Date, a
decrease in the rating of the Notes by either Rating Agency by
one or more gradations (including gradations within Rating
Categories as well as between Rating Categories).
Receivables Financings means:
(1) the A/R Facility, and
(2) any financing transaction or
series of financing transactions that have been or may be
entered into by the Company or a Subsidiary pursuant to which
the Company or a Subsidiary may sell, convey or otherwise
transfer to a Subsidiary or Affiliate, or any other Person, or
may grant a security interest in, any receivables or interests
therein secured by the merchandise or services financed thereby
(whether such receivables are then existing or arising in the
future) of the Company or such Subsidiary, as the case may be,
and any assets related thereto, including without limitation,
all security interests in merchandise or services financed
thereby, the proceeds of such receivables, and other assets
which are customarily sold or in respect of which security
interests are customarily granted in connection with
securitization transactions involving such assets.
Record Date means the Record Dates specified in the
Notes.
Redemption Date when used with respect to any
Note to be redeemed, means the date fixed for such redemption
pursuant to this Indenture and Paragraph 8 of the Notes.
Redemption Price when used with respect to any
Note to be redeemed, means the price fixed for such redemption
pursuant to this Indenture and Paragraphs 8 and 9 of the
Notes.
Refinance means, in respect of any Indebtedness, to
refinance, extend, renew, refund, repay, prepay, redeem, defease
or retire, or to issue other Indebtedness in exchange or
replacement for, such Indebtedness. Refinanced and
Refinancing shall have correlative meanings.
Refinancing Indebtedness means Indebtedness that
Refinances any Indebtedness of the Company or any Subsidiary
existing on the Closing Date or Incurred in compliance with
Section 4.3, including Indebtedness that Refinances
Refinancing Indebtedness;
provided
,
however
, that:
(1) such Refinancing Indebtedness
has a Stated Maturity no earlier than the Stated Maturity of the
Indebtedness being Refinanced,
(2) such Refinancing Indebtedness
has an Average Life at the time such Refinancing Indebtedness is
Incurred that is equal to or greater than the Average Life of
the Indebtedness being Refinanced, and
-17-
(3) such Refinancing Indebtedness
has an aggregate principal amount (or if Incurred with original
issue discount, an aggregate issue price) that is equal to or
less than the aggregate principal amount (or if Incurred with
original issue discount, the aggregate accreted value) then
outstanding or committed (plus fees and expenses, including any
premium and defeasance costs) under the Indebtedness being
Refinanced;
provided further
,
however
, that
Refinancing Indebtedness shall not include (x) Indebtedness
of a Subsidiary that Refinances Indebtedness of the Company or
(y) Indebtedness of the Company or a Subsidiary that
Refinances Indebtedness of another Subsidiary.
Registrar shall have the meaning set forth in
Section 2.3.
Regulation S means Regulation S (including
any successor regulation thereto) under the Securities Act, as
it may be amended from time to time.
Regulation S Global Note shall have the meaning
set forth in Section 2.1.
Regulation S Notes shall have the meaning set
forth in Section 2.1.
Relevant Taxing Jurisdiction shall have the meaning
set forth in Paragraph 2 of the Notes.
Responsible Officer means the chief executive
officer, president, chief financial officer, senior vice
presidentfinance, treasurer, assistant treasurer, managing
director, management board member or director of a company (or
in the case of the Company, a Responsible Officer of its General
Partner, other managing entity or other Person authorized to act
on its behalf, and if such Person is also a partnership, limited
liability company or similarly organized entity, a Responsible
Officer of the entity that may be authorized to act on behalf of
such Person).
Restricted Period shall have the meaning set forth
in Section 2.7(b) hereof.
Rule 144 means Rule 144 (including any
successor regulation thereto) under the Securities Act, as it
may be amended from time to time.
Rule 144A means Rule 144A (including any
successor regulation thereto) under the Securities Act, as it
may be amended from time to time.
Rule 144A Global Note shall have the meaning
set forth in Section 2.1 hereof.
Rule 144A Notes shall have the meaning set
forth in Section 2.1 hereof.
Sale and Leaseback Transaction means any direct or
indirect arrangement with any Person or to which any such Person
is a party, providing for the leasing to the Issuer or any
Guarantor or a Subsidiary of any property, whether owned by the
Issuer, a Guarantor or any Subsidiary at the Closing Date or
later acquired, which has been or is to be sold or transferred
by the Issuer, a Guarantor or such Subsidiary to such Person or
to any other Person from whom funds have been or are to be
advanced by such Person on the security of such property.
-18-
SEC means the U.S. Securities and Exchange
Commission, as from time to time constituted, created under the
Exchange Act, or if at any time after the execution of this
Indenture such Commission is not existing and performing the
duties now assigned to it under the Securities Act and the
Exchange Act, then the body performing such duties at such time.
Secured Indebtedness means any Indebtedness of the
Company secured by a Lien.
Securities Act means the U.S. Securities Act of
1933 or any successor statute thereto, in each case as amended
from time to time.
Significant Subsidiary means, with respect to any
Person, any Subsidiary of such Person that satisfies the
criteria for a significant subsidiary set forth in
Rule 1.02 of
Regulation S-X
under the Exchange Act.
S&P means Standard & Poors
Corporation and its successors.
Stated Maturity means, with respect to any security,
the date specified in such security as the fixed date on which
the final payment of principal of such security is due and
payable, including pursuant to any mandatory redemption
provision (but excluding any provision providing for the
repurchase of such security at the option of the holder thereof
upon the happening of any contingency unless such contingency
has occurred).
Subordinated Obligation means any Indebtedness of
the Issuer or a Guarantor (whether outstanding on the Closing
Date or thereafter Incurred) that is subordinate or junior in
right of payment to the Notes or such Guarantors Note
Guarantee pursuant to a written agreement to that effect.
Subsidiary means, with respect to any Person, any
corporation, limited liability company, association, partnership
or other business entity of which more than 50% of the total
voting power of shares of Voting Stock is at the time owned or
controlled, directly or indirectly, by:
(1) such Person;
(2) such Person and one or more
Subsidiaries of such Person; or
(3) one or more Subsidiaries of
such Person.
Unless otherwise provided, all references to a Subsidiary shall
be a Subsidiary of the Company.
Successor shall have the meaning set forth in
Section 5.3.
Surviving Person means, with respect to any Person
involved in any merger, consolidation or other business
combination or the sale, assignment, transfer, lease, conveyance
or other disposition of all or substantially all of such
Persons assets, the Person formed by or surviving such
transaction or the Person to which such disposition is made.
-19-
Tax Redemption Date when used with respect to
any Note to be redeemed, means the date fixed for such
redemption pursuant to this Indenture and Paragraph 9 of
the Notes.
Taxes shall have the meaning set forth in
Paragraph 2 of the Notes.
TIA means the Trust Indenture Act of 1939 (15
U.S. Code
77aaa-77bbbb)
as in effect on the date of this Indenture;
provided
,
however
, that in the event the Trust Indenture Act
of 1939 is amended after such date, TIA means, to
the extent required by any such amendment, the
Trust Indenture Act of 1939 as so amended.
Trust Officer means any officer of the Trustee
(or any successor of the Trustee), including any director,
managing director, vice president, assistant vice president,
corporate trust officer, assistant corporate trust officer,
associate or any other officer or assistant officer of the
Trustee customarily performing functions similar to those
performed by the Persons who at that time shall be such
officers, and also means, with respect to a particular corporate
trust matter, any other officer to whom such trust matter is
referred because of his or her knowledge of and familiarity with
the particular subject.
Trustee means the party named as such in this
Indenture until a successor replaces it in accordance with the
provisions of this Indenture and thereafter means such successor.
U.S. GAAP means generally accepted accounting
principles in the United States of America as in effect from
time to time, including those set forth in:
(1) the opinions and pronouncements
of the Accounting Principles Board of the American Institute of
Certified Public Accountants,
(2) statements and pronouncements
of the Financial Accounting Standards Board,
(3) such other statements by such
other entity as approved by a significant segment of the
accounting profession, and
(4) the rules and regulations of
the SEC governing the inclusion of financial statements
(including pro forma financial statements) in periodic reports
required to be filed pursuant to Section 13 of the Exchange
Act, including opinions and pronouncements in staff accounting
bulletins and similar written statements from the accounting
staff of the SEC.
Voting Stock of a Person means all classes of
Capital Stock or other interests (including partnership
interests) of such Person then outstanding and normally entitled
(without regard to the occurrence of any contingency) to vote in
the election of directors, managers or trustees thereof.
Wholly Owned Subsidiary means a Subsidiary all the
Capital Stock of which (other than directors qualifying
shares and shares held by other Persons to the extent such
shares are required by applicable law to be held by a Person
other than its parent or a Subsidiary of its
-20-
parent) is owned by the Company or by one or more Wholly Owned
Subsidiaries, or by the Company and one or more Wholly Owned
Subsidiaries.
SECTION 1.2
Rules of
Construction
. Unless the context otherwise requires:
(a) a term has the meaning assigned
to it;
(b) an accounting term not
otherwise defined has the meaning assigned to it in accordance
with Accounting Principles;
(c) or is not exclusive;
(d) words in the singular include
the plural, and words in the plural include the singular;
(e) provisions apply to successive
events and transactions; and
(f) herein,
hereof and other words of similar import refer to
this Indenture as a whole and not to any particular Article,
Section or other subdivision.
SECTION 1.3
Incorporation
by Reference of Trust Indenture Act
.
Whenever this Indenture refers to a provision of the TIA, the
provision is incorporated by reference in, and made a part of,
this Indenture.
The following TIA terms have the following meanings:
indenture securities means the Notes and any Note
Guarantee;
indenture security holder means a Holder;
indenture to be qualified means this Indenture;
indenture trustee or institutional
trustee means the Trustee;
obligor on the Notes means the Issuer and any
successor obligor upon the Notes or any Guarantor.
All other terms used in this Indenture that are defined by the
TIA, defined by TIA reference to another statute or defined by
the Commission rule under the TIA have the meanings so assigned
to them therein.
ARTICLE II
THE
NOTES
SECTION 2.1
Form and
Dating
. The Notes and the notation relating to the
Trustees certificate of authentication thereof, shall be
substantially in the form of
Exhibit A
(in the case
of Global Notes) and
Exhibit B
(in the case of the
Definitive Notes), as applicable. The
-21-
Notes may have notations, legends or endorsements required by
law, stock exchange rule or usage. The Issuer and the Trustee
shall approve the form of the Notes and any notation, legend or
endorsement on them not inconsistent with the terms of this
Indenture. Each Note shall be dated the Issue Date and shall
show the date of its authentication.
The terms and provisions contained in the Notes, annexed hereto
as
Exhibits A
and
B
, shall constitute, and
are hereby expressly made, a part of this Indenture and, to the
extent applicable, the Issuer, the Guarantors, the Trustee and
the Paying Agent, by their execution and delivery of this
Indenture, expressly agree to such terms and provisions and to
be bound thereby. The Notes will initially be represented by the
Global Notes. Definitive Notes will be issued in exchange for
Global Notes only in accordance with Section 2.6(a).
As long as the Notes are in global form, the Paying Agent (in
lieu of the Trustee) shall be responsible for:
(1) paying sums due on the Global
Notes; and
(2) arranging on behalf of and at
the expense of the Issuer for notices to be communicated to
Holders in accordance with the terms of this Indenture.
Each reference in this Indenture to the performance of duties
set forth in clauses (1) and (2) above by the Trustee
includes performance of such duties by the Paying Agent.
Notes offered and sold in their initial distribution in reliance
on Regulation S shall be initially issued as one or more
global notes, in registered, global form without interest
coupons, substantially in the form of
Exhibit A
hereto, with such applicable legends as are provided in
Section 2.7(f)(ii), except as otherwise permitted herein,
and shall be referred to collectively herein as the
Regulation S Global Note. The aggregate
principal amount of the Regulation S Global Note may from
time to time be increased or decreased by adjustments made on
the records of the Trustee (following receipt by the Trustee of
all the information required hereunder), as hereinafter provided
(or by the issue of a further Regulation S Global Note), in
connection with a corresponding decrease or increase in the
aggregate principal amount of the Rule 144A Global Note or
in consequence of the issue of Definitive Notes or Additional
Notes in the form of Regulation S Global Notes, as
hereinafter provided. The Regulation S Global Note and all
other Notes that are not Rule 144A Notes shall collectively
be referred to herein as the Regulation S Notes.
Notes offered and sold in their initial distribution in reliance
on Rule 144A shall be initially issued as one or more
global notes in registered, global form without interest
coupons, substantially in the form of
Exhibit A
hereto, with such applicable legends as are provided in
Section 2.7(f)(ii), except as otherwise permitted herein,
and shall be referred to collectively herein as the
Rule 144A Global Note. The aggregate principal
amount of the Rule 144A Global Note may from time to time
be increased or decreased by adjustments made on the records of
the Trustee (following receipt by the Trustee of all information
required hereunder), as hereinafter provided (or by the issue of
a further Rule 144A Global Note), in connection with a
corresponding decrease or increase in the aggregate principal
amount of the Regulation S Global Note, or in consequence
of the issue of Definitive Notes or Additional Rule 144A
Global Notes,
-22-
as hereinafter provided. The Rule 144A Global Note and all
other Notes (excluding interests in Rule 144A Global Notes
which are transferred in accordance with Section 2.7(a)
hereunder), if any, evidencing the debt, or any portion of the
debt, initially evidenced by such Rule 144A Global Note,
shall collectively be referred to herein as the
Rule 144A Notes.
SECTION 2.2
Execution and
Authentication
. One Responsible Officer of or one
Person duly authorized by all requisite corporate actions by the
Issuer shall sign the Notes for the Issuer by manual or
facsimile signature.
If a Responsible Officer whose signature is on a Note was a
Responsible Officer at the time of such execution but no longer
holds that office or position at the time the Trustee
authenticates the Note, the Note shall be valid nevertheless.
The Trustee shall be entitled to rely on such signature as
authentic and shall be under no obligation to make any
investigation in relation thereto.
A Note shall not be valid until an authorized signatory of the
Trustee manually signs the certificate of authentication on the
Note. The signature shall be conclusive evidence that the Note
has been authenticated under this Indenture.
Except as otherwise provided herein, the aggregate principal
amount of Notes which may be outstanding at any time under this
Indenture is not limited in amount. The Trustee shall
authenticate such Notes, which shall consist of (i) Initial
Notes for original issue on the Closing Date in an aggregate
principal amount not to exceed 300,000,000 and
(ii) Additional Notes from time to time for issuance after
the Closing Date to the extent otherwise permitted hereunder
(including, without limitation, under Section 4.3 hereof),
in each case upon receipt of an Issuer Order. Additional Notes
will be treated the same as the Notes for all purposes under
this Indenture, including, without limitation, for purposes of
waivers, amendments, redemptions and offers to purchase. Such
Issuer Order shall specify the aggregate principal amount of
Notes to be authenticated, the type of Notes, the date on which
the Notes are to be authenticated, the issue price and the date
from which interest on such Notes shall accrue, whether the
Notes are to be Initial Notes or Additional Notes and whether or
not the Notes shall bear the Private Placement Legend, or such
other information as the Trustee may reasonably request. In
authenticating the Notes and accepting the responsibilities
under this Indenture in relation to the Notes, the Trustee shall
be entitled to receive, and shall be fully protected in relying
upon, an Opinion of Counsel in a form reasonably satisfactory to
the Trustee stating that the form and terms thereof have been
established in conformity with the provisions of this Indenture,
do not give rise to a Default and that the issuance of such
Notes has been duly authorized by the Issuer. Upon receipt of an
Issuer Order, the Trustee shall authenticate Notes in
substitution for Notes originally issued to reflect any name
change of the Issuer.
The Trustee may appoint an authenticating agent
(Authenticating Agent) reasonably acceptable to the
Issuer to authenticate Notes. Unless otherwise provided in the
appointment, an Authenticating Agent may authenticate Notes
whenever the Trustee may do so. Each reference in this Indenture
to authentication by the Trustee includes authentication by such
Authenticating Agent. An Authenticating Agent has the same
rights as an Agent to deal with the Issuer and Affiliates of the
Issuer.
-23-
The Notes shall be issuable only in denominations of 1,000
and integral multiples of 1,000 in excess thereof.
SECTION 2.3
Registrar and
Paying Agent
. The Issuer shall maintain (i) an
office or agency where Notes may be presented for registration
of transfer or for exchange (Registrar),
(ii) an office or agency where Notes may be presented for
payment to Deutsche Bank Aktiengesellschaft and (iii) upon
issuance of Definitive Notes, an office or agency where
Definitive Notes may be presented for payment to the Luxembourg
Paying Agent. The Registrar shall keep a register of the Notes
and of their transfer and exchange. At the option of the Issuer,
payment of interest may be made by check mailed to the Holders
at their addresses set forth in the register of Holders. The
Issuer may appoint one or more co-registrars and one or more
additional paying agents. The term Registrar
includes any co-registrar and the term Paying Agent
includes any additional paying agent. The Issuer may change any
Paying Agent or Registrar without notice to any Holder. The
Issuer shall notify the Trustee in writing of the name and
address of any Agent not a party to this Indenture. If the
Issuer fails to appoint or maintain another entity as Registrar
or Paying Agent, the Trustee shall act as such. The Issuer, the
Company or any of its Subsidiaries may act as Paying Agent or
Registrar to the extent permitted under applicable laws or
regulations.
The Issuer shall notify the Trustee and the Trustee shall notify
the Holders of the name and address of any Agent not a party to
this Indenture. The Issuer shall enter into an appropriate
agency agreement with any Agent not a party to this Indenture,
which shall incorporate the provisions of the TIA. The agreement
shall implement the provisions of this Indenture and the Notes
that relate to such Agent. The Issuer shall notify the Trustee
of the name and address of any such Agent. If the Issuer fails
to maintain a Registrar or Paying Agent, or fails to give the
foregoing notice, the Trustee shall act as such, and shall be
entitled to appropriate compensation in accordance with
Section 7.7 hereof.
The Issuer initially appoints Deutsche Bank Aktiengesellschaft
to act as the paying agent (together with its successor in such
capacity, the Paying Agent) and the Trustee to act
as the Registrar. If and so long as the Notes are listed on the
Euro MTF Market of the Luxembourg Stock Exchange and the rules
of such stock exchange so require, the Issuer shall appoint
Deutsche Bank Luxembourg, or such other Person located in
Luxembourg and reasonably acceptable to the Trustee
(reasonableness to be determined objectively), as the Luxembourg
paying and transfer agent (together with its successor in such
capacity, the Luxembourg Paying Agent).
SECTION 2.4
Paying Agent To
Hold Assets in Trust
. The Issuer shall require the
Paying Agent to agree in writing that such Paying Agent shall
hold in trust for the benefit of Holders or the Trustee all
assets held by the Paying Agent for the payment of principal of,
Additional Amounts, if any, premium, if any, or interest on, the
Notes, and shall promptly notify the Trustee of any Default by
the Issuer in making any such payment. The Issuer at any time
may require a Paying Agent to distribute all assets held by it
to the Trustee and account for any assets distributed and the
Trustee may at any time during the continuance of any payment
Default, upon written request to a Paying Agent, require such
Paying Agent to distribute all assets held by it to the Trustee
and to account for any assets distributed. Upon distribution to
the Trus-
-24-
tee of all assets that shall have been delivered by the Issuer
to the Paying Agent pursuant to this Section 2.4, the
Paying Agent shall have no further liability for such assets.
SECTION 2.5
List of
Holders
. The Trustee shall preserve in as current a
form as is reasonably practicable the most recent list available
to it of the names and addresses of Holders. If the Trustee is
not the Registrar, the Issuer shall furnish to the Trustee
within two Business Days after each Record Date as of such
Record Date and at such other times as the Trustee may request
in writing a list as of such date and in such form as the
Trustee may reasonably require of the names and addresses of
Holders, which list may be conclusively relied upon by the
Trustee.
SECTION 2.6
Book-Entry
Provisions for Global Notes
. The Global Notes initially
shall (i) be deposited with and registered in the name of
BT Globenet Nominees Limited as nominee for Deutsche Bank
Aktiengesellschaft, as the common depository, for the accounts
of Euroclear Bank S.A./N.V. (Euroclear) and
Clearstream Banking, société anonyme
(Clearstream) and (ii) bear the following
legend:
THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE
INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME
OF THE CLEARING AGENCY OR A NOMINEE OF THE CLEARING AGENCY. THIS
NOTE IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE
NAME OF A PERSON OTHER THAN THE CLEARING AGENCY OR ITS NOMINEE
EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE,
AND NO TRANSFER OF THIS NOTE (OTHER THAN A TRANSFER OF THIS
NOTE AS A WHOLE TO THE CLEARING AGENCY OR A NOMINEE OF THE
CLEARING AGENCY) MAY BE REGISTERED EXCEPT IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE.
(a) Notwithstanding any other
provisions of this Indenture, a Global Note may not be
transferred as a whole except by the Clearing Agency to a
nominee of the Clearing Agency or by a nominee of the Clearing
Agency to the Clearing Agency or another successor of the
Clearing Agency or a nominee of such successor. Interests of
beneficial owners in the Global Notes may be transferred or
exchanged for Definitive Notes in accordance with the rules and
procedures of the Clearing Agency and the provisions of
Section 2.7. All Global Notes shall be exchanged by the
Issuer (with authentication by the Trustee) for one or more
Definitive Notes, if (a) the Clearing Agency (i) has
notified the Issuer that it is unwilling or unable to continue
as a Clearing Agency and (ii) a successor to the Clearing
Agency has not been appointed by the Issuer within 120 days
of such notification, (b) the Clearing Agency so requests
following an Event of Default hereunder or (c) in whole
(but not in part) at any time if the Issuer in its sole
discretion determines. If an Event of Default occurs and is
continuing, the Issuer shall, at the written request delivered
through the a Clearing Agency of the Holder thereof or of the
holder of an interest therein, exchange all or part of a Global
Note for one or more Definitive Notes (with authentication by
the Trustee); provided, however, that the principal amount of
such Definitive Notes and such Global Note after such exchange
shall be 1,000 or integral multiples of 1,000 in
excess thereof. Whenever all of a Global Note is exchanged for
one or more Definitive Notes, it shall be surrendered by the
Holder thereof to the Registrar for cancellation. Whenever a
part of a Global Note is exchanged for one or more Definitive
Notes, the Global Note shall be surrendered
-25-
by the Holder thereof to the Paying Agent who together with the
Trustee, following such surrender, shall cause an adjustment to
be made to Schedule A of such Global Note such that the
principal amount of such Global Note will be equal to the
portion of such Global Note not exchanged and shall thereafter
return such Global Note to such Holder. A Global Note may not be
exchanged for a Definitive Note other than as provided in this
Section 2.6(a).
(b) In connection with the transfer
of Global Notes as an entirety to beneficial owners pursuant to
Section 2.6(a), the Global Notes shall be deemed to be
surrendered to the Paying Agent for cancellation, and the Issuer
shall execute, and the Trustee shall upon written instructions
from the Issuer authenticate and make available for delivery, to
each beneficial owner in exchange for its beneficial interest in
the Global Notes, an equal aggregate principal amount of
Definitive Notes of authorized denominations.
(c) Any Definitive Note delivered
in exchange for an interest in a Global Note pursuant to
Section 2.6(a) shall, except as otherwise provided by
Section 2.7, bear the Private Placement Legend.
SECTION 2.7
Registration of
Transfer and Exchange
. Notwithstanding any provision to
the contrary herein, so long as a Note remains outstanding,
transfers of beneficial interests in Global Notes or transfers
of Definitive Notes, in whole or in part, shall be made only in
accordance with this Section 2.7.
(a) If a holder of a beneficial
interest in the Rule 144A Global Note wishes at any time to
exchange its interest in such Rule 144A Global Note for an
interest in the Regulation S Global Note, or to transfer
its interest in such Rule 144A Global Note to a Person who
wishes to take delivery thereof in the form of an interest in
such Regulation S Global Note, such holder may, subject to
the rules and procedures of the Clearing Agency, to the extent
applicable, and to the requirements set forth in this
Section 2.7(a), exchange or cause the exchange or transfer
or cause the transfer of such interest for an equivalent
beneficial interest in such Regulation S Global Note. Such
exchange or transfer shall only be made upon receipt by the
Paying Agent, as transfer agent, at its office in Frankfurt,
Germany or, so long as the Notes are listed on the Euro MTF
Market of the Luxembourg Stock Exchange and the rules of that
exchange so require, upon receipt by the Luxembourg Paying
Agent, as transfer agent, at its office in Luxembourg of
(1) written instructions given in accordance with the
procedures of the Clearing Agency, to the extent applicable,
from or on behalf of a holder of a beneficial interest in the
Rule 144A Global Note directing the Paying Agent, as
transfer agent, to credit or cause to be credited a beneficial
interest in the Regulation S Global Note in an amount equal
to the beneficial interest in the Rule 144A Global Note to
be exchanged or transferred, (2) a written order given in
accordance with the procedures of the Clearing Agency, to the
extent applicable, containing information regarding the account
to be credited with such increase and the name of such account,
and (3) a certificate in the form of
Exhibit D
given by the holder of such beneficial interest stating that the
exchange or transfer of such interest has been made pursuant to
and in accordance with Rule 903 or Rule 904 of
Regulation S or Rule 144 under the Securities Act.
Upon such receipt, the Paying Agent, as transfer agent, shall
promptly deliver instructions to the Clearing Agency, to reduce
or reflect on its records a reduction of the Rule 144A
Global Note by the aggregate principal amount of the beneficial
interest in such Rule 144A Global Note to be so exchanged
or transferred from the relevant participant, and the Paying
Agent, as transfer agent, shall promptly de-
-26-
liver instructions to the Clearing Agency concurrently with such
reduction, to increase or reflect on its records an increase of
the principal amount of such Regulation S Global Note by
the aggregate principal amount of the beneficial interest in
such Rule 144A Global Note to be so exchanged or
transferred, and to credit or cause to be credited to the
account of the Person specified in such instructions of a
beneficial interest in such Regulation S Global Note equal
to the reduction in the principal amount of such Rule 144A
Global Note. The Clearing Agency will promptly notify the
Trustee of any increases or decreases in the amount of each
Global Note.
(b) If a holder of a beneficial
interest in the Regulation S Global Note wishes at any time
to exchange its interest in such Regulation S Global Note
for an interest in the Rule 144A Global Note, or to
transfer its interest in such Regulation S Global Note to a
Person who wishes to take delivery thereof in the form of an
interest in such Rule 144A Global Note, such holder may,
subject to the rules and procedures of the Clearing Agency, to
the extent applicable, and to the requirements set forth in this
Section 2.7(b), exchange or cause the exchange or transfer
or cause the transfer of such interest for an equivalent
beneficial interest in such Rule 144A Global Note. Such
exchange or transfer shall only be made upon receipt by the
Paying Agent, as transfer agent, at its office in Frankfurt,
Germany or, so long as the Notes are listed on the Euro MTF
Market of the Luxembourg Stock Exchange and the rules of that
exchange so require, upon receipt by the Luxembourg Paying
Agent, as transfer agent, at its office in Luxembourg of
(l) instructions given in accordance with the procedures of
the Clearing Agency, to the extent applicable, from or on behalf
of a beneficial owner of an interest in the Regulation S
Global Note directing the Paying Agent, as transfer agent, to
credit or cause to be credited a beneficial interest in the
Rule 144A Global Note in an amount equal to the beneficial
interest in the Regulation S Global Note to be exchanged or
transferred, (2) a written order given in accordance with
the procedures of the Clearing Agency, to the extent applicable,
containing information regarding the account to be credited with
such increase and the name of such account, and (3) prior
to or on the 40th day after the later of the commencement
of the offering of the Notes and the relevant Issue Date (the
Restricted Period), a certificate in the form of
Exhibit E
given by the holder of such beneficial
interest and stating that the Person transferring such interest
in such Regulation S Note reasonably believes that the
Person acquiring such interest in such Rule 144A Note is a
Qualified Institutional Buyer (as defined in Rule 144A) and
is obtaining such beneficial interest in a transaction meeting
the requirements of Rule 144A and any applicable securities
laws of any state of the United States or any other
jurisdiction. Upon such receipt, the Paying Agent, as transfer
agent, shall promptly deliver instructions to the Clearing
Agency to reduce or reflect on its records a reduction of the
Regulation S Global Note by the aggregate principal amount
of the beneficial interest in such Regulation S Global Note
to be exchanged or transferred, and the Paying Agent, as
transfer agent, shall promptly deliver instructions to the
Clearing Agency concurrently with such reduction, to increase or
reflect on its records an increase of the principal amount of
such Rule 144A Global Note by the aggregate principal
amount of the beneficial interest in such Regulation S
Global Note to be so exchanged or transferred, and to credit or
cause to be credited to the account of the Person specified in
such instructions a beneficial interest in such Rule 144A
Global Note equal to the reduction in the principal amount of
such Regulation S Global Note. After the expiration of the
Restricted Period, the certification requirement set forth in
clause (3) of the second sentence of this
Section 2.7(b) will no longer apply to such transfers. The
Clearing Agency will promptly notify the Trustee of any
increases or decreases in the amount of each Global Note.
-27-
(c) Any beneficial interest in one
of the Global Notes that is transferred to a Person who takes
delivery in the form of an interest in another Global Note will,
upon transfer, cease to be an interest in such Global Note and
become an interest in the other Global Note and, accordingly,
will thereafter be subject to all transfer restrictions and
other procedures applicable to beneficial interests in such
other Global Note for as long as it remains such an interest.
(d) In the event that a Global Note
is exchanged for Definitive Notes in registered form without
interest coupons, pursuant to Section 2.6(a), or a
Definitive Note in registered form without interest coupons is
exchanged for another such Definitive Note in registered form
without interest coupons, or a Definitive Note is exchanged for
a beneficial interest in a Global Note, such Notes may be
exchanged or transferred for one another only in accordance with
such procedures as are substantially consistent with the
provisions of Sections 2.7(b) and (c) above (including
the certification requirements intended to ensure that such
exchanges or transfers comply with Rule 144, Rule 144A
or Regulation S, as the case may be) and as may be from
time to time adopted by the Issuer and the Trustee.
(e) Prior to the expiration of the
Restricted Period, beneficial interests in the Regulation S
Global Note may only be exchanged or transferred in accordance
with the certification requirements hereof.
(f) (i) Other than in the case
of Notes issued pursuant to a registration statement which has
been declared effective under the Securities Act, each Note
issued hereunder shall, upon issuance, bear the legend set forth
in clause (ii) below (the Private Placement
Legend) and such legend shall not be removed from such
Note except as provided in the next sentence. The legend on a
Note may be removed from a Note if there is delivered to the
Issuer and the Trustee such satisfactory evidence, which may
include an opinion of independent counsel licensed to practice
law in the State of New York, as may be reasonably required by
the Issuer and the Trustee, that neither such legend nor the
restrictions on transfer set forth therein are required to
ensure that transfers of such Note will not violate the
registration requirements of the Securities Act, and the Issuer
and the Trustee consent to such removal. Upon provision of such
satisfactory evidence, the Trustee, at the written direction of
the Issuer, shall authenticate and deliver in exchange for such
Note another Note or Notes having an equal aggregate principal
amount that does not bear such legend. If such a legend required
for a Note has been removed from a Note as provided above, no
other Note issued in exchange for all or any part of such Note
shall bear such legend, unless the Issuer has reasonable cause
to believe that such other Note is a restricted
security within the meaning of Rule 144 and instructs
the Trustee to cause a legend to appear thereon.
(ii) To the extent required by
paragraph (f)(i) above, the Notes shall bear the following
legend on the face thereof:
THE SECURITY (OR ITS PREDECESSOR) EVIDENCED HEREBY WAS
ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION
UNDER SECTION 5 OF THE UNITED STATES SECURITIES ACT OF
1933, AS AMENDED (THE SECURITIES ACT), AND THE
SECURITY EVIDENCED HEREBY MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN APPLICABLE
EXEMPTION
-28-
THEREFROM. EACH PURCHASER OF THE SECURITY EVIDENCED HEREBY
IS HEREBY NOTIFIED THAT THE SELLER MAY BE RELYING ON THE
EXEMPTION FROM THE PROVISIONS OF SECTION 5 OF THE
SECURITIES ACT PROVIDED BY RULE 144A THEREUNDER. THE HOLDER
OF THE SECURITY EVIDENCED HEREBY AGREES FOR THE BENEFIT OF THE
ISSUER THAT (A) SUCH SECURITY MAY BE RESOLD, PLEDGED OR
OTHERWISE TRANSFERRED, ONLY (1)(a) INSIDE THE UNITED STATES TO A
PERSON WHO THE SELLER REASONABLY BELIEVES IS A QUALIFIED
INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A UNDER THE
SECURITIES ACT) PURCHASING FOR ITS OWN ACCOUNT OR FOR THE
ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER IN A TRANSACTION
MEETING THE REQUIREMENTS OF RULE 144A UNDER THE SECURITIES
ACT, (b) OUTSIDE THE UNITED STATES TO A FOREIGN PERSON IN A
TRANSACTION MEETING THE REQUIREMENTS OF RULE 903 OR
RULE 904 OF REGULATION S UNDER THE SECURITIES ACT,
(c) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF
APPLICABLE) OR (d) IN ACCORDANCE WITH ANOTHER
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT (AND BASED UPON AN OPINION OF COUNSEL ACCEPTABLE
TO THE ISSUER IF THE ISSUER SO REQUESTS), (2) TO THE ISSUER
OR (3) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT AND,
IN EACH CASE, IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS
OF ANY STATE OF THE UNITED STATES OR ANY OTHER APPLICABLE
JURISDICTION AND (B) THE HOLDER WILL, AND EACH SUBSEQUENT
HOLDER IS REQUIRED TO, NOTIFY ANY PURCHASER OF THE SECURITY
EVIDENCED HEREBY OF THE RESALE RESTRICTIONS SET FORTH IN CLAUSE
(A) ABOVE. NO REPRESENTATION CAN BE MADE AS TO THE
AVAILABILITY OF THE EXEMPTION PROVIDED BY RULE 144 FOR
RESALE OF THE SECURITY EVIDENCED HEREBY.
(g) By its acceptance of any Note
bearing the Private Placement Legend, each Holder of such a Note
acknowledges the restrictions on transfer of such Note set forth
in this Indenture and in the Private Placement Legend and agrees
that it will transfer such Note only as provided in this
Indenture.
Neither the Trustee nor the Paying Agent shall have any
obligation or duty to monitor, and shall not be liable for any
failure to, determine or inquire as to compliance with any
restrictions on transfer imposed under this Indenture or under
applicable law with respect to any transfer of any interest in
any Note (including any transfers between or among Agent Members
or beneficial owners of interest in any Global Note) other than
to require delivery of such certificates and other documentation
or evidence as are expressly required by, and to do so if and
when expressly required by the terms of, this Indenture, and to
examine the same to determine substantial compliance as to form
with the express requirements hereof.
The Registrar shall retain copies of all letters, notices and
other written communications received pursuant to
Section 2.6 or this Section 2.7. The Issuer shall have
the right to
-29-
inspect and make copies of all such letters, notices or other
written communications at any reasonable time upon the giving of
reasonable written notice to the Registrar.
(h) Definitive Notes shall be
transferable only upon the surrender of a Definitive Note for
registration of transfer. When a Definitive Note is presented to
the Registrar or a co-registrar with a request to register a
transfer, the Registrar shall register the transfer as requested
if its requirements for such transfers are met. When Definitive
Notes are presented to the Registrar or a co-registrar with a
request to exchange them for an equal principal amount of
Definitive Notes of other denominations, the Registrar shall
make the exchange as requested if the same requirements are met.
When a Definitive Note is presented to the Registrar with a
request to transfer in part, the transferor shall be entitled to
receive without charge a Definitive Note representing the
balance of such Definitive Note not transferred. To permit
registration of transfers and exchanges, the Issuer shall
execute and the Trustee shall authenticate Definitive Notes at
the Registrars or co-registrars request.
(i) The Issuer shall not be
required to make, and the Registrar need not register transfers
or exchanges of, Definitive Notes (i) for a period of 15
calendar days prior to any date fixed for the redemption of the
Notes, (ii) for a period of 15 calendar days immediately
prior to the date fixed for selection of Notes to be redeemed in
part, (iii) for a payment period of 15 calendar days prior
to any Record Date, or (iv) that the registered Holder of
Notes has tendered (and not withdrawn) for repurchase in
connection with a Change of Control.
(j) Prior to the due presentation
for registration of transfer of any Definitive Note, the Issuer,
the Guarantors, the Trustee, the Paying Agent, the Registrar or
any co-registrar may deem and treat the Person in whose name a
Definitive Note is registered as the absolute owner of such
Definitive Note for the purpose of receiving payment of
principal, interest or Additional Amounts, if any, on such
Definitive Note and for all other purposes whatsoever, whether
or not such Definitive Note is overdue, and none of the Issuer,
the Guarantors, the Trustee, the Paying Agent, the Registrar or
any co-registrar shall be affected by notice to the contrary.
(k) The Issuer may require payment
of a sum sufficient to pay all taxes, assessments or other
governmental charges in connection with any transfer or exchange
pursuant to this Section 2.7.
(l) All Notes issued upon any
transfer or exchange pursuant to the terms of this Indenture
will evidence the same debt and will be entitled to the same
benefits under this Indenture as the Notes surrendered upon such
transfer or exchange.
(m) Holders of Notes (or holders of
interests therein) initially offered or sold in the United
States to Qualified Institutional Buyers as defined
in Rule 144A under the Securities Act pursuant to such rule
and prospective purchasers designated by such Holders (or
holders of interests therein) will have the right to obtain from
the Issuer upon request by such Holders (or holders of interests
therein) or prospective purchasers, during any period in which
the Issuer is not subject to Section 13 or 15(d) of the
Exchange Act, or not exempt from reporting pursuant to
Rule 12g3-2(b)
under the Exchange Act, the information required by paragraph
d(4)(i) of Rule 144A in connection with any transfer or
proposed transfer of such Notes.
-30-
SECTION 2.8
Replacement
Notes
. If a mutilated Definitive Note is surrendered to
the Registrar, if a mutilated Global Note is surrendered to the
Issuer or if the Holder of a Note claims that such Note has been
lost, destroyed or wrongfully taken, the Issuer shall issue and
the Trustee shall authenticate a replacement Note in such form
as the Note being replaced in the manner specified in this
Section 2.8. If required by the Trustee, the Registrar or
the Issuer, such Holder must provide an indemnity bond or other
indemnity, sufficient in the judgment of the Issuer, the
Registrar and the Trustee, to protect the Issuer, the Registrar,
the Trustee and any Agent from any loss which any of them may
suffer if a Note is replaced. The Issuer may charge such Holder
for its reasonable out of-pocket expenses in replacing a Note,
including reasonable fees and expenses of counsel. Every
replacement Note is an additional obligation of the Issuer. The
provisions of this Section 2.8 are exclusive and shall
preclude (to the extent lawful) all other rights and remedies
with respect to the replacement of mutilated, destroyed, lost,
stolen or taken Notes.
SECTION 2.9
Outstanding
Notes
. Notes outstanding at any time are all the Notes
that have been authenticated by the Trustee except those
canceled by it, those delivered to it for cancellation, those
reductions in the Global Note effected in accordance with the
provisions hereof and those described in this Section 2.9
as not outstanding. Subject to Section 2.10, a Note does
not cease to be outstanding because the Issuer or any of its
Affiliates holds the Note.
If a Note is replaced pursuant to Section 2.8 (other than a
mutilated Note surrendered for replacement), it ceases to be
outstanding unless the Trustee receives proof satisfactory to
it, and upon which it shall be entitled to rely in accordance
with Section 7.1(a), that the replaced Note is held by a
bona fide purchaser. A mutilated Note ceases to be outstanding
upon surrender of such Note and replacement thereof pursuant to
Section 2.8.
If the principal amount of any Note is considered paid under
Section 4.1 hereof, it ceases to be outstanding and
interest and Additional Amounts, if any, on it cease to accrue.
If on a Redemption Date or the Maturity Date the Paying
Agent holds cash sufficient to pay all of the principal and
interest due on the Notes payable on that date, then on and
after that date such Notes cease to be outstanding and interest
and Additional Amounts, if any, on such Notes cease to accrue.
SECTION 2.10
Treasury
Notes
. In determining whether the Holders of the
required principal amount of Notes have concurred in any
direction, waiver or consent, Notes owned by the Issuer, the
Guarantors or any of their Affiliates shall be disregarded,
except that, for the purposes of determining whether the Trustee
shall be protected in relying on any such direction, waiver or
consent, only Notes that a Trust Officer actually knows are
so owned shall be disregarded and the Trustee assumes no
liability in relation to any other Notes.
The Issuer shall notify the Trustee, in writing, when it or any
Guarantor or any of their Affiliates repurchases or otherwise
acquires Notes, of the aggregate principal amount of such Notes
so repurchased or otherwise acquired. The Trustee may require an
Officers Certificate, which shall promptly be provided
upon receipt by the appropriate Responsible Officers of the
requisite information, listing Notes owned by the Issuer, the
Guarantors a Subsidiary of the Issuer or the Guarantors or an
Affiliate of the Issuer or the Guarantors.
-31-
SECTION 2.11
Temporary
Notes
. Until permanent Definitive Notes are ready for
delivery, the Issuer may prepare and the Trustee shall
authenticate temporary Definitive Notes upon receipt of an
Issuer Order pursuant to Section 2.2. The Officers
Certificate shall specify the amount of temporary Definitive
Notes to be authenticated and the date on which the temporary
Definitive Notes are to be authenticated. Temporary Definitive
Notes shall be substantially in the form of permanent Definitive
Notes but may have variations that the Issuer considers
appropriate for temporary Definitive Notes. Without unreasonable
delay, the Issuer shall prepare and the Trustee shall
authenticate upon receipt of an Issuer Order pursuant to
Section 2.2 permanent Definitive Notes in exchange for
temporary Definitive Notes.
SECTION 2.12
Cancellation
. The
Issuer at any time may deliver Notes to the Trustee for
cancellation. The Registrar and the Paying Agent shall promptly
forward to the Trustee any Notes surrendered to them for
transfer, exchange or payment. The Trustee or, at the direction
of the Trustee, the Registrar or the Paying Agent, and no one
else, shall cancel and, at the written direction of the Issuer,
shall dispose of (subject to the record retention requirements
of the Exchange Act) all Notes surrendered for transfer,
exchange, payment or cancellation. Upon completion of any
disposal, the Trustee shall deliver a certificate of such
disposal to the Issuer, unless the Issuer directs the Trustee in
writing to deliver the cancelled Notes to the Issuer or the
Company. Subject to Section 2.8, the Issuer may not issue
new Notes to replace Notes that it has paid or delivered to the
Trustee for cancellation. If the Issuer shall acquire any of the
Notes, such acquisition shall not operate as a redemption or
satisfaction of the Indebtedness represented by such Notes
unless and until the same are surrendered to the Trustee for
cancellation pursuant to this Section 2.12.
SECTION 2.13
Defaulted
Interest
. If the Issuer defaults in a payment of
interest on the Notes, it shall pay the defaulted interest, plus
(to the extent lawful) any interest payable on the defaulted
interest, to the Holder thereof on a subsequent special record
date, which date shall be the fifteenth day next preceding the
date fixed by the Issuer for the payment of defaulted interest.
The Issuer shall promptly notify the Trustee and Paying Agent in
writing of the amount of defaulted interest proposed to be paid
on each Note and the date of the proposed payment (a
Default Interest Payment Date), and at the same time
the Issuer shall deposit with the Trustee or Paying Agent an
amount of money equal to the aggregate amount proposed to be
paid in respect of such defaulted interest or shall make
arrangements satisfactory to the Trustee or Paying Agent for
such deposit prior to the date of the proposed payment, such
money when deposited to be held in trust for the benefit of the
Persons entitled to such defaulted interest as in this
Section 2.13; provided, however, that in no event shall the
Issuer deposit monies proposed to be paid in respect of
defaulted interest later than 10:00 a.m. Frankfurt
time on the proposed Default Interest Payment Date with respect
to defaulted interest to be paid on the Note. At least
15 days before the subsequent special record date, the
Issuer shall mail to each Holder, with a copy to the Trustee, a
notice that states the subsequent special record date, the
payment date and the amount of defaulted interest, and interest
payable on such defaulted interest, if any, to be paid.
SECTION 2.14
ISINs and
Common Codes
. The Issuer in issuing the Notes may use
ISINs
and/or
Common Codes, and if it does so, the Trustee shall use the ISIN
and/or
Common Code in notices of redemption or exchange as a
convenience to Holders;
provided
that any such notice may
state that no representation is made as to the correctness or
accuracy of the ISIN
and/or
Common Code printed in the notice or on the Notes and that
reliance may be placed
-32-
only on the other identification numbers printed on the Notes.
The Issuer shall promptly notify the Trustee of any changes in
any ISINs
and/or
Common Codes.
SECTION 2.15
Deposit of
Moneys
. Prior to 10:00 a.m. Frankfurt time on
each interest payment date and Maturity Date, the Issuer shall
have deposited with the Trustee or the Paying Agent (which shall
be the Paying Agent or its successor) in immediately available
funds money sufficient to make cash payments, if any, due on
such interest payment date or Maturity Date, as the case may be,
on all Notes then outstanding. Such payments shall be made by
the Issuer in a timely manner which permits the Paying Agent to
remit payment to the Holders on such interest payment date or
Maturity Date, as the case may be. Promptly upon receipt of such
payment, the Paying Agent shall confirm by the medium chosen by
the Paying Agent to the Issuer the receipt of such payment.
SECTION 2.16
Certain
Matters Relating to Global Notes
. Members of or
participants in a Clearing Agency (Agent Members)
shall have no rights under this Indenture or any Global Note
with respect to any Global Note held on their behalf by the
Clearing Agency or its nominee, and the Clearing Agency or its
nominee may be treated by the Issuer, the Guarantors, the
Trustee, the Paying Agent, the Registrar and any agent of the
Issuer or the Guarantors as the absolute owner of the Global
Note for all purposes whatsoever. Notwithstanding the foregoing,
nothing herein shall prevent the Issuer, the Guarantors, the
Trustee or any agent of the Issuer or the Guarantors from giving
effect to any written certification, proxy or other
authorization furnished by the Clearing Agency or its nominee or
impair, as between the Clearing Agency and its Agent Members,
the operation of customary practices governing the exercise of
the rights of a Holder of any Note.
(a) The Holder of any Global Note
may grant proxies and otherwise authorize any Person, including
Euroclear and Clearstream and their Agent Members and Persons
that may hold interests through Agent Members, to take any
action which a Holder is entitled to take under this Indenture
or the Notes.
SECTION 2.17
Record
Date
. Unless otherwise set forth in this Indenture, the
record date for purposes of determining the identity of Holders
entitled to vote or consent to any action by vote or consent
authorized or permitted under this Indenture shall be determined
as provided for in TIA § 316(c).
ARTICLE III
REDEMPTION
SECTION 3.1
Optional
Redemption
. The Issuer may redeem all or, from time to
time, a part of the Notes, at its option, at a redemption price
equal to 100% of the principal amount of the Notes being
redeemed plus accrued interest, if any, to the redemption date,
plus the excess of:
(a) as determined by the
calculation agent (which shall initially be the Trustee), the
sum of the present values of the remaining scheduled payments of
principal and interest on the Notes being redeemed not including
any portion of such payment of interest accrued on
-33-
the date of redemption, from the redemption date to the maturity
date, discounted to the redemption date on a semi-annual basis
(assuming a
360-day
year
consisting of twelve
30-day
months) at the Bund Rate plus 50 basis points; over
(b) 100% of the principal amount of
the Notes being redeemed.
The Company shall certify to the Trustee the applicable Bund
Rate at the time of any such redemption.
SECTION 3.2
Notices to
Trustee
. If the Issuer elects to redeem Notes pursuant
to Paragraphs 8 or 9 of such Notes, it shall notify the
Trustee and the Paying Agent in writing of the
Redemption Date and the principal amount of Notes to be
redeemed at least 15 days prior to the giving of the notice
contemplated by Section 3.4 (or such shorter period as the
Trustee in its sole discretion shall determine). The Issuer
shall give notice of redemption as required under the relevant
paragraph of the Notes pursuant to which such Notes are being
redeemed.
SECTION 3.3
Selection of
Notes To Be Redeemed
. In the case of any partial
redemption, the Trustee will select the Notes for redemption in
compliance with the requirements of the principal securities
exchange, if any, on which such Notes are listed, or if such
Notes are not listed, on a
pro rata
basis, by lot or by
such other method as the Trustee in its sole discretion shall
deem to be fair and appropriate (and in such manner as complies
with applicable legal and exchange requirements); although no
Note of 1,000 in original principal amount or less shall
be redeemed in part. If any Note is to be redeemed in part only,
notice of redemption relating to that Note will state the
portion of the principal amount thereof to be redeemed. A new
Note in principal amount equal to the unredeemed portion thereof
will be issued and delivered to the Trustee, or in the case of
Definitive Notes, issued in the name of the Holder thereof upon
cancellation of the original Note. The selections made by the
Trustee pursuant to this Section 3.3 shall always be
subject to Section 7.2(d).
SECTION 3.4
Notice of
Redemption
. At least 30 days but not more than
60 days before a Redemption Date or a Tax
Redemption Date, as applicable, the Issuer shall, so long
as the Notes are in global form and are listed on the Euro MTF
Market of the Luxembourg Stock Exchange and the rules of such
stock exchange shall so require, publish in a newspaper having a
general circulation in Luxembourg (which is expected to be the
Luxemburger Wort
) or, to the extent and in the manner
permitted by such rules, posted on the official website of the
Luxembourg Stock Exchange (www.bourse.lu) and notify the
Holders, the Trustee and the Luxembourg Stock Exchange, if
applicable, or in the case of Definitive Notes, in addition to
such publication, mail to Holders (with a copy to the Trustee)
by first-class mail, postage prepaid, at their respective
addresses as they appear on the registration books of the
Registrar. At the Issuers request made at least
45 days before the Redemption Date or a Tax
Redemption Date, as applicable (or such shorter period as
the Trustee in its sole discretion shall determine), the Paying
Agent shall give the notice of redemption in the Issuers
name and at the Issuers expense;
provided, however
,
that the Issuer shall deliver to the Trustee (in advance) an
Officers Certificate requesting that the Trustee give such
notice and setting forth in full the information to be stated in
such notice as provided in the following items. Each notice for
redemption shall identify the Notes to be redeemed and shall
state:
-34-
(a) the Redemption Date or the
Tax Redemption Date, as applicable;
(b) the Redemption Prices and
the amount of accrued and unpaid interest, if any, and
Additional Amounts, if any, to be paid (subject to the right of
Holders of record on the relevant Record Date to receive
interest and Additional Amounts, if any, due on the relevant
interest payment date);
(c) the name and address of the
designated Paying Agent;
(d) that Notes called for
redemption must be surrendered to the designated Paying Agent to
collect the Redemption Price plus accrued and unpaid
interest, if any, and Additional Amounts, if any;
(e) that, unless the Issuer
defaults in making the redemption payment pursuant to the terms
of this Indenture, interest and Additional Amounts, if any, on
Notes called for redemption cease to accrue on and after the
Redemption Date or the Tax Redemption Date, as
applicable, and the only remaining right of the Holders of such
Notes is to receive payment of the Redemption Price upon
surrender to the Paying Agent of the Notes redeemed;
(f) (i) if any Global Note is being
redeemed in part, the portion of the principal amount of such
Note to be redeemed and that, after the Redemption Date,
interest and Additional Amounts, if any, shall cease to accrue
on the portion called for redemption, and upon surrender of such
Global Note (if applicable), the Global Note with a notation on
Schedule A thereof adjusting the principal amount thereof
to be equal to the unredeemed portion, will be returned and
(ii) if any Definitive Note is being redeemed in part, the
portion of the principal amount of such Note to be redeemed, and
that, after the Redemption Date, upon surrender of such
Definitive Note, a new Definitive Note or Notes in aggregate
principal amount equal to the unredeemed portion thereof will be
issued in the name of the Holder thereof, upon cancellation of
the original Note;
(g) if fewer than all the Notes are
to be redeemed, the identification of the particular Notes (or
portion thereof) to be redeemed, as well as the aggregate
principal amount of Notes to be redeemed and the aggregate
principal amount of Notes to be outstanding after such partial
redemption;
(h) the paragraph of the Notes
pursuant to which the Notes are to be redeemed; and
(i) the ISIN
and/or
Common Code, and that no representation is made as to the
correctness or accuracy of the ISIN
and/or
Common Code, if any, listed in such notice or printed on the
Notes.
Prior to the giving of any notice of redemption pursuant to
Paragraph 9 of the Notes, the Issuer will deliver to the
Trustee (a) an Officers Certificate of the Issuer
stating that the Issuer is entitled to effect such redemption
and setting forth a statement of facts showing that the
conditions precedent to the right of the Issuer so to redeem
have occurred and (b) an Opinion of Counsel qualified under
the laws of the relevant jurisdiction to the effect that the
Issuer has or
-35-
will become obligated to pay such Additional Amounts as a result
of a change in Tax law, and that the Issuer cannot avoid such
obligation by taking reasonable measures available to it.
SECTION 3.5
Effect of
Notice of Redemption
. Once notice of redemption is
given in accordance with Section 3.4, Notes called for
redemption become due and payable on the Redemption Date or
the Tax Redemption Date, as applicable, and at the
Redemption Price plus accrued and unpaid interest, if any,
and Additional Amounts, if any. Upon surrender to the Trustee or
Paying Agent, such Notes called for redemption shall be paid at
the Redemption Price (which shall include accrued and
unpaid interest thereon, if any, and Additional Amounts, if any,
to the Redemption Date or Tax Redemption Date, as
applicable), but installments of interest, the maturity of which
is on or prior to the Redemption Date or the Tax
Redemption Date, as applicable, shall be payable to Holders
of record at the close of business on the relevant Record Dates.
SECTION 3.6
Deposit of
Redemption Price
. Prior to
10:00 a.m. Frankfurt time on the Redemption Date
or the Tax Redemption Date, as applicable, the Issuer shall
deposit with the Trustee or the Paying Agent (which shall be the
Paying Agent or its successor) euro in
same-day
funds sufficient to pay the Redemption Price plus accrued
and unpaid interest (subject to, as provided in the Notes, the
right of Holders to receive interest on the relevant interest
payment date), if any, and Additional Amounts, if any, of all
Notes to be redeemed on that date other than Notes or portion of
Notes called for redemption that have been delivered by the
Issuer to the Trustee for cancellation. The designated Paying
Agent shall promptly return to the Issuer any cash so deposited
which is not required for that purpose upon the written request
of the Issuer. Promptly upon receipt of such payment the Paying
Agent shall confirm by the medium chosen by the Paying Agent to
the Issuer the receipt of such payment.
If the Issuer complies with the preceding paragraph, then,
unless the Issuer defaults in the payment of such
Redemption Price plus accrued and unpaid interest, if any,
and Additional Amounts, if any, interest and Additional Amounts
on the Notes to be redeemed will cease to accrue on and after
the applicable Redemption Date or Tax Redemption Date,
whether or not such Notes are presented for payment. With
respect to Definitive Notes, if a Definitive Note is redeemed on
or after an interest Record Date but on or prior to the related
interest payment date, then any accrued and unpaid interest, if
any, and Additional Amounts, if any, shall be paid to the Person
in whose name such Note was registered at the close of business
on such Record Date. If any Note called for redemption shall not
be so paid upon surrender for redemption because of the failure
of the Issuer to comply with the preceding paragraph, interest,
and Additional Amounts, if any, shall be paid on the unpaid
principal, from the Redemption Date or the Tax
Redemption Date, as applicable, until such principal is
paid, and to the extent lawful on any interest not paid on such
unpaid principal, in each case at the rate provided in the Notes
and in Section 4.1.
SECTION 3.7
Notes Redeemed
in Part
. Upon surrender and cancellation of a
Definitive Note that is redeemed in part, the Company shall
execute and the Trustee shall authenticate for the Holder (at
the Issuers expense) a new Definitive Note equal in
principal amount to the unredeemed portion of the Definitive
Note surrendered and canceled;
provided, however
, that
each such Definitive Note shall be in a principal amount at
maturity of 1,000 or integral multiples of 1,000 in
excess thereof. Upon surrender of a Global Note that is redeemed
in part, the Paying Agent shall promptly forward such Global
Note to the Trustee who shall
-36-
make a notation on Schedule A thereof to reduce the
principal amount of such Global Note to an amount equal to the
unredeemed portion of the Global Note surrendered;
provided
,
however
, that each such Global Note
shall be in a principal amount at maturity of 1,000 or
integral multiples of 1,000 in excess thereof.
SECTION 3.8
Special Tax
Redemption
. The Issuer is entitled to redeem the Notes,
at its option, in whole but not in part, upon not less than 30
nor more than 60 days notice, at 100% of the
principal amount of the Notes, plus accrued and unpaid interest
(if any) to the date of redemption (subject to the right of
holders of record on the relevant record date to receive
interest due on the relevant interest payment date), in the
event the Issuer has become or would become obligated to pay, on
the next date on which any amount would be payable with respect
to the Notes, any additional amounts as a result of:
(a) a change in or an amendment to
the laws, treaties, regulations or rulings of any Relevant
Taxing Jurisdiction; or
(b) any change in or amendment to
any official position regarding the application, administration
or interpretation of such laws, treaties, regulations or rulings
(including by virtue of a holding, judgment or order by a court
of competent jurisdiction);
which change or amendment to such laws or official position is
announced and becomes effective after the issuance of the Notes;
provided
that the Issuer determines, in its reasonable
judgment, that the obligation to pay such additional amounts
cannot be avoided by the use of reasonable measures available to
it;
provided
,
further
, that at the time such
notice is given, such obligation to pay Additional Amounts
remains in effect.
Notice of any such redemption must be given within 270 days
of the earlier of the announcement or effectiveness of any such
change.
ARTICLE IV
COVENANTS
SECTION 4.1
Payment of
Notes
.
(a) The Issuer shall pay the
principal, premium, if any, interest and Additional Amounts, if
any, on the Notes in the manner provided in such Notes and this
Indenture. An installment of principal of or interest, premium
or Additional Amounts on the Notes shall be considered paid on
the date it is due if the Trustee or Paying Agent holds prior to
10:00 a.m. Frankfurt time on that date money deposited
by the Issuer in immediately available funds and designated for,
and sufficient to pay the installment in full and is not
prohibited from paying such money to the Holders pursuant to the
terms of this Indenture.
(b) The Issuer shall pay, to the
extent such payments are lawful, interest (including
post-petition interest in any proceeding under any Bankruptcy
Law) on overdue principal and on overdue installments of
interest (without regard to any applicable grace periods), on
any Additional Amounts, from time to time on demand at the rate
borne by the Notes. Interest will be computed on the basis of a
360-day
year
comprised of twelve
30-day
months.
-37-
SECTION 4.2
Maintenance of
Office or Agency
. The Issuer shall maintain the office
or agency (which office may be an office of the Trustee or an
affiliate of the Trustee, Registrar or co-Registrar) required
under Section 2.3 where Notes may be surrendered for
registration of transfer or for exchange and where notices and
demands to or upon the Issuer in respect of the Notes and this
Indenture may be served. The Issuer shall give prompt written
notice to the Trustee of the location, and any change in the
location, of such office or agency. If at any time the Issuer
shall fail to maintain any such required office or agency or
shall fail to furnish the Trustee with the address thereof, such
presentations, surrenders, notices and demands may be made or
served at the address of the Trustee set forth in
Section 11.1. The Issuer hereby initially designates the
office of the Trustee, acting through its office at 100 Wall
Street, Suite 1600, New York, New York 10005, as its office
or agency as required under Section 2.3 hereof. If the
Notes are listed on the Euro MTF Market of the Luxembourg Stock
Exchange and the rules of such exchange so require, the Issuer
will appoint Deutsche Bank Luxembourg, or such other Person
located in Luxembourg and reasonably acceptable to the Trustee
(reasonableness to be determined objectively), as an additional
paying and transfer agent.
SECTION 4.3
Limitation on
Incurrence of Indebtedness
.
(a) The Issuer and the Company
shall not, and shall not permit any of their Subsidiaries to,
Incur, directly or indirectly, any Indebtedness;
provided
,
however,
that the Company and any
Subsidiary may Incur Indebtedness (and the Company and any
Subsidiary may Incur Acquired Indebtedness) if on the date
thereof:
(1) the Consolidated Coverage Ratio
of the Company is at least 2.0 to 1.0; and
(2) no Default or Event of Default
will have occurred and be continuing or would occur as a
consequence of Incurring the Indebtedness.
(b) The foregoing limitations
contained in paragraph (a) do not apply to the Incurrence
of any of the following Indebtedness:
(1) Indebtedness Incurred under the
Revolving Credit Facility in an aggregate amount not to exceed
$1.2 billion outstanding at any time;
(2) Indebtedness in respect of
Receivables Financings in an aggregate principal amount which,
together with all other Indebtedness in respect of Receivables
Financings outstanding on the date of such Incurrence (other
than Indebtedness permitted by paragraph (a) or
clause (3) of this paragraph (b)), does not exceed 85% of
the sum of (1) the total amount of accounts receivables
shown on the Companys most recent consolidated quarterly
balance sheet, plus (2) without duplication, the total
amount of accounts receivable already subject to a Receivables
Financing;
(3) Indebtedness of the Company
owed to and held by another Guarantor, Indebtedness of a Wholly
Owned Subsidiary owed to and held by another Wholly Owned
Subsidiary or Indebtedness of a Wholly Owned Subsidiary owing to
and held by the Company;
provided
,
however
, that
any subsequent issuance or transfer of any Capital Stock that
results in any such Indebtedness being held by a Person other
than the Company or another Wholly Owned Subsidiary or any
subsequent transfer of such Indebtedness
-38-
(other than to the Company or another Wholly Owned Subsidiary)
shall be deemed, in each case, to constitute the Incurrence of
such Indebtedness by the Company or the Subsidiary, as the case
may be;
(4) Indebtedness in respect of the
Notes issued on the Closing Date, and the related Note
Guarantees by the Company and the other Guarantors and
indebtedness issued in respect of the $650,000,000 aggregate
principal amount of 5.75% Senior Notes due 2021 (the
US Notes) issued on the Closing Date, and the
related Guarantees of the US Notes by the Company and the other
Guarantors;
(5) Capital Lease Obligations and
Indebtedness Incurred, in each case, to provide all or a portion
of the purchase price or cost of construction of an asset or, in
the case of a Sale and Leaseback Transaction, to finance the
value of such asset owned by the Company or a Subsidiary;
(6) Indebtedness (other than
Indebtedness of the type covered by clause (1) or clause
(2)) outstanding on the Closing Date after giving effect to the
application of proceeds from the Notes;
(7) Refinancing Indebtedness in
respect of Indebtedness Incurred pursuant to paragraph
(a) or pursuant to clause (4) or (6) of this
paragraph (b);
(8) Hedging Obligations entered
into in the ordinary course of the business and not for
speculative purposes as determined in good faith by the Company;
(9) customer deposits and advance
payments received from customers for goods purchased in the
ordinary course of business;
(10) Indebtedness arising under the
Cash Management Arrangements; and
(11) Indebtedness Incurred by the
Company or a Subsidiary in an aggregate principal amount which,
together with all other Indebtedness of the Company and its
Subsidiaries outstanding on the date of such Incurrence (other
than Indebtedness permitted by paragraph (a) or
clauses (1) through (10) of this paragraph (b)), does
not exceed $900 million.
(c) For purposes of determining
compliance with the foregoing covenant:
(1) in the event that an item of
Indebtedness meets the criteria of more than one of the types of
Indebtedness described above, the Company, in its sole
discretion, will classify and from time to time may reclassify
such item of Indebtedness and only be required to include the
amount and type of such Indebtedness in one of the above
clauses,
provided
that any Indebtedness outstanding on
the Closing Date and Indebtedness Incurred under clause (b)(5)
above may not be reclassified to clause (a) above; and
(2) an item of Indebtedness may be
divided and classified, or reclassified, in more than one of the
types of Indebtedness described above,
provided
that any
Indebted-
-39-
ness outstanding on the Closing Date and Indebtedness Incurred
under clause (b)(5) above may not be reclassified to
clause (a) above.
(d) If during any period the Notes
have achieved and continue to maintain Investment Grade Status
and no Event of Default has occurred and is continuing (such
period is referred to herein as an Investment Grade Status
Period), then upon notice by the Company to the Trustee by
the delivery of an Officers Certificate that it has
achieved Investment Grade Status, this covenant will be
suspended and will not during such period be applicable to the
Company and its Subsidiaries and shall only again be applicable
if such Investment Grade Status Period ends.
No action taken during an Investment Grade Status Period or
prior to an Investment Grade Status Period in compliance with
this Section 4.3 will require reversal or constitute a
default under the Notes in the event that this Section 4.3
is subsequently reinstated or suspended, as the case may be.
SECTION 4.4
Limitation on
Liens
. The Issuer and the Company may not, and may not
permit any Guarantor or any of their respective Subsidiaries to
directly, or indirectly, create, Incur or suffer to exist any
Lien (other than Permitted Liens) upon any of its property or
assets (including Capital Stock), whether owned on the date
hereof or acquired after that date, securing any Indebtedness,
unless contemporaneously with (or prior to) the Incurrence of
the Liens effective provision is made to secure the Indebtedness
due under this Indenture and the Notes, equally and ratably with
(or prior to in the case of Liens with respect to Subordinated
Obligations) the Indebtedness secured by such Lien for so long
as such Indebtedness is so secured.
SECTION 4.5
Ownership of
the Issuer
. The Company will continue to directly or
indirectly maintain 100% ownership of the Capital Stock of the
Issuer or any permitted successor of the Issuer,
provided
, that any permitted successor of the Company may
succeed to the Companys ownership of such Capital Stock.
The Company will cause the Issuer or its successor to engage
only in those activities that are necessary, convenient or
incidental to issuing and selling the Notes and any additional
Indebtedness permitted under Section 4.3 (including the
Issuers Guarantee of the Credit Facility and any
Additional Notes), and advancing or distributing the proceeds
thereof to the Company and its Subsidiaries and performing its
obligations relating to the Notes and any such additional
Indebtedness, pursuant to the terms thereof and of this
Indenture and any other applicable indenture.
SECTION 4.6
Existence
. Except
as permitted by Article V, the Company shall do or cause to
be done all things necessary to preserve and keep in full force
and effect the existence, rights (charter and statutory) and
franchises of the Company, the Issuer and each other Guarantor;
provided
,
however
, that the Company shall not be
required to preserve any such existence, right or franchise if
the Board of Directors of the Company in good faith shall
determine that the preservation thereof is no longer desirable
in the conduct of the business of the Company and that the loss
thereof at the time of such loss is not disadvantageous in any
material respect to the Holders.
-40-
SECTION 4.7
Maintenance of
Properties
. Except as permitted by Article V, the
Company shall cause all properties used or useful in the conduct
of its business or the business of any Subsidiary of the Company
to be maintained and kept in good condition, repair and working
order and supplied with all necessary equipment and will cause
to be made all necessary repairs, renewals, replacements,
betterments and improvements thereof, all as in the judgment of
the Company may be necessary so that the business carried on in
connection therewith may be properly and advantageously
conducted at all times;
provided
,
however
, that
nothing in this Section shall prevent the Company from
discontinuing the operation or maintenance of any of such
properties if such discontinuance is, as determined by the
Company, or its Responsible Officers, or any Subsidiary, or its
Responsible Officers, having managerial responsibility for any
such property, in good faith, desirable in the conduct of its
business or the business of any Subsidiary and not
disadvantageous in any material respect to the Holders.
SECTION 4.8
Payment of
Taxes and Other Claims
. The Company and the Guarantors
will pay or discharge or cause to be paid or discharged, before
the same shall become delinquent, (a) all material taxes,
assessments and governmental charges levied or imposed upon the
Company or any of its Subsidiaries or upon the income, profits
or property of the Company or any of its Subsidiaries (including
satisfying any withholding tax obligations), and (b) all
material lawful claims for labor, materials and supplies which,
if unpaid, might by law become a Lien upon the property of the
Company or the Guarantors or any of their Subsidiaries;
provided, however,
that the Company or the Guarantors
shall not be required to pay or discharge or cause to be paid or
discharged any such tax, assessment, charge or claim whose
amount, applicability or validity is being contested in good
faith by appropriate proceedings and for which adequate reserves
are maintained in accordance with Accounting Principles.
SECTION 4.9
Maintenance of
Insurance
. The Company shall, and shall cause its
Subsidiaries to, keep at all times all of their material
properties which are of an insurable nature insured against loss
or damage pursuant to self-insurance arrangements with insurers
believed by the Company to be responsible to the extent that
property of similar character is usually so insured by
corporations similarly situated and owning like properties in
accordance with good business practice. The Company shall, and
shall cause its Subsidiaries to, use the proceeds from any such
insurance policy to repair, replace or otherwise restore the
property to which such proceeds relate, except to the extent
that a different use of such proceeds is, as determined by the
Company, or any Subsidiary having managerial responsibility for
any such property, in good faith, desirable in the conduct of
its business or the business of any Subsidiary and not
disadvantageous in any material respect to the Holders.
SECTION 4.10
Reports
. For
so long as any Notes are outstanding, the Company will provide
the Trustee with:
(1) copies of the annual reports
and of the information, documents and other reports, and such
summaries thereof, as may be required by the TIA at the times
and in the manner provided by the TIA;
(2) its annual financial statements
and related notes thereto for the most recent two fiscal years
prepared in accordance with U.S. GAAP (or IFRS or any other
internationally generally acceptable accounting standard in the
event the Company is required
-41-
by applicable law to prepare its financial statements in
accordance with IFRS or such other standard or is permitted and
elects to do so, with appropriate reconciliation to
U.S. GAAP, unless not then required under the rules of the
SEC) and including segment data, together with an audit report
thereon, together with a discussion of the Operating
Results and Liquidity for such fiscal years
prepared in a manner substantially consistent with the
Operating and Financial Review and Prospects
required by
Form 20-F
under the Exchange Act (or any replacement or successor form)
appearing herein and a Business Summary of the Financial
Year and discussion of Business Segments
provided in a manner consistent with its annual report, a
description of Related Party Transactions, and a
description of Indebtedness, within 90 days of the end of
each fiscal year; and
(3) quarterly financial information
as of and for the period from the beginning of each year to the
close of each quarterly period (other than the fourth quarter),
together with comparable information for the corresponding
period of the preceding year, and a summary
Managements Discussion and Analysis of Financial
Condition and Results of Operations to the extent and in
the form required under the Exchange Act providing a brief
discussion of the results of operations for the period within
45 days following the end of the fiscal quarter.
The Company shall also comply with the other provisions of
Section 314(a) of the TIA. In addition, so long as the
Notes remain outstanding and during any period when the Issuer
or the Company is not subject to Section 13 or 15(d) of the
Exchange Act other than by virtue of the exemption therefrom
pursuant to
Rule 12g3-2(b),
the Company will furnish to any Holder or beneficial owner of
Notes initially offered and sold in the United States to
qualified institutional buyers as defined in
Rule 144A under the Securities Act pursuant to such rule
and any prospective purchaser in the United States designated by
such Holder or beneficial owner, upon request, any information
required to be delivered pursuant to Rule 144A(d)(4) under
the Securities Act.
If and so long as the Notes are listed on the Euro MTF Market of
the Luxembourg Stock Exchange, copies of such reports shall also
be available at the specified office of the Listing Agent in
Luxembourg.
Deliveries of such reports, information and documents to the
Trustee is for informational purposes only and the
Trustees receipt of such shall not constitute constructive
notice of any information contained therein or determinable from
information contained therein, including the Issuers, the
Companys or any Guarantors compliance with any of
its covenants hereunder (as to which the Trustee is entitled to
rely exclusively on Officers Certificates). The Trustee
shall have no obligation to review such reports to determine if
the information required by this Section 4.10 is contained
therein.
SECTION 4.11
Change of
Control
. Each Holder of the Notes, upon the occurrence
of a Change of Control Triggering Event, will have the right to
require that the Issuer repurchase such Holders Notes, at
a purchase price in cash equal to 101% of the principal amount
thereof plus accrued and unpaid interest, if any, to the date of
purchase (subject to the right of Holders of record on the
relevant record date to receive interest due on the relevant
interest payment date).
-42-
Within 30 days following a Change of Control Triggering
Event, the Issuer will mail a notice to each Holder with a copy
to the Trustee stating:
(1) that a Change of Control
Triggering Event has occurred and that such Holder has the right
to require the Issuer to purchase such Holders Notes, at a
purchase price in cash equal to 101% of the principal amount
thereof plus accrued and unpaid interest, if any, to the date of
purchase (subject to the right of Holders of record on the
relevant record date to receive interest on the relevant
interest payment date);
(2) the circumstances and relevant
facts regarding such Change of Control Triggering Event
(including information with respect to pro forma historical
income, cash flow and capitalization after giving effect to such
Change of Control Triggering Event);
(3) the repurchase date (which
shall be no earlier than 30 days nor later than
60 days from the date such notice is mailed);
(4) that each Note will be subject
to repurchase only in integral multiples of 1,000; and
(5) the instructions determined by
the Issuer, consistent with the covenant described hereunder,
that a Holder must follow in order to have its Notes purchased.
(6) that any Note not tendered will
continue to accrue interest;
(7) that, unless the Issuer
defaults in the payment of the Change of Control purchase price,
any Notes accepted for payment shall cease to accrue interest
after the repurchase date;
(8) that Holders accepting the
offer to have their Notes repurchased pursuant to a change of
control offer will be required to surrender the Notes to the
Paying Agent or any other Agent specified in the notice at the
address specified in the notice prior to the close of business
on the Business Day preceding the repurchase date;
(9) that Holders whose Notes are
being purchased only in part will be issued new Notes equal in
principal amount to the unpurchased portion of the Notes
surrendered;
(10) any other procedures that a holder
must follow to accept a change of control offer or effect
withdrawal of such acceptance; and
(11) the name and address of the Paying
Agent.
On the repurchase date, the Issuer shall, to the extent lawful:
(1) accept for payment Notes or
portions thereof validly tendered pursuant to the change of
control offer;
-43-
(2) deposit with the Paying Agent
money sufficient to pay the Change of Control purchase price in
respect of all Notes or portions thereof so tendered; and
(3) deliver or cause to be
delivered to the Trustee Notes so accepted together with an
Officers Certificate stating the Notes or portions thereof
tendered to the Issuer.
The Paying Agent shall promptly mail to each Holder of Notes so
accepted payment in an amount equal to the purchase price for
such Notes, and the Issuer shall execute and issue, and the
Trustee shall promptly authenticate and mail to such Holder, a
new Note equal in principal amount to any unpurchased portion of
the Notes surrendered; provided that each such new Note shall be
issued in an original principal amount in denominations of
1,000 and integral multiples of 1,000 in excess
thereof.
The Issuer will comply, to the extent applicable, with the
requirements of Section 14(e) of the Exchange Act and any
other securities laws or regulations in connection with the
repurchase of Notes pursuant to this Section 4.11. To the
extent that the provisions of any securities laws or regulations
or applicable listing requirements conflict with the provisions
of this Section 4.11, the Issuer will comply with the
applicable securities laws and regulations and will not be
deemed to have breached its obligations under this
Section 4.11 by virtue thereof.
SECTION 4.12
Additional
Amounts
. At least 30 days prior to each date on
which payment of principal, premium, if any, or interest or
other amounts on the Notes is to be made (unless such obligation
to pay Additional Amounts arises shortly before or after the
30th day prior to such date, in which case it shall be
promptly thereafter), if the Issuer or any Guarantor will be
obligated to pay Additional Amounts pursuant to Paragraph 2
of the Notes (the Additional Amounts) with respect
to any such payment, the Issuer will promptly furnish the
Trustee and the Paying Agent, if other than the Trustee, with an
Officers Certificate stating that such Additional Amounts
will be payable and the amounts so payable, and will set forth
such other information necessary to enable the Trustee or the
Paying Agent to pay such Additional Amounts to the Holders on
the payment date. The Issuer will pay to the Trustee or the
Paying Agent such Additional Amounts and, if paid to a Paying
Agent other than the Trustee, shall promptly provide the Trustee
with documentation evidencing the payment of such Additional
Amounts. Copies of such documentation shall be made available to
the Holders upon request. The Issuer shall indemnify the Trustee
and the Paying Agent for, and hold them harmless against, any
loss, liability or expense incurred without negligence or
willful misconduct on their part arising out of or in connection
with actions taken or omitted by any of them in reliance on any
Officers Certificate furnished to them pursuant to this
Section 4.12.
The Issuer will (i) make any required withholding or
deduction and (ii) remit the full amount deducted or
withheld to the Relevant Taxing Jurisdiction in accordance with
applicable law. The Issuer will use all reasonable efforts to
obtain certified copies of tax receipts evidencing the payment
of any Taxes so deducted or withheld from each Relevant Taxing
Jurisdiction imposing such Taxes and will provide such certified
copy to the Trustee.
If the Issuer or the Guarantors conduct business in any
jurisdiction (an Additional Taxing Jurisdiction)
other than a Relevant Taxing Jurisdiction and, as a result, are
required by the law of such Additional Taxing Jurisdiction to
deduct or withhold any amount on account
-44-
of taxes imposed by such Additional Taxing Jurisdiction from
payments under the Notes which would not have been required to
be so deducted or withheld but for such conduct of business in
such Additional Taxing Jurisdiction, the Additional Amounts
provision described above shall be considered to apply to such
Holders as if references in such provision to Taxes
included taxes imposed by way of deduction or withholding by any
such Additional Taxing Jurisdiction (or any political
subdivision thereof or taxing authority therein).
The Issuer will pay any present stamp, court or documentary
taxes, or any other excise, property or similar taxes, charges
or levies (including any penalties, interest or other
liabilities related thereto) which arise in Luxembourg (or any
political subdivision thereof or therein) from the execution,
delivery and registration of Notes upon original issuance and
initial resale of the Notes or any other document or instrument
referred to therein, or in connection with the enforcement of
the Notes or any Note Guarantee or any other document or
instrument referred to therein. If at any time the Issuer
changes its place of organization to outside of Luxembourg or
there is a new issuer organized outside of Luxembourg, the
Issuer or new issuer, as applicable, will pay any stamp, court
or documentary taxes, or any other excise, property or similar
taxes, charges or levies (including any penalties, interest or
other liabilities related thereto) which arise in the
jurisdiction in which the Issuer or new issuer is organized (or
any political subdivision thereof or therein) and are payable by
the Holders of the Notes in respect of the Notes or any other
document or instrument referred to therein under any law, rule
or regulation in effect at the time of such change.
The foregoing obligations of this Section 4.12 will survive
any termination, defeasance or discharge of this Indenture and
will apply
mutatis mutandis
to any successor Person to
the Issuer or the Guarantors.
Whenever in this Indenture or in the Notes there is mentioned,
in any context, the payment of principal, premium or interest,
if any, or any other amount payable under or with respect to any
Note, such mention shall be deemed to include mention of the
payment of Additional Amounts to the extent that, in such
context, Additional Amounts are, were or would be payable in
respect thereof.
SECTION 4.13
Compliance
Certificate; Notice of Default
. The Company shall
deliver to the Trustee, within 90 days after the end of
each fiscal year an Officers Certificate stating whether
or not to the best knowledge of the signor thereof, the Issuer
and the Guarantors, as the case may be, have complied with all
conditions and covenants under this Indenture, whether a Default
or an Event of Default has occurred during such period, and, if
a Default or an Event of Default has occurred during such
period, specifying all such Events of Default and the nature
thereof of which such Responsible Officer has knowledge. Upon
becoming aware of, and as of such time that the Issuer should
reasonably have become aware of, a Default, the Company also
shall deliver to the Trustee, within 30 days thereafter,
written notice of any events which would constitute a Default,
their status and what action the Issuer is taking or proposes to
take in respect thereof, and, in the case of a Default in the
payment of interest, principal, redemption payments or any other
amount due on the Notes or the Guarantees, such same notice to
the Paying Agent.
-45-
SECTION 4.14
Limitation on
Sale and Leaseback Transactions
. The Issuer and the
Company may not, and may not permit any Guarantor or any
Subsidiary to, enter into any Sale and Leaseback Transaction
unless:
(1) the Issuer or such Guarantor or
Subsidiary, as the case may be, receives consideration at the
time of such Sale and Leaseback Transaction at least equal to
the fair market value (as evidenced by an Officers
Certificate of a Responsible Officer, or, if the value exceeds
$25 million, a resolution of the Board of Directors of the
Issuer or such Guarantor or Subsidiary), of the property subject
to such transaction;
(2) the Issuer or such Guarantor or
Subsidiary, as the case may be, could have created a Lien on the
property subject to such Sale and Leaseback Transaction if such
transaction was financed with Indebtedness without securing the
Notes pursuant to Section 4.4; and
(3) the Issuer or such Guarantor or
Subsidiary, as the case may be, can Incur an amount of
Indebtedness equal to the Attributable Debt in respect of such
Sale and Leaseback Transaction.
ARTICLE V
SUCCESSOR
ISSUER OR GUARANTOR
SECTION 5.1
Limitation on
Mergers and Sales of Assets
. The Issuer and the Company
may not, and may not permit any other Guarantor to consolidate
or merge with or into (whether or not the Issuer or such
Guarantor is the Surviving Person), or sell, assign, transfer,
lease, convey or otherwise dispose of all or substantially all
of its properties and assets in one or more related
transactions, to another Person unless:
(1) the Surviving Person is an
entity organized and existing under the laws of Germany, the
United Kingdom, any other member state of the European Union (as
of December 31, 2003), Luxembourg, Switzerland, the United
States of America, or any State thereof or the District of
Columbia, or the jurisdiction of formation of the Issuer or any
Guarantor; or, if the Surviving Person is an entity organized
and existing under the laws of any other jurisdiction, the
Issuer delivers to the Trustee an Opinion of Counsel to the
effect that the rights of the Holders of the Notes, would not be
affected adversely as a result of the law of the jurisdiction of
organization of the Surviving Person, insofar as such law
affects the ability of the Surviving Person to pay and perform
its obligations and undertakings in connection with the Notes
(in a transaction involving the Issuer) or its Note Guarantee or
the ability of the Surviving Person to obligate itself to pay
and perform such obligations and undertakings or the ability of
the Holders to enforce such obligations and undertakings;
(2) the Surviving Person (if other
than the Issuer or a Guarantor) shall expressly assume,
(A) in a transaction or series of transactions involving
the Issuer, by a supplemental indenture in a form satisfactory
to the Trustee, all of the obligations of the Issuer,
(B) in a transaction or series of transactions involving
the Company, by a supple-
-46-
mental indenture in a form satisfactory to the Trustee, all of
the obligations of the Company under the Indenture, or
(C) in a transaction or series of transactions involving a
Guarantor (including the Company), by a Guarantee Agreement, in
a form satisfactory to the Trustee, all of the obligations of
such Guarantor under its Note Guarantee;
(3) at the time of and immediately
after such transaction, no Default or Event of Default shall
have occurred and be continuing; and
(4) the Issuer or such Guarantor
delivers to the Trustee an Officers Certificate and an
Opinion of Counsel, each stating that such consolidation,
merger, transfer, assignment, sale, lease or other disposition
and such supplemental indenture and Guarantee Agreement, if any,
comply with this Indenture.
SECTION 5.2
Successor
Entity Substituted
. Upon any consolidation or merger by
the Issuer, the Company or any other Guarantor with or into any
other Person, or any conveyance, transfer, sale, assignment,
lease or other disposition by the Issuer, the Company or any
other Guarantor in one or more transactions, of substantially
all of its properties and assets as an entirety to any Person in
accordance with Section 5.1, the Surviving Person shall
succeed to, and be substituted for, and may exercise every right
and power of, the Issuer or such Guarantor under this Indenture
with the same effect as if such Surviving Person had been named
as the Issuer or had been a Guarantor herein, and thereafter the
Issuer or such Guarantor shall be discharged from all
obligations and covenants hereunder and under the Notes.
Such Surviving Person (if the successor of the Issuer) may cause
to be signed, and may issue either in its own name or in the
name of the Issuer, any or all of the Notes issuable hereunder
which theretofore shall not have been signed by the Issuer and
delivered to the Trustee; and, upon the order of such Surviving
Person instead of the Issuer and subject to all the terms,
conditions and limitations in this Indenture prescribed, the
Trustee shall authenticate and shall deliver any Notes which
previously shall have been signed and delivered by the
Responsible Officers of the Issuer to the Trustee for
authentication pursuant to such provisions and any Notes which
such Surviving Person thereafter shall cause to be signed and
delivered to the Trustee on its behalf for the purpose pursuant
to such provisions. All the Notes so issued shall in all
respects have the same legal rank and benefit under this
Indenture as the Notes theretofore or thereafter issued in
accordance with the terms of this Indenture as though all of
such Notes had been issued at the date of the execution hereof.
In case of any such consolidation, merger, sale, assignment,
transfer, conveyance, lease, or other disposition such changes
in phraseology and form may be made in the Notes thereafter to
be issued as may be appropriate.
SECTION 5.3
Substitution of
the Issuer
. The Company, any other Guarantor or a
Finance Subsidiary (a Successor) may assume the
obligations of the Issuer under the Notes, by executing and
delivering to the Trustee (a) a supplemental indenture
which subjects such person to all of the provisions of the
Indenture and (b) an opinion of counsel to the effect that
such supplemental indenture has been duly authorized and
executed by such Person, and constitutes the legal, valid,
binding and enforceable obligation of such Person, subject to
customary exceptions; provided that (i) the Successor is
formed under the laws of the United States of
-47-
America, or any State thereof or the District of Columbia,
Germany, the United Kingdom or any other member state of the
European Union as of December 31, 2003 and (ii) no
Additional Amounts would be or become payable with respect to
the Notes at the time of such assumption, or as result of any
change in the laws of the jurisdiction of formation of such
Successor that was reasonably foreseeable at such time. The
Successor shall succeed to, and be substituted for, and may
exercise every right and power of, the Issuer under the
Indenture with the same effect as if it were the Issuer
thereunder, and the former Issuer shall be discharged from all
obligations and covenants under this Indenture and the Notes.
ARTICLE VI
DEFAULT
AND REMEDIES
SECTION 6.1
Events of
Default
. Whenever used herein with respect to the
Notes, Event of Default means any one of the
following events which shall have occurred and be continuing:
(1) failure for 30 days to pay
interest on the Notes, including any Additional Amounts in
respect thereof, when due; or
(2) failure to pay principal of or
premium, if any, on the Notes when due, whether at maturity,
upon redemption, by declaration or otherwise; or
(3) failure to observe or perform
any other covenant contained in this Indenture for 60 days
after notice as provided in this Indenture; or
(4) default under any mortgage,
indenture or instrument under which there may be issued or by
which there may be secured or evidenced any Indebtedness for
money borrowed by the Company or any of its Subsidiaries (or the
payment of which is Guaranteed by the Company), whether such
Indebtedness or Guarantee now exists or is Incurred after the
Closing Date, if (A) such default results in the
acceleration of such Indebtedness prior to its express maturity
or will constitute a default in the payment of such Indebtedness
and (B) the principal amount of any such Indebtedness that
has been accelerated or not paid at maturity, when added to the
aggregate principal amount of all other such Indebtedness, at
such time, that has been accelerated or not paid at maturity,
exceeds $100 million; or
(5) any final judgment or judgments
(not covered by insurance) which can no longer be appealed for
the payment of money in excess of $100 million shall be
rendered against the Issuer or the Company or any of its
Subsidiaries and shall not be discharged for any period of 60
consecutive days during which a stay of enforcement shall not be
in effect; or
(6) any Note Guarantee shall cease
to be in full force and effect in accordance with its terms for
any reason except pursuant to the terms of this Indenture
governing the release of Note Guarantees or the satisfaction in
full of all the obligations thereunder or shall be declared
invalid or unenforceable other than as contemplated by its
terms, or any Guarantor shall repudiate, deny or disaffirm any
of its obligations thereunder; or
-48-
(7) the Company, the Guarantors,
the Issuer or any of the Companys Significant Subsidiaries
pursuant to or within the meaning of any Bankruptcy Law:
(a) commences negotiations with any
one or more of its creditors with a view to the general
readjustment or rescheduling of its indebtedness or makes a
general assignment for the benefit of or a composition with its
creditors or, for any of the reasons set out in
Sections 17-19
of the German Insolvency Code (
Insolvenzordnung
), files
for insolvency (
Antrag auf Eröffnung eines
Insolvenzverfahrens
) or the board of directors
(
Geschäftsführer
) is required by law to file
for insolvency, a creditor files for the opening of insolvency
proceedings and such filing is not frivolous and not dismissed
within a period of one month by the competent insolvency court,
or the competent court takes any of the actions set out in
Section 21 of the German Insolvenzordnung or a competent
court institutes insolvency proceedings (
Eröffnung des
Insolvenzverfahrens
) or denies a petition for commencement
of insolvency proceeding by reason of insufficient assets,
(b) commences a voluntary case,
(c) consents to the entry of an
order for relief against it in an involuntary case,
(d) consents to the appointment of
a custodian of it or for all or substantially all of its
property,
(e) makes a general assignment for
the benefit of its creditors, or
(f) takes any corporate action to
authorize or effect any of the foregoing.
A default under clause (3) of this paragraph will not
constitute an Event of Default unless the Trustee or Holders of
25% in principal amount of the outstanding Notes notify the
Issuer and the Company of such default and such default is not
cured within the time specified in clause (3).
SECTION 6.2
Acceleration
. If
an Event of Default (other than an Event of Default described in
clause (7) of Section 6.1 hereof) occurs and is
continuing, the Trustee by notice to the Company, or the Holders
of at least 25% in aggregate principal amount of the outstanding
Notes by notice to the Issuer, the Company and the Trustee, may,
and the Trustee at the request of such Holders shall, declare
the principal of, premium, if any, and accrued and unpaid
interest, if any, and Additional Amounts, if any, on all the
Notes to be due and payable. Upon such a declaration, such
principal, premium, accrued and unpaid interest, and Additional
Amounts, if any, will be due and payable immediately. If an
Event of Default described in clause (7) of
section 6.1 above occurs and is continuing, the principal
of, premium, if any, and accrued and unpaid interest on all the
Notes will become and be immediately due and payable without any
declaration or other act on the part of the Trustee or any
Holders.
SECTION 6.3
Other
Remedies
. If an Event of Default of which the Trustee
is aware occurs and is continuing, the Trustee may pursue any
available remedy by proceeding at
-49-
law or in equity to collect the payment of principal of or,
premium, if any, interest, and Additional Amounts, if any, on
the Notes or to enforce the performance of any provision of the
Notes or this Indenture.
SECTION 6.4
The Trustee May
Enforce Claims Without Possession of Notes
. All rights
of action and claims under this Indenture or the Notes may be
prosecuted and enforced by the Trustee (without liability)
without the possession of any of the Notes or the production
thereof in any proceeding relating thereto.
SECTION 6.5
Rights and
Remedies Cumulative
. Except as otherwise provided with
respect to the replacement or payment of mutilated, destroyed,
lost or stolen Notes in Section 2.8, no right or remedy
herein conferred upon or reserved to the Trustee or to the
Holders of Notes is intended to be exclusive of any other right
or remedy, and every right and remedy shall, to the extent
permitted by law, be cumulative and in addition to every other
right and remedy given hereunder or now or hereafter existing at
law or in equity or otherwise. The assertion or employment of
any right or remedy hereunder, or otherwise, shall not prevent
the concurrent or subsequent assertion or employment of any
other appropriate right or remedy.
SECTION 6.6
Delay or
Omission Not Waiver
. No delay or omission of the
Trustee or of any Holder to exercise any right or remedy
accruing upon any Event of Default shall impair any such right
or remedy or constitute a waiver of any such Event of Default or
an acquiescence therein. Every right and remedy given by the
Indenture or by law to the Trustee or to the Holders of Notes
may be exercised from time to time, and as often as may be
deemed expedient, by the Trustee or by the Holders of Notes, in
each case in accordance with the terms of this Indenture.
SECTION 6.7
Waiver of Past
Defaults
. Subject to Sections 2.10, 6.10 and 9.2,
at any time after a declaration of acceleration with respect to
the Notes as described in Section 6.2, the Holders of at
least a majority in principal amount of the outstanding Notes by
written notice to the Issuer and to the Trustee, may waive all
past defaults (except with respect to nonpayment of principal,
premium or interest) and rescind any such declaration of
acceleration with respect to the Notes and its consequences if
(i) the rescission would not conflict with any judgment or
decree of a court of competent jurisdiction and (ii) all
existing Events of Default, other than the nonpayment of the
principal of, premium, if any, and interest on the Notes that
have become due solely by such declaration of acceleration, have
been cured or waived. Such waiver shall not excuse a continuing
Event of Default in the payment of interest, premium, if any,
principal or Additional Amounts, if any, on such Note held by a
non-consenting Holder, or in respect of a covenant or a
provision which cannot be amended or modified without the
consent of each Holder affected thereby. The Issuer shall
promptly deliver to the Trustee an Officers Certificate
stating that the requisite percentage of Holders has consented
to such waiver and attaching copies of such consents. When a
Default or Event of Default is waived, it is cured and ceases.
SECTION 6.8
Control by
Majority
. Subject to Section 2.10, the Holders of
not less than a majority in principal amount of the outstanding
Notes may, by written notice to the Trustee, direct the time,
method and place of conducting any proceeding for any remedy
available to the Trustee or exercising any trust or power
conferred on it. Subject to Section 7.1,
-50-
however, the Trustee may refuse to follow any direction that
conflicts with any law or this Indenture or that the Trustee
determines is unduly prejudicial to the rights of another Holder
of Notes, or that may involve the Trustee in personal liability;
provided
,
however
, that the Trustee may take any
other action deemed proper by the Trustee which is not
inconsistent with such direction. Prior to taking any action
under this Indenture, the Trustee will be entitled to
indemnification satisfactory to it in its sole discretion
against all losses and expenses caused by taking or not taking
such action in accordance with Section 7.7.
SECTION 6.9
Limitation on
Suits
. Subject to Section 6.10, no Holder of Notes
may pursue any remedy with respect to this Indenture or the
Notes unless:
(1) such Holder has previously
given the Trustee notice that an Event of Default is continuing;
(2) Holders of at least 25% in
principal amount of the outstanding Notes have requested the
Trustee to pursue the remedy;
(3) such Holders have offered the
Trustee reasonable security or indemnity satisfactory to the
Trustee against any loss, liability or expense;
(4) the Trustee has not complied
with such request within 60 days after the receipt of the
request and the offer of satisfactory security or
indemnity; and
(5) the Holders of a majority in
principal amount of the outstanding Notes have not given the
Trustee a direction that, in the opinion of the Trustee, is
inconsistent with such request within such
60-day
period.
SECTION 6.10
Rights of
Holders To Receive Payment
. Notwithstanding any other
provision of this Indenture (including, without limitation,
Section 8.9 hereof), the right of any Holder to receive
payment of principal of, premium, if any, interest, and
Additional Amounts, if any, on a Note, on or after the
respective due dates expressed in such Note, or to bring suit
for the enforcement of any such payment on or after such
respective dates, shall not be impaired or affected without the
consent of such Holder.
SECTION 6.11
Collection
Suit by Trustee
. If an Event of Default in payment of
principal, premium, if any, interest and Additional Amounts, if
any, specified in clause (1) or clause (2) of
Section 6.1 occurs and is continuing, the Trustee may
recover judgment in its own name and as trustee of an express
trust against the Company or any other obligor on the Notes for
the whole amount of principal, premium, if any, and accrued
interest remaining unpaid, together with interest on overdue
principal and, to the extent that payment of such interest is
lawful, interest on overdue installments of interest, in each
case at the rate per annum borne by the Notes and such further
amount as shall be sufficient to cover the costs and expenses of
collection, including the reasonable compensation, expenses,
disbursements and advances of the Trustee, its agents and
counsel, and any other amounts due the Trustee under
Section 7.7.
SECTION 6.12
Trustee May
File Proofs of Claim
. The Trustee may file such proofs
of claim and other papers or documents as may be necessary or
advisable in order to have the claims of the Trustee (including
any claim for the reasonable compensation, expenses, dis-
-51-
bursements and advances of the Trustee, its agents and counsel
and any other amount due to the Trustee under Section 7.7,
accountants and experts) and the Holders allowed in any judicial
proceedings relating to the Company, its creditors or its
property or other obligor on the Notes, its creditors and its
property and shall be entitled and empowered to collect and
receive any monies or other property payable or deliverable on
any such claims and to distribute the same, and any Custodian in
any such judicial proceedings is hereby authorized by each
Holder to make such payments to the Trustee and, in the event
that the Trustee shall consent to the making of such payments
directly to the Holders, to pay to the Trustee any amount due to
it for the reasonable compensation, expenses, disbursements and
advances of the Trustee, its agent and counsel, and any other
amounts due the Trustee under Section 7.7. To the extent
that the payment of any such compensation, expenses,
disbursements and advances of the Trustee, its agents and
counsel, and any other amounts due the Trustee under
Section 7.7 hereof out of the estate in any such
proceeding, shall be denied for any reason, payment of the same
shall be secured by a Lien on, and shall be paid out of, any and
all distributions, dividends, money, securities and other
properties which the Holders of the Notes may be entitled to
receive in such proceeding whether in liquidation or under any
plan of reorganization or arrangement or otherwise.
SECTION 6.13
Priorities
. If
the Trustee collects any money or property pursuant to this
Article VI, it shall pay out the money or property in the
following order:
First:
to the Trustee and the Agents for amounts due
under Section 7.7, including (but not limited to) payment
of all compensation, fees, expense and liabilities incurred, and
all advances made, by the Trustee and the costs and expenses of
collection;
Second:
to Holders for amounts due and unpaid on the
Notes for principal, premium, if any, interest and Additional
Amounts, if any, ratably, without preference or priority of any
kind, according to the amounts due and payable on the Notes for
principal, premium, if any, interest and Additional Amounts, if
any, respectively; and
Third:
to the Issuer, the Guarantors or any other
obligor on the Notes, as their interests may appear, or as a
court of competent jurisdiction may direct.
The Trustee, upon prior notice to the Issuer, may fix a record
date and payment date for any payment to Holders pursuant to
this Section 6.13;
provided
that the failure to give
any such notice shall not affect the establishment of such
record date or payment date for Holders pursuant to this
Section 6.13.
SECTION 6.14
Restoration of
Rights and Remedies
. If the Trustee or any Holder of
any Note has instituted any proceeding to enforce any right or
remedy under this Indenture and such proceeding has been
discontinued or abandoned for any reason, or has been determined
adversely to the Trustee or to such Holder, then and in every
such case, subject to any determination in such proceeding, the
Issuer, the Trustee and the Holders of Notes shall be restored
severally and respectively to their former positions hereunder
and thereafter all rights and remedies of the Trustee and the
Holders of Notes shall continue as though no such proceeding had
been instituted.
-52-
SECTION 6.15
Undertaking
for Costs
. In any suit for the enforcement of any right
or remedy under this Indenture or in any suit against the
Trustee for any action taken or omitted by it as Trustee, a
court in its discretion may require the filing by any party
litigant in the suit of an undertaking to pay the costs of the
suit, and the court in its discretion may assess reasonable
costs, including reasonable attorneys fees and expenses,
against any party litigant in the suit, having due regard to the
merits and good faith of the claims or defenses made by the
party litigant. This Section 6.15 does not apply to a suit
by the Trustee, a suit by a Holder pursuant to
Section 6.10, or a suit by a Holder or Holders of more than
10% in principal amount of the outstanding Notes.
SECTION 6.16
Notices of
Default
. If a Default occurs and is continuing and is
known to the Trustee, the Trustee must mail to each Holder of
Notes notice of the Default within 90 days after it has
become known to the Trustee. Except in the case of a Default in
the payment of principal of, premium, if any, interest and
Additional Amounts, if any, on any Note, the Trustee may
withhold notice if and so long as a committee of
Trust Officers determines that withholding notice is in the
interests of such Holders of Notes.
ARTICLE VII
TRUSTEE
SECTION 7.1
Duties of
Trustee
. If an Event of Default actually known to a
Trust Officer of the Trustee has occurred and is
continuing, the Trustee shall exercise such of the rights and
powers vested in it by this Indenture and use the same degree of
care and skill in their exercise as a prudent Person would
exercise or use under the circumstances in the conduct of his or
her own affairs. Subject to such provisions, the Trustee will be
under no obligation to exercise any of its rights or powers
under this Indenture at the request of any of the Holders of
Notes, unless they shall have offered to the Trustee reasonable
security and indemnity satisfactory to the Trustee against any
loss, liability or expense in accordance with the sixth
paragraph of Section 7.7.
(a) Except during the continuance
of an Event of Default actually known to the Trustee:
(1) The Trustee and the Agents will
perform only those duties as are specifically set forth herein
and no others and no implied covenants or obligations shall be
read into this Indenture against the Trustee or the Agents.
(2) In the absence of willful
misconduct on their part, the Trustee and the Agents may
conclusively rely, as to the truth of the statements and the
correctness of the opinions expressed therein, upon certificates
or opinions and such other documents delivered to them pursuant
to Section 11.2 and conforming to the requirements of this
Indenture. However, in the case of any such certificates or
opinions which by any provision hereof are required to be
furnished to the Trustee, the Trustee shall examine the
certificates and opinions to determine whether or not they
conform to the requirements of this Indenture.
-53-
(b) The Trustee may not be relieved
from liability for its own negligent action, its own negligent
failure to act, or its own willful misconduct, except that:
(1) This paragraph does not limit
the effect of subsection (a) of this Section 7.1.
(2) Neither the Trustee nor Agent
shall be liable for any error of judgment made in good faith by
a Trust Officer of such Trustee or Agent, unless it is
proved that the Trustee or such Agent was negligent in
ascertaining the pertinent facts.
(3) The Trustee shall not be liable
with respect to any action it takes or omits to take in good
faith in accordance with a direction received by it pursuant to
Section 6.2, 6.7 or 6.8.
(c) No provision of this Indenture
shall require the Trustee or any Agent to expend or risk its own
funds or otherwise incur any financial liability in the
performance of any of its duties hereunder or to take or omit to
take any action under this Indenture or take any action at the
request or direction of Holders if it shall have reasonable
grounds for believing that repayment of such funds is not
assured to it or it does not receive an indemnity satisfactory
to it in its sole discretion against such risk, liability, loss,
fee or expense which might be incurred by it in the performance
of any of its duties hereunder.
(d) Whether or not therein
expressly so provided, every provision of this Indenture that in
any way relates to the Trustee is subject to the first paragraph
and subsections (a), (b) and (c) of this
Section 7.1.
(e) Neither the Trustee nor the
Agents shall be liable for interest on any money received by it
except as the Trustee and any Agent may agree in writing with
the Issuer. Money held in trust by the Trustee or any Agent need
not be segregated from other funds except to the extent required
by law.
(f) Any provision hereof relating
to the conduct or affecting the liability of or affording
protection to the Trustee shall be subject to the provisions of
this Section 7.1.
SECTION 7.2
Rights of
Trustee
. Subject to Section 7.1:
(a) The Trustee and each Agent may
rely conclusively on and shall be protected from acting or
refraining from acting based upon any document believed by them
to be genuine and to have been signed or presented by the proper
Person. Neither the Trustee nor any Agent shall be bound to make
any investigation into the facts or matters stated in any
resolution, certificate, statement, instrument, opinion, report,
notice, request, consent order, approval, appraisal, bond,
debenture, note, coupon, security or other paper or document.
The Trustee shall not be deemed to have notice or any knowledge
of any matter (including without limitation Defaults or Events
of Default) unless a Trust Officer assigned to and working
in the Trustees Corporate Trust Office which is
administering this Indenture has actual knowledge thereof or
unless written notice thereof is received by the Trustee,
attention: Corporate Trust and such notice clearly references
the Notes, the Issuer or this Indenture.
-54-
(b) Before the Trustee acts or
refrains from acting, it may consult with counsel and may
require an Officers Certificate, Issuer Order (as
applicable) or an Opinion of Counsel or both. Neither the
Trustee nor any Agent shall be liable for any action it takes or
omits to take in good faith in reliance on such certificate or
opinion.
(c) The Trustee and any Agent may
act through their attorneys and agents and shall not be
responsible for the misconduct or negligence of any agent (other
than an agent who is an employee of the Trustee or such Agent)
appointed with due care.
(d) The Trustee shall not be liable
for any action it takes or omits to take in good faith which it
reasonably believes to be authorized or within its rights or
powers conferred upon it by this Indenture;
provided
,
however
, that the Trustees conduct does not
constitute willful misconduct, negligence or bad faith.
(e) The Trustee or any Agent may
consult with counsel of its selection and the advice or opinion
of such counsel as to matters of law shall be full and complete
authorization and protection from liability in respect of any
action taken, omitted or suffered by it hereunder and in
accordance with the advice or opinion of such counsel.
(f) Except to the extent provided
for in Section 9.1 and subject to Section 9.2 hereof,
the Trustee may (but shall not be obligated to), without the
consent of the Holders, give any consent, waiver or approval
required by the terms hereof, but shall not without the consent
of the Holders of not less than a majority in aggregate
principal amount of the Notes at the time outstanding
(i) give any consent, waiver or approval or (ii) agree
to any amendment or modification of this Indenture, in each
case, that shall have a material adverse effect on the interests
of any Holder. The Trustee shall be entitled to request and
conclusively rely on an Opinion of Counsel with respect to
whether any consent, waiver, approval, amendment or modification
shall have a material adverse effect on the interests of any
Holder.
SECTION 7.3
Individual
Rights of Trustee
. The Trustee or any Agent in its
respective individual or any other capacity may become the owner
or pledgee of Notes and may otherwise deal with the Issuer, the
Guarantors, their Subsidiaries, or their respective Affiliates
with the same rights it would have if it were not the Trustee or
an Agent. However, in the event that the Trustee acquires any
conflicting interest it must eliminate such conflict within
90 days, apply to the SEC for permission to continue as
trustee or resign. Any Agent may do the same with like rights.
SECTION 7.4
Trustees
Disclaimer
. The Trustee and the Agents shall not be
responsible for and make no representation as to the validity,
effectiveness or adequacy of this Indenture, the offering
materials related to the Notes or the Notes; they shall not be
accountable for the Issuers use of the proceeds from the
Notes or any money paid to the Issuer or upon the Issuers
direction under any provision hereof; and they shall not be
responsible for any statement or recital herein of the Issuer or
the Guarantors or any document issued in connection with the
sale of Notes or any statement in the Notes other than the
Trustees certificate of authentication.
SECTION 7.5
Notice of
Default
. If an Event of Default occurs and is
continuing and a Trust Officer of the Trustee receives
actual notice of such event, the Trustee shall
-55-
mail to each Holder, as their names and addresses appear on the
list of Holders described in Section 2.5, notice of the
uncured Default or Event of Default within 90 days after
the Trustee receives such notice. Except in the case of a
Default in payment of principal of, premium, if any, or interest
on any Note, the Trustee may withhold the notice if and so long
as a committee of its Trust Officers determines that
withholding the notice is in the interest of the Holders.
SECTION 7.6
Reports by
Trustee to Holders of the Notes
. Within 60 days
after each May 15 beginning with May 15, 2012, and for so
long as Notes remain outstanding, the Trustee shall mail to the
Holders a brief report dated as of such reporting date that
complies with TIA § 313(a) (but if no event described
in TIA § 313(a) has occurred within the twelve months
preceding the reporting date, no report need be transmitted).
The Trustee also shall comply with TIA § 313(b). The
Trustee shall also transmit by mail all reports as required by
TIA § 313(c).
A copy of each report at the time of its mailing to the Holders
shall be mailed to the Issuer and filed with the SEC and each
stock exchange on which the Issuer has informed the Trustee in
writing the Notes are listed in accordance with TIA
§ 313(d). The Issuer shall promptly notify the Trustee
when the Notes are listed on any stock exchange and of any
delisting thereof.
SECTION 7.7
Compensation
and Indemnity
. The Issuer shall pay to the Trustee and
Agents from time to time such compensation as the Issuer and the
Trustee or Agent, as applicable, shall from time to time agree
in writing for its acceptance of this Indenture and services
hereunder. The Trustees and the Agents compensation
shall not be limited by any law on compensation of a trustee of
an express trust. The Issuer shall reimburse the Trustee and
Agents upon request for all reasonable and duly documented and
invoiced disbursements, expenses and advances (including
reasonable fees and expenses of counsel) incurred or made by it
in addition to the compensation for their services, except any
such disbursements, expenses and advances as may be attributable
to the Trustees or any Agents negligence, willful
misconduct or bad faith. Such expenses shall include the
reasonable compensation, disbursements and expenses of the
Trustees and Agents accountants, experts and counsel
and any taxes or other expenses incurred by a trust created
pursuant to Section 8.4 hereof.
The Issuer agrees to pay the fees and expenses of the
Trustees legal counsel in connection with its review,
preparation and delivery of this Indenture and related
documentation.
The Issuer shall indemnify each of the Trustee, any predecessor
Trustee and the Agents (which, for purposes of this paragraph,
include such Trustees and Agents officers,
directors, employees and agents) for, and hold them harmless
against, any and all loss, damage, claim, proceedings, demands,
costs, expense or liability including taxes (other than taxes
based on the income of the Trustee) incurred by the Trustee or
an Agent without negligence or willful misconduct on its part in
connection with acceptance of administration of this trust and
performance of any provisions under this Indenture, including
the reasonable expenses and attorneys fees and expenses of
defending itself against any claim of liability arising
hereunder. The Trustee and the Agents shall notify the Issuer
promptly of any claim asserted against the Trustee or such Agent
for which it may seek indemnity. However, the failure by the
Trustee or the Agent to so notify the Issuer shall not relieve
the Issuer of its obligations hereunder. Subject to Section
-56-
7.1(b), the Issuer need not reimburse or indemnify against any
loss liability or expense incurred by the Trustee through its
own willful misconduct or negligence. The Issuer shall defend
the claim and the Trustee or such Agent shall cooperate in the
defense (and may employ its own counsel reasonably satisfactory
to the Trustee) at the Issuers expense. The Trustee or
such Agent may have separate counsel and the Issuer shall pay
the reasonable fees and expenses of such counsel. The Issuer
need not pay for any settlement made without its written
consent, which consent shall not be unreasonably withheld.
To secure the Issuers payment obligations in this
Section 7.7, the Trustee and the Agents shall have a senior
Lien prior to the Notes against all money or property held or
collected by the Trustee and the Agents, in its capacity as
Trustee or Agent, except money or property held in trust to pay
principal or premium, if any, and Additional Amounts, if any, or
interest on particular Notes.
When the Trustee or an Agent incurs expenses or renders services
after the occurrence of an Event of Default specified in
clause (7) of Section 6.1, the expenses (including the
reasonable fees and expenses of its agents and counsel) and the
compensation for the services shall be preferred over the status
of the Holders in a proceeding under any Bankruptcy Law and are
intended to constitute expenses of administration under any
Bankruptcy Law. The Issuers obligations under this
Section 7.7 and any claim or Lien arising hereunder shall
survive the termination of this Indenture, the resignation or
removal of any Trustee or Agent, the discharge of the
Issuers obligations pursuant to Article VIII and any
rejection or termination under any Bankruptcy Law.
Save as otherwise expressly provided in this Indenture, the
Trustee shall have absolute and uncontrolled discretion as to
the exercise of the discretion vested in the Trustee by this
Indenture but, whenever the Trustee is bound to act under this
Indenture at the request or direction of the Holders of Notes,
the Trustee shall nevertheless not be so bound unless first
indemnified to its satisfaction against all proceedings, claims
and demands to which it may render itself liable and all costs,
charges, expenses and liabilities which it may incur by so doing.
Whether or not therein expressly so provided, every provision of
this Indenture that in any way relates to the Trustee, is
subject to this Section 7.7.
The Company shall be jointly and severally liable with the
Issuer for all of the Issuers obligations pursuant to this
Section 7.7.
SECTION 7.8
Replacement of
Trustee
. The Trustee and any Agent may resign at any
time by so notifying the Issuer in writing. The Holders of a
majority in principal amount of the outstanding Notes may remove
the Trustee by so notifying the Issuer and the Trustee in
writing and may appoint a successor trustee with the
Issuers consent. A resignation or removal of the Trustee
or any Agent and appointment of a successor Trustee or Agent, as
the case may be, shall become effective only upon the acceptance
by the successor Trustee or the successor Agent, as the case may
be, of appointment as provided in this section. The Issuer may
remove the Trustee if:
-57-
(1) the Trustee is adjudged a
bankrupt or an insolvent or an order for relief is entered with
respect to the Trustee under any Bankruptcy Law;
(2) a receiver or other public
officer takes charge of the Trustee or its property; or
(3) the Trustee becomes incapable
of acting with respect to its duties hereunder.
If the Trustee resigns or is removed or if a vacancy exists in
the office of Trustee for any reason, the Issuer shall notify
each Holder of such event and shall promptly appoint a successor
Trustee. Within one year after the successor Trustee takes
office, the Holders of a majority in principal amount of the
then outstanding Notes may, with the Issuers consent,
appoint a successor Trustee to replace the successor Trustee
appointed by the Issuer. If the Issuer does not reasonably
promptly appoint a successor Trustee, the Holders of a majority
in principal amount of the then outstanding Notes may appoint a
successor Trustee.
A successor Trustee or successor Agent, as applicable, shall
deliver a written acceptance of its appointment to the retiring
Trustee or Agent, as applicable, and to the Issuer. Thereupon,
the resignation or removal of the retiring Trustee or Agent, as
applicable, shall become effective, and the successor Trustee or
Agent, as applicable, shall have all the rights, powers and
duties of the Trustee or Agent, as applicable, under this
Indenture. Promptly after that, the retiring Trustee or Agent,
as applicable, shall transfer, after payment of all sums then
owing to the Trustee or Agent, as applicable, pursuant to
Section 7.7, all property held by it as Trustee or Agent,
as applicable, to the successor Trustee or Agent, as applicable,
subject to the Lien provided in Section 7.7. A successor
Trustee or Agent, as applicable, shall mail notice of its
succession to each Holder.
If a successor Trustee does not take office within 60 days
after the retiring Trustee resigns or is removed, the retiring
Trustee, the Issuer or the Holders of at least 10% in principal
amount of the then outstanding Notes may petition any court of
competent jurisdiction for the appointment of a successor
Trustee.
Notwithstanding replacement of the Trustee pursuant to this
Section 7.8, the Issuers obligations under
Section 7.7 shall continue for the benefit of the retiring
Trustee and the Issuer shall pay to any replaced or removed
Trustee all amounts owed under Section 7.7 upon such
replacement or removal.
SECTION 7.9
Successor
Trustee by Merger, Etc
. If the Trustee consolidates
with, merges or converts into, or transfers all or substantially
all of its corporate trust business to, another corporation or
banking association, the resulting, surviving or transferee
corporation without any further act shall, if such resulting,
surviving or transferee corporation is otherwise eligible
hereunder, be the successor Trustee. In case any Notes shall
have been authenticated, but not delivered, by the Trustee then
in office, any successor by consolidation, merger or conversion
to such authenticating Trustee may adopt such authentication and
deliver the Notes so authenticated with the same effect as if
such successor Trustee had itself authenticated such Notes.
-58-
SECTION 7.10
Eligibility;
Disqualification
. There shall at all times be a Trustee
hereunder that is a corporation organized and doing business
under the laws of the United States of America or of any state
thereof that is authorized under such laws to exercise corporate
trustee power and that is subject to supervision or examination
by federal or state authorities. The Trustee together with its
affiliates shall at all times have a combined capital surplus of
at least $50.0 million as set forth in its most recent
annual report of condition.
This Indenture shall always have a Trustee who satisfies the
requirements of TIA §§ 310(a)(l), (2) and
(5). The Trustee is subject to TIA § 310(b) including
the provision in § 310(b)(1);
provided
that
there shall be excluded from the operation of TIA
§ 310(b)(1) any indenture or indentures under which
other securities, or conflicts of interest or participation in
other securities, of the Issuer or the Guarantors are
outstanding if the requirements for exclusion set forth in TIA
§ 310(b)(1) are met.
SECTION 7.11
Preferential
Collection of Claims Against the Company
. The Trustee
is subject to TIA § 311(a), excluding any creditor
relationship listed in TIA § 311(b). A Trustee who has
resigned or been removed shall be subject to TIA
§ 311(a) to the extent indicated therein.
ARTICLE VIII
SATISFACTION
AND DISCHARGE OF INDENTURE
SECTION 8.1
Option To
Effect Legal Defeasance or Covenant Defeasance
. The
Issuer may, at the option of its Board of Directors evidenced by
a Board Resolution, at any time, with respect to the Notes,
elect to have either Section 8.2 or 8.3 be applied to all
outstanding Notes upon compliance with the conditions set forth
below in this Article VIII.
SECTION 8.2
Legal
Defeasance and Discharge
. Upon the Issuers
exercise under Section 8.1 of the option applicable to this
Section 8.2, the Issuer shall be deemed to have been
discharged from its obligations with respect to all outstanding
Notes on the date the conditions set forth below are satisfied
(hereinafter, Legal Defeasance). For this purpose,
such Legal Defeasance means that the Issuer shall be deemed to
have paid and discharged all the obligations relating to the
outstanding Notes and the Notes shall thereafter be deemed to be
outstanding only for the purposes of
Section 8.6, Section 8.8 and the other Sections of
this Indenture referred to below in this Section 8.2, and
to have satisfied all of their other obligations under such
Notes and this Indenture and cured all then existing Events of
Default (and the Trustee, on demand of and at the expense of the
Issuer, shall execute proper instruments acknowledging the
same), except for the following which shall survive until
otherwise terminated or discharged hereunder: (a) the
rights of Holders of outstanding Notes to receive payments in
respect of the principal of, premium, if any, interest and
Additional Amounts, if any, on such Notes when such payments are
due or on the Redemption Date solely out of the Defeasance
Trust created pursuant to this Indenture; (b) the
Issuers obligations with respect to Notes concerning
issuing temporary Notes, or, where relevant, registration of
such Notes, mutilated, destroyed, lost or stolen Notes and the
maintenance of an office or agency for payment and money for
security payments held in trust; (c) the rights, powers,
trusts, duties and immunities of the Trustee, and the
Issuers or Gua-
-59-
rantors obligations in connection therewith; and
(d) this Article VIII and the obligations set forth in
Section 8.6 hereof.
Subject to compliance with this Article VIII, the Issuer
may exercise its option under Section 8.2 notwithstanding
the prior exercise of its option under Section 8.3 with
respect to the Notes.
SECTION 8.3
Covenant
Defeasance
. Upon the Issuers exercise under
Section 8.1 of the option applicable to this
Section 8.3, the Issuer, the Company and the other
Guarantors shall be released from any obligations under the
covenants contained in Article IV, Section 5.1(4),
Sections 6.1(3), (4) and (5), and Section 6.1 (7)
(with respect to the Company and the Subsidiaries other than the
Issuer), hereof with respect to the outstanding Notes on and
after the date the conditions set forth below are satisfied
(hereinafter, Covenant Defeasance), and the Notes
shall thereafter be deemed not outstanding for the
purposes of any direction, waiver, consent or declaration or act
of Holders (and the consequences of any thereof) in connection
with such covenants, but shall continue to be deemed
outstanding for all other purposes hereunder (it
being understood that such Notes shall not be deemed outstanding
for accounting purposes). For this purpose, such Covenant
Defeasance means that, (i) with respect to the outstanding
Notes, the Issuer may omit to comply with and shall have no
liability in respect of any term, condition or limitation set
forth in any such covenant, whether directly or indirectly, by
reason of any reference elsewhere herein to any such covenant or
by reason of any reference in any such covenant to any other
provision herein or in any other document and (ii) payment
on the Notes may not be accelerated because of an Event of
Default specified in Sections 6.1 (3), (4) or (5), or
Section 6.1 (7) (with respect only to the Company and the
Subsidiaries other than the Issuer).
SECTION 8.4
Conditions to
Legal or Covenant Defeasance
. In order to exercise
either of the defeasance options under Section 8.2 or
Section 8.3 hereof, the Issuer must comply with the
following conditions:
(1) the Issuer shall have
irrevocably deposited in trust (the Defeasance
Trust) with the Trustee or the Paying Agent for the
benefit of the Holders Designated Government Obligations, for
the payment of principal, premium, if any, interest on the Notes
to redemption or maturity, as the case may be;
(2) the Issuer shall have delivered
to the Trustee an Opinion of Counsel (subject to customary
exceptions and exclusions) to the effect that Holders of the
Notes will not recognize income, gain or loss for
U.S. federal income tax purposes as a result of such
deposit and defeasance and will be subject to U.S. federal
income tax on the same amount and in the same manner and at the
same times as would have been the case if such deposit and
defeasance had not occurred. In the case of legal defeasance
only, such Opinion of Counsel must be based on a ruling of the
Internal Revenue Service or other change in applicable
U.S. federal income tax law;
(3) the Issuer shall have delivered
to the Trustee an Opinion of Counsel in the Federal Republic of
Germany (subject to customary exceptions and exclusions) to the
effect that Holders of the Notes will not recognize income, gain
or loss for income tax purposes of the Federal Republic of
Germany as a result of such deposit and defeasance and
-60-
will be subject to income tax in the Federal Republic of Germany
on the same amount and in the same manner and at the same times
as would have been the case if such deposit and defeasance had
not occurred;
(4) the Issuer shall have delivered
to the Trustee an Opinion of Counsel in Luxembourg (subject to
customary exceptions and exclusions) to the effect that Holders
of the Notes will not recognize income, gain or loss for income
tax purposes of Luxembourg as a result of such deposit and
defeasance and will be subject to income tax in Luxembourg on
the same amount and in the same manner and at the same times as
would have been the case if such deposit and defeasance had not
occurred;
(5) no Default or Event of Default
(other than to Incur Indebtedness used to defease the Notes
under this Article) shall have occurred and be continuing on the
date of such deposit in the Defeasance Trust or insofar as
Events of Default from bankruptcy or insolvency events are
concerned, at any time in the period ending on the 91st day
after the date of deposit;
(6) such legal defeasance or
covenant defeasance shall not result in a breach or violation of
any other material agreement or instrument (other than this
Indenture) to which the Company or any of its Subsidiaries is a
party or by which the Company or any of its Subsidiaries is
bound;
(7) the Issuer shall have delivered
to the Trustee an Officers Certificate stating that the
deposit was not made by the Issuer with the intent of preferring
the Holders over any other creditors of the Issuer or with the
intent of defeating, hindering, delaying or defrauding any other
creditors of the Issuer or others; and
(8) the Issuer shall have delivered
to the Trustee an Officers Certificate and an Opinion of
Counsel, each stating that all conditions precedent provided for
or relating to the legal defeasance or the covenant defeasance
have been complied with.
SECTION 8.5
Satisfaction
and Discharge of Indenture
. This Indenture will be
discharged and will cease to be of further effect as to all
Notes issued thereunder when either (i) all such Notes
theretofore authenticated and delivered (except lost, stolen or
destroyed Notes which have been replaced or paid and Notes for
whose payment money has theretofore been deposited in trust and
thereafter repaid to the Issuer) have been delivered to the
Paying Agent or Trustee for cancellation or (ii) (A) all
such Notes not theretofore delivered to the Paying Agent or
Trustee for cancellation have become due and payable by reason
of the making of a notice of redemption or otherwise or will
become due and payable within one year and the Issuer has
irrevocably deposited or caused to be deposited with the Paying
Agent or Trustee as trust funds in trust an amount of money
sufficient to pay and discharge the entire indebtedness on such
Notes not theretofore delivered to the Paying Agent or Trustee
for cancellation for principal, premium, if any, and accrued and
unpaid interest and Additional Amounts, if any, to the date of
maturity or redemption, (B) no Default (other than to Incur
Indebtedness used to defease the Notes under this Article) with
respect to this Indenture or the Notes shall have occurred and
be continuing on the date of such deposit or shall occur as a
result of such deposit and such deposit will not result in a
breach or violation of, or constitute a default under, any other
instrument to which the Issuer, the
-61-
Company or any of the other Guarantors is a party or by which it
is bound, (C) the Issuer has paid, or caused to be paid,
all sums payable by it under this Indenture, and (D) the
Issuer has delivered irrevocable instructions to the Trustee
under this Indenture to give the notice of redemption and apply
the deposited money toward the payment of such Notes at maturity
or the Redemption Date, as the case may be. In addition,
the Issuer must deliver an Officers Certificate and an
Opinion of Counsel to the Trustee stating that all conditions
precedent to satisfaction and discharge have been satisfied.
Upon such discharge, the Paying Agent shall deliver the Notes to
the Issuer, marked paid, or at the option of the
Paying Agent, destroy the Notes and provide a certificate to the
Issuer and the Trustee certifying such destruction.
SECTION 8.6
Survival of
Certain Obligations
. Notwithstanding the satisfaction
and discharge of this Indenture and of the Notes in the manner
referred to in Section 8.1, 8.2, 8.3, 8.4 or 8.5, the
respective obligations of the Issuer, the Company, the other
Guarantors and the Trustee under Sections 2.2, 2.3, 2.4,
2.5, 2.6, 2.7, 2.9, 2.10, 2.11, 2.12, 2.13, 2.14, 4.1 (with
respect to the Trustee and, as far as the Issuer, the Company,
and each of the other Guarantors is concerned, subject to
Sections 8.2 and 8.5), 4.2, 4.6, 4.13 and 6.10,
Article VII and Article VIII shall survive until the
Notes are no longer outstanding, and thereafter the obligations
of the Issuer, the Company, the other Guarantors and the Trustee
under Articles VII and VIII shall survive. Nothing
contained in this Article VIII shall abrogate any of the
obligations or duties of the Trustee under this Indenture.
SECTION 8.7
Acknowledgment
of Discharge by Trustee
. Subject to Section 8.10,
after (i) the conditions of Section 8.4 or 8.5 have
been satisfied, (ii) the Issuer has paid or caused to be
paid all other sums payable hereunder by the Issuer and
(iii) the Issuer has delivered to the Trustee an
Officers Certificate and an Opinion of Counsel, each
stating that all conditions precedent referred to in
clause (i) above relating to the satisfaction and discharge
of this Indenture have been complied with, the Trustee upon
written request shall acknowledge in writing the discharge of
all of the Issuers, the Companys, and the other
Guarantors obligations under this Indenture except for
those surviving obligations specified in this Article VIII.
SECTION 8.8
Application of
Trust Moneys
. All cash deposited with the Trustee
pursuant to Section 8.4 or 8.5 in respect of Notes shall be
held in trust and applied by it, in accordance with the
provisions of such Notes and this Indenture, to the payment,
either directly or through any Paying Agent as the Trustee may
determine, to the Holders of the Notes of all sums due and to
become due thereon for principal, premium, if any, interest and
Additional Amounts, if any, but such money need not be
segregated from other funds except to the extent required by law.
The Issuer shall pay and indemnify the Trustee against any tax,
fee or other charge imposed on or assessed against the cash
deposited pursuant to Section 8.4 or 8.5 or the principal
and interest received in respect thereof other than any such
tax, fee or other charge which by law is for the account of the
Holders of outstanding Notes.
SECTION 8.9
Repayment to
the Issuer; Unclaimed Money
. The Trustee and any Paying
Agent shall promptly pay or return to the Issuer upon Issuer
Order any cash held by them at any time that are not required
for the payment of the principal of, premium, if any, inter-
-62-
est and Additional Amounts, if any, on the Notes for which cash
has been deposited pursuant to Section 8.4 or 8.5.
Any money held by the Trustee or any Paying Agent under this
Article VIII, in trust for the payment of the principal of,
premium, if any, interest and Additional Amounts, if any, on any
Note and remaining unclaimed for two years after such principal,
premium, if any, interest and Additional Amounts, if any, that
has become due and payable shall be paid to the Issuer upon
Issuer Order or if then held by the Issuer shall be discharged
from such trust; and the Holder of such Note shall thereafter,
as an unsecured general creditor, look only to the Issuer for
payment thereof, and all liability of the Trustee or such Paying
Agent with respect to such trust money, shall thereupon cease;
provided
,
however
, that the Trustee or such Paying
Agent, before being required to make any such repayment, may at
the expense of the Issuer give notice to the Holders or cause to
be published notice once, in a newspaper having general
circulation in Luxembourg (which is expected to be the
Luxemburger Wort
), if and so long as the Notes are listed
on the Euro MTF Market of the Luxembourg Stock Exchange and the
rules of such stock exchange shall so require, or, to the extent
and in the manner permitted by such rules, posted on the
official website of the Luxembourg Stock Exchange
(www.bourse.lu), or in the case of Definitive Notes, in addition
to such publication, mail to Holders by first-class mail,
postage prepaid, at their respective addresses as they appear on
the registration books of the Registrar (and, if and so long as
the Notes are listed on the Euro MTF Market of the Luxembourg
Stock Exchange and the rules of such Stock Exchange shall so
require, publish in a newspaper having a general circulation in
Luxembourg (which is expected to be the
Luxemburger Wort
)
or, to the extent and in the manner permitted by such rules,
posted on the official website of the Luxembourg Stock Exchange
(www.bourse.lu), that such money remains unclaimed and that,
after a date specified therein, which shall not be less than
30 days from the date of such notification, any unclaimed
balance of such money then remaining will be repaid to the
Issuer).
Claims against the Issuer for the payment of principal or
interest and Additional Amounts, if any, on the Notes will
become void unless presentment for payment is made (where so
required in this Indenture) within, in the case of principal and
Additional Amounts, if any, a period of ten years, or, in the
case of interest, a period of five years, in each case from the
applicable original payment date therefor.
SECTION 8.10
Reinstatement
. If
the Trustee or Paying Agent is unable to apply any cash in
accordance with Section 8.2, 8.3, 8.4 or 8.5 by reason of
any legal proceeding or by reason of any order or judgment of
any court or governmental authority enjoining, restraining or
otherwise prohibiting such application, the Issuers and
the Guarantors obligations under this Indenture and the
Notes shall be revived and reinstated as though no deposit had
occurred pursuant to Section 8.2, 8.3, 8.4 or 8.5 until
such time as the Trustee or Paying Agent is permitted to apply
all such cash in accordance with Section 8.2, 8.3, 8.4 or
8.5;
provided
,
however
, that if the Issuer has
made any payment of interest on, premium, if any, principal and
Additional Amounts, if any, of any Notes because of the
reinstatement of its obligations, the Issuer shall be subrogated
to the rights of the Holders of such Notes to receive such
payment from the money held by the Trustee or Paying Agent.
-63-
ARTICLE IX
AMENDMENTS,
SUPPLEMENTS AND WAIVERS
SECTION 9.1
Without Consent
of Holders of Notes
. Notwithstanding Section 9.2
hereof, the Issuer and the Trustee together may amend or
supplement this Indenture or the Notes without the consent of
any Holder of a Note to:
(1) cure any ambiguity, omission,
defect or inconsistency;
(2) provide for the assumption by a
successor entity of the obligations of the Issuer under and
pursuant to this Indenture or of a Guarantor (other than the
Company) under the Note Guarantees;
(3) provide for uncertificated
Notes in addition to or in place of certificated Notes
(
provided
that the uncertificated Notes are issued in
registered form for purposes of Section 163(f) of the Code,
or in a manner such that the uncertificated Notes are described
in Section 163(f)(B) of the Code);
(4) add Note Guarantees with
respect to the Notes;
(5) secure the Notes;
(6) add to the covenants of the
Issuer and the Guarantors for the benefit of the Holders or to
surrender any right or power conferred upon the Issuer;
(7) evidence and provide for the
acceptance and appointment under this Indenture of any successor
trustee;
(8) comply with the rules of any
applicable securities depositary;
(9) issue Additional Notes in
accordance with this Indenture; or
(10) make any change that does not
adversely affect the rights of any Holder of Notes under this
Indenture.
SECTION 9.2
With Consent of
Holders of Notes
. The Issuer and the Trustee may amend
or supplement this Indenture, the Notes or any amended or
supplemental indenture with the written consent of the Holders
of at least a majority in principal amount of the Notes then
outstanding (including without limitation consents obtained in
connection with a purchase of, or tender offer or exchange offer
for the Notes), and, subject to Sections 6.7 and 6.10, any
existing Default or Event of Default and its consequences or
compliance with any provision of this Indenture or the Notes may
be waived with the consent of the Holders of at least a majority
in principal amount of the Notes then outstanding (including
without limitation consents obtained in connection with a
purchase of, or tender offer or exchange offer for the Notes).
However, without the consent of each Holder of an outstanding
Note adversely affected, an amendment or waiver may not (with
respect to any Notes held by a non-consenting Holder of Notes):
-64-
(1) reduce the percentage of
principal amount of Notes whose Holders must consent to an
amendment;
(2) reduce the stated rate of or
extend the stated time for payment of interest on any such Note;
(3) reduce the principal of or
extend the Stated Maturity of any such Note;
(4) reduce the premium payable upon
the redemption of any such Note or change the time at which any
such Note may be redeemed as described under Section 3.1;
(5) reduce the premium payable upon
the repurchase of any Note, change the time at which any Note
may be repurchased, or change any of the associated definitions
related to the provisions of Section 4.11 once the
obligation to repurchase the Notes has arisen;
(6) make any such Note payable in
money other than that stated in such Note;
(7) impair the right of any Holder
to receive payment of premium, if any, principal of and interest
on such Holders Notes on or after the due dates therefor
or to institute suit for the enforcement of any payment on or
with respect to such Holders Notes;
(8) make any change in the
amendment provisions which require each Holders consent or
in the waiver provisions; or
(9) release the Company from its
Note Guarantee (other than in accordance with the terms of this
Indenture).
It shall not be necessary for the consent of the Holders of
Notes under this Section 9.2 to approve the particular form
of any proposed amendment or waiver, but it shall be sufficient
if such consent approves the substance thereof.
SECTION 9.3
Notice of
Amendment, Supplement or Waiver
. After an amendment,
supplement or waiver under Section 9.1 or 9.2 hereto
becomes effective, the Issuer shall mail to the Holders of Notes
a notice briefly describing the amendment, supplement or waiver.
Any failure of the Issuer to mail such notice, or any defect
therein, shall not, however, in any way impair or affect the
validity of any such amended or supplemental indenture or waiver.
SECTION 9.4
Revocation and
Effect of Consents
. Until an amendment, supplement or
waiver becomes effective, a consent to it by a Holder of a Note
is a continuing consent by the Holder of a Note and every
subsequent Holder of a Note or portion of a Note that evidences
the same debt as the consenting Holders Note, even if
notation of the consent is not made on any Note. However, any
such Holder of a Note or subsequent Holder of a Note may revoke
the consent as to its Note if the Trustee receives written
notice of revocation before the date the waiver, supplement or
amendment becomes effective. An amendment, supplement or waiver
becomes effective in accordance with its terms and thereafter
binds every Holder of a
-65-
Note. An amendment or waiver becomes effective once the
requisite number of consents is received by the Issuer or the
Trustee.
The Issuer may, but shall not be obligated to, fix a record date
for determining which Holders of the Notes must consent to such
amendment, supplement or waiver. If the Issuer fixes a record
date, the record date shall be fixed at (i) the later of
30 days prior to the first solicitation of such consent or
the date of the most recent list of Holders of Notes furnished
to the Trustee prior to such solicitation pursuant to
Section 2.5 or (ii) such other date as the Issuer
shall designate.
SECTION 9.5
Notation on or
Exchange of Notes
. The Trustee may place an appropriate
notation about an amendment, supplement or waiver on any Note
thereafter authenticated. The Issuer in exchange for all Notes
may issue and the Trustee shall authenticate new Notes that
reflect the amendment, supplement or waiver.
Failure to make the appropriate notation or issue a new Note
shall not affect the validity and effect of such amendment,
supplement or waiver.
SECTION 9.6
Trustee To Sign
Amendments, Etc
. The Trustee shall execute any
amendment, supplement or waiver authorized pursuant to this
Article IX;
provided
,
however
, that the
Trustee may, but shall not be obligated to, execute any such
amendment, supplement or waiver which adversely affects the
Trustees own rights, duties or immunities under this
Indenture. The Trustee shall be entitled to receive indemnity
reasonably satisfactory to it, and shall be fully protected in
relying upon, if delivered, an Opinion of Counsel and an
Officers Certificate each stating that the execution of
any such amendment, supplement or waiver is authorized or
permitted by this Indenture and constitutes the legal, valid and
binding obligations of the Issuer and the Guarantors enforceable
in accordance with its terms. Any Opinion of Counsel shall not
be an expense of the Trustee. With respect to any amendment,
supplement or waiver under Section 9.2, the Trustee shall
also be entitled to receive evidence satisfactory to it of the
consent of the Holders.
ARTICLE X
NOTE GUARANTEE
SECTION 10.1
Note
Guarantee
.
(a) Each Guarantor hereby jointly
and severally unconditionally Guarantees, on a senior unsecured
basis, to each Holder of a Note authenticated and delivered by
the Trustee, and to the Trustee on behalf of such Holder, the
due and punctual payment of the principal of (and premium, if
any) and interest (including Additional Amounts, if any) on such
Note when and as the same shall become due and payable, whether
at the Stated Maturity, by acceleration, call for redemption,
purchase or otherwise, in accordance with the terms of such Note
and of this Indenture. In case of the failure of the Issuer
punctually to make any such payment, each Guarantor hereby
jointly and severally agrees to cause such payment to be made
punctually when and as the same shall become due and payable,
whether at the Stated Maturity or by acceleration, call for
redemption, purchase or otherwise, and as if such payment were
made by the Issuer. The
-66-
Note Guarantee extends to the Issuers repurchase
obligations arising from a Change of Control pursuant to
Section 4.11.
Each Guarantor hereby jointly and severally agrees that its
obligations hereunder shall be unconditional, irrespective of
the validity, regularity or enforceability of such Note or this
Indenture, the absence of any action to enforce the same, any
exchange, release or non-perfection of any Lien on any
collateral for, or any release or amendment or waiver of any
term of any other Guarantee of, or any consent to departure from
any requirement of any other Guarantee of all or any of the
Notes, the effects of Bankruptcy Law applicable in the event of
bankruptcy proceedings being opened with respect to the Issuer,
of all or any portion of the claims of the Trustee or any of the
Holders for payment of any of the Notes, any waiver or consent
by the Holder of such Note or by the Trustee with respect to any
provisions thereof or of this Indenture, the obtaining of any
judgment against the Issuer or any action to enforce the same or
any other circumstances which might otherwise constitute a legal
or equitable discharge or defense of a guarantor. Each Guarantor
hereby waives the benefits of diligence, presentment, demand for
payment, any requirement that the Trustee or any of the Holders
protect, secure, perfect or insure any security interest in or
other Lien on any property subject thereto or exhaust any right
or take any action against the Issuer or any other Person or any
collateral, filing of claims with a court in the event of
insolvency or bankruptcy of the Issuer, any right to require a
proceeding first against the Issuer, protest or notice with
respect to such Note or the Indebtedness evidenced thereby and
all demands whatsoever, and covenants that this Note Guarantee
will not be discharged in respect of such Note except by
complete performance of the obligations contained in such Note
and in this Note Guarantee. Each Guarantor hereby agrees that,
in the event of a default in payment of principal (or premium,
if any) or interest (including Additional Amounts, if any) on
such Note, whether at its Stated Maturity, by acceleration, call
for redemption, purchase or otherwise, legal proceedings may be
instituted by the Trustee on behalf of, or by, the Holder of
such Note, subject to the terms and conditions set forth in this
Indenture, directly against each Guarantor to enforce the Note
Guarantee without first proceeding against the Issuer. Each
Guarantor agrees that, to the extent permitted by applicable
law, if, after the occurrence and during the continuance of an
Event of Default, the Trustee or any of the Holders is prevented
by applicable law from exercising its respective rights to
accelerate the maturity of the Notes, to collect interest on the
Notes, or to enforce or exercise any other right or remedy with
respect to the Notes, or the Trustee or the Holders are
prevented from taking any action to realize on any collateral,
such Guarantor agrees to pay to the Trustee for the account of
the Holders, upon demand therefor, the amount that would
otherwise have been due and payable had such rights and remedies
been permitted to be exercised by the Trustee or any of the
Holders.
No provision of the Note Guarantee or of this Indenture shall
alter or impair the Note Guarantee of any Guarantor, which is
absolute and unconditional, of the due and punctual payment of
the principal of (and premium, if any) and interest (including
Additional Amounts, if any) on the Note upon which such Note
Guarantee is endorsed.
Each Note Guarantee shall remain in full force and effect and
continue to be effective should any petition be filed by or
against the Issuer for liquidation or reorganization or
equivalent proceeding under applicable law, should the Issuer
become insolvent or make an assignment for the benefit of
creditors or should a receiver or trustee be appointed for all
or any significant part of the Issuers assets, or the
equivalent of any of the foregoing under applicable
-67-
law, and shall, to the fullest extent permitted by applicable
law, continue to be effective or be reinstated, as the case may
be, if at any time payment and performance of the Notes, is,
pursuant to applicable law, rescinded or reduced in amount, or
must otherwise be restored or returned by any obligee on the
Notes, whether as a voidable preference, fraudulent transfer, or
as otherwise provided under similar laws affecting the rights of
creditors generally or under applicable laws of the jurisdiction
of formation of the Issuer, all as though such payment or
performance had not been made. In the event that any payment, or
any part thereof, is rescinded, reduced, restored or returned,
the Notes shall, to the fullest extent permitted by law, be
reinstated and deemed reduced only by such amount paid and not
so rescinded, reduced, restored or returned.
The Guarantors shall have the right to seek contribution from
any non-paying Guarantor so long as the exercise of such right
does not impair the rights of the Holders under the Note
Guarantee.
(b) Each Note Guarantee (other than
the Companys Note Guarantee) will be limited in amount to
an amount not to exceed the maximum amount that can be
guaranteed by the applicable Guarantor without rendering the
Note Guarantee, as it relates to such Guarantor, voidable under
applicable law relating to fraudulent conveyance or fraudulent
transfer or similar laws affecting the rights of creditors
generally or under applicable law of the jurisdiction of
incorporation of such Guarantor.
(c) In the case of Fresenius
Medical Care Deutschland GmbH (FMCD), the following
provisions apply:
Without limiting the agreements set forth in Section 11.8,
the Note Guarantee of FMCD will be limited if and to the extent
payment under such Note Guarantee or the application of
enforcement proceeds would cause (i) FMCDs net assets
(
Reinvermögen
- calculated as the sum of the balance
sheet positions shown under § 266(2)(A), (B) and
(C) German Commercial Code (
Handelsgesetzbuch
)) less
the sum of the liabilities (shown under the balance sheet
positions pursuant to § 266(3)(B), (C) and
(D) German Commercial Code) to fall below FMCDs
registered share capital (
Stammkapital
) or (ii) (if the
amount of the net assets is already an amount less than the
registered share capital) cause such amount to be further
reduced and, in either case, thereby affecting the assets
required for the obligatory preservation of its registered share
capital according to section 30, 31 of the German Limited
Liability Company Act (GmbHG) (such event a Capital
Impairment). For the purposes of calculating the Capital
Impairment, the following adjustments will be made: (i) the
amount of any increase of the registered share capital out of
retained earnings (
Kapitalerhöhung aus
Gesellschaftsmitteln
) after the Closing Date that has been
effected without the prior consent of the Trustee shall be
deducted from the registered share capital; and
(ii) liabilities incurred in violation of the provisions of
the Notes and this Indenture shall be disregarded. In the event
FMCDs net assets fall below its registered share capital,
FMCD, upon request of the Trustee will realize in due course, to
the extent legally permitted, any and all of its assets that are
shown in the balance sheet with a book value (
Buchwert
)
that is significantly lower than the market value of the assets
if the relevant assets are not necessary for FMCDs
business (
nicht betriebsnotwendiges Vermögen
).
-68-
If FMCD objects to the amount demanded by the Trustee under the
Note Guarantee within twenty (20) business days after the
Trustee has submitted to FMCD a payment demand FMCD shall
appoint within five (5) business days a reputable
international auditor to determine the exact amount. The auditor
shall notify FMCD and the Trustee of the maximum amount payable
under the Note Guarantee within forty (40) business days
after its appointment. The costs of such auditors
determination shall be borne by FMCD. The determination of the
auditor shall be binding for FMCD, and the Holders (except for
manifest error). To the extent that any payment has been made
under the Note Guarantee by FMCD that would be necessary for
FMCD to be able to cure any Capital Impairment or Liquidity
Impairment such payment shall immediately upon
FMCDs demand be returned to FMCD by any person
receiving such payment, provided, however, in no event shall the
Trustee or Paying Agent have any responsibility or liability for
the return of any amount distributed to any Holder or beneficial
owner of the Notes by the Trustee or Paying Agent, including,
without limitation, any obligation to seek return of such
amounts from such Holder or beneficial owner.
If (i) FMCD does not object to the payment amount within
the 20 business days period or (ii) if FMCD does not
appoint the auditor within the 5 business days period or
(iii) if the auditor fails to notify the amount payable
within the 40 days period, then the Trustee shall be
entitled to enforce the Note Guarantee without further delay.
The burden of demonstration and proof (
Darlegungs- und
Beweislast
) regarding the Capital Impairment and the maximum
amount payable under the Note Guarantee shall remain with FMCD.
The maximum amount payable under the guarantee shall be limited
to the extent and as long as FMCD as a consequence of the
payment would become unable to pay its debts when due
(
zahlungsunfähig
) within the meaning of
section 64 GmbHG (such event a Liquidity
Impairment). For the purpose of establishing whether a
Liquidity Impairment would occur, payments made by FMCD after
the Trustee has notified FMCD of its intention to enforce the
Note Guarantee with respect to payment obligations that are not
due at the time of the payment shall be disregarded, unless the
Trustee has consented to such payments (at the direction of the
Holders of at least a majority in principal amount of the Notes
then outstanding). From the time the Trustee has notified FMCD
and the Company of its intention to enforce the Note Guarantee,
the Company may not make any payment demands against FMCD under
shareholder loans and all such payment obligations of FMCD
towards the Company shall be deferred, subordinated or waived as
the Company sees fit, until the Trustee notifies FMCD that it is
no longer enforcing the Note Guarantee or the Trustee consents
(at the direction of the Holders of at least a majority in
principal amount of the Notes then outstanding) to the payments
to be made to the Company. Such notice may be delivered by the
Trustee at any time and, if not previously delivered, will be
delivered by the Trustee after the Notes have been repaid in
full and all other obligations under this Indenture are
satisfied.
The limitations in this Section 10.1(c) as to the Capital
Impairment shall not apply to the extent FMCD has an adequate
compensation claim (
vollwertiger Gegenleistungs- oder
Rückgewähranspruch
) against the Company that
compensates for any loss incurred due to any payment by FMCD
under the Note Guarantee.
-69-
SECTION 10.2
Execution and
Delivery of Note Guarantees
. The Note Guarantees to be
endorsed on the Notes shall be in the form attached hereto as
Exhibit C
. Each Guarantor hereby agrees to execute
its Note Guarantee, in the form attached hereto as
Exhibit C
, to be endorsed on each Note authenticated
and delivered by the Trustee.
The Note Guarantee shall be executed on behalf of the Company by
two members of the Management Board of its General Partner and
on behalf of any other Guarantor by such Person or Persons duly
authorized by the Board of Directors or Management Board of such
Guarantor. The signature of any or all of these Persons on the
Note Guarantee may be manual or facsimile.
A Note Guarantee bearing the manual or facsimile signature of
individuals who were at any time the Responsible Officers of a
Guarantor shall bind such Guarantor, notwithstanding that such
individuals or any of them have ceased to hold such offices
prior to the authentication and delivery of the Note on which
such Note Guarantee is endorsed or did not hold such offices at
the date of such Note Guarantee.
The delivery of any Note by the Trustee, after the
authentication thereof in accordance with this Indenture, shall
constitute due delivery of the Note Guarantee endorsed thereon
on behalf of the Guarantors. Each of the Guarantors hereby
jointly and severally agrees that its Note Guarantee set forth
in Section 10.1 shall remain in full force and effect
notwithstanding any failure to endorse a Note Guarantee on any
Note.
SECTION 10.3
Guarantors May
Consolidate, Etc., On Certain Terms
. Except as set
forth in Section 10.4 and in Article V hereof, nothing
contained in this Indenture or in any of the Notes shall prevent
any consolidation or merger of a Guarantor with or into the
Company, the Issuer or another Guarantor or shall prevent any
sale, transfer, assignment, lease, conveyance or other
disposition of the property of a Guarantor as an entirety or
substantially as an entirety to the Company, the Issuer or
another Guarantor.
SECTION 10.4
Release of
Guarantors
. Subject to the limitations set forth in
Sections 5.1 and 5.2 hereof, (a) concurrently with any
consolidation or merger of a Guarantor or any sale, transfer,
assignment, lease, conveyance or other disposition of the
property of a Guarantor as an entirety or substantially as an
entirety, in each case as permitted by Sections 5.1, 5.2
and 10.3 hereof, and upon delivery by the Company or the Issuer
to the Trustee of an Officers Certificate and an Opinion
of Counsel to the effect that such consolidation, merger, sale,
transfer, assignment, conveyance or other disposition was made
in accordance with Sections 5.1, 5.2 and 10.3 hereof, the
Trustee shall execute any documents reasonably required in order
to acknowledge the release of such Guarantor from its
obligations under its Note Guarantee endorsed on the Notes and
under this Indenture. Any Guarantor not released from its
obligations under its Note Guarantee endorsed on the Notes and
under this Indenture shall remain liable for the full amount of
principal of (premium, if any) and interest (including
Additional Amounts, if any) on the Notes and for the other
obligations of a Guarantor under its Note Guarantee endorsed on
the Notes and under this Indenture. Concurrently with the
defeasance of the Notes under Section 8.2 or satisfaction
and discharge of this Indenture under Section 8.5 hereof,
the Guarantors shall be released from all of their obligations
under their Note Guarantees endorsed on the Notes and under this
Indenture, without any action on the part of the Trustee or any
Holder of Notes.
-70-
(b) Upon the sale or other
disposition (including by way of merger or consolidation) of any
Guarantor or the sale, conveyance, transfer, assignment, lease
or other disposition of all or substantially all the assets of a
Guarantor pursuant to Section 5.1 hereof, such Guarantor
shall automatically be released from all obligations under its
Note Guarantees endorsed on the Notes and under this Indenture
in accordance with Sections 5.1 and 5.2.
(c) At the time a Guarantor (other
than the Company) is no longer a borrower or guarantor under the
Credit Facility, such Guarantor will be released and relieved
from all of its obligations under its Note Guarantee.
ARTICLE XI
MISCELLANEOUS
SECTION 11.1
Notices
. Any
notices or other communications required or permitted hereunder
shall be in writing, and shall be sufficiently given if made by
hand delivery, by telecopier or first-class mail, postage
prepaid, addressed as follows:
if to the Company or to FMCD, to it at:
Else-Kröner Strasse 1
61352 Bad Homburg
Germany
Facsimile: 011-49-6172-609-2280
Attention: Chief Financial Officer
if to the Issuer:
FMC Finance VII S.A.
28-30,
Val
St. André,
L-1128 Luxembourg
Facsimile: 011-352-263375-909
Attention: Mrs. Gabriele Dux
if to FMCH:
920 Winter Street
Waltham MA
02451-1457
Facsimile: 781
699-9713
Attn: Ronald J. Kuerbitz, Esq.
-71-
in each case, with a copy to:
Fresenius Medical Care AG & Co. KGaA
Else-Kröner Strasse 1
61352 Bad Homburg
Germany
Facsimile: 011-49-6172-609-2422
Attention: Dr. Rainer Runte
if to the Trustee:
U.S. Bank National Association
225 Asylum Street, 23rd Floor
Hartford, CT 06103
Attention: Elizabeth C. Hammer
Telecopier: 860-241-6897
Telephone: 860-241-6817
if to the Paying Agent:
Deutsche Bank Aktiengesellschaft
Grosse Gallusstrasse
10-14
60262 Frankfurt
Germany
Attention: Debt Services
Telecopier.: +49 69 910 38672
Telephone: +49 69 910 30094
Each of the Issuer and the Trustee by written notice to each
other such Person may designate additional or different
addresses for notices to such Person. Any notice or
communication to the Issuer or the Trustee, shall be deemed to
have been given or made as of the date so delivered if
personally delivered; when receipt is acknowledged, if
telecopied; and five (5) calendar days after mailing if
sent by first class mail, postage prepaid (except that a notice
of change of address shall not be deemed to have been given
until actually received by the addressee).
Any notice or communication mailed to a Holder shall be mailed
to such Person by first-class mail or other equivalent means at
such Persons address as it appears on the registration
books of the Registrar and shall be sufficiently given to him if
so mailed within the time prescribed.
Failure to mail a notice or communication to a Holder or any
defect in it shall not affect its sufficiency with respect to
other Holders. If a notice or communication is mailed in the
manner provided above, it is duly given, whether or not the
addressee receives it.
If and so long as Notes are listed on the Euro MTF Market of the
Luxembourg Stock Exchange and the rules of such Stock Exchange
shall so require, notices regarding the
-72-
Notes given to the Holders will be published by the Issuer in a
newspaper having general circulation in Luxembourg (which is
expected to be the
Luxemburger Wort
) or, to the extent
and in the manner permitted by such rules, posted on the
official website of the Luxembourg Stock Exchange
(www.bourse.lu), and in the event the Notes are in the form of
Definitive Notes, sent by the Issuer, by first-class mail, with
a copy to the Trustee, to each Holder of the Notes at such
Holders address as it appears on the registration books of
the registrar. If and so long as such Notes are listed on any
other securities exchange, notices will also be given by the
Issuer in accordance with any applicable requirements of such
securities exchange. If and so long as any Notes are represented
by one or more Global Notes and ownership of Book-Entry
Interests therein are shown on the records of the Clearing
Agency or any successor appointed by the Clearing Agency at the
request of the Issuer, notices will be delivered to the Clearing
Agency or such successor for communication to the owners of such
Book-Entry Interests. Notices given by publication will be
deemed given on the first date on which any of the required
publications is made and notices given by first-class mail,
postage prepaid, will be deemed given five calendar days after
mailing.
SECTION 11.2
Certificate
and Opinion as to Conditions Precedent
. Upon any
request or application by the Issuer to the Trustee or an Agent
to take any action under this Indenture, the Issuer and the
Guarantors shall furnish to the Trustee at the request of the
Trustee:
(1) an Officers Certificate,
in form and substance reasonably acceptable to the Trustee
(reasonableness to be determined objectively), stating that, in
the opinion of the signers, all conditions precedent and
covenants, if any, provided for in this Indenture relating to
the proposed action have been satisfied or complied
with; and
(2) an Opinion of Counsel in form
and substance reasonably acceptable to the Trustee or such Agent
(reasonableness to be determined objectively) stating that, in
the opinion of such counsel, all such conditions precedent and
covenants have been satisfied or complied with.
In any case where several matters are required to be certified
by, or covered by an Opinion of Counsel of, any specified
Person, it is not necessary that all such matters be certified
by, or covered by the Opinion of Counsel of, only one such
Person, or that they be so certified or covered by only one
document, but one such Person may certify or give an Opinion of
Counsel with respect to some matters and one or more such
Persons as to other matters, and any such Person may certify or
give an Opinion of Counsel as to such matters in one or several
documents.
Any certificate of a Responsible Officer of the Issuer may be
based, insofar as it relates to legal matters, upon an Opinion
of Counsel, unless such Responsible Officer knows, or in the
exercise of reasonable care should know, that such Opinion of
Counsel with respect to the matters upon which his certificate
is based are erroneous. Any Opinion of Counsel may be based, and
may state that it is so based, insofar as it relates to factual
matters, upon a certificate of, or representations by, a
Responsible Officer or Responsible Officers of the Issuer
stating that the information with respect to such factual
matters is in the possession of the Issuer, unless such counsel
knows, or in the exercise of reasonable care should know, that
the certificate or representations with respect to such matters
are erroneous.
-73-
Where any Person is required to make, give or execute two or
more applications, requests, consents, certificates, statements,
opinions or other instruments under this Indenture, they may,
but need not, be consolidated and form one instrument.
SECTION 11.3
Statements
Required in Certificate or Opinion
. Each certificate or
opinion with respect to compliance with a condition or covenant
provided for in this Indenture shall include:
(1) a statement that the Person making such
certificate or opinion has read such covenant or condition;
(2) a brief statement as to the nature and scope of
the examination or investigation upon which the statements or
opinions contained in such certificate or opinion are based;
(3) a statement that, in the opinion of such Person,
such Person has made such examination or investigation as is
necessary to enable such Person to express an informed opinion
as to whether or not such covenant or condition has been
complied with; and
(4) a statement as to whether or not, in the opinion
of each such Person, such condition or covenant has been
complied with.
SECTION 11.4
Rules by
Trustee, Paying Agent, Registrar
. The Trustee, Paying
Agent or Registrar may make reasonable rules for its functions.
SECTION 11.5
Legal
Holidays
. If a payment date is not a Business Day,
payment may be made on the next succeeding day that is a
Business Day, and no interest shall accrue for the intervening
period.
SECTION 11.6
Governing
Law
. THIS INDENTURE AND THE NOTES, AND THE RIGHTS AND
DUTIES OF THE PARTIES HEREUNDER AND THEREUNDER, SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE
STATE OF NEW YORK. THE NOTE GUARANTEES WILL BE GOVERNED BY,
AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW
YORK EXCEPT THAT THE LIMITATIONS OF THE NOTE GUARANTEES
EXPRESSED IN SECTIONS 10.1(c) HEREOF (AND THE EQUIVALENT
PROVISION CONTAINED IN THE NOTE GUARANTEE ENDORSED ON THE
NOTES) WILL BE CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE
FEDERAL REPUBLIC OF GERMANY.
SECTION 11.7
Submission to
Jurisdiction
. To the fullest extent permitted by
applicable law, each of the Issuer and the Guarantors
irrevocably submits to the non-exclusive jurisdiction of any
U.S. federal or state court in the Borough of Manhattan in
the City of New York, County and State of New York, United
States of America, in any suit or proceeding based on or arising
under this Indenture or the Notes, and irrevocably agrees that
all claims in respect of such suit or proceeding may be
determined in any such court. Each of the Issuer and the
Guarantors, to the fullest extent permitted by applicable law,
irrevocably and fully waives the defense of an inconvenient
forum to the maintenance of such suit or proceeding and
irrevocably waives to the fullest extent it may effectively do
so any objection which it may now or hereafter
-74-
have to the laying of venue of any such proceeding, and each of
the Issuer and the Guarantors hereby irrevocably consents to be
served with notice and service of process by delivery or by
registered mail with return receipt requested addressed to
FMCHs registered agent, which as of the date hereof is CT
Corporation System, 111 Eighth Avenue, New York, NY 10011 (which
service of process by registered mail shall be effective with
respect to the Issuer and the Guarantors so long as such return
receipt is obtained, or in the event of a refusal to sign such
receipt any Holder or the Trustee is able to produce evidence of
attempted delivery by such means). Each of the Issuer and the
Guarantors further agrees that such service of process and
written notice of such service to the Issuer and the Guarantors
in the circumstances described above shall be deemed in every
respect effective notice and service of process upon each of the
Issuer and the Guarantors in any such action or proceeding.
Nothing herein shall affect the right of any Person to serve
process in any other manner permitted by law. Each of the Issuer
and the Guarantors agrees that a final action in any such suit
or proceeding shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in any other lawful
manner. Notwithstanding the foregoing, each of the Issuer and
the Guarantors hereby agrees that any action arising out of or
based on this Indenture or the Notes may also be instituted in
any competent court in Germany, and it expressly accepts the
jurisdiction of any such court in any such action.
Each of the Issuer and the Guarantors hereby irrevocably waives,
to the extent permitted by law, any immunity to jurisdiction to
which it may otherwise be entitled (including, without
limitation, immunity to pre-judgment attachment, post-judgment
attachment and execution) in any legal suit, action or
proceeding against it arising out of or based on this Indenture
or the Notes.
The provisions of this Section 11.7 are intended to be
effective upon the execution of this Indenture without any
further action by the Issuer and the Guarantors and the
introduction of a true copy of this Indenture into evidence
shall be conclusive and final evidence as to such matters.
SECTION 11.8
No Personal
Liability of Directors, Officers, Employees and Stockholders
No member of the Board of Directors, director, officer,
employee, incorporator or stockholder of the Issuer, Fresenius
SE, Fresenius SEs general partner, the Company, the
Companys General Partner, or the Guarantors, as such,
shall have any liability for any obligations of the Issuer or
any Guarantor under the Notes, this Indenture or the Note
Guarantees or for any claim based on, in respect of, or by
reason of, such obligations or their creation. Each Holder by
accepting a Note waives and releases all such liability and
agrees not to enforce any claim in respect of the Notes, the
Indenture or the Notes Guarantees to the extent that it would
give rise to such personal liability. The waiver and release are
part of the consideration for issuance of the Notes and the Note
Guarantees. Such waiver and release may not be effective to
waive liabilities under the U.S. federal securities laws
and it is the view of the SEC that such a waiver is against
public policy. In addition, such waiver and release may not be
effective under the laws of the Federal Republic of Germany.
SECTION 11.9
Successors
. All
agreements of the Issuer in this Indenture and the Notes and the
Guarantors in this Indenture and the Note Guarantees shall bind
their respective successors. All agreements of the Trustee in
this Indenture shall bind its successors.
-75-
SECTION 11.10
Counterpart
Originals
. All parties hereto may sign any number of
copies of this Indenture. Each signed copy or counterpart shall
be an original, but all of them together shall represent one and
the same agreement.
SECTION 11.11
Severability
. In
case any one or more of the provisions in this Indenture or in
the Notes shall be held invalid, illegal or unenforceable, in
any respect for any reason, the validity, legality and
enforceability of any such provision in every other respect and
of the remaining provisions shall not in any way be affected or
impaired thereby, it being intended that all of the provisions
hereof shall be enforceable to the full extent permitted by law.
SECTION 11.12
Table of
Contents, Headings, etc
. The Table of Contents,
Cross-Reference Table and headings of the Articles and Sections
of this Indenture have been inserted for convenience of
reference only, are not to be considered a part of this
Indenture and shall in no way modify or restrict any of the
terms or provisions hereof.
SECTION 11.13
Trust Indenture
Act Controls
. If any provision of this Indenture
limits, qualifies or conflicts with the duties imposed by TIA
§ 318(c), the imposed duties shall control.
SECTION 11.14
Currency
Indemnity
. Any payment on account of an amount that is
payable in euros (the
Required Currency
),
which is made to or for the account of any Holder of the Notes
or the Trustee in lawful currency of any other jurisdiction (the
Judgment Currency
), whether as a result of
any judgment or order or the enforcement thereof or the
liquidation of the Issuer or a Guarantor, shall constitute a
discharge of the Issuer or the Guarantors obligation under
this Indenture and the Notes or Note Guarantee, as the case may
be, only to the extent of the amount of the Required Currency
which such holder or the Trustee, as the case may be, could
purchase in the London foreign exchange markets with the amount
of the Judgment Currency in accordance with normal banking
procedures at the rate of exchange prevailing on the first
Business Day following receipt of the payment in the Judgment
Currency. If the amount of the Required Currency that could be
so purchased is less than the amount of the Required Currency
originally due to such Holder or the Trustee, as the case may
be, the Issuer shall indemnify and hold harmless the Holder or
the Trustee, as the case may be, from and against all loss or
damage arising out of, or as a result of, such deficiency. This
indemnity shall constitute an obligation separate and
independent from the other obligations contained in this
Indenture or the Notes, shall give rise to a separate and
independent cause of action, shall apply irrespective of any
indulgence granted by any Holder or the Trustee from time to
time and shall continue in full force and effect notwithstanding
any judgment or order for a liquidated sum in respect of an
amount due hereunder or under any judgment or order.
SECTION 11.15
Information
. For
so long as the Notes are listed on the Euro MTF Market of the
Luxembourg Stock Exchange, and the rules of such stock exchange
so require, copies of this Indenture will be made available in
Luxembourg through the offices of the Luxembourg Paying Agent in
such city.
-76-
IN WITNESS WHEREOF, the parties hereto have caused this
Indenture to be duly executed, as of the date first written
above.
FMC FINANCE VII S.A.
Name: Gabriele
Dux
FRESENIUS MEDICAL CARE
AG & CO. KGaA,
a partnership limited by shares, represented by
FRESENIUS MEDICAL CARE MANAGEMENT
AG, its general partner
Name: Michael
Brosnan
|
|
|
|
Title:
|
Member of Management Board
|
Name: Kent
Wanzek
|
|
|
|
Title:
|
Member of Management Board
|
FRESENIUS MEDICAL CARE DEUTSCHLAND
GmbH
|
|
|
|
By:
|
/s/ Alexandra
Dambeck
|
Name: Alexandra
Dambeck
Name: Eberhard
Sieger
FRESENIUS MEDICAL CARE HOLDINGS,
INC.
Name: Mark
Fawcett
|
|
|
|
Title:
|
Vice President &
Assistant Treasurer
|
-77-
U.S. BANK NATIONAL ASSOCIATION,
as Trustee
|
|
|
|
By:
|
/s/ Elizabeth
C. Hammer
|
Name: Elizabeth
C. Hammer
DEUTSCHE BANK AKTIENGESELLSCHAFT,
as Paying Agent
Name: Vivian
Wichmann
Name: Bernd
Birck
|
|
|
|
Title:
|
Assistant Vice President
|
EXHIBIT A
TO THE INDENTURE
[FORM OF
FACE OF GLOBAL NOTE]
[Global Note
Legend]
THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE
INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME
OF THE CLEARING AGENCY OR A NOMINEE OF THE CLEARING AGENCY. THIS
NOTE IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE
NAME OF A PERSON OTHER THAN THE CLEARING AGENCY OR ITS NOMINEE
EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE,
AND NO TRANSFER OF THIS NOTE (OTHER THAN A TRANSFER OF THIS
NOTE AS A WHOLE TO THE CLEARING AGENCY OR A NOMINEE OF THE
CLEARING AGENCY) MAY BE REGISTERED EXCEPT IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE.
[Private
Placement Legend]
THE SECURITY (OR ITS PREDECESSOR) EVIDENCED HEREBY WAS
ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION
UNDER SECTION 5 OF THE UNITED STATES SECURITIES ACT OF
1933, AS AMENDED (THE SECURITIES ACT), AND THE
SECURITY EVIDENCED HEREBY MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN APPLICABLE
EXEMPTION THEREFROM. EACH PURCHASER OF THE SECURITY
EVIDENCED HEREBY IS HEREBY NOTIFIED THAT THE SELLER MAY BE
RELYING ON THE EXEMPTION FROM THE PROVISIONS OF
SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A
THEREUNDER. THE HOLDER OF THE SECURITY EVIDENCED HEREBY AGREES
FOR THE BENEFIT OF THE ISSUER THAT (A) SUCH SECURITY MAY BE
RESOLD, PLEDGED OR OTHERWISE TRANSFERRED, ONLY (1)(a) INSIDE THE
UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS
A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A
UNDER THE SECURITIES ACT) PURCHASING FOR ITS OWN ACCOUNT OR FOR
THE ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER IN A TRANSACTION
MEETING THE REQUIREMENTS OF RULE 144A UNDER THE SECURITIES
ACT, (b) OUTSIDE THE UNITED STATES TO A FOREIGN PERSON IN A
TRANSACTION MEETING THE REQUIREMENTS OF RULE 903 OR
RULE 904 OF REGULATION S UNDER THE SECURITIES ACT,
(c) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF
APPLICABLE) OR (d) IN ACCORDANCE WITH ANOTHER
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT (AND BASED UPON AN OPINION OF COUNSEL
A-1
ACCEPTABLE TO THE ISSUER IF THE ISSUER SO REQUESTS), (2) TO
THE ISSUER OR (3) PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT AND, IN EACH CASE, IN ACCORDANCE WITH ANY APPLICABLE
SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR ANY OTHER
APPLICABLE JURISDICTION AND (B) THE HOLDER WILL, AND EACH
SUBSEQUENT HOLDER IS REQUIRED TO, NOTIFY ANY PURCHASER OF THE
SECURITY EVIDENCED HEREBY OF THE RESALE RESTRICTIONS SET FORTH
IN CLAUSE (A) ABOVE. NO REPRESENTATION CAN BE MADE AS TO
THE AVAILABILITY OF THE EXEMPTION PROVIDED BY RULE 144
FOR RESALE OF THE SECURITY EVIDENCED HEREBY.
FMC
FINANCE VII S.A.
5.25% Senior
Note due 2021
Common Code
No.:
ISIN
No.:
No.
FMC FINANCE VII S.A., a société anonyme organized
under the laws of Luxembourg (the Issuer, which term
includes any successor entity), for value received, promises to
pay to Deutsche Bank Aktiengesellschaft or its registered
assigns upon surrender hereof the principal sum indicated on
Schedule A hereof, on February 15, 2021.
Interest Payment Dates: February 15 and August 15,
commencing August 15, 2011
Record Dates: February 1 and August 1 immediately preceding the
Interest Payment Dates
Reference is made to the further provisions of this Note
contained herein, which will for all purposes have the same
effect as if set forth at this place.
A-2
IN WITNESS WHEREOF, the Issuer has caused this instrument to be
duly executed.
Dated:
FMC FINANCE VII S.A.
Name:
Title:
Trustees
Certificate of Authentication
This is one of the Securities with the Guarantees endorsed
thereon referred to in the within-mentioned Indenture.
U.S. BANK NATIONAL ASSOCIATION, as
Trustee
Name:
Title:
A-3
[FORM OF
REVERSE]
FMC
FINANCE VII S.A.
5.25% Senior Note due 2021
1.
Interest
. FMC
FINANCE VII S.A., a société anonyme organized under
the laws of Luxembourg (the Issuer), promises to pay
interest on the principal amount of this Note at the rate and in
the manner specified below. Interest on the Notes will accrue at
5.25% per annum on the principal amount then outstanding, and be
payable semi-annually in cash in arrears on each February 15 and
August 15, or if any such day is not a Business Day, on the
next succeeding Business Day, commencing August 15, 2011,
to the Holder hereof. Notwithstanding any exchange of this Note
for a Definitive Note during the period starting on a Record
Date relating to such Definitive Note and ending on the
immediately succeeding interest payment date, the interest due
on such interest payment date shall be payable to the Person in
whose name this Global Note is registered at the close of
business on the Record Date for such interest. Interest on the
Notes will accrue from the most recent date to which interest
has been paid. Interest will be computed on the basis of a
360-day
year
of twelve
30-day
months.
The Issuer shall pay interest on overdue principal and on
overdue installments of interest (without regard to any
applicable grace periods) and on any Additional Amounts, from
time to time on demand at the rate borne by the Notes. Any
interest paid on this Note shall be increased to the extent
necessary to pay Additional Amounts as set forth herein.
2.
Additional
Amounts
. All payments made under or with respect to the
Notes under the Indenture or pursuant to any Note Guarantee must
be made free and clear of and without withholding or deduction
for or on account of any present or future tax, duty, levy,
impost, assessment or other governmental charge (including
penalties, interest and other liabilities related thereto)
imposed or levied by or on behalf of (1) the United States,
Germany, Luxembourg, the United Kingdom or any political
subdivision or governmental authority thereof or therein having
the power to tax, (2) any jurisdiction from or through
which payment on the Notes or any Note Guarantee is made, or any
political subdivision or governmental authority thereof or
therein having the power to tax or (3) any other
jurisdiction in which the payor is organized or otherwise
considered to be a resident or engaged in business for tax
purposes, or any political subdivision or governmental authority
thereof or therein having the power to tax (each a
Relevant Taxing Jurisdiction), collectively,
Taxes, unless the Issuer or any Guarantor is
required to withhold or deduct Taxes by law or by the
interpretation or administration thereof by the relevant
government authority or agency provided, however, that in
determining what withholding is required by law for
U.S. federal income and withholding tax purposes, the
Issuer and any Guarantor shall be entitled to treat any payments
on or in respect of the Notes or any Note Guarantee as if the
Notes or any Note Guarantee were issued by a U.S. person as
defined in section 7701(a)(30) of the Code. If the Issuer
or any Guarantor is so required to withhold or deduct any amount
for or on account of Taxes from any payment made under or with
respect to the Notes or any Note Guarantee, the Issuer or such
Guarantor, as the case may be, will be required to pay such
amount Additional Amounts as
may be necessary so that the net amount (including Additional
Amounts) received by each Holder after such withholding or
deduction (including any withholding or deduction on such
Additional Amounts) will not be less than the amount such
A-4
Holder would have received if such Taxes had not been withheld
or deducted;
provided
,
however
, that no Additional
Amounts will be payable with respect to payments made to any
Holder or beneficial owner to the extent such Taxes are imposed
by reason of (i) such Holder or beneficial owner being
considered to be or to have been connected with a Relevant
Taxing Jurisdiction, otherwise than by the acquisition,
ownership, holding or disposition of the Notes, the enforcement
of rights under the Notes or under any Note Guarantee or the
receipt of payments in respect of the Notes or any Note
Guarantee, or (ii) such Holder or beneficial owner not
completing any procedural formalities that it is legally
eligible to complete and are necessary for the Issuer or the
Guarantors to make or obtain authorization to make payments
without such Taxes (including, without limitation, providing
prior to the receipt of any payment on or in respect of a Note
or any Note Guarantee, a complete, correct and executed IRS
Form W-8
or
W-9
or
successor form, as applicable, with all appropriate
attachments);
provided, however
, that for purposes of
this obligation to pay Additional Amounts, the Issuer and any
Guarantor shall be entitled, for U.S. federal income and
withholding tax purposes, to treat any payments on or in respect
of the Notes as if the Notes were issued by a U.S. person
as defined in section 7701(a)(30) of the Code. Further, no
Additional Amounts shall be payable with respect to (i) any
Tax imposed by the United States or any political subdivision or
governmental authority thereof or therein on interest by reason
of any Holder or beneficial owner holding or owning, actually or
constructively, 10% or more of the total combined voting power
of all classes of stock of the Issuer or any Guarantor entitled
to vote or (ii) any Tax imposed by the United States or any
political subdivision or governmental authority thereof or
therein on interest by reason of any Holder or beneficial owner
being a controlled foreign corporation that is a related person
within the meaning of Section 864(d)(4) of the Code with
respect to the Issuer or any Guarantor. The Issuer or Guarantor
(as applicable) will also make such withholding or deduction and
remit the full amount deducted or withheld to the relevant
authority as and when required in accordance with applicable
law. The Issuer or Guarantor (as applicable) will use all
reasonable efforts to obtain certified copies of tax receipts
evidencing the payment by the Issuer or Guarantor (as
applicable) of any Taxes so deducted or withheld from each
Relevant Taxing Jurisdiction imposing such Taxes and will
provide such certified copies to the Trustee.
Wherever in the Indenture or the Notes or any Note Guarantee
there are mentioned, in any context, (1) the payment of
principal, (2) purchase prices in connection with a
purchase of Notes under the Indenture or the Notes,
(3) interest or (4) any other amount payable on or
with respect to any of the Notes or any Note Guarantee, such
reference shall be deemed to include payment of Additional
Amounts as described under this heading to the extent that, in
such context, Additional Amounts are, were or would be payable
in respect thereof.
The Issuer will pay any present stamp, court or documentary
taxes, or any other excise, property or similar taxes, charges
or levies (including any penalties, interest or other
liabilities related thereto) which arise in Luxembourg or any
political subdivision thereof or therein, from the execution,
delivery and registration of Notes upon original issuance and
initial resale of the Notes or any other document or instrument
referred to therein, or in connection with the enforcement of
the Notes or any Note Guarantee or any other document or
instrument referred to herein or therein. If at any time the
Issuer changes its place of organization to outside of
Luxembourg or there is a new issuer organized outside of
Luxembourg, the Issuer or new issuer, as applicable, will pay
any stamp, court or documentary taxes, or any other excise,
property or similar taxes, charges or levies (including any
penalties, interest or other liabilities related thereto)
A-5
which arise in the jurisdiction in which the Issuer or new
issuer is organized (or any political subdivision thereof or
therein) and are payable by the Holders of the Notes in respect
of the Notes or any other document or instrument referred to
therein under any law, rule or regulation in effect at the time
of such change.
The foregoing obligations will survive any termination,
defeasance or discharge of the Indenture. References in this
section (Additional Amounts) to the Issuer or any
Guarantor shall apply to any successor(s) thereto.
3.
Method of
Payment
. The Issuer shall pay interest on the Notes
(except defaulted interest) to the Person in whose name this
Note is registered at the close of business on the Record Date
for such interest. The Issuer shall pay principal and interest
in Euros. Immediately available funds for the payment of the
principal of (and premium, if any), interest and Additional
Amounts, if any, on this Note due on any interest payment date,
Maturity Date, Redemption Date or other repurchase date
will be made available to the Paying Agent to permit the Paying
Agent to pay such funds to the Holders on such respective dates.
4.
Paying Agent and
Registrar
. Initially, Deutsche Bank Aktiengesellschaft
will act as Paying Agent and U.S. Bank National Association
will act as Registrar. In the event that a Paying Agent or
transfer agent is replaced, the Issuer will provide notice
thereof (so long as the Notes are Global Notes) published in a
newspaper having a general circulation in Luxembourg (which is
expected to be the
Luxemburger Wort
), or posted on the
official website of the Luxembourg Stock Exchange
(www.bourse.lu), if and so long as the Notes are listed on the
Euro MTF Market of the Luxembourg Stock Exchange and the rules
of such stock exchange shall so require, and (in the case of
Definitive Notes), in addition to such publication, mailed by
first-class mail to each Holders registered address. The
Issuer may change any Registrar without notice to the Holders.
The Issuer, the Company or any of their Subsidiaries may,
subject to certain exceptions, act in the capacity of Registrar
or transfer agent.
5.
Indenture
. The
Issuer issued the Notes under an Indenture, dated as of
February 3, 2011 (the Indenture), among the
Issuer, Fresenius Medical Care AG & Co. KGaA (the
Company), Fresenius Medical Care Holdings, Inc.
(FMCH), Fresenius Medical Care Deutschland GmbH
(FMCD and together with the Company and FMCH, the
Guarantors), U.S. Bank National Association
(the Trustee) as Trustee and Deutsche Bank
Aktiengesellschaft (the Paying Agent) as Paying
Agent. This Note is one of a duly authorized issue of Notes (as
defined in the Indenture) of the Issuer designated as its
5.25% Senior Notes due 2021. The terms of the Notes include
those stated in the Indenture. Notwithstanding anything to the
contrary herein, the Notes are subject to all such terms, and
Holders of Notes are referred to the Indenture for a statement
of them. The Notes are general obligations of the Issuer. The
Notes are not limited in aggregate principal amount and
Additional Notes (as defined in the Indenture) may be issued
from time to time under the Indenture, in each case subject to
the terms of the Indenture;
provided
that the aggregate
principal amount of Notes that will be issued on the Closing
Date (as defined in the Indenture) will not exceed
300,000,000. Each Holder, by accepting a Note, agrees to
be bound by all of the terms and provisions of the Indenture, as
the same may be amended from time to time.
A-6
6.
Ranking
. The Notes
will be senior unsecured obligations of the Issuer and the Note
Guarantees will be senior unsecured obligations of the
Guarantors. The payment of the principal of, premium, if any,
and interest on the Notes and the obligations of the Guarantors
under the Note Guarantees will:
|
|
|
|
|
rank
pari passu
in right of payment with all other
Indebtedness of the Issuer and the Guarantors, as applicable,
that is not by its terms expressly subordinated to other
Indebtedness of the Issuer and the Guarantors, as applicable;
|
|
|
|
rank senior in right of payment to all Indebtedness of the
Issuer and the Guarantors, as applicable, that is, by its terms,
expressly subordinated to the senior Indebtedness of the Issuer
and the Guarantors, as applicable;
|
|
|
|
be effectively subordinated to the Secured Indebtedness of the
Issuer and the Guarantors, as applicable, to the extent of the
value of the collateral securing such Indebtedness, and to the
Indebtedness of the Subsidiaries that are not Guarantors of the
Notes; and
|
|
|
|
in the case of the Note Guarantee of Fresenius Medical Care
Deutschland GmbH, be effectively subordinated to the claims of
such Guarantors third-party creditors as a result of
limitations applicable to the Note Guarantee as set forth in
Section 10.1(c) of the Indenture.
|
7.
Note Guarantee
. As
provided in the Indenture and subject to certain limitations set
forth therein, the obligations of the Issuer under the Indenture
and this Note are Guaranteed on a senior unsecured basis
pursuant to Note Guarantees endorsed hereon. The Indenture
provides that a Guarantor shall be released from its Note
Guarantee upon compliance with certain conditions.
8.
Optional
Redemption
. The Issuer may redeem all or, from time to
time, a part of the Notes, at its option, at redemption prices
equal to 100% of the principal amount of the Notes being
redeemed plus accrued interest, if any, to the redemption date,
plus the excess of:
(a) as determined by the calculation agent (which
shall initially be the Trustee), the sum of the present values
of the remaining scheduled payments of principal and interest on
the Notes being redeemed not including any portion of such
payment of interest accrued on the date of redemption, from the
redemption date to the maturity date, discounted to the
redemption date on a semi-annual basis (assuming a
360-day
year
consisting of twelve
30-day
months) at the Bund Rate plus 50 basis points; over
(b) 100% of the principal amount of the Notes being
redeemed.
If the optional redemption date is on or after an interest
record date and on or before the related interest payment date,
the accrued and unpaid interest, if any, will be paid to the
Person in whose name the Note is registered at the close of
business on such record date, and no
A-7
additional interest will be payable to beneficial Holders whose
Notes will be subject to redemption by the Issuer.
In the case of any partial redemption, the Trustee will select
the Notes for redemption in compliance with the requirements of
the principal securities exchange, if any, on which the Notes
are listed or, if the Notes are not listed, then on a pro rata
basis, by lot or by such other method as the Trustee in its sole
discretion will deem to be fair and appropriate, although no
Note of 1,000 in original principal amount or less will be
redeemed in part. If any Note is to be redeemed in part only,
the notice of redemption relating to that Note will state the
portion of the principal amount thereof to be redeemed. A new
Note in principal amount equal to the unredeemed portion thereof
will be issued and delivered to the Trustee, or in the case of
Definitive Notes, issued in the name of the Holder thereof upon
cancellation of the original Note.
9.
Special Tax
Redemption
. The Issuer is entitled to redeem the Notes,
at its option, in whole but not in part, upon not less than 30
nor more than 60 days notice, at 100% of the
principal amount of the Notes, plus accrued and unpaid interest
(if any) to the date of redemption (subject to the right of
Holders of record on the relevant record date to receive
interest due on the relevant interest payment date), in the
event the Issuer has become or would become obligated to pay, on
the next date on which any amount would be payable with respect
to the Notes, any additional amounts as a result of:
(a) a change in or an amendment to
the laws, treaties, regulations or rulings of any Relevant
Taxing Jurisdiction; or
(b) any change in or amendment to
any official position regarding the application, administration
or interpretation of such laws, treaties, regulations or rulings
(including by virtue of a holding, judgment or order by a court
of competent jurisdiction);
which change or amendment to such laws or official position is
announced and becomes effective after the issuance of the Notes;
provided
that the Issuer determines, in its reasonable
judgment, that the obligation to pay such additional amounts
cannot be avoided by the use of reasonable measures available to
it;
provided
,
further
, that at the time such
notice is given, such obligation to pay Additional Amounts
remains in effect.
Notice of any such redemption must be given within 270 days
of the earlier of the announcement or effectiveness of any such
change.
10.
Notice of
Redemption
. Notice of redemption will be given at least
30 days but not more than 60 days before the
Redemption Date or Tax Redemption Date, as the case
may be, (i) so long as the Notes are in global form, by
publishing in a newspaper having a general circulation in
Luxembourg (which is expected to be the
Luxemburger
Wort
), or posted on the official website of the Luxembourg
Stock Exchange (www.bourse.lu), if and so long as the Notes are
listed on the Euro MTF Market of the Luxembourg Stock Exchange
and the rules of such stock exchange shall so require, and
notify the Holders, the Trustee and the Luxembourg Stock
Exchange, if applicable and (ii) in the case of Definitive
Notes, in addition to such publication, by mailing first-class
mail to each Holders registered address. Notes in
denominations of 1,000 may be redeemed only in whole. The
Trustee may select for redemption portions (equal
A-8
to 1,000 or any integral multiple of 1,000 in excess
thereof) of the principal of Notes that have denominations
larger than 1,000.
Except as set forth in the Indenture, from and after any
Redemption Date or Tax Redemption Date, as the case
may be, if monies for the redemption of the Notes called for
redemption shall have been deposited with the Paying Agent for
redemption on such Redemption Date or Tax
Redemption Date, as the case may be, then, unless the
Issuer defaults in the payment of such Redemption Price,
the Notes called for redemption will cease to bear interest and
Additional Amounts, if any, and the only right of the Holders of
such Notes will be to receive payment of the
Redemption Price.
11.
Change of
Control
. Each Holder of the Notes, upon the occurrence
of a Change of Control Triggering Event, will have the right to
require that the Issuer repurchase such Holders Notes, at
a purchase price in cash equal to 101% of the principal amount
thereof plus accrued and unpaid interest, if any, to the date of
purchase (subject to the right of Holders of record on the
relevant record date to receive interest due on the relevant
interest payment date). Holders of Notes that are subject to an
offer to purchase will receive a Change of Control offer from
the Company prior to any related Change of Control payment date
and may elect to have such Notes purchased by completing the
form entitled Option of Holder to Elect Purchase
appearing below.
12.
Denominations;
Form
. The Global Notes are in registered global form,
without coupons, in denominations of 1,000 and integral
multiples of 1,000 in excess thereof.
13.
Persons Deemed
Owners
. The registered Holder of this Note shall be
treated as the owner of it for all purposes, subject to the
terms of the Indenture.
14.
Unclaimed Funds
. If
funds for the payment of principal, interest, premium or
Additional Amounts remain unclaimed for two years, the Trustee
and the Paying Agents will repay the funds to the Issuer at its
written request. After that, all liability of the Trustee and
such Paying Agents with respect to such funds shall cease.
15.
Legal Defeasance and
Covenant Defeasance
. The Issuer may be discharged from
its obligations under the Indenture and the Notes except for
certain provisions thereof (Legal Defeasance), and
may be discharged from its obligations to comply with certain
covenants contained in the Indenture (Covenant
Defeasance), in each case upon satisfaction of certain
conditions specified in the Indenture.
16.
Amendment; Supplement;
Waiver
. Subject to certain exceptions specified in the
Indenture, the Indenture or the Notes may be amended or
supplemented with the written consent of the Holders of at least
a majority in principal amount of the Notes then outstanding,
and any existing Default or Event of Default or compliance with
any provision of the Indenture or the Notes may be waived with
the consent of the Holders of a majority in principal amount of
the Notes then outstanding.
17.
Restrictive
Covenants
. The Indenture imposes certain covenants
that, among other things, limit the ability of the Issuer, the
Company, the Guarantors and their Subsidiaries to incur
additional Indebtedness, to incur additional Liens, to enter
into Sale and Leaseback
A-9
Transactions and enter into certain consolidations or mergers.
The limitations are subject to a number of important
qualifications and exceptions. The Issuer must annually report
to the Trustee on compliance with such limitations.
18.
Successors
. When a
successor assumes all the obligations of its predecessor under
the Notes and the Indenture in accordance with the terms of the
Indenture, the predecessor will be released from those
obligations.
19.
Defaults and
Remedies
. If an Event of Default (other than an Event
of Default specified in clause (7) of Section 6.1 of
the Indenture) occurs and is continuing, the Trustee or the
Holders of at least 25% in principal amount of the then
outstanding Notes may declare all the Notes to be due and
payable immediately in the manner and with the effect provided
in the Indenture. Holders of Notes may not enforce the Indenture
or the Notes except as provided in the Indenture. The Trustee is
not obligated to enforce the Indenture or the Notes unless it
has received full indemnity. The Indenture permits, subject to
certain limitations therein provided, Holders of a majority in
aggregate principal amount of the Notes then outstanding to
direct the Trustee in its exercise of any trust or power. The
Trustee may withhold from Holders of Notes notice of any
continuing Default or Event of Default (except a Default in
payment of principal, premium, interest and Additional Amounts,
if any, including an accelerated payment) if it determines that
withholding notice is in their interest.
20.
Trustee Dealings with
Issuer
. The Trustee under the Indenture, in its
individual or any other capacity, may become the owner or
pledgee of Notes and may otherwise deal with the Company, its
Subsidiaries or their respective Affiliates as if it were not
the Trustee.
21.
No Recourse Against
Others
. No member of the Board of Directors, director,
officer, employee, incorporator or stockholder of the Issuer,
Fresenius SE, Fresenius SEs general partner, the Company,
the Companys General Partner or the Guarantors, as such,
shall have any liability for any obligations of the Issuer or
any Guarantor under the Notes, the Indenture or the Note
Guarantees or for any claim based on, in respect of, or by
reason of, such obligations or their creation. Each Holder by
accepting a Note waives and releases all such liability and
agrees not to enforce any claim in respect of the Notes, the
Indenture or the Notes Guarantees to the extent that it would
give rise to such personal liability. The waiver and release are
part of the consideration for issuance of the Notes and the Note
Guarantees. Such waiver and release may not be effective to
waive liabilities under the U.S. federal securities laws
and it is the view of the SEC that such a waiver is against
public policy. In addition, such waiver and release may not be
effective under the laws of the Federal Republic of Germany. The
waiver and release are part of the consideration for issuance of
the Notes.
22.
Authentication
. This
Note shall not be valid until the Trustee or authenticating
agent signs the certificate of authentication on this Note.
23.
Abbreviations and Defined
Terms
. Customary abbreviations may be used in the name
of a Holder of a Note or an assignee, such as: TEN COM (=
tenants in common), TEN ENT (= tenants by the entireties), JT
TEN (= joint tenants with right of survivorship and not as
tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform
Gifts to Minors
A-10
Act). Unless otherwise defined herein, terms defined in the
Indenture are used herein as defined therein.
24.
ISINs and Common
Codes
. The Issuer will cause ISINs
and/or
Common Codes to be printed on the Notes as a convenience to the
Holders of the Notes. No representation is made as to the
accuracy of such numbers as printed on the Notes and reliance
may be placed only on the other identification numbers printed
hereon.
25.
Governing Law
. THIS
NOTE AND THE INDENTURE, AND THE RIGHTS AND DUTIES OF THE
PARTIES HEREUNDER AND THEREUNDER, SHALL BE GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.
THE NOTE GUARANTEES WILL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK EXCEPT
CERTAIN MATTERS CONCERNING LIMITATION THEREOF WILL BE CONSTRUED
IN ACCORDANCE WITH THE LAWS OF THE FEDERAL REPUBLIC OF GERMANY.
A-11
SCHEDULE A
SCHEDULE OF
PRINCIPAL AMOUNT
The initial principal amount at maturity of this Note shall be
[principal amount]. The following decreases/increases in
the principal amount at maturity of this Note have been made:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Principal
|
|
|
Notation
|
|
|
|
|
|
|
|
|
|
|
Amount
|
|
|
Made by
|
|
Date of
|
|
|
Decrease in
|
|
|
Increase in
|
|
|
Following Such
|
|
|
or on
|
|
Decrease/
|
|
|
Principal
|
|
|
Principal
|
|
|
Decrease/
|
|
|
Behalf of
|
|
Increase
|
|
|
Amount
|
|
|
Amount
|
|
|
Increase
|
|
|
Trustee
|
|
|
A-12
OPTION OF
HOLDER TO ELECT PURCHASE
If you want to elect to have this Note purchased by the Issuer
pursuant to Section 4.11 of the Indenture, check the box
below:
o
If you want to elect to have only part of this Note purchased by
the Issuer pursuant to Section 4.11 of the Indenture, state
the amount:
Date:
Your
Signature:
(Sign exactly as your name appears
on the other side of this Note)
Signature
Guarantee:
Participant in a recognized
Signature Guarantee Medallion Program
(or other signature guarantor
program reasonably acceptable to the Trustee)
A-13
EXHIBIT B
TO THE INDENTURE
[FORM OF
FACE OF DEFINITIVE NOTE]
THIS NOTE IS A DEFINITIVE NOTE WITHIN THE MEANING OF
THE INDENTURE HEREINAFTER REFERRED TO.
[Private
Placement Legend]
THE SECURITY (OR ITS PREDECESSOR) EVIDENCED HEREBY WAS
ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION
UNDER SECTION 5 OF THE UNITED STATES SECURITIES ACT OF
1933, AS AMENDED (THE SECURITIES ACT), AND THE
SECURITY EVIDENCED HEREBY MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN APPLICABLE
EXEMPTION THEREFROM. EACH PURCHASER OF THE SECURITY
EVIDENCED HEREBY IS HEREBY NOTIFIED THAT THE SELLER MAY BE
RELYING ON THE EXEMPTION FROM THE PROVISIONS OF
SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A
THEREUNDER. THE HOLDER OF THE SECURITY EVIDENCED HEREBY AGREES
FOR THE BENEFIT OF THE ISSUER THAT (A) SUCH SECURITY MAY BE
RESOLD, PLEDGED OR OTHERWISE TRANSFERRED, ONLY (1)(a) INSIDE THE
UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS
A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A
UNDER THE SECURITIES ACT) PURCHASING FOR ITS OWN ACCOUNT OR FOR
THE ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER IN A TRANSACTION
MEETING THE REQUIREMENTS OF RULE 144A UNDER THE SECURITIES
ACT, (b) OUTSIDE THE UNITED STATES TO A FOREIGN PERSON IN A
TRANSACTION MEETING THE REQUIREMENTS OF RULE 903 OR
RULE 904 OF REGULATION S UNDER THE SECURITIES ACT,
(c) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF
APPLICABLE) OR (d) IN ACCORDANCE WITH ANOTHER
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT (AND BASED UPON AN OPINION OF COUNSEL ACCEPTABLE
TO THE ISSUER IF THE ISSUER SO REQUESTS), (2) TO THE ISSUER
OR (3) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT AND,
IN EACH CASE, IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS
OF ANY STATE OF THE UNITED STATES OR ANY OTHER APPLICABLE
JURISDICTION AND (B) THE HOLDER WILL, AND EACH SUBSEQUENT
HOLDER IS REQUIRED TO, NOTIFY ANY PURCHASER OF THE SECURITY
EVIDENCED HEREBY OF THE RESALE RESTRICTIONS SET FORTH IN CLAUSE
(A) ABOVE. NO REPRESENTATION CAN BE MADE AS TO THE
AVAILABILITY OF THE EXEMPTION PROVIDED BY RULE 144 FOR
RESALE OF THE SECURITY EVIDENCED HEREBY.
FMC
FINANCE VII S.A.
5.25% Senior
Note due 2021
Common Code
No.:
ISIN
No.:
No.
FMC FINANCE VII S.A., a société anonyme organized
under the laws of Luxembourg (the Issuer, which term
includes any successor entity), for value received, promises to
pay to
[ ]
or its registered assigns upon surrender hereof the principal
sum of
,
on February 15, 2021.
Interest Payment Dates: February 15 and
August 15, commencing August 15, 2011
Record Dates: February 1 and August 1 immediately
preceding the Interest Payment Dates
Reference is made to the further provisions of this Note
contained herein, which will for all purposes have the same
effect as if set forth at this place.
B-2
IN WITNESS WHEREOF, the Issuer has caused this instrument to be
duly executed.
Dated:
FMC FINANCE VII S.A.
Name:
Title:
Trustees
Certificate of Authentication
This is one of the Securities with the Guarantees endorsed
thereon referred to in the within-mentioned Indenture.
U.S. BANK NATIONAL ASSOCIATION, as Trustee
Name:
Title:
B-3
[FORM OF
REVERSE]
FMC FINANCE VII S.A.
5.25% Senior Note due 2021
1.
Interest
. FMC
FINANCE VII S.A., a société anonyme organized under
the laws of Luxembourg (the Issuer), promises to pay
interest on the principal amount of this Note at the rate and in
the manner specified below. Interest on the Notes will accrue at
5.25% per annum on the principal amount then outstanding, and be
payable semi-annually in cash in arrears on each February 15 and
August15, or if any such day is not a Business Day, on the next
succeeding Business Day, commencing August 15, 2011, to the
Holder hereof. Notwithstanding any exchange of this Note for a
Definitive Note during the period starting on a Record Date
relating to such Definitive Note and ending on the immediately
succeeding interest payment date, the interest due on such
interest payment date shall be payable to the Person in whose
name this Global Note is registered at the close of business on
the Record Date for such interest. Interest on the Notes will
accrue from the most recent date to which interest has been
paid. Interest will be computed on the basis of a
360-day
year
of twelve
30-day
months.
The Issuer shall pay interest on overdue principal and on
overdue installments of interest (without regard to any
applicable grace periods) and on any Additional Amounts, from
time to time on demand at the rate borne by the Notes. Any
interest paid on this Note shall be increased to the extent
necessary to pay Additional Amounts as set forth herein.
2.
Additional
Amounts
. All payments made under or with respect to the
Notes under the Indenture or pursuant to any Note Guarantee must
be made free and clear of and without withholding or deduction
for or on account of any present or future tax, duty, levy,
impost, assessment or other governmental charge (including
penalties, interest and other liabilities related thereto)
imposed or levied by or on behalf of (1) the United States,
Germany, Luxembourg, the United Kingdom or any political
subdivision or governmental authority thereof or therein having
the power to tax, (2) any jurisdiction from or through
which payment on the Notes or any Note Guarantee is made, or any
political subdivision or governmental authority thereof or
therein having the power to tax or (3) any other
jurisdiction in which the payor is organized or otherwise
considered to be a resident or engaged in business for tax
purposes, or any political subdivision or governmental authority
thereof or therein having the power to tax (each a
Relevant Taxing Jurisdiction), collectively,
Taxes, unless the Issuer or any Guarantor is
required to withhold or deduct Taxes by law or by the
interpretation or administration thereof by the relevant
government authority or agency provided, however, that in
determining what withholding is required by law for
U.S. federal income and withholding tax purposes, the
Issuer and any Guarantor shall be entitled to treat any payments
on or in respect of the Notes or any Note Guarantee as if the
Notes or any Note Guarantee were issued by a U.S. person as
defined in section 7701(a)(30) of the Code. If the Issuer
or any Guarantor is so required to withhold or deduct any amount
for or on account of Taxes from any payment made under or with
respect to the Notes or any Note Guarantee, the Issuer or such
Guarantor, as the case may be, will be required to pay such
amount Additional Amounts as
may be necessary so that the net amount (including Additional
Amounts) received by each Holder after such withholding or
deduction (including
B-4
any withholding or deduction on such Additional Amounts) will
not be less than the amount such Holder would have received if
such Taxes had not been withheld or deducted;
provided
,
however
, that no Additional Amounts will be payable with
respect to payments made to any Holder or beneficial owner to
the extent such Taxes are imposed by reason of (i) such
Holder or beneficial owner being considered to be or to have
been connected with a Relevant Taxing Jurisdiction, otherwise
than by the acquisition, ownership, holding or disposition of
the Notes, the enforcement of rights under the Notes or under
any Note Guarantee or the receipt of payments in respect of the
Notes or any Note Guarantee, or (ii) such Holder or
beneficial owner not completing any procedural formalities that
it is legally eligible to complete and are necessary for the
Issuer or the Guarantors to make or obtain authorization to make
payments without such Taxes (including, without limitation,
providing prior to the receipt of any payment on or in respect
of a Note or any Note Guarantee, a complete, correct and
executed IRS
Form W-8
or
W-9
or
successor form, as applicable, with all appropriate
attachments);
provided, however
, that for purposes of
this obligation to pay Additional Amounts, the Issuer and any
Guarantor shall be entitled, for U.S. federal income and
withholding tax purposes, to treat any payments on or in respect
of the Notes as if the Notes were issued by a U.S. person
as defined in section 7701(a)(30) of the Code. Further, no
Additional Amounts shall be payable with respect to (i) any
Tax imposed by the United States or any political subdivision or
governmental authority thereof or therein on interest by reason
of any Holder or beneficial owner holding or owning, actually or
constructively, 10% or more of the total combined voting power
of all classes of stock of the Issuer or any Guarantor entitled
to vote or (ii) any Tax imposed by the United States or any
political subdivision or governmental authority thereof or
therein on interest by reason of any Holder or beneficial owner
being a controlled foreign corporation that is a related person
within the meaning of Section 864(d)(4) of the Code with
respect to the Issuer or any Guarantor. The Issuer or Guarantor
(as applicable) will also make such withholding or deduction and
remit the full amount deducted or withheld to the relevant
authority as and when required in accordance with applicable
law. The Issuer or Guarantor (as applicable) will use all
reasonable efforts to obtain certified copies of tax receipts
evidencing the payment by the Issuer or Guarantor (as
applicable) of any Taxes so deducted or withheld from each
Relevant Taxing Jurisdiction imposing such Taxes and will
provide such certified copies to the Trustee.
Wherever in the Indenture or the Notes or any Note Guarantee
there are mentioned, in any context, (1) the payment of
principal, (2) purchase prices in connection with a
purchase of Notes under the Indenture or the Notes,
(3) interest or (4) any other amount payable on or
with respect to any of the Notes or any Note Guarantee, such
reference shall be deemed to include payment of Additional
Amounts as described under this heading to the extent that, in
such context, Additional Amounts are, were or would be payable
in respect thereof.
The Issuer will pay any present stamp, court or documentary
taxes, or any other excise, property or similar taxes, charges
or levies (including any penalties, interest or other
liabilities related thereto) which arise in Luxembourg or any
political subdivision thereof or therein, from the execution,
delivery and registration of Notes upon original issuance and
initial resale of the Notes or any other document or instrument
referred to therein, or in connection with the enforcement of
the Notes or any Note Guarantee or any other document or
instrument referred to herein or therein. If at any time the
Issuer changes its place of organization to outside of
Luxembourg or there is a new issuer organized outside of
Luxembourg, the Issuer or new issuer, as applicable, will pay
any stamp, court or documentary taxes, or any other excise,
property or simi-
B-5
lar taxes, charges or levies (including any penalties, interest
or other liabilities related thereto) which arise in the
jurisdiction in which the Issuer or new issuer is organized (or
any political subdivision thereof or therein) and are payable by
the Holders of the Notes in respect of the Notes or any other
document or instrument referred to therein under any law, rule
or regulation in effect at the time of such change.
The foregoing obligations will survive any termination,
defeasance or discharge of the Indenture. References in this
section (Additional Amounts) to the Issuer or
Guarantor shall apply to any successor(s) thereto.
3.
Method of
Payment
. The Issuer shall pay interest on the Notes
(except defaulted interest) to the Person in whose name this
Note is registered at the close of business on the Record Date
for such interest. Holders must surrender Notes to a Paying
Agent to collect principal payments. The Issuer shall pay
principal and interest in Euros. Immediately available funds for
the payment of the principal of (and premium, if any), interest
and Additional Amounts, if any, on this Note due on any interest
payment date, Maturity Date, Redemption Date or other
repurchase date will be made available to the Paying Agent to
permit the Paying Agent to pay such funds to the Holders on such
respective dates.
4.
Paying Agent and
Registrar
. Initially, Deutsche Bank Aktiengesellschaft
will act as Paying Agent and U.S. Bank National Association
will act as Registrar. In the event that a Paying Agent or
transfer agent is replaced, the Issuer will provide notice
thereof (so long as the Notes are Global Notes) published in a
newspaper having a general circulation in Luxembourg (which is
expected to be the
Luxemburger Wort
), or posted on the
official website of the Luxembourg Stock Exchange
(www.bourse.lu), if and so long as the Notes are listed on the
Euro MTF Market of the Luxembourg Stock Exchange and the rules
of such stock exchange shall so require, and (in the case of
Definitive Notes), in addition to such publication, mailed by
first-class mail to each Holders registered address. The
Issuer may change any Registrar without notice to the Holders.
The Issuer, the Company or any of their Subsidiaries may,
subject to certain exceptions, act in the capacity of Registrar
or transfer agent.
5.
Indenture
. The
Issuer issued the Notes under an Indenture, dated as of
February 3, 2011 (the Indenture), among the
Issuer, Fresenius Medical Care AG & Co. KGaA (the
Company), Fresenius Medical Care Holdings, Inc.
(FMCH), Fresenius Medical Care Deutschland GmbH
(FMCD and together with the Company and FMCH, the
Guarantors), U.S. Bank National Association
(the Trustee) as Trustee and Deutsche Bank
Aktiengesellschaft (the Paying Agent) as Paying
Agent. This Note is one of a duly authorized issue of Notes (as
defined in the Indenture) of the Issuer designated as its
5.25% Senior Notes due 2021. The terms of the Notes include
those stated in the Indenture. Notwithstanding anything to the
contrary herein, the Notes are subject to all such terms, and
Holders of Notes are referred to the Indenture for a statement
of them. The Notes are general obligations of the Issuer. The
Notes are not limited in aggregate principal amount and
Additional Notes (as defined in the Indenture) may be issued
from time to time under the Indenture, in each case subject to
the terms of the Indenture;
provided
that the aggregate
principal amount of Notes that will be issued on the Closing
Date (as defined in the Indenture) will not exceed
300,000,000. Each Holder, by accepting a Note, agrees to
be bound by all of the terms and provisions of the Indenture, as
the same may be amended from time to time.
B-6
6.
Ranking
. The Notes
will be senior unsecured obligations of the Issuer and the Note
Guarantees will be senior unsecured obligations of the
Guarantors. The payment of the principal of, premium, if any,
and interest on the Notes and the obligations of the Guarantors
under the Note Guarantees will:
|
|
|
|
|
rank
pari passu
in right of payment with all other
Indebtedness of the Issuer and the Guarantors, as applicable,
that is not by its terms expressly subordinated to other
Indebtedness of the Issuer and the Guarantors, as applicable;
|
|
|
|
rank senior in right of payment to all Indebtedness of the
Issuer and the Guarantors, as applicable, that is, by its terms,
expressly subordinated to the senior Indebtedness of the Issuer
and the Guarantors, as applicable;
|
|
|
|
be effectively subordinated to the Secured Indebtedness of the
Issuer and the Guarantors, as applicable, to the extent of the
value of the collateral securing such Indebtedness, and to the
Indebtedness of the Subsidiaries that are not Guarantors of the
Notes; and
|
|
|
|
in the case of the Note Guarantee of Fresenius Medical Care
Deutschland GmbH, be effectively subordinated to the claims of
such Guarantors third-party creditors as a result of
limitations applicable to the Note Guarantee as set forth in
Section 10.1(c) of the Indenture.
|
7.
Note Guarantee
. As
provided in the Indenture and subject to certain limitations set
forth therein, the obligations of the Issuer under the Indenture
and this Note are Guaranteed on a senior unsecured basis
pursuant to Note Guarantees endorsed hereon. The Indenture
provides that a Guarantor shall be released from its Note
Guarantee upon compliance with certain conditions.
8.
Optional
Redemption
. The Issuer may redeem all or, from time to
time, a part of the Notes, at its option, at redemption prices
equal to 100% of the principal amount of the Notes being
redeemed plus accrued interest, if any, to the redemption date,
plus the excess of:
(a) as determined by the
calculation agent (which shall initially be the Trustee), the
sum of the present values of the remaining scheduled payments of
principal and interest on the Notes being redeemed not including
any portion of such payment of interest accrued on the date of
redemption, from the redemption date to the maturity date,
discounted to the redemption date on a semi-annual basis
(assuming a
360-day
year
consisting of twelve
30-day
months) at the Bund Rate plus 50 basis points; over
(b) 100% of the principal amount of
the Notes being redeemed.
If the optional redemption date is on or after an interest
record date and on or before the related interest payment date,
the accrued and unpaid interest, if any, will be paid to the
Person in whose name the Note is registered at the close of
business on such record date, and no
B-7
additional interest will be payable to beneficial Holders whose
Notes will be subject to redemption by the Issuer.
In the case of any partial redemption, the Trustee will select
the Notes for redemption in compliance with the requirements of
the principal securities exchange, if any, on which the Notes
are listed or, if the Notes are not listed, then on a pro rata
basis, by lot or by such other method as the Trustee in its sole
discretion will deem to be fair and appropriate, although no
Note of 1,000 in original principal amount or less will be
redeemed in part. If any Note is to be redeemed in part only,
the notice of redemption relating to that Note will state the
portion of the principal amount thereof to be redeemed. A new
Note in principal amount equal to the unredeemed portion thereof
will be issued and delivered to the Trustee, or in the case of
Definitive Notes, issued in the name of the Holder thereof upon
cancellation of the original Note.
9.
Special Tax
Redemption
. The Issuer is entitled to redeem the Notes,
at its option, in whole but not in part, upon not less than 30
nor more than 60 days notice, at 100% of the
principal amount of the Notes, plus accrued and unpaid interest
(if any) to the date of redemption (subject to the right of
Holders of record on the relevant record date to receive
interest due on the relevant interest payment date), in the
event the Issuer has become or would become obligated to pay, on
the next date on which any amount would be payable with respect
to the Notes, any additional amounts as a result of:
(a) a change in or an amendment to
the laws, treaties, regulations or rulings of any Relevant
Taxing Jurisdiction; or
(b) any change in or amendment to
any official position regarding the application, administration
or interpretation of such laws, treaties, regulations or rulings
(including by virtue of a holding, judgment or order by a court
of competent jurisdiction);
which change or amendment to such laws or official position is
announced and becomes effective after the issuance of the Notes;
provided
that the Issuer determines, in its reasonable
judgment, that the obligation to pay such additional amounts
cannot be avoided by the use of reasonable measures available to
it;
provided
,
further
, that at the time such
notice is given, such obligation to pay Additional Amounts
remains in effect.
Notice of any such redemption must be given within 270 days
of the earlier of the announcement or effectiveness of any such
change.
10.
Notice of
Redemption
. Notice of redemption will be given at least
30 days but not more than 60 days before the
Redemption Date or Tax Redemption Date, as the case
may be, (i) so long as the Notes are in global form, by
publishing in a newspaper having a general circulation in
Luxembourg (which is expected to be the
Luxemburger
Wort
), or posted on the official website of the Luxembourg
Stock Exchange (www.bourse.lu), if and so long as the Notes are
listed on the Euro MTF Market of the Luxembourg Stock Exchange
and the rules of such stock exchange shall so require, and
notify the Holders, the Trustee and the Luxembourg Stock
Exchange, if applicable and (ii) in the case of Definitive
Notes, in addition to such publication, by mailing first-class
mail to each Holders registered address. Notes in
denominations of 1,000 may be redeemed only in whole. The
Trustee may select for redemption portions (equal
B-8
to 1,000 or any integral multiple of 1,000 in excess
thereof) of the principal of Notes that have denominations
larger than 1,000.
Except as set forth in the Indenture, from and after any
Redemption Date or Tax Redemption Date, as the case
may be, if monies for the redemption of the Notes called for
redemption shall have been deposited with the Paying Agent for
redemption on such Redemption Date or Tax
Redemption Date, as the case may be, then, unless the
Issuer defaults in the payment of such Redemption Price,
the Notes called for redemption will cease to bear interest and
Additional Amounts, if any, and the only right of the Holders of
such Notes will be to receive payment of the
Redemption Price.
11.
Change of
Control
. Each Holder of the Notes, upon the occurrence
of a Change of Control Triggering Event, will have the right to
require that the Issuer repurchase such Holders Notes, at
a purchase price in cash equal to 101% of the principal amount
thereof plus accrued and unpaid interest, if any, to the date of
purchase (subject to the right of Holders of record on the
relevant record date to receive interest due on the relevant
interest payment date). Holders of Notes that are subject to an
offer to purchase will receive a Change of Control offer from
the Company prior to any related Change of Control payment date
and may elect to have such Notes purchased by completing the
form entitled Option of Holder to Elect Purchase
appearing below.
12.
Denominations;
Form
. The Global Notes are in registered global form,
without coupons, in denominations of 1,000 and integral
multiples of 1,000 in excess thereof.
13.
Persons Deemed
Owners
. The registered Holder of this Note shall be
treated as the owner of it for all purposes, subject to the
terms of the Indenture.
14.
Unclaimed Funds
. If
funds for the payment of principal, interest, premium or
Additional Amounts remain unclaimed for two years, the Trustee
and the Paying Agents will repay the funds to the Issuer at its
written request. After that, all liability of the Trustee and
such Paying Agents with respect to such funds shall cease.
15.
Legal Defeasance and
Covenant Defeasance
. The Issuer may be discharged from
its obligations under the Indenture and the Notes except for
certain provisions thereof (Legal Defeasance), and
may be discharged from its obligations to comply with certain
covenants contained in the Indenture (Covenant
Defeasance), in each case upon satisfaction of certain
conditions specified in the Indenture.
16.
Amendment; Supplement;
Waiver
. Subject to certain exceptions specified in the
Indenture, the Indenture or the Notes may be amended or
supplemented with the written consent of the Holders of at least
a majority in principal amount of the Notes then outstanding,
and any existing Default or Event of Default or compliance with
any provision of the Indenture or the Notes may be waived with
the consent of the Holders of a majority in principal amount of
the Notes then outstanding.
17.
Restrictive
Covenants
. The Indenture imposes certain covenants
that, among other things, limit the ability of the Issuer, the
Company, the Guarantors and their Subsidiaries to incur
additional Indebtedness, to incur additional Liens, to enter
into Sale and Leaseback
B-9
Transactions and enter into certain consolidations or mergers.
The limitations are subject to a number of important
qualifications and exceptions. The Issuer must annually report
to the Trustee on compliance with such limitations.
18.
Successors
. When a
successor assumes all the obligations of its predecessor under
the Notes and the Indenture in accordance with the terms of the
Indenture, the predecessor will be released from those
obligations.
19.
Defaults and
Remedies
. If an Event of Default (other than an Event
of Default specified in clause (7) of Section 6.1 of
the Indenture) occurs and is continuing, the Trustee or the
Holders of at least 25% in principal amount of the then
outstanding Notes may declare all the Notes to be due and
payable immediately in the manner and with the effect provided
in the Indenture. Holders of Notes may not enforce the Indenture
or the Notes except as provided in the Indenture. The Trustee is
not obligated to enforce the Indenture or the Notes unless it
has received full indemnity. The Indenture permits, subject to
certain limitations therein provided, Holders of a majority in
aggregate principal amount of the Notes then outstanding to
direct the Trustee in its exercise of any trust or power. The
Trustee may withhold from Holders of Notes notice of any
continuing Default or Event of Default (except a Default in
payment of principal, premium, interest and Additional Amounts,
if any, including an accelerated payment) if it determines that
withholding notice is in their interest.
20.
Trustee Dealings with
Issuer
. The Trustee under the Indenture, in its
individual or any other capacity, may become the owner or
pledgee of Notes and may otherwise deal with the Company, its
Subsidiaries or their respective Affiliates as if it were not
the Trustee.
21.
No Recourse Against
Others
. No member of the Board of Directors, director,
officer, employee, incorporator or stockholder of the Issuer,
Fresenius SE, Fresenius SEs general partner, the Company,
the Companys General Partner, or the Guarantors, as such,
shall have any liability for any obligations of the Issuer or
any Guarantor under the Notes, the Indenture or the Note
Guarantees or for any claim based on, in respect of, or by
reason of, such obligations or their creation. Each Holder by
accepting a Note waives and releases all such liability and
agrees not to enforce any claim in respect of the Notes, the
Indenture or the Notes Guarantees to the extent that it would
give rise to such personal liability. The waiver and release are
part of the consideration for issuance of the Notes and the Note
Guarantees. Such waiver and release may not be effective to
waive liabilities under the U.S. federal securities laws
and it is the view of the SEC that such a waiver is against
public policy. In addition, such waiver and release may not be
effective under the laws of the Federal Republic of Germany. The
waiver and release are part of the consideration for issuance of
the Notes.
22.
Authentication
. This
Note shall not be valid until the Trustee or authenticating
agent signs the certificate of authentication on this Note.
23.
Abbreviations and Defined
Terms
. Customary abbreviations may be used in the name
of a Holder of a Note or an assignee, such as: TEN COM (=
tenants in common), TEN ENT (= tenants by the entireties), JT
TEN (= joint tenants with right of survivorship and not as
tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform
Gifts to Minors
B-10
Act). Unless otherwise defined herein, terms defined in the
Indenture are used herein as defined therein.
24.
ISINs and Common
Codes
. The Issuer will cause ISINs
and/or
Common Codes to be printed on the Notes as a convenience to the
Holders of the Notes. No representation is made as to the
accuracy of such numbers as printed on the Notes and reliance
may be placed only on the other identification numbers printed
hereon.
25.
Governing Law
. THIS
NOTE AND THE INDENTURE, AND THE RIGHTS AND DUTIES OF THE
PARTIES HEREUNDER AND THEREUNDER, SHALL BE GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.
THE NOTE GUARANTEES WILL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK EXCEPT
CERTAIN MATTERS CONCERNING LIMITATION THEREOF WILL BE CONSTRUED
IN ACCORDANCE WITH THE LAWS OF THE FEDERAL REPUBLIC OF GERMANY.
B-11
ASSIGNMENT
FORM
To assign this Note fill in the form below:
I or we assign and transfer this Note to
(Print or type assignees
name, address and zip code)
(Insert assignees social
security or tax I.D. No.)
and irrevocably
appoint
agent to transfer this Note on the books of the Issuer. The
agent may substitute another to act for him.
Date:
Your
Signature:
Sign exactly as your name appears
on the other side of this Note.
B-12
OPTION OF
HOLDER TO ELECT PURCHASE
If you want to elect to have this Note purchased by the Issuer
pursuant to Section 4.11 of the Indenture, check the box
below:
o
If you want to elect to have only part of this Note purchased by
the Issuer pursuant to Section 4.11 of the Indenture, state
the amount:
Date:
Your
Signature:
(Sign exactly as your name appears on the other side of this
Note)
Signature
Guarantee:
Participant in a recognized Signature Guarantee Medallion
Program
(or other signature guarantor program reasonably acceptable to
the Trustee)
B-13
EXHIBIT C
TO THE INDENTURE
FORM OF
NOTE GUARANTEE
For value received, each of the Guarantors hereby jointly and
severally unconditionally Guarantees, on a senior unsecured
basis, to each Holder of a Note authenticated and delivered by
the Trustee, and to the Trustee on behalf of such Holder, the
due and punctual payment of the principal of (and premium, if
any) and interest (including Additional Amounts, if any) on such
Note when and as the same shall become due and payable, whether
at the Stated Maturity, by acceleration, call for redemption,
purchase or otherwise, in accordance with the terms of such Note
and of the Indenture.
In case of the failure of the Issuer punctually to make any such
payment, each of the Guarantors hereby jointly and severally
agrees to cause such payment to be made punctually when and as
the same shall become due and payable, whether at the Stated
Maturity or by acceleration, call for redemption, purchase or
otherwise, and as if such payment were made by the Issuer. The
Note Guarantee extends to the Issuers repurchase
obligations arising from a Change of Control pursuant to the
Indenture.
Each of the Guarantors hereby jointly and severally agrees that
its obligations hereunder shall be unconditional, irrespective
of the validity, regularity or enforceability of such Note or
the Indenture, the absence of any action to enforce the same,
any exchange, release or non-perfection of any Lien on any
collateral for, or any release or amendment or waiver of any
term of any other Guarantee of, or any consent to departure from
any requirement of any other Guarantee of, all or any of the
Notes, the effects of Bankruptcy Law applicable in the event of
bankruptcy proceedings being opened with respect to the Issuer,
of all or any portion of the claims of the Trustee or any of the
Holders for payment of any of the Notes, any waiver or consent
by the Holder of such Note or by the Trustee with respect to any
provisions thereof or of the Indenture, the obtaining of any
judgment against the Issuer or any action to enforce the same or
any other circumstances which might otherwise constitute a legal
or equitable discharge or defense of a guarantor. Each of the
Guarantors hereby waives the benefits of diligence, presentment,
demand for payment, any requirement that the Trustee or any of
the Holders protect, secure, perfect or insure any security
interest in or other Lien on any property subject thereto or
exhaust any right or take any action against the Issuer or any
other Person or any collateral, filing of claims with a court in
the event of insolvency or bankruptcy of the Issuer, any right
to require a proceeding first against the Issuer, protest or
notice with respect to such Note or the Indebtedness evidenced
thereby and all demands whatsoever, and covenants that this Note
Guarantee will not be discharged in respect of such Note except
by complete performance of the obligations contained in such
Note and in this Note Guarantee. Each of the Guarantors hereby
agrees that, in the event of a default in payment of principal
(or premium, if any) or interest (including Additional Amounts,
if any) on such Note, whether at its Stated Maturity, by
acceleration, call for redemption, purchase or otherwise, legal
proceedings may be instituted by the Trustee on behalf of, or
by, the Holder of such Note, subject to the terms and conditions
set forth in the Indenture, directly against each of the
Guarantors to enforce this Note Guarantee without first
proceeding
C-1
against the Issuer. Each Guarantor agrees that, to the extent
permitted by applicable law, if, after the occurrence and during
the continuance of an Event of Default, the Trustee or any of
the Holders is prevented by applicable law from exercising its
respective rights to accelerate the maturity of the Notes, to
collect interest on the Notes, or to enforce or exercise any
other right or remedy with respect to the Notes, or the Trustee
or the Holders are prevented from taking any action to realize
on any collateral, such Guarantor agrees to pay to the Trustee
for the account of the Holders, upon demand therefor, the amount
that would otherwise have been due and payable had such rights
and remedies been permitted to be exercised by the Trustee or
any of the Holders.
No reference herein to the Indenture and no provision of this
Note Guarantee or of the Indenture shall alter or impair the
Note Guarantee of any Guarantor, which is absolute and
unconditional, of the due and punctual payment of the principal
of (and premium, if any) and interest (including Additional
Amounts, if any) on the Note upon which this Note Guarantee is
endorsed.
This Note Guarantee shall remain in full force and effect and
continue to be effective should any petition be filed by or
against the Issuer for liquidation or reorganization, or
equivalent proceeding under applicable law, should the Issuer
become insolvent or make an assignment for the benefit of
creditors or should a receiver or trustee be appointed for all
or any significant part of the Issuers assets, or the
equivalent of any of the foregoing under applicable law, and
shall, to the fullest extent permitted by applicable law,
continue to be effective or be reinstated, as the case may be,
if at any time payment and performance of the Notes is, pursuant
to applicable law, rescinded or reduced in amount, or must
otherwise be restored or returned by any obligee on the Notes
whether as a voidable preference, fraudulent transfer, or as
otherwise provided under similar laws affecting the rights of
creditors generally or under applicable laws of the jurisdiction
of formation of the Issuer, all as though such payment or
performance had not been made. In the event that any payment, or
any part thereof, is rescinded, reduced, restored or returned,
the Notes shall, to the fullest extent permitted by applicable
law, be reinstated and deemed reduced only by such amount paid
and not so rescinded, reduced, restored or returned.
The Guarantors shall have the right to seek contribution from
any non-paying Guarantor so long as the exercise of such right
does not impair the rights of the Holders under this Note
Guarantee. The Guarantors or any particular Guarantor shall be
released from this Note Guarantee upon the terms and subject to
certain conditions provided in the Indenture.
By delivery of a supplemental indenture to the Trustee in
accordance with the terms of the Indenture or the execution of a
Guarantee Agreement, each Person that becomes, or assumes the
obligations of, a Guarantor after the date of the Indenture will
be deemed to have executed and delivered this Note Guarantee for
the benefit of the Holder of this Note with the same effect as
if such Guarantor were named below.
All terms used in this Note Guarantee which are defined in the
Indenture referred to in the Note upon which this Note Guarantee
is endorsed shall have the meanings assigned to them in such
Indenture.
C-2
This Note Guarantee shall not be valid or obligatory for any
purpose until the certificate of authentication on the Note upon
which this Note Guarantee is endorsed shall have been executed
by the Trustee under the Indenture by manual signature.
Each Note Guarantee (other than that of the Company) will be
limited in amount to an amount not to exceed the maximum amount
that can be guaranteed by the applicable Guarantor without
rendering the Note Guarantee, as it relates to such Guarantor,
voidable under applicable law relating to fraudulent conveyance
or fraudulent transfer or similar laws affecting the rights of
creditors generally or under applicable law of the jurisdiction
of incorporation of such Guarantor.
In the case of Fresenius Medical Care Deutschland GmbH
(FMCD), the following provisions apply:
Without limiting the agreements set forth in Section 11.8,
the Note Guarantee of FMCD will be limited if and to the extent
payment under such Note Guarantee or the application of
enforcement proceeds would cause (i) FMCDs net assets
(
Reinvermögen
- calculated as the sum of the balance
sheet positions shown under § 266(2)(A), (B) and
(C) German Commercial Code (
Handelsgesetzbuch
)) less
the sum of the liabilities (shown under the balance sheet
positions pursuant to § 266(3)(B), (C) and
(D) German Commercial Code) to fall below FMCDs
registered share capital (
Stammkapital
) or (ii) (if the
amount of the net assets is already an amount less than the
registered share capital) cause such amount to be further
reduced and, in either case, thereby affecting the assets
required for the obligatory preservation of its registered share
capital according to section 30, 31 of the German Limited
Liability Company Act (GmbHG) (such event a Capital
Impairment). For the purposes of calculating the Capital
Impairment, the following adjustments will be made: (i) the
amount of any increase of the registered share capital out of
retained earnings (
Kapitalerhöhung aus
Gesellschaftsmitteln
) after the Closing Date that has been
effected without the prior consent of the Trustee shall be
deducted from the registered share capital; and
(ii) liabilities incurred in violation of the provisions of
the Notes and this Indenture shall be disregarded. In the event
FMCDs net assets fall below its registered share capital,
FMCD, upon request of the Trustee will realize in due course, to
the extent legally permitted, any and all of its assets that are
shown in the balance sheet with a book value (
Buchwert
)
that is significantly lower than the market value of the assets
if the relevant assets are not necessary for FMCDs
business (
nicht betriebsnotwendiges Vermögen
).
If FMCD objects to the amount demanded by the Trustee under the
Note Guarantee within twenty (20) business days after the
Trustee has submitted to FMCD a payment demand FMCD shall
appoint within five (5) business days a reputable
international auditor to determine the exact amount. The auditor
shall notify FMCD and the Trustee of the maximum amount payable
under the Note Guarantee within forty (40) business days
after its appointment. The costs of such auditors
determination shall be borne by FMCD. The determination of the
auditor shall be binding for FMCD, and the Holders (except for
manifest error). To the extent that any payment has been made
under the Note Guarantee by FMCD that would be necessary for
FMCD to be able to cure any Capital Impairment or Liquidity
Impairment such payment shall immediately upon
FMCDs demand be
C-3
returned to FMCD by any person receiving such payment, provided,
however, in no event shall the Trustee or Paying Agent have any
responsibility or liability for the return of any amount
distributed to any Holder or beneficial owner of the Notes by
the Trustee or Paying Agent, including, without limitation, any
obligation to seek return of such amounts from such Holder or
beneficial owner.
If (i) FMCD does not object to the payment amount within
the 20 business days period or (ii) if FMCD does not
appoint the auditor within the 5 business days period or
(iii) if the auditor fails to notify the amount payable
within the 40 days period, then the Trustee shall be
entitled to enforce the Note Guarantee without further delay.
The burden of demonstration and proof (
Darlegungs- und
Beweislast
) regarding the Capital Impairment and the maximum
amount payable under the Note Guarantee shall remain with FMCD.
The maximum amount payable under the guarantee shall be limited
to the extent and as long as FMCD as a consequence of the
payment would become unable to pay its debts when due
(
zahlungsunfähig
) within the meaning of
section 64 GmbHG (such event a Liquidity
Impairment). For the purpose of establishing whether a
Liquidity Impairment would occur, payments made by FMCD after
the Trustee has notified FMCD of its intention to enforce the
Note Guarantee with respect to payment obligations that are not
due at the time of the payment shall be disregarded, unless the
Trustee has consented to such payments (at the direction of the
Holders of at least a majority in principal amount of the Notes
then outstanding). From the time the Trustee has notified FMCD
and the Company of its intention to enforce the Note Guarantee,
the Company may not make any payment demands against FMCD under
shareholder loans and all such payment obligations of FMCD
towards the Company shall be deferred, subordinated or waived as
the Company sees fit, until the Trustee notifies FMCD that it is
no longer enforcing the Note Guarantee or the Trustee consents
(at the direction of the Holders of at least a majority in
principal amount of the Notes then outstanding) to the payments
to be made to the Company. Such notice may be delivered by the
Trustee at any time and, if not previously delivered, will be
delivered by the Trustee after the Notes have been repaid in
full and all other obligations under this Indenture are
satisfied.
The limitations as to the Capital Impairment shall not apply to
the extent FMCD has an adequate compensation claim
(
vollwertiger Gegenleistungs- oder
Rückgewähranspruch
) against the Company that
compensates for any loss incurred due to any payment by FMCD
under this Note Guarantee.
Reference is made to Article X of the Indenture for further
provisions with respect to this Note Guarantee.
THE NOTE GUARANTEES WILL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK EXCEPT THAT
THE LIMITATIONS OF THE NOTE GUARANTEES EXPRESSED IN
SECTION 10.1(c) OF THE INDENTURE (AND THE EQUIVALENT
PROVISIONS IN THE ELEVENTH PARAGRAPH HEREOF) WILL BE
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE FEDERAL REPUBLIC OF
GERMANY.
C-4
IN WITNESS WHEREOF, each of the undersigned has caused this Note
Guarantee to be duly executed.
FRESENIUS MEDICAL CARE
AG & CO. KGaA, a partnership limited by shares and
represented by FRESENIUS MEDICAL CARE MANAGEMENT AG, its general
partner
Name:
|
|
|
|
Title:
|
Member of the Management Board
|
Name:
|
|
|
|
Title:
|
Member of the Management Board
|
FRESENIUS MEDICAL CARE HOLDINGS,
INC
Name:
Title:
FRESENIUS MEDICAL CARE DEUTSCHLAND
GMBH
Name:
Title:
Name:
Title:
C-5
EXHIBIT D
TO THE
INDENTURE
FORM OF
TRANSFER CERTIFICATE FOR TRANSFER FROM
RULE 144A GLOBAL NOTE TO REGULATION S GLOBAL
NOTE
(Transfers pursuant to Section 2.7(a) of the Indenture)
FMC Finance VII S.A.
c/o U.S. Bank
National Association
225 Asylum Street, 23rd Floor
Hartford, CT 06103
|
|
Attention:
|
Corporate Trust and Agency Services
Elizabeth C. Hammer
|
|
|
|
|
RE:
|
5.25% Senior Notes due 2021
(the Notes) of FMC Finance VII S.A.
|
Reference is hereby made to the Indenture dated as of
February 3, 2011 (the Indenture) between FMC
Finance VII S.A., Fresenius Medical Care AG & Co.
KGaA, Fresenius Medical Care Holdings, Inc., Fresenius Medical
Care Deutschland GmbH, and U.S. Bank National Association,
as Trustee. Capitalized terms used but not defined herein shall
have the meanings given them in the Indenture.
This letter relates to
(being in a minimum amount of 1,000 and any integral
multiple of 1,000 in excess thereof) principal amount of
Notes beneficially held through interests in the Rule 144A
Global Note (ISIN: XS0576395551 Common Code:
057639555) with Euroclear and Clearstream Banking in the
name of
(the
Transferor), account
number
.
The Transferor hereby requests that on [INSERT DATE] such
beneficial interest in the Rule 144A Global Note be
transferred or exchanged for an interest in the
Regulation S Global Note (ISIN: XS0576395478 Common Code:
057639547) in the same principal denomination and
transferred
to
(account
no.
).
If this is a partial transfer, a minimum amount of 1,000
and any integral multiple of 1,000 in excess thereof of
the Rule 144A Global Note will remain outstanding.
In connection with such request and in respect of such Notes,
the Transferor does hereby certify that such transfer has been
effected in accordance with the transfer restrictions set forth
in the Indenture and the Notes and pursuant to and in accordance
with Rule 903 or 904 of Regulation S under the
Securities Act, and accordingly the Transferor further certifies
that:
(A) (1) the offer of the Notes
was not made to a Person in the United States;
D-1
(2) either (a) at the time the
buy order was originated, the transferee was outside the United
States or we and any Person acting on our behalf reasonably
believed that the transferee was outside the United States or
(b) the transaction was executed in, on or through the
facilities of a designated offshore securities market and
neither the Transferor nor any Person acting on our behalf knows
that the transaction was prearranged with a buyer in the United
States;
(3) no directed selling efforts
have been made in contravention of the requirements of
Rule 903(b) or 904(a) of Regulation S, as
applicable; and
(4) the transaction is not part of
a plan or scheme to evade the registration requirements of the
Securities Act.
OR
(B) such transfer is being made in
accordance with Rule 144 under the Securities Act.
D-2
This certificate and the statements contained herein are made
for your benefit and the benefit of the Issuer. Terms used in
this certificate and not otherwise defined in the Indenture have
the meanings set forth in Regulation S under the Securities
Act.
Dated:
[Name of Transferor]
Name:
Title:
Telephone No.:
|
|
Please print name and address (including zip code number)
|
|
D-3
EXHIBIT E
TO THE
INDENTURE
FORM OF
TRANSFER CERTIFICATE FOR TRANSFER FROM
REGULATION S GLOBAL NOTE TO RULE 144A GLOBAL
NOTE
(Transfers pursuant to Section 2.7(b) of the Indenture)
FMC Finance VII S.A.
c/o U.S. Bank
National Association
225 Asylum Street, 23rd Floor
Hartford, CT 06103
|
|
Attention:
|
Corporate Trust and Agency Services
|
Elizabeth C. Hammer
|
|
|
|
RE:
|
5.25% Senior Notes due 2021
(
the Notes) of FMC Finance VII S.A
.
|
Reference is hereby made to the Indenture dated as of
February 3, 2011 (the
Indenture
) between
FMC Finance VII S.A., Fresenius Medical Care AG & Co.
KGaA, Fresenius Medical Care Holdings, Inc., Fresenius Medical
Care Deutschland GmbH, and U.S. Bank National Association,
as Trustee. Capitalized terms used but not defined herein shall
have the meanings given them in the Indenture.
This letter relates to
(being in a minimum amount of 1,000 and in an integral
multiple of 1,000 in excess thereof) principal amount of
Notes beneficially held through interests in the
Regulation S Global Note (ISIN: XS0576395478 Common Code:
057639547) with Euroclear and Clearstream Banking in the
name
of
(the Transferor), account number
.
The Transferor hereby requests that on [INSERT DATE] such
beneficial interest in the Regulation S Global Note be
transferred or exchanged for an interest in the Rule 144A
Global Note (ISIN: XS0576395551 Common Code: 057639555)in the
same principal denomination and transferred to
(account
no.
).
If this is a partial transfer, a minimum of 1,000 and any
integral multiple of 1,000 in excess thereof of the
Regulation S Global Note will remain outstanding.
In connection with such request, and in respect of such Notes,
the Transferor does hereby certify that such Notes are being
transferred in accordance with Rule 144A under the
Securities Act to a transferee that the Transferor knows or
reasonably believes is purchasing the Notes for its own account
or an account with respect to which the transferee exercises
sole investment discretion and the transferee and any such
account is a qualified institutional buyer within
the meaning of Rule 144A, in each case in a transaction
meeting the requirements of Rule 144A and in accordance
with any applicable securities laws of any state of the United
States or any other jurisdiction.
E-1
This certificate and the statements contained herein are made
for your benefit and the benefit of the Issuer.
Dated:
[Name of Transferor]
Name:
Title:
Telephone No.:
|
|
Please print name and address (including zip code number)
|
|
E-2
Exhibit 2.22
FRESENIUS MEDICAL CARE US
FINANCE, INC.
as Issuer
U.S. BANK NATIONAL ASSOCIATION
as Trustee
FRESENIUS MEDICAL CARE
AG & Co. KGaA,
FRESENIUS MEDICAL CARE HOLDINGS, INC. and
FRESENIUS MEDICAL CARE DEUTSCHLAND GmbH
as Guarantors
INDENTURE
DATED AS OF FEBRUARY 3, 2011
with respect to the issuance of
5.75% SENIOR NOTES DUE 2021
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
ARTICLE I
|
|
DEFINITIONS AND INCORPORATION BY REFERENCE
|
|
|
|
|
|
|
|
|
|
|
SECTION 1.1
|
|
|
Definitions
|
|
|
1
|
|
|
SECTION 1.2
|
|
|
Rules of Construction
|
|
|
20
|
|
|
SECTION 1.3
|
|
|
Incorporation by Reference of Trust Indenture Act
|
|
|
20
|
|
|
ARTICLE II
|
|
THE NOTES
|
|
|
|
|
|
|
|
|
|
|
SECTION 2.1
|
|
|
Form and Dating
|
|
|
21
|
|
|
SECTION 2.2
|
|
|
Execution and Authentication
|
|
|
22
|
|
|
SECTION 2.3
|
|
|
Registrar and Paying Agent
|
|
|
23
|
|
|
SECTION 2.4
|
|
|
Paying Agent To Hold Assets in Trust
|
|
|
24
|
|
|
SECTION 2.5
|
|
|
List of Holders
|
|
|
24
|
|
|
SECTION 2.6
|
|
|
Book-Entry Provisions for Global Notes
|
|
|
24
|
|
|
SECTION 2.7
|
|
|
Registration of Transfer and Exchange
|
|
|
25
|
|
|
SECTION 2.8
|
|
|
Replacement Notes
|
|
|
30
|
|
|
SECTION 2.9
|
|
|
Outstanding Notes
|
|
|
30
|
|
|
SECTION 2.10
|
|
|
Treasury Notes
|
|
|
31
|
|
|
SECTION 2.11
|
|
|
Temporary Notes
|
|
|
31
|
|
|
SECTION 2.12
|
|
|
Cancellation
|
|
|
31
|
|
|
SECTION 2.13
|
|
|
Defaulted Interest
|
|
|
32
|
|
|
SECTION 2.14
|
|
|
CUSIP Numbers
|
|
|
32
|
|
|
SECTION 2.15
|
|
|
Deposit of Moneys
|
|
|
32
|
|
|
SECTION 2.16
|
|
|
Certain Matters Relating to Global Notes
|
|
|
32
|
|
|
SECTION 2.17
|
|
|
Record Date
|
|
|
33
|
|
|
ARTICLE III
|
|
REDEMPTION
|
|
|
|
|
|
|
|
|
|
|
SECTION 3.1
|
|
|
Optional Redemption
|
|
|
33
|
|
|
SECTION 3.2
|
|
|
Notices to Trustee
|
|
|
33
|
|
|
SECTION 3.3
|
|
|
Selection of Notes To Be Redeemed
|
|
|
33
|
|
|
SECTION 3.4
|
|
|
Notice of Redemption
|
|
|
34
|
|
|
SECTION 3.5
|
|
|
Effect of Notice of Redemption
|
|
|
35
|
|
|
SECTION 3.6
|
|
|
Deposit of Redemption Price
|
|
|
35
|
|
|
SECTION 3.7
|
|
|
Notes Redeemed in Part
|
|
|
36
|
|
|
SECTION 3.8
|
|
|
Special Tax Redemption
|
|
|
36
|
|
-i-
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
ARTICLE IV
|
|
COVENANTS
|
|
|
|
|
|
|
|
|
|
|
SECTION 4.1
|
|
|
Payment of Notes
|
|
|
37
|
|
|
SECTION 4.2
|
|
|
Maintenance of Office or Agency
|
|
|
37
|
|
|
SECTION 4.3
|
|
|
Limitation on Incurrence of Indebtedness
|
|
|
37
|
|
|
SECTION 4.4
|
|
|
Limitation on Liens
|
|
|
39
|
|
|
SECTION 4.5
|
|
|
Ownership of the Issuer
|
|
|
40
|
|
|
SECTION 4.6
|
|
|
Existence
|
|
|
40
|
|
|
SECTION 4.7
|
|
|
Maintenance of Properties
|
|
|
40
|
|
|
SECTION 4.8
|
|
|
Payment of Taxes and Other Claims
|
|
|
40
|
|
|
SECTION 4.9
|
|
|
Maintenance of Insurance
|
|
|
41
|
|
|
SECTION 4.10
|
|
|
Reports
|
|
|
41
|
|
|
SECTION 4.11
|
|
|
Change of Control
|
|
|
42
|
|
|
SECTION 4.12
|
|
|
Additional Amounts
|
|
|
44
|
|
|
SECTION 4.13
|
|
|
Compliance Certificate; Notice of Default
|
|
|
45
|
|
|
SECTION 4.14
|
|
|
Limitation on Sale and Leaseback Transactions
|
|
|
45
|
|
|
ARTICLE V
|
|
SUCCESSOR ISSUER OR GUARANTOR
|
|
|
|
|
|
|
|
|
|
|
SECTION 5.1
|
|
|
Limitation on Mergers and Sales of Assets
|
|
|
46
|
|
|
SECTION 5.2
|
|
|
Successor Entity Substituted
|
|
|
46
|
|
|
SECTION 5.3
|
|
|
Substitution of the Issuer
|
|
|
47
|
|
|
ARTICLE VI
|
|
DEFAULT AND REMEDIES
|
|
|
|
|
|
|
|
|
|
|
SECTION 6.1
|
|
|
Events of Default
|
|
|
47
|
|
|
SECTION 6.2
|
|
|
Acceleration
|
|
|
49
|
|
|
SECTION 6.3
|
|
|
Other Remedies
|
|
|
49
|
|
|
SECTION 6.4
|
|
|
The Trustee May Enforce Claims Without Possession of Notes
|
|
|
49
|
|
|
SECTION 6.5
|
|
|
Rights and Remedies Cumulative
|
|
|
49
|
|
|
SECTION 6.6
|
|
|
Delay or Omission Not Waiver
|
|
|
50
|
|
|
SECTION 6.7
|
|
|
Waiver of Past Defaults
|
|
|
50
|
|
|
SECTION 6.8
|
|
|
Control by Majority
|
|
|
50
|
|
|
SECTION 6.9
|
|
|
Limitation on Suits
|
|
|
50
|
|
|
SECTION 6.10
|
|
|
Rights of Holders To Receive Payment
|
|
|
51
|
|
|
SECTION 6.11
|
|
|
Collection Suit by Trustee
|
|
|
51
|
|
|
SECTION 6.12
|
|
|
Trustee May File Proofs of Claim
|
|
|
51
|
|
|
SECTION 6.13
|
|
|
Priorities
|
|
|
52
|
|
|
SECTION 6.14
|
|
|
Restoration of Rights and Remedies
|
|
|
52
|
|
|
SECTION 6.15
|
|
|
Undertaking for Costs
|
|
|
52
|
|
|
SECTION 6.16
|
|
|
Notices of Default
|
|
|
52
|
|
-ii-
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
ARTICLE VII
|
|
TRUSTEE
|
|
|
|
|
|
|
|
|
|
|
SECTION 7.1
|
|
|
Duties of Trustee
|
|
|
53
|
|
|
SECTION 7.2
|
|
|
Rights of Trustee
|
|
|
54
|
|
|
SECTION 7.3
|
|
|
Individual Rights of Trustee
|
|
|
55
|
|
|
SECTION 7.4
|
|
|
Trustees Disclaimer
|
|
|
55
|
|
|
SECTION 7.5
|
|
|
Notice of Default
|
|
|
55
|
|
|
SECTION 7.6
|
|
|
Reports by Trustee to Holders of the Notes
|
|
|
55
|
|
|
SECTION 7.7
|
|
|
Compensation and Indemnity
|
|
|
56
|
|
|
SECTION 7.8
|
|
|
Replacement of Trustee
|
|
|
57
|
|
|
SECTION 7.9
|
|
|
Successor Trustee by Merger, Etc
|
|
|
58
|
|
|
SECTION 7.10
|
|
|
Eligibility; Disqualification
|
|
|
58
|
|
|
SECTION 7.11
|
|
|
Preferential Collection of Claims Against the Company
|
|
|
58
|
|
|
ARTICLE VIII
|
|
SATISFACTION AND DISCHARGE OF INDENTURE
|
|
|
|
|
|
|
|
|
|
|
SECTION 8.1
|
|
|
Option To Effect Legal Defeasance or Covenant Defeasance
|
|
|
59
|
|
|
SECTION 8.2
|
|
|
Legal Defeasance and Discharge
|
|
|
59
|
|
|
SECTION 8.3
|
|
|
Covenant Defeasance
|
|
|
59
|
|
|
SECTION 8.4
|
|
|
Conditions to Legal or Covenant Defeasance
|
|
|
60
|
|
|
SECTION 8.5
|
|
|
Satisfaction and Discharge of Indenture
|
|
|
61
|
|
|
SECTION 8.6
|
|
|
Survival of Certain Obligations
|
|
|
61
|
|
|
SECTION 8.7
|
|
|
Acknowledgment of Discharge by Trustee
|
|
|
62
|
|
|
SECTION 8.8
|
|
|
Application of Trust Moneys
|
|
|
62
|
|
|
SECTION 8.9
|
|
|
Repayment to the Issuer; Unclaimed Money
|
|
|
62
|
|
|
SECTION 8.10
|
|
|
Reinstatement
|
|
|
63
|
|
|
ARTICLE IX
|
|
AMENDMENTS, SUPPLEMENTS AND WAIVERS
|
|
|
|
|
|
|
|
|
|
|
SECTION 9.1
|
|
|
Without Consent of Holders of Notes
|
|
|
63
|
|
|
SECTION 9.2
|
|
|
With Consent of Holders of Notes
|
|
|
64
|
|
|
SECTION 9.3
|
|
|
Notice of Amendment, Supplement or Waiver
|
|
|
65
|
|
|
SECTION 9.4
|
|
|
Revocation and Effect of Consents
|
|
|
65
|
|
|
SECTION 9.5
|
|
|
Notation on or Exchange of Notes
|
|
|
65
|
|
|
SECTION 9.6
|
|
|
Trustee To Sign Amendments, Etc
|
|
|
65
|
|
|
ARTICLE X
|
|
NOTE GUARANTEE
|
|
|
|
|
|
|
|
|
|
|
SECTION 10.1
|
|
|
Note Guarantee
|
|
|
66
|
|
-iii-
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
|
SECTION 10.2
|
|
|
Execution and Delivery of Note Guarantees
|
|
|
69
|
|
|
SECTION 10.3
|
|
|
Guarantors May Consolidate, Etc., on Certain Terms
|
|
|
70
|
|
|
SECTION 10.4
|
|
|
Release of Guarantors
|
|
|
70
|
|
|
ARTICLE XI
|
|
MISCELLANEOUS
|
|
|
|
|
|
|
|
|
|
|
SECTION 11.1
|
|
|
Notices
|
|
|
70
|
|
|
SECTION 11.2
|
|
|
Certificate and Opinion as to Conditions Precedent
|
|
|
72
|
|
|
SECTION 11.3
|
|
|
Statements Required in Certificate or Opinion
|
|
|
73
|
|
|
SECTION 11.4
|
|
|
Rules by Trustee, Paying Agent, Registrar
|
|
|
73
|
|
|
SECTION 11.5
|
|
|
Legal Holidays
|
|
|
73
|
|
|
SECTION 11.6
|
|
|
Governing Law
|
|
|
73
|
|
|
SECTION 11.7
|
|
|
Submission to Jurisdiction
|
|
|
74
|
|
|
SECTION 11.8
|
|
|
No Personal Liability of Directors, Officers, Employees and
|
|
|
|
|
|
|
|
|
Stockholders
|
|
|
74
|
|
|
SECTION 11.9
|
|
|
Successors
|
|
|
75
|
|
|
SECTION 11.10
|
|
|
Counterpart Originals
|
|
|
75
|
|
|
SECTION 11.11
|
|
|
Severability
|
|
|
75
|
|
|
SECTION 11.12
|
|
|
Table of Contents, Headings, Etc
|
|
|
75
|
|
|
SECTION 11.13
|
|
|
Trust Indenture Act Controls
|
|
|
75
|
|
|
SECTION 11.14
|
|
|
Currency Indemnity
|
|
|
|
|
|
SECTION 11.15
|
|
|
Information
|
|
|
76
|
|
-iv-
|
|
|
|
|
EXHIBITS
|
|
|
|
|
Exhibit A
|
|
-
|
|
Form of Initial Global Note
|
Exhibit B
|
|
-
|
|
Form of Initial Definitive Note
|
Exhibit C
|
|
-
|
|
Form of Note Guarantee
|
Exhibit D
|
|
-
|
|
Form of Transfer Certificate for Transfer from Rule 144A
Global Note to Regulation S Global Note
|
Exhibit E
|
|
-
|
|
Form of Transfer Certificate for Transfer from Regulation S
Global Note to Rule 144A Global Note
|
NOTE: This Table of Contents shall not, for any purpose, be
deemed to be part of this Indenture.
-v-
INDENTURE dated as of February 3, 2011, among FRESENIUS
MEDICAL CARE US FINANCE, INC., a Delaware corporation (the
Issuer), as Issuer, FRESENIUS MEDICAL CARE
AG & Co. KGaA, a partnership limited by shares
(Kommanditgesellschaft auf Aktien) organized under the laws of
the Federal Republic of Germany (the Company),
FRESENIUS MEDICAL CARE HOLDINGS, INC., a New York corporation
(FMCH) and FRESENIUS MEDICAL CARE DEUTSCHLAND GmbH,
a limited liability company organized under the laws of the
Federal Republic of Germany (FMCD and, together with
the Company and FMCH, the Guarantors) and
U.S. BANK NATIONAL ASSOCIATION, a national banking
association, as trustee (the Trustee).
The Issuer has duly authorized the creation and issuance of its
5.75% Senior Notes due 2021. The Notes consist of
(i) $650,000,000 aggregate principal amount of notes issued
on the date hereof (the Initial Notes) and
(ii) Additional Notes (as defined herein) that may be
issued on any Issue Date (all such notes referred to in
clauses (i) and (ii) being referred to as the
Notes); and, to provide therefor, the Issuer has
duly authorized the execution and delivery of this Indenture.
The Notes will be guaranteed (the Note Guarantee) on
a senior unsecured basis by each Guarantor. Each of the Issuer
and the Guarantors has duly authorized the execution and
delivery of this Indenture. All things necessary to make the
Notes, when duly issued and executed by the Issuer and
authenticated and delivered by the Trustee hereunder, the valid
obligations of the Issuer, and the Note Guarantee, when executed
by each Guarantor and endorsed upon the Notes, the valid
obligation of each Guarantor and to make this Indenture a valid
agreement of the Issuer and each Guarantor, have been done.
Each party agrees as follows for the benefit of the other
parties and for the equal and ratable benefit of the Holders:
ARTICLE I
DEFINITIONS AND INCORPORATION
BY REFERENCE
SECTION 1.1
Definitions
. As
used in this Indenture, the following terms shall have the
following meanings:
Accounting Principles means U.S. GAAP, or, upon
adoption thereof by the Company and notice to the Trustee, IFRS
or any other accounting standards which are generally acceptable
in the jurisdiction of organization of the Company, approved by
the relevant regulatory or other accounting bodies in that
jurisdiction and internationally generally acceptable and, in
the case of IFRS or such other accounting standards, as in
effect from time to time.
Acquired Indebtedness means Indebtedness of a Person
existing at the time such Person becomes a Subsidiary or is
merged into or consolidated with any other Person or that is
assumed in connection with the acquisition of assets from such
Person and, in each case, not Incurred by such Person in
connection with, or in anticipation or contemplation of, such
Person becoming a Subsidiary or such merger, consolidation or
acquisition.
Additional Amounts shall have the meaning set forth
in Section 4.12 hereof.
Additional Notes means additional 5.75% Senior
Notes due 2021.
Additional Taxing Jurisdiction shall have the
meaning set forth in Section 4.12 hereof.
Affiliate of any specified Person means:
(1) any other Person, directly or
indirectly, controlling or controlled by, or
(2) under direct or indirect common
control with such specified Person.
For the purposes of this definition, control when
used with respect to any Person means the power to direct the
management and policies of such Person, directly or indirectly,
whether through the ownership of voting securities, by contract
or otherwise; and the terms controlling and
controlled have meanings correlative to the
foregoing.
Agent means the Paying Agent, any Registrar,
Authenticating Agent or co-Registrar.
Agent Members shall have the meaning set forth in
Section 2.16.
A/R Facility means the accounts receivable facility
established pursuant to the Fifth Amended and Restated Transfer
and Administration Agreement dated as of November 17, 2009
by and among NMC Funding Corporation, as transferor, National
Medical Care, Inc., as initial collection agent, Compass US
Acquisition LLC, and other conduit investors party thereto, the
financial institutions party thereto, The Bank of Nova Scotia,
Barclays Bank PLC, Credit Agricole Corporate and Investment
Bank, New York Branch and Royal Bank of Canada, as
administrative agents, and WestLB AG, New York Branch, as
administrative agent and as agent (as amended, modified,
renewed, refunded, replaced, restated or refinanced from time to
time).
Asset Disposition means any direct or indirect sale,
issuance, conveyance, transfer, lease (other than operating
leases entered into in the ordinary course of business),
assignment or other transfer for value by the Company or any of
its Subsidiaries (including any Sale and Leaseback Transaction)
to any Person other than the Company or a Wholly Owned
Subsidiary of the Company, including any disposition by means of
a merger, consolidation or similar transaction (each referred to
for the purposes of this definition as a
disposition), of:
(1) any shares of Capital Stock of
any Subsidiary (other than directors qualifying shares or
shares required by applicable law to be held by a Person other
than the Company or a Subsidiary),
(2) all or substantially all the
assets of any division or line of business of the Company or any
Subsidiary, or
(3) any other assets of the Company
or any Subsidiary outside of the ordinary course of business of
the Company or such Subsidiary,
other than, in the case of clauses (1), (2) and
(3) above,
-2-
(A) a disposition of assets or
issuance of Capital Stock by a Subsidiary to the Company or by
the Company or a Subsidiary to a Wholly Owned Subsidiary,
(B) transactions permitted under
Section 5.1, and
(C) dispositions in connection with
Permitted Liens, foreclosures on assets and any release of
claims which have been written down or written off.
Attributable Debt means, in respect of any Sale and
Leaseback Transaction, as of the time of determination, the
total obligation (discounted to present value at the rate per
annum equal to the discount rate which would be applicable to a
Capital Lease Obligation with the like term in accordance with
Accounting Principles) of the lessee for rental payments (other
than amounts required to be paid on account of property taxes,
maintenance, repairs, insurance, water rates and other items
which do not constitute payments for property rights) during the
remaining portion of the initial term of the lease included in
such Sale and Leaseback Transaction.
Authenticating Agent shall have the meaning set
forth in Section 2.2.
Average Life means, as of the date of determination,
with respect to any Indebtedness or Preferred Stock, the
quotient obtained by dividing:
(1) the sum of the products of
numbers of years from the date of determination to the dates of
each successive scheduled principal payment of such Indebtedness
or redemption or similar payment with respect to such Preferred
Stock multiplied by the amount of such payment by,
(2) the sum of all such payments.
Bankruptcy Law means (i) for purposes of the
Company and FMCD organized under the laws of the Federal
Republic of Germany, any bankruptcy, insolvency, reorganization,
moratorium and other similar laws of general application
(including, without limitation, the German Insolvency Code
(
Insolvenzordnung
) and (ii) for purposes
of the Issuer and FMCH, or the Trustee, Title 11, United
States Code or any similar federal, state or foreign law for the
relief of debtors.
Board of Directors means, with respect to the Issuer
or any Guarantor, as the case may be, the Board of Directors (or
other body performing functions similar to any of those
performed by a Board of Directors including those performed, in
the case of a German stock corporation, by the management board
or, in the case of a KGaA, by the General Partner) of such
Person or any committee thereof duly authorized to act on behalf
of such Board (or other body).
Board Resolution means, with respect to the Issuer
or a Guarantor, a copy of a resolution certified by the
Secretary or an Assistant Secretary or a member of the Board of
Directors or Management Board of the Issuer or such Guarantor to
have been duly adopted by the Board of Directors or the
Management Board, or such committee of the Board of Directors or
the Management Board or officers of the Issuer or such Guarantor
to which authority to act on behalf of the Board of Directors or
the Management Board has been delegated, and to be in full force
and effect on the date of such certification, and delivered to
the Trustee by the Issuer or the Gua-
-3-
rantor, as the case may be, and the Trustee shall be entitled to
rely on such certification as conclusive evidence thereof.
Business Day means any day other than:
(1) a Saturday or Sunday,
(2) a day on which banking
institutions in New York City, Frankfurt am Main or the
jurisdiction of organization of the Issuer or of the office of
the Paying Agent (other than the Trustee) are authorized or
required by law or executive order to remain closed, or
(3) a day on which the Corporate
Trust Office of the Trustee is closed for business.
Capital Lease Obligations means an obligation that
is required to be classified and accounted for as a capital
lease for financial reporting purposes in accordance with
Accounting Principles, and the amount of Indebtedness
represented by such obligation shall be the capitalized amount
of such obligation determined in accordance with Accounting
Principles; and the Stated Maturity thereof shall be the date of
the last payment of rent or any other amount due under such
lease prior to the first date upon which such lease may be
terminated by the lessee without payment of a penalty.
Capital Stock of any Person means any and all
shares, interests, rights to purchase, warrants, options,
participations or other equivalents of or interests in (however
designated) equity of such Person, including any Preferred
Stock, but excluding any debt securities convertible into such
equity.
Cash Management Arrangements means the cash
management arrangements of the Company and its Affiliates
(including any Indebtedness arising thereunder) which
arrangements are in the ordinary course of business consistent
with past practice.
Change of Control means the occurrence of one or
more of the following events:
(1) so long as the Company is
organized as a KGaA, if the General Partner of the Company
charged with management of the Company shall at any time fail to
be a Subsidiary of Fresenius SE, or if Fresenius SE shall fail
at any time to own and control more than 25% of the capital
stock with ordinary voting power in the Company;
(2) if the Company is no longer
organized as a KGaA, any event the result of which is that
(A) any person or group (as such
terms are used in Sections 13(d) and 14(d) of the Exchange
Act), other than Fresenius SE, is or becomes the beneficial
owner (as defined in
Rules 13d-3
and
13d-5
under the Exchange Act, except that such Person or group shall
be deemed to have beneficial ownership of all shares
that any such Person or group has the right to acquire, whether
such right is exercisable immediately or only after the passage
of time), directly or indirectly, of more than 35% of the total
voting power of the Voting Stock of the Company and
(B) Fresenius SE does not beneficially
-4-
own (as defined in
Rules 13d-3
and
13d-5
of
the Exchange Act), directly or indirectly, in the aggregate a
greater percentage of the total voting power of the Voting Stock
of the Company;
(3) any sale, lease, exchange or
other transfer (in one transaction or a series of related
transactions) of all or substantially all of the assets of the
Company to any Person or group of related Persons for purposes
of Section 13(d) of the Exchange Act (a Group),
together with any Affiliates thereof (whether or not otherwise
in compliance with the provisions herein).
Change of Control Triggering Event means the
occurrence of a Change of Control and a Ratings Decline.
Closing Date means the date of this Indenture.
Code means the United States Internal Revenue Code
of 1986, as amended.
Company means the party named as such in this
Indenture until a successor replaces it pursuant to this
Indenture and thereafter means such successor.
Consolidated Coverage Ratio of any Person as of any
date of determination means the ratio of (x) the aggregate
amount of EBITDA for such Persons most recently ended four
full fiscal quarters for which internal financial statements are
available immediately preceding the date of such determination
to (y) Consolidated Interest Expense for such four fiscal
quarters;
provided
,
however
, that:
(1) if such Person or any of its
Subsidiaries has Incurred or repaid, repurchased, defeased or
otherwise discharged (in each case other than Indebtedness under
any revolving credit facility unless such Indebtedness has been
permanently repaid and any related commitment has been
terminated) any Indebtedness since the beginning of such period
that remains outstanding or discharged or if the transaction
giving rise to the need to calculate the Consolidated Coverage
Ratio is an Incurrence or discharge of Indebtedness, or both,
EBITDA and Consolidated Interest Expense for such period shall
be calculated after giving effect on a pro forma basis to such
Indebtedness as if such Indebtedness had been Incurred or
discharged on the first day of such period and the Incurrence or
discharge of any other Indebtedness as if such Incurrence or
discharge had occurred on the first day of such period,
(2) if since the beginning of such
period such Person or any of its Subsidiaries shall have made
any Asset Disposition, the EBITDA for such period shall be
reduced by an amount equal to the EBITDA (if positive) directly
attributable to the assets which are the subject of such Asset
Disposition for such period, or increased by an amount equal to
the EBITDA (if negative), directly attributable thereto for such
period and Consolidated Interest Expense for such period shall
be reduced by an amount equal to the Consolidated Interest
Expense directly attributable to any Indebtedness of such Person
or any of its Subsidiaries repaid, repurchased, defeased or
otherwise discharged with respect to such Person and its
continuing Subsidiaries in connection with such Asset
Disposition for such period (or, if the Capital Stock of any
Subsidiary is sold, the Consolidated Interest Ex-
-5-
pense for such period of credit and directly attributable to the
Indebtedness of such Subsidiary to the extent such Person and
its continuing Subsidiaries are no longer liable for such
Indebtedness after such Asset Disposition),
(3) if since the beginning of such
period such Person or any of its Subsidiaries (by merger or
otherwise) shall have made an Investment in any Subsidiary (or
any Person which becomes a Subsidiary) or an acquisition of
assets, which constitutes all or substantially all of an
operating unit of a business, EBITDA and Consolidated Interest
Expense for such period shall be calculated after giving pro
forma effect thereto (including the Incurrence of any
Indebtedness) as if such Investment or acquisition occurred on
the first day of such period, and
(4) if since the beginning of such
period any Person (that subsequently became a Subsidiary or was
merged with or into such Person or any of its Subsidiaries since
the beginning of such period) shall have made any Asset
Disposition, any Investment or acquisition of assets that would
have required an adjustment pursuant to clause (2) or
(3) above if made by such Person or a Subsidiary of such
Person during such period, EBITDA and Consolidated Interest
Expense for such period shall be calculated after giving pro
forma effect thereto as if such Asset Disposition, Investment or
acquisition occurred on the first day of such period.
For purposes of this definition, whenever pro forma effect is to
be given to an acquisition of assets, the amount of income or
earnings relating thereto and the amount of Consolidated
Interest Expense associated with any Indebtedness Incurred in
connection therewith, the pro forma calculations shall be
determined in good faith by a responsible financial or
accounting officer of the Company, as applicable. If any
Indebtedness bears a floating rate of interest and is being
given pro forma effect, the interest of such Indebtedness shall
be calculated as if the rate in effect on the date of
determination had been the applicable rate for the entire period
(taking into account any Interest Rate Agreement applicable to
such Indebtedness if such Interest Rate Agreement has a
remaining term in excess of 12 months).
Consolidated Interest Expense means, with respect to
any Person for any period, the total interest expense of such
Person and its consolidated Subsidiaries, including the
amortization of debt discount and premium, the interest
component under capital leases and the implied interest
component (if any) under any Receivables Financing, in each case
on a consolidated basis determined in accordance with Accounting
Principles.
Consolidated Net Income means, with respect to any
Person for any period, the net income of such Person and its
consolidated Subsidiaries (including, for any period after
January 1, 2009, any net income attributable to
non-controlling interest of such Person and its consolidated
Subsidiaries), in each case as determined on a consolidated
basis in accordance with Accounting Principles;
provided
that extraordinary gains and losses shall be excluded from
Consolidated Net Income.
Consolidated Net Tangible Assets means, as of any
date of determination, the total amount of all assets of the
Company and its Subsidiaries, determined on a consolidated ba-
-6-
sis in accordance with Accounting Principles, as of the end of
the most recent fiscal quarter for which the Companys
financial statements are available, less the sum of:
(1) the Companys consolidated
current liabilities as of such quarter end, determined on a
consolidated basis in accordance with Accounting
Principles; and
(2) the Companys consolidated
assets that are properly classified as intangible assets as of
such quarter end, determined on a consolidated basis in
accordance with Accounting Principles.
Corporate Trust Office means the address of the
Trustee specified in Section 11.1, or such other address as
to which the Trustee may, from time to time, give written notice
to the Company.
Covenant Defeasance shall have the meaning set forth
in Section 8.3.
Credit Facility means (i) the bank credit
agreement entered into as of March 31, 2006 among the
Company, FMCH, the other borrowers identified therein, the
guarantors identified therein, the lenders party thereto and
Bank of America, N.A., as administrative agent, as extended on
September 29, 2010 and as amended, modified, renewed,
refunded, replaced, restated or refinanced from time to time
(the Revolving Credit Facility) and (ii) the
term loan credit agreement entered into as of March 31,
2006 among the Company, FMCH, the other borrowers identified
therein, the guarantors identified therein, the lenders party
thereto and Bank of America, N.A., as administrative agent, as
extended on September 29, 2010 and as amended, modified,
renewed, refunded, replaced, restated or refinanced from time to
time.
Currency Agreement means any foreign currency
exchange contract, currency swap agreement or other similar
agreement or arrangement.
Custodian means any receiver, trustee, assignee,
liquidator, sequestration or similar official under any
Bankruptcy Law.
Default means any event that is, or after notice or
passage of time or both would be, an Event of Default (as
defined herein).
Default Interest Payment Date shall have the meaning
set forth in Section 2.13.
Defeasance Trust shall have the meaning set forth in
Section 8.4.
Definitive Notes means Notes in definitive
registered form substantially in the form of
Exhibit B
.
Depositary or DTC means, with respect to
the Notes issued in the form of one or more Global Notes, The
Depository Trust Company or another Person designated as
Depositary by the Company, which Person must be a depositary
registered under the Exchange Act.
Designated Government Obligations means direct
non-callable and non-redeemable obligations (in each case, with
respect to the issuer thereof) of any member state of
-7-
the European Union that is a member of the European Union as of
the date of this Indenture or of the United States of America
(including, in each case, any agency or instrumentality
thereof), as the case may be, the payment of which is secured by
the full faith and credit of the applicable member state or of
the United States of America, as the case may be.
Disqualified Stock means, with respect to any
Person, any Capital Stock that by its terms (or by the terms of
any security into which it is convertible or for which it is
exchangeable) or upon the happening of any event:
(1) matures or is mandatorily
redeemable pursuant to a sinking fund obligation or otherwise;
(2) is convertible or exchangeable
for Indebtedness or Disqualified Stock; or
(3) is redeemable at the option of
the holder thereof, in whole or in part,
in each case on or prior to the first anniversary of the Stated
Maturity of the Notes;
provided
,
however
, that any
Capital Stock that would not constitute Disqualified Stock but
for provisions thereof giving holders thereof the right to
require such Person to repurchase or redeem such Capital Stock
upon the occurrence of an asset sale or change
of control occurring prior to the first anniversary of the
Stated Maturity of the Notes shall not constitute Disqualified
Stock if the asset sale or change of
control provisions applicable to such Capital Stock are
not more favorable to the holders of such Capital Stock than the
provisions of Section 4.11.
EBITDA for any Person for any period means the sum
of Consolidated Net Income of such Person, plus Consolidated
Interest Expense of such Person plus the following to the extent
deducted in calculating such Consolidated Net Income:
(1) all income tax expense of such
Person and its Subsidiaries,
(2) depreciation expense, and
(3) amortization expense, in each
case for such period.
Notwithstanding the foregoing, the provision for taxes based on
the income or profits of, and the depreciation and amortization
of, a Subsidiary that is not a Wholly Owned Subsidiary shall be
added to Consolidated Net Income to compute EBITDA only to the
extent (and in the same proportion) that the net income of such
Subsidiary was included in calculating Consolidated Net Income
and only if a corresponding amount would be permitted at the
date of determination to be dividended to such Person by such
Subsidiary without prior approval (that has not been obtained),
pursuant to the terms of its charter and all agreements,
instruments, judgments, decrees, orders, statutes, rules and
governmental regulations applicable to such Subsidiary or its
stockholders.
Event of Default shall have the meaning set forth in
Section 6.1.
Exchange Act means the United States Securities
Exchange Act of 1934, as amended.
-8-
Finance Subsidiary means any Wholly Owned Subsidiary
of the Company created for the sole purpose of issuing evidences
of Indebtedness and which is subject to similar restrictions on
its activities as the Issuer.
Fresenius SE means Fresenius SE & Co.
KGaA, a partnership limited by shares (
Kommanditgesellschaft
auf Aktien
) resulting from the change of legal form of
Fresenius SE, a European Company (Societas Europaea) previously
called Fresenius AG, a German stock corporation.
General Partner means Fresenius Medical Care
Management AG, a German stock corporation, including its
successors and assigns and other Persons, in each case who serve
as the general partner (
persönlich haftender
Gesellschafter
) of the Company from time to time.
Global Notes shall mean Notes in registered global
form substantially in the form of
Exhibit A
.
Guarantee means any obligation, contingent or
otherwise, of any Person directly or indirectly guaranteeing any
Indebtedness or other obligation of any Person (other than, in
the case of subsidiaries, obligations which would not constitute
Indebtedness) and any obligation, direct or indirect, contingent
or otherwise, of such Person:
(1) to purchase or pay (or advance
or supply funds for the purchase or payment of) such
Indebtedness or other obligation of such Person (whether arising
by virtue of partnership arrangements, or by agreements to
keep-well, to purchase assets, goods, securities or services, to
take-or-pay
or to maintain financial statement conditions or
otherwise), or
(2) entered into for the purpose of
assuring in any other manner the obligee of such Indebtedness or
other obligation of the payment thereof or to protect such
obligee against loss in respect thereof (in whole or in part);
provided
,
however
, that the term
Guarantee shall not include endorsements for
collection or deposit in the ordinary course of business. The
term Guarantee used as a verb has a corresponding
meaning.
Guarantee Agreement means, in the context of a
consolidation, merger or sale of all or substantially all of the
assets of a Guarantor, an agreement by which the Surviving
Person from such a transaction expressly assumes all of the
obligations of such Guarantor under its Note Guarantee.
Guarantor means each of the Company, FMCH and FMCD
and any successor or additional Guarantor, unless released from
its obligations under its Note Guarantee in accordance with the
terms of this Indenture.
Hedging Obligations of any Person means the
obligations of such Person pursuant to any Interest Rate
Agreement or Currency Agreement.
-9-
Holder means a Person in whose name a Note is
registered on the Registrars books.
IFRS means international financial reporting
standards and interpretations issued by the International
Accounting Standards Board and adopted by the European
Commission, as in effect from time to time.
Incur means issue, assume, guarantee, incur or
otherwise become liable for;
provided
,
however
,
that any Indebtedness or Capital Stock of a Person existing at
the time such Person becomes a Subsidiary (whether by merger,
consolidation, acquisition or otherwise) shall be deemed to be
Incurred by such Subsidiary at the time it becomes a Subsidiary.
The term Incurrence when used as a noun shall have a
correlative meaning. The accretion of principal of a
non-interest bearing or other discount security shall be deemed
the Incurrence of Indebtedness.
Indebtedness means, with respect to any Person on
any date of determination (without duplication):
(1) the principal of and premium
(if any) in respect of (A) indebtedness of such Person for
money borrowed and (B) indebtedness evidenced by notes,
debentures, bonds or other similar instruments for the payment
of which such Person is responsible or liable,
(2) all Capital Lease Obligations
of such Person,
(3) all obligations of such Person
issued or assumed as the deferred purchase price of property or
services, all conditional sale obligations of such Person and
all obligations of such Person under any title retention
agreement (other than (x) customary reservations or
retentions of title under agreements with suppliers entered into
in the ordinary course of business, (y) trade debt Incurred
in the ordinary course of business and not overdue by
90 days or more and (z) obligations Incurred under a
pension, retirement or deferred compensation program or
arrangement regulated under the Employee Retirement Income
Security Act of 1974, as amended, or the laws of a foreign
government),
(4) all obligations of such Person
for the reimbursement of any obligor on any letter of credit,
bank guarantee, bankers acceptance or similar credit
transaction (except to the extent such reimbursement obligation
relates to trade debt in the ordinary course of business and
such reimbursement obligation is paid within 30 days after
payment of the trade debt),
(5) the amount of all obligations
of such Person with respect to the redemption, repayment or
other repurchase of any Disqualified Stock or, with respect to
any subsidiary of such Person, any Preferred Stock (but
excluding, in each case, any accrued dividends),
(6) all obligations of the type
referred to in clauses (1) through (5) of other
Persons and all dividends of other Persons for the payment of
which, in either case, such Person is responsible or liable,
directly or indirectly, as obligor, guarantor or otherwise,
including by means of any Guarantee,
-10-
(7) all obligations of the type
referred to in clauses (1) through (6) of other
Persons secured by any Lien on any property or asset of such
Person (whether or not such obligation is assumed by such
Person), the amount of such obligation being deemed to be the
lesser of the value of such property or assets or the amount of
the obligation so secured, and
(8) to the extent not otherwise
included in this definition, Hedging Obligations of such Person.
The amount of Indebtedness of any Person at any date shall be
the outstanding balance at such date of all unconditional
obligations as described above and the maximum liability, upon
the occurrence of the contingency giving rise to the obligation,
of any contingent obligations at such date. For the avoidance of
doubt, the following will not be treated as Indebtedness:
(1) Indebtedness Incurred in
respect of workers compensation claims, self insurance
obligations, performance, surety and similar bonds and
completion guarantees provided in this ordinary course of
business;
(2) Indebtedness arising from
agreements providing for indemnification, adjustment of purchase
price or similar obligations, in each case, Incurred or assumed
in connection with the disposition or acquisition of any
business, assets or Capital Stock of a Subsidiary,
provided
, that the maximum aggregate liability in respect
of all such Indebtedness (other than in respect of tax and
environmental indemnities) shall at no time exceed, in the case
of a disposition, the gross proceeds actually received by the
Company and its Subsidiaries in connection with such disposition
and, in the case of an acquisition, the fair market value of any
business assets or Capital Stock acquired;
(3) Indebtedness arising from the
honoring by a bank or other financial institution of a check,
draft or similar instrument (except in the case of daylight
overdrafts) drawn against insufficient funds in the ordinary
course of business,
provided
that such Indebtedness is
extinguished within five Business Days of the Incurrence.
Indenture means this Indenture, as amended, modified
or supplemented from time to time in accordance with the terms
hereof.
Initial Notes shall have the meaning set forth in
the preamble to this Indenture.
Interest Rate Agreement means any interest rate swap
agreement, interest rate cap agreement or other similar
financial agreement or arrangement.
Investment in any Person means any direct or
indirect advance, loan (other than advances to customers in the
ordinary course of business that are recorded as accounts
receivable on the balance sheet of such Person) or other
extensions of credit (including by way of Guarantee or similar
arrangement) or capital contribution to (by means of any
transfer of cash or other property to others or any payment for
property or services for the account or use of others), or any
purchase or acquisition of Capital Stock, Indebtedness or other
similar instruments issued by such Person;
provided
,
however
, that advances, loans or other extensions of
credit arising under the Cash Management Arrangements shall not
be deemed Investments.
-11-
Investment Grade means a rating of BBB- or higher by
S&P and Baa3 or higher by Moodys or the equivalent of
such ratings by S&P or Moodys and the equivalent in
respect of Rating Categories of any Rating Agencies substituted
for S&P or Moodys.
Investment Grade Status exists as of any time if at
such time both (i) the rating assigned to the Notes by
Moodys is at least Baa3 (or the equivalent) or higher and
(ii) the rating assigned to the Notes by S&P is at
least BBB- (or the equivalent) or higher and the equivalent in
respect of Rating Categories of any Rating Agencies substituted
for S&P or Moodys.
Issue Date means the date on which any Notes are
issued.
Issuer means Fresenius Medical Care US Finance, Inc.
until a successor replaces it pursuant to this Indenture and
thereafter means such successor.
Issuer Order means a written order or request signed
in the name of the Issuer by a Responsible Officer of the Issuer
and delivered to the Trustee by the Issuer.
KGaA means a German partnership limited by shares
(
Kommanditgesellschaft auf Aktien
).
Legal Defeasance shall have the meaning set forth in
Section 8.2.
Lien means any mortgage, pledge, security interest,
encumbrance, lien or charge of any kind (including any
conditional sale or other title retention agreement or lease in
the nature thereof).
Listing Agent means BNP Paribas Securities Services,
Luxembourg Branch.
Luxembourg Paying Agent shall have the meaning set
forth in Section 2.3.
Maturity Date means February 15, 2021.
Moodys means Moodys Investors Service,
Inc. and its successors.
Note Guarantee means the Guarantee by a Guarantor of
the Issuers obligations with respect to the Notes.
Notes shall have the meaning set forth in the
preamble of this Indenture.
Officers Certificate means a certificate
signed by two Responsible Officers of the Issuer or of any
Guarantor.
Opinion of Counsel means a written opinion from
legal counsel who is reasonably acceptable to the Trustee. The
counsel may be an employee of or counsel to the Issuer, a
Guarantor or the Trustee.
Paying Agent shall have the meaning set forth in
Section 2.3.
Permitted Liens means, with respect to any Person:
-12-
(1) pledges or deposits by such
Person under workmens compensation laws, unemployment
insurance laws or similar legislation, or good faith deposits in
connection with bids, tenders, contracts (other than for the
payment of Indebtedness) or leases to which such Person is a
party, or deposits to secure public or statutory obligations of
such Person or deposits or cash or Designated Government
Obligations to secure surety or appeal bonds to which such
Person is a party, or deposits as security for contested taxes
or import or customs duties or for the payment of rent, in each
case Incurred in the ordinary course of business;
(2) Liens imposed by law, including
carriers, warehousemens and mechanics Liens,
in each case for sums not yet due or being contested in good
faith if a reserve or other appropriate provisions, if any, as
are required by Accounting Principles have been made in respect
thereof;
(3) Liens for taxes, assessments or
other governmental charges not yet subject to penalties for
non-payment or which are being contested in good faith provided
appropriate reserves, if any, as are required by Accounting
Principles have been made in respect thereof;
(4) Liens in favor of issuers of
surety or performance bonds or letters of credit or
bankers acceptances issued pursuant to the request of and
for the account of such Person in the ordinary course of its
business;
(5) encumbrances, easements or
reservations of, or rights of others for, licenses, rights of
way, sewers, electric lines, telegraph and telephone lines and
other similar purposes, or zoning or other restrictions as to
the use of real properties or liens incidental to the conduct of
the business of such Person or to the ownership of its
properties which do not in the aggregate materially adversely
affect the value of said properties or materially impair their
use in the operation of the business of such Person;
(6) Liens securing Hedging
Obligations so long as the related Indebtedness is, and is
permitted to be, secured by a Lien on the same property securing
such Hedging Obligation or Interest Rate Agreement;
(7) leases, subleases and licenses
of real property which do not materially interfere with the
ordinary conduct of the business of the Company or any of its
Subsidiaries and leases, subleases and licenses of other assets
in the ordinary course of business;
(8) judgment Liens not giving rise
to an Event of Default so long as such Lien is adequately bonded
and any appropriate legal proceedings which may have been duly
initiated for the review of such judgment have not been finally
terminated or the period within which such proceedings may be
initiated has not expired;
(9) Liens for the purpose of
securing the payment (or the refinancing of the payment) of all
or a part of the purchase price of, or Capital Lease Obligations
with respect to, assets or property acquired or constructed in
the ordinary course of business;
provided
that:
-13-
(a) the aggregate principal amount
secured by such Liens does not exceed the cost of the assets or
property so acquired or constructed; and
(b) such Liens are created within
180 days of construction or acquisition of such assets or
property (or, upon a refinancing, replace Liens created within
such period) and do not encumber any other assets or property of
the Company or any Subsidiary other than such assets or property
and assets affixed or appurtenant thereto;
(10) Liens arising solely by virtue
of any statutory or common law provisions relating to
bankers Liens, rights of set-off or similar rights and
remedies as to deposit accounts or other funds maintained with a
depositary institution;
provided
that such deposit
account is not intended by the Company or any Subsidiary to
provide collateral to the depositary institution;
(11) Liens arising from United
States Uniform Commercial Code financing statement filings (or
similar filings in other applicable jurisdictions) regarding
operating leases entered into by the Company and its
Subsidiaries in the ordinary course of business;
(12) Liens existing on the Closing
Date (other than Liens under clause (19));
(13) Liens on property or shares of
stock of a Person at the time such Person becomes a Subsidiary;
provided
,
however
, that such Liens are not
created, Incurred or assumed in connection with, or in
contemplation of, such other Person becoming a Subsidiary;
provided further, however, that any such Lien may not extend to
any other property owned by the Company or any Subsidiary;
(14) Liens on property at the time
the Company or a Subsidiary acquired the property, including any
acquisition by means of a merger or consolidation with or into
the Company or any Subsidiary;
provided
,
however
,
that such Liens are not created, Incurred or assumed in
connection with, or in contemplation of, such acquisition;
provided further
,
however
, that such Liens may not
extend to any other property owned by the Company or any
Subsidiary;
(15) Liens securing Indebtedness or
other obligations of the Company to a Subsidiary or of a
Subsidiary owing to the Company or a Subsidiary;
(16) Liens securing the Notes and
all other Indebtedness which by its terms must be secured if the
Notes are secured;
(17) Liens securing Indebtedness
Incurred to refinance Indebtedness that was previously secured
(other than Liens under clause (19));
provided
, that such
Lien is limited to all or part of the same property or assets
that secured the Indebtedness refinanced;
(18) Liens arising by operation of
law or by agreement to the same effect in the ordinary course of
business;
-14-
(19) Liens securing Indebtedness
and other obligations under the Credit Facility in an aggregate
principal amount of Indebtedness secured thereby not to exceed
the greater of (x) $4.6 billion, the maximum amount of
Indebtedness that could be incurred under the Credit Facility as
of March 31, 2006, and (y) 2.5 times the
Companys aggregate EBITDA for the most recently ended four
full fiscal quarters for which internal financial statements are
available;
(20) Liens securing the A/R
Facility; and
(21) other Liens securing
Indebtedness having an aggregate principal amount, measured as
of the date of creation of any such Lien and the date of
Incurrence of any such Indebtedness, not to exceed 5% of the
Companys Consolidated Net Tangible Assets.
Person means any individual, corporation,
partnership, joint venture, association, joint-stock company,
trust, unincorporated organization, government or any agency,
instrumentality or political subdivision thereof, or any other
entity.
Preferred Stock, as applied to the Capital Stock of
any corporation, means Capital Stock of any class or classes
(however designated) which is preferred as to the payment of
dividends, or as to the distribution of assets upon any
voluntary or involuntary liquidation or dissolution of such
corporation, over shares of Capital Stock of any other class of
such corporation.
Private Placement Legend means the legend set forth
in Section 2.7(f).
Qualified Capital Stock means any Capital Stock
which is not Disqualified Stock.
Rating Agencies means:
(1) S&P and
(2) Moodys, or
(3) if S&P or Moodys or
both shall not make a rating of the Notes publicly available,
despite the Company using its commercially reasonable efforts to
obtain such a rating, a nationally recognized securities rating
agency or agencies, as the case may be, selected by the Company,
which shall be substituted for S&P or Moodys or both,
as the case may be.
Rating Category means:
(1) with respect to S&P, any
of the following categories: BB, B, CCC, CC, C and D (or
equivalent successor categories),
(2) with respect to Moodys,
any of the following categories: Ba, B, Caa, Ca, C and D (or
equivalent successor categories), and
-15-
(3) the equivalent of any such
category of S&P or Moodys used by another rating
agency. In determining whether the rating of the Notes has
decreased by one or more gradations, gradations within rating
categories (+ and - for S&P, 1, 2 and 3 for Moodys;
or the equivalent gradations for another rating agency) shall be
taken into account (
e.g
., with respect to S&P, a
decline in a rating from BB+ to BB, as well as from BB- to B+,
which constitute a decrease of one gradation).
Rating Date means the date which is 90 days
prior to the earlier of (1) a Change of Control and
(2) public notice of the occurrence of a Change of Control
or of the intention by the Company or any Person to effect a
Change of Control.
Ratings Decline means the occurrence on or within
90 days after the date of the first public notice of either
the occurrence of a Change of Control or of a transaction which
will effect a Change of Control, whichever is earlier (which
period shall be extended so long as any Rating Agency has
publicly announced that it is considering a possible downgrade
of the Notes) of (1) in the event the Notes are rated by
either Moodys or S&P on the Rating Date as Investment
Grade, a decrease in the rating of the Notes by both Rating
Agencies to a rating that is below Investment Grade, or
(2) in the event the Notes are rated below Investment Grade
by both Rating Agencies on the Rating Date, a decrease in the
rating of the Notes by either Rating Agency by one or more
gradations (including gradations within Rating Categories as
well as between Rating Categories).
Receivables Financings means:
(1) the A/R Facility, and
(2) any financing transaction or
series of financing transactions that have been or may be
entered into by the Company or a Subsidiary pursuant to which
the Company or a Subsidiary may sell, convey or otherwise
transfer to a Subsidiary or Affiliate, or any other Person, or
may grant a security interest in, any receivables or interests
therein secured by the merchandise or services financed thereby
(whether such receivables are then existing or arising in the
future) of the Company or such Subsidiary, as the case may be,
and any assets related thereto, including without limitation,
all security interests in merchandise or services financed
thereby, the proceeds of such receivables, and other assets
which are customarily sold or in respect of which security
interests are customarily granted in connection with
securitization transactions involving such assets.
Record Date means the Record Dates specified in the
Notes.
Redemption Date when used with respect to any
Note to be redeemed, means the date fixed for such redemption
pursuant to this Indenture and Paragraph 8 of the Notes.
Redemption Price when used with respect to any
Note to be redeemed, means the price fixed for such redemption
pursuant to this Indenture and Paragraphs 8 and 9 of the
Notes.
Refinance means, in respect of any Indebtedness, to
refinance, extend, renew, refund, repay, prepay, redeem, defease
or retire, or to issue other Indebtedness in exchange or
-16-
replacement for, such Indebtedness. Refinanced and
Refinancing shall have correlative meanings.
Refinancing Indebtedness means Indebtedness that
Refinances any Indebtedness of the Company or any Subsidiary
existing on the Closing Date or Incurred in compliance with
Section 4.3, including Indebtedness that Refinances
Refinancing Indebtedness;
provided
,
however
, that:
(1) such Refinancing Indebtedness
has a Stated Maturity no earlier than the Stated Maturity of the
Indebtedness being Refinanced,
(2) such Refinancing Indebtedness
has an Average Life at the time such Refinancing Indebtedness is
Incurred that is equal to or greater than the Average Life of
the Indebtedness being Refinanced, and
(3) such Refinancing Indebtedness
has an aggregate principal amount (or if Incurred with original
issue discount, an aggregate issue price) that is equal to or
less than the aggregate principal amount (or if Incurred with
original issue discount, the aggregate accreted value) then
outstanding or committed (plus fees and expenses, including any
premium and defeasance costs) under the Indebtedness being
Refinanced;
provided further
,
however
, that
Refinancing Indebtedness shall not include (x) Indebtedness
of a Subsidiary that Refinances Indebtedness of the Company or
(y) Indebtedness of the Company or a Subsidiary that
Refinances Indebtedness of another Subsidiary.
Registrar shall have the meaning set forth in
Section 2.3.
Regulation S means Regulation S (including
any successor regulation thereto) under the Securities Act, as
it may be amended from time to time.
Regulation S Global Note shall have the meaning
set forth in Section 2.1.
Regulation S Notes shall have the meaning set
forth in Section 2.1.
Relevant Taxing Jurisdiction shall have the meaning
set forth in Paragraph 2 of the Notes.
Responsible Officer means the chief executive
officer, president, chief financial officer, senior vice
president finance, treasurer, assistant treasurer,
managing director, management board member or director of a
company (or in the case of the Company, a Responsible Officer of
its General Partner, other managing entity or other Person
authorized to act on its behalf, and if such Person is also a
partnership, limited liability company or similarly organized
entity, a Responsible Officer of the entity that may be
authorized to act on behalf of such Person).
Restricted Period shall have the meaning set forth
in Section 2.7(b) hereof.
Rule 144 means Rule 144 (including any
successor regulation thereto) under the Securities Act, as it
may be amended from time to time.
-17-
Rule 144A means Rule 144A (including any
successor regulation thereto) under the Securities Act, as it
may be amended from time to time.
Rule 144A Global Note shall have the meaning
set forth in Section 2.1 hereof.
Rule 144A Notes shall have the meaning set
forth in Section 2.1 hereof.
Sale and Leaseback Transaction means any direct or
indirect arrangement with any Person or to which any such Person
is a party, providing for the leasing to the Issuer or any
Guarantor or a Subsidiary of any property, whether owned by the
Issuer, a Guarantor or any Subsidiary at the Closing Date or
later acquired, which has been or is to be sold or transferred
by the Issuer, a Guarantor or such Subsidiary to such Person or
to any other Person from whom funds have been or are to be
advanced by such Person on the security of such property.
SEC means the U.S. Securities and Exchange
Commission, as from time to time constituted, created under the
Exchange Act, or if at any time after the execution of this
Indenture such Commission is not existing and performing the
duties now assigned to it under the Securities Act and the
Exchange Act, then the body performing such duties at such time.
Secured Indebtedness means any Indebtedness of the
Company secured by a Lien.
Securities Act means the U.S. Securities Act of
1933 or any successor statute thereto, in each case as amended
from time to time.
Significant Subsidiary means, with respect to any
Person, any Subsidiary of such Person that satisfies the
criteria for a significant subsidiary set forth in
Rule 1.02 of
Regulation S-X
under the Exchange Act.
S&P means Standard & Poors
Corporation and its successors.
Stated Maturity means, with respect to any security,
the date specified in such security as the fixed date on which
the final payment of principal of such security is due and
payable, including pursuant to any mandatory redemption
provision (but excluding any provision providing for the
repurchase of such security at the option of the holder thereof
upon the happening of any contingency unless such contingency
has occurred).
Subordinated Obligation means any Indebtedness of
the Issuer or a Guarantor (whether outstanding on the Closing
Date or thereafter Incurred) that is subordinate or junior in
right of payment to the Notes or such Guarantors Note
Guarantee pursuant to a written agreement to that effect.
Subsidiary means, with respect to any Person, any
corporation, limited liability company, association, partnership
or other business entity of which more than 50% of the total
voting power of shares of Voting Stock is at the time owned or
controlled, directly or indirectly, by:
(1) such Person;
-18-
(2) such Person and one or more
Subsidiaries of such Person; or
(3) one or more Subsidiaries of
such Person.
Unless otherwise provided, all references to a Subsidiary shall
be a Subsidiary of the Company.
Successor shall have the meaning set forth in
Section 5.3.
Surviving Person means, with respect to any Person
involved in any merger, consolidation or other business
combination or the sale, assignment, transfer, lease, conveyance
or other disposition of all or substantially all of such
Persons assets, the Person formed by or surviving such
transaction or the Person to which such disposition is made.
Tax Redemption Date when used with respect to
any Note to be redeemed, means the date fixed for such
redemption pursuant to this Indenture and Paragraph 9 of
the Notes.
Taxes shall have the meaning set forth in
Paragraph 2 of the Notes.
TIA means the Trust Indenture Act of 1939 (15
U.S. Code
77aaa-77bbbb)
as in effect on the date of this Indenture;
provided
,
however
, that in the event the Trust Indenture Act
of 1939 is amended after such date, TIA means, to
the extent required by any such amendment, the
Trust Indenture Act of 1939 as so amended.
Treasury Rate means, with respect to a
Redemption Date, the yield to maturity at the time of
computation of United States Treasury securities with a constant
maturity (as compiled and published in the most recent Federal
Reserve Statistical Release H. 15(519) that has become publicly
available at least two Business Days prior to such
Redemption Date (or, if such Statistical Release is no
longer published, any publicly available source of similar
market data)) most nearly equal to the period from such
Redemption Date to February 15, 2021; provided,
however, that if the period from the Redemption Date to
such date is not equal to the constant maturity of a United
States Treasury security for which a weekly average yield is
given, the Treasury Rate shall be obtained by linear
interpolation (calculated to the nearest one-twelfth of a year)
from the weekly average yields of United States Treasury
securities for which such yields are given, except that if the
period from the Redemption Date to such date is less than
one year, the weekly average yield on actually traded United
States Treasury securities adjusted to a constant maturity of
one year shall be used.
Trust Officer means any officer of the Trustee
(or any successor of the Trustee), including any director,
managing director, vice president, assistant vice president,
corporate trust officer, assistant corporate trust officer,
associate or any other officer or assistant officer of the
Trustee customarily performing functions similar to those
performed by the Persons who at that time shall be such
officers, and also means, with respect to a particular corporate
trust matter, any other officer to whom such trust matter is
referred because of his or her knowledge of and familiarity with
the particular subject.
Trustee means the party named as such in this
Indenture until a successor replaces it in accordance with the
provisions of this Indenture and thereafter means such successor.
-19-
U.S. GAAP means generally accepted accounting
principles in the United States of America as in effect from
time to time, including those set forth in:
(1) the opinions and pronouncements
of the Accounting Principles Board of the American Institute of
Certified Public Accountants,
(2) statements and pronouncements
of the Financial Accounting Standards Board,
(3) such other statements by such
other entity as approved by a significant segment of the
accounting profession, and
(4) the rules and regulations of
the SEC governing the inclusion of financial statements
(including pro forma financial statements) in periodic reports
required to be filed pursuant to Section 13 of the Exchange
Act, including opinions and pronouncements in staff accounting
bulletins and similar written statements from the accounting
staff of the SEC.
Voting Stock of a Person means all classes of
Capital Stock or other interests (including partnership
interests) of such Person then outstanding and normally entitled
(without regard to the occurrence of any contingency) to vote in
the election of directors, managers or trustees thereof.
Wholly Owned Subsidiary means a Subsidiary all the
Capital Stock of which (other than directors qualifying
shares and shares held by other Persons to the extent such
shares are required by applicable law to be held by a Person
other than its parent or a Subsidiary of its parent) is owned by
the Company or by one or more Wholly Owned Subsidiaries, or by
the Company and one or more Wholly Owned Subsidiaries.
SECTION 1.2
Rules of
Construction
. Unless the context otherwise requires:
(a) a term has the meaning assigned
to it;
(b) an accounting term not
otherwise defined has the meaning assigned to it in accordance
with Accounting Principles;
(c) or is not exclusive;
(d) words in the singular include
the plural, and words in the plural include the singular;
(e) provisions apply to successive
events and transactions; and
(f) herein,
hereof and other words of similar import refer to
this Indenture as a whole and not to any particular Article,
Section or other subdivision.
SECTION 1.3
Incorporation
by Reference of Trust Indenture Act
.
-20-
Whenever this Indenture refers to a provision of the TIA, the
provision is incorporated by reference in, and made a part of,
this Indenture.
The following TIA terms have the following meanings:
indenture securities means the Notes and any Note
Guarantee;
indenture security holder means a Holder;
indenture to be qualified means this Indenture;
indenture trustee or institutional
trustee means the Trustee;
obligor on the Notes means the Issuer and any
successor obligor upon the Notes or any Guarantor.
All other terms used in this Indenture that are defined by the
TIA, defined by TIA reference to another statute or defined by
the Commission rule under the TIA have the meanings so assigned
to them therein.
ARTICLE II
THE
NOTES
SECTION 2.1
Form and
Dating
. The Notes and the notation relating to the
Trustees certificate of authentication thereof, shall be
substantially in the form of
Exhibit A
(in the case
of Global Notes) and
Exhibit B
(in the case of the
Definitive Notes), as applicable. The Notes may have notations,
legends or endorsements required by law, stock exchange rule or
usage. The Issuer and the Trustee shall approve the form of the
Notes and any notation, legend or endorsement on them not
inconsistent with the terms of this Indenture. Each Note shall
be dated the Issue Date and shall show the date of its
authentication.
The terms and provisions contained in the Notes, annexed hereto
as
Exhibits A
and
B
, shall constitute, and
are hereby expressly made, a part of this Indenture and, to the
extent applicable, the Issuer, the Guarantors, the Trustee and
the Paying Agent, by their execution and delivery of this
Indenture, expressly agree to such terms and provisions and to
be bound thereby. The Notes will initially be represented by the
Global Notes. Definitive Notes will be issued in exchange for
Global Notes only in accordance with Section 2.6(a).
As long as the Notes are in global form, the Paying Agent (in
lieu of the Trustee) shall be responsible for:
(1) paying sums due on the Global Notes; and
(2) arranging on behalf of and at the expense of the
Issuer for notices to be communicated to Holders in accordance
with the terms of this Indenture.
-21-
Each reference in this Indenture to the performance of duties
set forth in clauses (1) and (2) above by the Trustee
includes performance of such duties by the Paying Agent.
Notes offered and sold in their initial distribution in reliance
on Regulation S shall be initially issued as one or more
global notes, in registered, global form without interest
coupons, substantially in the form of
Exhibit A
hereto, with such applicable legends as are provided in
Section 2.7(f)(ii), except as otherwise permitted herein,
and shall be referred to collectively herein as the
Regulation S Global Note. The aggregate
principal amount of the Regulation S Global Note may from
time to time be increased or decreased by adjustments made on
the records of the Trustee (following receipt by the Trustee of
all the information required hereunder), as hereinafter provided
(or by the issue of a further Regulation S Global Note), in
connection with a corresponding decrease or increase in the
aggregate principal amount of the Rule 144A Global Note or
in consequence of the issue of Definitive Notes or Additional
Notes in the form of Regulation S Global Notes, as
hereinafter provided. The Regulation S Global Note and all
other Notes that are not Rule 144A Notes shall collectively
be referred to herein as the Regulation S Notes.
Notes offered and sold in their initial distribution in reliance
on Rule 144A shall be initially issued as one or more
global notes in registered, global form without interest
coupons, substantially in the form of
Exhibit A
hereto, with such applicable legends as are provided in
Section 2.7(f)(ii), except as otherwise permitted herein,
and shall be referred to collectively herein as the
Rule 144A Global Note. The aggregate principal
amount of the Rule 144A Global Note may from time to time
be increased or decreased by adjustments made on the records of
the Trustee (following receipt by the Trustee of all information
required hereunder), as hereinafter provided (or by the issue of
a further Rule 144A Global Note), in connection with a
corresponding decrease or increase in the aggregate principal
amount of the Regulation S Global Note, or in consequence
of the issue of Definitive Notes or Additional Rule 144A
Global Notes, as hereinafter provided. The Rule 144A Global
Note and all other Notes (excluding interests in Rule 144A
Global Notes which are transferred in accordance with
Section 2.7(a) hereunder), if any, evidencing the debt, or
any portion of the debt, initially evidenced by such
Rule 144A Global Note, shall collectively be referred to
herein as the Rule 144A Notes.
SECTION 2.2
Execution and
Authentication
. One Responsible Officer of or one
Person duly authorized by all requisite corporate actions by the
Issuer shall sign the Notes for the Issuer by manual or
facsimile signature.
If a Responsible Officer whose signature is on a Note was a
Responsible Officer at the time of such execution but no longer
holds that office or position at the time the Trustee
authenticates the Note, the Note shall be valid nevertheless.
The Trustee shall be entitled to rely on such signature as
authentic and shall be under no obligation to make any
investigation in relation thereto.
A Note shall not be valid until an authorized signatory of the
Trustee manually signs the certificate of authentication on the
Note. The signature shall be conclusive evidence that the Note
has been authenticated under this Indenture.
-22-
Except as otherwise provided herein, the aggregate principal
amount of Notes which may be outstanding at any time under this
Indenture is not limited in amount. The Trustee shall
authenticate such Notes, which shall consist of (i) Initial
Notes for original issue on the Closing Date in an aggregate
principal amount not to exceed $650,000,000 and
(ii) Additional Notes from time to time for issuance after
the Closing Date to the extent otherwise permitted hereunder
(including, without limitation, under Section 4.3 hereof),
in each case upon receipt of an Issuer Order. Additional Notes
will be treated the same as the Notes for all purposes under
this Indenture, including, without limitation, for purposes of
waivers, amendments, redemptions and offers to purchase. Such
Issuer Order shall specify the aggregate principal amount of
Notes to be authenticated, the type of Notes, the date on which
the Notes are to be authenticated, the issue price and the date
from which interest on such Notes shall accrue, whether the
Notes are to be Initial Notes or Additional Notes and whether or
not the Notes shall bear the Private Placement Legend, or such
other information as the Trustee may reasonably request. In
authenticating the Notes and accepting the responsibilities
under this Indenture in relation to the Notes, the Trustee shall
be entitled to receive, and shall be fully protected in relying
upon, an Opinion of Counsel in a form reasonably satisfactory to
the Trustee stating that the form and terms thereof have been
established in conformity with the provisions of this Indenture,
do not give rise to a Default and that the issuance of such
Notes has been duly authorized by the Issuer. Upon receipt of an
Issuer Order, the Trustee shall authenticate Notes in
substitution for Notes originally issued to reflect any name
change of the Issuer.
The Trustee may appoint an authenticating agent
(Authenticating Agent) reasonably acceptable to the
Issuer to authenticate Notes. Unless otherwise provided in the
appointment, an Authenticating Agent may authenticate Notes
whenever the Trustee may do so. Each reference in this Indenture
to authentication by the Trustee includes authentication by such
Authenticating Agent. An Authenticating Agent has the same
rights as an Agent to deal with the Issuer and Affiliates of the
Issuer.
The Notes shall be issuable only in denominations of $2,000 and
integral multiples of $1,000 in excess thereof.
SECTION 2.3
Registrar and
Paying Agent
. The Issuer shall maintain (i) an
office or agency where Notes may be presented for registration
of transfer or for exchange (Registrar),
(ii) an office or agency where Notes may be presented for
payment and (iii) upon issuance of Definitive Notes, an
office or agency where Definitive Notes may be presented for
payment to the Luxembourg Paying Agent. The Registrar shall keep
a register of the Notes and of their transfer and exchange. At
the option of the Issuer, payment of interest may be made by
check mailed to the Holders at their addresses set forth in the
register of Holders. The Issuer may appoint one or more
co-registrars and one or more additional paying agents. The term
Registrar includes any co-registrar and the term
Paying Agent includes any additional paying agent.
The Issuer may change any Paying Agent or Registrar without
notice to any Holder. The Issuer shall notify the Trustee in
writing of the name and address of any Agent not a party to this
Indenture. If the Issuer fails to appoint or maintain another
entity as Registrar or Paying Agent, the Trustee shall act as
such. The Issuer, the Company or any of its Subsidiaries may act
as Paying Agent or Registrar to the extent permitted under
applicable laws or regulations.
-23-
The Issuer shall notify the Trustee and the Trustee shall notify
the Holders of the name and address of any Agent not a party to
this Indenture. The Issuer shall enter into an appropriate
agency agreement with any Agent not a party to this Indenture,
which shall incorporate the provisions of the TIA. The agreement
shall implement the provisions of this Indenture and the Notes
that relate to such Agent. The Issuer shall notify the Trustee
of the name and address of any such Agent. If the Issuer fails
to maintain a Registrar or Paying Agent, or fails to give the
foregoing notice, the Trustee shall act as such, and shall be
entitled to appropriate compensation in accordance with
Section 7.7 hereof.
The Issuer initially appoints the Trustee to act as the
Registrar and Paying Agent. If and so long as the Notes are
listed on the Euro MTF Market of the Luxembourg Stock Exchange
and the rules of such stock exchange so require, the Issuer
shall appoint Deutsche Bank Luxembourg, or such other Person
located in Luxembourg and reasonably acceptable to the Trustee
(reasonableness to be determined objectively), as the Luxembourg
paying and transfer agent (together with its successor in such
capacity, the Luxembourg Paying Agent).
The Issuer initially appoints DTC to act as the Depositary with
respect to the Global Notes.
SECTION 2.4
Paying Agent To
Hold Assets in Trust
. The Issuer shall require the
Paying Agent to agree in writing that such Paying Agent shall
hold in trust for the benefit of Holders or the Trustee all
assets held by the Paying Agent for the payment of principal of,
Additional Amounts, if any, premium, if any, or interest on, the
Notes, and shall promptly notify the Trustee of any Default by
the Issuer in making any such payment. The Issuer at any time
may require a Paying Agent to distribute all assets held by it
to the Trustee and account for any assets distributed and the
Trustee may at any time during the continuance of any payment
Default, upon written request to a Paying Agent, require such
Paying Agent to distribute all assets held by it to the Trustee
and to account for any assets distributed. Upon distribution to
the Trustee of all assets that shall have been delivered by the
Issuer to the Paying Agent pursuant to this Section 2.4,
the Paying Agent shall have no further liability for such assets.
SECTION 2.5
List of
Holders
. The Trustee shall preserve in as current a
form as is reasonably practicable the most recent list available
to it of the names and addresses of Holders. If the Trustee is
not the Registrar, the Issuer shall furnish to the Trustee
within two Business Days after each Record Date as of such
Record Date and at such other times as the Trustee may request
in writing a list as of such date and in such form as the
Trustee may reasonably require of the names and addresses of
Holders, which list may be conclusively relied upon by the
Trustee.
SECTION 2.6
Book-Entry
Provisions for Global Notes
. The Global Notes initially
shall (i) be registered in the name of the DTC or its
nominee, (ii) be delivered to the DTC or its custodian and
(iii) bear the following legend:
THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE
INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME
OF THE DEPOSITORY TRUST COMPANY OR A NOMINEE OF THE
DEPOSITORY TRUST COMPANY. THIS NOTE IS NOT
EXCHANGEABLE FOR
-24-
SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE
DEPOSITORY TRUST COMPANY OR ITS NOMINEE EXCEPT IN THE
LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO
TRANSFER OF THIS NOTE (OTHER THAN A TRANSFER OF THIS
NOTE AS A WHOLE TO THE DEPOSITORY TRUST COMPANY OR A
NOMINEE OF THE DEPOSITORY TRUST COMPANY) MAY BE REGISTERED
EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE.
(a) Notwithstanding any other
provisions of this Indenture, a Global Note may not be
transferred as a whole except by the DTC to a nominee of the DTC
or by a nominee of the DTC to the DTC or another successor of
the DTC or a nominee of such successor. Interests of beneficial
owners in the Global Notes may be transferred or exchanged for
Definitive Notes in accordance with the rules and procedures of
the DTC and the provisions of Section 2.7. All Global Notes
shall be exchanged by the Issuer (with authentication by the
Trustee) for one or more Definitive Notes, if (a) the DTC
(i) has notified the Issuer that it is unwilling or unable
to continue as Depositary and (ii) a successor to the DTC
has not been appointed by the Issuer within 90 days of such
notification, (b) the DTC so requests following an Event of
Default hereunder or (c) in whole (but not in part) at any
time if the Issuer in its sole discretion determines. If an
Event of Default occurs and is continuing, the Issuer shall, at
the written request delivered through the DTC, exchange all or
part of a Global Note for one or more Definitive Notes (with
authentication by the Trustee); provided, however, that the
principal amount of such Definitive Notes and such Global Note
after such exchange shall be $2,000 or integral multiples of
$1,000 in excess thereof. Whenever all of a Global Note is
exchanged for one or more Definitive Notes, it shall be
surrendered by the Holder thereof to the Trustee for
cancellation. Whenever a part of a Global Note is exchanged for
one or more Definitive Notes, the Global Note shall be
surrendered by the Holder thereof to the Paying Agent who
together with the Trustee, following such surrender, shall cause
an adjustment to be made to Schedule A of such Global Note
such that the principal amount of such Global Note will be equal
to the portion of such Global Note not exchanged and shall
thereafter return such Global Note to such Holder. A Global Note
may not be exchanged for a Definitive Note other than as
provided in this Section 2.6(a).
(b) In connection with the transfer
of Global Notes as an entirety to beneficial owners pursuant to
Section 2.6(a), the Global Notes shall be deemed to be
surrendered to the Paying Agent for cancellation, and the Issuer
shall execute, and the Trustee shall upon written instructions
from the Issuer authenticate and make available for delivery, to
each beneficial owner in exchange for its beneficial interest in
the Global Notes, an equal aggregate principal amount of
Definitive Notes of authorized denominations.
(c) Any Definitive Note delivered
in exchange for an interest in a Global Note pursuant to
Section 2.6(a) shall, except as otherwise provided by
Section 2.7, bear the Private Placement Legend.
SECTION 2.7
Registration of
Transfer and Exchange
. Notwithstanding any provision to
the contrary herein, so long as a Note remains outstanding,
transfers of beneficial interests in Global Notes or transfers
of Definitive Notes, in whole or in part, shall be made only in
accordance with this Section 2.7.
-25-
(a) If a holder of a beneficial
interest in the Rule 144A Global Note wishes at any time to
exchange its interest in such Rule 144A Global Note for an
interest in the Regulation S Global Note, or to transfer
its interest in such Rule 144A Global Note to a Person who
wishes to take delivery thereof in the form of an interest in
such Regulation S Global Note, such holder may, subject to
the rules and procedures of the DTC, to the extent applicable,
and to the requirements set forth in this Section 2.7(a),
exchange or cause the exchange or transfer or cause the transfer
of such interest for an equivalent beneficial interest in such
Regulation S Global Note. Such exchange or transfer shall
only be made upon receipt by the Paying Agent, as transfer
agent, at its Corporate Trust Office or, so long as the
Notes are listed on the Euro MTF Market of the Luxembourg Stock
Exchange and the rules of that exchange so require, upon receipt
by the Luxembourg Paying Agent, as transfer agent, at its office
in Luxembourg of (1) written instructions given in
accordance with the procedures of the DTC, to the extent
applicable, from or on behalf of a holder of a beneficial
interest in the Rule 144A Global Note directing the Paying
Agent, as transfer agent, to credit or cause to be credited a
beneficial interest in the Regulation S Global Note in an
amount equal to the beneficial interest in the Rule 144A
Global Note to be exchanged or transferred, (2) a written
order given in accordance with the procedures of the DTC, to the
extent applicable, containing information regarding the account
to be credited with such increase and the name of such account,
and (3) a certificate in the form of Exhibit D given
by the holder of such beneficial interest stating that the
exchange or transfer of such interest has been made pursuant to
and in accordance with Rule 903 or Rule 904 of
Regulation S or Rule 144 under the Securities Act.
Upon such receipt, the Paying Agent, as transfer agent, shall
promptly deliver instructions to the DTC, to reduce or reflect
on its records a reduction of the Rule 144A Global Note by
the aggregate principal amount of the beneficial interest in
such Rule 144A Global Note to be so exchanged or
transferred from the relevant participant, and the Paying Agent,
as transfer agent, shall promptly deliver instructions to the
DTC concurrently with such reduction, to increase or reflect on
its records an increase of the principal amount of such
Regulation S Global Note by the aggregate principal amount
of the beneficial interest in such Rule 144A Global Note to
be so exchanged or transferred, and to credit or cause to be
credited to the account of the Person specified in such
instructions of a beneficial interest in such Regulation S
Global Note equal to the reduction in the principal amount of
such Rule 144A Global Note.
(b) If a holder of a beneficial
interest in the Regulation S Global Note wishes at any time
to exchange its interest in such Regulation S Global Note
for an interest in the Rule 144A Global Note, or to
transfer its interest in such Regulation S Global Note to a
Person who wishes to take delivery thereof in the form of an
interest in such Rule 144A Global Note, such holder may,
subject to the rules and procedures of the DTC, to the extent
applicable, and to the requirements set forth in this
Section 2.7(b), exchange or cause the exchange or transfer
or cause the transfer of such interest for an equivalent
beneficial interest in such Rule 144A Global Note. Such
exchange or transfer shall only be made upon receipt by the
Paying Agent, as transfer agent, at its Corporate
Trust Office or, so long as the Notes are listed on the
Euro MTF Market of the Luxembourg Stock Exchange and the rules
of that exchange so require, upon receipt by the Luxembourg
Paying Agent, as transfer agent, at its office in Luxembourg of
(l) instructions given in accordance with the procedures of
the DTC, to the extent applicable, from or on behalf of a
beneficial owner of an interest in the Regulation S Global
Note directing the Paying Agent, as transfer agent, to credit or
cause to be credited a beneficial interest in the Rule 144A
Global Note in an amount equal to the beneficial interest in the
Regulation S Global Note to be exchanged or transferred,
(2) a written order given in accordance with the procedures
of the DTC, to the extent
-26-
applicable, containing information regarding the account to be
credited with such increase and the name of such account, and
(3) prior to or on the 40th day after the later of the
commencement of the offering of the Notes and the relevant Issue
Date (the Restricted Period), a certificate in the
form of Exhibit E given by the holder of such beneficial
interest and stating that the Person transferring such interest
in such Regulation S Note reasonably believes that the
Person acquiring such interest in such Rule 144A Note is a
Qualified Institutional Buyer (as defined in Rule 144A) and
is obtaining such beneficial interest in a transaction meeting
the requirements of Rule 144A and any applicable securities
laws of any state of the United States or any other
jurisdiction. Upon such receipt, the Paying Agent, as transfer
agent, shall promptly deliver instructions to the DTC to reduce
or reflect on its records a reduction of the Regulation S
Global Note by the aggregate principal amount of the beneficial
interest in such Regulation S Global Note to be exchanged
or transferred, and the Paying Agent, as transfer agent, shall
promptly deliver instructions to the DTC concurrently with such
reduction, to increase or reflect on its records an increase of
the principal amount of such Rule 144A Global Note by the
aggregate principal amount of the beneficial interest in such
Regulation S Global Note to be so exchanged or transferred,
and to credit or cause to be credited to the account of the
Person specified in such instructions a beneficial interest in
such Rule 144A Global Note equal to the reduction in the
principal amount of such Regulation S Global Note. After
the expiration of the Restricted Period, the certification
requirement set forth in clause (3) of the second sentence
of this Section 2.7(b) will no longer apply to such
transfers.
(c) Any beneficial interest in one
of the Global Notes that is transferred to a Person who takes
delivery in the form of an interest in another Global Note will,
upon transfer, cease to be an interest in such Global Note and
become an interest in the other Global Note and, accordingly,
will thereafter be subject to all transfer restrictions and
other procedures applicable to beneficial interests in such
other Global Note for as long as it remains such an interest.
(d) In the event that a Global Note
is exchanged for Definitive Notes in registered form without
interest coupons, pursuant to Section 2.6(a), or a
Definitive Note in registered form without interest coupons is
exchanged for another such Definitive Note in registered form
without interest coupons, or a Definitive Note is exchanged for
a beneficial interest in a Global Note, such Notes may be
exchanged or transferred for one another only in accordance with
such procedures as are substantially consistent with the
provisions of Sections 2.7(b) and (c) above (including
the certification requirements intended to ensure that such
exchanges or transfers comply with Rule 144, Rule 144A
or Regulation S, as the case may be) and as may be from
time to time adopted by the Issuer and the Trustee.
(e) Prior to the expiration of the
Restricted Period, beneficial interests in the Regulation S
Global Note may only be exchanged or transferred in accordance
with the certification requirements hereof.
(f) (i) Other than in the case
of Notes issued pursuant to a registration statement which has
been declared effective under the Securities Act, each Note
issued hereunder shall, upon issuance, bear the legend set forth
in clause (ii) below (the Private Placement
Legend) and such legend shall not be removed from such
Note except as provided in the next sentence. The legend on a
Note may be removed from a Note if there is delivered to the
Issuer and the Trustee such satisfactory evidence, which may
include an opinion of independent counsel
-27-
licensed to practice law in the State of New York, as may be
reasonably required by the Issuer and the Trustee, that neither
such legend nor the restrictions on transfer set forth therein
are required to ensure that transfers of such Note will not
violate the registration requirements of the Securities Act, and
the Issuer and the Trustee consent to such removal. Upon
provision of such satisfactory evidence, the Trustee, at the
written direction of the Issuer, shall authenticate and deliver
in exchange for such Note another Note or Notes having an equal
aggregate principal amount that does not bear such legend. If
such a legend required for a Note has been removed from a Note
as provided above, no other Note issued in exchange for all or
any part of such Note shall bear such legend, unless the Issuer
has reasonable cause to believe that such other Note is a
restricted security within the meaning of
Rule 144 and instructs the Trustee to cause a legend to
appear thereon.
(ii) To the extent required by
paragraph (f)(i) above, the Notes shall bear the following
legend on the face thereof:
THE SECURITY (OR ITS PREDECESSOR) EVIDENCED HEREBY WAS
ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION
UNDER SECTION 5 OF THE UNITED STATES SECURITIES ACT OF
1933, AS AMENDED (THE SECURITIES ACT), AND THE
SECURITY EVIDENCED HEREBY MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN APPLICABLE
EXEMPTION THEREFROM. EACH PURCHASER OF THE SECURITY
EVIDENCED HEREBY IS HEREBY NOTIFIED THAT THE SELLER MAY BE
RELYING ON THE EXEMPTION FROM THE PROVISIONS OF
SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A
THEREUNDER. THE HOLDER OF THE SECURITY EVIDENCED HEREBY AGREES
FOR THE BENEFIT OF THE ISSUER THAT (A) SUCH SECURITY MAY BE
RESOLD, PLEDGED OR OTHERWISE TRANSFERRED, ONLY (1)(a) INSIDE THE
UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS
A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A
UNDER THE SECURITIES ACT) PURCHASING FOR ITS OWN ACCOUNT OR FOR
THE ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER IN A TRANSACTION
MEETING THE REQUIREMENTS OF RULE 144A UNDER THE SECURITIES
ACT, (b) OUTSIDE THE UNITED STATES TO A FOREIGN PERSON IN A
TRANSACTION MEETING THE REQUIREMENTS OF RULE 903 OR
RULE 904 OF REGULATION S UNDER THE SECURITIES ACT,
(c) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF
APPLICABLE) OR (d) IN ACCORDANCE WITH ANOTHER
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT (AND BASED UPON AN OPINION OF COUNSEL ACCEPTABLE
TO THE ISSUER IF THE ISSUER SO REQUESTS), (2) TO THE ISSUER
OR (3) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT AND,
IN EACH CASE, IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS
OF ANY STATE OF THE UNITED STATES OR ANY OTHER APPLICABLE
JURISDICTION AND (B) THE HOLDER WILL, AND EACH SUBSEQUENT
HOLDER IS REQUIRED TO, NOTIFY ANY PURCHASER OF THE SECURITY
EVIDENCED HEREBY OF THE RESALE RESTRICTIONS SET FORTH IN
-28-
CLAUSE (A) ABOVE. NO REPRESENTATION CAN BE MADE AS TO THE
AVAILABILITY OF THE EXEMPTION PROVIDED BY RULE 144 FOR
RESALE OF THE SECURITY EVIDENCED HEREBY.
(g) By its acceptance of any Note
bearing the Private Placement Legend, each Holder of such a Note
acknowledges the restrictions on transfer of such Note set forth
in this Indenture and in the Private Placement Legend and agrees
that it will transfer such Note only as provided in this
Indenture.
Neither the Trustee nor the Paying Agent shall have any
obligation or duty to monitor, and shall not be liable for any
failure to, determine or inquire as to compliance with any
restrictions on transfer imposed under this Indenture or under
applicable law with respect to any transfer of any interest in
any Note (including any transfers between or among Agent Members
or beneficial owners of interest in any Global Note) other than
to require delivery of such certificates and other documentation
or evidence as are expressly required by, and to do so if and
when expressly required by the terms of, this Indenture, and to
examine the same to determine substantial compliance as to form
with the express requirements hereof.
The Registrar shall retain copies of all letters, notices and
other written communications received pursuant to
Section 2.6 or this Section 2.7. The Issuer shall have
the right to inspect and make copies of all such letters,
notices or other written communications at any reasonable time
upon the giving of reasonable written notice to the Registrar.
(h) Definitive Notes shall be
transferable only upon the surrender of a Definitive Note for
registration of transfer. When a Definitive Note is presented to
the Registrar or a co-registrar with a request to register a
transfer, the Registrar shall register the transfer as requested
if its requirements for such transfers are met. When Definitive
Notes are presented to the Registrar or a co-registrar with a
request to exchange them for an equal principal amount of
Definitive Notes of other denominations, the Registrar shall
make the exchange as requested if the same requirements are met.
When a Definitive Note is presented to the Registrar with a
request to transfer in part, the transferor shall be entitled to
receive without charge a Definitive Note representing the
balance of such Definitive Note not transferred. To permit
registration of transfers and exchanges, the Issuer shall
execute and the Trustee shall authenticate Definitive Notes at
the Registrars or co-registrars request.
(i) The Issuer shall not be
required to make, and the Registrar need not register transfers
or exchanges of, Definitive Notes (i) for a period of 15
calendar days prior to any date fixed for the redemption of the
Notes, (ii) for a period of 15 calendar days immediately
prior to the date fixed for selection of Notes to be redeemed in
part, (iii) for a payment period of 15 calendar days prior
to any Record Date, or (iv) that the registered Holder of
Notes has tendered (and not withdrawn) for repurchase in
connection with a Change of Control.
(j) Prior to the due presentation
for registration of transfer of any Definitive Note, the Issuer,
the Guarantors, the Trustee, the Paying Agent, the Registrar or
any co-registrar may deem and treat the Person in whose name a
Definitive Note is registered as the absolute owner of such
Definitive Note for the purpose of receiving payment of
principal, interest or Ad-
-29-
ditional Amounts, if any, on such Definitive Note and for all
other purposes whatsoever, whether or not such Definitive Note
is overdue, and none of the Issuer, the Guarantors, the Trustee,
the Paying Agent, the Registrar or any co-registrar shall be
affected by notice to the contrary.
(k) The Issuer may require payment
of a sum sufficient to pay all taxes, assessments or other
governmental charges in connection with any transfer or exchange
pursuant to this Section 2.7.
(l) All Notes issued upon any
transfer or exchange pursuant to the terms of this Indenture
will evidence the same debt and will be entitled to the same
benefits under this Indenture as the Notes surrendered upon such
transfer or exchange.
(m) Holders of Notes (or holders of
interests therein) initially offered or sold in the United
States to Qualified Institutional Buyers as defined
in Rule 144A under the Securities Act pursuant to such rule
and prospective purchasers designated by such Holders (or
holders of interests therein) will have the right to obtain from
the Issuer upon request by such Holders (or holders of interests
therein) or prospective purchasers, during any period in which
the Issuer is not subject to Section 13 or 15(d) of the
Exchange Act, or not exempt from reporting pursuant to
Rule 12g3-2(b)
under the Exchange Act, the information required by paragraph
d(4)(i) of Rule 144A in connection with any transfer or
proposed transfer of such Notes.
SECTION 2.8
Replacement
Notes
. If a mutilated Definitive Note is surrendered to
the Registrar, if a mutilated Global Note is surrendered to the
Issuer or if the Holder of a Note claims that such Note has been
lost, destroyed or wrongfully taken, the Issuer shall issue and
the Trustee shall authenticate a replacement Note in such form
as the Note being replaced in the manner specified in this
Section 2.8. If required by the Trustee, the Registrar or
the Issuer, such Holder must provide an indemnity bond or other
indemnity, sufficient in the judgment of the Issuer, the
Registrar and the Trustee, to protect the Issuer, the Registrar,
the Trustee and any Agent from any loss which any of them may
suffer if a Note is replaced. The Issuer may charge such Holder
for its reasonable out of-pocket expenses in replacing a Note,
including reasonable fees and expenses of counsel. Every
replacement Note is an additional obligation of the Issuer. The
provisions of this Section 2.8 are exclusive and shall
preclude (to the extent lawful) all other rights and remedies
with respect to the replacement of mutilated, destroyed, lost,
stolen or taken Notes.
SECTION 2.9
Outstanding
Notes
. Notes outstanding at any time are all the Notes
that have been authenticated by the Trustee except those
canceled by it, those delivered to it for cancellation, those
reductions in the Global Note effected in accordance with the
provisions hereof and those described in this Section 2.9
as not outstanding. Subject to Section 2.10, a Note does
not cease to be outstanding because the Issuer or any of its
Affiliates holds the Note.
If a Note is replaced pursuant to Section 2.8 (other than a
mutilated Note surrendered for replacement), it ceases to be
outstanding unless the Trustee receives proof satisfactory to
it, and upon which it shall be entitled to rely in accordance
with Section 7.1(a), that the replaced Note is held by a
bona fide
purchaser. A mutilated Note ceases to be
outstanding upon surrender of such Note and replacement thereof
pursuant to Section 2.8.
-30-
If the principal amount of any Note is considered paid under
Section 4.1 hereof, it ceases to be outstanding and
interest and Additional Amounts, if any, on it cease to accrue.
If on a Redemption Date or the Maturity Date the Paying
Agent holds cash sufficient to pay all of the principal and
interest due on the Notes payable on that date, then on and
after that date such Notes cease to be outstanding and interest
and Additional Amounts, if any, on such Notes cease to accrue.
SECTION 2.10
Treasury
Notes
. In determining whether the Holders of the
required principal amount of Notes have concurred in any
direction, waiver or consent, Notes owned by the Issuer, the
Guarantors or any of their Affiliates shall be disregarded,
except that, for the purposes of determining whether the Trustee
shall be protected in relying on any such direction, waiver or
consent, only Notes that a Trust Officer actually knows are
so owned shall be disregarded and the Trustee assumes no
liability in relation to any other Notes.
The Issuer shall notify the Trustee, in writing, when it or any
Guarantor or any of their Affiliates repurchases or otherwise
acquires Notes, of the aggregate principal amount of such Notes
so repurchased or otherwise acquired. The Trustee may require an
Officers Certificate, which shall promptly be provided
upon receipt by the appropriate Responsible Officers of the
requisite information, listing Notes owned by the Issuer, the
Guarantors a Subsidiary of the Issuer or the Guarantors or an
Affiliate of the Issuer or the Guarantors.
SECTION 2.11
Temporary
Notes
. Until permanent Definitive Notes are ready for
delivery, the Issuer may prepare and the Trustee shall
authenticate temporary Definitive Notes upon receipt of an
Issuer Order pursuant to Section 2.2. The Officers
Certificate shall specify the amount of temporary Definitive
Notes to be authenticated and the date on which the temporary
Definitive Notes are to be authenticated. Temporary Definitive
Notes shall be substantially in the form of permanent Definitive
Notes but may have variations that the Issuer considers
appropriate for temporary Definitive Notes. Without unreasonable
delay, the Issuer shall prepare and the Trustee shall
authenticate upon receipt of an Issuer Order pursuant to
Section 2.2 permanent Definitive Notes in exchange for
temporary Definitive Notes.
SECTION 2.12
Cancellation
. The
Issuer at any time may deliver Notes to the Trustee for
cancellation. The Registrar and the Paying Agent shall promptly
forward to the Trustee any Notes surrendered to them for
transfer, exchange or payment. The Trustee or, at the direction
of the Trustee, the Registrar or the Paying Agent, and no one
else, shall cancel and, at the written direction of the Issuer,
shall dispose of (subject to the record retention requirements
of the Exchange Act) all Notes surrendered for transfer,
exchange, payment or cancellation. Upon completion of any
disposal, the Trustee shall deliver a certificate of such
disposal to the Issuer, unless the Issuer directs the Trustee in
writing to deliver the cancelled Notes to the Issuer or the
Company. Subject to Section 2.8, the Issuer may not issue
new Notes to replace Notes that it has paid or delivered to the
Trustee for cancellation. If the Issuer shall acquire any of the
Notes, such acquisition shall not operate as a redemption or
satisfaction of the Indebtedness represented by such Notes
unless and until the same are surrendered to the Trustee for
cancellation pursuant to this Section 2.12.
-31-
SECTION 2.13
Defaulted
Interest
. If the Issuer defaults in a payment of
interest on the Notes, it shall pay the defaulted interest, plus
(to the extent lawful) any interest payable on the defaulted
interest, to the Holder thereof on a subsequent special record
date, which date shall be the fifteenth day next preceding the
date fixed by the Issuer for the payment of defaulted interest.
The Issuer shall promptly notify the Trustee and Paying Agent in
writing of the amount of defaulted interest proposed to be paid
on each Note and the date of the proposed payment (a
Default Interest Payment Date), and at the same time
the Issuer shall deposit with the Trustee or Paying Agent an
amount of money equal to the aggregate amount proposed to be
paid in respect of such defaulted interest or shall make
arrangements satisfactory to the Trustee or Paying Agent for
such deposit prior to the date of the proposed payment, such
money when deposited to be held in trust for the benefit of the
Persons entitled to such defaulted interest as in this
Section 2.13;
provided
,
however
, that in no
event shall the Issuer deposit monies proposed to be paid in
respect of defaulted interest later than
10:00 a.m. New York City time on the proposed Default
Interest Payment Date with respect to defaulted interest to be
paid on the Note. At least 15 days before the subsequent
special record date, the Issuer shall mail to each Holder, with
a copy to the Trustee, a notice that states the subsequent
special record date, the payment date and the amount of
defaulted interest, and interest payable on such defaulted
interest, if any, to be paid.
SECTION 2.14
CUSIP
Numbers
. The Issuer in issuing the Notes may use
CUSIP numbers, and if it does so, the Trustee shall
use the CUSIP numbers in notices of redemption or exchange as a
convenience to Holders;
provided
that any such notice may
state that no representation is made as to the correctness or
accuracy of the CUSIP numbers printed in the notice or on the
Notes and that reliance may be placed only on the other
identification numbers printed on the Notes. The Issuer shall
promptly notify the Trustee of any change in the CUSIP numbers.
SECTION 2.15
Deposit of
Moneys
. Prior to 10:00 a.m. New York City
time on each interest payment date and Maturity Date, the Issuer
shall have deposited with the Trustee or its designated Paying
Agent (which shall be the Paying Agent or its successor unless
otherwise notified to the Issuer by the Trustee) in immediately
available funds money sufficient to make cash payments, if any,
due on such interest payment date or Maturity Date, as the case
may be, on all Notes then outstanding. Such payments shall be
made by the Issuer in a timely manner which permits the Paying
Agent to remit payment to the Holders on such interest payment
date or Maturity Date, as the case may be. Promptly upon receipt
of such payment, the Paying Agent shall confirm by the medium
chosen by the Paying Agent to the Issuer the receipt of such
payment.
SECTION 2.16
Certain
Matters Relating to Global Notes
. Members of or
participants in the DTC (Agent Members) shall have
no rights under this Indenture or any Global Note with respect
to any Global Note held on their behalf by the DTC or its
nominee, and the DTC or its nominee may be treated by the
Issuer, the Guarantors, the Trustee, the Paying Agent, the
Registrar and any agent of the Issuer or the Guarantors as the
absolute owner of the Global Note for all purposes whatsoever.
Notwithstanding the foregoing, nothing herein shall prevent the
Issuer, the Guarantors, the Trustee or any agent of the Issuer
or the Guarantors from giving effect to any written
certification, proxy or other authorization furnished by the DTC
or its nomi-
-32-
nee or impair, as between the DTC and its Agent Members, the
operation of customary practices governing the exercise of the
rights of a Holder of any Note.
(a) The Holder of any Global Note
may grant proxies and otherwise authorize any Person, including
DTC and its Agent Members and Persons that may hold interests
through Agent Members, to take any action which a Holder is
entitled to take under this Indenture or the Notes.
SECTION 2.17
Record
Date
. Unless otherwise set forth in this Indenture, the
record date for purposes of determining the identity of Holders
entitled to vote or consent to any action by vote or consent
authorized or permitted under this Indenture shall be determined
as provided for in TIA § 316(c).
ARTICLE III
REDEMPTION
SECTION 3.1
Optional
Redemption
. The Issuer may redeem all or, from time to
time, a part of the Notes, at its option, at a redemption price
equal to 100% of the principal amount of the Notes being
redeemed plus accrued interest, if any, to the redemption date,
plus the excess of:
(a) as determined by the
calculation agent (which shall initially be the Trustee), the
sum of the present values of the remaining scheduled payments of
principal and interest on the Notes being redeemed not including
any portion of such payment of interest accrued on the date of
redemption, from the redemption date to the maturity date,
discounted to the redemption date on a semi-annual basis
(assuming a
360-day
year
consisting of twelve
30-day
months) at the Treasury Rate plus 50 basis points; over
(b) 100% of the principal amount of
the Notes being redeemed.
The Company shall certify to the Trustee the applicable Treasury
Rate at the time of any such redemption.
SECTION 3.2
Notices to
Trustee
. If the Issuer elects to redeem Notes pursuant
to Paragraphs 8 or 9 of such Notes, it shall notify the
Trustee and the Paying Agent in writing of the
Redemption Date and the principal amount of Notes to be
redeemed at least 15 days prior to the giving of the notice
contemplated by Section 3.4 (or such shorter period as the
Trustee in its sole discretion shall determine). The Issuer
shall give notice of redemption as required under the relevant
paragraph of the Notes pursuant to which such Notes are being
redeemed.
SECTION 3.3
Selection of
Notes To Be Redeemed
. In the case of any partial
redemption, the Trustee will select the Notes for redemption in
compliance with the requirements of the principal securities
exchange, if any, on which such Notes are listed,
and/or
in
compliance with the requirements of the DTC, or if such Notes
are not listed, on a
pro rata
basis, by lot or by such
other method as the Trustee in its sole discretion shall deem to
be fair and appropriate (and in such manner as complies with
applicable legal and exchange requirements); although no Note of
$2,000 in original principal amount or less shall be redeemed in
part. If any Note is to be re-
-33-
deemed in part only, notice of redemption relating to that Note
will state the portion of the principal amount thereof to be
redeemed. A new Note in principal amount equal to the unredeemed
portion thereof will be issued and delivered to the Trustee, or
in the case of Definitive Notes, issued in the name of the
Holder thereof upon cancellation of the original Note. The
selections made by the Trustee pursuant to this Section 3.3
shall always be subject to Section 7.2(d).
SECTION 3.4
Notice of
Redemption
. At least 30 days but not more than
60 days before a Redemption Date or a Tax
Redemption Date, as applicable, the Issuer shall, so long
as the Notes are in global form, publish in a leading newspaper
having a general circulation in New York (which is expected to
be The Wall Street Journal) (and, if and so long as the Notes
are listed on the Euro MTF Market of the Luxembourg Stock
Exchange and the rules of such stock exchange shall so require,
publish in a newspaper having a general circulation in
Luxembourg (which is expected to be the
Luxemburger Wort
)
or, to the extent and in the manner permitted by such rules,
posted on the official website of the Luxembourg Stock Exchange
(www.bourse.lu)) and notify the Holders, the Trustee and the
Luxembourg Stock Exchange, if applicable, or in the case of
Definitive Notes, in addition to such publication, mail to
Holders (with a copy to the Trustee) by first-class mail,
postage prepaid, at their respective addresses as they appear on
the registration books of the Registrar. At the Issuers
request made at least 45 days before the
Redemption Date or a Tax Redemption Date, as
applicable (or such shorter period as the Trustee in its sole
discretion shall determine), the Paying Agent shall give the
notice of redemption in the Issuers name and at the
Issuers expense;
provided
,
however
, that the
Issuer shall deliver to the Trustee (in advance) an
Officers Certificate requesting that the Trustee give such
notice and setting forth in full the information to be stated in
such notice as provided in the following items. Each notice for
redemption shall identify the Notes to be redeemed and shall
state:
(a) the Redemption Date or the
Tax Redemption Date, as applicable;
(b) the Redemption Prices and
the amount of accrued and unpaid interest, if any, and
Additional Amounts, if any, to be paid (subject to the right of
Holders of record on the relevant Record Date to receive
interest and Additional Amounts, if any, due on the relevant
interest payment date);
(c) the name and address of the
designated Paying Agent;
(d) that Notes called for
redemption must be surrendered to the designated Paying Agent to
collect the Redemption Price plus accrued and unpaid
interest, if any, and Additional Amounts, if any;
(e) that, unless the Issuer
defaults in making the redemption payment pursuant to the terms
of this Indenture, interest and Additional Amounts, if any, on
Notes called for redemption cease to accrue on and after the
Redemption Date or the Tax Redemption Date, as
applicable, and the only remaining right of the Holders of such
Notes is to receive payment of the Redemption Price upon
surrender to the Paying Agent of the Notes redeemed;
(f) (i) if any Global Note is
being redeemed in part, the portion of the principal amount of
such Note to be redeemed and that, after the
Redemption Date, interest and Addi-
-34-
tional Amounts, if any, shall cease to accrue on the portion
called for redemption, and upon surrender of such Global Note
(if applicable), the Global Note with a notation on
Schedule A thereof adjusting the principal amount thereof
to be equal to the unredeemed portion, will be returned and
(ii) if any Definitive Note is being redeemed in part, the
portion of the principal amount of such Note to be redeemed, and
that, after the Redemption Date, upon surrender of such
Definitive Note, a new Definitive Note or Notes in aggregate
principal amount equal to the unredeemed portion thereof will be
issued in the name of the Holder thereof, upon cancellation of
the original Note;
(g) if fewer than all the Notes are
to be redeemed, the identification of the particular Notes (or
portion thereof) to be redeemed, as well as the aggregate
principal amount of Notes to be redeemed and the aggregate
principal amount of Notes to be outstanding after such partial
redemption;
(h) the paragraph of the Notes
pursuant to which the Notes are to be redeemed; and
(i) the CUSIP numbers, and that no
representation is made as to the correctness or accuracy of the
CUSIP numbers, if any, listed in such notice or printed on the
Notes.
Prior to the giving of any notice of redemption pursuant to
Paragraph 9 of the Notes, the Issuer will deliver to the
Trustee (a) an Officers Certificate of the Issuer
stating that the Issuer is entitled to effect such redemption
and setting forth a statement of facts showing that the
conditions precedent to the right of the Issuer so to redeem
have occurred and (b) an Opinion of Counsel qualified under
the laws of the relevant jurisdiction to the effect that the
Issuer has or will become obligated to pay such Additional
Amounts as a result of a change in Tax law, and that the Issuer
cannot avoid such obligation by taking reasonable measures
available to it.
SECTION 3.5
Effect of
Notice of Redemption
. Once notice of redemption is
given in accordance with Section 3.4, Notes called for
redemption become due and payable on the Redemption Date or
the Tax Redemption Date, as applicable, and at the
Redemption Price plus accrued and unpaid interest, if any,
and Additional Amounts, if any. Upon surrender to the Trustee or
Paying Agent, such Notes called for redemption shall be paid at
the Redemption Price (which shall include accrued and
unpaid interest thereon, if any, and Additional Amounts, if any,
to the Redemption Date or Tax Redemption Date, as
applicable), but installments of interest, the maturity of which
is on or prior to the Redemption Date or the Tax
Redemption Date, as applicable, shall be payable to Holders
of record at the close of business on the relevant Record Dates.
SECTION 3.6
Deposit of
Redemption Price
. Prior to
10:00 a.m. New York City time on the
Redemption Date or the Tax Redemption Date, as
applicable, the Issuer shall deposit with the Trustee or its
designated Paying Agent (which shall be the Paying Agent or its
successor unless otherwise notified to the Issuer by the
Trustee) cash sufficient to pay the Redemption Price plus
accrued and unpaid interest (subject to, as provided in the
Notes, the right of Holders to receive interest on the relevant
interest payment date), if any, and Additional Amounts, if any,
of all Notes to be redeemed on that date other than Notes or
portion of Notes called for redemption that have been delivered
by the Issuer to the Trustee for cancellation. The designated
Paying Agent shall promptly return to the Issuer any cash so
deposited which is not
-35-
required for that purpose upon the written request of the
Issuer. Promptly upon receipt of such payment the Paying Agent
shall confirm by the medium chosen by the Paying Agent to the
Issuer the receipt of such payment.
If the Issuer complies with the preceding paragraph, then,
unless the Issuer defaults in the payment of such
Redemption Price plus accrued and unpaid interest, if any,
and Additional Amounts, if any, interest and Additional Amounts
on the Notes to be redeemed will cease to accrue on and after
the applicable Redemption Date or Tax Redemption Date,
whether or not such Notes are presented for payment. With
respect to Definitive Notes, if a Definitive Note is redeemed on
or after an interest Record Date but on or prior to the related
interest payment date, then any accrued and unpaid interest, if
any, and Additional Amounts, if any, shall be paid to the Person
in whose name such Note was registered at the close of business
on such Record Date. If any Note called for redemption shall not
be so paid upon surrender for redemption because of the failure
of the Issuer to comply with the preceding paragraph, interest,
and Additional Amounts, if any, shall be paid on the unpaid
principal, from the Redemption Date or the Tax
Redemption Date, as applicable, until such principal is
paid, and to the extent lawful on any interest not paid on such
unpaid principal, in each case at the rate provided in the Notes
and in Section 4.1.
SECTION 3.7
Notes Redeemed
in Part
. Upon surrender and cancellation of a
Definitive Note that is redeemed in part, the Company shall
execute and the Trustee shall authenticate for the Holder (at
the Issuers expense) a new Definitive Note equal in
principal amount to the unredeemed portion of the Definitive
Note surrendered and canceled;
provided
,
however
,
that each such Definitive Note shall be in a principal amount at
maturity of $2,000 or integral multiples of $1,000 in excess
thereof. Upon surrender of a Global Note that is redeemed in
part, the Paying Agent shall promptly forward such Global Note
to the Trustee who shall make a notation on Schedule A
thereof to reduce the principal amount of such Global Note to an
amount equal to the unredeemed portion of the Global Note
surrendered;
provided
,
however
, that each such
Global Note shall be in a principal amount at maturity of $2,000
or integral multiples of $1,000 in excess thereof.
SECTION 3.8
Special Tax
Redemption
. The Issuer is entitled to redeem the Notes,
at its option, in whole but not in part, upon not less than 30
nor more than 60 days notice, at 100% of the
principal amount of the Notes, plus accrued and unpaid interest
(if any) to the date of redemption (subject to the right of
holders of record on the relevant record date to receive
interest due on the relevant interest payment date), in the
event the Issuer has become or would become obligated to pay, on
the next date on which any amount would be payable with respect
to the Notes, any additional amounts as a result of:
(a) a change in or an amendment to
the laws, treaties, regulations or rulings of any Relevant
Taxing Jurisdiction; or
(b) any change in or amendment to
any official position regarding the application, administration
or interpretation of such laws, treaties, regulations or rulings
(including by virtue of a holding, judgment or order by a court
of competent jurisdiction);
-36-
which change or amendment to such laws or official position is
announced and becomes effective after the issuance of the Notes;
provided
that the Issuer determines, in its reasonable
judgment, that the obligation to pay such additional amounts
cannot be avoided by the use of reasonable measures available to
it;
provided
,
further
, that at the time such
notice is given, such obligation to pay Additional Amounts
remains in effect.
Notice of any such redemption must be given within 270 days
of the earlier of the announcement or effectiveness of any such
change.
ARTICLE IV
COVENANTS
SECTION 4.1
Payment of
Notes
.
(a) The Issuer shall pay the
principal, premium, if any, interest and Additional Amounts, if
any, on the Notes in the manner provided in such Notes and this
Indenture. An installment of principal of or interest, premium
or Additional Amounts on the Notes shall be considered paid on
the date it is due if the Trustee or Paying Agent holds prior to
10:00 a.m. New York City time on that date money
deposited by the Issuer in immediately available funds and
designated for, and sufficient to pay the installment in full
and is not prohibited from paying such money to the Holders
pursuant to the terms of this Indenture.
(b) The Issuer shall pay, to the
extent such payments are lawful, interest (including
post-petition interest in any proceeding under any Bankruptcy
Law) on overdue principal and on overdue installments of
interest (without regard to any applicable grace periods), on
any Additional Amounts, from time to time on demand at the rate
borne by the Notes. Interest will be computed on the basis of a
360-day
year
comprised of twelve
30-day
months.
SECTION 4.2
Maintenance of
Office or Agency
. The Issuer shall maintain the office
or agency (which office may be an office of the Trustee or an
affiliate of the Trustee, Registrar or co-Registrar) required
under Section 2.3 where Notes may be surrendered for
registration of transfer or for exchange and where notices and
demands to or upon the Issuer in respect of the Notes and this
Indenture may be served. The Issuer shall give prompt written
notice to the Trustee of the location, and any change in the
location, of such office or agency. If at any time the Issuer
shall fail to maintain any such required office or agency or
shall fail to furnish the Trustee with the address thereof, such
presentations, surrenders, notices and demands may be made or
served at the address of the Trustee set forth in
Section 11.1. The Issuer hereby initially designates the
office of the Trustee, acting through its office at 100 Wall
Street, Suite 1600, New York, New York 10005, as its office
or agency as required under Section 2.3 hereof. If the
Notes are listed on the Euro MTF Market of the Luxembourg Stock
Exchange and the rules of such exchange so require, the Issuer
will appoint Deutsche Bank Luxembourg, or such other Person
located in Luxembourg and reasonably acceptable to the Trustee
(reasonableness to be determined objectively), as an additional
paying and transfer agent.
SECTION 4.3
Limitation on
Incurrence of Indebtedness
.
-37-
(a) The Issuer and the Company
shall not, and shall not permit any of their Subsidiaries to,
Incur, directly or indirectly, any Indebtedness;
provided
,
however,
that the Company and any
Subsidiary may Incur Indebtedness (and the Company and any
Subsidiary may Incur Acquired Indebtedness) if on the date
thereof:
(1) the Consolidated Coverage Ratio
of the Company is at least 2.0 to 1.0; and
(2) no Default or Event of Default
will have occurred and be continuing or would occur as a
consequence of Incurring the Indebtedness.
(b) The foregoing limitations
contained in paragraph (a) do not apply to the Incurrence
of any of the following Indebtedness:
(1) Indebtedness Incurred under the
Revolving Credit Facility in an aggregate amount not to exceed
$1.2 billion outstanding at any time;
(2) Indebtedness in respect of
Receivables Financings in an aggregate principal amount which,
together with all other Indebtedness in respect of Receivables
Financings outstanding on the date of such Incurrence (other
than Indebtedness permitted by paragraph (a) or
clause (3) of this paragraph (b)), does not exceed 85% of
the sum of (1) the total amount of accounts receivables
shown on the Companys most recent consolidated quarterly
balance sheet, plus (2) without duplication, the total
amount of accounts receivable already subject to a Receivables
Financing;
(3) Indebtedness of the Company
owed to and held by another Guarantor, Indebtedness of a Wholly
Owned Subsidiary owed to and held by another Wholly Owned
Subsidiary or Indebtedness of a Wholly Owned Subsidiary owing to
and held by the Company;
provided
,
however
, that
any subsequent issuance or transfer of any Capital Stock that
results in any such Indebtedness being held by a Person other
than the Company or another Wholly Owned Subsidiary or any
subsequent transfer of such Indebtedness (other than to the
Company or another Wholly Owned Subsidiary) shall be deemed, in
each case, to constitute the Incurrence of such Indebtedness by
the Company or the Subsidiary, as the case may be;
(4) Indebtedness in respect of the
Notes issued on the Closing Date, and the related Note
Guarantees by the Company and the other Guarantors and
indebtedness issued in respect of the 300,000,000
aggregate principal amount of 5.25% Senior Notes due 2021
(the Euro Notes) issued on the Closing Date, and the
related Guarantees of the Euro Notes by the Company and the
other Guarantors;
(5) Capital Lease Obligations and
Indebtedness Incurred, in each case, to provide all or a portion
of the purchase price or cost of construction of an asset or, in
the case of a Sale and Leaseback Transaction, to finance the
value of such asset owned by the Company or a Subsidiary;
(6) Indebtedness (other than
Indebtedness of the type covered by clause (1) or clause
(2)) outstanding on the Closing Date after giving effect to the
application of proceeds from the Notes;
-38-
(7) Refinancing Indebtedness in
respect of Indebtedness Incurred pursuant to paragraph
(a) or pursuant to clause (4) or (6) of this
paragraph (b);
(8) Hedging Obligations entered
into in the ordinary course of the business and not for
speculative purposes as determined in good faith by the Company;
(9) customer deposits and advance
payments received from customers for goods purchased in the
ordinary course of business;
(10) Indebtedness arising under the
Cash Management Arrangements; and
(11) Indebtedness Incurred by the
Company or a Subsidiary in an aggregate principal amount which,
together with all other Indebtedness of the Company and its
Subsidiaries outstanding on the date of such Incurrence (other
than Indebtedness permitted by paragraph (a) or
clauses (1) through (10) of this paragraph (b)), does
not exceed $900 million.
(c) For purposes of determining
compliance with the foregoing covenant:
(1) in the event that an item of
Indebtedness meets the criteria of more than one of the types of
Indebtedness described above, the Company, in its sole
discretion, will classify and from time to time may reclassify
such item of Indebtedness and only be required to include the
amount and type of such Indebtedness in one of the above
clauses,
provided
that any Indebtedness outstanding on
the Closing Date and Indebtedness Incurred under clause (b)(5)
above may not be reclassified to clause (a) above; and
(2) an item of Indebtedness may be
divided and classified, or reclassified, in more than one of the
types of Indebtedness described above,
provided
that any
Indebtedness outstanding on the Closing Date and Indebtedness
Incurred under clause (b)(5) above may not be reclassified to
clause (a) above.
(d) If during any period the Notes
have achieved and continue to maintain Investment Grade Status
and no Event of Default has occurred and is continuing (such
period is referred to herein as an Investment Grade Status
Period), then upon notice by the Company to the Trustee by
the delivery of an Officers Certificate that it has
achieved Investment Grade Status, this covenant will be
suspended and will not during such period be applicable to the
Company and its Subsidiaries and shall only again be applicable
if such Investment Grade Status Period ends.
No action taken during an Investment Grade Status Period or
prior to an Investment Grade Status Period in compliance with
this Section 4.3 will require reversal or constitute a
default under the Notes in the event that this Section 4.3
is subsequently reinstated or suspended, as the case may be.
SECTION 4.4
Limitation on
Liens
. The Issuer and the Company may not, and may not
permit any Guarantor or any of their respective Subsidiaries to
directly, or indirectly, create, Incur or suffer to exist any
Lien (other than Permitted Liens) upon any of its property or
assets (including Capital Stock), whether owned on the date
hereof or acquired after that date,
-39-
securing any Indebtedness, unless contemporaneously with (or
prior to) the Incurrence of the Liens effective provision is
made to secure the Indebtedness due under this Indenture and the
Notes, equally and ratably with (or prior to in the case of
Liens with respect to Subordinated Obligations) the Indebtedness
secured by such Lien for so long as such Indebtedness is so
secured.
SECTION 4.5
Ownership of
the Issuer
. The Company will continue to directly or
indirectly maintain 100% ownership of the Capital Stock of the
Issuer or any permitted successor of the Issuer,
provided
, that any permitted successor of the Company may
succeed to the Companys ownership of such Capital Stock.
The Company will cause the Issuer or its successor to engage
only in those activities that are necessary, convenient or
incidental to issuing and selling the Notes and any additional
Indebtedness permitted under Section 4.3 (including the
Issuers Guarantee of the Credit Facility and any
Additional Notes), and advancing or distributing the proceeds
thereof to the Company and its Subsidiaries and performing its
obligations relating to the Notes and any such additional
Indebtedness, pursuant to the terms thereof and of this
Indenture and any other applicable indenture.
SECTION 4.6
Existence
. Except
as permitted by Article V, the Company shall do or cause to
be done all things necessary to preserve and keep in full force
and effect the existence, rights (charter and statutory) and
franchises of the Company, the Issuer and each other Guarantor;
provided
,
however
, that the Company shall not be
required to preserve any such existence, right or franchise if
the Board of Directors of the Company in good faith shall
determine that the preservation thereof is no longer desirable
in the conduct of the business of the Company and that the loss
thereof at the time of such loss is not disadvantageous in any
material respect to the Holders.
SECTION 4.7
Maintenance of
Properties
. Except as permitted by Article V, the
Company shall cause all properties used or useful in the conduct
of its business or the business of any Subsidiary of the Company
to be maintained and kept in good condition, repair and working
order and supplied with all necessary equipment and will cause
to be made all necessary repairs, renewals, replacements,
betterments and improvements thereof, all as in the judgment of
the Company may be necessary so that the business carried on in
connection therewith may be properly and advantageously
conducted at all times;
provided
,
however
, that
nothing in this Section shall prevent the Company from
discontinuing the operation or maintenance of any of such
properties if such discontinuance is, as determined by the
Company, or its Responsible Officers, or any Subsidiary, or its
Responsible Officers, having managerial responsibility for any
such property, in good faith, desirable in the conduct of its
business or the business of any Subsidiary and not
disadvantageous in any material respect to the Holders.
SECTION 4.8
Payment of
Taxes and Other Claims
. The Company and the Guarantors
will pay or discharge or cause to be paid or discharged, before
the same shall become delinquent, (a) all material taxes,
assessments and governmental charges levied or imposed upon the
Company or any of its Subsidiaries or upon the income, profits
or property of the Company or any of its Subsidiaries (including
satisfying any withholding tax obligations), and (b) all
material lawful claims for labor, materials and supplies which,
if unpaid, might by law become a Lien upon the property of the
Company or the Guarantors or any of their Subsidiaries;
provided,
-40-
however,
that the Company or the Guarantors shall not be
required to pay or discharge or cause to be paid or discharged
any such tax, assessment, charge or claim whose amount,
applicability or validity is being contested in good faith by
appropriate proceedings and for which adequate reserves are
maintained in accordance with Accounting Principles.
SECTION 4.9
Maintenance of
Insurance
. The Company shall, and shall cause its
Subsidiaries to, keep at all times all of their material
properties which are of an insurable nature insured against loss
or damage pursuant to self-insurance arrangements with insurers
believed by the Company to be responsible to the extent that
property of similar character is usually so insured by
corporations similarly situated and owning like properties in
accordance with good business practice. The Company shall, and
shall cause its Subsidiaries to, use the proceeds from any such
insurance policy to repair, replace or otherwise restore the
property to which such proceeds relate, except to the extent
that a different use of such proceeds is, as determined by the
Company, or any Subsidiary having managerial responsibility for
any such property, in good faith, desirable in the conduct of
its business or the business of any Subsidiary and not
disadvantageous in any material respect to the Holders.
SECTION 4.10
Reports
. For
so long as any Notes are outstanding, the Company will provide
the Trustee with:
(1) copies of the annual reports
and of the information, documents and other reports, and such
summaries thereof, as may be required by the TIA at the times
and in the manner provided by the TIA;
(2) its annual financial statements
and related notes thereto for the most recent two fiscal years
prepared in accordance with U.S. GAAP (or IFRS or any other
internationally generally acceptable accounting standard in the
event the Company is required by applicable law to prepare its
financial statements in accordance with IFRS or such other
standard or is permitted and elects to do so, with appropriate
reconciliation to U.S. GAAP, unless not then required under
the rules of the SEC) and including segment data, together with
an audit report thereon, together with a discussion of the
Operating Results and Liquidity for such
fiscal years prepared in a manner substantially consistent with
the Operating and Financial Review and Prospects
required by
Form 20-F
under the Exchange Act (or any replacement or successor form)
appearing herein and a Business Summary of the Financial
Year and discussion of Business Segments
provided in a manner consistent with its annual report, a
description of Related Party Transactions, and a
description of Indebtedness, within 90 days of the end of
each fiscal year; and
(3) quarterly financial information
as of and for the period from the beginning of each year to the
close of each quarterly period (other than the fourth quarter),
together with comparable information for the corresponding
period of the preceding year, and a summary
Managements Discussion and Analysis of Financial
Condition and Results of Operations to the extent and in
the form required under the Exchange Act providing a brief
discussion of the results of operations for the period within
45 days following the end of the fiscal quarter.
-41-
The Company shall also comply with the other provisions of
Section 314(a) of the TIA. In addition, so long as the
Notes remain outstanding and during any period when the Issuer
or the Company is not subject to Section 13 or 15(d) of the
Exchange Act other than by virtue of the exemption therefrom
pursuant to
Rule 12g3-2(b),
the Company will furnish to any Holder or beneficial owner of
Notes initially offered and sold in the United States to
qualified institutional buyers as defined in
Rule 144A under the Securities Act pursuant to such rule
and any prospective purchaser in the United States designated by
such Holder or beneficial owner, upon request, any information
required to be delivered pursuant to Rule 144A(d)(4) under
the Securities Act.
If and so long as the Notes are listed on the Euro MTF Market of
the Luxembourg Stock Exchange, copies of such reports shall also
be available at the specified office of the Listing Agent in
Luxembourg.
Deliveries of such reports, information and documents to the
Trustee is for informational purposes only and the
Trustees receipt of such shall not constitute constructive
notice of any information contained therein or determinable from
information contained therein, including the Issuers, the
Companys or any Guarantors compliance with any of
its covenants hereunder (as to which the Trustee is entitled to
rely exclusively on Officers Certificates). The Trustee
shall have no obligation to review such reports to determine if
the information required by this Section 4.10 is contained
therein.
SECTION 4.11
Change of
Control
. Each Holder of the Notes, upon the occurrence
of a Change of Control Triggering Event, will have the right to
require that the Issuer repurchase such Holders Notes, at
a purchase price in cash equal to 101% of the principal amount
thereof plus accrued and unpaid interest, if any, to the date of
purchase (subject to the right of Holders of record on the
relevant record date to receive interest due on the relevant
interest payment date).
Within 30 days following a Change of Control Triggering
Event, the Issuer will mail a notice to each Holder with a copy
to the Trustee stating:
(1) that a Change of Control
Triggering Event has occurred and that such Holder has the right
to require the Issuer to purchase such Holders Notes, at a
purchase price in cash equal to 101% of the principal amount
thereof plus accrued and unpaid interest, if any, to the date of
purchase (subject to the right of Holders of record on the
relevant record date to receive interest on the relevant
interest payment date);
(2) the circumstances and relevant
facts regarding such Change of Control Triggering Event
(including information with respect to pro forma historical
income, cash flow and capitalization after giving effect to such
Change of Control Triggering Event);
(3) the repurchase date (which
shall be no earlier than 30 days nor later than
60 days from the date such notice is mailed);
(4) that each Note will be subject
to repurchase only in amounts of $2,000 or integral multiples of
$1,000 in excess thereof; and
-42-
(5) the instructions determined by
the Issuer, consistent with the covenant described hereunder,
that a Holder must follow in order to have its Notes purchased.
(6) that any Note not tendered will
continue to accrue interest;
(7) that, unless the Issuer
defaults in the payment of the Change of Control purchase price,
any Notes accepted for payment shall cease to accrue interest
after the repurchase date;
(8) that Holders accepting the
offer to have their Notes repurchased pursuant to a change of
control offer will be required to surrender the Notes to the
Paying Agent or any other Agent specified in the notice at the
address specified in the notice prior to the close of business
on the Business Day preceding the repurchase date;
(9) that Holders whose Notes are
being purchased only in part will be issued new Notes equal in
principal amount to the unpurchased portion of the Notes
surrendered;
(10) any other procedures that a holder
must follow to accept a change of control offer or effect
withdrawal of such acceptance; and
(11) the name and address of the Paying
Agent.
On the repurchase date, the Issuer shall, to the extent lawful:
(1) accept for payment Notes or
portions thereof validly tendered pursuant to the change of
control offer;
(2) deposit with the Paying Agent
money sufficient to pay the Change of Control purchase price in
respect of all Notes or portions thereof so tendered; and
(3) deliver or cause to be
delivered to the Trustee Notes so accepted together with an
Officers Certificate stating the Notes or portions thereof
tendered to the Issuer.
The Paying Agent shall promptly mail to each Holder of Notes so
accepted payment in an amount equal to the purchase price for
such Notes, and the Issuer shall execute and issue, and the
Trustee shall promptly authenticate and mail to such Holder, a
new Note equal in principal amount to any unpurchased portion of
the Notes surrendered; provided that each such new Note shall be
issued in an original principal amount in denominations of
$2,000 and integral multiples of $1,000 in excess thereof.
The Issuer will comply, to the extent applicable, with the
requirements of Section 14(e) of the Exchange Act and any
other securities laws or regulations in connection with the
repurchase of Notes pursuant to this Section 4.11. To the
extent that the provisions of any securities laws or regulations
or applicable listing requirements conflict with the provisions
of this Section 4.11, the Issuer will comply with the
applicable securities laws and regulations and will not be
deemed to have breached its obligations under this
Section 4.11 by virtue thereof.
-43-
SECTION 4.12
Additional
Amounts
. At least 30 days prior to each date on
which payment of principal, premium, if any, or interest or
other amounts on the Notes is to be made (unless such obligation
to pay Additional Amounts arises shortly before or after the
30th day prior to such date, in which case it shall be
promptly thereafter), if the Issuer or any Guarantor will be
obligated to pay Additional Amounts pursuant to Paragraph 2
of the Notes (the Additional Amounts) with respect
to any such payment, the Issuer will promptly furnish the
Trustee and the Paying Agent, if other than the Trustee, with an
Officers Certificate stating that such Additional Amounts
will be payable and the amounts so payable, and will set forth
such other information necessary to enable the Trustee or the
Paying Agent to pay such Additional Amounts to the Holders on
the payment date. The Issuer will pay to the Trustee or the
Paying Agent such Additional Amounts and, if paid to a Paying
Agent other than the Trustee, shall promptly provide the Trustee
with documentation evidencing the payment of such Additional
Amounts. Copies of such documentation shall be made available to
the Holders upon request. The Issuer shall indemnify the Trustee
and the Paying Agent for, and hold them harmless against, any
loss, liability or expense incurred without negligence or
willful misconduct on their part arising out of or in connection
with actions taken or omitted by any of them in reliance on any
Officers Certificate furnished to them pursuant to this
Section 4.12.
The Issuer will (i) make any required withholding or
deduction and (ii) remit the full amount deducted or
withheld to the Relevant Taxing Jurisdiction in accordance with
applicable law. The Issuer will use all reasonable efforts to
obtain certified copies of tax receipts evidencing the payment
of any Taxes so deducted or withheld from each Relevant Taxing
Jurisdiction imposing such Taxes and will provide such certified
copy to the Trustee.
If the Issuer or the Guarantors conduct business in any
jurisdiction (an Additional Taxing Jurisdiction)
other than a Relevant Taxing Jurisdiction and, as a result, are
required by the law of such Additional Taxing Jurisdiction to
deduct or withhold any amount on account of taxes imposed by
such Additional Taxing Jurisdiction from payments under the
Notes which would not have been required to be so deducted or
withheld but for such conduct of business in such Additional
Taxing Jurisdiction, the Additional Amounts provision described
above shall be considered to apply to such Holders as if
references in such provision to Taxes included taxes
imposed by way of deduction or withholding by any such
Additional Taxing Jurisdiction (or any political subdivision
thereof or taxing authority therein).
The Issuer will pay any present stamp, court or documentary
taxes, or any other excise, property or similar taxes, charges
or levies (including any penalties, interest or other
liabilities related thereto) which arise in the United States
(or any political subdivision thereof or therein) from the
execution, delivery and registration of Notes upon original
issuance and initial resale of the Notes or any other document
or instrument referred to therein, or in connection with the
enforcement of the Notes or any Note Guarantee or any other
document or instrument referred to therein. If at any time the
Issuer changes its place of organization to outside of the
United States or there is a new issuer organized outside of the
United States, the Issuer or new issuer, as applicable, will pay
any stamp, court or documentary taxes, or any other excise,
property or similar taxes, charges or levies (including any
penalties, interest or other liabilities related thereto) which
arise in the jurisdiction in which the Issuer or new issuer is
organized (or any political subdivision thereof or therein) and
are payable by the Holders of the Notes in respect of
-44-
the Notes or any other document or instrument referred to
therein under any law, rule or regulation in effect at the time
of such change.
The foregoing obligations of this Section 4.12 will survive
any termination, defeasance or discharge of this Indenture and
will apply
mutatis mutandis
to any successor Person to
the Issuer or the Guarantors.
Whenever in this Indenture or in the Notes there is mentioned,
in any context, the payment of principal, premium or interest,
if any, or any other amount payable under or with respect to any
Note, such mention shall be deemed to include mention of the
payment of Additional Amounts to the extent that, in such
context, Additional Amounts are, were or would be payable in
respect thereof.
SECTION 4.13
Compliance
Certificate; Notice of Default
. The Company shall
deliver to the Trustee, within 90 days after the end of
each fiscal year an Officers Certificate stating whether
or not to the best knowledge of the signor thereof, the Issuer
and the Guarantors, as the case may be, have complied with all
conditions and covenants under this Indenture, whether a Default
or an Event of Default has occurred during such period, and, if
a Default or an Event of Default has occurred during such
period, specifying all such Events of Default and the nature
thereof of which such Responsible Officer has knowledge. Upon
becoming aware of, and as of such time that the Issuer should
reasonably have become aware of, a Default, the Company also
shall deliver to the Trustee, within 30 days thereafter,
written notice of any events which would constitute a Default,
their status and what action the Issuer is taking or proposes to
take in respect thereof, and, in the case of a Default in the
payment of interest, principal, redemption payments or any other
amount due on the Notes or the Guarantees, such same notice to
the Paying Agent.
SECTION 4.14
Limitation on
Sale and Leaseback Transactions
. The Issuer and the
Company may not, and may not permit any Guarantor or any
Subsidiary to, enter into any Sale and Leaseback Transaction
unless:
(1) the Issuer or such Guarantor or
Subsidiary, as the case may be, receives consideration at the
time of such Sale and Leaseback Transaction at least equal to
the fair market value (as evidenced by an Officers
Certificate of a Responsible Officer, or, if the value exceeds
$25 million, a resolution of the Board of Directors of the
Issuer or such Guarantor or Subsidiary), of the property subject
to such transaction;
(2) the Issuer or such Guarantor or
Subsidiary, as the case may be, could have created a Lien on the
property subject to such Sale and Leaseback Transaction if such
transaction was financed with Indebtedness without securing the
Notes pursuant to Section 4.4; and
(3) the Issuer or such Guarantor or
Subsidiary, as the case may be, can Incur an amount of
Indebtedness equal to the Attributable Debt in respect of such
Sale and Leaseback Transaction.
-45-
ARTICLE V
SUCCESSOR
ISSUER OR GUARANTOR
SECTION 5.1
Limitation on
Mergers and Sales of Assets
. The Issuer and the Company
may not, and may not permit any other Guarantor to consolidate
or merge with or into (whether or not the Issuer or such
Guarantor is the Surviving Person), or sell, assign, transfer,
lease, convey or otherwise dispose of all or substantially all
of its properties and assets in one or more related
transactions, to another Person unless:
(1) the Surviving Person is an
entity organized and existing under the laws of Germany, the
United Kingdom, any other member state of the European Union (as
of December 31, 2003), Luxembourg, Switzerland, the United
States of America, or any State thereof or the District of
Columbia, or the jurisdiction of formation of the Issuer or any
Guarantor; or, if the Surviving Person is an entity organized
and existing under the laws of any other jurisdiction, the
Issuer delivers to the Trustee an Opinion of Counsel to the
effect that the rights of the Holders of the Notes, would not be
affected adversely as a result of the law of the jurisdiction of
organization of the Surviving Person, insofar as such law
affects the ability of the Surviving Person to pay and perform
its obligations and undertakings in connection with the Notes
(in a transaction involving the Issuer) or its Note Guarantee or
the ability of the Surviving Person to obligate itself to pay
and perform such obligations and undertakings or the ability of
the Holders to enforce such obligations and undertakings;
(2) the Surviving Person (if other
than the Issuer or a Guarantor) shall expressly assume,
(A) in a transaction or series of transactions involving
the Issuer, by a supplemental indenture in a form satisfactory
to the Trustee, all of the obligations of the Issuer,
(B) in a transaction or series of transactions involving
the Company, by a supplemental indenture in a form satisfactory
to the Trustee, all of the obligations of the Company under the
Indenture, or (C) in a transaction or series of
transactions involving a Guarantor (including the Company), by a
Guarantee Agreement, in a form satisfactory to the Trustee, all
of the obligations of such Guarantor under its Note Guarantee;
(3) at the time of and immediately
after such transaction, no Default or Event of Default shall
have occurred and be continuing; and
(4) the Issuer or such Guarantor
delivers to the Trustee an Officers Certificate and an
Opinion of Counsel, each stating that such consolidation,
merger, transfer, assignment, sale, lease or other disposition
and such supplemental indenture and Guarantee Agreement, if any,
comply with this Indenture.
SECTION 5.2
Successor
Entity Substituted
. Upon any consolidation or merger by
the Issuer, the Company or any other Guarantor with or into any
other Person, or any conveyance, transfer, sale, assignment,
lease or other disposition by the Issuer, the Company or any
other Guarantor in one or more transactions, of substantially
all of its properties and assets as an entirety to any Person in
accordance with Section 5.1, the Surviving Person shall
succeed to, and be substituted for, and may exercise every right
and power of, the Issuer or such Guarantor under
-46-
this Indenture with the same effect as if such Surviving Person
had been named as the Issuer or had been a Guarantor herein, and
thereafter the Issuer or such Guarantor shall be discharged from
all obligations and covenants hereunder and under the Notes.
Such Surviving Person (if the successor of the Issuer) may cause
to be signed, and may issue either in its own name or in the
name of the Issuer, any or all of the Notes issuable hereunder
which theretofore shall not have been signed by the Issuer and
delivered to the Trustee; and, upon the order of such Surviving
Person instead of the Issuer and subject to all the terms,
conditions and limitations in this Indenture prescribed, the
Trustee shall authenticate and shall deliver any Notes which
previously shall have been signed and delivered by the
Responsible Officers of the Issuer to the Trustee for
authentication pursuant to such provisions and any Notes which
such Surviving Person thereafter shall cause to be signed and
delivered to the Trustee on its behalf for the purpose pursuant
to such provisions. All the Notes so issued shall in all
respects have the same legal rank and benefit under this
Indenture as the Notes theretofore or thereafter issued in
accordance with the terms of this Indenture as though all of
such Notes had been issued at the date of the execution hereof.
In case of any such consolidation, merger, sale, assignment,
transfer, conveyance, lease, or other disposition such changes
in phraseology and form may be made in the Notes thereafter to
be issued as may be appropriate.
SECTION 5.3
Substitution of
the Issuer
. The Company, any other Guarantor or a
Finance Subsidiary (a Successor) may assume the
obligations of the Issuer under the Notes, by executing and
delivering to the Trustee (a) a supplemental indenture
which subjects such person to all of the provisions of the
Indenture and (b) an opinion of counsel to the effect that
such supplemental indenture has been duly authorized and
executed by such Person, and constitutes the legal, valid,
binding and enforceable obligation of such Person, subject to
customary exceptions; provided that (i) the Successor is
formed under the laws of the United States of America, or any
State thereof or the District of Columbia, Germany, the United
Kingdom or any other member state of the European Union as of
December 31, 2003 and (ii) no Additional Amounts would
be or become payable with respect to the Notes at the time of
such assumption, or as result of any change in the laws of the
jurisdiction of formation of such Successor that was reasonably
foreseeable at such time. The Successor shall succeed to, and be
substituted for, and may exercise every right and power of, the
Issuer under the Indenture with the same effect as if it were
the Issuer thereunder, and the former Issuer shall be discharged
from all obligations and covenants under this Indenture and the
Notes.
ARTICLE VI
DEFAULT
AND REMEDIES
SECTION 6.1
Events of
Default
. Whenever used herein with respect to the
Notes, Event of Default means any one of the
following events which shall have occurred and be continuing:
(1) failure for 30 days to pay
interest on the Notes, including any Additional Amounts in
respect thereof, when due; or
-47-
(2) failure to pay principal of or
premium, if any, on the Notes when due, whether at maturity,
upon redemption, by declaration or otherwise; or
(3) failure to observe or perform
any other covenant contained in this Indenture for 60 days
after notice as provided in this Indenture; or
(4) default under any mortgage,
indenture or instrument under which there may be issued or by
which there may be secured or evidenced any Indebtedness for
money borrowed by the Company or any of its Subsidiaries (or the
payment of which is Guaranteed by the Company), whether such
Indebtedness or Guarantee now exists or is Incurred after the
Closing Date, if (A) such default results in the
acceleration of such Indebtedness prior to its express maturity
or will constitute a default in the payment of such Indebtedness
and (B) the principal amount of any such Indebtedness that
has been accelerated or not paid at maturity, when added to the
aggregate principal amount of all other such Indebtedness, at
such time, that has been accelerated or not paid at maturity,
exceeds $100 million; or
(5) any final judgment or judgments
(not covered by insurance) which can no longer be appealed for
the payment of money in excess of $100 million shall be
rendered against the Issuer or the Company or any of its
Subsidiaries and shall not be discharged for any period of 60
consecutive days during which a stay of enforcement shall not be
in effect; or
(6) any Note Guarantee shall cease
to be in full force and effect in accordance with its terms for
any reason except pursuant to the terms of this Indenture
governing the release of Note Guarantees or the satisfaction in
full of all the obligations thereunder or shall be declared
invalid or unenforceable other than as contemplated by its
terms, or any Guarantor shall repudiate, deny or disaffirm any
of its obligations thereunder; or
(7) the Company, the Guarantors,
the Issuer or any of the Companys Significant Subsidiaries
pursuant to or within the meaning of any Bankruptcy Law:
(a) commences negotiations with any
one or more of its creditors with a view to the general
readjustment or rescheduling of its indebtedness or makes a
general assignment for the benefit of or a composition with its
creditors or, for any of the reasons set out in
Sections 17-19
of the German Insolvency Code (
Insolvenzordnung
), files
for insolvency (
Antrag auf Eröffnung eines
Insolvenzverfahrens
) or the board of directors
(
Geschäftsführer
) is required by law to file
for insolvency, a creditor files for the opening of insolvency
proceedings and such filing is not frivolous and not dismissed
within a period of one month by the competent insolvency court,
or the competent court takes any of the actions set out in
Section 21 of the German Insolvenzordnung or a competent
court institutes insolvency proceedings (
Eröffnung des
Insolvenzverfahrens
) or denies a petition for commencement
of insolvency proceeding by reason of insufficient assets,
(b) commences a voluntary case,
-48-
(c) consents to the entry of an
order for relief against it in an involuntary case,
(d) consents to the appointment of
a custodian of it or for all or substantially all of its
property,
(e) makes a general assignment for
the benefit of its creditors, or
(f) takes any corporate action to
authorize or effect any of the foregoing.
A default under clause (3) of this paragraph will not
constitute an Event of Default unless the Trustee or Holders of
25% in principal amount of the outstanding Notes notify the
Issuer and the Company of such default and such default is not
cured within the time specified in clause (3).
SECTION 6.2
Acceleration
. If
an Event of Default (other than an Event of Default described in
clause (7) of Section 6.1 hereof) occurs and is
continuing, the Trustee by notice to the Company, or the Holders
of at least 25% in aggregate principal amount of the outstanding
Notes by notice to the Issuer, the Company and the Trustee, may,
and the Trustee at the request of such Holders shall, declare
the principal of, premium, if any, and accrued and unpaid
interest, if any, and Additional Amounts, if any, on all the
Notes to be due and payable. Upon such a declaration, such
principal, premium, accrued and unpaid interest, and Additional
Amounts, if any, will be due and payable immediately. If an
Event of Default described in clause (7) of
section 6.1 above occurs and is continuing, the principal
of, premium, if any, and accrued and unpaid interest on all the
Notes will become and be immediately due and payable without any
declaration or other act on the part of the Trustee or any
Holders.
SECTION 6.3
Other
Remedies
. If an Event of Default of which the Trustee
is aware occurs and is continuing, the Trustee may pursue any
available remedy by proceeding at law or in equity to collect
the payment of principal of or, premium, if any, interest, and
Additional Amounts, if any, on the Notes or to enforce the
performance of any provision of the Notes or this Indenture.
SECTION 6.4
The Trustee May
Enforce Claims Without Possession of Notes
. All rights
of action and claims under this Indenture or the Notes may be
prosecuted and enforced by the Trustee (without liability)
without the possession of any of the Notes or the production
thereof in any proceeding relating thereto.
SECTION 6.5
Rights and
Remedies Cumulative
. Except as otherwise provided with
respect to the replacement or payment of mutilated, destroyed,
lost or stolen Notes in Section 2.8, no right or remedy
herein conferred upon or reserved to the Trustee or to the
Holders of Notes is intended to be exclusive of any other right
or remedy, and every right and remedy shall, to the extent
permitted by law, be cumulative and in addition to every other
right and remedy given hereunder or now or hereafter existing at
law or in equity or otherwise. The assertion or employment of
any right or remedy hereunder, or otherwise, shall not prevent
the concurrent or subsequent assertion or employment of any
other appropriate right or remedy.
-49-
SECTION 6.6
Delay or
Omission Not Waiver
. No delay or omission of the
Trustee or of any Holder to exercise any right or remedy
accruing upon any Event of Default shall impair any such right
or remedy or constitute a waiver of any such Event of Default or
an acquiescence therein. Every right and remedy given by the
Indenture or by law to the Trustee or to the Holders of Notes
may be exercised from time to time, and as often as may be
deemed expedient, by the Trustee or by the Holders of Notes, in
each case in accordance with the terms of this Indenture.
SECTION 6.7
Waiver of Past
Defaults
. Subject to Sections 2.10, 6.10 and 9.2,
at any time after a declaration of acceleration with respect to
the Notes as described in Section 6.2, the Holders of at
least a majority in principal amount of the outstanding Notes by
written notice to the Issuer and to the Trustee, may waive all
past defaults (except with respect to nonpayment of principal,
premium or interest) and rescind any such declaration of
acceleration with respect to the Notes and its consequences if
(i) the rescission would not conflict with any judgment or
decree of a court of competent jurisdiction and (ii) all
existing Events of Default, other than the nonpayment of the
principal of, premium, if any, and interest on the Notes that
have become due solely by such declaration of acceleration, have
been cured or waived. Such waiver shall not excuse a continuing
Event of Default in the payment of interest, premium, if any,
principal or Additional Amounts, if any, on such Note held by a
non-consenting Holder, or in respect of a covenant or a
provision which cannot be amended or modified without the
consent of each Holder affected thereby. The Issuer shall
promptly deliver to the Trustee an Officers Certificate
stating that the requisite percentage of Holders has consented
to such waiver and attaching copies of such consents. When a
Default or Event of Default is waived, it is cured and ceases.
SECTION 6.8
Control by
Majority
. Subject to Section 2.10, the Holders of
not less than a majority in principal amount of the outstanding
Notes may, by written notice to the Trustee, direct the time,
method and place of conducting any proceeding for any remedy
available to the Trustee or exercising any trust or power
conferred on it. Subject to Section 7.1, however, the
Trustee may refuse to follow any direction that conflicts with
any law or this Indenture or that the Trustee determines is
unduly prejudicial to the rights of another Holder of Notes, or
that may involve the Trustee in personal liability;
provided
,
however
, that the Trustee may take any
other action deemed proper by the Trustee which is not
inconsistent with such direction. Prior to taking any action
under this Indenture, the Trustee will be entitled to
indemnification satisfactory to it in its sole discretion
against all losses and expenses caused by taking or not taking
such action in accordance with Section 7.7.
SECTION 6.9
Limitation on
Suits
. Subject to Section 6.10, no Holder of Notes
may pursue any remedy with respect to this Indenture or the
Notes unless:
(1) such Holder has previously
given the Trustee notice that an Event of Default is continuing;
(2) Holders of at least 25% in
principal amount of the outstanding Notes have requested the
Trustee to pursue the remedy;
-50-
(3) such Holders have offered the
Trustee reasonable security or indemnity satisfactory to the
Trustee against any loss, liability or expense;
(4) the Trustee has not complied
with such request within 60 days after the receipt of the
request and the offer of satisfactory security or
indemnity; and
(5) the Holders of a majority in
principal amount of the outstanding Notes have not given the
Trustee a direction that, in the opinion of the Trustee, is
inconsistent with such request within such
60-day
period.
SECTION 6.10
Rights of
Holders To Receive Payment
. Notwithstanding any other
provision of this Indenture (including, without limitation,
Section 8.9 hereof), the right of any Holder to receive
payment of principal of, premium, if any, interest, and
Additional Amounts, if any, on a Note, on or after the
respective due dates expressed in such Note, or to bring suit
for the enforcement of any such payment on or after such
respective dates, shall not be impaired or affected without the
consent of such Holder.
SECTION 6.11
Collection
Suit by Trustee
. If an Event of Default in payment of
principal, premium, if any, interest and Additional Amounts, if
any, specified in clause (1) or clause (2) of
Section 6.1 occurs and is continuing, the Trustee may
recover judgment in its own name and as trustee of an express
trust against the Company or any other obligor on the Notes for
the whole amount of principal, premium, if any, and accrued
interest remaining unpaid, together with interest on overdue
principal and, to the extent that payment of such interest is
lawful, interest on overdue installments of interest, in each
case at the rate per annum borne by the Notes and such further
amount as shall be sufficient to cover the costs and expenses of
collection, including the reasonable compensation, expenses,
disbursements and advances of the Trustee, its agents and
counsel, and any other amounts due the Trustee under
Section 7.7.
SECTION 6.12
Trustee May
File Proofs of Claim
. The Trustee may file such proofs
of claim and other papers or documents as may be necessary or
advisable in order to have the claims of the Trustee (including
any claim for the reasonable compensation, expenses,
disbursements and advances of the Trustee, its agents and
counsel and any other amount due to the Trustee under
Section 7.7, accountants and experts) and the Holders
allowed in any judicial proceedings relating to the Company, its
creditors or its property or other obligor on the Notes, its
creditors and its property and shall be entitled and empowered
to collect and receive any monies or other property payable or
deliverable on any such claims and to distribute the same, and
any Custodian in any such judicial proceedings is hereby
authorized by each Holder to make such payments to the Trustee
and, in the event that the Trustee shall consent to the making
of such payments directly to the Holders, to pay to the Trustee
any amount due to it for the reasonable compensation, expenses,
disbursements and advances of the Trustee, its agent and
counsel, and any other amounts due the Trustee under
Section 7.7. To the extent that the payment of any such
compensation, expenses, disbursements and advances of the
Trustee, its agents and counsel, and any other amounts due the
Trustee under Section 7.7 hereof out of the estate in any
such proceeding, shall be denied for any reason, payment of the
same shall be secured by a Lien on, and shall be paid out of,
any and all distributions, dividends, money, securities and
other properties which the Holders of the Notes may be entitled
to receive in such proceeding whether in liquidation or under
any plan of reorganization or arrangement or otherwise.
-51-
SECTION 6.13
Priorities
. If
the Trustee collects any money or property pursuant to this
Article VI, it shall pay out the money or property in the
following order:
First:
to the Trustee and the Agents for
amounts due under Section 7.7, including (but not limited
to) payment of all compensation, fees, expense and liabilities
incurred, and all advances made, by the Trustee and the costs
and expenses of collection;
Second:
to Holders for amounts due and unpaid
on the Notes for principal, premium, if any, interest and
Additional Amounts, if any, ratably, without preference or
priority of any kind, according to the amounts due and payable
on the Notes for principal, premium, if any, interest and
Additional Amounts, if any, respectively; and
Third:
to the Issuer, the Guarantors or any
other obligor on the Notes, as their interests may appear, or as
a court of competent jurisdiction may direct.
The Trustee, upon prior notice to the Issuer, may fix a record
date and payment date for any payment to Holders pursuant to
this Section 6.13;
provided
that the failure to give
any such notice shall not affect the establishment of such
record date or payment date for Holders pursuant to this
Section 6.13.
SECTION 6.14
Restoration of
Rights and Remedies
. If the Trustee or any Holder of
any Note has instituted any proceeding to enforce any right or
remedy under this Indenture and such proceeding has been
discontinued or abandoned for any reason, or has been determined
adversely to the Trustee or to such Holder, then and in every
such case, subject to any determination in such proceeding, the
Issuer, the Trustee and the Holders of Notes shall be restored
severally and respectively to their former positions hereunder
and thereafter all rights and remedies of the Trustee and the
Holders of Notes shall continue as though no such proceeding had
been instituted.
SECTION 6.15
Undertaking
for Costs
. In any suit for the enforcement of any right
or remedy under this Indenture or in any suit against the
Trustee for any action taken or omitted by it as Trustee, a
court in its discretion may require the filing by any party
litigant in the suit of an undertaking to pay the costs of the
suit, and the court in its discretion may assess reasonable
costs, including reasonable attorneys fees and expenses,
against any party litigant in the suit, having due regard to the
merits and good faith of the claims or defenses made by the
party litigant. This Section 6.15 does not apply to a suit
by the Trustee, a suit by a Holder pursuant to
Section 6.10, or a suit by a Holder or Holders of more than
10% in principal amount of the outstanding Notes.
SECTION 6.16
Notices of
Default
. If a Default occurs and is continuing and is
known to the Trustee, the Trustee must mail to each Holder of
Notes notice of the Default within 90 days after it has
become known to the Trustee. Except in the case of a Default in
the payment of principal of, premium, if any, interest and
Additional Amounts, if any, on any Note, the Trustee may
withhold notice if and so long as a committee of
Trust Officers determines that withholding notice is in the
interests of such Holders of Notes.
-52-
ARTICLE VII
TRUSTEE
SECTION 7.1
Duties of
Trustee
. If an Event of Default actually known to a
Trust Officer of the Trustee has occurred and is
continuing, the Trustee shall exercise such of the rights and
powers vested in it by this Indenture and use the same degree of
care and skill in their exercise as a prudent Person would
exercise or use under the circumstances in the conduct of his or
her own affairs. Subject to such provisions, the Trustee will be
under no obligation to exercise any of its rights or powers
under this Indenture at the request of any of the Holders of
Notes, unless they shall have offered to the Trustee reasonable
security and indemnity satisfactory to the Trustee against any
loss, liability or expense in accordance with the sixth
paragraph of Section 7.7.
(a) Except during the continuance
of an Event of Default actually known to the Trustee:
(1) The Trustee and the Agents will
perform only those duties as are specifically set forth herein
and no others and no implied covenants or obligations shall be
read into this Indenture against the Trustee or the Agents.
(2) In the absence of willful
misconduct on their part, the Trustee and the Agents may
conclusively rely, as to the truth of the statements and the
correctness of the opinions expressed therein, upon certificates
or opinions and such other documents delivered to them pursuant
to Section 11.2 and conforming to the requirements of this
Indenture. However, in the case of any such certificates or
opinions which by any provision hereof are required to be
furnished to the Trustee, the Trustee shall examine the
certificates and opinions to determine whether or not they
conform to the requirements of this Indenture.
(b) The Trustee may not be relieved
from liability for its own negligent action, its own negligent
failure to act, or its own willful misconduct, except that:
(1) This paragraph does not limit
the effect of subsection (a) of this Section 7.1.
(2) Neither the Trustee nor Agent
shall be liable for any error of judgment made in good faith by
a Trust Officer of such Trustee or Agent, unless it is
proved that the Trustee or such Agent was negligent in
ascertaining the pertinent facts.
(3) The Trustee shall not be liable
with respect to any action it takes or omits to take in good
faith in accordance with a direction received by it pursuant to
Section 6.2, 6.7 or 6.8.
(c) No provision of this Indenture
shall require the Trustee or any Agent to expend or risk its own
funds or otherwise incur any financial liability in the
performance of any of its duties hereunder or to take or omit to
take any action under this Indenture or take any action at the
request or direction of Holders if it shall have reasonable
grounds for believing that
-53-
repayment of such funds is not assured to it or it does not
receive an indemnity satisfactory to it in its sole discretion
against such risk, liability, loss, fee or expense which might
be incurred by it in the performance of any of its duties
hereunder.
(d) Whether or not therein
expressly so provided, every provision of this Indenture that in
any way relates to the Trustee is subject to the first paragraph
and subsections (a), (b) and (c) of this
Section 7.1.
(e) Neither the Trustee nor the
Agents shall be liable for interest on any money received by it
except as the Trustee and any Agent may agree in writing with
the Issuer. Money held in trust by the Trustee or any Agent need
not be segregated from other funds except to the extent required
by law.
(f) Any provision hereof relating
to the conduct or affecting the liability of or affording
protection to the Trustee shall be subject to the provisions of
this Section 7.1.
SECTION 7.2
Rights of
Trustee
. Subject to Section 7.1:
(a) The Trustee and each Agent may
rely conclusively on and shall be protected from acting or
refraining from acting based upon any document believed by them
to be genuine and to have been signed or presented by the proper
Person. Neither the Trustee nor any Agent shall be bound to make
any investigation into the facts or matters stated in any
resolution, certificate, statement, instrument, opinion, report,
notice, request, consent order, approval, appraisal, bond,
debenture, note, coupon, security or other paper or document.
The Trustee shall not be deemed to have notice or any knowledge
of any matter (including without limitation Defaults or Events
of Default) unless a Trust Officer assigned to and working
in the Trustees Corporate Trust Office which is
administering this Indenture has actual knowledge thereof or
unless written notice thereof is received by the Trustee,
attention: Corporate Trust and such notice clearly references
the Notes, the Issuer or this Indenture.
(b) Before the Trustee acts or
refrains from acting, it may consult with counsel and may
require an Officers Certificate, Issuer Order (as
applicable) or an Opinion of Counsel or both. Neither the
Trustee nor any Agent shall be liable for any action it takes or
omits to take in good faith in reliance on such certificate or
opinion.
(c) The Trustee and any Agent may
act through their attorneys and agents and shall not be
responsible for the misconduct or negligence of any agent (other
than an agent who is an employee of the Trustee or such Agent)
appointed with due care.
(d) The Trustee shall not be liable
for any action it takes or omits to take in good faith which it
reasonably believes to be authorized or within its rights or
powers conferred upon it by this Indenture;
provided
,
however
, that the Trustees conduct does not
constitute willful misconduct, negligence or bad faith.
(e) The Trustee or any Agent may
consult with counsel of its selection and the advice or opinion
of such counsel as to matters of law shall be full and complete
authorization and protection from liability in respect of any
action taken, omitted or suffered by it hereunder and in
accordance with the advice or opinion of such counsel.
-54-
(f) Except to the extent provided
for in Section 9.1 and subject to Section 9.2 hereof,
the Trustee may (but shall not be obligated to), without the
consent of the Holders, give any consent, waiver or approval
required by the terms hereof, but shall not without the consent
of the Holders of not less than a majority in aggregate
principal amount of the Notes at the time outstanding
(i) give any consent, waiver or approval or (ii) agree
to any amendment or modification of this Indenture, in each
case, that shall have a material adverse effect on the interests
of any Holder. The Trustee shall be entitled to request and
conclusively rely on an Opinion of Counsel with respect to
whether any consent, waiver, approval, amendment or modification
shall have a material adverse effect on the interests of any
Holder.
SECTION 7.3
Individual
Rights of Trustee
. The Trustee or any Agent in its
respective individual or any other capacity may become the owner
or pledgee of Notes and may otherwise deal with the Issuer, the
Guarantors, their Subsidiaries, or their respective Affiliates
with the same rights it would have if it were not the Trustee or
an Agent. However, in the event that the Trustee acquires any
conflicting interest it must eliminate such conflict within
90 days, apply to the SEC for permission to continue as
trustee or resign. Any Agent may do the same with like rights.
SECTION 7.4
Trustees
Disclaimer
. The Trustee and the Agents shall not be
responsible for and make no representation as to the validity,
effectiveness or adequacy of this Indenture, the offering
materials related to the Notes or the Notes; they shall not be
accountable for the Issuers use of the proceeds from the
Notes or any money paid to the Issuer or upon the Issuers
direction under any provision hereof; and they shall not be
responsible for any statement or recital herein of the Issuer or
the Guarantors or any document issued in connection with the
sale of Notes or any statement in the Notes other than the
Trustees certificate of authentication.
SECTION 7.5
Notice of
Default
. If an Event of Default occurs and is
continuing and a Trust Officer of the Trustee receives
actual notice of such event, the Trustee shall mail to each
Holder, as their names and addresses appear on the list of
Holders described in Section 2.5, notice of the uncured
Default or Event of Default within 90 days after the
Trustee receives such notice. Except in the case of a Default in
payment of principal of, premium, if any, or interest on any
Note, the Trustee may withhold the notice if and so long as a
committee of its Trust Officers determines that withholding
the notice is in the interest of the Holders.
SECTION 7.6
Reports by
Trustee to Holders of the Notes
. Within 60 days
after each May 15 beginning with May 15, 2012, and for so
long as Notes remain outstanding, the Trustee shall mail to the
Holders a brief report dated as of such reporting date that
complies with TIA § 313(a) (but if no event described
in TIA § 313(a) has occurred within the twelve months
preceding the reporting date, no report need be transmitted).
The Trustee also shall comply with TIA § 313(b). The
Trustee shall also transmit by mail all reports as required by
TIA § 313(c).
A copy of each report at the time of its mailing to the Holders
shall be mailed to the Issuer and filed with the SEC and each
stock exchange on which the Issuer has informed the Trustee in
writing the Notes are listed in accordance with TIA
§ 313(d). The Issuer shall promptly notify the Trustee
when the Notes are listed on any stock exchange and of any
delisting thereof.
-55-
SECTION 7.7
Compensation
and Indemnity
. The Issuer shall pay to the Trustee and
Agents from time to time such compensation as the Issuer and the
Trustee or Agent, as applicable, shall from time to time agree
in writing for its acceptance of this Indenture and services
hereunder. The Trustees and the Agents compensation
shall not be limited by any law on compensation of a trustee of
an express trust. The Issuer shall reimburse the Trustee and
Agents upon request for all reasonable and duly documented and
invoiced disbursements, expenses and advances (including
reasonable fees and expenses of counsel) incurred or made by it
in addition to the compensation for their services, except any
such disbursements, expenses and advances as may be attributable
to the Trustees or any Agents negligence, willful
misconduct or bad faith. Such expenses shall include the
reasonable compensation, disbursements and expenses of the
Trustees and Agents accountants, experts and counsel
and any taxes or other expenses incurred by a trust created
pursuant to Section 8.4 hereof.
The Issuer agrees to pay the fees and expenses of the
Trustees legal counsel in connection with its review,
preparation and delivery of this Indenture and related
documentation.
The Issuer shall indemnify each of the Trustee, any predecessor
Trustee and the Agents (which, for purposes of this paragraph,
include such Trustees and Agents officers,
directors, employees and agents) for, and hold them harmless
against, any and all loss, damage, claim, proceedings, demands,
costs, expense or liability including taxes (other than taxes
based on the income of the Trustee) incurred by the Trustee or
an Agent without negligence or willful misconduct on its part in
connection with acceptance of administration of this trust and
performance of any provisions under this Indenture, including
the reasonable expenses and attorneys fees and expenses of
defending itself against any claim of liability arising
hereunder. The Trustee and the Agents shall notify the Issuer
promptly of any claim asserted against the Trustee or such Agent
for which it may seek indemnity. However, the failure by the
Trustee or the Agent to so notify the Issuer shall not relieve
the Issuer of its obligations hereunder. Subject to
Section 7.1(b), the Issuer need not reimburse or indemnify
against any loss liability or expense incurred by the Trustee
through its own willful misconduct or negligence. The Issuer
shall defend the claim and the Trustee or such Agent shall
cooperate in the defense (and may employ its own counsel
reasonably satisfactory to the Trustee) at the Issuers
expense. The Trustee or such Agent may have separate counsel and
the Issuer shall pay the reasonable fees and expenses of such
counsel. The Issuer need not pay for any settlement made without
its written consent, which consent shall not be unreasonably
withheld.
To secure the Issuers payment obligations in this
Section 7.7, the Trustee and the Agents shall have a senior
Lien prior to the Notes against all money or property held or
collected by the Trustee and the Agents, in its capacity as
Trustee or Agent, except money or property held in trust to pay
principal or premium, if any, and Additional Amounts, if any, or
interest on particular Notes.
When the Trustee or an Agent incurs expenses or renders services
after the occurrence of an Event of Default specified in
clause (7) of Section 6.1, the expenses (including the
reasonable fees and expenses of its agents and counsel) and the
compensation for the services shall be preferred over the status
of the Holders in a proceeding under any Bankruptcy Law and are
intended to constitute expenses of administration under any
Bankruptcy Law. The Issuers obligations under this
Section 7.7 and any claim or Lien arising hereunder shall
survive the ter-
-56-
mination of this Indenture, the resignation or removal of any
Trustee or Agent, the discharge of the Issuers obligations
pursuant to Article VIII and any rejection or termination
under any Bankruptcy Law.
Save as otherwise expressly provided in this Indenture, the
Trustee shall have absolute and uncontrolled discretion as to
the exercise of the discretion vested in the Trustee by this
Indenture but, whenever the Trustee is bound to act under this
Indenture at the request or direction of the Holders of Notes,
the Trustee shall nevertheless not be so bound unless first
indemnified to its satisfaction against all proceedings, claims
and demands to which it may render itself liable and all costs,
charges, expenses and liabilities which it may incur by so doing.
Whether or not therein expressly so provided, every provision of
this Indenture that in any way relates to the Trustee, is
subject to this Section 7.7.
The Company shall be jointly and severally liable with the
Issuer for all of the Issuers obligations pursuant to this
Section 7.7.
SECTION 7.8
Replacement of
Trustee
. The Trustee and any Agent may resign at any
time by so notifying the Issuer in writing. The Holders of a
majority in principal amount of the outstanding Notes may remove
the Trustee by so notifying the Issuer and the Trustee in
writing and may appoint a successor trustee with the
Issuers consent. A resignation or removal of the Trustee
or any Agent and appointment of a successor Trustee or Agent, as
the case may be, shall become effective only upon the acceptance
by the successor Trustee or the successor Agent, as the case may
be, of appointment as provided in this section. The Issuer may
remove the Trustee if:
(1) the Trustee is adjudged a
bankrupt or an insolvent or an order for relief is entered with
respect to the Trustee under any Bankruptcy Law;
(2) a receiver or other public
officer takes charge of the Trustee or its property; or
(3) the Trustee becomes incapable
of acting with respect to its duties hereunder.
If the Trustee resigns or is removed or if a vacancy exists in
the office of Trustee for any reason, the Issuer shall notify
each Holder of such event and shall promptly appoint a successor
Trustee. Within one year after the successor Trustee takes
office, the Holders of a majority in principal amount of the
then outstanding Notes may, with the Issuers consent,
appoint a successor Trustee to replace the successor Trustee
appointed by the Issuer. If the Issuer does not reasonably
promptly appoint a successor Trustee, the Holders of a majority
in principal amount of the then outstanding Notes may appoint a
successor Trustee.
A successor Trustee or successor Agent, as applicable, shall
deliver a written acceptance of its appointment to the retiring
Trustee or Agent, as applicable, and to the Issuer. Thereupon,
the resignation or removal of the retiring Trustee or Agent, as
applicable, shall become effective, and the successor Trustee or
Agent, as applicable, shall have all the rights, powers and
duties of the Trustee or Agent, as applicable, under this
Indenture. Promptly after that,
-57-
the retiring Trustee or Agent, as applicable, shall transfer,
after payment of all sums then owing to the Trustee or Agent, as
applicable, pursuant to Section 7.7, all property held by
it as Trustee or Agent, as applicable, to the successor Trustee
or Agent, as applicable, subject to the Lien provided in
Section 7.7. A successor Trustee or Agent, as applicable,
shall mail notice of its succession to each Holder.
If a successor Trustee does not take office within 60 days
after the retiring Trustee resigns or is removed, the retiring
Trustee, the Issuer or the Holders of at least 10% in principal
amount of the then outstanding Notes may petition any court of
competent jurisdiction for the appointment of a successor
Trustee.
Notwithstanding replacement of the Trustee pursuant to this
Section 7.8, the Issuers obligations under
Section 7.7 shall continue for the benefit of the retiring
Trustee and the Issuer shall pay to any replaced or removed
Trustee all amounts owed under Section 7.7 upon such
replacement or removal.
SECTION 7.9
Successor
Trustee by Merger, Etc
. If the Trustee consolidates
with, merges or converts into, or transfers all or substantially
all of its corporate trust business to, another corporation or
banking association, the resulting, surviving or transferee
corporation without any further act shall, if such resulting,
surviving or transferee corporation is otherwise eligible
hereunder, be the successor Trustee. In case any Notes shall
have been authenticated, but not delivered, by the Trustee then
in office, any successor by consolidation, merger or conversion
to such authenticating Trustee may adopt such authentication and
deliver the Notes so authenticated with the same effect as if
such successor Trustee had itself authenticated such Notes.
SECTION 7.10
Eligibility;
Disqualification
. There shall at all times be a Trustee
hereunder that is a corporation organized and doing business
under the laws of the United States of America or of any state
thereof that is authorized under such laws to exercise corporate
trustee power and that is subject to supervision or examination
by federal or state authorities. The Trustee together with its
affiliates shall at all times have a combined capital surplus of
at least $50.0 million as set forth in its most recent
annual report of condition.
This Indenture shall always have a Trustee who satisfies the
requirements of TIA §§ 310(a)(l), (2) and
(5). The Trustee is subject to TIA § 310(b) including
the provision in § 310(b)(1);
provided
that
there shall be excluded from the operation of TIA
§ 310(b)(1) any indenture or indentures under which
other securities, or conflicts of interest or participation in
other securities, of the Issuer or the Guarantors are
outstanding if the requirements for exclusion set forth in TIA
§ 310(b)(1) are met.
SECTION 7.11
Preferential
Collection of Claims Against the Company
. The Trustee
is subject to TIA § 311(a), excluding any creditor
relationship listed in TIA § 311(b). A Trustee who has
resigned or been removed shall be subject to TIA
§ 311(a) to the extent indicated therein.
-58-
ARTICLE VIII
SATISFACTION
AND DISCHARGE OF INDENTURE
SECTION 8.1
Option To
Effect Legal Defeasance or Covenant Defeasance
. The
Issuer may, at the option of its Board of Directors evidenced by
a Board Resolution, at any time, with respect to the Notes,
elect to have either Section 8.2 or 8.3 be applied to all
outstanding Notes upon compliance with the conditions set forth
below in this Article VIII.
SECTION 8.2
Legal
Defeasance and Discharge
. Upon the Issuers
exercise under Section 8.1 of the option applicable to this
Section 8.2, the Issuer shall be deemed to have been
discharged from its obligations with respect to all outstanding
Notes on the date the conditions set forth below are satisfied
(hereinafter, Legal Defeasance). For this purpose,
such Legal Defeasance means that the Issuer shall be deemed to
have paid and discharged all the obligations relating to the
outstanding Notes and the Notes shall thereafter be deemed to be
outstanding only for the purposes of
Section 8.6, Section 8.8 and the other Sections of
this Indenture referred to below in this Section 8.2, and
to have satisfied all of their other obligations under such
Notes and this Indenture and cured all then existing Events of
Default (and the Trustee, on demand of and at the expense of the
Issuer, shall execute proper instruments acknowledging the
same), except for the following which shall survive until
otherwise terminated or discharged hereunder: (a) the
rights of Holders of outstanding Notes to receive payments in
respect of the principal of, premium, if any, interest and
Additional Amounts, if any, on such Notes when such payments are
due or on the Redemption Date solely out of the Defeasance
Trust created pursuant to this Indenture; (b) the
Issuers obligations with respect to Notes concerning
issuing temporary Notes, or, where relevant, registration of
such Notes, mutilated, destroyed, lost or stolen Notes and the
maintenance of an office or agency for payment and money for
security payments held in trust; (c) the rights, powers,
trusts, duties and immunities of the Trustee, and the
Issuers or Guarantors obligations in connection
therewith; and (d) this Article VIII and the
obligations set forth in Section 8.6 hereof.
Subject to compliance with this Article VIII, the Issuer
may exercise its option under Section 8.2 notwithstanding
the prior exercise of its option under Section 8.3 with
respect to the Notes.
SECTION 8.3
Covenant
Defeasance
. Upon the Issuers exercise under
Section 8.1 of the option applicable to this
Section 8.3, the Issuer, the Company and the other
Guarantors shall be released from any obligations under the
covenants contained in Article IV, Section 5.1(4),
Sections 6.1(3), (4) and (5), and Section 6.1 (7)
(with respect to the Company and the Subsidiaries other than the
Issuer), hereof with respect to the outstanding Notes on and
after the date the conditions set forth below are satisfied
(hereinafter, Covenant Defeasance), and the Notes
shall thereafter be deemed not outstanding for the
purposes of any direction, waiver, consent or declaration or act
of Holders (and the consequences of any thereof) in connection
with such covenants, but shall continue to be deemed
outstanding for all other purposes hereunder (it
being understood that such Notes shall not be deemed outstanding
for accounting purposes). For this purpose, such Covenant
Defeasance means that, (i) with respect to the outstanding
Notes, the Issuer may omit to comply with and shall have no
liability in respect of any term, condition or limitation set
forth in any such covenant, whether directly or indirectly, by
reason of
-59-
any reference elsewhere herein to any such covenant or by reason
of any reference in any such covenant to any other provision
herein or in any other document and (ii) payment on the
Notes may not be accelerated because of an Event of Default
specified in Sections 6.1 (3), (4) or (5), or
Section 6.1 (7) (with respect only to the Company and the
Subsidiaries other than the Issuer).
SECTION 8.4
Conditions to
Legal or Covenant Defeasance
. In order to exercise
either of the defeasance options under Section 8.2 or
Section 8.3 hereof, the Issuer must comply with the
following conditions:
(1) the Issuer shall have
irrevocably deposited in trust (the Defeasance
Trust) with the Trustee for the benefit of the Holders
Designated Government Obligations, for the payment of principal,
premium, if any, interest on the Notes to redemption or
maturity, as the case may be;
(2) the Issuer shall have delivered
to the Trustee an Opinion of Counsel (subject to customary
exceptions and exclusions) to the effect that Holders of the
Notes will not recognize income, gain or loss for
U.S. federal income tax purposes as a result of such
deposit and defeasance and will be subject to U.S. federal
income tax on the same amount and in the same manner and at the
same times as would have been the case if such deposit and
defeasance had not occurred. In the case of legal defeasance
only, such Opinion of Counsel must be based on a ruling of the
Internal Revenue Service or other change in applicable
U.S. federal income tax law;
(3) the Issuer shall have delivered
to the Trustee an Opinion of Counsel in the Federal Republic of
Germany (subject to customary exceptions and exclusions) to the
effect that Holders of the Notes will not recognize income, gain
or loss for income tax purposes of the Federal Republic of
Germany as a result of such deposit and defeasance and will be
subject to income tax in the Federal Republic of Germany on the
same amount and in the same manner and at the same times as
would have been the case if such deposit and defeasance had not
occurred;
(4) the Issuer shall have delivered
to the Trustee an Opinion of Counsel in Luxembourg (subject to
customary exceptions and exclusions) to the effect that Holders
of the Notes will not recognize income, gain or loss for income
tax purposes of Luxembourg as a result of such deposit and
defeasance and will be subject to income tax in Luxembourg on
the same amount and in the same manner and at the same times as
would have been the case if such deposit and defeasance had not
occurred;
(5) no Default or Event of Default
(other than to Incur Indebtedness used to defease the Notes
under this Article) shall have occurred and be continuing on the
date of such deposit in the Defeasance Trust or insofar as
Events of Default from bankruptcy or insolvency events are
concerned, at any time in the period ending on the 91st day
after the date of deposit;
(6) such legal defeasance or
covenant defeasance shall not result in a breach or violation of
any other material agreement or instrument (other than this
Indenture) to
-60-
which the Company or any of its Subsidiaries is a party or by
which the Company or any of its Subsidiaries is bound;
(7) the Issuer shall have delivered
to the Trustee an Officers Certificate stating that the
deposit was not made by the Issuer with the intent of preferring
the Holders over any other creditors of the Issuer or with the
intent of defeating, hindering, delaying or defrauding any other
creditors of the Issuer or others; and
(8) the Issuer shall have delivered
to the Trustee an Officers Certificate and an Opinion of
Counsel, each stating that all conditions precedent provided for
or relating to the legal defeasance or the covenant defeasance
have been complied with.
SECTION 8.5
Satisfaction
and Discharge of Indenture
. This Indenture will be
discharged and will cease to be of further effect as to all
Notes issued thereunder when either (i) all such Notes
theretofore authenticated and delivered (except lost, stolen or
destroyed Notes which have been replaced or paid and Notes for
whose payment money has theretofore been deposited in trust and
thereafter repaid to the Issuer) have been delivered to the
Trustee for cancellation or (ii) (A) all such Notes not
theretofore delivered to the Trustee for cancellation have
become due and payable by reason of the making of a notice of
redemption or otherwise or will become due and payable within
one year and the Issuer has irrevocably deposited or caused to
be deposited with the Trustee as trust funds in trust an amount
of money sufficient to pay and discharge the entire indebtedness
on such Notes not theretofore delivered to the Trustee for
cancellation for principal, premium, if any, and accrued and
unpaid interest and Additional Amounts, if any, to the date of
maturity or redemption, (B) no Default (other than to Incur
Indebtedness used to defease the Notes under this Article) with
respect to this Indenture or the Notes shall have occurred and
be continuing on the date of such deposit or shall occur as a
result of such deposit and such deposit will not result in a
breach or violation of, or constitute a default under, any other
instrument to which the Issuer, the Company or any of the other
Guarantors is a party or by which it is bound, (C) the
Issuer has paid, or caused to be paid, all sums payable by it
under this Indenture, and (D) the Issuer has delivered
irrevocable instructions to the Trustee under this Indenture to
give the notice of redemption and apply the deposited money
toward the payment of such Notes at maturity or the
Redemption Date, as the case may be. In addition, the
Issuer must deliver an Officers Certificate and an Opinion
of Counsel to the Trustee stating that all conditions precedent
to satisfaction and discharge have been satisfied.
SECTION 8.6
Survival of
Certain Obligations
. Notwithstanding the satisfaction
and discharge of this Indenture and of the Notes in the manner
referred to in Section 8.1, 8.2, 8.3, 8.4 or 8.5, the
respective obligations of the Issuer, the Company, the other
Guarantors and the Trustee under Sections 2.2, 2.3, 2.4,
2.5, 2.6, 2.7, 2.9, 2.10, 2.11, 2.12, 2.13, 2.14, 4.1 (with
respect to the Trustee and, as far as the Issuer, the Company,
and each of the other Guarantors is concerned, subject to
Sections 8.2 and 8.5), 4.2, 4.6, 4.13 and 6.10,
Article VII and Article VIII shall survive until the
Notes are no longer outstanding, and thereafter the obligations
of the Issuer, the Company, the other Guarantors and the Trustee
under Articles VII and VIII shall survive. Nothing
contained in this Article VIII shall abrogate any of the
obligations or duties of the Trustee under this Indenture.
-61-
SECTION 8.7
Acknowledgment
of Discharge by Trustee
. Subject to Section 8.10,
after (i) the conditions of Section 8.4 or 8.5 have
been satisfied, (ii) the Issuer has paid or caused to be
paid all other sums payable hereunder by the Issuer and
(iii) the Issuer has delivered to the Trustee an
Officers Certificate and an Opinion of Counsel, each
stating that all conditions precedent referred to in
clause (i) above relating to the satisfaction and discharge
of this Indenture have been complied with, the Trustee upon
written request shall acknowledge in writing the discharge of
all of the Issuers, the Companys, and the other
Guarantors obligations under this Indenture except for
those surviving obligations specified in this Article VIII.
SECTION 8.8
Application of
Trust Moneys
. All cash deposited with the Trustee
pursuant to Section 8.4 or 8.5 in respect of Notes shall be
held in trust and applied by it, in accordance with the
provisions of such Notes and this Indenture, to the payment,
either directly or through any Paying Agent as the Trustee may
determine, to the Holders of the Notes of all sums due and to
become due thereon for principal, premium, if any, interest and
Additional Amounts, if any, but such money need not be
segregated from other funds except to the extent required by law.
The Issuer shall pay and indemnify the Trustee against any tax,
fee or other charge imposed on or assessed against the cash
deposited pursuant to Section 8.4 or 8.5 or the principal
and interest received in respect thereof other than any such
tax, fee or other charge which by law is for the account of the
Holders of outstanding Notes.
SECTION 8.9
Repayment to
the Issuer; Unclaimed Money
. The Trustee and any Paying
Agent shall promptly pay or return to the Issuer upon Issuer
Order any cash held by them at any time that are not required
for the payment of the principal of, premium, if any, interest
and Additional Amounts, if any, on the Notes for which cash has
been deposited pursuant to Section 8.4 or 8.5.
Any money held by the Trustee or any Paying Agent under this
Article VIII, in trust for the payment of the principal of,
premium, if any, interest and Additional Amounts, if any, on any
Note and remaining unclaimed for two years after such principal,
premium, if any, interest and Additional Amounts, if any, that
has become due and payable shall be paid to the Issuer upon
Issuer Order or if then held by the Issuer shall be discharged
from such trust; and the Holder of such Note shall thereafter,
as an unsecured general creditor, look only to the Issuer for
payment thereof, and all liability of the Trustee or such Paying
Agent with respect to such trust money, shall thereupon cease;
provided
,
however
, that the Trustee or such Paying
Agent, before being required to make any such repayment, may at
the expense of the Issuer give notice to the Holders or cause to
be published notice once, in a leading newspaper having a
general circulation in New York (which is expected to be
The
Wall Street Journal
) (and, if and so long as the Notes are
listed on the Euro MTF Market of the Luxembourg Stock Exchange
and the rules of such stock exchange shall so require, a
newspaper having a general circulation in Luxembourg (which is
expected to be the
Luxemburger Wort
or, to the extent and
in the manner permitted by such rules, posted on the official
website of the Luxembourg Stock Exchange (www.bourse.lu)) or in
the case of Definitive Notes, in addition to such publication,
mail to Holders by first-class mail, postage prepaid, at their
respective addresses as they appear on the registration books of
the Registrar (and, if and so long as the Notes are listed on
the Euro MTF Market of the Luxembourg Stock Exchange and the
rules of such Stock Exchange shall so require, publish in a
newspaper
-62-
having a general circulation in Luxembourg (which is expected to
be the
Luxemburger Wort)
or, to the extent and in the
manner permitted by such rules, posted on the official website
of the Luxembourg Stock Exchange (www.bourse.lu)), that such
money remains unclaimed and that, after a date specified
therein, which shall not be less than 30 days from the date
of such notification, any unclaimed balance of such money then
remaining will be repaid to the Issuer).
Claims against the Issuer for the payment of principal or
interest and Additional Amounts, if any, on the Notes will
become void unless presentment for payment is made (where so
required in this Indenture) within, in the case of principal and
Additional Amounts, if any, a period of ten years, or, in the
case of interest, a period of five years, in each case from the
applicable original payment date therefor.
SECTION 8.10
Reinstatement
. If
the Trustee or Paying Agent is unable to apply any cash in
accordance with Section 8.2, 8.3, 8.4 or 8.5 by reason of
any legal proceeding or by reason of any order or judgment of
any court or governmental authority enjoining, restraining or
otherwise prohibiting such application, the Issuers and
the Guarantors obligations under this Indenture and the
Notes shall be revived and reinstated as though no deposit had
occurred pursuant to Section 8.2, 8.3, 8.4 or 8.5 until
such time as the Trustee or Paying Agent is permitted to apply
all such cash in accordance with Section 8.2, 8.3, 8.4 or
8.5;
provided
,
however
, that if the Issuer has
made any payment of interest on, premium, if any, principal and
Additional Amounts, if any, of any Notes because of the
reinstatement of its obligations, the Issuer shall be subrogated
to the rights of the Holders of such Notes to receive such
payment from the money held by the Trustee or Paying Agent.
ARTICLE IX
AMENDMENTS,
SUPPLEMENTS AND WAIVERS
SECTION 9.1
Without Consent
of Holders of Notes
. Notwithstanding Section 9.2
hereof, the Issuer and the Trustee together may amend or
supplement this Indenture or the Notes without the consent of
any Holder of a Note to:
(1) cure any ambiguity, omission,
defect or inconsistency;
(2) provide for the assumption by a
successor entity of the obligations of the Issuer under and
pursuant to this Indenture or of a Guarantor (other than the
Company) under the Note Guarantees;
(3) provide for uncertificated
Notes in addition to or in place of certificated Notes
(
provided
that the uncertificated Notes are issued in
registered form for purposes of Section 163(f) of the Code,
or in a manner such that the uncertificated Notes are described
in Section 163(f)(B) of the Code);
(4) add Note Guarantees with
respect to the Notes;
(5) secure the Notes;
-63-
(6) add to the covenants of the
Issuer and the Guarantors for the benefit of the Holders or to
surrender any right or power conferred upon the Issuer;
(7) evidence and provide for the
acceptance and appointment under this Indenture of any successor
trustee;
(8) comply with the rules of any
applicable securities depositary;
(9) issue Additional Notes in
accordance with this Indenture; or
(10) make any change that does not
adversely affect the rights of any Holder of Notes under this
Indenture.
SECTION 9.2
With Consent of
Holders of Notes
. The Issuer and the Trustee may amend
or supplement this Indenture, the Notes or any amended or
supplemental indenture with the written consent of the Holders
of at least a majority in principal amount of the Notes then
outstanding (including without limitation consents obtained in
connection with a purchase of, or tender offer or exchange offer
for the Notes), and, subject to Sections 6.7 and 6.10, any
existing Default or Event of Default and its consequences or
compliance with any provision of this Indenture or the Notes may
be waived with the consent of the Holders of at least a majority
in principal amount of the Notes then outstanding (including
without limitation consents obtained in connection with a
purchase of, or tender offer or exchange offer for the Notes).
However, without the consent of each Holder of an outstanding
Note adversely affected, an amendment or waiver may not (with
respect to any Notes held by a non-consenting Holder of Notes):
(1) reduce the percentage of
principal amount of Notes whose Holders must consent to an
amendment;
(2) reduce the stated rate of or
extend the stated time for payment of interest on any such Note;
(3) reduce the principal of or
extend the Stated Maturity of any such Note;
(4) reduce the premium payable upon
the redemption of any such Note or change the time at which any
such Note may be redeemed as described under Section 3.1;
(5) reduce the premium payable upon
the repurchase of any Note, change the time at which any Note
may be repurchased, or change any of the associated definitions
related to the provisions of Section 4.11 once the
obligation to repurchase the Notes has arisen;
(6) make any such Note payable in
money other than that stated in such Note;
(7) impair the right of any Holder
to receive payment of premium, if any, principal of and interest
on such Holders Notes on or after the due dates therefor
or to institute suit for the enforcement of any payment on or
with respect to such Holders Notes;
-64-
(8) make any change in the
amendment provisions which require each Holders consent or
in the waiver provisions; or
(9) release the Company from its
Note Guarantee (other than in accordance with the terms of this
Indenture).
It shall not be necessary for the consent of the Holders of
Notes under this Section 9.2 to approve the particular form
of any proposed amendment or waiver, but it shall be sufficient
if such consent approves the substance thereof.
SECTION 9.3
Notice of
Amendment, Supplement or Waiver
. After an amendment,
supplement or waiver under Section 9.1 or 9.2 hereto
becomes effective, the Issuer shall mail to the Holders of Notes
a notice briefly describing the amendment, supplement or waiver.
Any failure of the Issuer to mail such notice, or any defect
therein, shall not, however, in any way impair or affect the
validity of any such amended or supplemental indenture or waiver.
SECTION 9.4
Revocation and
Effect of Consents
. Until an amendment, supplement or
waiver becomes effective, a consent to it by a Holder of a Note
is a continuing consent by the Holder of a Note and every
subsequent Holder of a Note or portion of a Note that evidences
the same debt as the consenting Holders Note, even if
notation of the consent is not made on any Note. However, any
such Holder of a Note or subsequent Holder of a Note may revoke
the consent as to its Note if the Trustee receives written
notice of revocation before the date the waiver, supplement or
amendment becomes effective. An amendment, supplement or waiver
becomes effective in accordance with its terms and thereafter
binds every Holder of a Note. An amendment or waiver becomes
effective once the requisite number of consents is received by
the Issuer or the Trustee.
The Issuer may, but shall not be obligated to, fix a record date
for determining which Holders of the Notes must consent to such
amendment, supplement or waiver. If the Issuer fixes a record
date, the record date shall be fixed at (i) the later of
30 days prior to the first solicitation of such consent or
the date of the most recent list of Holders of Notes furnished
to the Trustee prior to such solicitation pursuant to
Section 2.5 or (ii) such other date as the Issuer
shall designate.
SECTION 9.5
Notation on or
Exchange of Notes
. The Trustee may place an appropriate
notation about an amendment, supplement or waiver on any Note
thereafter authenticated. The Issuer in exchange for all Notes
may issue and the Trustee shall authenticate new Notes that
reflect the amendment, supplement or waiver.
Failure to make the appropriate notation or issue a new Note
shall not affect the validity and effect of such amendment,
supplement or waiver.
SECTION 9.6
Trustee To Sign
Amendments, Etc
. The Trustee shall execute any
amendment, supplement or waiver authorized pursuant to this
Article IX;
provided
,
however
, that the
Trustee may, but shall not be obligated to, execute any such
amendment, supplement or waiver which adversely affects the
Trustees own rights, duties or immunities under this
Indenture. The Trustee shall be entitled to receive indemnity
reasonably satisfactory to it, and shall be fully protected in
relying upon, if delivered, an Opinion of Counsel and an
Officers Certificate
-65-
each stating that the execution of any such amendment,
supplement or waiver is authorized or permitted by this
Indenture and constitutes the legal, valid and binding
obligations of the Issuer and the Guarantors enforceable in
accordance with its terms. Any Opinion of Counsel shall not be
an expense of the Trustee. With respect to any amendment,
supplement or waiver under Section 9.2, the Trustee shall
also be entitled to receive evidence satisfactory to it of the
consent of the Holders.
ARTICLE X
NOTE GUARANTEE
SECTION 10.1
Note
Guarantee
.
(a) Each Guarantor hereby jointly
and severally unconditionally Guarantees, on a senior unsecured
basis, to each Holder of a Note authenticated and delivered by
the Trustee, and to the Trustee on behalf of such Holder, the
due and punctual payment of the principal of (and premium, if
any) and interest (including Additional Amounts, if any) on such
Note when and as the same shall become due and payable, whether
at the Stated Maturity, by acceleration, call for redemption,
purchase or otherwise, in accordance with the terms of such Note
and of this Indenture. In case of the failure of the Issuer
punctually to make any such payment, each Guarantor hereby
jointly and severally agrees to cause such payment to be made
punctually when and as the same shall become due and payable,
whether at the Stated Maturity or by acceleration, call for
redemption, purchase or otherwise, and as if such payment were
made by the Issuer. The Note Guarantee extends to the
Issuers repurchase obligations arising from a Change of
Control pursuant to Section 4.11.
Each Guarantor hereby jointly and severally agrees that its
obligations hereunder shall be unconditional, irrespective of
the validity, regularity or enforceability of such Note or this
Indenture, the absence of any action to enforce the same, any
exchange, release or non-perfection of any Lien on any
collateral for, or any release or amendment or waiver of any
term of any other Guarantee of, or any consent to departure from
any requirement of any other Guarantee of all or any of the
Notes, the effects of Bankruptcy Law applicable in the event of
bankruptcy proceedings being opened with respect to the Issuer,
of all or any portion of the claims of the Trustee or any of the
Holders for payment of any of the Notes, any waiver or consent
by the Holder of such Note or by the Trustee with respect to any
provisions thereof or of this Indenture, the obtaining of any
judgment against the Issuer or any action to enforce the same or
any other circumstances which might otherwise constitute a legal
or equitable discharge or defense of a guarantor. Each Guarantor
hereby waives the benefits of diligence, presentment, demand for
payment, any requirement that the Trustee or any of the Holders
protect, secure, perfect or insure any security interest in or
other Lien on any property subject thereto or exhaust any right
or take any action against the Issuer or any other Person or any
collateral, filing of claims with a court in the event of
insolvency or bankruptcy of the Issuer, any right to require a
proceeding first against the Issuer, protest or notice with
respect to such Note or the Indebtedness evidenced thereby and
all demands whatsoever, and covenants that this Note Guarantee
will not be discharged in respect of such Note except by
complete performance of the obligations contained in such Note
and in this Note Guarantee. Each Guarantor hereby agrees that,
in the event of a default in payment of principal (or premium,
if any) or interest (including Additional Amounts, if any) on
such
-66-
Note, whether at its Stated Maturity, by acceleration, call for
redemption, purchase or otherwise, legal proceedings may be
instituted by the Trustee on behalf of, or by, the Holder of
such Note, subject to the terms and conditions set forth in this
Indenture, directly against each Guarantor to enforce the Note
Guarantee without first proceeding against the Issuer. Each
Guarantor agrees that, to the extent permitted by applicable
law, if, after the occurrence and during the continuance of an
Event of Default, the Trustee or any of the Holders is prevented
by applicable law from exercising its respective rights to
accelerate the maturity of the Notes, to collect interest on the
Notes, or to enforce or exercise any other right or remedy with
respect to the Notes, or the Trustee or the Holders are
prevented from taking any action to realize on any collateral,
such Guarantor agrees to pay to the Trustee for the account of
the Holders, upon demand therefor, the amount that would
otherwise have been due and payable had such rights and remedies
been permitted to be exercised by the Trustee or any of the
Holders.
No provision of the Note Guarantee or of this Indenture shall
alter or impair the Note Guarantee of any Guarantor, which is
absolute and unconditional, of the due and punctual payment of
the principal of (and premium, if any) and interest (including
Additional Amounts, if any) on the Note upon which such Note
Guarantee is endorsed.
Each Note Guarantee shall remain in full force and effect and
continue to be effective should any petition be filed by or
against the Issuer for liquidation or reorganization or
equivalent proceeding under applicable law, should the Issuer
become insolvent or make an assignment for the benefit of
creditors or should a receiver or trustee be appointed for all
or any significant part of the Issuers assets, or the
equivalent of any of the foregoing under applicable law, and
shall, to the fullest extent permitted by applicable law,
continue to be effective or be reinstated, as the case may be,
if at any time payment and performance of the Notes, is,
pursuant to applicable law, rescinded or reduced in amount, or
must otherwise be restored or returned by any obligee on the
Notes, whether as a voidable preference, fraudulent transfer, or
as otherwise provided under similar laws affecting the rights of
creditors generally or under applicable laws of the jurisdiction
of formation of the Issuer, all as though such payment or
performance had not been made. In the event that any payment, or
any part thereof, is rescinded, reduced, restored or returned,
the Notes shall, to the fullest extent permitted by law, be
reinstated and deemed reduced only by such amount paid and not
so rescinded, reduced, restored or returned.
The Guarantors shall have the right to seek contribution from
any non-paying Guarantor so long as the exercise of such right
does not impair the rights of the Holders under the Note
Guarantee.
(b) Each Note Guarantee (other than
the Companys Note Guarantee) will be limited in amount to
an amount not to exceed the maximum amount that can be
guaranteed by the applicable Guarantor without rendering the
Note Guarantee, as it relates to such Guarantor, voidable under
applicable law relating to fraudulent conveyance or fraudulent
transfer or similar laws affecting the rights of creditors
generally or under applicable law of the jurisdiction of
incorporation of such Guarantor.
(c) In the case of Fresenius
Medical Care Deutschland GmbH (FMCD), the following
provisions apply:
-67-
Without limiting the agreements set forth in Section 11.8,
the Note Guarantee of FMCD will be limited if and to the extent
payment under such Note Guarantee or the application of
enforcement proceeds would cause (i) FMCDs net assets
(
Reinvermögen
- calculated as the sum of the balance
sheet positions shown under § 266(2)(A), (B) and
(C) German Commercial Code (
Handelsgesetzbuch
)) less
the sum of the liabilities (shown under the balance sheet
positions pursuant to § 266(3)(B), (C) and
(D) German Commercial Code) to fall below FMCDs
registered share capital (
Stammkapital
) or (ii) (if the
amount of the net assets is already an amount less than the
registered share capital) cause such amount to be further
reduced and, in either case, thereby affecting the assets
required for the obligatory preservation of its registered share
capital according to section 30, 31 of the German Limited
Liability Company Act (GmbHG) (such event a Capital
Impairment). For the purposes of calculating the Capital
Impairment, the following adjustments will be made: (i) the
amount of any increase of the registered share capital out of
retained earnings (
Kapitalerhöhung aus
Gesellschaftsmitteln
) after the Closing Date that has been
effected without the prior consent of the Trustee shall be
deducted from the registered share capital; and
(ii) liabilities incurred in violation of the provisions of
the Notes and this Indenture shall be disregarded. In the event
FMCDs net assets fall below its registered share capital,
FMCD, upon request of the Trustee will realize in due course, to
the extent legally permitted, any and all of its assets that are
shown in the balance sheet with a book value (
Buchwert
)
that is significantly lower than the market value of the assets
if the relevant assets are not necessary for FMCDs
business (
nicht betriebsnotwendiges Vermögen
).
If FMCD objects to the amount demanded by the Trustee under the
Note Guarantee within twenty (20) business days after the
Trustee has submitted to FMCD a payment demand FMCD shall
appoint within five (5) business days a reputable
international auditor to determine the exact amount. The auditor
shall notify FMCD and the Trustee of the maximum amount payable
under the Note Guarantee within forty (40) business days
after its appointment. The costs of such auditors
determination shall be borne by FMCD. The determination of the
auditor shall be binding for FMCD, and the Holders (except for
manifest error). To the extent that any payment has been made
under the Note Guarantee by FMCD that would be necessary for
FMCD to be able to cure any Capital Impairment or Liquidity
Impairment such payment shall immediately upon
FMCDs demand be returned to FMCD by any person
receiving such payment, provided, however, in no event shall the
Trustee or Paying Agent have any responsibility or liability for
the return of any amount distributed to any Holder or beneficial
owner of the Notes by the Trustee or Paying Agent, including,
without limitation, any obligation to seek return of such
amounts from such Holder or beneficial owner.
If (i) FMCD does not object to the payment amount within
the 20 business days period or (ii) if FMCD does not
appoint the auditor within the 5 business days period or
(iii) if the auditor fails to notify the amount payable
within the 40 days period, then the Trustee shall be
entitled to enforce the Note Guarantee without further delay.
The burden of demonstration and proof (
Darlegungs- und
Beweislast
) regarding the Capital Impairment and the maximum
amount payable under the Note Guarantee shall remain with FMCD.
-68-
The maximum amount payable under the guarantee shall be limited
to the extent and as long as FMCD as a consequence of the
payment would become unable to pay its debts when due
(
zahlungsunfähig
) within the meaning of
section 64 GmbHG (such event a Liquidity
Impairment). For the purpose of establishing whether a
Liquidity Impairment would occur, payments made by FMCD after
the Trustee has notified FMCD of its intention to enforce the
Note Guarantee with respect to payment obligations that are not
due at the time of the payment shall be disregarded, unless the
Trustee has consented to such payments (at the direction of the
Holders of at least a majority in principal amount of the Notes
then outstanding). From the time the Trustee has notified FMCD
and the Company of its intention to enforce the Note Guarantee,
the Company may not make any payment demands against FMCD under
shareholder loans and all such payment obligations of FMCD
towards the Company shall be deferred, subordinated or waived as
the Company sees fit, until the Trustee notifies FMCD that it is
no longer enforcing the Note Guarantee or the Trustee consents
(at the direction of the Holders of at least a majority in
principal amount of the Notes then outstanding) to the payments
to be made to the Company. Such notice may be delivered by the
Trustee at any time and, if not previously delivered, will be
delivered by the Trustee after the Notes have been repaid in
full and all other obligations under this Indenture are
satisfied.
The limitations in this Section 10.1(c) as to the Capital
Impairment shall not apply to the extent FMCD has an adequate
compensation claim (
vollwertiger Gegenleistungs- oder
Rückgewähranspruch
) against the Company that
compensates for any loss incurred due to any payment by FMCD
under the Note Guarantee.
SECTION 10.2
Execution
and Delivery of Note Guarantees
. The Note Guarantees to
be endorsed on the Notes shall be in the form attached hereto as
Exhibit C
. Each Guarantor hereby agrees to
execute its Note Guarantee, in the form attached hereto as
Exhibit C
, to be endorsed on each Note authenticated
and delivered by the Trustee.
The Note Guarantee shall be executed on behalf of the Company by
two members of the Management Board of its General Partner and
on behalf of any other Guarantor by such Person or Persons duly
authorized by the Board of Directors or Management Board of such
Guarantor. The signature of any or all of these Persons on the
Note Guarantee may be manual or facsimile.
A Note Guarantee bearing the manual or facsimile signature of
individuals who were at any time the Responsible Officers of a
Guarantor shall bind such Guarantor, notwithstanding that such
individuals or any of them have ceased to hold such offices
prior to the authentication and delivery of the Note on which
such Note Guarantee is endorsed or did not hold such offices at
the date of such Note Guarantee.
The delivery of any Note by the Trustee, after the
authentication thereof in accordance with this Indenture, shall
constitute due delivery of the Note Guarantee endorsed thereon
on behalf of the Guarantors. Each of the Guarantors hereby
jointly and severally agrees that its Note Guarantee set forth
in Section 10.1 shall remain in full force and effect
notwithstanding any failure to endorse a Note Guarantee on any
Note.
-69-
SECTION 10.3
Guarantors May
Consolidate, Etc., on Certain Terms
. Except as set
forth in Section 10.4 and in Article V hereof, nothing
contained in this Indenture or in any of the Notes shall prevent
any consolidation or merger of a Guarantor with or into the
Company, the Issuer or another Guarantor or shall prevent any
sale, transfer, assignment, lease, conveyance or other
disposition of the property of a Guarantor as an entirety or
substantially as an entirety to the Company, the Issuer or
another Guarantor.
SECTION 10.4
Release of
Guarantors
. Subject to the limitations set forth in
Sections 5.1 and 5.2 hereof, (a) concurrently with any
consolidation or merger of a Guarantor or any sale, transfer,
assignment, lease, conveyance or other disposition of the
property of a Guarantor as an entirety or substantially as an
entirety, in each case as permitted by Sections 5.1, 5.2
and 10.3 hereof, and upon delivery by the Company or the Issuer
to the Trustee of an Officers Certificate and an Opinion
of Counsel to the effect that such consolidation, merger, sale,
transfer, assignment, conveyance or other disposition was made
in accordance with Sections 5.1, 5.2 and 10.3 hereof, the
Trustee shall execute any documents reasonably required in order
to acknowledge the release of such Guarantor from its
obligations under its Note Guarantee endorsed on the Notes and
under this Indenture. Any Guarantor not released from its
obligations under its Note Guarantee endorsed on the Notes and
under this Indenture shall remain liable for the full amount of
principal of (premium, if any) and interest (including
Additional Amounts, if any) on the Notes and for the other
obligations of a Guarantor under its Note Guarantee endorsed on
the Notes and under this Indenture. Concurrently with the
defeasance of the Notes under Section 8.2 or satisfaction
and discharge of this Indenture under Section 8.5 hereof,
the Guarantors shall be released from all of their obligations
under their Note Guarantees endorsed on the Notes and under this
Indenture, without any action on the part of the Trustee or any
Holder of Notes.
(b) Upon the sale or other
disposition (including by way of merger or consolidation) of any
Guarantor or the sale, conveyance, transfer, assignment, lease
or other disposition of all or substantially all the assets of a
Guarantor pursuant to Section 5.1 hereof, such Guarantor
shall automatically be released from all obligations under its
Note Guarantees endorsed on the Notes and under this Indenture
in accordance with Sections 5.1 and 5.2.
(c) At the time a Guarantor (other
than the Company) is no longer a borrower or guarantor under the
Credit Facility, such Guarantor will be released and relieved
from all of its obligations under its Note Guarantee.
ARTICLE XI
MISCELLANEOUS
SECTION 11.1
Notices
. Any
notices or other communications required or permitted hereunder
shall be in writing, and shall be sufficiently given if made by
hand delivery, by telecopier or first-class mail, postage
prepaid, addressed as follows:
if to the Company or to FMCD, to it at:
Else-Kröner Strasse 1
61352 Bad Homburg
-70-
Germany
Facsimile: 011-49-6172-609-2280
Attention: Chief Financial Officer
if to the Issuer:
Fresenius Medical Care US Finance, Inc.
920 Winter Street
Waltham MA
02451-1457
Facsimile: 781
699-9713
Attn: Ronald J. Kuerbitz, Esq.
if to FMCH:
920 Winter Street
Waltham MA
02451-1457
Facsimile: 781
699-9713
Attn: Ronald J. Kuerbitz, Esq.
in each case, with a copy to:
Fresenius Medical Care AG & Co. KGaA
Else-Kröner Strasse 1
61352 Bad Homburg
Germany
Facsimile: 011-49-6172-609-2422
Attention: Dr. Rainer Runte
if to the Trustee:
U.S. Bank National Association
225 Asylum Street, 23rd Floor
Hartford, CT 06103
Attention: Elizabeth C. Hammer
Telecopier: 860-241-6897
Telephone: 860-241-6817
Each of the Issuer and the Trustee by written notice to each
other such Person may designate additional or different
addresses for notices to such Person. Any notice or
communication to the Issuer or the Trustee, shall be deemed to
have been given or made as of the date so delivered if
personally delivered; when receipt is acknowledged, if
telecopied; and five (5) calendar days after mailing if
sent by first class mail, postage prepaid (except that a notice
of change of address shall not be deemed to have been given
until actually received by the addressee).
Any notice or communication mailed to a Holder shall be mailed
to such Person by first-class mail or other equivalent means at
such Persons address as it appears on the regis-
-71-
tration books of the Registrar and shall be sufficiently given
to him if so mailed within the time prescribed.
Failure to mail a notice or communication to a Holder or any
defect in it shall not affect its sufficiency with respect to
other Holders. If a notice or communication is mailed in the
manner provided above, it is duly given, whether or not the
addressee receives it.
Notices regarding the Notes given to the Holders will be
(a) sent to a leading newspaper having general circulation
in New York (which is expected to be The Wall Street Journal
(and, if and so long as Notes are listed on the Euro MTF Market
of the Luxembourg Stock Exchange and the rules of such Stock
Exchange shall so require, published by the Issuer in a
newspaper having general circulation in Luxembourg (which is
expected to be the
Luxemburger Wort)
or, to the extent
and in the manner permitted by such rules, posted on the
official website of the Luxembourg Stock Exchange
(www.bourse.lu)) and (b) in the event the Notes are in the
form of Definitive Notes, sent by the Issuer, by first-class
mail, with a copy to the Trustee, to each Holder of the Notes at
such Holders address as it appears on the registration
books of the registrar. If and so long as such Notes are listed
on any other securities exchange, notices will also be given by
the Issuer in accordance with any applicable requirements of
such securities exchange. If and so long as any Notes are
represented by one or more Global Notes and ownership of
Book-Entry Interests therein are shown on the records of DTC or
any successor appointed by DTC at the request of the Issuer,
notices will be delivered to DTC or such successor for
communication to the owners of such Book-Entry Interests.
Notices given by publication will be deemed given on the first
date on which any of the required publications is made and
notices given by first-class mail, postage prepaid, will be
deemed given five calendar days after mailing.
SECTION 11.2
Certificate
and Opinion as to Conditions Precedent
. Upon any
request or application by the Issuer to the Trustee or an Agent
to take any action under this Indenture, the Issuer and the
Guarantors shall furnish to the Trustee at the request of the
Trustee:
(1) an Officers Certificate,
in form and substance reasonably acceptable to the Trustee
(reasonableness to be determined objectively), stating that, in
the opinion of the signers, all conditions precedent and
covenants, if any, provided for in this Indenture relating to
the proposed action have been satisfied or complied
with; and
(2) an Opinion of Counsel in form
and substance reasonably acceptable to the Trustee or such Agent
(reasonableness to be determined objectively) stating that, in
the opinion of such counsel, all such conditions precedent and
covenants have been satisfied or complied with.
In any case where several matters are required to be certified
by, or covered by an Opinion of Counsel of, any specified
Person, it is not necessary that all such matters be certified
by, or covered by the Opinion of Counsel of, only one such
Person, or that they be so certified or covered by only one
document, but one such Person may certify or give an Opinion of
Counsel with respect to some matters and one or more such
Persons as to other matters, and any such Person may certify or
give an Opinion of Counsel as to such matters in one or several
documents.
-72-
Any certificate of a Responsible Officer of the Issuer may be
based, insofar as it relates to legal matters, upon an Opinion
of Counsel, unless such Responsible Officer knows, or in the
exercise of reasonable care should know, that such Opinion of
Counsel with respect to the matters upon which his certificate
is based are erroneous. Any Opinion of Counsel may be based, and
may state that it is so based, insofar as it relates to factual
matters, upon a certificate of, or representations by, a
Responsible Officer or Responsible Officers of the Issuer
stating that the information with respect to such factual
matters is in the possession of the Issuer, unless such counsel
knows, or in the exercise of reasonable care should know, that
the certificate or representations with respect to such matters
are erroneous.
Where any Person is required to make, give or execute two or
more applications, requests, consents, certificates, statements,
opinions or other instruments under this Indenture, they may,
but need not, be consolidated and form one instrument.
SECTION 11.3
Statements
Required in Certificate or Opinion
. Each certificate or
opinion with respect to compliance with a condition or covenant
provided for in this Indenture shall include:
(1) a statement that the Person
making such certificate or opinion has read such covenant or
condition;
(2) a brief statement as to the
nature and scope of the examination or investigation upon which
the statements or opinions contained in such certificate or
opinion are based;
(3) a statement that, in the
opinion of such Person, such Person has made such examination or
investigation as is necessary to enable such Person to express
an informed opinion as to whether or not such covenant or
condition has been complied with; and
(4) a statement as to whether or
not, in the opinion of each such Person, such condition or
covenant has been complied with.
SECTION 11.4
Rules by
Trustee, Paying Agent, Registrar
. The Trustee, Paying
Agent or Registrar may make reasonable rules for its functions.
SECTION 11.5
Legal
Holidays
. If a payment date is not a Business Day,
payment may be made on the next succeeding day that is a
Business Day, and no interest shall accrue for the intervening
period.
SECTION 11.6
Governing
Law
. THIS INDENTURE AND THE NOTES, AND THE RIGHTS AND DUTIES
OF THE PARTIES HEREUNDER AND THEREUNDER, SHALL BE GOVERNED BY,
AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW
YORK. THE NOTE GUARANTEES WILL BE GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK
EXCEPT THAT THE LIMITATIONS OF THE NOTE GUARANTEES
EXPRESSED IN SECTIONS 10.1(c) HEREOF (AND THE EQUIVALENT
PROVISION CONTAINED IN THE NOTE GUARANTEE ENDORSED ON THE
NOTES) WILL BE CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE
FEDERAL REPUBLIC OF GERMANY.
-73-
SECTION 11.7
Submission to
Jurisdiction
. To the fullest extent permitted by
applicable law, each of the Issuer and the Guarantors
irrevocably submits to the non-exclusive jurisdiction of any
U.S. federal or state court in the Borough of Manhattan in
the City of New York, County and State of New York, United
States of America, in any suit or proceeding based on or arising
under this Indenture or the Notes, and irrevocably agrees that
all claims in respect of such suit or proceeding may be
determined in any such court. Each of the Issuer and the
Guarantors, to the fullest extent permitted by applicable law,
irrevocably and fully waives the defense of an inconvenient
forum to the maintenance of such suit or proceeding and
irrevocably waives to the fullest extent it may effectively do
so any objection which it may now or hereafter have to the
laying of venue of any such proceeding, and each of the Issuer
and the Guarantors hereby irrevocably consents to be served with
notice and service of process by delivery or by registered mail
with return receipt requested addressed to FMCHs
registered agent, which as of the date hereof is CT Corporation
System, 111 Eighth Avenue, New York, NY 10011 (which service of
process by registered mail shall be effective with respect to
the Issuer and the Guarantors so long as such return receipt is
obtained, or in the event of a refusal to sign such receipt any
Holder or the Trustee is able to produce evidence of attempted
delivery by such means). Each of the Issuer and the Guarantors
further agrees that such service of process and written notice
of such service to the Issuer and the Guarantors in the
circumstances described above shall be deemed in every respect
effective notice and service of process upon each of the Issuer
and the Guarantors in any such action or proceeding. Nothing
herein shall affect the right of any Person to serve process in
any other manner permitted by law. Each of the Issuer and the
Guarantors agrees that a final action in any such suit or
proceeding shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in any other lawful
manner. Notwithstanding the foregoing, each of the Issuer and
the Guarantors hereby agrees that any action arising out of or
based on this Indenture or the Notes may also be instituted in
any competent court in Germany, and it expressly accepts the
jurisdiction of any such court in any such action.
Each of the Issuer and the Guarantors hereby irrevocably waives,
to the extent permitted by law, any immunity to jurisdiction to
which it may otherwise be entitled (including, without
limitation, immunity to pre-judgment attachment, post-judgment
attachment and execution) in any legal suit, action or
proceeding against it arising out of or based on this Indenture
or the Notes.
The provisions of this Section 11.7 are intended to be
effective upon the execution of this Indenture without any
further action by the Issuer and the Guarantors and the
introduction of a true copy of this Indenture into evidence
shall be conclusive and final evidence as to such matters.
SECTION 11.8
No
Personal Liability of Directors, Officers, Employees and
Stockholders
No member of the Board of Directors, director,
officer, employee, incorporator or stockholder of the Issuer,
Fresenius SE, Fresenius SEs general partner, the Company,
the Companys General Partner or the Guarantors, as such,
shall have any liability for any obligations of the Issuer or
any Guarantor under the Notes, this Indenture or the Note
Guarantees or for any claim based on, in respect of, or by
reason of, such obligations or their creation. Each Holder by
accepting a Note waives and releases all such liability and
agrees not to enforce any claim in respect of the Notes, the
Indenture or the Notes Guarantees to the extent that it would
give rise to such personal liability. The waiver and release are
part of the consideration for issuance of the
-74-
Notes and the Note Guarantees. Such waiver and release may not
be effective to waive liabilities under the U.S. federal
securities laws and it is the view of the SEC that such a waiver
is against public policy. In addition, such waiver and release
may not be effective under the laws of the Federal Republic of
Germany.
SECTION 11.9
Successors
. All
agreements of the Issuer in this Indenture and the Notes and the
Guarantors in this Indenture and the Note Guarantees shall bind
their respective successors. All agreements of the Trustee in
this Indenture shall bind its successors.
SECTION 11.10
Counterpart
Originals
. All parties hereto may sign any number of
copies of this Indenture. Each signed copy or counterpart shall
be an original, but all of them together shall represent one and
the same agreement.
SECTION 11.11
Severability
. In
case any one or more of the provisions in this Indenture or in
the Notes shall be held invalid, illegal or unenforceable, in
any respect for any reason, the validity, legality and
enforceability of any such provision in every other respect and
of the remaining provisions shall not in any way be affected or
impaired thereby, it being intended that all of the provisions
hereof shall be enforceable to the full extent permitted by law.
SECTION 11.12
Table of
Contents, Headings, Etc
. The Table of Contents,
Cross-Reference Table and headings of the Articles and Sections
of this Indenture have been inserted for convenience of
reference only, are not to be considered a part of this
Indenture and shall in no way modify or restrict any of the
terms or provisions hereof.
SECTION 11.13
Trust Indenture
Act Controls
. If any provision of this Indenture
limits, qualifies or conflicts with the duties imposed by TIA
§ 318(c), the imposed duties shall control.
Currency Indemnity.
The U.S. dollar (or
any of its successor currencies) is the sole currency of account
and payment for all sums payable by the Issuer under this
Indenture. Any amount received or recovered in a currency other
than the U.S. dollar in respect of the Notes (whether as a
result of, or of the enforcement of, a judgment or order of a
court of any jurisdiction, in the
winding-up
or dissolution of the Issuer, any Guarantor, any Subsidiary or
otherwise) by the Holder in respect of any sum expressed to be
due to it from the Issuer will constitute a discharge of the
Issuer only to the extent of the U.S. dollar amount which
the recipient is able to purchase with the amount so received or
recovered in that other currency on the date of that receipt or
recovery (or, if it is not possible to make that purchase on
that date, on the first date on which it is possible to do so).
If that U.S. dollar amount is less than the
U.S. dollar amount expressed to be due to the recipient
under any Note, the Issuer will indemnify the recipient against
any loss sustained by it as a result. In any event the Issuer
will indemnify the recipient against the cost of making any such
purchase.
For the purposes of this indemnity, it will be sufficient for
the Holder to certify that it would have suffered a loss had an
actual purchase of U.S. dollars been made with the amount
so received in that other currency on the date of receipt or
recovery (or, if a purchase of U.S. dollars on such date
had not been practicable, on the first date on which it would
have been practicable). These indemnities constitute a separate
and independent obligation from the other obligations of the
Issuer, will give rise to a separate and independent cause of
action, will apply irrespective of any waiver granted by any
holder and will continue in full force and effect despite
-75-
any other judgment, order, claim or proof for a liquidated
amount in respect of any sum due under any Note or any other
judgment or order.
SECTION 11.15
Information
. For
so long as the Notes are listed on the Euro MTF Market of the
Luxembourg Stock Exchange, and the rules of such stock exchange
so require, copies of this Indenture will be made available in
Luxembourg through the offices of the Luxembourg Paying Agent in
such city.
-76-
IN WITNESS WHEREOF, the parties hereto have caused this
Indenture to be duly executed, as of the date first written
above.
FRESENIUS MEDICAL CARE US
FINANCE,
INC.
Name: Mark
Fawcett
|
|
|
|
Title:
|
Vice President and Treasurer
|
FRESENIUS MEDICAL CARE
AG & CO. KGaA,
a partnership limited by shares,
represented by
FRESENIUS MEDICAL CARE MANAGEMENT
AG, its general partner
Name: Michael
Brosnan
|
|
|
|
Title:
|
Member of Management Board
|
Name: Kent
Wanzek
|
|
|
|
Title:
|
Member of Management Board
|
FRESENIUS MEDICAL CARE DEUTSCHLAND
GmbH
|
|
|
|
By:
|
/s/ Alexandra
Dambeck
|
Name: Alexandra
Dambeck
Name: Eberhard
Sieger
FRESENIUS MEDICAL CARE HOLDINGS,
INC.
Name: Mark
Fawcett
|
|
|
|
Title:
|
Vice President &
Assistant Treasurer
|
-77-
U.S. BANK NATIONAL ASSOCIATION,
as Trustee
|
|
|
|
By:
|
/s/ Elizabeth
C. Hammer
|
Name: Elizabeth
C. Hammer
-78-
EXHIBIT A
TO THE INDENTURE
[FORM OF
FACE OF GLOBAL NOTE]
[Global Note
Legend]
THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE
INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME
OF THE DEPOSITORY TRUST COMPANY OR A NOMINEE OF THE
DEPOSITORY TRUST COMPANY. THIS NOTE IS NOT
EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON
OTHER THAN THE DEPOSITORY TRUST COMPANY OR ITS NOMINEE
EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE,
AND NO TRANSFER OF THIS NOTE (OTHER THAN A TRANSFER OF THIS
NOTE AS A WHOLE TO THE DEPOSITORY TRUST COMPANY OR A
NOMINEE OF THE DEPOSITORY TRUST COMPANY) MAY BE REGISTERED
EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE.
[Private
Placement Legend]
THE SECURITY (OR ITS PREDECESSOR) EVIDENCED HEREBY WAS
ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION
UNDER SECTION 5 OF THE UNITED STATES SECURITIES ACT OF
1933, AS AMENDED (THE SECURITIES ACT), AND THE
SECURITY EVIDENCED HEREBY MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN APPLICABLE
EXEMPTION THEREFROM. EACH PURCHASER OF THE SECURITY
EVIDENCED HEREBY IS HEREBY NOTIFIED THAT THE SELLER MAY BE
RELYING ON THE EXEMPTION FROM THE PROVISIONS OF
SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A
THEREUNDER. THE HOLDER OF THE SECURITY EVIDENCED HEREBY AGREES
FOR THE BENEFIT OF THE ISSUER THAT (A) SUCH SECURITY MAY BE
RESOLD, PLEDGED OR OTHERWISE TRANSFERRED, ONLY (1)(a) INSIDE THE
UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS
A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A
UNDER THE SECURITIES ACT) PURCHASING FOR ITS OWN ACCOUNT OR FOR
THE ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER IN A TRANSACTION
MEETING THE REQUIREMENTS OF RULE 144A UNDER THE SECURITIES
ACT, (b) OUTSIDE THE UNITED STATES TO A FOREIGN PERSON IN A
TRANSACTION MEETING THE REQUIREMENTS OF RULE 903 OR
RULE 904 OF REGULATION S UNDER THE SECURITIES ACT,
(c) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF
APPLICABLE) OR (d) IN ACCORDANCE WITH ANOTHER
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
A-1
SECURITIES ACT (AND BASED UPON AN OPINION OF COUNSEL ACCEPTABLE
TO THE ISSUER IF THE ISSUER SO REQUESTS), (2) TO THE ISSUER
OR (3) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT AND,
IN EACH CASE, IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS
OF ANY STATE OF THE UNITED STATES OR ANY OTHER APPLICABLE
JURISDICTION AND (B) THE HOLDER WILL, AND EACH SUBSEQUENT
HOLDER IS REQUIRED TO, NOTIFY ANY PURCHASER OF THE SECURITY
EVIDENCED HEREBY OF THE RESALE RESTRICTIONS SET FORTH IN CLAUSE
(A) ABOVE. NO REPRESENTATION CAN BE MADE AS TO THE
AVAILABILITY OF THE EXEMPTION PROVIDED BY RULE 144 FOR
RESALE OF THE SECURITY EVIDENCED HEREBY.
FRESENIUS
MEDICAL CARE US FINANCE, INC.
5.75% Senior
Note due 2021
CUSIP
No.:
No.
$
FRESENIUS MEDICAL CARE US FINANCE, INC., a Delaware corporation
(the Issuer, which term includes any successor
entity), for value received, promises to pay to Cede &
Co. or its registered assigns upon surrender hereof the
principal sum indicated on Schedule A hereof, on
February 15, 2021.
Interest Payment Dates: February 15 and
August 15, commencing August 15, 2011
Record Dates: February 1 and August 1 immediately
preceding the Interest Payment Dates
Reference is made to the further provisions of this Note
contained herein, which will for all purposes have the same
effect as if set forth at this place.
A-2
IN WITNESS WHEREOF, the Issuer has caused this instrument to be
duly executed.
Dated:
FRESENIUS MEDICAL CARE US FINANCE,
INC.
Name:
Title:
Trustees
Certificate of Authentication
This is one of the Securities with the Guarantees endorsed
thereon referred to in the within-mentioned Indenture.
U.S. BANK NATIONAL ASSOCIATION, as Trustee
Name:
Title:
A-3
[FORM OF
REVERSE]
FRESENIUS
MEDICAL CARE US FINANCE, INC.
5.75% Senior
Note due 2021
1.
Interest
. FRESENIUS
MEDICAL CARE US FINANCE, INC., a Delaware corporation (the
Issuer), promises to pay interest on the principal
amount of this Note at the rate and in the manner specified
below. Interest on the Notes will accrue at 5.75% per annum on
the principal amount then outstanding, and be payable
semi-annually in cash in arrears on each February 15 and
August 15, or if any such day is not a Business Day, on the
next succeeding Business Day, commencing August 15, 2011,
to the Holder hereof. Notwithstanding any exchange of this Note
for a Definitive Note during the period starting on a Record
Date relating to such Definitive Note and ending on the
immediately succeeding interest payment date, the interest due
on such interest payment date shall be payable to the Person in
whose name this Global Note is registered at the close of
business on the Record Date for such interest. Interest on the
Notes will accrue from the most recent date to which interest
has been paid. Interest will be computed on the basis of a
360-day
year
of twelve
30-day
months.
The Issuer shall pay interest on overdue principal and on
overdue installments of interest (without regard to any
applicable grace periods) and on any Additional Amounts, from
time to time on demand at the rate borne by the Notes. Any
interest paid on this Note shall be increased to the extent
necessary to pay Additional Amounts as set forth herein.
2.
Additional
Amounts
. All payments made under or with respect to the
Notes under the Indenture or pursuant to any Note Guarantee must
be made free and clear of and without withholding or deduction
for or on account of any present or future tax, duty, levy,
impost, assessment or other governmental charge (including
penalties, interest and other liabilities related thereto)
imposed or levied by or on behalf of (1) the United States,
Germany, Luxembourg, the United Kingdom or any political
subdivision or governmental authority thereof or therein having
the power to tax, (2) any jurisdiction from or through
which payment on the Notes or any Note Guarantee is made, or any
political subdivision or governmental authority thereof or
therein having the power to tax or (3) any other
jurisdiction in which the payor is organized or otherwise
considered to be a resident or engaged in business for tax
purposes, or any political subdivision or governmental authority
thereof or therein having the power to tax (each a
Relevant Taxing Jurisdiction), collectively,
Taxes, unless the Issuer or any Guarantor is
required to withhold or deduct Taxes by law or by the
interpretation or administration thereof by the relevant
government authority or agency provided, however, that in
determining what withholding is required by law for
U.S. federal income and withholding tax purposes, the
Issuer and any Guarantor shall be entitled to treat any payments
on or in respect of the Notes or any Note Guarantee as if the
Notes or any Note Guarantee were issued by a U.S. person as
defined in section 7701(a)(30) of the Code. If the Issuer
or any Guarantor is so required to withhold or deduct any amount
for or on account of Taxes from any payment made under or with
respect to the Notes or any Note Guarantee, the Issuer or such
Guarantor, as the case may be, will be required to pay such
amount Additional Amounts as
may be necessary so that the net amount (including Additional
Amounts) received by each Holder after such withholding or
deduction (including any withholding or deduction on such
Additional Amounts) will not be less than the amount such
A-4
Holder would have received if such Taxes had not been withheld
or deducted;
provided
,
however
, that no Additional
Amounts will be payable with respect to payments made to any
Holder or beneficial owner to the extent such Taxes are imposed
by reason of (i) such Holder or beneficial owner being
considered to be or to have been connected with a Relevant
Taxing Jurisdiction, otherwise than by the acquisition,
ownership, holding or disposition of the Notes, the enforcement
of rights under the Notes or under any Note Guarantee or the
receipt of payments in respect of the Notes or any Note
Guarantee, or (ii) such Holder or beneficial owner not
completing any procedural formalities that it is legally
eligible to complete and are necessary for the Issuer or the
Guarantors to make or obtain authorization to make payments
without such Taxes (including, without limitation, providing
prior to the receipt of any payment on or in respect of a Note
or any Note Guarantee, a complete, correct and executed IRS
Form W-8
or
W-9
or
successor form, as applicable, with all appropriate
attachments);
provided, however
, that for purposes of
this obligation to pay Additional Amounts, the Issuer and any
Guarantor shall be entitled, for U.S. federal income and
withholding tax purposes, to treat any payments on or in respect
of the Notes as if the Notes were issued by a U.S. person
as defined in section 7701(a)(30) of the Code. Further, no
Additional Amounts shall be payable with respect to (i) any
Tax imposed by the United States or any political subdivision or
governmental authority thereof or therein on interest by reason
of any Holder or beneficial owner holding or owning, actually or
constructively, 10% or more of the total combined voting power
of all classes of stock of the Issuer or any Guarantor entitled
to vote or (ii) any Tax imposed by the United States or any
political subdivision or governmental authority thereof or
therein on interest by reason of any Holder or beneficial owner
being a controlled foreign corporation that is a related person
within the meaning of Section 864(d)(4) of the Code with
respect to the Issuer or any Guarantor. The Issuer or Guarantor
(as applicable) will also make such withholding or deduction and
remit the full amount deducted or withheld to the relevant
authority as and when required in accordance with applicable
law. The Issuer or Guarantor (as applicable) will use all
reasonable efforts to obtain certified copies of tax receipts
evidencing the payment by the Issuer or Guarantor (as
applicable) of any Taxes so deducted or withheld from each
Relevant Taxing Jurisdiction imposing such Taxes and will
provide such certified copies to the Trustee.
Wherever in the Indenture or the Notes or any Note Guarantee
there are mentioned, in any context, (1) the payment of
principal, (2) purchase prices in connection with a
purchase of Notes under the Indenture or the Notes,
(3) interest or (4) any other amount payable on or
with respect to any of the Notes or any Note Guarantee, such
reference shall be deemed to include payment of Additional
Amounts as described under this heading to the extent that, in
such context, Additional Amounts are, were or would be payable
in respect thereof.
The Issuer will pay any present stamp, court or documentary
taxes, or any other excise, property or similar taxes, charges
or levies (including any penalties, interest or other
liabilities related thereto) which arise in the United States or
any political subdivision thereof or therein, from the
execution, delivery and registration of Notes upon original
issuance and initial resale of the Notes or any other document
or instrument referred to therein or in connection with the
enforcement of the Notes or any Note Guarantee or any other
document or instrument referred to herein or therein. If at any
time the Issuer changes its place of organization to outside of
the United States or there is a new issuer organized outside of
the United States, the Issuer or new issuer, as applicable, will
pay any stamp, court or documentary taxes, or any other excise,
property or similar taxes, charges or levies (including any
penalties, interest or other liabilities
A-5
related thereto) which arise in the jurisdiction in which the
Issuer or new issuer is organized (or any political subdivision
thereof or therein) and are payable by the Holders of the Notes
in respect of the Notes or any other document or instrument
referred to therein under any law, rule or regulation in effect
at the time of such change.
The foregoing obligations will survive any termination,
defeasance or discharge of the Indenture. References in this
section (Additional Amounts) to the Issuer or any
Guarantor shall apply to any successor(s) thereto.
3.
Method of
Payment
. The Issuer shall pay interest on the Notes
(except defaulted interest) to the Person in whose name this
Note is registered at the close of business on the Record Date
for such interest. The Issuer shall pay principal and interest
in U.S. dollars. Immediately available funds for the
payment of the principal of (and premium, if any), interest and
Additional Amounts, if any, on this Note due on any interest
payment date, Maturity Date, Redemption Date or other
repurchase date will be made available to the Paying Agent to
permit the Paying Agent to pay such funds to the Holders on such
respective dates.
4.
Paying Agent and
Registrar
. Initially, U.S. Bank National
Association will act as Paying Agent and as Registrar. In the
event that a Paying Agent or transfer agent is replaced, the
Issuer will provide notice thereof (so long as the Notes are
Global Notes) published in a leading newspaper having general
circulation in New York City (which is expected to be
The
Wall Street Journal
) (and, if and so long as the Notes are
listed on the Euro MTF Market of the Luxembourg Stock Exchange
and the rules of such stock exchange shall so require, published
in a newspaper having a general circulation in Luxembourg (which
is expected to be the
Luxemburger Wort
or, to the extent
and in the manner permitted by such rules, posted on the
official website of the Luxembourg Stock Exchange
(www.bourse.lu)) and (in the case of Definitive Notes), in
addition to such publication, mailed by first-class mail to each
Holders registered address. The Issuer may change any
Registrar without notice to the Holders. The Issuer, the Company
or any of their Subsidiaries may, subject to certain exceptions,
act in the capacity of Registrar or transfer agent.
5.
Indenture
. The
Issuer issued the Notes under an Indenture, dated as of
February 3, 2011 (the Indenture), among the
Issuer, Fresenius Medical Care AG & Co. KGaA (the
Company), Fresenius Medical Care Holdings, Inc.
(FMCH), Fresenius Medical Care Deutschland GmbH
(FMCD and together with the Company and FMCH, the
Guarantors) and U.S. Bank National Association
(the Trustee) as Trustee. This Note is one of a duly
authorized issue of Notes (as defined in the Indenture) of the
Issuer designated as its 5.75% Senior Notes due 2021. The
terms of the Notes include those stated in the Indenture.
Notwithstanding anything to the contrary herein, the Notes are
subject to all such terms, and Holders of Notes are referred to
the Indenture for a statement of them. The Notes are general
obligations of the Issuer. The Notes are not limited in
aggregate principal amount and Additional Notes (as defined in
the Indenture) may be issued from time to time under the
Indenture, in each case subject to the terms of the Indenture;
provided
that the aggregate principal amount of Notes
that will be issued on the Closing Date (as defined in the
Indenture) will not exceed $650,000,000. Each Holder, by
accepting a Note, agrees to be bound by all of the terms and
provisions of the Indenture, as the same may be amended from
time to time.
A-6
6.
Ranking
. The Notes
will be senior unsecured obligations of the Issuer and the Note
Guarantees will be senior unsecured obligations of the
Guarantors. The payment of the principal of, premium, if any,
and interest on the Notes and the obligations of the Guarantors
under the Note Guarantees will:
|
|
|
|
|
rank
pari passu
in right of payment with all other
Indebtedness of the Issuer and the Guarantors, as applicable,
that is not by its terms expressly subordinated to other
Indebtedness of the Issuer and the Guarantors, as applicable;
|
|
|
|
rank senior in right of payment to all Indebtedness of the
Issuer and the Guarantors, as applicable, that is, by its terms,
expressly subordinated to the senior Indebtedness of the Issuer
and the Guarantors, as applicable;
|
|
|
|
be effectively subordinated to the Secured Indebtedness of the
Issuer and the Guarantors, as applicable, to the extent of the
value of the collateral securing such Indebtedness, and to the
Indebtedness of the Subsidiaries that are not Guarantors of the
Notes; and
|
|
|
|
in the case of the Note Guarantee of Fresenius Medical Care
Deutschland GmbH, be effectively subordinated to the claims of
such Guarantors third-party creditors as a result of
limitations applicable to the Note Guarantee as set forth in
Section 10.1(c) of the Indenture.
|
7.
Note Guarantee
. As
provided in the Indenture and subject to certain limitations set
forth therein, the obligations of the Issuer under the Indenture
and this Note are Guaranteed on a senior unsecured basis
pursuant to Note Guarantees endorsed hereon. The Indenture
provides that a Guarantor shall be released from its Note
Guarantee upon compliance with certain conditions.
8.
Optional
Redemption
. The Issuer may redeem all or, from time to
time, a part of the Notes, at its option, at redemption prices
equal to 100% of the principal amount of the Notes being
redeemed plus accrued interest, if any, to the redemption date,
plus the excess of:
(a) as determined by the
calculation agent (which shall initially be the Trustee), the
sum of the present values of the remaining scheduled payments of
principal and interest on the Notes being redeemed not including
any portion of such payment of interest accrued on the date of
redemption, from the redemption date to the maturity date,
discounted to the redemption date on a semi-annual basis
(assuming a
360-day
year
consisting of twelve
30-day
months) at the Treasury Rate plus 50 basis points; over
(b) 100% of the principal amount of
the Notes being redeemed.
If the optional redemption date is on or after an interest
record date and on or before the related interest payment date,
the accrued and unpaid interest, if any, will be paid to the
Person in whose name the Note is registered at the close of
business on such record date, and no
A-7
additional interest will be payable to beneficial Holders whose
Notes will be subject to redemption by the Issuer.
In the case of any partial redemption, the Trustee will select
the Notes for redemption in compliance with the requirements of
the principal securities exchange, if any, on which the Notes
are listed or, if the Notes are not listed, then on a pro rata
basis, by lot or by such other method as the Trustee in its sole
discretion will deem to be fair and appropriate, although no
Note of $2,000 in original principal amount or less will be
redeemed in part. If any Note is to be redeemed in part only,
the notice of redemption relating to that Note will state the
portion of the principal amount thereof to be redeemed. A new
Note in principal amount equal to the unredeemed portion thereof
will be issued and delivered to the Trustee, or in the case of
Definitive Notes, issued in the name of the Holder thereof upon
cancellation of the original Note.
9.
Special Tax
Redemption
. The Issuer is entitled to redeem the Notes,
at its option, in whole but not in part, upon not less than 30
nor more than 60 days notice, at 100% of the
principal amount of the Notes, plus accrued and unpaid interest
(if any) to the date of redemption (subject to the right of
Holders of record on the relevant record date to receive
interest due on the relevant interest payment date), in the
event the Issuer has become or would become obligated to pay, on
the next date on which any amount would be payable with respect
to the Notes, any additional amounts as a result of:
(a) a change in or an amendment to
the laws, treaties, regulations or rulings of any Relevant
Taxing Jurisdiction; or
(b) any change in or amendment to
any official position regarding the application, administration
or interpretation of such laws, treaties, regulations or rulings
(including by virtue of a holding, judgment or order by a court
of competent jurisdiction);
which change or amendment to such laws or official position is
announced and becomes effective after the issuance of the Notes;
provided
that the Issuer determines, in its reasonable
judgment, that the obligation to pay such additional amounts
cannot be avoided by the use of reasonable measures available to
it;
provided
,
further
, that at the time such
notice is given, such obligation to pay Additional Amounts
remains in effect.
Notice of any such redemption must be given within 270 days
of the earlier of the announcement or effectiveness of any such
change.
10.
Notice of
Redemption
. Notice of redemption will be given at least
30 days but not more than 60 days before the
Redemption Date or Tax Redemption Date, as the case
may be, (i) so long as the Notes are in global form, by
publishing in a leading newspaper having a general circulation
in New York (which is expected to be
The Wall Street
Journal
) (and, if and so long as the Notes are listed on the
Euro MTF Market of the Luxembourg Stock Exchange and the rules
of such stock exchange shall so require, a newspaper having a
general circulation in Luxembourg (which is expected to be the
Luxemburger Wort
or, to the extent and in the manner
permitted by such rules, posted on the official website of the
Luxembourg Stock Exchange (www.bourse.lu)) and notify the
Holders, the Trustee and the Luxembourg Stock Exchange, if
applicable and (ii) in the case of Definitive Notes, in
addition to such publication, by mailing
A-8
first-class mail to each Holders registered address. Notes
in denominations of $2,000 may be redeemed only in whole. The
Trustee may select for redemption portions (equal to $2,000 or
any integral multiple of $1,000 in excess thereof) of the
principal of Notes that have denominations larger than $2,000.
Except as set forth in the Indenture, from and after any
Redemption Date or Tax Redemption Date, as the case
may be, if monies for the redemption of the Notes called for
redemption shall have been deposited with the Paying Agent for
redemption on such Redemption Date or Tax
Redemption Date, as the case may be, then, unless the
Issuer defaults in the payment of such Redemption Price,
the Notes called for redemption will cease to bear interest and
Additional Amounts, if any, and the only right of the Holders of
such Notes will be to receive payment of the
Redemption Price.
11.
Change of
Control
. Each Holder of the Notes, upon the occurrence
of a Change of Control Triggering Event, will have the right to
require that the Issuer repurchase such Holders Notes, at
a purchase price in cash equal to 101% of the principal amount
thereof plus accrued and unpaid interest, if any, to the date of
purchase (subject to the right of Holders of record on the
relevant record date to receive interest due on the relevant
interest payment date). Holders of Notes that are subject to an
offer to purchase will receive a Change of Control offer from
the Company prior to any related Change of Control payment date
and may elect to have such Notes purchased by completing the
form entitled Option of Holder to Elect Purchase
appearing below.
12.
Denominations;
Form
. The Global Notes are in registered global form,
without coupons, in denominations of $2,000 and integral
multiples of $1,000 in excess thereof.
13.
Persons Deemed
Owners
. The registered Holder of this Note shall be
treated as the owner of it for all purposes, subject to the
terms of the Indenture.
14.
Unclaimed Funds
. If
funds for the payment of principal, interest, premium or
Additional Amounts remain unclaimed for two years, the Trustee
and the Paying Agents will repay the funds to the Issuer at its
written request. After that, all liability of the Trustee and
such Paying Agents with respect to such funds shall cease.
15.
Legal Defeasance and
Covenant Defeasance
. The Issuer may be discharged from
its obligations under the Indenture and the Notes except for
certain provisions thereof (Legal Defeasance), and
may be discharged from its obligations to comply with certain
covenants contained in the Indenture (Covenant
Defeasance), in each case upon satisfaction of certain
conditions specified in the Indenture.
16.
Amendment; Supplement;
Waiver
. Subject to certain exceptions specified in the
Indenture, the Indenture or the Notes may be amended or
supplemented with the written consent of the Holders of at least
a majority in principal amount of the Notes then outstanding,
and any existing Default or Event of Default or compliance with
any provision of the Indenture or the Notes may be waived with
the consent of the Holders of a majority in principal amount of
the Notes then outstanding.
A-9
17.
Restrictive
Covenants
. The Indenture imposes certain covenants
that, among other things, limit the ability of the Issuer, the
Company, the Guarantors and their Subsidiaries to incur
additional Indebtedness, to incur additional Liens, to enter
into Sale and Leaseback Transactions and enter into certain
consolidations or mergers. The limitations are subject to a
number of important qualifications and exceptions. The Issuer
must annually report to the Trustee on compliance with such
limitations.
18.
Successors
. When a
successor assumes all the obligations of its predecessor under
the Notes and the Indenture in accordance with the terms of the
Indenture, the predecessor will be released from those
obligations.
19.
Defaults and
Remedies
. If an Event of Default (other than an Event
of Default specified in clause (7) of Section 6.1 of
the Indenture) occurs and is continuing, the Trustee or the
Holders of at least 25% in principal amount of the then
outstanding Notes may declare all the Notes to be due and
payable immediately in the manner and with the effect provided
in the Indenture. Holders of Notes may not enforce the Indenture
or the Notes except as provided in the Indenture. The Trustee is
not obligated to enforce the Indenture or the Notes unless it
has received full indemnity. The Indenture permits, subject to
certain limitations therein provided, Holders of a majority in
aggregate principal amount of the Notes then outstanding to
direct the Trustee in its exercise of any trust or power. The
Trustee may withhold from Holders of Notes notice of any
continuing Default or Event of Default (except a Default in
payment of principal, premium, interest and Additional Amounts,
if any, including an accelerated payment) if it determines that
withholding notice is in their interest.
20.
Trustee Dealings with
Issuer
. The Trustee under the Indenture, in its
individual or any other capacity, may become the owner or
pledgee of Notes and may otherwise deal with the Company, its
Subsidiaries or their respective Affiliates as if it were not
the Trustee.
21.
No Recourse Against
Others
. No member of the Board of Directors, director,
officer, employee, incorporator or stockholder of the Issuer,
Fresenius SE, Fresenius SEs general partner, the Company,
the Companys General Partner or the Guarantors, as such,
shall have any liability for any obligations of the Issuer or
any Guarantor under the Notes, the Indenture or the Note
Guarantees or for any claim based on, in respect of, or by
reason of, such obligations or their creation. Each Holder by
accepting a Note waives and releases all such liability and
agrees not to enforce any claim in respect of the Notes, the
Indenture or the Notes Guarantees to the extent that it would
give rise to such personal liability. The waiver and release are
part of the consideration for issuance of the Notes and the Note
Guarantees. Such waiver and release may not be effective to
waive liabilities under the U.S. federal securities laws
and it is the view of the SEC that such a waiver is against
public policy. In addition, such waiver and release may not be
effective under the laws of the Federal Republic of Germany. The
waiver and release are part of the consideration for issuance of
the Notes.
22.
Authentication
. This
Note shall not be valid until the Trustee or authenticating
agent signs the certificate of authentication on this Note.
23.
Abbreviations and Defined
Terms
. Customary abbreviations may be used in the name
of a Holder of a Note or an assignee, such as: TEN COM (=
tenants in common),
A-10
TEN ENT (= tenants by the entireties), JT TEN (= joint tenants
with right of survivorship and not as tenants in common), CUST
(= Custodian), and U/G/M/A (= Uniform Gifts to Minors Act).
Unless otherwise defined herein, terms defined in the Indenture
are used herein as defined therein.
24.
CUSIP Numbers
. The
Issuer will cause the CUSIP numbers to be printed on the Notes
as a convenience to the Holders of the Notes. No representation
is made as to the accuracy of such numbers as printed on the
Notes and reliance may be placed only on the other
identification numbers printed hereon.
25.
Governing Law
. THIS
NOTE AND THE INDENTURE, AND THE RIGHTS AND DUTIES OF THE
PARTIES HEREUNDER AND THEREUNDER, SHALL BE GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.
THE NOTE GUARANTEES WILL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK EXCEPT
CERTAIN MATTERS CONCERNING LIMITATION THEREOF WILL BE CONSTRUED
IN ACCORDANCE WITH THE LAWS OF THE FEDERAL REPUBLIC OF GERMANY.
A-11
SCHEDULE A
SCHEDULE OF
PRINCIPAL AMOUNT
The initial principal amount at maturity of this Note shall be
$[principal amount]. The following decreases/increases in the
principal amount at maturity of this Note have been made:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Principal
|
|
Notation
|
|
|
|
|
|
|
Amount
|
|
Made by
|
Date of
|
|
Decrease in
|
|
Increase in
|
|
Following Such
|
|
or on
|
Decrease/
|
|
Principal
|
|
Principal
|
|
Decrease/
|
|
Behalf of
|
Increase
|
|
Amount
|
|
Amount
|
|
Increase
|
|
Trustee
|
|
A-12
OPTION OF
HOLDER TO ELECT PURCHASE
If you want to elect to have this Note purchased by the Issuer
pursuant to Section 4.11 of the Indenture, check the box
below:
o
If you want to elect to have only part of this Note purchased by
the Issuer pursuant to Section 4.11 of the Indenture, state
the amount:
$
Date:
Your
Signature:
(Sign exactly as your name appears
on the other side of this Note)
Signature
Guarantee:
Participant in a recognized
Signature Guarantee Medallion Program
(or other signature guarantor program reasonably acceptable to
the Trustee)
A-13
EXHIBIT B
TO THE INDENTURE
[FORM OF
FACE OF DEFINITIVE NOTE]
THIS NOTE IS A DEFINITIVE NOTE WITHIN THE MEANING OF
THE INDENTURE HEREINAFTER REFERRED TO.
[Private
Placement Legend]
THE SECURITY (OR ITS PREDECESSOR) EVIDENCED HEREBY WAS
ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION
UNDER SECTION 5 OF THE UNITED STATES SECURITIES ACT OF
1933, AS AMENDED (THE SECURITIES ACT), AND THE
SECURITY EVIDENCED HEREBY MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN APPLICABLE
EXEMPTION THEREFROM. EACH PURCHASER OF THE SECURITY
EVIDENCED HEREBY IS HEREBY NOTIFIED THAT THE SELLER MAY BE
RELYING ON THE EXEMPTION FROM THE PROVISIONS OF
SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A
THEREUNDER. THE HOLDER OF THE SECURITY EVIDENCED HEREBY AGREES
FOR THE BENEFIT OF THE ISSUER THAT (A) SUCH SECURITY MAY BE
RESOLD, PLEDGED OR OTHERWISE TRANSFERRED, ONLY (1)(a) INSIDE THE
UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS
A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A
UNDER THE SECURITIES ACT) PURCHASING FOR ITS OWN ACCOUNT OR FOR
THE ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER IN A TRANSACTION
MEETING THE REQUIREMENTS OF RULE 144A UNDER THE SECURITIES
ACT, (b) OUTSIDE THE UNITED STATES TO A FOREIGN PERSON IN A
TRANSACTION MEETING THE REQUIREMENTS OF RULE 903 OR
RULE 904 OF REGULATION S UNDER THE SECURITIES ACT,
(c) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF
APPLICABLE) OR (d) IN ACCORDANCE WITH ANOTHER
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT (AND BASED UPON AN OPINION OF COUNSEL ACCEPTABLE
TO THE ISSUER IF THE ISSUER SO REQUESTS), (2) TO THE ISSUER
OR (3) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT AND,
IN EACH CASE, IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS
OF ANY STATE OF THE UNITED STATES OR ANY OTHER APPLICABLE
JURISDICTION AND (B) THE HOLDER WILL, AND EACH SUBSEQUENT
HOLDER IS REQUIRED TO, NOTIFY ANY PURCHASER OF THE SECURITY
EVIDENCED HEREBY OF THE RESALE RESTRICTIONS SET FORTH IN CLAUSE
(A) ABOVE. NO REPRESENTATION CAN BE MADE AS TO THE
AVAILABILITY OF THE EXEMPTION PROVIDED BY RULE 144 FOR
RESALE OF THE SECURITY EVIDENCED HEREBY.
B-1
FRESENIUS
MEDICAL CARE US FINANCE, INC.
5.75% Senior
Note due 2021
CUSIP
No.:
No.
$
FRESENIUS MEDICAL CARE US FINANCE, INC., a Delaware corporation
(the Issuer, which term includes any successor
entity), for value received, promises to pay to Cede &
Co. or its registered assigns upon surrender hereof the
principal sum of
$
,
on February 15, 2021.
Interest Payment Dates: February 15 and August 15,
commencing August 15, 2011
Record Dates: February 1 and August 1 immediately preceding the
Interest Payment Dates
Reference is made to the further provisions of this Note
contained herein, which will for all purposes have the same
effect as if set forth at this place.
B-2
IN WITNESS WHEREOF, the Issuer has caused this instrument to be
duly executed.
Dated:
FRESENIUS MEDICAL CARE US FINANCE,
INC.
Name:
Title:
Trustees
Certificate of Authentication
This is one of the Securities with the Guarantees endorsed
thereon referred to in the within-mentioned Indenture.
U.S. BANK NATIONAL ASSOCIATION, as Trustee
Name:
Title:
B-3
[FORM OF
REVERSE]
FRESENIUS
MEDICAL CARE US FINANCE, INC.
5.75% Senior
Note due 2021
1.
Interest
. FRESENIUS
MEDICAL CARE US FINANCE, INC., a Delaware corporation (the
Issuer), promises to pay interest on the principal
amount of this Note at the rate and in the manner specified
below. Interest on the Notes will accrue at 5.75% per annum on
the principal amount then outstanding, and be payable
semi-annually in cash in arrears on each February 15 and
August 15, or if any such day is not a Business Day, on the
next succeeding Business Day, commencing August 15, 2011,
to the Holder hereof. Notwithstanding any exchange of this Note
for a Definitive Note during the period starting on a Record
Date relating to such Definitive Note and ending on the
immediately succeeding interest payment date, the interest due
on such interest payment date shall be payable to the Person in
whose name this Global Note is registered at the close of
business on the Record Date for such interest. Interest on the
Notes will accrue from the most recent date to which interest
has been paid. Interest will be computed on the basis of a
360-day
year
of twelve
30-day
months.
The Issuer shall pay interest on overdue principal and on
overdue installments of interest (without regard to any
applicable grace periods) and on any Additional Amounts, from
time to time on demand at the rate borne by the Notes. Any
interest paid on this Note shall be increased to the extent
necessary to pay Additional Amounts as set forth herein.
2.
Additional
Amounts
. All payments made under or with respect to the
Notes under the Indenture or pursuant to any Note Guarantee must
be made free and clear of and without withholding or deduction
for or on account of any present or future tax, duty, levy,
impost, assessment or other governmental charge (including
penalties, interest and other liabilities related thereto)
imposed or levied by or on behalf of (1) the United States,
Germany, Luxembourg, the United Kingdom or any political
subdivision or governmental authority thereof or therein having
the power to tax, (2) any jurisdiction from or through
which payment on the Notes or any Note Guarantee is made, or any
political subdivision or governmental authority thereof or
therein having the power to tax or (3) any other
jurisdiction in which the payor is organized or otherwise
considered to be a resident or engaged in business for tax
purposes, or any political subdivision or governmental authority
thereof or therein having the power to tax (each a
Relevant Taxing Jurisdiction), collectively,
Taxes, unless the Issuer or any Guarantor is
required to withhold or deduct Taxes by law or by the
interpretation or administration thereof by the relevant
government authority or agency provided, however, that in
determining what withholding is required by law for
U.S. federal income and withholding tax purposes, the
Issuer and any Guarantor shall be entitled to treat any payments
on or in respect of the Notes or any Note Guarantee as if the
Notes or any Note Guarantee were issued by a U.S. person as
defined in section 7701(a)(30) of the Code. If the Issuer
or any Guarantor is so required to withhold or deduct any amount
for or on account of Taxes from any payment made under or with
respect to the Notes or any Note Guarantee, the Issuer or such
Guarantor, as the case may be, will be required to pay such
amount Additional Amounts as
may be necessary so that the net amount (including Additional
Amounts) received by each Holder after such withholding or
deduction (including
B-4
any withholding or deduction on such Additional Amounts) will
not be less than the amount such Holder would have received if
such Taxes had not been withheld or deducted;
provided
,
however
, that no Additional Amounts will be payable with
respect to payments made to any Holder or beneficial owner to
the extent such Taxes are imposed by reason of (i) such
Holder or beneficial owner being considered to be or to have
been connected with a Relevant Taxing Jurisdiction, otherwise
than by the acquisition, ownership, holding or disposition of
the Notes, the enforcement of rights under the Notes or under
any Note Guarantee or the receipt of payments in respect of the
Notes or any Note Guarantee, or (ii) such Holder or
beneficial owner not completing any procedural formalities that
it is legally eligible to complete and are necessary for the
Issuer or the Guarantors to make or obtain authorization to make
payments without such Taxes (including, without limitation,
providing prior to the receipt of any payment on or in respect
of a Note or any Note Guarantee, a complete, correct and
executed IRS
Form W-8
or
W-9
or
successor form, as applicable, with all appropriate
attachments);
provided, however
, that for purposes of
this obligation to pay Additional Amounts, the Issuer and any
Guarantor shall be entitled, for U.S. federal income and
withholding tax purposes, to treat any payments on or in respect
of the Notes as if the Notes were issued by a U.S. person
as defined in section 7701(a)(30) of the Code. Further, no
Additional Amounts shall be payable with respect to (i) any
Tax imposed by the United States or any political subdivision or
governmental authority thereof or therein on interest by reason
of any Holder or beneficial owner holding or owning, actually or
constructively, 10% or more of the total combined voting power
of all classes of stock of the Issuer or any Guarantor entitled
to vote or (ii) any Tax imposed by the United States or any
political subdivision or governmental authority thereof or
therein on interest by reason of any Holder or beneficial owner
being a controlled foreign corporation that is a related person
within the meaning of Section 864(d)(4) of the Code with
respect to the Issuer or any Guarantor. The Issuer or Guarantor
(as applicable) will also make such withholding or deduction and
remit the full amount deducted or withheld to the relevant
authority as and when required in accordance with applicable
law. The Issuer or Guarantor (as applicable) will use all
reasonable efforts to obtain certified copies of tax receipts
evidencing the payment by the Issuer or Guarantor (as
applicable) of any Taxes so deducted or withheld from each
Relevant Taxing Jurisdiction imposing such Taxes and will
provide such certified copies to the Trustee.
Wherever in the Indenture or the Notes or any Note Guarantee
there are mentioned, in any context, (1) the payment of
principal, (2) purchase prices in connection with a
purchase of Notes under the Indenture or the Notes,
(3) interest or (4) any other amount payable on or
with respect to any of the Notes or any Note Guarantee, such
reference shall be deemed to include payment of Additional
Amounts as described under this heading to the extent that, in
such context, Additional Amounts are, were or would be payable
in respect thereof.
The Issuer will pay any present stamp, court or documentary
taxes, or any other excise, property or similar taxes, charges
or levies (including any penalties, interest or other
liabilities related thereto) which arise in the United States or
any political subdivision thereof or therein, from the
execution, delivery and registration of Notes upon original
issuance and initial resale of the Notes or any other document
or instrument referred to therein, or in connection with the
enforcement of the Notes or any Note Guarantee or any other
document or instrument referred to herein or therein. If at any
time the Issuer changes its place of organization to outside of
the United States or there is a new issuer organized outside of
the United States, the Issuer or new issuer, as applicable, will
pay any stamp, court or documentary taxes, or any other excise,
B-5
property or similar taxes, charges or levies (including any
penalties, interest or other liabilities related thereto) which
arise in the jurisdiction in which the Issuer or new issuer is
organized (or any political subdivision thereof or therein) and
are payable by the Holders of the Notes in respect of the Notes
or any other document or instrument referred to therein under
any law, rule or regulation in effect at the time of such change.
The foregoing obligations will survive any termination,
defeasance or discharge of the Indenture. References in this
section (Additional Amounts) to the Issuer or any
Guarantor shall apply to any successor(s) thereto.
3.
Method of
Payment
. The Issuer shall pay interest on the Notes
(except defaulted interest) to the Person in whose name this
Note is registered at the close of business on the Record Date
for such interest. Holders must surrender Notes to a Paying
Agent to collect principal payments. The Issuer shall pay
principal and interest in U.S. dollars. Immediately
available funds for the payment of the principal of (and
premium, if any), interest and Additional Amounts, if any, on
this Note due on any interest payment date, Maturity Date,
Redemption Date or other repurchase date will be made
available to the Paying Agent to permit the Paying Agent to pay
such funds to the Holders on such respective dates.
4.
Paying Agent and
Registrar
. Initially, U.S. Bank National
Association will act as Paying Agent and as Registrar. In the
event that a Paying Agent or transfer agent is replaced, the
Issuer will provide notice thereof (so long as the Notes are
Global Notes) published in a leading newspaper having general
circulation in New York City (which is expected to be
The
Wall Street Journal
) (and, if and so long as the Notes are
listed on the Euro MTF Market of the Luxembourg Stock Exchange
and the rules of such stock exchange shall so require, published
in a newspaper having a general circulation in Luxembourg (which
is expected to be the
Luxemburger Wort
or, to the extent
and in the manner permitted by such rules, posted on the
official website of the Luxembourg Stock Exchange
(www.bourse.lu)) and (in the case of Definitive Notes), in
addition to such publication, mailed by first-class mail to each
Holders registered address. The Issuer may change any
Registrar without notice to the Holders. The Issuer, the Company
or any of their Subsidiaries may, subject to certain exceptions,
act in the capacity of Registrar or transfer agent.
5.
Indenture
. The
Issuer issued the Notes under an Indenture, dated as of
February 3, 2011 (the Indenture), among the
Issuer, Fresenius Medical Care AG & Co. KGaA (the
Company), Fresenius Medical Care Holdings, Inc.
(FMCH), Fresenius Medical Care Deutschland GmbH
(FMCD and together with the Company and FMCH, the
Guarantors) and U.S. Bank National Association
(the Trustee) as Trustee. This Note is one of a duly
authorized issue of Notes (as defined in the Indenture) of the
Issuer designated as its 5.75% Senior Notes due 2021. The
terms of the Notes include those stated in the Indenture.
Notwithstanding anything to the contrary herein, the Notes are
subject to all such terms, and Holders of Notes are referred to
the Indenture for a statement of them. The Notes are general
obligations of the Issuer. The Notes are not limited in
aggregate principal amount and Additional Notes (as defined in
the Indenture) may be issued from time to time under the
Indenture, in each case subject to the terms of the Indenture;
provided
that the aggregate principal amount of Notes
that will be issued on the Closing Date (as defined in the
Indenture) will not exceed $650,000,000. Each Holder, by ac-
B-6
cepting a Note, agrees to be bound by all of the terms and
provisions of the Indenture, as the same may be amended from
time to time.
6.
Ranking
. The Notes
will be senior unsecured obligations of the Issuer and the Note
Guarantees will be senior unsecured obligations of the
Guarantors. The payment of the principal of, premium, if any,
and interest on the Notes and the obligations of the Guarantors
under the Note Guarantees will:
|
|
|
|
|
rank
pari passu
in right of payment with all other
Indebtedness of the Issuer and the Guarantors, as applicable,
that is not by its terms expressly subordinated to other
Indebtedness of the Issuer and the Guarantors, as applicable;
|
|
|
|
rank senior in right of payment to all Indebtedness of the
Issuer and the Guarantors, as applicable, that is, by its terms,
expressly subordinated to the senior Indebtedness of the Issuer
and the Guarantors, as applicable;
|
|
|
|
be effectively subordinated to the Secured Indebtedness of the
Issuer and the Guarantors, as applicable, to the extent of the
value of the collateral securing such Indebtedness, and to the
Indebtedness of the Subsidiaries that are not Guarantors of the
Notes; and
|
|
|
|
in the case of the Note Guarantee of Fresenius Medical Care
Deutschland GmbH, be effectively subordinated to the claims of
such Guarantors third-party creditors as a result of
limitations applicable to the Note Guarantee as set forth in
Section 10.1(c) of the Indenture.
|
7.
Note Guarantee
. As
provided in the Indenture and subject to certain limitations set
forth therein, the obligations of the Issuer under the Indenture
and this Note are Guaranteed on a senior unsecured basis
pursuant to Note Guarantees endorsed hereon. The Indenture
provides that a Guarantor shall be released from its Note
Guarantee upon compliance with certain conditions.
8.
Optional
Redemption
. The Issuer may redeem all or, from time to
time, a part of the Notes, at its option, at redemption prices
equal to 100% of the principal amount of the Notes being
redeemed plus accrued interest, if any, to the redemption date,
plus the excess of:
(a) as determined by the
calculation agent (which shall initially be the Trustee), the
sum of the present values of the remaining scheduled payments of
principal and interest on the Notes being redeemed not including
any portion of such payment of interest accrued on the date of
redemption, from the redemption date to the maturity date,
discounted to the redemption date on a semi-annual basis
(assuming a
360-day
year
consisting of twelve
30-day
months) at the Treasury Rate plus 50 basis points; over
(b) 100% of the principal amount of
the Notes being redeemed.
If the optional redemption date is on or after an interest
record date and on or before the related interest payment date,
the accrued and unpaid interest, if any, will be paid to the
B-7
Person in whose name the Note is registered at the close of
business on such record date, and no additional interest will be
payable to beneficial Holders whose Notes will be subject to
redemption by the Issuer.
In the case of any partial redemption, the Trustee will select
the Notes for redemption in compliance with the requirements of
the principal securities exchange, if any, on which the Notes
are listed or, if the Notes are not listed, then on a pro rata
basis, by lot or by such other method as the Trustee in its sole
discretion will deem to be fair and appropriate, although no
Note of $2,000 in original principal amount or less will be
redeemed in part. If any Note is to be redeemed in part only,
the notice of redemption relating to that Note will state the
portion of the principal amount thereof to be redeemed. A new
Note in principal amount equal to the unredeemed portion thereof
will be issued and delivered to the Trustee, or in the case of
Definitive Notes, issued in the name of the Holder thereof upon
cancellation of the original Note.
9.
Special Tax
Redemption
. The Issuer is entitled to redeem the Notes,
at its option, in whole but not in part, upon not less than 30
nor more than 60 days notice, at 100% of the
principal amount of the Notes, plus accrued and unpaid interest
(if any) to the date of redemption (subject to the right of
Holders of record on the relevant record date to receive
interest due on the relevant interest payment date), in the
event the Issuer has become or would become obligated to pay, on
the next date on which any amount would be payable with respect
to the Notes, any additional amounts as a result of:
(a) a change in or an amendment to
the laws, treaties, regulations or rulings of any Relevant
Taxing Jurisdiction; or
(b) any change in or amendment to
any official position regarding the application, administration
or interpretation of such laws, treaties, regulations or rulings
(including by virtue of a holding, judgment or order by a court
of competent jurisdiction);
which change or amendment to such laws or official position is
announced and becomes effective after the issuance of the Notes;
provided
that the Issuer determines, in its reasonable
judgment, that the obligation to pay such additional amounts
cannot be avoided by the use of reasonable measures available to
it;
provided
,
further
, that at the time such
notice is given, such obligation to pay Additional Amounts
remains in effect.
Notice of any such redemption must be given within 270 days
of the earlier of the announcement or effectiveness of any such
change.
10.
Notice of
Redemption
. Notice of redemption will be given at least
30 days but not more than 60 days before the
Redemption Date or Tax Redemption Date, as the case
may be, (i) so long as the Notes are in global form, by
publishing in a leading newspaper having a general circulation
in New York (which is expected to be
The Wall Street
Journal
) (and, if and so long as the Notes are listed on the
Euro MTF Market of the Luxembourg Stock Exchange and the rules
of such stock exchange shall so require, a newspaper having a
general circulation in Luxembourg (which is expected to be the
Luxemburger Wort
or, to the extent and in the manner
permitted by such rules, posted on the official website of the
Luxembourg Stock Exchange (www.bourse.lu)) and notify the
Holders, the Trustee and the Luxembourg Stock Exchange, if
B-8
applicable and (ii) in the case of Definitive Notes, in
addition to such publication, by mailing first-class mail to
each Holders registered address. Notes in denominations of
$2,000 may be redeemed only in whole. The Trustee may select for
redemption portions (equal to $2,000 or any integral multiple of
$1,000 in excess thereof) of the principal of Notes that have
denominations larger than $2,000.
Except as set forth in the Indenture, from and after any
Redemption Date or Tax Redemption Date, as the case
may be, if monies for the redemption of the Notes called for
redemption shall have been deposited with the Paying Agent for
redemption on such Redemption Date or Tax
Redemption Date, as the case may be, then, unless the
Issuer defaults in the payment of such Redemption Price,
the Notes called for redemption will cease to bear interest and
Additional Amounts, if any, and the only right of the Holders of
such Notes will be to receive payment of the
Redemption Price.
11.
Change of
Control
. Each Holder of the Notes, upon the occurrence
of a Change of Control Triggering Event, will have the right to
require that the Issuer repurchase such Holders Notes, at
a purchase price in cash equal to 101% of the principal amount
thereof plus accrued and unpaid interest, if any, to the date of
purchase (subject to the right of Holders of record on the
relevant record date to receive interest due on the relevant
interest payment date). Holders of Notes that are subject to an
offer to purchase will receive a Change of Control offer from
the Company prior to any related Change of Control payment date
and may elect to have such Notes purchased by completing the
form entitled Option of Holder to Elect Purchase
appearing below.
12.
Denominations;
Form
. The Global Notes are in registered global form,
without coupons, in denominations of $2,000 and integral
multiples of $1,000 in excess thereof.
13.
Persons Deemed
Owners
. The registered Holder of this Note shall be
treated as the owner of it for all purposes, subject to the
terms of the Indenture.
14.
Unclaimed Funds
. If
funds for the payment of principal, interest, premium or
Additional Amounts remain unclaimed for two years, the Trustee
and the Paying Agents will repay the funds to the Issuer at its
written request. After that, all liability of the Trustee and
such Paying Agents with respect to such funds shall cease.
15.
Legal Defeasance and
Covenant Defeasance
. The Issuer may be discharged from
its obligations under the Indenture and the Notes except for
certain provisions thereof (Legal Defeasance), and
may be discharged from its obligations to comply with certain
covenants contained in the Indenture (Covenant
Defeasance), in each case upon satisfaction of certain
conditions specified in the Indenture.
16.
Amendment; Supplement;
Waiver
. Subject to certain exceptions specified in the
Indenture, the Indenture or the Notes may be amended or
supplemented with the written consent of the Holders of at least
a majority in principal amount of the Notes then outstanding,
and any existing Default or Event of Default or compliance with
any provision of the Indenture or the Notes may be waived with
the consent of the Holders of a majority in principal amount of
the Notes then outstanding.
B-9
17.
Restrictive
Covenants
. The Indenture imposes certain covenants
that, among other things, limit the ability of the Issuer, the
Company, the Guarantors and their Subsidiaries to incur
additional Indebtedness, to incur additional Liens, to enter
into Sale and Leaseback Transactions and enter into certain
consolidations or mergers. The limitations are subject to a
number of important qualifications and exceptions. The Issuer
must annually report to the Trustee on compliance with such
limitations.
18.
Successors
. When a
successor assumes all the obligations of its predecessor under
the Notes and the Indenture in accordance with the terms of the
Indenture, the predecessor will be released from those
obligations.
19.
Defaults and
Remedies
. If an Event of Default (other than an Event
of Default specified in clause (7) of Section 6.1 of
the Indenture) occurs and is continuing, the Trustee or the
Holders of at least 25% in principal amount of the then
outstanding Notes may declare all the Notes to be due and
payable immediately in the manner and with the effect provided
in the Indenture. Holders of Notes may not enforce the Indenture
or the Notes except as provided in the Indenture. The Trustee is
not obligated to enforce the Indenture or the Notes unless it
has received full indemnity. The Indenture permits, subject to
certain limitations therein provided, Holders of a majority in
aggregate principal amount of the Notes then outstanding to
direct the Trustee in its exercise of any trust or power. The
Trustee may withhold from Holders of Notes notice of any
continuing Default or Event of Default (except a Default in
payment of principal, premium, interest and Additional Amounts,
if any, including an accelerated payment) if it determines that
withholding notice is in their interest.
20.
Trustee Dealings with
Issuer
. The Trustee under the Indenture, in its
individual or any other capacity, may become the owner or
pledgee of Notes and may otherwise deal with the Company, its
Subsidiaries or their respective Affiliates as if it were not
the Trustee.
21.
No Recourse Against
Others
. No member of the Board of Directors, director,
officer, employee, incorporator or stockholder of the Issuer,
Fresenius SE, Fresenius SEs general partner, the Company,
the Companys General Partner or the Guarantors, as such,
shall have any liability for any obligations of the Issuer or
any Guarantor under the Notes, the Indenture or the Note
Guarantees or for any claim based on, in respect of, or by
reason of, such obligations or their creation. Each Holder by
accepting a Note waives and releases all such liability and
agrees not to enforce any claim in respect of the Notes, the
Indenture or the Notes Guarantees to the extent that it would
give rise to such personal liability. The waiver and release are
part of the consideration for issuance of the Notes and the Note
Guarantees. Such waiver and release may not be effective to
waive liabilities under the U.S. federal securities laws
and it is the view of the SEC that such a waiver is against
public policy. In addition, such waiver and release may not be
effective under the laws of the Federal Republic of Germany. The
waiver and release are part of the consideration for issuance of
the Notes.
22.
Authentication
. This
Note shall not be valid until the Trustee or authenticating
agent signs the certificate of authentication on this Note.
23.
Abbreviations and Defined
Terms
. Customary abbreviations may be used in the name
of a Holder of a Note or an assignee, such as: TEN COM (=
tenants in common),
B-10
TEN ENT (= tenants by the entireties), JT TEN (= joint tenants
with right of survivorship and not as tenants in common), CUST
(= Custodian), and U/G/M/A (= Uniform Gifts to Minors Act).
Unless otherwise defined herein, terms defined in the Indenture
are used herein as defined therein.
24.
CUSIP Numbers
. The
Issuer will cause the CUSIP numbers to be printed on the Notes
as a convenience to the Holders of the Notes. No representation
is made as to the accuracy of such numbers as printed on the
Notes and reliance may be placed only on the other
identification numbers printed hereon.
25.
Governing Law
. THIS
NOTE AND THE INDENTURE, AND THE RIGHTS AND DUTIES OF THE
PARTIES HEREUNDER AND THEREUNDER, SHALL BE GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.
THE NOTE GUARANTEES WILL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK EXCEPT
CERTAIN MATTERS CONCERNING LIMITATION THEREOF WILL BE CONSTRUED
IN ACCORDANCE WITH THE LAWS OF THE FEDERAL REPUBLIC OF GERMANY.
B-11
ASSIGNMENT
FORM
To assign this Note fill in the form below:
I or we assign and transfer this Note to
(Print
or type assignees name, address and zip code)
(Insert
assignees social security or tax I.D. No.)
and irrevocably
appoint
agent to transfer this Note on the books of the Issuer. The
agent may substitute another to act for him.
Date:
Your
Signature:
Sign
exactly as your name appears on the other side of this Note.
B-12
OPTION OF
HOLDER TO ELECT PURCHASE
If you want to elect to have this Note purchased by the Issuer
pursuant to Section 4.11 of the Indenture, check the box
below:
o
If you want to elect to have only part of this Note purchased by
the Issuer pursuant to Section 4.11 of the Indenture, state
the amount: $
Date:
Your
Signature:
(Sign exactly as your name appears
on the other side of this Note)
Signature
Guarantee:
Participant in a recognized
Signature Guarantee Medallion Program
(or other signature guarantor program reasonably acceptable to
the Trustee)
B-13
EXHIBIT C
TO THE INDENTURE
FORM OF
NOTE GUARANTEE
For value received, each of the Guarantors hereby jointly and
severally unconditionally Guarantees, on a senior unsecured
basis, to each Holder of a Note authenticated and delivered by
the Trustee, and to the Trustee on behalf of such Holder, the
due and punctual payment of the principal of (and premium, if
any) and interest (including Additional Amounts, if any) on such
Note when and as the same shall become due and payable, whether
at the Stated Maturity, by acceleration, call for redemption,
purchase or otherwise, in accordance with the terms of such Note
and of the Indenture.
In case of the failure of the Issuer punctually to make any such
payment, each of the Guarantors hereby jointly and severally
agrees to cause such payment to be made punctually when and as
the same shall become due and payable, whether at the Stated
Maturity or by acceleration, call for redemption, purchase or
otherwise, and as if such payment were made by the Issuer. The
Note Guarantee extends to the Issuers repurchase
obligations arising from a Change of Control pursuant to the
Indenture.
Each of the Guarantors hereby jointly and severally agrees that
its obligations hereunder shall be unconditional, irrespective
of the validity, regularity or enforceability of such Note or
the Indenture, the absence of any action to enforce the same,
any exchange, release or non-perfection of any Lien on any
collateral for, or any release or amendment or waiver of any
term of any other Guarantee of, or any consent to departure from
any requirement of any other Guarantee of, all or any of the
Notes, the effects of Bankruptcy Law applicable in the event of
bankruptcy proceedings being opened with respect to the Issuer,
of all or any portion of the claims of the Trustee or any of the
Holders for payment of any of the Notes, any waiver or consent
by the Holder of such Note or by the Trustee with respect to any
provisions thereof or of the Indenture, the obtaining of any
judgment against the Issuer or any action to enforce the same or
any other circumstances which might otherwise constitute a legal
or equitable discharge or defense of a guarantor. Each of the
Guarantors hereby waives the benefits of diligence, presentment,
demand for payment, any requirement that the Trustee or any of
the Holders protect, secure, perfect or insure any security
interest in or other Lien on any property subject thereto or
exhaust any right or take any action against the Issuer or any
other Person or any collateral, filing of claims with a court in
the event of insolvency or bankruptcy of the Issuer, any right
to require a proceeding first against the Issuer, protest or
notice with respect to such Note or the Indebtedness evidenced
thereby and all demands whatsoever, and covenants that this Note
Guarantee will not be discharged in respect of such Note except
by complete performance of the obligations contained in such
Note and in this Note Guarantee. Each of the Guarantors hereby
agrees that, in the event of a default in payment of principal
(or premium, if any) or interest (including Additional Amounts,
if any) on such Note, whether at its Stated Maturity, by
acceleration, call for redemption, purchase or otherwise, legal
proceedings may be instituted by the Trustee on behalf of, or
by, the Holder of such Note, subject to the terms and conditions
set forth in the Indenture, directly against each of the
Guarantors to enforce this Note Guarantee without first
proceeding
C-1
against the Issuer. Each Guarantor agrees that, to the extent
permitted by applicable law, if, after the occurrence and during
the continuance of an Event of Default, the Trustee or any of
the Holders is prevented by applicable law from exercising its
respective rights to accelerate the maturity of the Notes, to
collect interest on the Notes, or to enforce or exercise any
other right or remedy with respect to the Notes, or the Trustee
or the Holders are prevented from taking any action to realize
on any collateral, such Guarantor agrees to pay to the Trustee
for the account of the Holders, upon demand therefor, the amount
that would otherwise have been due and payable had such rights
and remedies been permitted to be exercised by the Trustee or
any of the Holders.
No reference herein to the Indenture and no provision of this
Note Guarantee or of the Indenture shall alter or impair the
Note Guarantee of any Guarantor, which is absolute and
unconditional, of the due and punctual payment of the principal
of (and premium, if any) and interest (including Additional
Amounts, if any) on the Note upon which this Note Guarantee is
endorsed.
This Note Guarantee shall remain in full force and effect and
continue to be effective should any petition be filed by or
against the Issuer for liquidation or reorganization, or
equivalent proceeding under applicable law, should the Issuer
become insolvent or make an assignment for the benefit of
creditors or should a receiver or trustee be appointed for all
or any significant part of the Issuers assets, or the
equivalent of any of the foregoing under applicable law, and
shall, to the fullest extent permitted by applicable law,
continue to be effective or be reinstated, as the case may be,
if at any time payment and performance of the Notes is, pursuant
to applicable law, rescinded or reduced in amount, or must
otherwise be restored or returned by any obligee on the Notes
whether as a voidable preference, fraudulent transfer, or as
otherwise provided under similar laws affecting the rights of
creditors generally or under applicable laws of the jurisdiction
of formation of the Issuer, all as though such payment or
performance had not been made. In the event that any payment, or
any part thereof, is rescinded, reduced, restored or returned,
the Notes shall, to the fullest extent permitted by applicable
law, be reinstated and deemed reduced only by such amount paid
and not so rescinded, reduced, restored or returned.
The Guarantors shall have the right to seek contribution from
any non-paying Guarantor so long as the exercise of such right
does not impair the rights of the Holders under this Note
Guarantee. The Guarantors or any particular Guarantor shall be
released from this Note Guarantee upon the terms and subject to
certain conditions provided in the Indenture.
By delivery of a supplemental indenture to the Trustee in
accordance with the terms of the Indenture or the execution of a
Guarantee Agreement, each Person that becomes, or assumes the
obligations of, a Guarantor after the date of the Indenture will
be deemed to have executed and delivered this Note Guarantee for
the benefit of the Holder of this Note with the same effect as
if such Guarantor were named below.
All terms used in this Note Guarantee which are defined in the
Indenture referred to in the Note upon which this Note Guarantee
is endorsed shall have the meanings assigned to them in such
Indenture.
C-2
This Note Guarantee shall not be valid or obligatory for any
purpose until the certificate of authentication on the Note upon
which this Note Guarantee is endorsed shall have been executed
by the Trustee under the Indenture by manual signature.
Each Note Guarantee (other than that of the Company) will be
limited in amount to an amount not to exceed the maximum amount
that can be guaranteed by the applicable Guarantor without
rendering the Note Guarantee, as it relates to such Guarantor,
voidable under applicable law relating to fraudulent conveyance
or fraudulent transfer or similar laws affecting the rights of
creditors generally or under applicable law of the jurisdiction
of incorporation of such Guarantor.
In the case of Fresenius Medical Care Deutschland GmbH
(FMCD), the following provisions apply:
Without limiting the agreements set forth in Section 11.8,
the Note Guarantee of FMCD will be limited if and to the extent
payment under such Note Guarantee or the application of
enforcement proceeds would cause (i) FMCDs net assets
(
Reinvermögen
- calculated as the sum of the balance
sheet positions shown under § 266(2)(A), (B) and
(C) German Commercial Code (
Handelsgesetzbuch
)) less
the sum of the liabilities (shown under the balance sheet
positions pursuant to § 266(3)(B), (C) and
(D) German Commercial Code) to fall below FMCDs
registered share capital (
Stammkapital
) or (ii) (if the
amount of the net assets is already an amount less than the
registered share capital) cause such amount to be further
reduced and, in either case, thereby affecting the assets
required for the obligatory preservation of its registered share
capital according to section 30, 31 of the German Limited
Liability Company Act (GmbHG) (such event a Capital
Impairment). For the purposes of calculating the Capital
Impairment, the following adjustments will be made: (i) the
amount of any increase of the registered share capital out of
retained earnings (
Kapitalerhöhung aus
Gesellschaftsmitteln
) after the Closing Date that has been
effected without the prior consent of the Trustee shall be
deducted from the registered share capital; and
(ii) liabilities incurred in violation of the provisions of
the Notes and this Indenture shall be disregarded. In the event
FMCDs net assets fall below its registered share capital,
FMCD, upon request of the Trustee will realize in due course, to
the extent legally permitted, any and all of its assets that are
shown in the balance sheet with a book value (
Buchwert
)
that is significantly lower than the market value of the assets
if the relevant assets are not necessary for FMCDs
business (
nicht betriebsnotwendiges Vermögen
).
If FMCD objects to the amount demanded by the Trustee under the
Note Guarantee within twenty (20) business days after the
Trustee has submitted to FMCD a payment demand FMCD shall
appoint within five (5) business days a reputable
international auditor to determine the exact amount. The auditor
shall notify FMCD and the Trustee of the maximum amount payable
under the Note Guarantee within forty (40) business days
after its appointment. The costs of such auditors
determination shall be borne by FMCD. The determination of the
auditor shall be binding for FMCD, and the Holders (except for
manifest error). To the extent that any payment has been made
under the Note Guarantee by FMCD that would be necessary for
FMCD to be able to cure any Capital Impairment or Liquidity
Impairment such payment shall immediately upon
FMCDs demand be
C-3
returned to FMCD by any person receiving such payment, provided,
however, in no event shall the Trustee or Paying Agent have any
responsibility or liability for the return of any amount
distributed to any Holder or beneficial owner of the Notes by
the Trustee or Paying Agent, including, without limitation, any
obligation to seek return of such amounts from such Holder or
beneficial owner.
If (i) FMCD does not object to the payment amount within
the 20 business days period or (ii) if FMCD does not
appoint the auditor within the 5 business days period or
(iii) if the auditor fails to notify the amount payable
within the 40 days period, then the Trustee shall be
entitled to enforce the Note Guarantee without further delay.
The burden of demonstration and proof (
Darlegungs- und
Beweislast
) regarding the Capital Impairment and the maximum
amount payable under the Note Guarantee shall remain with FMCD.
The maximum amount payable under the guarantee shall be limited
to the extent and as long as FMCD as a consequence of the
payment would become unable to pay its debts when due
(
zahlungsunfähig
) within the meaning of
section 64 GmbHG (such event a Liquidity
Impairment). For the purpose of establishing whether a
Liquidity Impairment would occur, payments made by FMCD after
the Trustee has notified FMCD of its intention to enforce the
Note Guarantee with respect to payment obligations that are not
due at the time of the payment shall be disregarded, unless the
Trustee has consented to such payments (at the direction of the
Holders of at least a majority in principal amount of the Notes
then outstanding). From the time the Trustee has notified FMCD
and the Company of its intention to enforce the Note Guarantee,
the Company may not make any payment demands against FMCD under
shareholder loans and all such payment obligations of FMCD
towards the Company shall be deferred, subordinated or waived as
the Company sees fit, until the Trustee notifies FMCD that it is
no longer enforcing the Note Guarantee or the Trustee consents
(at the direction of the Holders of at least a majority in
principal amount of the Notes then outstanding) to the payments
to be made to the Company. Such notice may be delivered by the
Trustee at any time and, if not previously delivered, will be
delivered by the Trustee after the Notes have been repaid in
full and all other obligations under this Indenture are
satisfied.
The limitations as to the Capital Impairment shall not apply to
the extent FMCD has an adequate compensation claim
(
vollwertiger Gegenleistungs- oder
Rückgewähranspruch
) against the Company that
compensates for any loss incurred due to any payment by FMCD
under this Note Guarantee.
Reference is made to Article X of the Indenture for further
provisions with respect to this Note Guarantee.
THE NOTE GUARANTEES WILL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK EXCEPT THAT
THE LIMITATIONS OF THE NOTE GUARANTEES EXPRESSED IN
SECTION 10.1(c) OF THE INDENTURE (AND THE EQUIVALENT
PROVISIONS IN THE ELEVENTH PARAGRAPH HEREOF) WILL BE
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE FEDERAL REPUBLIC OF
GERMANY.
C-4
IN WITNESS WHEREOF, each of the undersigned has caused this Note
Guarantee to be duly executed.
FRESENIUS MEDICAL CARE
AG & CO. KGaA, a partnership limited by shares and
represented by FRESENIUS MEDICAL CARE MANAGEMENT AG, its general
partner
Name:
|
|
|
|
Title:
|
Member of the Management Board
|
Name:
|
|
|
|
Title:
|
Member of the Management Board
|
FRESENIUS MEDICAL CARE HOLDINGS,
INC.
Name:
Title:
FRESENIUS MEDICAL CARE DEUTSCHLAND
GMBH
Name:
Title:
Name:
Title:
C-5
EXHIBIT D
TO THE INDENTURE
FORM OF
TRANSFER CERTIFICATE FOR TRANSFER FROM
RULE 144A GLOBAL NOTE TO REGULATION S GLOBAL
NOTE
(Transfers pursuant to Section 2.7(a) of the Indenture)
Fresenius Medical Care US Finance, Inc.
c/o U.S. Bank
National Association
225 Asylum Street, 23rd Floor
Hartford, CT 06103
|
|
Attention:
|
Corporate Trust and Agency Services
Elizabeth C. Hammer
|
|
|
|
|
RE:
|
5.75% Senior Notes due 2021
(the Notes) of Fresenius Medical Care US Finance,
Inc.
|
Reference is hereby made to the Indenture dated as of
February 3, 2011 (the Indenture) between
Fresenius Medical Care US Finance, Inc., Fresenius Medical Care
AG & Co. KGaA, Fresenius Medical Care Holdings, Inc.,
Fresenius Medical Care Deutschland GmbH, and U.S. Bank
National Association, as Trustee. Capitalized terms used but not
defined herein shall have the meanings given them in the
Indenture.
This letter relates to
$
(being in a minimum amount of $2,000 and any integral multiple
of $1,000 in excess thereof) principal amount of Notes
beneficially held through interests in the Rule 144A Global
Note (CUSIP No. 35803Q AA5) with DTC in the name of
(the Transferor), account number
. The Transferor hereby requests that on [INSERT DATE] such
beneficial interest in the Rule 144A Global Note be
transferred or exchanged for an interest in the
Regulation S Global Note (CUSIP No. U31433 AA0) in the
same principal denomination and transferred to
(account no.
).
If this is a partial transfer, a minimum amount of $2,000 and
any integral multiple of $1,000 in excess thereof of the
Rule 144A Global Note will remain outstanding.
In connection with such request and in respect of such Notes,
the Transferor does hereby certify that such transfer has been
effected in accordance with the transfer restrictions set forth
in the Indenture and the Notes and pursuant to and in accordance
with Rule 903 or 904 of Regulation S under the
Securities Act, and accordingly the Transferor further certifies
that:
(A) (1) the
offer of the Notes was not made to a Person in the United States;
(2) either (a) at the time the
buy order was originated, the transferee was outside the United
States or we and any Person acting on our behalf reasonably be-
D-1
lieved that the transferee was outside the United States or
(b) the transaction was executed in, on or through the
facilities of a designated offshore securities market and
neither the Transferor nor any Person acting on our behalf knows
that the transaction was prearranged with a buyer in the United
States;
(3) no directed selling efforts
have been made in contravention of the requirements of
Rule 903(b) or 904(a) of Regulation S, as
applicable; and
(4) the transaction is not part of
a plan or scheme to evade the registration requirements of the
Securities Act.
OR
(B) such transfer is being made in
accordance with Rule 144 under the Securities Act.
D-2
This certificate and the statements contained herein are made
for your benefit and the benefit of the Issuer. Terms used in
this certificate and not otherwise defined in the Indenture have
the meanings set forth in Regulation S under the Securities
Act.
Dated:
[Name of Transferor]
Name:
Title:
Telephone No.:
|
|
Please print name and address (including zip code number)
|
|
D-3
EXHIBIT E
TO THE INDENTURE
FORM OF
TRANSFER CERTIFICATE FOR TRANSFER FROM
REGULATION S GLOBAL NOTE TO RULE 144A GLOBAL
NOTE
(Transfers pursuant to Section 2.7(b) of the Indenture)
Fresenius Medical Care US Finance, Inc.
c/o U.S. Bank
National Association
225 Asylum Street, 23rd Floor
Hartford, CT 06103
|
|
Attention:
|
Corporate Trust and Agency Services
Elizabeth C. Hammer
|
|
|
|
|
RE:
|
5.75% Senior Notes due 2021
(the Notes) of Fresenius Medical Care US Finance,
Inc.
|
Reference is hereby made to the Indenture dated as of
February 3, 2011 (the
Indenture
) between
Fresenius Medical Care US Finance, Inc., Fresenius Medical Care
AG & Co. KGaA, Fresenius Medical Care Holdings, Inc.,
Fresenius Medical Care Deutschland GmbH, and U.S. Bank
National Association, as Trustee. Capitalized terms used but not
defined herein shall have the meanings given them in the
Indenture.
This letter relates to
$
(being in a minimum amount of $2,000 and in an integral multiple
of $1,000 in excess thereof) principal amount of Notes
beneficially held through interests in the Regulation S
Global Note (CUSIP No. U31433 AAO) with DTC in the name of
(the Transferor), account number
.
The Transferor hereby requests that on [INSERT DATE] such
beneficial interest in the Regulation S Global Note be
transferred or exchanged for an interest in the Rule 144A
Global Note (CUSIP No. 35803Q AA5) in the same principal
denomination and transferred to
(account no.
).
If this is a partial transfer, a minimum of $2,000 and any
integral multiple of $1,000 in excess thereof of the
Regulation S Global Note will remain outstanding.
In connection with such request, and in respect of such Notes,
the Transferor does hereby certify that such Notes are being
transferred in accordance with Rule 144A under the
Securities Act to a transferee that the Transferor knows or
reasonably believes is purchasing the Notes for its own account
or an account with respect to which the transferee exercises
sole investment discretion and the transferee and any such
account is a qualified institutional buyer within
the meaning of Rule 144A, in each case in a transaction
meeting the requirements of Rule 144A and in accordance
with any applicable securities laws of any state of the United
States or any other jurisdiction.
E-1
This certificate and the statements contained herein are made
for your benefit and the benefit of the Issuer.
Dated:
[Name of Transferor]
Name:
Title:
Telephone No.:
|
|
Please print name and address (including zip code number)
|
|
E-2